<?xml version="1.0" encoding="UTF-8"?>
<search_results count="997">
  <query>COVID-19</query>
  <!-- Additional study fields may be added over time -->
  <study rank="1">
    <nct_id>NCT04364698</nct_id>
    <title>Observational Cohort of COVID-19 Patients at Raymond-Poincare</title>
    <acronym>COVID-RPC</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>clinical, biological and radiological characteristics</outcome_measure>
      <outcome_measure>patients' journey description</outcome_measure>
      <outcome_measure>Treatments effects</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>May 2020</primary_completion_date>
    <completion_date>May 2020</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Department of Infectiology, Raymond Poincaré Hospital, APHP, Garches, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04364698</url>
  </study>
  <study rank="2">
    <nct_id>NCT04333550</nct_id>
    <title>Application of Desferal to Treat COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Deferoxamine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mortality rate</outcome_measure>
      <outcome_measure>change in patients clinical manifestation</outcome_measure>
      <outcome_measure>change in patients PaO2</outcome_measure>
      <outcome_measure>Length of hospitalization</outcome_measure>
      <outcome_measure>C-reactive protein</outcome_measure>
      <outcome_measure>lymphocyte count</outcome_measure>
      <outcome_measure>length of intensive care unit stay</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Kermanshah University of Medical Sciences</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>3 Years</min_age>
    <max_age>99 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>September 2020</primary_completion_date>
    <completion_date>March 2021</completion_date>
    <study_first_posted>April 3, 2020</study_first_posted>
    <last_update_posted>April 6, 2020</last_update_posted>
    <locations>
      <location>Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran, Kermanshah, Iran, Islamic Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04333550</url>
  </study>
  <study rank="3">
    <nct_id>NCT04336904</nct_id>
    <title>Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Favipiravir</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time from randomization to clinical recovery</outcome_measure>
      <outcome_measure>Time from randomization to negativity in RT-PCR nucleic acid test</outcome_measure>
      <outcome_measure>Incidence of deterioration/aggravation of pneumonia</outcome_measure>
      <outcome_measure>Time from randomization to resolution of pyrexia</outcome_measure>
      <outcome_measure>Time from randomization to relief of cough</outcome_measure>
      <outcome_measure>Time from randomization to relief of dyspnoea</outcome_measure>
      <outcome_measure>Rate of auxiliary oxygen therapy</outcome_measure>
      <outcome_measure>ICU admission rate</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Giuliano Rizzardini</lead_sponsor>
      <collaborator>ASST Fatebenefratelli Sacco</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Care Provider)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 25, 2020</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>July 2020</completion_date>
    <study_first_posted>April 7, 2020</study_first_posted>
    <last_update_posted>April 8, 2020</last_update_posted>
    <locations>
      <location>Asst Fatebenefratelli Sacco, Milano, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04336904</url>
  </study>
  <study rank="4">
    <nct_id>NCT04351802</nct_id>
    <title>CORonavirus (COVID-19) Diagnostic Lung UltraSound Study</title>
    <acronym>COR-DLUS</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Lung ultrasound</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Diagnosis of COVID-19 on lung ultrasound</outcome_measure>
      <outcome_measure>Difference in diagnosis of COVID-19 on lung ultrasound vs. chest x-ray</outcome_measure>
      <outcome_measure>Diagnosis of alternative condition to COVID-19 on lung ultrasound vs. chest x-ray</outcome_measure>
      <outcome_measure>Ability of surveillance lung ultrasound to predict clinical trajectory / outcome in patients with COVID-19</outcome_measure>
      <outcome_measure>Consistency of lung ultrasound interpretation in patients presenting with suspected COVID-19</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital Plymouth NHS Trust</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>180</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>January 20, 2021</primary_completion_date>
    <completion_date>January 20, 2021</completion_date>
    <study_first_posted>April 17, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04351802</url>
  </study>
  <study rank="5">
    <nct_id>NCT04354831</nct_id>
    <title>A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">anti-SARS-CoV-2 convalescent plasma</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Overall Mortality within 60 days</outcome_measure>
      <outcome_measure>Length of ICU stay during current admission for COVID</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Medical College of Wisconsin</lead_sponsor>
      <collaborator>Froedtert Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>131</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 1, 2020</start_date>
    <primary_completion_date>May 1, 2022</primary_completion_date>
    <completion_date>May 1, 2023</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04354831</url>
  </study>
  <study rank="6">
    <nct_id>NCT04345445</nct_id>
    <title>Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tocilizumab</intervention>
      <intervention type="Drug">Methylprednisolone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The proportion of patients requiring mechanical ventilation</outcome_measure>
      <outcome_measure>Mean days of ventilation</outcome_measure>
      <outcome_measure>The proportion of patients requiring ICU admission</outcome_measure>
      <outcome_measure>Overall 28-day survival</outcome_measure>
      <outcome_measure>Change in symptom severity assessed by the World Health Organization (WHO) Coronavirus Disease 2019 (COVID19) ordinal scale measured daily up to 7 days from baseline</outcome_measure>
      <outcome_measure>Duration of hospital and ICU stay</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Malaya</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>310</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>October 31, 2020</primary_completion_date>
    <completion_date>October 31, 2020</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>University Malaya Medical Centre, Kuala Lumpur, Malaysia</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04345445</url>
  </study>
  <study rank="7">
    <nct_id>NCT04359095</nct_id>
    <title>Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Drug">Lopinavir / Ritonavir Pill</intervention>
      <intervention type="Drug">Azithromycin</intervention>
      <intervention type="Other">Standard treatment</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>Number of Participants with Treatment Related Severe Adverse Events as Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection</outcome_measure>
      <outcome_measure>Time to death</outcome_measure>
      <outcome_measure>Number of Participants that are transferred to the Intensive Care Unit (ICU)</outcome_measure>
      <outcome_measure>Number of Participants that need Mechanical Ventilation Support with endotracheal intubation.</outcome_measure>
      <outcome_measure>Number of participants Cured assessed by Nasopharyngeal swab, oropharyngeal swab, and blood aspiration for COVID19 (RT-PCR) without clinical symptoms and normal chest X ray</outcome_measure>
      <outcome_measure>Number of Participants with Any Adverse Event Related to Treatment Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Universidad Nacional de Colombia</lead_sponsor>
      <collaborator>Pontificia Universidad Javeriana</collaborator>
      <collaborator>Clínica Universitaria Colombia</collaborator>
      <collaborator>Hospital Universitario San Ignacio</collaborator>
      <collaborator>Hospital Universitario Nacional de Colombia</collaborator>
      <collaborator>Clínica Reina Sofía</collaborator>
      <collaborator>Fundación Cardio Infantil</collaborator>
      <collaborator>Hospital Universitario de Neiva</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1600</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 11, 2020</start_date>
    <primary_completion_date>October 11, 2020</primary_completion_date>
    <completion_date>October 31, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Hospital Universitario de Neiva, Neiva, Huila, Colombia</location>
      <location>Clínica Reina Sofía, Bogotá, Colombia</location>
      <location>Fundacion Cardio Infantil, Bogotá, Colombia</location>
      <location>Hospital Universitario San Ignacio, Bogotá, Colombia</location>
      <location>Clinica Universitaria Colombia, Bogotá, Colombia</location>
      <location>Hospital Universitario Nacional de Colombia, Bogotá, Colombia</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04359095</url>
  </study>
  <study rank="8">
    <nct_id>NCT04361422</nct_id>
    <title>Isotretinoin in Treatment of COVID-19</title>
    <acronym>Randomized</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Isotretinoin Only Product in Oral Dose Form</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clinical clearance</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tanta University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>40 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 21, 2020</start_date>
    <primary_completion_date>June 2020</primary_completion_date>
    <completion_date>September 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04361422</url>
  </study>
  <study rank="9">
    <nct_id>NCT04355741</nct_id>
    <title>Gut Microbiota, &quot;Spark and Flame&quot; of COVID-19 Disease</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Exposure</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Differences in gut microbiota composition between COVID-19 patients with different degrees of disease severity.</outcome_measure>
      <outcome_measure>Differences in gut microbiota composition between COVID-19 patients in relation to mortality.</outcome_measure>
      <outcome_measure>Differences in gut microbiota composition between COVID-19 patients in relation to length of stay in hospitals.</outcome_measure>
      <outcome_measure>Differences in gut microbiota composition between COVID-19 patients in relation to duration of mechanical ventilation.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Universidade Nova de Lisboa</lead_sponsor>
      <collaborator>NOVA Medical School of Universidade NOVA de Lisboa</collaborator>
      <collaborator>Hospital de São Francisco Xavier, Centro Hospitalar de Lisboa Ocidental</collaborator>
      <collaborator>Centro Hospitalar Universitário São João</collaborator>
      <collaborator>CUF Academic and Research Medical Center</collaborator>
      <collaborator>Hospital CUF Infante Santo, S.A.</collaborator>
      <collaborator>Centro de Medicina Laboratorial Germano de Sousa, S.A.</collaborator>
      <collaborator>CINTESIS - Center for Health Technology and Services Research</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>Hospital CUF Infante Santo, S.A., Lisbon, Portugal</location>
      <location>Hospital de São Francisco Xavier, Lisbon, Portugal</location>
      <location>Centro Hospitalar Universitário São João, Oporto, Portugal</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04355741</url>
  </study>
  <study rank="10">
    <nct_id>NCT04331509</nct_id>
    <title>COVID-19 Symptom Tracker</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">No Intervention</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Physical health symptoms</outcome_measure>
      <outcome_measure>Lack of physical health symptoms</outcome_measure>
      <outcome_measure>Fever</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>King's College London</lead_sponsor>
      <collaborator>Zoe Global Limited</collaborator>
      <collaborator>Massachusetts General Hospital</collaborator>
      <collaborator>Harvard School of Public Health</collaborator>
      <collaborator>Stanford University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>10000000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 23, 2020</start_date>
    <primary_completion_date>March 23, 2022</primary_completion_date>
    <completion_date>March 23, 2022</completion_date>
    <study_first_posted>April 2, 2020</study_first_posted>
    <last_update_posted>April 7, 2020</last_update_posted>
    <locations>
      <location>Massachusetts General Hospital, Boston, Massachusetts, United States</location>
      <location>King's College London, London, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04331509</url>
  </study>
  <study rank="11">
    <nct_id>NCT04347915</nct_id>
    <title>The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Clevudine</intervention>
      <intervention type="Drug">Hydroxychloroquine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The rate of subjects tested as negative SARS-Coronavirus-2 (SARS-CoV-2)</outcome_measure>
      <outcome_measure>The rate of subjects tested as negative SARS-Coronavirus-2 (SARS-CoV-2) in consecutive two days of Real-Time RT-PCR tests</outcome_measure>
      <outcome_measure>The rate of subjects indicated by the improvement of lung invasive</outcome_measure>
      <outcome_measure>The change of viral load</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Bukwang Pharmaceutical</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>19 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 24, 2020</start_date>
    <primary_completion_date>September 30, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04347915</url>
  </study>
  <study rank="12">
    <nct_id>NCT04343183</nct_id>
    <title>Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19 (COVID-19) Infection</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Hyperbaric Oxygen Therapy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Decrease incidence of intubation by 30% or greater</outcome_measure>
      <outcome_measure>Decrease renal injury</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ochsner Health System</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>48</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>June 2020</primary_completion_date>
    <completion_date>June 2020</completion_date>
    <study_first_posted>April 13, 2020</study_first_posted>
    <last_update_posted>April 13, 2020</last_update_posted>
    <locations>
      <location>Ochsner Medical Center, New Orleans, Louisiana, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04343183</url>
  </study>
  <study rank="13">
    <nct_id>NCT04333407</nct_id>
    <title>Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.</title>
    <acronym>C-19-ACS</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Aspirin 75mg</intervention>
      <intervention type="Drug">Clopidogrel 75mg</intervention>
      <intervention type="Drug">Rivaroxaban 2.5 MG</intervention>
      <intervention type="Drug">Atorvastatin 40mg</intervention>
      <intervention type="Drug">Omeprazole 20mg</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>All-cause mortality at 30 days after admission</outcome_measure>
      <outcome_measure>Absolute change in serum troponin from admission to peak value</outcome_measure>
      <outcome_measure>Discharge Rate</outcome_measure>
      <outcome_measure>Intubation Rate</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Imperial College London</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>3170</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 3, 2020</start_date>
    <primary_completion_date>March 30, 2021</primary_completion_date>
    <completion_date>March 30, 2021</completion_date>
    <study_first_posted>April 3, 2020</study_first_posted>
    <last_update_posted>April 9, 2020</last_update_posted>
    <locations>
      <location>Charing Cross Hospital, London, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04333407</url>
  </study>
  <study rank="14">
    <nct_id>NCT04342637</nct_id>
    <title>COVID-19 Endoscopy Survey</title>
    <acronym>COVID-19 Endo</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Practice details</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Effect of GI societies recommendations on prevention of SARS-CoV-2 infection</outcome_measure>
      <outcome_measure>To measure the percentage change in performed endoscopic procedure in response to COVID-19</outcome_measure>
      <outcome_measure>Effect of COVID-19 precautions on procedure time</outcome_measure>
      <outcome_measure>Effect of COVID-19 precautions on time of disinfection</outcome_measure>
      <outcome_measure>Effect of COVID-19 precautions on procedure success</outcome_measure>
      <outcome_measure>Effect of COVID-19 precautions on complications</outcome_measure>
      <outcome_measure>Effect of COVID-19 precautions on working time</outcome_measure>
      <outcome_measure>Effect of COVID-19 precautions on staff number</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Al-Azhar University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>30 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 10, 2020</start_date>
    <primary_completion_date>October 10, 2020</primary_completion_date>
    <completion_date>December 10, 2020</completion_date>
    <study_first_posted>April 13, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>Kings County Hospital Center, Brooklyn, NY, USA, Albertson, New York, United States</location>
      <location>Faculty of Medicine, Zagazig University, Zagazig, Sharkia, Egypt</location>
      <location>Al-Azhar Univerisity, Cairo, Egypt</location>
      <location>Ahvaz Imam hospital, Ahvaz, Iran, Islamic Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04342637</url>
  </study>
  <study rank="15">
    <nct_id>NCT04291053</nct_id>
    <title>The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Huaier Granule</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mortality rate</outcome_measure>
      <outcome_measure>Clinical status assessed according to the official guideline</outcome_measure>
      <outcome_measure>The differences in oxygen intake methods</outcome_measure>
      <outcome_measure>Duration (days) of supplemental oxygenation</outcome_measure>
      <outcome_measure>Duration (days) of mechanical ventilation</outcome_measure>
      <outcome_measure>The mean PaO2/FiO2</outcome_measure>
      <outcome_measure>Length of hospital stay (days)</outcome_measure>
      <outcome_measure>Length of ICU stay (days)</outcome_measure>
      <outcome_measure>Pulmonary function</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tongji Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>550</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>August 1, 2020</primary_completion_date>
    <completion_date>September 1, 2020</completion_date>
    <study_first_posted>March 2, 2020</study_first_posted>
    <last_update_posted>March 17, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04291053</url>
  </study>
  <study rank="16">
    <nct_id>NCT04336462</nct_id>
    <title>Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19</title>
    <acronym>COVID-19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Device">oxyhydrogen</intervention>
      <intervention type="Device">Oxygen</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Recovery time</outcome_measure>
      <outcome_measure>Clinical Symptom Remission time</outcome_measure>
      <outcome_measure>fever duration</outcome_measure>
      <outcome_measure>Leicester cough questionaire (LCQ)</outcome_measure>
      <outcome_measure>minimum oxygen</outcome_measure>
      <outcome_measure>Negative conversion rate</outcome_measure>
      <outcome_measure>white blood cell(WBC)</outcome_measure>
      <outcome_measure>Red blood cells(RBC)</outcome_measure>
      <outcome_measure>Hemoglobin(Hb )</outcome_measure>
      <outcome_measure>Platelets(PLT)</outcome_measure>
      <outcome_measure>Lymphocyte count</outcome_measure>
      <outcome_measure>The percentage of lymphocyte</outcome_measure>
      <outcome_measure>neutrophils</outcome_measure>
      <outcome_measure>C-reactive protein (CRP)</outcome_measure>
      <outcome_measure>Myocardial enzyme</outcome_measure>
      <outcome_measure>liver function</outcome_measure>
      <outcome_measure>Renal function</outcome_measure>
      <outcome_measure>Muscle enzyme</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Shanghai Asclepius Meditec Inc.</lead_sponsor>
      <collaborator>Shanghai Public Health Clinical Center</collaborator>
      <collaborator>Henan Provincial People's Hospital</collaborator>
      <collaborator>Shenzhen Third People's Hospital</collaborator>
      <collaborator>The First People's Hospital of Yunnan</collaborator>
      <collaborator>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</collaborator>
      <collaborator>Shanghai 6th People's Hospital</collaborator>
      <collaborator>Guangdong Provincial Hospital of Traditional Chinese Medicine</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>February 15, 2020</start_date>
    <primary_completion_date>February 21, 2020</primary_completion_date>
    <completion_date>August 1, 2020</completion_date>
    <study_first_posted>April 7, 2020</study_first_posted>
    <last_update_posted>April 7, 2020</last_update_posted>
    <locations>
      <location>First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04336462</url>
  </study>
  <study rank="17">
    <nct_id>NCT04342689</nct_id>
    <title>The Role of Resistant Starch in COVID-19 Infection</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Dietary Supplement containing resistant starch</intervention>
      <intervention type="Dietary Supplement">Placebo Starch</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Rates of hospitalization for a COVID-19 related complication</outcome_measure>
      <outcome_measure>Time to clinical recovery (TTCR)</outcome_measure>
      <outcome_measure>Symptom Severity Score</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yale University</lead_sponsor>
      <collaborator>University of Michigan</collaborator>
      <collaborator>University of Minnesota</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>19 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 1, 2020</start_date>
    <primary_completion_date>May 1, 2021</primary_completion_date>
    <completion_date>May 1, 2021</completion_date>
    <study_first_posted>April 13, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04342689</url>
  </study>
  <study rank="18">
    <nct_id>NCT04363346</nct_id>
    <title>Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">FT516</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of participants with Dose Limiting Toxicity Events</outcome_measure>
      <outcome_measure>The time in days from the 1st FT516 infusion to the elimination of viral shedding in nasal pharyngeal and stool samples</outcome_measure>
      <outcome_measure>The time in days from the 1st FT516 infusion to discontinued need for supplemental oxygen</outcome_measure>
      <outcome_measure>The time in days from the 1st FT516 infusion to hospital discharge</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Masonic Cancer Center, University of Minnesota</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>76 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 4, 2020</start_date>
    <primary_completion_date>January 2022</primary_completion_date>
    <completion_date>January 2022</completion_date>
    <study_first_posted>April 27, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>University of Minnesota, Minneapolis, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04363346</url>
  </study>
  <study rank="19">
    <nct_id>NCT04324489</nct_id>
    <title>DAS181 for Severe COVID-19: Compassionate Use</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DAS181</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Improved clinical status</outcome_measure>
      <outcome_measure>Return to room air</outcome_measure>
      <outcome_measure>SARS-CoV-2 RNA</outcome_measure>
      <outcome_measure>Discharge</outcome_measure>
      <outcome_measure>Death</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Renmin Hospital of Wuhan University</lead_sponsor>
      <collaborator>Ansun Biopharma, Inc.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>4</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 6, 2020</start_date>
    <primary_completion_date>April 25, 2020</primary_completion_date>
    <completion_date>April 30, 2020</completion_date>
    <study_first_posted>March 27, 2020</study_first_posted>
    <last_update_posted>April 2, 2020</last_update_posted>
    <locations>
      <location>Renmin Hospital of Wuhan University, Wuhan, Hubei, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04324489</url>
  </study>
  <study rank="20">
    <nct_id>NCT04347993</nct_id>
    <title>A Prospective &quot;Universal&quot; Observational Database for COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Need for hospitalization</outcome_measure>
      <outcome_measure>Duration of hospitalization</outcome_measure>
      <outcome_measure>Need for ICU/Ventilator Support</outcome_measure>
      <outcome_measure>Duration of ICU/Ventilator Support</outcome_measure>
      <outcome_measure>Overall Survival</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hackensack Meridian Health</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>5000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 27, 2020</start_date>
    <primary_completion_date>April 2021</primary_completion_date>
    <completion_date>April 2021</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Hackensack Meridian Health - John Theurer Cancer Center, Hackensack, New Jersey, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04347993</url>
  </study>
  <study rank="21">
    <nct_id>NCT04323228</nct_id>
    <title>Anti-inflammatory/Antioxidant Oral Nutrition Supplementation in COVID-19</title>
    <acronym>ONSCOVID19</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">oral nutrition supplement (ONS) enriched in eicosapentaenoic acid, gamma-linolenic acid and antioxidants</intervention>
      <intervention type="Dietary Supplement">isocaloric/isonutrigenous ONS</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change from baseline score of Nutrition risk screening-2002 (NRS-2002) at end of the trial</outcome_measure>
      <outcome_measure>Change from baseline Serum ferritin level at end of the trial</outcome_measure>
      <outcome_measure>Change from baseline serum Interleukin-6 concentration at end of the trial</outcome_measure>
      <outcome_measure>Change from baseline serum C-reactive protein concentration at end of the trial</outcome_measure>
      <outcome_measure>Change from baseline serum Tumor necrosis factor-α concentration at end of the trial</outcome_measure>
      <outcome_measure>Change from baseline serum monocyte chemoattractant protein 1 (MCP-1) at end of the trial</outcome_measure>
      <outcome_measure>Change from baseline Weight at end of the trial</outcome_measure>
      <outcome_measure>Height</outcome_measure>
      <outcome_measure>Change from baseline BMI at end of the trial</outcome_measure>
      <outcome_measure>Change from baseline mid arm circumference at end of the trial</outcome_measure>
      <outcome_measure>Change from baseline triceps skin-fold thickness at end of the trial</outcome_measure>
      <outcome_measure>Change from baseline MAMA at end of the trial</outcome_measure>
      <outcome_measure>Change from baseline percentage of peripheral O2 saturation at end of the trial</outcome_measure>
      <outcome_measure>Change from baseline degree of body temperature at end of the trial</outcome_measure>
      <outcome_measure>Change from baseline count the total leukocyte at end of the trial</outcome_measure>
      <outcome_measure>Change from baseline differential lymphocytic count at end of the trial</outcome_measure>
      <outcome_measure>Change from baseline Neutrophil count at end of the trial</outcome_measure>
      <outcome_measure>Change from baseline neutrophil to lymphocyte ratio at end of the trial</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>King Saud University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Care Provider)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <start_date>May 1, 2020</start_date>
    <primary_completion_date>October 1, 2020</primary_completion_date>
    <completion_date>October 30, 2020</completion_date>
    <study_first_posted>March 26, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04323228</url>
  </study>
  <study rank="22">
    <nct_id>NCT04335123</nct_id>
    <title>Study of Open Label Losartan in COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Losartan</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of participants with treatment-related adverse events as assessed by protocol definition of AE</outcome_measure>
      <outcome_measure>Number of days on supplemental oxygen in respiratory failure due to COVID-19</outcome_measure>
      <outcome_measure>Incidence of mechanical ventilation use</outcome_measure>
      <outcome_measure>Days on mechanical ventilation</outcome_measure>
      <outcome_measure>Incidence of non-invasive positive pressure ventilation or heated high flow nasal cannula use</outcome_measure>
      <outcome_measure>Days on non-invasive positive pressure ventilation or high flow nasal cannula</outcome_measure>
      <outcome_measure>Incidence of transfer to ICU from non-ICU hospital bed</outcome_measure>
      <outcome_measure>ICU length of stay (days)</outcome_measure>
      <outcome_measure>30-day mortality rate</outcome_measure>
      <outcome_measure>Hospital length of stay (days)</outcome_measure>
      <outcome_measure>Cumulative incidence of severe adverse events</outcome_measure>
      <outcome_measure>Cumulative incidence of adverse events</outcome_measure>
      <outcome_measure>Change from baseline in oxygenation</outcome_measure>
      <outcome_measure>Incidence of medications with possible antiviral activity (hydroxychloroquine, lopinavir/ritonavir, ribavirin or remdesivir) or adjunctive therapy use (e.g., tocilizumab)</outcome_measure>
      <outcome_measure>Incidence (and length in days) of extracorporeal membrane oxygenation use</outcome_measure>
      <outcome_measure>Incidence (and length in days) of renal replacement therapy use</outcome_measure>
      <outcome_measure>Intolerance of high dose (50mg) losartan after tolerating 25mg</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Kansas Medical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 25, 2020</start_date>
    <primary_completion_date>September 2020</primary_completion_date>
    <completion_date>October 2020</completion_date>
    <study_first_posted>April 6, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>University of Kansas Medical Center, Kansas City, Kansas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04335123</url>
  </study>
  <study rank="23">
    <nct_id>NCT04360356</nct_id>
    <title>Ivermectin and Nitazoxanide Combination Therapy for COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Combination Product">Ivermectin plus Nitazoxanide</intervention>
      <intervention type="Other">Standard Care</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of Patients with COVID-19-negative PCR</outcome_measure>
      <outcome_measure>Number of patients with improved respiratory rate</outcome_measure>
      <outcome_measure>Number of patients with improved PaO2</outcome_measure>
      <outcome_measure>Number of patients with normalized Serum IL6</outcome_measure>
      <outcome_measure>Number of patients with normalized Serum TNFα</outcome_measure>
      <outcome_measure>Number of patients with normalized Serum iron</outcome_measure>
      <outcome_measure>Number of patients with normalized Serum ferritin</outcome_measure>
      <outcome_measure>Number of patients with normalized International normalized ratio &quot;INR&quot; for prothrombin time</outcome_measure>
      <outcome_measure>Number of patients with normalized complete blood count &quot;CBC&quot;</outcome_measure>
      <outcome_measure>The Mortality rate among treated patients</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tanta University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 2020</start_date>
    <primary_completion_date>October 2020</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04360356</url>
  </study>
  <study rank="24">
    <nct_id>NCT04333420</nct_id>
    <title>Open-label, Randomized Study of IFX-1 in Patients With Severe COVID-19 Pneumonia</title>
    <acronym>PANAMO</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19 Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Best supportive Care (BSC) + IFX-1</intervention>
      <intervention type="Drug">Best supportive care only</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in PaO2/FiO2</outcome_measure>
      <outcome_measure>Patients achieving early response</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>InflaRx GmbH</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>130</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 31, 2020</start_date>
    <primary_completion_date>October 31, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>April 3, 2020</study_first_posted>
    <last_update_posted>April 16, 2020</last_update_posted>
    <locations>
      <location>University Amsterdam, Amsterdam, Netherlands</location>
      <location>University Amsterdam, Amsterdam, Netherlands</location>
      <location>University Maastricht, Maastricht, Netherlands</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04333420</url>
  </study>
  <study rank="25">
    <nct_id>NCT04350593</nct_id>
    <title>Dapagliflozin in Respiratory Failure in Patients With COVID-19</title>
    <acronym>DARE-19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Dapagliflozin 10 MG</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to first occurrence of either death from any cause or new/worsened organ dysfunction through 30 days of follow up, defined as at least one of the following:</outcome_measure>
      <outcome_measure>Hierarchical composite outcome measures:</outcome_measure>
      <outcome_measure>Time to hospital discharge</outcome_measure>
      <outcome_measure>Total number of days alive, out of hospital, and/or free from mechanical ventilation</outcome_measure>
      <outcome_measure>Total number of days alive, not in the ICU, and free from mechanical ventilation (as defined in the primary outcome measure)</outcome_measure>
      <outcome_measure>Time to death from any cause</outcome_measure>
      <outcome_measure>Time to new/worsened organ dysfunction</outcome_measure>
      <outcome_measure>Time to acute kidney injury (defined as doubling of s-Creatinine compared to baseline)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Saint Luke's Health System</lead_sponsor>
      <collaborator>AstraZeneca</collaborator>
      <collaborator>George Clinical Pty Ltd</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>900</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>October 2020</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>April 17, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations>
      <location>Saint Luke's Mid America Heart Institute, Kansas City, Missouri, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04350593</url>
  </study>
  <study rank="26">
    <nct_id>NCT04343755</nct_id>
    <title>Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Convalescent Plasma</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>For patients hospitalized for COVID-19 but not intubated</outcome_measure>
      <outcome_measure>Primary objective for patients with COVID-19 already intubated</outcome_measure>
      <outcome_measure>Duration of hospitalization</outcome_measure>
      <outcome_measure>Duration of mechanical ventilation</outcome_measure>
      <outcome_measure>Time to symptoms resolution</outcome_measure>
      <outcome_measure>Overall survival</outcome_measure>
      <outcome_measure>Rate of virologic clearance by nasopharyngeal swab at day 10</outcome_measure>
      <outcome_measure>Impact of donor titers level on efficacy</outcome_measure>
      <outcome_measure>Impact of donor titers level on safety</outcome_measure>
      <outcome_measure>Recipient Anti-SARS-CoV2 titer assessment on days 0 (pre-infusion),3,10,30, 60</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hackensack Meridian Health</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>55</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 9, 2020</start_date>
    <primary_completion_date>April 2021</primary_completion_date>
    <completion_date>April 2021</completion_date>
    <study_first_posted>April 13, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations>
      <location>Hackensack University Medical Center, Hackensack, New Jersey, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04343755</url>
  </study>
  <study rank="27">
    <nct_id>NCT04321421</nct_id>
    <title>Hyperimmune Plasma for Critical Patients With COVID-19</title>
    <acronym>COV19-PLASMA</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">hyperimmune plasma</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>death</outcome_measure>
      <outcome_measure>time to extubation</outcome_measure>
      <outcome_measure>length of intensive care unit stay</outcome_measure>
      <outcome_measure>time to CPAP weaning</outcome_measure>
      <outcome_measure>viral load</outcome_measure>
      <outcome_measure>immune response</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Foundation IRCCS San Matteo Hospital</lead_sponsor>
      <collaborator>OSPEDALE CARLO POMA ASST MANTOVA</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>49</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 17, 2020</start_date>
    <primary_completion_date>May 31, 2020</primary_completion_date>
    <completion_date>May 31, 2020</completion_date>
    <study_first_posted>March 25, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>Catherine Klersy, Pavia, PV, Italy</location>
      <location>Ospedale Asst Carlo Poma Mantova, Mantova, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04321421</url>
  </study>
  <study rank="28">
    <nct_id>NCT04329611</nct_id>
    <title>ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Composite of hospitalization, invasive mechanical ventilation or death within 30 days</outcome_measure>
      <outcome_measure>mortality</outcome_measure>
      <outcome_measure>Symptom duration</outcome_measure>
      <outcome_measure>Disposition at 30 days defined as recovered, ongoing symptoms but not hospitalized, hospitalized, or deceased.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Dr. Michael Hill</lead_sponsor>
      <collaborator>Alberta Health Services</collaborator>
      <collaborator>University of Alberta</collaborator>
      <collaborator>University of Calgary</collaborator>
      <collaborator>Calgary Health Trust</collaborator>
      <collaborator>Alberta Innovates Health Solutions</collaborator>
      <collaborator>Government of Alberta</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1660</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 13, 2020</start_date>
    <primary_completion_date>August 31, 2020</primary_completion_date>
    <completion_date>September 30, 2020</completion_date>
    <study_first_posted>April 1, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>University of Calgary/Foothills Medical Centre, Calgary, Alberta, Canada</location>
      <location>University of Alberta, Edmonton, Alberta, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04329611</url>
  </study>
  <study rank="29">
    <nct_id>NCT04352582</nct_id>
    <title>COVID-19 and Vaccination Attitudes</title>
    <acronym>VACAT</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Survey</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>How vaccination and other attitudes are affected by COVID</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Geneva</lead_sponsor>
      <collaborator>University of Zurich</collaborator>
      <collaborator>University of Lausanne</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 14, 2020</start_date>
    <primary_completion_date>April 30, 2020</primary_completion_date>
    <completion_date>April 30, 2020</completion_date>
    <study_first_posted>April 20, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations>
      <location>Survey, London, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04352582</url>
  </study>
  <study rank="30">
    <nct_id>NCT04325633</nct_id>
    <title>Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection</title>
    <acronym>ENACOVID</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">1: Naproxen</intervention>
      <intervention type="Drug">2: Standard of care</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mortality all causes at day30</outcome_measure>
      <outcome_measure>Number of days alive free of mechanical ventilation</outcome_measure>
      <outcome_measure>Number of days alive outside</outcome_measure>
      <outcome_measure>Number of days alive outside hospital</outcome_measure>
      <outcome_measure>Maximal changes in Sofa score</outcome_measure>
      <outcome_measure>Time to negativation of virus titer in the nasopharyngeal aspirate (NPA)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>584</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 13, 2020</start_date>
    <primary_completion_date>May 13, 2021</primary_completion_date>
    <completion_date>July 13, 2021</completion_date>
    <study_first_posted>March 27, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04325633</url>
  </study>
  <study rank="31">
    <nct_id>NCT04351659</nct_id>
    <title>Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Blood donation from convalescent donor</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Success rate in production of SARS-CoV-2 specific T cells from convalescent donor</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>KK Women's and Children's Hospital</lead_sponsor>
      <collaborator>Singapore General Hospital</collaborator>
      <collaborator>National University Hospital, Singapore</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>8</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>August 2020</primary_completion_date>
    <completion_date>August 2020</completion_date>
    <study_first_posted>April 17, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations>
      <location>National University Hospital, Singapore, Singapore</location>
      <location>Singapore General Hospital, Singapore, Singapore</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04351659</url>
  </study>
  <study rank="32">
    <nct_id>NCT04323332</nct_id>
    <title>Traditional Chinese Medicine for Severe COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Traditional Chinese Medicine Prescription</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Length of hospital stay (days)</outcome_measure>
      <outcome_measure>Duration (days) of supplemental oxygenation</outcome_measure>
      <outcome_measure>CT imaging changes</outcome_measure>
      <outcome_measure>Mortality rate</outcome_measure>
      <outcome_measure>Time to Clinical Improvement (TTCI)</outcome_measure>
      <outcome_measure>The pneumonia severity index scores</outcome_measure>
      <outcome_measure>Time to COVID-19 nucleic acid testing negativity in throat swab</outcome_measure>
      <outcome_measure>Blood immune cell count</outcome_measure>
      <outcome_measure>Serum inflammatory markers</outcome_measure>
      <outcome_measure>Erythrocyte sedimentation rate</outcome_measure>
      <outcome_measure>Platelet and D-dimer changes</outcome_measure>
      <outcome_measure>Creatinine changes</outcome_measure>
      <outcome_measure>Muscle enzymes changes</outcome_measure>
      <outcome_measure>Usage of antibiotics</outcome_measure>
      <outcome_measure>Usage of glucocorticoids</outcome_measure>
      <outcome_measure>Frequency of adverse events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Xiyuan Hospital of China Academy of Chinese Medical Sciences</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 2020</start_date>
    <primary_completion_date>March 2020</primary_completion_date>
    <completion_date>April 2020</completion_date>
    <study_first_posted>March 26, 2020</study_first_posted>
    <last_update_posted>March 26, 2020</last_update_posted>
    <locations>
      <location>Hao Li, Beijing, Beijing, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04323332</url>
  </study>
  <study rank="33">
    <nct_id>NCT04352348</nct_id>
    <title>Cohort of Patients Infected With SARS-CoV2 (COVID-19) or Suspected of Being</title>
    <acronym>COVIDeF</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">blood samples</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Identification of prognostic factors for progression to a severe form of COVID-19 infection</outcome_measure>
      <outcome_measure>Clinical aggravation of the infection</outcome_measure>
      <outcome_measure>Discharge of hospitalization</outcome_measure>
      <outcome_measure>Death</outcome_measure>
      <outcome_measure>Description of clinical manifestations</outcome_measure>
      <outcome_measure>Description of biological manifestations</outcome_measure>
      <outcome_measure>Description of radiological manifestations</outcome_measure>
      <outcome_measure>Description of physiological manifestations</outcome_measure>
      <outcome_measure>Patient-related prognostic factors</outcome_measure>
      <outcome_measure>Virus-related risk factors</outcome_measure>
      <outcome_measure>Comparison of the results of different diagnosis tests</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>2000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <start_date>March 31, 2020</start_date>
    <primary_completion_date>May 31, 2021</primary_completion_date>
    <completion_date>March 31, 2022</completion_date>
    <study_first_posted>April 20, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>GH Pitié-Salpêtrière / Service d'Accueil des Urgences, Paris, Ile-de-France, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04352348</url>
  </study>
  <study rank="34">
    <nct_id>NCT04344015</nct_id>
    <title>COVID-19 Plasma Collection</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Plasma Donation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of patients who screen eligible for donation</outcome_measure>
      <outcome_measure>Number of patients who consent to plasma donation</outcome_measure>
      <outcome_measure>Number of plasma donations received</outcome_measure>
      <outcome_measure>Safety of donation procedures</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Thomas Jefferson University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>2000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <start_date>April 13, 2020</start_date>
    <primary_completion_date>April 12, 2021</primary_completion_date>
    <completion_date>April 12, 2021</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 16, 2020</last_update_posted>
    <locations>
      <location>Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04344015</url>
  </study>
  <study rank="35">
    <nct_id>NCT04339660</nct_id>
    <title>Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">UC-MSCs</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The immune function (TNF-α 、IL-1β、IL-6、TGF-β、IL-8、PCT、CRP)</outcome_measure>
      <outcome_measure>Blood oxygen saturation</outcome_measure>
      <outcome_measure>Rate of mortality within 28-days</outcome_measure>
      <outcome_measure>Size of lesion area by chest imaging</outcome_measure>
      <outcome_measure>CD4+ and CD8+ T cells count</outcome_measure>
      <outcome_measure>Peripheral blood count recovery time</outcome_measure>
      <outcome_measure>Duration of respiratory symptoms (fever, dry cough, difficulty breathing, etc.)</outcome_measure>
      <outcome_measure>COVID-19 nucleic acid negative time</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Puren Hospital Affiliated to Wuhan University of Science and Technology</lead_sponsor>
      <collaborator>Shanghai University</collaborator>
      <collaborator>Qingdao Co-orient Watson Biotechnology group co. LTD</collaborator>
      <collaborator>Basic Medical Sciences, Chinese Academy of Medical Sciences</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>February 1, 2020</start_date>
    <primary_completion_date>June 30, 2020</primary_completion_date>
    <completion_date>June 30, 2020</completion_date>
    <study_first_posted>April 9, 2020</study_first_posted>
    <last_update_posted>April 9, 2020</last_update_posted>
    <locations>
      <location>Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04339660</url>
  </study>
  <study rank="36">
    <nct_id>NCT04306497</nct_id>
    <title>Clinical Trial on Regularity of TCM Syndrome and Differentiation Treatment of COVID-19.</title>
    <acronym>CTOROTSADTOC</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TCM prescriptions</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The relief / disappearance rate of main symptoms</outcome_measure>
      <outcome_measure>Chest CT absorption</outcome_measure>
      <outcome_measure>Virus antigen negative conversion rate</outcome_measure>
      <outcome_measure>Clinical effective time: the average effective time</outcome_measure>
      <outcome_measure>The number of severe and critical conversion cases</outcome_measure>
      <outcome_measure>Incidence of complications</outcome_measure>
      <outcome_measure>Traditional Chinese Medicine Syndrome Score</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Jiangsu Famous Medical Technology Co., Ltd.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>340</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 2, 2020</start_date>
    <primary_completion_date>May 2020</primary_completion_date>
    <completion_date>May 2020</completion_date>
    <study_first_posted>March 13, 2020</study_first_posted>
    <last_update_posted>March 17, 2020</last_update_posted>
    <locations>
      <location>Huai'an fourth people's Hospital, Huaian, Jiangsu, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04306497</url>
  </study>
  <study rank="37">
    <nct_id>NCT04354857</nct_id>
    <title>Qualitative and Quantitative Evaluation of Anosmia Over Time in Clinically Symptomatic Patients Tested for COVID-19 Infection</title>
    <acronym>Anosmie-COVID</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">olfactory and gustatory tests</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>SARS-CoV-2 infection status</outcome_measure>
      <outcome_measure>Olfactory and gustatory loss</outcome_measure>
      <outcome_measure>Ability to detect odor</outcome_measure>
      <outcome_measure>Ability to detect salty taste</outcome_measure>
      <outcome_measure>Ability to detect sweet taste</outcome_measure>
      <outcome_measure>Severity of infection according to hospitalization rate</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier Universitaire de Nīmes</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>454</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 27, 2020</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>November 2020</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>CHU de Nimes, Nîmes, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04354857</url>
  </study>
  <study rank="38">
    <nct_id>NCT04287686</nct_id>
    <title>Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Recombinant human angiotensin-converting enzyme 2 (rhACE2)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time course of body temperature (fever)</outcome_measure>
      <outcome_measure>Viral load over time</outcome_measure>
      <outcome_measure>P/F ratio over time</outcome_measure>
      <outcome_measure>Sequential organ failure assessment score(SOFA score) over time</outcome_measure>
      <outcome_measure>Pulmonary Severity Index (PSI)</outcome_measure>
      <outcome_measure>Image examination of chest over time</outcome_measure>
      <outcome_measure>Proportion of subjects who progressed to critical illness or death</outcome_measure>
      <outcome_measure>Time from first dose to conversion to normal or mild pneumonia</outcome_measure>
      <outcome_measure>T-lymphocyte counts over time</outcome_measure>
      <outcome_measure>C-reactive protein levels over time</outcome_measure>
      <outcome_measure>Angiotensin II (Ang II) changes over time</outcome_measure>
      <outcome_measure>Angiotensin 1-7 (Ang 1-7) changes over time</outcome_measure>
      <outcome_measure>Angiotensin 1-5 (Ang 1-5) changes over time</outcome_measure>
      <outcome_measure>Renin changes over time</outcome_measure>
      <outcome_measure>Aldosterone changes over time</outcome_measure>
      <outcome_measure>Angiotensin-converting enzyme (ACE) changes over time</outcome_measure>
      <outcome_measure>Angiotensin-converting enzyme 2 (ACE2) changes over time</outcome_measure>
      <outcome_measure>Interleukin 6 (IL-6) changes over time</outcome_measure>
      <outcome_measure>Interleukin 8 (IL-8) changes over time</outcome_measure>
      <outcome_measure>Soluble tumor necrosis factor receptor type II (sTNFrII) changes over time</outcome_measure>
      <outcome_measure>Plasminogen activator inhibitor type-1 (PAI-1) changes over time</outcome_measure>
      <outcome_measure>Von willebrand factor (vWF) changes over time</outcome_measure>
      <outcome_measure>Tumor necrosis factor-α (TNF-α) changes over time</outcome_measure>
      <outcome_measure>Soluble receptor for advanced glycation end products (sRAGE) changes over time</outcome_measure>
      <outcome_measure>Surfactant protein-D (SP-D) changes over time</outcome_measure>
      <outcome_measure>Angiopoietin-2 changes over time</outcome_measure>
      <outcome_measure>Frequency of adverse events and severe adverse events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>The First Affiliated Hospital of Guangzhou Medical University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>February 2020</start_date>
    <primary_completion_date>April 2020</primary_completion_date>
    <completion_date>April 2020</completion_date>
    <study_first_posted>February 27, 2020</study_first_posted>
    <last_update_posted>March 17, 2020</last_update_posted>
    <locations>
      <location>GCP Office of The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04287686</url>
  </study>
  <study rank="39">
    <nct_id>NCT04362813</nct_id>
    <title>Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia</title>
    <acronym>CAN-COVID</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Canakinumab</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of patients with clinical response</outcome_measure>
      <outcome_measure>COVID-19-related death rate during the 4-week period after study treatment</outcome_measure>
      <outcome_measure>Ratio to baseline in the C-reactive protein (CRP)</outcome_measure>
      <outcome_measure>Ratio to baseline in the serum ferritin</outcome_measure>
      <outcome_measure>Ratio to baseline in the D-dimer</outcome_measure>
      <outcome_measure>Number of participants with Adverse Event (AE), serious adverse events (SAE), clinically significant changes in laboratory measures, and vital signs</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>450</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 30, 2020</start_date>
    <primary_completion_date>October 5, 2020</primary_completion_date>
    <completion_date>October 5, 2020</completion_date>
    <study_first_posted>April 27, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04362813</url>
  </study>
  <study rank="40">
    <nct_id>NCT04354389</nct_id>
    <title>DAS181 for STOP COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DAS181</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>COVID-19 Clinical Status Scale (CCSS)</outcome_measure>
      <outcome_measure>Clinical Status Scale</outcome_measure>
      <outcome_measure>Return To Room Air (RTRA)</outcome_measure>
      <outcome_measure>Death (all cause)</outcome_measure>
      <outcome_measure>SARS-CoV-2 RNA undetectable</outcome_measure>
      <outcome_measure>Percent of subjects discharged</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ansun Biopharma, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>82</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 25, 2020</start_date>
    <primary_completion_date>June 30, 2020</primary_completion_date>
    <completion_date>July 31, 2020</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milano, Italy</location>
      <location>A.O.U Policlinico Di Modena, Modena, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04354389</url>
  </study>
  <study rank="41">
    <nct_id>NCT04361916</nct_id>
    <title>Home Care for Patients With COVID-19: Active Monitoring in Two Italian Health Units (Casale Monferrato and Torino)</title>
    <acronym>Mon-Covid</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">home care monitoring</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>SpO2</outcome_measure>
      <outcome_measure>in-hospital mortality</outcome_measure>
      <outcome_measure>need of intubation</outcome_measure>
      <outcome_measure>feasibility of active monitoring</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Mario Negri Institute for Pharmacological Research</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>425</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Health Services Research</study_design>
    </study_designs>
    <start_date>April 21, 2020</start_date>
    <primary_completion_date>October 31, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Asl Alessandria, Casale Monferrato, Alessandria, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04361916</url>
  </study>
  <study rank="42">
    <nct_id>NCT04355338</nct_id>
    <title>Assessment of Incidence of SARS-CoV-2 Infection and COVID-19 in Brazil (AVISA)</title>
    <acronym>AVISA</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Incidence of SARS-CoV-2 infection</outcome_measure>
      <outcome_measure>Incidence of COVID-19</outcome_measure>
      <outcome_measure>Incidence of hospitalization due to COVID-19</outcome_measure>
      <outcome_measure>Level of neutralizing antibodies</outcome_measure>
      <outcome_measure>Previous SARS-CoV-2 infection</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Butantan Institute</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>4100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>May 15, 2020</start_date>
    <primary_completion_date>November 30, 2020</primary_completion_date>
    <completion_date>May 15, 2022</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04355338</url>
  </study>
  <study rank="43">
    <nct_id>NCT04344145</nct_id>
    <title>Exhaustion and Needs in Frontline COVID-19 Healthcare Workers: Cross-sectional Study in a Belgian Population</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Burnout</outcome_measure>
      <outcome_measure>Emotional Distress</outcome_measure>
      <outcome_measure>Insomnia</outcome_measure>
      <outcome_measure>Needs and difficulties in work situations</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Université Libre de Bruxelles</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <start_date>April 16, 2020</start_date>
    <primary_completion_date>June 15, 2020</primary_completion_date>
    <completion_date>July 15, 2020</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations>
      <location>Erasme Hospital CUB, Brussels, Belgium</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04344145</url>
  </study>
  <study rank="44">
    <nct_id>NCT04324996</nct_id>
    <title>A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clinical response</outcome_measure>
      <outcome_measure>Side effects in the treatment group</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Chongqing Public Health Medical Center</lead_sponsor>
      <collaborator>Chongqing Sidemu Biotechnology Technology Co.,Ltd.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 21, 2020</start_date>
    <primary_completion_date>May 31, 2020</primary_completion_date>
    <completion_date>September 30, 2020</completion_date>
    <study_first_posted>March 27, 2020</study_first_posted>
    <last_update_posted>March 27, 2020</last_update_posted>
    <locations>
      <location>Chongqing Public Health Medical Center, Chongqing, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04324996</url>
  </study>
  <study rank="45">
    <nct_id>NCT04362137</nct_id>
    <title>Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)</title>
    <acronym>RUXCOVID</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ruxolitinib</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Proportion of patients who die, develop respiratory failure [require mechanical ventilation] or require intensive care unit (ICU) care</outcome_measure>
      <outcome_measure>Clinical status</outcome_measure>
      <outcome_measure>Percentage of patients with at least two-point improvement from baseline in clinical status</outcome_measure>
      <outcome_measure>Percentage of patients with at least one-point improvement from baseline in clinical status</outcome_measure>
      <outcome_measure>Percentage of patients with at least one-point deterioration from baseline in clinical status</outcome_measure>
      <outcome_measure>Time to improvement in clinical status</outcome_measure>
      <outcome_measure>Mean change from baseline in the clinical status</outcome_measure>
      <outcome_measure>Mortality rate</outcome_measure>
      <outcome_measure>Proportion of patients requiring mechanical ventilation</outcome_measure>
      <outcome_measure>Duration of hospitalization</outcome_measure>
      <outcome_measure>Time to discharge or to a NEWS2 score of ≤2</outcome_measure>
      <outcome_measure>Change from baseline in NEWS2 score</outcome_measure>
      <outcome_measure>Change from baseline in SpO2/FiO2 ratio.</outcome_measure>
      <outcome_measure>Proportion of patients with no oxygen therapy</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Incyte Corporation</collaborator>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>12 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>402</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 30, 2020</start_date>
    <primary_completion_date>June 29, 2020</primary_completion_date>
    <completion_date>June 29, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04362137</url>
  </study>
  <study rank="46">
    <nct_id>NCT04348071</nct_id>
    <title>Safety and Efficacy of Ruxolitinib for COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ruxolitinib</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Phase 2: Cumulative incidence of Grade 3 and 4 adverse events (AEs)</outcome_measure>
      <outcome_measure>Phase 2: Cumulative incidence of serious adverse events (SAEs)</outcome_measure>
      <outcome_measure>Phase 2: Changes in white blood cell count (CBC) through Day 15</outcome_measure>
      <outcome_measure>Phase 2: Changes in hemoglobin through Day 15</outcome_measure>
      <outcome_measure>Phase 2: Changes in platelets through Day 15</outcome_measure>
      <outcome_measure>Phase 2: Changes in creatinine through Day 15</outcome_measure>
      <outcome_measure>Phase 2: Changes in glucose through Day 15</outcome_measure>
      <outcome_measure>Phase 2: Changes in prothrombin time (PT) through Day 15</outcome_measure>
      <outcome_measure>Phase 2: Changes in total bilirubin through Day 15</outcome_measure>
      <outcome_measure>Phase 2: Changes in ALT through Day 15</outcome_measure>
      <outcome_measure>Phase 2: Changes in AST through Day 15</outcome_measure>
      <outcome_measure>Phase 2: Changes in white blood cell count (CBC) through End of Study (EOS)</outcome_measure>
      <outcome_measure>Phase 2: Changes in hemoglobin through End of Study (EOS)</outcome_measure>
      <outcome_measure>Phase 2: Changes in platelets through End of Study (EOS)</outcome_measure>
      <outcome_measure>Phase 2: Changes in creatinine through End of Study (EOS)</outcome_measure>
      <outcome_measure>Phase 2: Changes in glucose through End of Study (EOS)</outcome_measure>
      <outcome_measure>Phase 2: Changes in prothrombin time (PT) though End of Study (EOS)</outcome_measure>
      <outcome_measure>Phase 2: Changes in total bilirubin through End of Study (EOS)</outcome_measure>
      <outcome_measure>Phase 2: Changes in ALT through End of Study (EOS)</outcome_measure>
      <outcome_measure>Phase 2: Changes in AST through End of Study (EOS)</outcome_measure>
      <outcome_measure>Phase 3: Percentage of patients reporting each severity on an 8-point ordinal scale at Day 15</outcome_measure>
      <outcome_measure>Phase 2: Change in the 8-point ordinal scale</outcome_measure>
      <outcome_measure>Phase 2: Change in National Early Warning Score (NEWS)</outcome_measure>
      <outcome_measure>Phase 3: Change in the 8-point ordinal scale</outcome_measure>
      <outcome_measure>Phase 3: Change in National Early Warning Score (NEWS)</outcome_measure>
      <outcome_measure>Phase 3: Time to an improvement of one category using the 8-point ordinal scale</outcome_measure>
      <outcome_measure>Phase 3: Time to an improvement of two categories using the 8-point ordinal scale</outcome_measure>
      <outcome_measure>Phase 3: Time to discharge or to a NEWS ≤2 and maintained for 24 hours, whichever occurs first</outcome_measure>
      <outcome_measure>Phase 3: Cumulative incidence of Grade 3 and 4 adverse events (AEs)</outcome_measure>
      <outcome_measure>Phase 3: Cumulative incidence of serious adverse events (SAEs)</outcome_measure>
      <outcome_measure>Phase 3: Duration of hospitalization</outcome_measure>
      <outcome_measure>Phase 3: Duration of new oxygen use</outcome_measure>
      <outcome_measure>Phase 3: Duration of new ventilator or ECMO use</outcome_measure>
      <outcome_measure>Phase 3: Incidence of discontinuation or temporary suspension of drug for any reason</outcome_measure>
      <outcome_measure>Phase 3: Incidence of new oxygen use</outcome_measure>
      <outcome_measure>Phase 3: Incidence of new ventilator use</outcome_measure>
      <outcome_measure>Phase 3: Number of oxygen free days</outcome_measure>
      <outcome_measure>Phase 3: Number of ventilator or ECMO free days</outcome_measure>
      <outcome_measure>Phase 3: 14 day mortality rate</outcome_measure>
      <outcome_measure>Phase 3: 28 day mortality rate</outcome_measure>
      <outcome_measure>Phase 3: Changes in white blood cell count (CBC) through Day 15</outcome_measure>
      <outcome_measure>Phase 3: Changes in hemoglobin through Day 15</outcome_measure>
      <outcome_measure>Phase 3: Changes in platelets through Day 15</outcome_measure>
      <outcome_measure>Phase 3: Changes in creatinine through Day 15</outcome_measure>
      <outcome_measure>Phase 3: Changes in glucose through Day 15</outcome_measure>
      <outcome_measure>Phase 3: Changes in prothrombin time (PT) through Day 15</outcome_measure>
      <outcome_measure>Phase 3: Changes in total bilirubin through Day 15</outcome_measure>
      <outcome_measure>Phase 3: Changes in ALT through Day 15</outcome_measure>
      <outcome_measure>Phase 3: Changes in AST through Day 15</outcome_measure>
      <outcome_measure>Phase 3: Changes in white blood cell count (CBC) through End of Study (EOS)</outcome_measure>
      <outcome_measure>Phase 3: Changes in hemoglobin through End of Study (EOS)</outcome_measure>
      <outcome_measure>Phase 3: Changes in platelets through End of Study (EOS)</outcome_measure>
      <outcome_measure>Phase 3: Changes in creatinine through End of Study (EOS)</outcome_measure>
      <outcome_measure>Phase 3: Changes in glucose through End of Study (EOS)</outcome_measure>
      <outcome_measure>Phase 3: Changes in prothrombin time (PT) though End of Study (EOS)</outcome_measure>
      <outcome_measure>Phase 3: Changes in total bilirubin through End of Study (EOS)</outcome_measure>
      <outcome_measure>Phase 3: Changes in ALT through End of Study (EOS)</outcome_measure>
      <outcome_measure>Phase 3: Changes in AST through End of Study (EOS)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Colorado, Denver</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>89 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>August 2020</primary_completion_date>
    <completion_date>October 2020</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04348071</url>
  </study>
  <study rank="47">
    <nct_id>NCT04340232</nct_id>
    <title>Safety and Efficacy of Baricitinib for COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Baricitinib</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Phase 2: Cumulative incidence of Grade 3 and 4 adverse events (AEs)</outcome_measure>
      <outcome_measure>Phase 2: Cumulative incidence of serious adverse events (SAEs)</outcome_measure>
      <outcome_measure>Phase 2: Changes in white blood cell count (CBC) through Day 15</outcome_measure>
      <outcome_measure>Phase 2: Changes in hemoglobin through Day 15</outcome_measure>
      <outcome_measure>Phase 2: Changes in platelets through Day 15</outcome_measure>
      <outcome_measure>Phase 2: Changes in creatinine through Day 15</outcome_measure>
      <outcome_measure>Phase 2: Changes in glucose through Day 15</outcome_measure>
      <outcome_measure>Phase 2: Changes in prothrombin time (PT) through Day 15</outcome_measure>
      <outcome_measure>Phase 2: Changes in total bilirubin through Day 15</outcome_measure>
      <outcome_measure>Phase 2: Changes in ALT through Day 15</outcome_measure>
      <outcome_measure>Phase 2: Changes in AST through Day 15</outcome_measure>
      <outcome_measure>Phase 2: Changes in white blood cell count (CBC) through End of Study (EOS)</outcome_measure>
      <outcome_measure>Phase 2: Changes in hemoglobin through End of Study (EOS)</outcome_measure>
      <outcome_measure>Phase 2: Changes in platelets through End of Study (EOS)</outcome_measure>
      <outcome_measure>Phase 2: Changes in creatinine through End of Study (EOS)</outcome_measure>
      <outcome_measure>Phase 2: Changes in glucose through End of Study (EOS)</outcome_measure>
      <outcome_measure>Phase 2: Changes in prothrombin time (PT) though End of Study (EOS)</outcome_measure>
      <outcome_measure>Phase 2: Changes in total bilirubin through End of Study (EOS)</outcome_measure>
      <outcome_measure>Phase 2: Changes in ALT through End of Study (EOS)</outcome_measure>
      <outcome_measure>Phase 2: Changes in AST through End of Study (EOS)</outcome_measure>
      <outcome_measure>Phase 3: Percentage of patients reporting each severity on an 8-point ordinal scale at Day 15</outcome_measure>
      <outcome_measure>Phase 2: Change in the 8-point ordinal scale</outcome_measure>
      <outcome_measure>Phase 2: Change in National Early Warning Score (NEWS)</outcome_measure>
      <outcome_measure>Phase 3: Change in the 8-point ordinal scale</outcome_measure>
      <outcome_measure>Phase 3: Change in National Early Warning Score (NEWS)</outcome_measure>
      <outcome_measure>Phase 3: Time to an improvement of one category using the 8-point ordinal scale</outcome_measure>
      <outcome_measure>Phase 3: Time to an improvement of two categories using the 8-point ordinal scale</outcome_measure>
      <outcome_measure>Phase 3: Time to discharge or to a NEWS ≤2 and maintained for 24 hours, whichever occurs first</outcome_measure>
      <outcome_measure>Phase 3: Cumulative incidence of Grade 3 and 4 adverse events (AEs)</outcome_measure>
      <outcome_measure>Phase 3: Cumulative incidence of serious adverse events (SAEs)</outcome_measure>
      <outcome_measure>Phase 3: Duration of hospitalization</outcome_measure>
      <outcome_measure>Phase 3: Duration of new oxygen use</outcome_measure>
      <outcome_measure>Phase 3: Duration of new ventilator or ECMO use</outcome_measure>
      <outcome_measure>Phase 3: Incidence of discontinuation or temporary suspension of drug for any reason</outcome_measure>
      <outcome_measure>Phase 3: Incidence of new oxygen use</outcome_measure>
      <outcome_measure>Phase 3: Incidence of new ventilator use</outcome_measure>
      <outcome_measure>Phase 3: Number of oxygen free days</outcome_measure>
      <outcome_measure>Phase 3: Number of ventilator or ECMO free days</outcome_measure>
      <outcome_measure>Phase 3: 14 day mortality rate</outcome_measure>
      <outcome_measure>Phase 3: 28 day mortality rate</outcome_measure>
      <outcome_measure>Phase 3: Changes in white blood cell count (CBC) through Day 15</outcome_measure>
      <outcome_measure>Phase 3: Changes in hemoglobin through Day 15</outcome_measure>
      <outcome_measure>Phase 3: Changes in platelets through Day 15</outcome_measure>
      <outcome_measure>Phase 3: Changes in creatinine through Day 15</outcome_measure>
      <outcome_measure>Phase 3: Changes in glucose through Day 15</outcome_measure>
      <outcome_measure>Phase 3: Changes in prothrombin time (PT) through Day 15</outcome_measure>
      <outcome_measure>Phase 3: Changes in total bilirubin through Day 15</outcome_measure>
      <outcome_measure>Phase 3: Changes in ALT through Day 15</outcome_measure>
      <outcome_measure>Phase 3: Changes in AST through Day 15</outcome_measure>
      <outcome_measure>Phase 3: Changes in white blood cell count (CBC) through End of Study (EOS)</outcome_measure>
      <outcome_measure>Phase 3: Changes in hemoglobin through End of Study (EOS)</outcome_measure>
      <outcome_measure>Phase 3: Changes in platelets through End of Study (EOS)</outcome_measure>
      <outcome_measure>Phase 3: Changes in creatinine through End of Study (EOS)</outcome_measure>
      <outcome_measure>Phase 3: Changes in glucose through End of Study (EOS)</outcome_measure>
      <outcome_measure>Phase 3: Changes in prothrombin time (PT) though End of Study (EOS)</outcome_measure>
      <outcome_measure>Phase 3: Changes in total bilirubin through End of Study (EOS)</outcome_measure>
      <outcome_measure>Phase 3: Changes in ALT through End of Study (EOS)</outcome_measure>
      <outcome_measure>Phase 3: Changes in AST through End of Study (EOS)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Colorado, Denver</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>89 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>August 2020</primary_completion_date>
    <completion_date>October 2020</completion_date>
    <study_first_posted>April 9, 2020</study_first_posted>
    <last_update_posted>April 9, 2020</last_update_posted>
    <locations>
      <location>University of Colorado, Denver, Aurora, Colorado, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04340232</url>
  </study>
  <study rank="48">
    <nct_id>NCT04359615</nct_id>
    <title>Favipiravir in Hospitalized COVID-19 Patients</title>
    <acronym>FIC</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Favipiravir</intervention>
      <intervention type="Drug">Hydroxychloroquine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to clinical improvement</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>oxygen saturation by pulse oximetry (SpO2) Improvement</outcome_measure>
      <outcome_measure>Incidence of new mechanical ventilation use</outcome_measure>
      <outcome_measure>Duration of hospitalization</outcome_measure>
      <outcome_measure>Cumulative incidence of serious adverse events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Shahid Beheshti University of Medical Sciences</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>May 3, 2020</primary_completion_date>
    <completion_date>May 5, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04359615</url>
  </study>
  <study rank="49">
    <nct_id>NCT04321993</nct_id>
    <title>Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients</title>
    <acronym/>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Lopinavir/ritonavir</intervention>
      <intervention type="Drug">Hydroxychloroquine sulfate</intervention>
      <intervention type="Drug">Baricitinib (janus kinase inhibitor)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clinical status of subject at day 15 (on a 7 point ordinal scale).</outcome_measure>
      <outcome_measure>Status on an ordinal scale assessed daily while hospitalized and on days 15 and 29 and 180.</outcome_measure>
      <outcome_measure>Length of time to clinical improvement</outcome_measure>
      <outcome_measure>Number of participants with normal pulmonary function and normal O2 saturation on days 11, 15 and 29</outcome_measure>
      <outcome_measure>Number of participants that developed Acute Respiratory Distress Syndrome (ARDS) after treatment</outcome_measure>
      <outcome_measure>Length of time to clinical progression</outcome_measure>
      <outcome_measure>Cause of death (if applicable)</outcome_measure>
      <outcome_measure>Sequential Organ Failure Assessment (SOFA) score, daily while hospitalized and on days 15 and 29. (Initial, highest, deltas and mean)</outcome_measure>
      <outcome_measure>Length of time to normalization of fever</outcome_measure>
      <outcome_measure>Length of time to normalization of oxygen saturation</outcome_measure>
      <outcome_measure>Duration of supplemental oxygen (if applicable)</outcome_measure>
      <outcome_measure>Duration of mechanical ventilation (if applicable)</outcome_measure>
      <outcome_measure>Duration of hospitalization</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Lisa Barrett</lead_sponsor>
      <collaborator>Nova Scotia Health Authority</collaborator>
      <collaborator>Dalhousie University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 17, 2020</start_date>
    <primary_completion_date>February 2021</primary_completion_date>
    <completion_date>July 2021</completion_date>
    <study_first_posted>March 26, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Nova Scotia Health Authority, Halifax, Nova Scotia, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04321993</url>
  </study>
  <study rank="50">
    <nct_id>NCT04359316</nct_id>
    <title>Azithromycin in Hospitalized COVID-19 Patients</title>
    <acronym>AIC</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Drug">Azithromycin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to clinical improvement</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>SpO2 Improvement</outcome_measure>
      <outcome_measure>Incidence of new mechanical ventilation use</outcome_measure>
      <outcome_measure>Duration of hospitalization</outcome_measure>
      <outcome_measure>Cumulative incidence of serious adverse events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Shahid Beheshti University of Medical Sciences</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>May 3, 2020</primary_completion_date>
    <completion_date>May 5, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04359316</url>
  </study>
  <study rank="51">
    <nct_id>NCT04364828</nct_id>
    <title>NGS Diagnostic in COVID-19 Hosts - Genetic Cause Relating to the Course of Disease Progression</title>
    <acronym>COVID-19 NGS</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Genetic">Whole Genome Analysis</intervention>
      <intervention type="Genetic">T-cell receptor (TCR) repertoire</intervention>
      <intervention type="Genetic">SARS-CoV-2 viral composition</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Viral evolution</outcome_measure>
      <outcome_measure>Immune response</outcome_measure>
      <outcome_measure>Disease severity</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital Tuebingen</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>April 2021</primary_completion_date>
    <completion_date>August 2021</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04364828</url>
  </study>
  <study rank="52">
    <nct_id>NCT04358536</nct_id>
    <title>Classification of COVID-19 Infection in Posteroanterior Chest X-rays</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Device">CovX</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Identification of COVID-19</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Dascena</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>230</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>April 17, 2020</primary_completion_date>
    <completion_date>April 17, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Dascena, Oakland, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04358536</url>
  </study>
  <study rank="53">
    <nct_id>NCT04358835</nct_id>
    <title>Keto-diet for Intubated Critical Care COVID-19</title>
    <acronym>KICC-COVID19</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Ketogenic diet</intervention>
      <intervention type="Other">standard of care</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in the partial pressure of carbon dioxide (PaCO2)</outcome_measure>
      <outcome_measure>Change in minute ventilation</outcome_measure>
      <outcome_measure>Change in respiratory system compliance</outcome_measure>
      <outcome_measure>Change in driving pressure</outcome_measure>
      <outcome_measure>Change in ventilator synchrony</outcome_measure>
      <outcome_measure>Change in mean arterial pressure</outcome_measure>
      <outcome_measure>Change in the fraction of inspired oxygen percentage of oxygen (FiO2)</outcome_measure>
      <outcome_measure>Change in the partial pressure of carbon dioxide (PaO2) to the fraction of inspired oxygen percentage of oxygen (FiO2) ratio</outcome_measure>
      <outcome_measure>Change in hydrogen ion activity (pH)</outcome_measure>
      <outcome_measure>Change in Bicarbonate (HCO3)</outcome_measure>
      <outcome_measure>Change in red blood cell count</outcome_measure>
      <outcome_measure>Change in white blood cell count</outcome_measure>
      <outcome_measure>Change in white cell differential</outcome_measure>
      <outcome_measure>Change in hemoglobin levels</outcome_measure>
      <outcome_measure>Change in hematocrit</outcome_measure>
      <outcome_measure>Change in mean cell volume</outcome_measure>
      <outcome_measure>Change in mean cell hemoglobin</outcome_measure>
      <outcome_measure>Change in mean cell hemoglobin concentration</outcome_measure>
      <outcome_measure>Change in platelet count</outcome_measure>
      <outcome_measure>Change in red cell distribution width</outcome_measure>
      <outcome_measure>Change in blood albumin level</outcome_measure>
      <outcome_measure>Change in serum alkaline phosphatase level</outcome_measure>
      <outcome_measure>Change in serum aspartate transaminase level</outcome_measure>
      <outcome_measure>Change in serum alanine aminotransferase level</outcome_measure>
      <outcome_measure>Change in blood urea nitrogen levels</outcome_measure>
      <outcome_measure>Change in serum calcium level</outcome_measure>
      <outcome_measure>Change in serum chloride level</outcome_measure>
      <outcome_measure>Change in serum potassium level</outcome_measure>
      <outcome_measure>Change in serum creatinine level</outcome_measure>
      <outcome_measure>Date patient is re-intubated or need mechanical ventilation for a second time</outcome_measure>
      <outcome_measure>Length of intensive care unit stay</outcome_measure>
      <outcome_measure>The total hospital stay</outcome_measure>
      <outcome_measure>Disposition at discharge</outcome_measure>
      <outcome_measure>Change in heart rate</outcome_measure>
      <outcome_measure>Change in the dosage of vasopressor medication</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Johns Hopkins University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>August 1, 2020</primary_completion_date>
    <completion_date>August 1, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04358835</url>
  </study>
  <study rank="54">
    <nct_id>NCT04317092</nct_id>
    <title>Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)</title>
    <acronym>TOCIVID-19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19 Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tocilizumab Injection</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>One-month mortality rate</outcome_measure>
      <outcome_measure>Interleukin-6 level</outcome_measure>
      <outcome_measure>Lymphocyte count</outcome_measure>
      <outcome_measure>CRP (C-reactive protein) level</outcome_measure>
      <outcome_measure>PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)</outcome_measure>
      <outcome_measure>Change of the SOFA (Sequential Organ Failure Assessment)</outcome_measure>
      <outcome_measure>Number of participants with treatment-related side effects as assessed by Common Terminology Criteria for Adverse Event (CTCAE) version 5.0</outcome_measure>
      <outcome_measure>Radiological response</outcome_measure>
      <outcome_measure>Duration of hospitalization</outcome_measure>
      <outcome_measure>Remission of respiratory symptoms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Cancer Institute, Naples</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 19, 2020</start_date>
    <primary_completion_date>December 19, 2020</primary_completion_date>
    <completion_date>December 19, 2022</completion_date>
    <study_first_posted>March 20, 2020</study_first_posted>
    <last_update_posted>April 7, 2020</last_update_posted>
    <locations>
      <location>Azienda Ospedaliera &quot;SS. Antonio e Biagio e C. Arrigo&quot; (Dipartimento Internistico SSD Reumatologia), Alessandria, Italy</location>
      <location>Ospedale di Busto Arsizio ASST Valle Olona (U.O.C. Malattie Infettive), Busto Arsizio, Italy</location>
      <location>A.O.U. Policlinico V. Emanuele (U.O. di Malattie infettive, U.O. di Anestesia e Rianimazione, U.O. di Medicina d'Urgenza), Catania, Italy</location>
      <location>AOE Cannizzaro di Catania (U.O. di Malattie Infettive, U.O. di Anestesia e Rianimazione, U.O., Catania, Italy</location>
      <location>Ospedale Annunziata Azienda Ospedaliera di Cosenza (U.O.C. Malattie Infettive), Cosenza, Italy</location>
      <location>ASST OVEST MILANESE presidi Legnano - Magenta, Magenta, Italy</location>
      <location>Azienda Ospedaliero-Universitaria di Modena, Modena, Italy</location>
      <location>A.O.U. di Modena (Dipartimento Chirurgie Generali e Specialità Chirurgiche - Struttura Complessa di Anestesia e Rianimazione I), Modena, Italy</location>
      <location>A.O.U. di Modena (Dipartimento Chirurgie Generali e Specialità Chirurgiche - Struttura Complessa di Anestesia e Rianimazione II), Modena, Italy</location>
      <location>A.O.U. di Modena (Dipartimento Medicine Specialistiche - Struttura Complessa Malattie Infettive), Modena, Italy</location>
      <location>Dipartimento Medicine Specialistiche - Struttura Complessa Malattie dell'Apparato Respiratorio, Modena, Italy</location>
      <location>A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Oncologia), Naples, Italy</location>
      <location>National Cancer Institute, Naples, Italy</location>
      <location>A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Anestesia Rianimazione e terapia intensiva), Naples, Italy</location>
      <location>A.O.R.N. Ospedale dei Colli Monaldi-Cotugno-CTO (U.O.C. Malattie Infettive ad indirizzo respiratorio), Naples, Italy</location>
      <location>A.O. Ospedali Riuniti Marche Nord - Presidio Ospedaliero San Salvatore di Pesaro (UOC Pronto Soccorso e Medicina d'Urgenza), Pesaro, Italy</location>
      <location>Denominazione: UOC di Medicina e Chirurgia d'Accettazione e d'Urgenza dell'Ospedale Santa Maria delle Grazie di Pozzuoli, Pozzuoli, Italy</location>
      <location>Ospedale Santa Maria delle Croci, AUSL della Romagna (U.O. Anestesia e Rianimazione), Ravenna, Italy</location>
      <location>Grande Ospedale Metropolitano, Reggio Calabria, Reggio Calabria, Italy</location>
      <location>Ospedale Infermi, AUSL della Romagna (U.O. Malattie Infettive), Rimini, Italy</location>
      <location>Policlinico Gemelli (U.O.C. Dipartimento Scienze di Laboratorio e Infettivologiche), Rome, Italy</location>
      <location>ASST Sette Laghi (Dipartimento di Medicina Interna), Varese, Italy</location>
      <location>ASST Sette Laghi (Dipartimento Emergenze ed Urgenze), Varese, Italy</location>
      <location>ASST Sette Laghi (U.O.C. Anestesia e Rianimazione Neurochirurgica e Generale), Varese, Italy</location>
      <location>ASST Sette Laghi (U.O.C. Malattie Infettive e Tropicali), Varese, Italy</location>
      <location>A.O.U. Integrata di Verona (Dip. Malattie Infettive), Verona, Italy</location>
      <location>Ospedale Magalini (U.O. Malattie Infettive), Villafranca Di Verona, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04317092</url>
  </study>
  <study rank="55">
    <nct_id>NCT04355793</nct_id>
    <title>Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection</title>
    <acronym/>
    <status open="Y">Available</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ruxolitinib</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Incyte Corporation</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>12 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Expanded Access</study_types>
    <exp_acc_types>
      <exp_acc_type>Treatment IND/Protocol</exp_acc_type>
    </exp_acc_types>
    <study_designs/>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04355793</url>
  </study>
  <study rank="56">
    <nct_id>NCT04343768</nct_id>
    <title>An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial</title>
    <acronym>DIC</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Drug">Lopinavir / Ritonavir</intervention>
      <intervention type="Drug">Interferon Beta-1A</intervention>
      <intervention type="Drug">Interferon Beta-1B</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to clinical improvement</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>SpO2 Improvement</outcome_measure>
      <outcome_measure>Incidence of new mechanical ventilation use</outcome_measure>
      <outcome_measure>Duration of hospitalization</outcome_measure>
      <outcome_measure>Cumulative incidence of serious adverse events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Shahid Beheshti University of Medical Sciences</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 5, 2020</start_date>
    <primary_completion_date>April 19, 2020</primary_completion_date>
    <completion_date>April 19, 2020</completion_date>
    <study_first_posted>April 13, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04343768</url>
  </study>
  <study rank="57">
    <nct_id>NCT04364815</nct_id>
    <title>The University of the Philippines Hydroxychloroquine PEP Against COVID-19 Trial</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine plus standard preventive measures</intervention>
      <intervention type="Drug">Placebo plus standard preventive measures</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Efficacy of HCQ Prophylaxis in Preventing COVID-19 infection</outcome_measure>
      <outcome_measure>Efficacy of study drug as post-exposure prophylaxis in preventing COVID-19 related symptoms (to be reported as absolute number and frequency of events)</outcome_measure>
      <outcome_measure>Time to COVID-19 infection in patients receiving study drug (in days)</outcome_measure>
      <outcome_measure>Safety and tolerability of study drug (to be reported as absolute number and frequency of events)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of the Philippines</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>59 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>960</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>May 2021</primary_completion_date>
    <completion_date>May 2021</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04364815</url>
  </study>
  <study rank="58">
    <nct_id>NCT04329832</nct_id>
    <title>Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19</title>
    <acronym>HAHPS</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Drug">Azithromycin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>COVID Ordinal Outcomes Scale at 14 days</outcome_measure>
      <outcome_measure>Hospital-free days at 28 days (number of days patient not in hospital)</outcome_measure>
      <outcome_measure>Ventilator-free days at 28 days (number of days patient not on a ventilator)</outcome_measure>
      <outcome_measure>ICU-free days at 28 days (number of days patient not in an ICU)</outcome_measure>
      <outcome_measure>Time to a 1-point decrease in the WHO ordinal recovery score</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Intermountain Health Care, Inc.</lead_sponsor>
      <collaborator>University of Utah</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 30, 2020</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>December 31, 2021</completion_date>
    <study_first_posted>April 1, 2020</study_first_posted>
    <last_update_posted>April 9, 2020</last_update_posted>
    <locations>
      <location>Intermountain Medical Center, Murray, Utah, United States</location>
      <location>University of Utah, Salt Lake City, Utah, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04329832</url>
  </study>
  <study rank="59">
    <nct_id>NCT04252118</nct_id>
    <title>Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">MSCs</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Size of lesion area by chest radiograph or CT</outcome_measure>
      <outcome_measure>Side effects in the MSCs treatment group</outcome_measure>
      <outcome_measure>Improvement of Clinical symptoms including duration of fever and respiratory</outcome_measure>
      <outcome_measure>Time of nucleic acid turning negative</outcome_measure>
      <outcome_measure>Rate of mortality within 28-days</outcome_measure>
      <outcome_measure>CD4+ and CD8+ T celll count</outcome_measure>
      <outcome_measure>Alanine aminotransferase</outcome_measure>
      <outcome_measure>C-reactive protein</outcome_measure>
      <outcome_measure>Creatine kinase</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Beijing 302 Hospital</lead_sponsor>
      <collaborator>Innovative Precision Medicine Group (IPM), Hangzhou, China.</collaborator>
      <collaborator>Huoshenshan Hospital</collaborator>
      <collaborator>Tianjin Haihe Hospital</collaborator>
      <collaborator>VCANBIO CELL &amp; GENE ENGINEERING CORP.,LTD, China</collaborator>
      <collaborator>Shenzhen Third People's Hospital</collaborator>
      <collaborator>Fifth Affiliated Hospital, Sun Yat-Sen University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>January 27, 2020</start_date>
    <primary_completion_date>December 2020</primary_completion_date>
    <completion_date>December 2021</completion_date>
    <study_first_posted>February 5, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>Beijing 302 Military Hospital of China, Beijing, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04252118</url>
  </study>
  <study rank="60">
    <nct_id>NCT04348396</nct_id>
    <title>Clinical and Biological Predictors of COVID-19 Disease in Older Patients</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Descriptive-epidemiological analysis of health conditions</outcome_measure>
      <outcome_measure>Evaluation of frailty condition</outcome_measure>
      <outcome_measure>Identification of biomarkers of inflammation</outcome_measure>
      <outcome_measure>Assessment of functional capacity</outcome_measure>
      <outcome_measure>Evaluation of drug consumption</outcome_measure>
      <outcome_measure>Evaluation of inflamma-miRs</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Istituto Nazionale di Ricovero e Cura per Anziani</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>65 Years</min_age>
    <age_groups>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>December 2020</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>April 16, 2020</study_first_posted>
    <last_update_posted>April 16, 2020</last_update_posted>
    <locations>
      <location>IRCCS INRCA Hospital, Ancona, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04348396</url>
  </study>
  <study rank="61">
    <nct_id>NCT04362865</nct_id>
    <title>Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Characterize immune response</outcome_measure>
      <outcome_measure>B- and T-cell arm immune response</outcome_measure>
      <outcome_measure>Immune response and outcome</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Cancer Institute (NCI)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>May 1, 2020</start_date>
    <primary_completion_date>December 1, 2023</primary_completion_date>
    <completion_date>December 1, 2024</completion_date>
    <study_first_posted>April 27, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>National Institutes of Health Clinical Center, Bethesda, Maryland, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04362865</url>
  </study>
  <study rank="62">
    <nct_id>NCT04346199</nct_id>
    <title>Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. CALAVI (Calquence Against the Virus)</title>
    <acronym>ACE-ID-201</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Acalabrutinib</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Treatment failure rate</outcome_measure>
      <outcome_measure>Number of days alive free of assisted ventilation</outcome_measure>
      <outcome_measure>Number of days with assisted ventilator use</outcome_measure>
      <outcome_measure>Number of days hospitalized</outcome_measure>
      <outcome_measure>Number of days in ICU</outcome_measure>
      <outcome_measure>Number of days alive outside of hospital</outcome_measure>
      <outcome_measure>Occurrence of Adverse Events and Serious Adverse Events</outcome_measure>
      <outcome_measure>Pharmacokinetics of acalabrutinib and its active metabolite ACP-5862 (Cmax)</outcome_measure>
      <outcome_measure>Pharmacokinetics of acalabrutinib and its active metabolite ACP-5862 (Tmax)</outcome_measure>
      <outcome_measure>Pharmacokinetics of acalabrutinib and its active metabolite ACP-5862 (AUC)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>AstraZeneca</lead_sponsor>
      <collaborator>Acerta Pharma B.V.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>130 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>428</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 24, 2020</start_date>
    <primary_completion_date>September 1, 2020</primary_completion_date>
    <completion_date>September 1, 2020</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations>
      <location>Research Site, Barcelona, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04346199</url>
  </study>
  <study rank="63">
    <nct_id>NCT04331171</nct_id>
    <title>Epidemiological Observation From a Smartphone Self-monitoring Application for Suspected COVID-19 Patients' Triage</title>
    <acronym>COVID CALL 15</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Web application users</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>To assess of the evolution of the number of calls to Emergency service within 12 days after the launch of the application https://www.maladiecoronavirus.fr/</outcome_measure>
      <outcome_measure>To assess of the evolution of the proportion of relevant calls to Emergency service within 12 days after the launch of the application https://www.maladiecoronavirus.fr/</outcome_measure>
      <outcome_measure>To assess the evolution over time of the COVID 19 epidemic</outcome_measure>
      <outcome_measure>To assess the evolution over space of the COVID 19 epidemic</outcome_measure>
      <outcome_measure>To assess symptoms</outcome_measure>
      <outcome_measure>To assess the users population</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Weprom</lead_sponsor>
      <collaborator>Institut Pasteur</collaborator>
      <collaborator>Assistance Publique - Hôpitaux de Paris</collaborator>
      <collaborator>DOCAPOST</collaborator>
      <collaborator>Direction Générale de l'Offre de Soins</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>3000000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 17, 2020</start_date>
    <primary_completion_date>March 31, 2020</primary_completion_date>
    <completion_date>July 31, 2020</completion_date>
    <study_first_posted>April 2, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations>
      <location>All French Emergency services, Le Mans, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04331171</url>
  </study>
  <study rank="64">
    <nct_id>NCT04364022</nct_id>
    <title>Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland</title>
    <acronym>COPEP</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Prevention of COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine Sulfate 200 MG [Plaquenil]</intervention>
      <intervention type="Drug">Lopinavir/ritonavir</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>21-day incidence of COVID-19 in individuals exposed to SARS-CoV- 2 who are asymptomatic at baseline (intent-to-treat (ITT) analysis).</outcome_measure>
      <outcome_measure>21-day incidence of COVID-19 in individuals exposed to SARS-CoV- 2 who are asymptomatic, PCR-confirmed SARS-CoV-2 negative and have negative SARS-CoV-2 serology at baseline (modified ITT)</outcome_measure>
      <outcome_measure>21-day incidence of SARS-CoV-2 infection in individuals exposed to SARS-CoV-2 who are asymptomatic, PCR-confirmed SARS-CoV-2 negative and have negative SARS-CoV-2 serology at baseline (modified ITT)</outcome_measure>
      <outcome_measure>Severity of clinical COVID-19 on a 7-point ordinal scale</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Calmy Alexandra</lead_sponsor>
      <collaborator>University Hospital, Geneva</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>420</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>October 2020</primary_completion_date>
    <completion_date>October 2020</completion_date>
    <study_first_posted>April 27, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>Universitätsspital Basel and SwissTPH, Basel, Switzerland</location>
      <location>Hôpitaux Universitaires de Genève, Geneva, Switzerland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04364022</url>
  </study>
  <study rank="65">
    <nct_id>NCT04354714</nct_id>
    <title>Ruxolitinib to Combat COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ruxolitinib</intervention>
      <intervention type="Procedure">Peripheral blood draw</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Overall survival</outcome_measure>
      <outcome_measure>Length of hospital stay</outcome_measure>
      <outcome_measure>Length of ICU stay</outcome_measure>
      <outcome_measure>Duration of ventilator use</outcome_measure>
      <outcome_measure>Duration of vasopressors use</outcome_measure>
      <outcome_measure>Duration on renal replacement therapy</outcome_measure>
      <outcome_measure>Viral kinetics as measured by virologic failure</outcome_measure>
      <outcome_measure>Number of adverse events as measured by CTCAE v. 5.0</outcome_measure>
      <outcome_measure>Proportion of participants with detectable virus</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Washington University School of Medicine</lead_sponsor>
      <collaborator>Incyte Corporation</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>June 30, 2020</start_date>
    <primary_completion_date>July 31, 2021</primary_completion_date>
    <completion_date>December 31, 2021</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Washington University School of Medicine, Saint Louis, Missouri, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04354714</url>
  </study>
  <study rank="66">
    <nct_id>NCT04365257</nct_id>
    <title>Prazosin to Prevent COVID-19 (PREVENT-COVID Trial)</title>
    <acronym>PREVENT</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Prazosin</intervention>
      <intervention type="Other">Standard of care</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Death</outcome_measure>
      <outcome_measure>Hospitalized, requiring mechanical ventilation and/or high flow nasal cannula and/or ICU/CCU admission (or equivalent) and/or ECMO</outcome_measure>
      <outcome_measure>Hospitalized, requiring supplemental oxygen, not requiring ICU/CCU level care (or interventions listed under Outcome 2)</outcome_measure>
      <outcome_measure>Cumulative incidence of grade 3 and 4 adverse events</outcome_measure>
      <outcome_measure>Number of participants with serious adverse events</outcome_measure>
      <outcome_measure>Incidence of symptomatic hypotension or hypotension requiring cessation of prazosin</outcome_measure>
      <outcome_measure>Number of participants with laboratory abnormalities in peripheral blood</outcome_measure>
      <outcome_measure>Duration of laboratory abnormalities in peripheral blood</outcome_measure>
      <outcome_measure>Number of participants with laboratory abnormalities in plasma</outcome_measure>
      <outcome_measure>Duration of laboratory abnormalities in plasma</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Johns Hopkins University</lead_sponsor>
      <collaborator>Fast Grants</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>45 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>220</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>December 2020</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Johns Hopkins Hospital, Baltimore, Maryland, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04365257</url>
  </study>
  <study rank="67">
    <nct_id>NCT04350671</nct_id>
    <title>Interferon Beta 1a in Hospitalized COVID-19 Patients</title>
    <acronym>IB1aIC</acronym>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Interferon Beta-1A</intervention>
      <intervention type="Drug">Lopinavir / Ritonavir</intervention>
      <intervention type="Drug">Single Dose of Hydroxychloroquine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to clinical improvement</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>SpO2 Improvement</outcome_measure>
      <outcome_measure>Incidence of new mechanical ventilation use</outcome_measure>
      <outcome_measure>Duration of hospitalization</outcome_measure>
      <outcome_measure>Cumulative incidence of serious adverse events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Shahid Beheshti University of Medical Sciences</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>April 20, 2020</primary_completion_date>
    <completion_date>April 24, 2020</completion_date>
    <study_first_posted>April 17, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations>
      <location>Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04350671</url>
  </study>
  <study rank="68">
    <nct_id>NCT04350684</nct_id>
    <title>Umifenovir in Hospitalized COVID-19 Patients</title>
    <acronym>UAIIC</acronym>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Umifenovir</intervention>
      <intervention type="Drug">Interferon-β 1a</intervention>
      <intervention type="Drug">Lopinavir / Ritonavir</intervention>
      <intervention type="Drug">Single Dose of Hydroxychloroquine</intervention>
      <intervention type="Drug">Standards of Care</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to clinical improvement</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>SpO2 Improvement</outcome_measure>
      <outcome_measure>Incidence of new mechanical ventilation use</outcome_measure>
      <outcome_measure>Duration of hospitalization</outcome_measure>
      <outcome_measure>Cumulative incidence of serious adverse events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Shahid Beheshti University of Medical Sciences</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>April 22, 2020</primary_completion_date>
    <completion_date>April 24, 2020</completion_date>
    <study_first_posted>April 17, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations>
      <location>Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04350684</url>
  </study>
  <study rank="69">
    <nct_id>NCT04330586</nct_id>
    <title>A Trial of Ciclesonide in Adults With Mild COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ciclesonide Metered Dose Inhaler [Alvesco]</intervention>
      <intervention type="Drug">Hydroxychloroquine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Rate of SARS-CoV-2 eradication at day 14 from study enrollment</outcome_measure>
      <outcome_measure>Rate of SARS-CoV-2 eradication at day 7 from study enrollment</outcome_measure>
      <outcome_measure>Time to SARS-CoV-2 eradication (days)</outcome_measure>
      <outcome_measure>Viral load area-under-the-curve (AUC) reduction versus control</outcome_measure>
      <outcome_measure>Time to clinical improvement (days)</outcome_measure>
      <outcome_measure>Proportion of clinical failure</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Korea University Guro Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>141</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>June 30, 2020</primary_completion_date>
    <completion_date>September 30, 2020</completion_date>
    <study_first_posted>April 1, 2020</study_first_posted>
    <last_update_posted>April 1, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04330586</url>
  </study>
  <study rank="70">
    <nct_id>NCT04348656</nct_id>
    <title>CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)</title>
    <acronym>CONCOR-1</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Convalescent plasma</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Intubation or death in hospital</outcome_measure>
      <outcome_measure>Need for Intubation</outcome_measure>
      <outcome_measure>Time to intubation</outcome_measure>
      <outcome_measure>Ventilator-free days</outcome_measure>
      <outcome_measure>In-hospital death</outcome_measure>
      <outcome_measure>Time to in-hospital death</outcome_measure>
      <outcome_measure>Death at 30 days</outcome_measure>
      <outcome_measure>Length of stay in intensive care unit (ICU)</outcome_measure>
      <outcome_measure>Length of stay in hospital</outcome_measure>
      <outcome_measure>Need for extracorpeal membrane oxygenation (ECMO)</outcome_measure>
      <outcome_measure>Need for renal replacement therapy</outcome_measure>
      <outcome_measure>Development of myocarditis</outcome_measure>
      <outcome_measure>Adverse events and serious adverse events</outcome_measure>
      <outcome_measure>Transfusion-associated adverse events (AE)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hamilton Health Sciences Corporation</lead_sponsor>
      <collaborator>Canadian Blood Services</collaborator>
      <collaborator>Héma-Québec</collaborator>
      <collaborator>University of Toronto</collaborator>
      <collaborator>Université de Montréal</collaborator>
      <collaborator>McMaster University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>16 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 27, 2020</start_date>
    <primary_completion_date>October 31, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>April 16, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>University of Alberta, Edmonton, Alberta, Canada</location>
      <location>Vancouver General Hospital, Vancouver, British Columbia, Canada</location>
      <location>Royal Jubilee Hospital, Victoria, British Columbia, Canada</location>
      <location>Victoria General Hospital, Victoria, British Columbia, Canada</location>
      <location>Health Sciences Centre, Winnipeg, Manitoba, Canada</location>
      <location>Hamilton General Hospital, Hamilton, Ontario, Canada</location>
      <location>St. Jospeh's Healthcare Hamtilon, Hamilton, Ontario, Canada</location>
      <location>Juravinski Hospital, Hamilton, Ontario, Canada</location>
      <location>London Health Sciences Centre - University Hospital, London, Ontario, Canada</location>
      <location>Ottawa Hospital - General Campus, Ottawa, Ontario, Canada</location>
      <location>Ottawa Hospital - Civic Campus, Ottawa, Ontario, Canada</location>
      <location>Thunder Bay Regional Health Sciences Centre - Cancer Centre, Thunder Bay, Ontario, Canada</location>
      <location>Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada</location>
      <location>Unity Health Toronto, Toronto, Ontario, Canada</location>
      <location>Sinai Health System, Toronto, Ontario, Canada</location>
      <location>Toronto General Hospital, Toronto, Ontario, Canada</location>
      <location>Toronto Western Hospital, Toronto, Ontario, Canada</location>
      <location>Hôpital de la Cité-de-la-Santé, Laval, Quebec, Canada</location>
      <location>Hôpital Maisonneuve-Rosemont, Montréal, Quebec, Canada</location>
      <location>Centre hospitalier de l'Université de Montréal, Montréal, Quebec, Canada</location>
      <location>Centre hospitalier universitaire Sainte-Justine, Montréal, Quebec, Canada</location>
      <location>Jewish General Hospital, Montréal, Quebec, Canada</location>
      <location>McGill University Health Centre, Montréal, Quebec, Canada</location>
      <location>Hôpital du Sacré-Coeur de Montreal, Montréal, Quebec, Canada</location>
      <location>Centre hospitalier universitaire de Québec, Quebec City, Quebec, Canada</location>
      <location>Centre hospitalier universitaire de Sherbrooke, Sherbrooke, Quebec, Canada</location>
      <location>Centre hospitalier affilié universitaire régional de Trois-Rivières, Trois-Rivières, Quebec, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04348656</url>
  </study>
  <study rank="71">
    <nct_id>NCT04362943</nct_id>
    <title>Clinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older Adults</title>
    <acronym>COVID-AGE</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Baricitinib or Anakinra</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>X-ray changes</outcome_measure>
      <outcome_measure>Disability changes</outcome_measure>
      <outcome_measure>Ambulation changes</outcome_measure>
      <outcome_measure>lymphocyte count changes</outcome_measure>
      <outcome_measure>C-Reactive Protein changes</outcome_measure>
      <outcome_measure>Ferritin changes</outcome_measure>
      <outcome_measure>D-Dimer changes</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Complejo Hospitalario Universitario de Albacete</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>70 Years</min_age>
    <age_groups>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>576</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>May 15, 2020</primary_completion_date>
    <completion_date>July 31, 2020</completion_date>
    <study_first_posted>April 27, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>Complejo Hospitalario Universitario de Albacete, Albacete, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04362943</url>
  </study>
  <study rank="72">
    <nct_id>NCT04344587</nct_id>
    <title>COVID-19 smArtphone-based Trial of Non-ICU Admission Prone Positioning</title>
    <acronym>CATNAP</acronym>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Self-prone position recommendation</intervention>
      <intervention type="Other">Usual care</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in respiratory status</outcome_measure>
      <outcome_measure>Length of time participant spends in the prone position</outcome_measure>
      <outcome_measure>Length of time participant spends in the supine position</outcome_measure>
      <outcome_measure>Length of time participant spends lying on side</outcome_measure>
      <outcome_measure>Length of time participant spends sitting up</outcome_measure>
      <outcome_measure>Length of time participant spends standing or walking</outcome_measure>
      <outcome_measure>Dyspnea or difficult/labored breathing</outcome_measure>
      <outcome_measure>Discomfort with proning</outcome_measure>
      <outcome_measure>Length of hospital stay</outcome_measure>
      <outcome_measure>Invasive mechanical ventilation</outcome_measure>
      <outcome_measure>Loss of IV access as a consequence of turning in bed</outcome_measure>
      <outcome_measure>Acute respiratory distress syndrome (ARDS) diagnosis</outcome_measure>
      <outcome_measure>Hospital mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Boston University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>380</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>July 2020</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Boston Medical Center, Boston, Massachusetts, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04344587</url>
  </study>
  <study rank="73">
    <nct_id>NCT04350073</nct_id>
    <title>Longitudinal Energy Expenditure and Metabolic Effects in Patients With COVID-19 (LEEP-COVID)</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Q-NRG Metobolic Cart Device</intervention>
      <intervention type="Device">MuscleSound Ultrasound</intervention>
      <intervention type="Device">Multifrequency Bioimpedance Spectroscopy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Metabolic and Nutritional Needs of COVID-19 Patients: Measured by Changes of Resting Energy expenditure(REE) over time, as measured by the indirect calorimetry Q-NRG device</outcome_measure>
      <outcome_measure>Metabolic and Nutritional Needs of COVID-19 Patients:Changes of the Respiratory Exchange Ratio (RER) as measured by the indirect calorimetry Q-NRG device</outcome_measure>
      <outcome_measure>Cardiac Output and Cardiac Measures (non-invasive) in COVID-19 patients</outcome_measure>
      <outcome_measure>Muscle Mass and Quality Changes from COVID-19: Measured via Changes of Intramuscular Adipose Tissue (IMAT) Content From CT Scans of the Psoas at the Level of L3/Th3</outcome_measure>
      <outcome_measure>Muscle Mass, Quality, Glycogen Changes in COVID-19: Via Metabolic/Muscle Imaging Derived From Muscle-Specific Ultrasound of Leg/Intercostal/Head Muscles</outcome_measure>
      <outcome_measure>Body Composition in COVID-19 Patients: Measured via Multifrequency Bioimpedance Spectroscopy</outcome_measure>
      <outcome_measure>Phase Angle in COVID-19 Patients: Measured via Multifrequency</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Duke University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>October 1, 2020</primary_completion_date>
    <completion_date>December 1, 2020</completion_date>
    <study_first_posted>April 16, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Duke University Medial Center, Durham, North Carolina, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04350073</url>
  </study>
  <study rank="74">
    <nct_id>NCT04361318</nct_id>
    <title>Hydroxychloroquine and Nitazoxanide Combination Therapy for COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Combination Product">Hydroxychloroquine plus Nitazoxanide</intervention>
      <intervention type="Other">Standard care</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of patients with COVID-19-negative PCR</outcome_measure>
      <outcome_measure>Number of patients with improved respiratory rate</outcome_measure>
      <outcome_measure>Number of patients with improved PaO2</outcome_measure>
      <outcome_measure>Number of patients with normalized Serum IL6</outcome_measure>
      <outcome_measure>Number of patients with normalized Serum TNFα</outcome_measure>
      <outcome_measure>Number of patients with normalized Serum iron</outcome_measure>
      <outcome_measure>Number of patients with normalized Serum ferritin</outcome_measure>
      <outcome_measure>Number of patients with normalized International normalized ratio &quot;INR&quot; for prothrombin time</outcome_measure>
      <outcome_measure>Number of patients with normalized complete blood count &quot;CBC&quot;</outcome_measure>
      <outcome_measure>The Mortality rate among treated patients</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tanta University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Care Provider)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 2020</start_date>
    <primary_completion_date>October 2020</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04361318</url>
  </study>
  <study rank="75">
    <nct_id>NCT04328285</nct_id>
    <title>Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers</title>
    <acronym>COVIDAXIS</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Drug">Placebo of Hydroxychloroquine</intervention>
      <intervention type="Drug">Lopinavir and ritonavir</intervention>
      <intervention type="Drug">Placebo of LPV/r Tablets</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Occurrence of an symptomatic or asymptomatic SARS-CoV-2 infection among healthcare workers (HCWs)</outcome_measure>
      <outcome_measure>Evaluation of the occurrence of adverse events in each arm,</outcome_measure>
      <outcome_measure>Evaluation of the discontinuation rates of the investigational drug in each arm,</outcome_measure>
      <outcome_measure>Evaluation of the adherence of participants to study drug,</outcome_measure>
      <outcome_measure>Evaluation of the incidence of symptomatic cases of SARS-CoV-2 infection in each arm,</outcome_measure>
      <outcome_measure>Evaluation of the incidence of asymptomatic cases of SARS-CoV-2 infection in each arm</outcome_measure>
      <outcome_measure>Evaluation of the incidence of severe cases of SARS-CoV-2 infection in each arm.</outcome_measure>
      <outcome_measure>corrected QT interval (ms)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier Universitaire de Saint Etienne</lead_sponsor>
      <collaborator>Institut Pasteur</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 14, 2020</start_date>
    <primary_completion_date>November 30, 2020</primary_completion_date>
    <completion_date>November 30, 2020</completion_date>
    <study_first_posted>March 31, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>CHU d'Angers, Angers, France</location>
      <location>CHU de Bordeaux, Bordeaux, France</location>
      <location>CHU de Clermont-Ferrand, Clermont-ferrand, France</location>
      <location>CHU de Nancy, Nancy, France</location>
      <location>CHU de Nantes, Nantes, France</location>
      <location>AP-HP - Hôpital Bichat, Paris, France</location>
      <location>CHU de Rennes, Rennes, France</location>
      <location>CHU de Rouen, Rouen, France</location>
      <location>CHU de Saint-Etienne, Saint-Étienne, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04328285</url>
  </study>
  <study rank="76">
    <nct_id>NCT04275947</nct_id>
    <title>The COVID-19 Mobile Health Study (CMHS)</title>
    <acronym>CMHS</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">nCapp, a cell phone-based auto-diagnosis system</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Accuracy of nCapp COVID-19 risk diagnostic model</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Chinese Alliance Against Lung Cancer</lead_sponsor>
      <collaborator>Shanghai Respiratory Research Institution</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>450</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>February 14, 2020</start_date>
    <primary_completion_date>April 30, 2020</primary_completion_date>
    <completion_date>May 31, 2020</completion_date>
    <study_first_posted>February 19, 2020</study_first_posted>
    <last_update_posted>February 19, 2020</last_update_posted>
    <locations>
      <location>Renmin Hospital of Wuhan University, Wuhan, Hubei, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04275947</url>
  </study>
  <study rank="77">
    <nct_id>NCT04361942</nct_id>
    <title>Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV)</title>
    <acronym>COVID_MSV</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19 Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Mesenchymal Stromal Cells</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Proportion of patients who have achieved withdrawal of invasive mechanical ventilation</outcome_measure>
      <outcome_measure>Rate of mortality</outcome_measure>
      <outcome_measure>Proportion of patients who have achieved clinical response</outcome_measure>
      <outcome_measure>Proportion of patients who have achieved radiological responses</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Red de Terapia Celular</lead_sponsor>
      <collaborator>Citospin</collaborator>
      <collaborator>University of Valladolid</collaborator>
      <collaborator>Castilla-León Health Service</collaborator>
      <collaborator>Hospital del Río Hortega</collaborator>
      <collaborator>Instituto de Salud Carlos III</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>November 30, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Hospital Universitario Rio Hortega, Valladolid, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04361942</url>
  </study>
  <study rank="78">
    <nct_id>NCT04315298</nct_id>
    <title>Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sarilumab</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Percent change in C-reactive protein (CRP) levels</outcome_measure>
      <outcome_measure>Time to improvement (2 points) in clinical status assessment using the 7-point ordinal scale in patients with serum IL-6 levels greater than the upper limit of normal</outcome_measure>
      <outcome_measure>Time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale in severe or critical patients with serum IL-6 levels greater than the upper limit of normal</outcome_measure>
      <outcome_measure>Time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale reporting in severe or critical patients with all IL-6 levels</outcome_measure>
      <outcome_measure>Time to resolution of fever for at least 48 hours without antipyretics in patients with documented fever</outcome_measure>
      <outcome_measure>Time to resolution of fever for at least 48 hours without antipyretics by clinical severity</outcome_measure>
      <outcome_measure>Time to resolution of fever for at least 48 hours without antipyretics by baseline IL-6 levels</outcome_measure>
      <outcome_measure>Time to improvement in oxygenation for at least 48 hours</outcome_measure>
      <outcome_measure>Time to improvement in oxygenation for at least 48 hours by clinical severity</outcome_measure>
      <outcome_measure>Time to improvement in oxygenation for at least 48 hours by baseline IL-6 levels</outcome_measure>
      <outcome_measure>Time to resolution of fever and improvement in oxygenation for at least 48 hours</outcome_measure>
      <outcome_measure>Mean change in the 7-point ordinal scale</outcome_measure>
      <outcome_measure>Percentage of patients in each clinical status category using the 7-point ordinal scale</outcome_measure>
      <outcome_measure>Time to discharge or to a National Early Warning Score 2 (NEWS2) of ≤2 and maintained for 24 hours</outcome_measure>
      <outcome_measure>Change from baseline in NEWS2 scoring system</outcome_measure>
      <outcome_measure>Number of days with fever</outcome_measure>
      <outcome_measure>Proportion of patients alive, off oxygen</outcome_measure>
      <outcome_measure>Number of days of resting respiratory rate &gt;24 breaths/min</outcome_measure>
      <outcome_measure>Number of days with hypoxemia</outcome_measure>
      <outcome_measure>Number of days of supplemental oxygen use</outcome_measure>
      <outcome_measure>Time to saturation ≥94% on room air</outcome_measure>
      <outcome_measure>Number of ventilator free days in the first 28 days</outcome_measure>
      <outcome_measure>Number of patients requiring initiation of mechanical ventilation</outcome_measure>
      <outcome_measure>Number of patients requiring non-invasive ventilation</outcome_measure>
      <outcome_measure>Number of patients requiring the use of high flow nasal cannula</outcome_measure>
      <outcome_measure>Number of patients admitted into an intensive care unit (ICU)</outcome_measure>
      <outcome_measure>Number of days of hospitalization among survivors</outcome_measure>
      <outcome_measure>Number of deaths due to any cause</outcome_measure>
      <outcome_measure>Change in serum CRP levels</outcome_measure>
      <outcome_measure>Incidence of serious adverse events</outcome_measure>
      <outcome_measure>Incidence of Grade 4 neutropenia (ANC &lt;500/mm3)</outcome_measure>
      <outcome_measure>Incidence of severe or life-threatening bacterial, invasive fungal, or opportunistic infection</outcome_measure>
      <outcome_measure>Incidence of severe or life-threatening bacterial, invasive fungal, or opportunistic infection in patients with Grade 4 neutropenia</outcome_measure>
      <outcome_measure>Incidence of hypersensitivity reactions</outcome_measure>
      <outcome_measure>Incidence of infusion reactions</outcome_measure>
      <outcome_measure>Incidence of gastrointestinal perforation</outcome_measure>
      <outcome_measure>White blood cell count</outcome_measure>
      <outcome_measure>Hemoglobin levels</outcome_measure>
      <outcome_measure>Platelet count</outcome_measure>
      <outcome_measure>Creatinine levels</outcome_measure>
      <outcome_measure>Total bilirubin level</outcome_measure>
      <outcome_measure>Alanine aminotransferase (ALT) level</outcome_measure>
      <outcome_measure>Aspartate aminotransferase (AST) level</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Regeneron Pharmaceuticals</lead_sponsor>
      <collaborator>Sanofi</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 18, 2020</start_date>
    <primary_completion_date>March 9, 2021</primary_completion_date>
    <completion_date>April 1, 2021</completion_date>
    <study_first_posted>March 19, 2020</study_first_posted>
    <last_update_posted>April 6, 2020</last_update_posted>
    <locations>
      <location>Regeneron Study Site, Los Angeles, California, United States</location>
      <location>Regeneron Study Site, Sacramento, California, United States</location>
      <location>Regeneron Study Site, Santa Monica, California, United States</location>
      <location>Regeneron Study Site, Aurora, Colorado, United States</location>
      <location>Regeneron Study Site, Denver, Colorado, United States</location>
      <location>Regeneron Study Site, New Haven, Connecticut, United States</location>
      <location>Regeneron Study Site, Washington, District of Columbia, United States</location>
      <location>Regeneron Study Site, Coral Gables, Florida, United States</location>
      <location>Regeneron Study Site, Gainesville, Florida, United States</location>
      <location>Regeneron Study Site, Orlando, Florida, United States</location>
      <location>Regeneron Study Site, Atlanta, Georgia, United States</location>
      <location>Regeneron Study Site, Decatur, Georgia, United States</location>
      <location>Regeneron Study Site, Marietta, Georgia, United States</location>
      <location>Regeneron Study Site, Chicago, Illinois, United States</location>
      <location>Regeneron Study Site, Chicago, Illinois, United States</location>
      <location>Regeneron Study Site, New Orleans, Louisiana, United States</location>
      <location>Regeneron Study Site, Baltimore, Maryland, United States</location>
      <location>Regeneron Study Site, Boston, Massachusetts, United States</location>
      <location>Regeneron Study Site, Boston, Massachusetts, United States</location>
      <location>Regeneron Study Site, Boston, Massachusetts, United States</location>
      <location>Regneron Study Site, Boston, Massachusetts, United States</location>
      <location>Regeneron Study Site, Ann Arbor, Michigan, United States</location>
      <location>Regeneron Study Site, Detroit, Michigan, United States</location>
      <location>Regeneron Study Site, Rochester, Minnesota, United States</location>
      <location>Regeneron Study Site, Edison, New Jersey, United States</location>
      <location>Regeneron Study Site, Hackensack, New Jersey, United States</location>
      <location>Regeneron Study Site, Livingston, New Jersey, United States</location>
      <location>Regeneron Study Site, Morristown, New Jersey, United States</location>
      <location>Regeneron Study Site, Neptune, New Jersey, United States</location>
      <location>Regeneron Study Site, Newark, New Jersey, United States</location>
      <location>Regeneron Study Site, Teaneck, New Jersey, United States</location>
      <location>Regeneron Study Site, Bronx, New York, United States</location>
      <location>Regeneron Study Site 1, Bronx, New York, United States</location>
      <location>Regeneron Study Site 2, Bronx, New York, United States</location>
      <location>Regeneron Study Site, Bronx, New York, United States</location>
      <location>Regeneron Study Site, Brooklyn, New York, United States</location>
      <location>Regeneron Study Site, Elmhurst, New York, United States</location>
      <location>Regeneron Study Facility 2, Manhasset, New York, United States</location>
      <location>Regeneron Study Site 1, Manhasset, New York, United States</location>
      <location>Regeneron Study Site, New York, New York, United States</location>
      <location>Regeneron Study Site, New York, New York, United States</location>
      <location>Regeneron Study Site 1, New York, New York, United States</location>
      <location>Regeneron Study Site 2, New York, New York, United States</location>
      <location>Regeneron Study Site, New York, New York, United States</location>
      <location>Regeneron Study Site, New York, New York, United States</location>
      <location>Regeneron Study Site, New York, New York, United States</location>
      <location>Regeneron Study Site, New York, New York, United States</location>
      <location>Regeneron Study Site, New York, New York, United States</location>
      <location>Regeneron Study Site, Stony Brook, New York, United States</location>
      <location>Regeneron Study Site, Valhalla, New York, United States</location>
      <location>Regeneron Study Site, Tulsa, Oklahoma, United States</location>
      <location>Regeneron Study Site, Portland, Oregon, United States</location>
      <location>Regeneron Study Site, Portland, Oregon, United States</location>
      <location>Regeneron Study Site, Danville, Pennsylvania, United States</location>
      <location>Regeneron Study Site, Philadelphia, Pennsylvania, United States</location>
      <location>Regeneron Study Site, Scranton, Pennsylvania, United States</location>
      <location>Regeneron Study Site, Wilkes-Barre, Pennsylvania, United States</location>
      <location>Regeneron Study Site, Dallas, Texas, United States</location>
      <location>Regeneron Study Site, Dallas, Texas, United States</location>
      <location>Regeneron Study Site, Murray, Utah, United States</location>
      <location>Regeneron Study Site, Falls Church, Virginia, United States</location>
      <location>Regeneron Study Site, Everett, Washington, United States</location>
      <location>Regeneron Study Site, Renton, Washington, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04315298</url>
  </study>
  <study rank="79">
    <nct_id>NCT04337996</nct_id>
    <title>Dynamic Evaluation of COVID-19 Diagnostic Tests</title>
    <acronym>TRODVID-19</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">COVID-19 diagnostic test</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Positive or negative character of the three tests</outcome_measure>
      <outcome_measure>sensitivity and specificity of the tests according to the time elapsed since the first symptoms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tourcoing Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>176</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>October 2020</completion_date>
    <study_first_posted>April 8, 2020</study_first_posted>
    <last_update_posted>April 8, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04337996</url>
  </study>
  <study rank="80">
    <nct_id>NCT04352933</nct_id>
    <title>PROLIFIC ChemoprophylaxisTrial (COVID-19)</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine - Daily dosing</intervention>
      <intervention type="Drug">Hydroxychloroquine - Weekly Dosing</intervention>
      <intervention type="Other">Matched Placebo Hydroxychloroquine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to positive COVID-19 disease</outcome_measure>
      <outcome_measure>Number of COVID-19 test positive cases</outcome_measure>
      <outcome_measure>Number of COVID-19 serological test positive cases</outcome_measure>
      <outcome_measure>Severity of COVID-19 disease between each arm</outcome_measure>
      <outcome_measure>Number of common COVID-19 complications between each arm</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Cambridge University Hospitals NHS Foundation Trust</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>October 31, 2020</primary_completion_date>
    <completion_date>April 2021</completion_date>
    <study_first_posted>April 20, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04352933</url>
  </study>
  <study rank="81">
    <nct_id>NCT04359797</nct_id>
    <title>COVID-19 Patient Positioning Pragmatic Trial</title>
    <acronym/>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Prone</intervention>
      <intervention type="Other">Usual Care</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Modified WHO Ordinal Scale</outcome_measure>
      <outcome_measure>Mean FIO2</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Vanderbilt University Medical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <start_date>April 27, 2020</start_date>
    <primary_completion_date>April 2021</primary_completion_date>
    <completion_date>June 2021</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Vanderbilt University Medical Center, Nashville, Tennessee, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04359797</url>
  </study>
  <study rank="82">
    <nct_id>NCT04361214</nct_id>
    <title>Leflunomide in Mild COVID-19 Patients</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Leflunomide</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Tolerability of high dose leflunomide as measured by leflunomide dose modifications</outcome_measure>
      <outcome_measure>Tolerability of high dose leflunomide as measured by discontinuation of leflunomide</outcome_measure>
      <outcome_measure>Tolerability of high dose leflunomide as measured by Adverse Events</outcome_measure>
      <outcome_measure>Rate of hospitalization due to COVID-19 as measured by number of patients hospitalized</outcome_measure>
      <outcome_measure>Time to defervescence as measured in days while on treatment protocol</outcome_measure>
      <outcome_measure>Resolution of other COVID-19 symptoms measured in days while on treatment protocol</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>July 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>University of Chicago, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04361214</url>
  </study>
  <study rank="83">
    <nct_id>NCT04359953</nct_id>
    <title>Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19</title>
    <acronym>COVID-Aging</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19 Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Drug">Azithromycin</intervention>
      <intervention type="Drug">Telmisartan</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Two-weeks survival rate</outcome_measure>
      <outcome_measure>Rate of undetectable RT-PCR of SARS-CoV-2</outcome_measure>
      <outcome_measure>Rate of death</outcome_measure>
      <outcome_measure>Hypotension</outcome_measure>
      <outcome_measure>Hypothermia and hyperthermia</outcome_measure>
      <outcome_measure>Pneumonia severity according to WHO</outcome_measure>
      <outcome_measure>Pneumonia severity according to PSI (Hung et al 2017)</outcome_measure>
      <outcome_measure>Rate of no cough</outcome_measure>
      <outcome_measure>Rate of no dyspnea</outcome_measure>
      <outcome_measure>Rate of no fever</outcome_measure>
      <outcome_measure>Rate of no requiring supplemental oxygen</outcome_measure>
      <outcome_measure>Rate of SARS-Cov-2 undetectable</outcome_measure>
      <outcome_measure>Recovery time</outcome_measure>
      <outcome_measure>Critical admission rate</outcome_measure>
      <outcome_measure>Mechanical ventilation rate</outcome_measure>
      <outcome_measure>Changes in Activity of Daily Living (ADL) Activity of Daily Living)</outcome_measure>
      <outcome_measure>Changes in Activity of Daily Living IADL (Instrumental Activity of Daily Living)</outcome_measure>
      <outcome_measure>The number and dose of added corticosteroids, immonumodulators or immunosuppressants</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Strasbourg, France</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>60 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1600</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 24, 2020</start_date>
    <primary_completion_date>June 1, 2021</primary_completion_date>
    <completion_date>June 1, 2021</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>CHU de Strasbourg, Strasbourg, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04359953</url>
  </study>
  <study rank="84">
    <nct_id>NCT04330638</nct_id>
    <title>Treatment of COVID-19 Patients With Anti-interleukin Drugs</title>
    <acronym>COV-AID</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Usual Care</intervention>
      <intervention type="Drug">Anakinra</intervention>
      <intervention type="Drug">Siltuximab</intervention>
      <intervention type="Drug">Tocilizumab</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to Clinical Improvement</outcome_measure>
      <outcome_measure>Time to improvement in oxygenation</outcome_measure>
      <outcome_measure>Mean change in oxygenation</outcome_measure>
      <outcome_measure>Number of days with hypoxia</outcome_measure>
      <outcome_measure>Number of days of supplemental oxygen use</outcome_measure>
      <outcome_measure>Time to absence fever for more than 48h without antipyretics</outcome_measure>
      <outcome_measure>Number of days with fever</outcome_measure>
      <outcome_measure>Time to halving of CRP levels compared to peak value during trial</outcome_measure>
      <outcome_measure>Time to halving of ferritin levels compared to peak value during trial</outcome_measure>
      <outcome_measure>Incidence of AEs (Adverse Events)</outcome_measure>
      <outcome_measure>Incidence of SAEs (Serious Adverse Events)</outcome_measure>
      <outcome_measure>Duration of hospital stay</outcome_measure>
      <outcome_measure>Duration of hospital stay in survivors</outcome_measure>
      <outcome_measure>Mean change in clinical sign score between day 1 and day 7</outcome_measure>
      <outcome_measure>Mean change in clinical sign score between day 1 and day 15</outcome_measure>
      <outcome_measure>Time to clinical sign score &lt;6 maintained for 24h</outcome_measure>
      <outcome_measure>Mean change of SOFA score (Sequential Organ Failure Assessment) between day 1 and day 7</outcome_measure>
      <outcome_measure>Mean change of SOFA score between day 1 and day 15</outcome_measure>
      <outcome_measure>Mean change NEWS2 (National Early Warning) score between day 1 and day 7</outcome_measure>
      <outcome_measure>Mean change NEWS2 score between day 1 and day 15</outcome_measure>
      <outcome_measure>Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-1</outcome_measure>
      <outcome_measure>Percentage of patients reporting each severity rating on a 6-point ordinal scale in relation to serum IL-6</outcome_measure>
      <outcome_measure>Incidence of nosocomial bacterial or invasive fungal infection</outcome_measure>
      <outcome_measure>incidence of secondary haemophagocytic lymphohistiocytosis</outcome_measure>
      <outcome_measure>Incidence of secondary haemophagocytic lymphohistiocytosisscore in relation to serum IL-1</outcome_measure>
      <outcome_measure>Incidence of secondary haemophagocytic lymphohistiocytosis in relation to serum IL-6</outcome_measure>
      <outcome_measure>Time to first use of high-flow oxygen devices, non-invasive or invasive mechanical ventilation in non-ventilated patients</outcome_measure>
      <outcome_measure>Time to first use of salvage systemic steroids in ventilated patients</outcome_measure>
      <outcome_measure>Number of ventilator free days</outcome_measure>
      <outcome_measure>Duration of mechanical ventilation in ventilated patients</outcome_measure>
      <outcome_measure>Duration of ICU stay in patients that enrolled in trial while already on invasive or non-invasive mechanical ventilation</outcome_measure>
      <outcome_measure>Time to progression to ARDS in ventilated patients</outcome_measure>
      <outcome_measure>Time to progression to ARDS in ventilated patients according to IL-1</outcome_measure>
      <outcome_measure>Time to progression to ARDS in ventilated patients according to IL-6</outcome_measure>
      <outcome_measure>All-cause mortality rate (excluding group that entered during ventilation)</outcome_measure>
      <outcome_measure>Percentage of patients in clinical status on 6-point Ordinal Scale</outcome_measure>
      <outcome_measure>Incidence of lung function abnormalities</outcome_measure>
      <outcome_measure>Incidence of lung fibrosis on chest CT scan</outcome_measure>
      <outcome_measure>All-cause mortality rate</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Ghent</lead_sponsor>
      <collaborator>Belgium Health Care Knowledge Centre</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>342</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>September 2020</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>April 1, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>AZ Sint-Jan Brugge, Brugge, Belgium</location>
      <location>University Hospital Saint-Pierre, Brussels, Belgium</location>
      <location>Erasmus University Hospital, Brussels, Belgium</location>
      <location>University Hospital Saint-Luc, Brussels, Belgium</location>
      <location>University Hospital Antwerp, Edegem, Belgium</location>
      <location>Ziekenhuis Oost-Limurg, Genk, Belgium</location>
      <location>AZ Sint-Lucas, Gent, Belgium</location>
      <location>University Hospital Ghent, Gent, Belgium</location>
      <location>Jessa ZH, Hasselt, Belgium</location>
      <location>University Hospital Brussels, Jette, Belgium</location>
      <location>CHU Tivoli, La Louvière, Belgium</location>
      <location>CHR de la Citadelle, Liège, Belgium</location>
      <location>University Hospital Liège, Liège, Belgium</location>
      <location>Cliniques Saint-Pierre Ottignies, Ottignies-Louvain-la-Neuve, Belgium</location>
      <location>AZ Delta, Roeselare, Belgium</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04330638</url>
  </study>
  <study rank="85">
    <nct_id>NCT04337762</nct_id>
    <title>Beat COVID-19 - Observational Trial</title>
    <acronym>JUPITER</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Health Outcomes</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Beat COVID LLC</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>110 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100000</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 6, 2020</start_date>
    <primary_completion_date>December 2020</primary_completion_date>
    <completion_date>July 2021</completion_date>
    <study_first_posted>April 8, 2020</study_first_posted>
    <last_update_posted>April 9, 2020</last_update_posted>
    <locations>
      <location>Beat COIVD, LLC, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04337762</url>
  </study>
  <study rank="86">
    <nct_id>NCT04348942</nct_id>
    <title>A COVID-19 Symptom, Exposure and Immune Response Registry</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Registry Data</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>ObvioHealth</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>10000</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>May 1, 2021</primary_completion_date>
    <completion_date>May 1, 2021</completion_date>
    <study_first_posted>April 16, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04348942</url>
  </study>
  <study rank="87">
    <nct_id>NCT04363372</nct_id>
    <title>A Study for Efficacy and Safety of Live Biotherapeutic MRx4DP0004 to Treat COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MRx-4DP0004</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in mean clinical status score in each treatment arm</outcome_measure>
      <outcome_measure>Number of adverse events in each treatment arm</outcome_measure>
      <outcome_measure>Number of patients with an improvement in clinical status score in each treatment arm</outcome_measure>
      <outcome_measure>Number of patients with a deterioration in clinical status score in each treatment arm</outcome_measure>
      <outcome_measure>Number of patients with at least 95% oxygen saturation on room air in each treatment arm</outcome_measure>
      <outcome_measure>Time to patients with at least 95% oxygen saturation on room air in each treatment arm</outcome_measure>
      <outcome_measure>Number of patients with an improvement in the National Early Warning Score (NEWS) 2 in each treatment arm</outcome_measure>
      <outcome_measure>Number of patients with an deterioration in the National Early Warning Score (NEWS) 2 in each treatment arm</outcome_measure>
      <outcome_measure>Number of patients requiring Continuous Positive Airway Pressure in each treatment arm</outcome_measure>
      <outcome_measure>Number of patients requiring Intermittent Positive Pressure Ventilation in each treatment arm</outcome_measure>
      <outcome_measure>Time to patients requiring Continuous Positive Airway Pressure in each treatment arm</outcome_measure>
      <outcome_measure>Time to patients requiring Intermittent Positive Pressure Ventilation in each treatment arm</outcome_measure>
      <outcome_measure>Time to discharge in each treatment arm</outcome_measure>
      <outcome_measure>Number of deaths in each treatment arm</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>4D pharma plc</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 2020</start_date>
    <primary_completion_date>August 2020</primary_completion_date>
    <completion_date>September 2020</completion_date>
    <study_first_posted>April 27, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04363372</url>
  </study>
  <study rank="88">
    <nct_id>NCT04343690</nct_id>
    <title>COPING With COVID-19( CWC-19)</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Crisis management coaching</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in stress level as measured by survey</outcome_measure>
      <outcome_measure>Change wellness as measured by survey</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Duke University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <start_date>April 13, 2020</start_date>
    <primary_completion_date>June 30, 2020</primary_completion_date>
    <completion_date>June 30, 2020</completion_date>
    <study_first_posted>April 13, 2020</study_first_posted>
    <last_update_posted>April 13, 2020</last_update_posted>
    <locations>
      <location>Duke University, Durham, North Carolina, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04343690</url>
  </study>
  <study rank="89">
    <nct_id>NCT04332081</nct_id>
    <title>Hyperbaric Oxygen for COVID-19 Patients</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Device">hyperbaric oxygen therapy (HBOT)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>Days on invasive mechanical ventilation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>NYU Langone Health</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 6, 2020</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>July 2020</completion_date>
    <study_first_posted>April 2, 2020</study_first_posted>
    <last_update_posted>April 9, 2020</last_update_posted>
    <locations>
      <location>NYU Winthrop Hospital, Mineola, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04332081</url>
  </study>
  <study rank="90">
    <nct_id>NCT04355936</nct_id>
    <title>Telmisartan for Treatment of COVID-19 Patients</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19 Drug Treatment</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care.</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Need for supplementary oxygen</outcome_measure>
      <outcome_measure>PAFI02 measure</outcome_measure>
      <outcome_measure>Number of opacified quadrants on lung Rx</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Laboratorio Elea S.A.C.I.F. y A.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>October 1, 2020</primary_completion_date>
    <completion_date>October 1, 2020</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>Hospital de Clínicas 'José de San Martín', Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Ciudad De Buenos Aires, Argentina</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04355936</url>
  </study>
  <study rank="91">
    <nct_id>NCT04365699</nct_id>
    <title>Cardiovascular Effects of COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">AT-001</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Proportion of subjects with decreased left ventricular ejection fraction ≥10% from baseline at time of hospitalization</outcome_measure>
      <outcome_measure>Incidence of Adverse Events for patients receiving AT-001</outcome_measure>
      <outcome_measure>Change in left ventricular ejection fraction</outcome_measure>
      <outcome_measure>Change in left ventricular end-diastolic diameter</outcome_measure>
      <outcome_measure>Change in left ventricular end-systolic diameter</outcome_measure>
      <outcome_measure>Change in biomarkers of cardiac injury</outcome_measure>
      <outcome_measure>Frequency of atrial fibrillation</outcome_measure>
      <outcome_measure>Frequency of heart block</outcome_measure>
      <outcome_measure>Frequency of non-sustained ventricular tachycardia</outcome_measure>
      <outcome_measure>Frequency of sustained ventricular tachycardia</outcome_measure>
      <outcome_measure>Frequency of ventricular fibrillation</outcome_measure>
      <outcome_measure>Proportion of subjects requiring mechanical ventilation</outcome_measure>
      <outcome_measure>Proportion of subjects with decrease in left ventricular ejection fraction ≥10% from baseline at time of hospitalization</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>NYU Langone Health</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 8, 2020</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>NYU Langone Health, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04365699</url>
  </study>
  <study rank="92">
    <nct_id>NCT04304313</nct_id>
    <title>A Pilot Study of Sildenafil in COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sildenafil citrate tablets</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Rate of disease remission</outcome_measure>
      <outcome_measure>Rate of entering the critical stage</outcome_measure>
      <outcome_measure>Time of entering the critical stage</outcome_measure>
      <outcome_measure>Rate of no fever</outcome_measure>
      <outcome_measure>Rate of respiratory symptom remission</outcome_measure>
      <outcome_measure>Rate of lung imaging recovery</outcome_measure>
      <outcome_measure>Rate of C-reactive protein (CRP) recovery</outcome_measure>
      <outcome_measure>Rate of Biochemical criterion (CK, ALT, Mb) recovery</outcome_measure>
      <outcome_measure>Rate of undetectable viral RNA (continuous twice)</outcome_measure>
      <outcome_measure>Time for hospitalization</outcome_measure>
      <outcome_measure>Rate of adverse event</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tongji Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>February 9, 2020</start_date>
    <primary_completion_date>March 1, 2020</primary_completion_date>
    <completion_date>November 9, 2020</completion_date>
    <study_first_posted>March 11, 2020</study_first_posted>
    <last_update_posted>March 17, 2020</last_update_posted>
    <locations>
      <location>Department and Institute of Infectious Disease, Wuhan, Hubei, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04304313</url>
  </study>
  <study rank="93">
    <nct_id>NCT04326920</nct_id>
    <title>Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC)</title>
    <acronym>SARPAC</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sargramostim</intervention>
      <intervention type="Other">Control</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Improvement in oxygenation at a dose of 250 mcg daily during 5 days improves oxygenation in COVID-19 patients with acute hypoxic respiratory failure</outcome_measure>
      <outcome_measure>Incidence of AE (Adverse Event)</outcome_measure>
      <outcome_measure>Incidence of SAEs (Serious Adverse Event)</outcome_measure>
      <outcome_measure>Clinical Status using 6-point ordinal scale</outcome_measure>
      <outcome_measure>Clinical Status using Clincal sign score</outcome_measure>
      <outcome_measure>Clinical Status using SOFA score (Sequential Organ Failure Assessment score),</outcome_measure>
      <outcome_measure>Clinical Status using NEWS2 score (National Early Warning Score)</outcome_measure>
      <outcome_measure>incidence of severe or life-threatening bacterial, invasive fungal or opportunistic infection</outcome_measure>
      <outcome_measure>number of patients requiring initiation of mechanical ventilation</outcome_measure>
      <outcome_measure>Number of deaths due to any cause at 4 weeks</outcome_measure>
      <outcome_measure>Number of deaths due to any cause at 20 weeks</outcome_measure>
      <outcome_measure>number of patients developing features of secondary haemophagocytic lymphohistiocytosis</outcome_measure>
      <outcome_measure>long term Clinical status defined by 6-point ordinal scale</outcome_measure>
      <outcome_measure>long term Clinical status defined by chest X-ray</outcome_measure>
      <outcome_measure>long term Clinical status defined lung function</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Ghent</lead_sponsor>
      <collaborator>Flanders Institute of Biotechnology</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 24, 2020</start_date>
    <primary_completion_date>October 31, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>March 30, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>AZ Sint Jan Brugge, Brugge, Belgium</location>
      <location>University Hospital Ghent, Gent, Belgium</location>
      <location>UZ Brussel, Jette, Belgium</location>
      <location>AZ Delta Roeselare, Roeselare, Belgium</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04326920</url>
  </study>
  <study rank="94">
    <nct_id>NCT04363034</nct_id>
    <title>Arkansas Expanded Access COVID-19 Convalescent Plasma Treatment Program</title>
    <acronym/>
    <status open="N">Temporarily not available</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Convalescent Plasma</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>University of Arkansas</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Expanded Access</study_types>
    <exp_acc_types>
      <exp_acc_type>Intermediate-size Population</exp_acc_type>
    </exp_acc_types>
    <study_designs/>
    <study_first_posted>April 27, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04363034</url>
  </study>
  <study rank="95">
    <nct_id>NCT04353284</nct_id>
    <title>Camostat Mesylate in COVID-19 Outpatients</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Camostat Mesilate</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in SARS-COV-2 viral load</outcome_measure>
      <outcome_measure>Change in positive COVID-19 status</outcome_measure>
      <outcome_measure>Change in COVID-19 symptom severity</outcome_measure>
      <outcome_measure>Change in COVID-19 symptom frequency</outcome_measure>
      <outcome_measure>Change in body temperature</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yale University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>114</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 30, 2020</start_date>
    <primary_completion_date>May 31, 2021</primary_completion_date>
    <completion_date>May 31, 2021</completion_date>
    <study_first_posted>April 20, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04353284</url>
  </study>
  <study rank="96">
    <nct_id>NCT04337541</nct_id>
    <title>Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Surgical facial mask</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Reduction in COVID-19 infection frequency</outcome_measure>
      <outcome_measure>Antibody-screening</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Rigshospitalet, Denmark</lead_sponsor>
      <collaborator>Nordsjaellands Hospital</collaborator>
      <collaborator>Hvidovre University Hospital</collaborator>
      <collaborator>Herlev Hospital</collaborator>
      <collaborator>Technical University of Denmark</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>6000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 2, 2020</start_date>
    <primary_completion_date>July 1, 2020</primary_completion_date>
    <completion_date>July 1, 2020</completion_date>
    <study_first_posted>April 7, 2020</study_first_posted>
    <last_update_posted>April 7, 2020</last_update_posted>
    <locations>
      <location>Rigshospitalet, Copenhagen, Denmark</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04337541</url>
  </study>
  <study rank="97">
    <nct_id>NCT04338347</nct_id>
    <title>CAP-1002 in Severe COVID-19 Disease</title>
    <acronym/>
    <status open="Y">Available</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">CAP-1002 Allogeneic Cardiosphere-Derived Cells</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Capricor Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Expanded Access</study_types>
    <exp_acc_types>
      <exp_acc_type>Intermediate-size Population</exp_acc_type>
      <exp_acc_type>Treatment IND/Protocol</exp_acc_type>
    </exp_acc_types>
    <study_designs/>
    <study_first_posted>April 8, 2020</study_first_posted>
    <last_update_posted>April 8, 2020</last_update_posted>
    <locations>
      <location>Cedars-Sinai Medical Center, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04338347</url>
  </study>
  <study rank="98">
    <nct_id>NCT04348422</nct_id>
    <title>Evaluating the Immune Response for COVID-19</title>
    <acronym>COVIDIMMUNE</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">COVID-19 RT-PCR</intervention>
      <intervention type="Diagnostic Test">COVID-19 Serology</intervention>
      <intervention type="Other">Symptoms questionnare</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Proportion of symptomatic patients with immune response (IgM/IgG/IgA)</outcome_measure>
      <outcome_measure>Proportion of Asymptomatic patients with immune response (IgM/IgG/IgA)</outcome_measure>
      <outcome_measure>Time to IgM</outcome_measure>
      <outcome_measure>Time to IgG</outcome_measure>
      <outcome_measure>Time to IgA</outcome_measure>
      <outcome_measure>Serology kits inter-observer agreement</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assaf-Harofeh Medical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>December 1, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>April 16, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04348422</url>
  </study>
  <study rank="99">
    <nct_id>NCT04356690</nct_id>
    <title>Etoposide in Patients With COVID-19 Infection</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Etoposide</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in pulmonary status</outcome_measure>
      <outcome_measure>Change in ferritin levels</outcome_measure>
      <outcome_measure>Change in C-reactive protein levels</outcome_measure>
      <outcome_measure>Change in d-dimer levels</outcome_measure>
      <outcome_measure>Change in white blood cell count</outcome_measure>
      <outcome_measure>Incidence of serious adverse events</outcome_measure>
      <outcome_measure>Overall survival</outcome_measure>
      <outcome_measure>Length of hospitalization</outcome_measure>
      <outcome_measure>Duration of ventilation</outcome_measure>
      <outcome_measure>Ventilator free days</outcome_measure>
      <outcome_measure>Improvement in arterial oxygen partial pressure (PaO2) to fractional inspired oxygen (FiO2)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Boston Medical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>134</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>December 2020</primary_completion_date>
    <completion_date>December 2021</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04356690</url>
  </study>
  <study rank="100">
    <nct_id>NCT04359277</nct_id>
    <title>A Randomized Trial of Anticoagulation Strategies in COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Enoxaparin Higher Dose</intervention>
      <intervention type="Drug">Lower-dose prophylactic anticoagulation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>All-cause mortality</outcome_measure>
      <outcome_measure>Incidence of Cardiac Arrest</outcome_measure>
      <outcome_measure>Incidence of symptomatic Deep Venous Thrombosis</outcome_measure>
      <outcome_measure>Incidence of Pulmonary Embolism</outcome_measure>
      <outcome_measure>Incidence of Arterial thromboembolism</outcome_measure>
      <outcome_measure>Incidence of myocardial infarction</outcome_measure>
      <outcome_measure>Incidence of hemodynamic shock</outcome_measure>
      <outcome_measure>Incidence of Renal failure</outcome_measure>
      <outcome_measure>Days of hypoxemia</outcome_measure>
      <outcome_measure>Cardiac injury (e.g. troponin, NTproBNP)</outcome_measure>
      <outcome_measure>Hypercoagulability (e.g. D-dimer, fibrinogen)</outcome_measure>
      <outcome_measure>DIC score</outcome_measure>
      <outcome_measure>Incidence of major bleeding</outcome_measure>
      <outcome_measure>Time to change in NEWS2 from baseline</outcome_measure>
      <outcome_measure>Requirement of invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)</outcome_measure>
      <outcome_measure>Requirement of non-invasive ventilation or high flow oxygen devices</outcome_measure>
      <outcome_measure>Requirement of supplemental oxygen</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>NYU Langone Health</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 16, 2020</start_date>
    <primary_completion_date>April 16, 2021</primary_completion_date>
    <completion_date>April 16, 2021</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>NYU Langone Health, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04359277</url>
  </study>
  <study rank="101">
    <nct_id>NCT04351763</nct_id>
    <title>Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms</title>
    <acronym>ReCOVery-SIRIO</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Amiodarone</intervention>
      <intervention type="Drug">Verapamil</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clinical improvement</outcome_measure>
      <outcome_measure>Mean change in the 7-point ordinal scale</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>Time to resolution of fever</outcome_measure>
      <outcome_measure>Clinical improvement or fever resolution</outcome_measure>
      <outcome_measure>Tachyarrhythmias</outcome_measure>
      <outcome_measure>Mortality or tachyarrhythmias</outcome_measure>
      <outcome_measure>Time to clinical improvement from admission using the 7-point ordinal scale</outcome_measure>
      <outcome_measure>Change in NEWS2 score</outcome_measure>
      <outcome_measure>Duration of hospitalization</outcome_measure>
      <outcome_measure>PO2/FIO2</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Nicolaus Copernicus University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>99 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>804</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 27, 2020</start_date>
    <primary_completion_date>March 2, 2021</primary_completion_date>
    <completion_date>April 10, 2021</completion_date>
    <study_first_posted>April 17, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations>
      <location>Nicolaus Copernicus University, Bydgoszcz, Poland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04351763</url>
  </study>
  <study rank="102">
    <nct_id>NCT04354805</nct_id>
    <title>Administration of Chloropromazine as a Treatment for COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Chlorpromazine Injection</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Lactate dehydrogenase (LDH)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Cairo University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 2020</start_date>
    <primary_completion_date>August 2020</primary_completion_date>
    <completion_date>September 2020</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>Cairo University, Cairo, Egypt</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04354805</url>
  </study>
  <study rank="103">
    <nct_id>NCT04340544</nct_id>
    <title>Hydroxychloroquine for the Treatment of Mild COVID-19 Disease</title>
    <acronym>COMIHY</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Difference in time to resolution of clinical signs and symptoms of mild COVID-19 treated with hydroxychloroquine or placebo as assessed by daily self-assessment</outcome_measure>
      <outcome_measure>Difference between hydroxychloroquine- and placebotreated patients on an ordinal outcome scale until Day 28 (death, admission to intensive care, hospitalization, continuing disease, recovered)</outcome_measure>
      <outcome_measure>All-cause mortality within 28 days</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital Tuebingen</lead_sponsor>
      <collaborator>Robert Bosch Medical Center</collaborator>
      <collaborator>Universitätsklinikum Hamburg-Eppendorf</collaborator>
      <collaborator>Bernhard Nocht Institute for Tropical Medicine</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>99 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>2700</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 10, 2020</start_date>
    <primary_completion_date>November 30, 2021</primary_completion_date>
    <completion_date>September 30, 2022</completion_date>
    <study_first_posted>April 9, 2020</study_first_posted>
    <last_update_posted>April 9, 2020</last_update_posted>
    <locations>
      <location>Institute for Tropical Medicine, Tübingen, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04340544</url>
  </study>
  <study rank="104">
    <nct_id>NCT04334512</nct_id>
    <title>A Study of Quintuple Therapy to Treat COVID-19 Infection</title>
    <acronym>HAZDpaC</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Drug">Azithromycin</intervention>
      <intervention type="Dietary Supplement">vitamin C</intervention>
      <intervention type="Dietary Supplement">Vitamin D</intervention>
      <intervention type="Dietary Supplement">Zinc</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Successful treatment as determined by Negative Test and resolution of symptoms</outcome_measure>
      <outcome_measure>Safety of Quintuple Therapy</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>ProgenaBiome</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>600</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>April 2021</primary_completion_date>
    <completion_date>July 2021</completion_date>
    <study_first_posted>April 6, 2020</study_first_posted>
    <last_update_posted>April 13, 2020</last_update_posted>
    <locations>
      <location>ProgenaBiome, Ventura, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04334512</url>
  </study>
  <study rank="105">
    <nct_id>NCT04366115</nct_id>
    <title>Evaluating AVM0703 for Treatment of COVID-19</title>
    <acronym>AVM0703</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">AVM0703</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">hydrocortisone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Dose-Limiting Toxicities</outcome_measure>
      <outcome_measure>28 day all-cause mortality will be a primary end point for Phase 1 and 2</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>AVM Biotechnology LLC</lead_sponsor>
      <collaborator>Medpace, Inc.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>126</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>June 2020</start_date>
    <primary_completion_date>June 2022</primary_completion_date>
    <completion_date>June 2023</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04366115</url>
  </study>
  <study rank="106">
    <nct_id>NCT04327674</nct_id>
    <title>The Use of Focused Lung Ultrasound in Patients Suspected of COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>FLUS findings and respiratory failure</outcome_measure>
      <outcome_measure>FLUS findings and chest x-ray.</outcome_measure>
      <outcome_measure>FLUS findings and admission to intensive care.</outcome_measure>
      <outcome_measure>FLUS findings and SAR-CoV-2 PCR-test result.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Aarhus</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>375</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 14, 2020</start_date>
    <primary_completion_date>May 15, 2020</primary_completion_date>
    <completion_date>May 15, 2020</completion_date>
    <study_first_posted>March 31, 2020</study_first_posted>
    <last_update_posted>March 31, 2020</last_update_posted>
    <locations>
      <location>Lungemedicinsk Forskningsafdeling. Aarhus University Hospital, Aarhus, Denmark</location>
      <location>Regionshospitalet Horsens., Horsens, Denmark</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04327674</url>
  </study>
  <study rank="107">
    <nct_id>NCT04361981</nct_id>
    <title>Influence of COVID-19 Infection in Thromboembolic Venous Disease: National Cohort Study</title>
    <acronym>TVP-COVID-RIV</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Deep Venous Disease Diagnostic</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Deep Venous Disease Incidence</outcome_measure>
      <outcome_measure>30-days mortality</outcome_measure>
      <outcome_measure>ICU admission</outcome_measure>
      <outcome_measure>Anticoagulant treatment</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sociedad Espanola de Angiologia y Cirugia Vascular</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>August 31, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>Red de Investigacion Vascular (SEACV), Madrid, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04361981</url>
  </study>
  <study rank="108">
    <nct_id>NCT04366050</nct_id>
    <title>Ramipril for the Treatment of COVID-19</title>
    <acronym>RAMIC</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ramipril 2.5 MG Oral Capsule</intervention>
      <intervention type="Drug">Placebo oral capsule</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Composite of mortality or need for ICU admission or ventilator use</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of California, San Diego</lead_sponsor>
      <collaborator>Pfizer</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>560</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>April 2021</primary_completion_date>
    <completion_date>April 2021</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04366050</url>
  </study>
  <study rank="109">
    <nct_id>NCT04341675</nct_id>
    <title>Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia</title>
    <acronym>SCOPE</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sirolimus</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Proportion of patients who progress to require advanced respiratory support</outcome_measure>
      <outcome_measure>Proportion of patients who require escalation in care</outcome_measure>
      <outcome_measure>Change over time in study-specific biomarkers (LDH, Ferritin, D-dimer, lymphocyte count)</outcome_measure>
      <outcome_measure>Proportion of patients surviving to hospital discharge</outcome_measure>
      <outcome_measure>Drug safety profile</outcome_measure>
      <outcome_measure>Duration of advanced respiratory support</outcome_measure>
      <outcome_measure>Duration of hospital stay</outcome_measure>
      <outcome_measure>Time from treatment initiation to death</outcome_measure>
      <outcome_measure>Time to resolution of fever</outcome_measure>
      <outcome_measure>Proportion of patients who require initiation of off-label therapies</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Cincinnati</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 24, 2020</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>September 2020</completion_date>
    <study_first_posted>April 10, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>University of Cincinnati, Cincinnati, Ohio, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04341675</url>
  </study>
  <study rank="110">
    <nct_id>NCT04329923</nct_id>
    <title>The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)</title>
    <acronym>PATCH</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine Sulfate 400 mg twice a day</intervention>
      <intervention type="Drug">Hydroxychloroquine Sulfate 600 mg twice a day</intervention>
      <intervention type="Drug">Hydroxychloroquine Sulfate 600 mg once a day</intervention>
      <intervention type="Drug">Placebo oral tablet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Median release from quarantine time</outcome_measure>
      <outcome_measure>Rate of hospital discharge</outcome_measure>
      <outcome_measure>Rate of infection</outcome_measure>
      <outcome_measure>Rate of housemate infection</outcome_measure>
      <outcome_measure>Rate of hospitalization</outcome_measure>
      <outcome_measure>Cohort 1 adverse event rate</outcome_measure>
      <outcome_measure>Time to condition appropriate for discharge</outcome_measure>
      <outcome_measure>Rate of ICU admission</outcome_measure>
      <outcome_measure>Time to PCR negativity</outcome_measure>
      <outcome_measure>Cohort 2 adverse events</outcome_measure>
      <outcome_measure>Scheduled shifts missed</outcome_measure>
      <outcome_measure>Cohort 3 adverse events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ravi Amaravadi, MD</lead_sponsor>
      <collaborator>University of Pennsylvania</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 9, 2020</start_date>
    <primary_completion_date>April 1, 2021</primary_completion_date>
    <completion_date>December 1, 2021</completion_date>
    <study_first_posted>April 1, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>University of Pennsylvania, Philadelphia, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04329923</url>
  </study>
  <study rank="111">
    <nct_id>NCT04365725</nct_id>
    <title>Multicenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 Infections</title>
    <acronym>REMDECO-19</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Remdesivir</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clinical course on Day 15.</outcome_measure>
      <outcome_measure>Clinical course on Day 3.</outcome_measure>
      <outcome_measure>Clinical course on Day 8</outcome_measure>
      <outcome_measure>Clinical course on Day 11.</outcome_measure>
      <outcome_measure>Clinical course on Day 29.</outcome_measure>
      <outcome_measure>Duration of treatment</outcome_measure>
      <outcome_measure>Sepsis-related Organ Failure Assessment score</outcome_measure>
      <outcome_measure>Duration without mechanical ventilation</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>cumulative incidence of grade 3 and 4 adverse events (AEs).</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>April 2020</primary_completion_date>
    <completion_date>May 2020</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Hôpital Cochin, Paris, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04365725</url>
  </study>
  <study rank="112">
    <nct_id>NCT04361643</nct_id>
    <title>Low-dose Lenalidomide for Non-severe COVID-19 Treatment Trial</title>
    <acronym>GETAFE</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Lenalidomide as a 5 mg capsule PO daily, days 1, 3, and 5.</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clinical improvement</outcome_measure>
      <outcome_measure>Immune-inflammatory improvement</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hospital Universitario Getafe</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>60 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 27, 2020</start_date>
    <primary_completion_date>August 31, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04361643</url>
  </study>
  <study rank="113">
    <nct_id>NCT04351646</nct_id>
    <title>Diagnostics of COVID-19/DARTS (Development and Assessment of Rapid Testing for SARS-CoV-2 Outbreak)</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Antibody titres to SARS-CoV-2</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>St George's, University of London</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>April 15, 2022</primary_completion_date>
    <completion_date>April 15, 2022</completion_date>
    <study_first_posted>April 17, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations>
      <location>St. Georges Hospital Foundation Trust, London, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04351646</url>
  </study>
  <study rank="114">
    <nct_id>NCT04330690</nct_id>
    <title>Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial</title>
    <acronym>CATCO</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Lopinavir/ritonavir</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Efficacy of Intervention</outcome_measure>
      <outcome_measure>Time to improvement of one catergory from admission</outcome_measure>
      <outcome_measure>Subject clinical status</outcome_measure>
      <outcome_measure>Change in Subject clinical status</outcome_measure>
      <outcome_measure>Oxygen free days</outcome_measure>
      <outcome_measure>Incidence of oxygen use</outcome_measure>
      <outcome_measure>Duration of oxygen use</outcome_measure>
      <outcome_measure>Incidence of new mechanical ventilation</outcome_measure>
      <outcome_measure>Duration of mechanical ventilation</outcome_measure>
      <outcome_measure>Duration of hospitalization</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>Cumulative Incidence of Grade 3 and 4 Adverse Events (AEs) and Serious Adverse Events (SAEs)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sunnybrook Health Sciences Centre</lead_sponsor>
      <collaborator>AbbVie</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>6 Months</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>440</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 18, 2020</start_date>
    <primary_completion_date>March 18, 2022</primary_completion_date>
    <completion_date>May 18, 2022</completion_date>
    <study_first_posted>April 1, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>University of Alberta Hopsital, Edmonton, Alberty, Canada</location>
      <location>Vancouver General Hospital, Vancouver Coastal Health, Univeristy of British Columbia, Vancouver, British Columbia, Canada</location>
      <location>St Paul's Hospital, Vancouver, British Columbia, Canada</location>
      <location>Island Health - Royal Jubilee Hospital, Victoria, British Columbia, Canada</location>
      <location>Island Health - Victoria General Hospital, Victoria, British Columbia, Canada</location>
      <location>The Ottawa Hospital - General Campus, Ottawa, Ontario, Canada</location>
      <location>The Ottawa Hospital - Civic Campus, Ottawa, Ontario, Canada</location>
      <location>North York General Hospital, Toronto, Ontario, Canada</location>
      <location>Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada</location>
      <location>Toronto Western Hospital, Toronto, Ontario, Canada</location>
      <location>McGill University Health Centre-Glen Site Royal Victoria Hospital, Montréal, Quebec, Canada</location>
      <location>CHU de Québec - Université Laval, Québec, Quebec, Canada</location>
      <location>Institut Universitaire de Cardiologie et de Pneumologie de Québec- Université Laval, Québec, Quebec, Canada</location>
      <location>Centre Intégré Universitaire de Santé et de Services Sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04330690</url>
  </study>
  <study rank="115">
    <nct_id>NCT04355143</nct_id>
    <title>Colchicine to Reduce Myocardial Injury in COVID-19 (COLHEART-19)</title>
    <acronym>COLHEART-19</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Colchicine Tablets</intervention>
      <intervention type="Other">Current care per UCLA treating physicians</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Maximum troponin level</outcome_measure>
      <outcome_measure>Delta (baseline to peak) troponin level</outcome_measure>
      <outcome_measure>Delta (baseline to peak) brain natriuretic peptide (BNP) level</outcome_measure>
      <outcome_measure>Change in left ventricular ejection fraction (LVEF) on echocardiography</outcome_measure>
      <outcome_measure>Delta (baseline to peak) C-Reactive protein (CRP) inflammatory biomarker level</outcome_measure>
      <outcome_measure>Delta (baseline to peak) D-Dimer inflammatory biomarker level</outcome_measure>
      <outcome_measure>Hospital length of stay</outcome_measure>
      <outcome_measure>Number of participants requiring mechanical ventilation or ICU care</outcome_measure>
      <outcome_measure>Re-hospitalization</outcome_measure>
      <outcome_measure>All-cause mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of California, Los Angeles</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 25, 2020</start_date>
    <primary_completion_date>April 25, 2021</primary_completion_date>
    <completion_date>April 25, 2021</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04355143</url>
  </study>
  <study rank="116">
    <nct_id>NCT04318418</nct_id>
    <title>ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19</title>
    <acronym>CODIV-ACE</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Severe COVID-19</outcome_measure>
      <outcome_measure>Death</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Neuromed IRCCS</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>5000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>March 23, 2020</start_date>
    <primary_completion_date>April 10, 2020</primary_completion_date>
    <completion_date>April 30, 2020</completion_date>
    <study_first_posted>March 24, 2020</study_first_posted>
    <last_update_posted>March 24, 2020</last_update_posted>
    <locations>
      <location>IRCCS Neuromed, Department of Epidemiology and Prevention, Pozzilli, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04318418</url>
  </study>
  <study rank="117">
    <nct_id>NCT04333355</nct_id>
    <title>Safety in Convalescent Plasma Transfusion to COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Convalescent Plasma</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Side effects</outcome_measure>
      <outcome_measure>Heart Failure</outcome_measure>
      <outcome_measure>Pulmonary Edema</outcome_measure>
      <outcome_measure>Allergic Reaction</outcome_measure>
      <outcome_measure>Lung infiltrates</outcome_measure>
      <outcome_measure>Viral load of SARS-CoV-2</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hospital San Jose Tec de Monterrey</lead_sponsor>
      <collaborator>Tecnologico de Monterrey</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>December 20, 2020</primary_completion_date>
    <completion_date>April 30, 2021</completion_date>
    <study_first_posted>April 3, 2020</study_first_posted>
    <last_update_posted>April 3, 2020</last_update_posted>
    <locations>
      <location>Hospital San José, Monterrey, Nuevo Leon, Mexico</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04333355</url>
  </study>
  <study rank="118">
    <nct_id>NCT04365738</nct_id>
    <title>Pulmonary Rehabilitation in Post-Acute Period of COVID-19 Infection</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Rehabilitation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Dyspnea</outcome_measure>
      <outcome_measure>Chest expansion</outcome_measure>
      <outcome_measure>Fatigue severity</outcome_measure>
      <outcome_measure>Visual Analog Scale for pain</outcome_measure>
      <outcome_measure>Hospital anxiety and depression scale</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Istanbul Bilgi University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>28 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>270</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 11, 2020</start_date>
    <primary_completion_date>April 10, 2020</primary_completion_date>
    <completion_date>April 26, 2020</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Istanbul Bilgi University, Istanbul, Turkey</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04365738</url>
  </study>
  <study rank="119">
    <nct_id>NCT04333628</nct_id>
    <title>Chloroquine for Mild Symptomatic and Asymptomatic COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">chloroquine</intervention>
      <intervention type="Other">standard care</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>change in virus duration (viral shedding)</outcome_measure>
      <outcome_measure>change in the number of patients going from asymptomatic to moderately disease</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>HaEmek Medical Center, Israel</lead_sponsor>
      <collaborator>T MAY BIOPHARMA LTD.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>210</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>April 2021</primary_completion_date>
    <completion_date>December 2021</completion_date>
    <study_first_posted>April 3, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04333628</url>
  </study>
  <study rank="120">
    <nct_id>NCT04330599</nct_id>
    <title>Longitudinal Population-based Observational Study of COVID-19 in the UK Population</title>
    <acronym>COVIDENCE UK</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Incidence of confirmed COVID-19</outcome_measure>
      <outcome_measure>Incidence of probable or suspected COVID-19</outcome_measure>
      <outcome_measure>Incidence of COVID-19 requiring hospitalisation</outcome_measure>
      <outcome_measure>Incidence of COVID-19 requiring ventilatory support</outcome_measure>
      <outcome_measure>Incidence of fatal COVID-19</outcome_measure>
      <outcome_measure>Symptom duration per COVID-19 episode</outcome_measure>
      <outcome_measure>Symptom severity per COVID-19 episode</outcome_measure>
      <outcome_measure>Incidence of seroconversion to SARS-CoV-2</outcome_measure>
      <outcome_measure>Incidence of recurrent COVID-19</outcome_measure>
      <outcome_measure>EQ-5D-3L health-related quality of life score</outcome_measure>
      <outcome_measure>Health care costs associated with incident COVID-19</outcome_measure>
      <outcome_measure>Impact of the COVID-19 pandemic and the societal response on participants' financial status</outcome_measure>
      <outcome_measure>Incidence of COVID-19 on participant's physical health</outcome_measure>
      <outcome_measure>Impact of COVID-19 on participants' mental health</outcome_measure>
      <outcome_measure>Impact of COVID-19 on physical health of offspring born to participants during follow-up</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Queen Mary University of London</lead_sponsor>
      <collaborator>King's College London</collaborator>
      <collaborator>London School of Hygiene and Tropical Medicine</collaborator>
      <collaborator>University of Edinburgh</collaborator>
      <collaborator>Swansea University</collaborator>
      <collaborator>Queen's University, Belfast</collaborator>
      <collaborator>Barts Charity</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>16 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>12000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>May 5, 2020</start_date>
    <primary_completion_date>April 1, 2025</primary_completion_date>
    <completion_date>April 1, 2025</completion_date>
    <study_first_posted>April 1, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04330599</url>
  </study>
  <study rank="121">
    <nct_id>NCT04285801</nct_id>
    <title>Critically Ill Patients With COVID-19 in Hong Kong: a Multicentre Observational Cohort Study</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>28 day mortality</outcome_measure>
      <outcome_measure>vasopressor days</outcome_measure>
      <outcome_measure>days on mechanical ventilation</outcome_measure>
      <outcome_measure>sequential organ function assessment score</outcome_measure>
      <outcome_measure>ECMO use</outcome_measure>
      <outcome_measure>percentage nitric oxide use</outcome_measure>
      <outcome_measure>percentage free from oxygen supplement</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Chinese University of Hong Kong</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>8</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>February 14, 2020</start_date>
    <primary_completion_date>February 25, 2020</primary_completion_date>
    <completion_date>February 25, 2020</completion_date>
    <study_first_posted>February 26, 2020</study_first_posted>
    <last_update_posted>March 10, 2020</last_update_posted>
    <locations>
      <location>Pamela Youde Nethersole Eastern Hospital, Hong Kong, Hong Kong</location>
      <location>Prince of Wales Hospital, Hong Kong, Hong Kong</location>
      <location>Princess Margaret Hospital, Hong Kong, Hong Kong</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04285801</url>
  </study>
  <study rank="122">
    <nct_id>NCT04361500</nct_id>
    <title>Registry of COVID-19 Patients Treated With the Seraph 100 Microbind Affinity Blood Filter</title>
    <acronym>COSA</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Seraph 100</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Survival</outcome_measure>
      <outcome_measure>Length of ICU stay</outcome_measure>
      <outcome_measure>Length of Hospital stay</outcome_measure>
      <outcome_measure>Length of ventilator therapy</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hannover Medical School</lead_sponsor>
      <collaborator>Medical Clinic V Nephrology, Academic Teaching Hospital Brunswick</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>99 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>October 1, 2020</primary_completion_date>
    <completion_date>October 1, 2021</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Academic Teaching Hospital Brunswick, Brunswick, Lower Saxony, Germany</location>
      <location>Hannover Medical School, Hannover, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04361500</url>
  </study>
  <study rank="123">
    <nct_id>NCT04304053</nct_id>
    <title>Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention</title>
    <acronym>HCQ4COV19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Treatment and prophylaxis</intervention>
      <intervention type="Other">Standard Public Health measures</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Effectiveness of chemoprophylaxis assessed by incidence of secondary COVID-19 cases</outcome_measure>
      <outcome_measure>The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at days 3</outcome_measure>
      <outcome_measure>The mortality rate of subjects at weeks 2</outcome_measure>
      <outcome_measure>Proportion of participants that drop out of study</outcome_measure>
      <outcome_measure>Proportion of participants that show non-compliance with study drug</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Fundacio Lluita Contra la SIDA</lead_sponsor>
      <collaborator>Germans Trias i Pujol Hospital</collaborator>
      <collaborator>Department of Health, Generalitat de Catalunya</collaborator>
      <collaborator>FUNDACIÓN FLS DE LUCHA CONTRA EL SIDA, LAS ENFERMEDADES INFECCIOSAS Y LA PROMOCIÓN DE LA SALUD Y LA CIENCIA</collaborator>
      <collaborator>Laboratorios Gebro Pharma SA</collaborator>
      <collaborator>Laboratorios Rubió</collaborator>
      <collaborator>Institut Catala de Salut</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>3040</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>March 18, 2020</start_date>
    <primary_completion_date>June 15, 2020</primary_completion_date>
    <completion_date>June 15, 2020</completion_date>
    <study_first_posted>March 11, 2020</study_first_posted>
    <last_update_posted>April 16, 2020</last_update_posted>
    <locations>
      <location>Departament de Salut, Barcelona, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04304053</url>
  </study>
  <study rank="124">
    <nct_id>NCT04362085</nct_id>
    <title>Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Therapeutic Anticoagulation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Composite outcome of ICU admission (yes/no), non-invasive positive pressure ventilation (yes/no), invasive mechanical ventilation (yes/no), or all-cause death (yes/no) up to 28 days.</outcome_measure>
      <outcome_measure>All-cause death</outcome_measure>
      <outcome_measure>Composite outcome of ICU admission or all-cause death</outcome_measure>
      <outcome_measure>Major bleeding</outcome_measure>
      <outcome_measure>Number of participants who received red blood cell transfusion</outcome_measure>
      <outcome_measure>Number of participants with transfusion of platelets, frozen plasma, prothrombin complex concentrate, cryoprecipitate and/or fibrinogen concentrate.</outcome_measure>
      <outcome_measure>Number of hospital-free days alive up to day 28</outcome_measure>
      <outcome_measure>Number of ICU-free days alive up to day 28</outcome_measure>
      <outcome_measure>Number of ventilator-free days alive up to day 28</outcome_measure>
      <outcome_measure>Number of participants with venous thromboembolism</outcome_measure>
      <outcome_measure>Number of participants with arterial thromboembolism</outcome_measure>
      <outcome_measure>Number of participants with heparin induced thrombocytopenia</outcome_measure>
      <outcome_measure>Changes in D-dimer up to day 3</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>St. Michael's Hospital, Toronto</lead_sponsor>
      <collaborator>University of Vermont Medical Center</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>462</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>November 2020</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04362085</url>
  </study>
  <study rank="125">
    <nct_id>NCT04351620</nct_id>
    <title>High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Tolerability of high dose HCQ as measured by HCQ dose modification</outcome_measure>
      <outcome_measure>Tolerability of high dose HCQ as measured by discontinuation of HCQ</outcome_measure>
      <outcome_measure>Tolerability of High Dose HCQ as measured by Adverse Events</outcome_measure>
      <outcome_measure>Rate of hospitalization due to COVID-19 as measured by number of patients hospitalized</outcome_measure>
      <outcome_measure>Time to defervescence as measured in days while on treatment protocol</outcome_measure>
      <outcome_measure>Resolution of other COVID-19 symptoms measured in days while on treatment protocol</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>June 2020</primary_completion_date>
    <completion_date>June 2020</completion_date>
    <study_first_posted>April 17, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations>
      <location>University of Chicago, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04351620</url>
  </study>
  <study rank="126">
    <nct_id>NCT04360278</nct_id>
    <title>Plasma Collection From Convalescent and/or Immunized Donors for the Treatment of COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Collection of convalescent plasma</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institutes of Health Clinical Center (CC)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1500</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>May 1, 2020</start_date>
    <primary_completion_date>April 14, 2030</primary_completion_date>
    <completion_date>April 14, 2030</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>National Institutes of Health Clinical Center, Bethesda, Maryland, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04360278</url>
  </study>
  <study rank="127">
    <nct_id>NCT04363216</nct_id>
    <title>Pharmacologic Ascorbic Acid as an Activator of Lymphocyte Signaling for COVID-19 Treatment</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ascorbic Acid</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clinical Improvement</outcome_measure>
      <outcome_measure>Patient status upgraded to ICU level [Clinical decline]</outcome_measure>
      <outcome_measure>Oxygen supplementation</outcome_measure>
      <outcome_measure>Days with fever</outcome_measure>
      <outcome_measure>Days to discharge</outcome_measure>
      <outcome_measure>SAEs</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Thomas Jefferson University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>66</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>April 2021</primary_completion_date>
    <completion_date>April 2021</completion_date>
    <study_first_posted>April 27, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04363216</url>
  </study>
  <study rank="128">
    <nct_id>NCT04319315</nct_id>
    <title>Social Media Effect on Knowledge Dissemination During COVID-19 Virus Outbreak</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">survey</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of physicians affected by social media measured by online survey designed to measure the influence of social media on medical practice</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assiut University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>25 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 11, 2020</start_date>
    <primary_completion_date>April 1, 2020</primary_completion_date>
    <completion_date>April 16, 2020</completion_date>
    <study_first_posted>March 24, 2020</study_first_posted>
    <last_update_posted>April 7, 2020</last_update_posted>
    <locations>
      <location>Assiut University Hospitals, Assiut, Egypt</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04319315</url>
  </study>
  <study rank="129">
    <nct_id>NCT04334382</nct_id>
    <title>Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19</title>
    <acronym>HyAzOUT</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Drug">Azithromycin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Hospitalization within 14 days of enrollment</outcome_measure>
      <outcome_measure>Duration of COVID-19-attributable symptoms</outcome_measure>
      <outcome_measure>Hospital-free days at 28 days</outcome_measure>
      <outcome_measure>Ventilator-free days at 28 days</outcome_measure>
      <outcome_measure>ICU-free days at 28 days</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Intermountain Health Care, Inc.</lead_sponsor>
      <collaborator>University of Utah</collaborator>
      <collaborator>Utah Department of Health</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>45 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1550</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2, 2020</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>December 31, 2021</completion_date>
    <study_first_posted>April 6, 2020</study_first_posted>
    <last_update_posted>April 9, 2020</last_update_posted>
    <locations>
      <location>Intermountain Medical Center, Murray, Utah, United States</location>
      <location>University of Utah, Salt Lake City, Utah, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04334382</url>
  </study>
  <study rank="130">
    <nct_id>NCT04357990</nct_id>
    <title>Kerecis Oral and Nasal Spray for Treating the Symptoms of COVID-19</title>
    <acronym>KONS-COVID-19</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Kerecis Oral and Nasal Spray</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of days until complete resolution of symptoms per group</outcome_measure>
      <outcome_measure>Number of hospital admissions per group</outcome_measure>
      <outcome_measure>Number of days until a reduction in symptoms per group</outcome_measure>
      <outcome_measure>Number of adverse events per group</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Kerecis Ltd.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>81</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>July 2020</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04357990</url>
  </study>
  <study rank="131">
    <nct_id>NCT04358211</nct_id>
    <title>Expanded Access to Convalescent Plasma to Treat and Prevent Pulmonary Complications Associated With COVID-19</title>
    <acronym/>
    <status open="Y">Available</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Biological: COVID-19 convalescent plasma</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Nakhle Saba, MD</lead_sponsor>
      <collaborator>Tulane University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Expanded Access</study_types>
    <exp_acc_types>
      <exp_acc_type>Intermediate-size Population</exp_acc_type>
      <exp_acc_type>Treatment IND/Protocol</exp_acc_type>
    </exp_acc_types>
    <study_designs/>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Tulane Medical Center, New Orleans, Louisiana, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04358211</url>
  </study>
  <study rank="132">
    <nct_id>NCT04335136</nct_id>
    <title>Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19</title>
    <acronym>APN01-COVID-19</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">RhACE2 APN01</intervention>
      <intervention type="Drug">Physiological saline solution</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Cause of death or invasive mechanical ventilation</outcome_measure>
      <outcome_measure>LDH level</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>VFD</outcome_measure>
      <outcome_measure>Time to death</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Apeiron Biologics</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>35 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>September 2020</primary_completion_date>
    <completion_date>November 2020</completion_date>
    <study_first_posted>April 6, 2020</study_first_posted>
    <last_update_posted>April 6, 2020</last_update_posted>
    <locations>
      <location>Medizinische Universität Innsbruck, Innsbruck, Austria</location>
      <location>Kaiser Franz Josef Spital, 4. Medizinische Abteilung mit Infektions- und Tropenmedizin, Wien, Austria</location>
      <location>Medizinische Universität Wien, Wien, Austria</location>
      <location>The National University Hospital, Rigshospitalet, Copenhagen, Denmark</location>
      <location>Herlev Gentofte Hospital, Herlev, Denmark</location>
      <location>Nordsjællands Hospital, Hillerød, Denmark</location>
      <location>Hvidovre Hospital, Hvidovre, Denmark</location>
      <location>Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany</location>
      <location>Klinikum rechts der Isar, Technische Universität München, München, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04335136</url>
  </study>
  <study rank="133">
    <nct_id>NCT04331366</nct_id>
    <title>Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19</title>
    <acronym>GO2 PEEP</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Device">GO2 PEEP MOUTHPIECE</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in Oxygen Saturation by Pulse Oximetry</outcome_measure>
      <outcome_measure>Change in Respiratory Rate</outcome_measure>
      <outcome_measure>Change in Heart Rate</outcome_measure>
      <outcome_measure>Change in Blood Pressure</outcome_measure>
      <outcome_measure>Change in Subjective Work of Breathing</outcome_measure>
      <outcome_measure>Change in Partial Pressure of Oxygen (PaO2)</outcome_measure>
      <outcome_measure>Change in Partial Pressure of Carbon Dioxide (PaCO2)</outcome_measure>
      <outcome_measure>Change in pH</outcome_measure>
      <outcome_measure>Change in Bicarbonate (HCO3)</outcome_measure>
      <outcome_measure>Change in Oxygen Saturation (O2Sat) by Arterial Blood Gas Test</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Emory University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>5</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <start_date>April 8, 2020</start_date>
    <primary_completion_date>May 2020</primary_completion_date>
    <completion_date>May 2020</completion_date>
    <study_first_posted>April 2, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>Emory University Hospital, Atlanta, Georgia, United States</location>
      <location>Emory St. Joseph's Hospital, Atlanta, Georgia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04331366</url>
  </study>
  <study rank="134">
    <nct_id>NCT04362189</nct_id>
    <title>Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">HB-adMSC</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">HC</intervention>
      <intervention type="Drug">AZ</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>28-day mortality</outcome_measure>
      <outcome_measure>Invasive mechanical ventilation</outcome_measure>
      <outcome_measure>Leukocyte differential</outcome_measure>
      <outcome_measure>C Reactive protein</outcome_measure>
      <outcome_measure>TNF alpha</outcome_measure>
      <outcome_measure>IL-6</outcome_measure>
      <outcome_measure>Glucose</outcome_measure>
      <outcome_measure>Calcium</outcome_measure>
      <outcome_measure>Albumin</outcome_measure>
      <outcome_measure>Total protein</outcome_measure>
      <outcome_measure>Sodium</outcome_measure>
      <outcome_measure>Total carbon dioxide</outcome_measure>
      <outcome_measure>Potassium</outcome_measure>
      <outcome_measure>Chloride</outcome_measure>
      <outcome_measure>BUN</outcome_measure>
      <outcome_measure>Creatinine</outcome_measure>
      <outcome_measure>Alkaline phosphatase</outcome_measure>
      <outcome_measure>Alanine aminotransferase</outcome_measure>
      <outcome_measure>Total bilirubin</outcome_measure>
      <outcome_measure>White blood cells</outcome_measure>
      <outcome_measure>Red blood cells</outcome_measure>
      <outcome_measure>Hemoglobin</outcome_measure>
      <outcome_measure>Hematocrit</outcome_measure>
      <outcome_measure>Mean corpuscular volume</outcome_measure>
      <outcome_measure>Mean corpuscular hemoglobin</outcome_measure>
      <outcome_measure>Mean corpuscular hemoglobin concentration</outcome_measure>
      <outcome_measure>Red cell distribution width</outcome_measure>
      <outcome_measure>Neutrophils</outcome_measure>
      <outcome_measure>Lymphs</outcome_measure>
      <outcome_measure>Monocytes</outcome_measure>
      <outcome_measure>Eosinophils</outcome_measure>
      <outcome_measure>Basophils</outcome_measure>
      <outcome_measure>Absolute neutrophils</outcome_measure>
      <outcome_measure>Absolute lymphs</outcome_measure>
      <outcome_measure>Absolute monocytes</outcome_measure>
      <outcome_measure>Absolute eosinophils</outcome_measure>
      <outcome_measure>Absolute basophils</outcome_measure>
      <outcome_measure>Immature granulocytes</outcome_measure>
      <outcome_measure>Platelets</outcome_measure>
      <outcome_measure>Prothrombin time</outcome_measure>
      <outcome_measure>INR</outcome_measure>
      <outcome_measure>NK cell surface antigen (CD3-CD54+)</outcome_measure>
      <outcome_measure>CD4+/CD8+ ratio</outcome_measure>
      <outcome_measure>IL-10</outcome_measure>
      <outcome_measure>VEGF</outcome_measure>
      <outcome_measure>D-dimer</outcome_measure>
      <outcome_measure>Myoglobin</outcome_measure>
      <outcome_measure>Troponin</outcome_measure>
      <outcome_measure>Creatinine kinase</outcome_measure>
      <outcome_measure>Serum ferritin</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hope Biosciences</lead_sponsor>
      <collaborator>Advanced Diagnostics Healthcare</collaborator>
      <collaborator>Hope Biosciences Stem Cell Research Foundation</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>110</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 15, 2020</start_date>
    <primary_completion_date>October 31, 2020</primary_completion_date>
    <completion_date>October 31, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>River Oaks Hospital and Clinics, Houston, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04362189</url>
  </study>
  <study rank="135">
    <nct_id>NCT04359511</nct_id>
    <title>Efficacy and Safety of Corticosteroids in Oxygen-dependent Patients With COVID-19 Pneumonia</title>
    <acronym>CORTICOVIDHUGO</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Prednisone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clinical improvement defined by the improvement of 2 points on a 7-category ordinal scale, at 14 days.</outcome_measure>
      <outcome_measure>Proportion of patients free of oxygen at day 14 and 28</outcome_measure>
      <outcome_measure>Proportion of patients discharged alive from hospital at day 14 and 28</outcome_measure>
      <outcome_measure>Time to discharge for patients alive</outcome_measure>
      <outcome_measure>Proportion of patients that were hospitalized to ICU or who died at day 14 and 28</outcome_measure>
      <outcome_measure>14 and 28 day mortality rate</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Tours</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>210</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 2020</start_date>
    <primary_completion_date>November 2020</primary_completion_date>
    <completion_date>November 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04359511</url>
  </study>
  <study rank="136">
    <nct_id>NCT04331795</nct_id>
    <title>Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis</title>
    <acronym>COVIDOSE</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tocilizumab</intervention>
      <intervention type="Drug">Tocilizumab</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clinical response</outcome_measure>
      <outcome_measure>Biochemical response</outcome_measure>
      <outcome_measure>Overall survival</outcome_measure>
      <outcome_measure>Survival to hospital discharge</outcome_measure>
      <outcome_measure>Progression of COVID-19 pneumonitis</outcome_measure>
      <outcome_measure>Rate of non-elective mechanical ventilation</outcome_measure>
      <outcome_measure>Duration of mechanical ventilation</outcome_measure>
      <outcome_measure>Time to mechanical ventilation</outcome_measure>
      <outcome_measure>Rate of vasopressor/inotrope utilization</outcome_measure>
      <outcome_measure>Duration of vasopressor/inotrope utilization</outcome_measure>
      <outcome_measure>Time to vasopressor or inotropic utilization</outcome_measure>
      <outcome_measure>Number of ICU days</outcome_measure>
      <outcome_measure>Duration of Increased Supplemental Oxygen Requirement from Baseline</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 4, 2020</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>April 2, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations>
      <location>University of Chicago Medicine, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04331795</url>
  </study>
  <study rank="137">
    <nct_id>NCT04333225</nct_id>
    <title>Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers</title>
    <acronym/>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Rate of COVID-19 positive conversion</outcome_measure>
      <outcome_measure>Time-to-first clinical event</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Baylor Research Institute</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>360</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 3, 2020</start_date>
    <primary_completion_date>July 30, 2020</primary_completion_date>
    <completion_date>July 30, 2020</completion_date>
    <study_first_posted>April 3, 2020</study_first_posted>
    <last_update_posted>April 10, 2020</last_update_posted>
    <locations>
      <location>Baylor University Medical Center, Dallas, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04333225</url>
  </study>
  <study rank="138">
    <nct_id>NCT04351724</nct_id>
    <title>Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)</title>
    <acronym>ACOVACT</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Chloroquine or Hydroxychloroquine</intervention>
      <intervention type="Drug">Lopinavir/Ritonavir</intervention>
      <intervention type="Other">Best standard of care</intervention>
      <intervention type="Drug">Rivaroxaban</intervention>
      <intervention type="Drug">Thromboprophylaxis</intervention>
      <intervention type="Drug">Candesartan</intervention>
      <intervention type="Drug">non-RAS blocking antihypertensives</intervention>
      <intervention type="Drug">Clazakizumab</intervention>
      <intervention type="Drug">placebo for clazakizumab</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>sustained improvement (&gt;48h) of one point on the WHO Scale</outcome_measure>
      <outcome_measure>Time to improvement on WHO Scale</outcome_measure>
      <outcome_measure>Mean change in the ranking on an ordinal scale from baseline</outcome_measure>
      <outcome_measure>time to discharge or a National Early Warning Score (NEWS) ≤2 (maintained for 24h), whichever occurs first</outcome_measure>
      <outcome_measure>change from baseline in National Early Warning Score (NEWS)</outcome_measure>
      <outcome_measure>Oxygenation free days</outcome_measure>
      <outcome_measure>Incidence of new oxygen use during the trial</outcome_measure>
      <outcome_measure>duration of oxygen use during the trial</outcome_measure>
      <outcome_measure>Ventilator free days until day 29</outcome_measure>
      <outcome_measure>Incidence of new mechanical ventilation use during the trial</outcome_measure>
      <outcome_measure>duration of mechanical ventilation use during the trial</outcome_measure>
      <outcome_measure>Viral load/viral clearance</outcome_measure>
      <outcome_measure>Duration of Hospitalization</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>Obesity - mortality</outcome_measure>
      <outcome_measure>Obesity - duration of hospitalization</outcome_measure>
      <outcome_measure>Obesity - ICU admission</outcome_measure>
      <outcome_measure>Obesity - new oxygen use</outcome_measure>
      <outcome_measure>Drug-drug interactions with lopinavir/ritonavir</outcome_measure>
      <outcome_measure>Renin Angiotensin System (RAS) fingerprint</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Medical University of Vienna</lead_sponsor>
      <collaborator>Kaiser Franz Josef Hospital</collaborator>
      <collaborator>SMZ-Ost Donauspital</collaborator>
      <collaborator>Otto Wagner Hospital</collaborator>
      <collaborator>Hospital Hietzing</collaborator>
      <collaborator>Wilhelminenspital Vienna</collaborator>
      <collaborator>Medical University Innsbruck</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>99 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 16, 2020</start_date>
    <primary_completion_date>December 1, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>April 17, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Medical University of Innsbruck, Innsbruck, Tirol, Austria</location>
      <location>Medical University of Vienna, Vienna, Austria</location>
      <location>Wilhelminenspital, Vienna, Austria</location>
      <location>SMZ Süd Kaiser Franz Josef Spital, Vienna, Austria</location>
      <location>KH Hietzing, Vienna, Austria</location>
      <location>SMZ Baumgartner Höhe Otto Wagner Spital, Vienna, Austria</location>
      <location>SMZ Ost Donauspital, Vienna, Austria</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04351724</url>
  </study>
  <study rank="139">
    <nct_id>NCT04344444</nct_id>
    <title>Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease</title>
    <acronym>RCT</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Drug">Azithromycin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Most severe outcome</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>LCMC Health</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>100 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>600</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 10, 2020</start_date>
    <primary_completion_date>April 10, 2021</primary_completion_date>
    <completion_date>December 10, 2021</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>University Medical Center New Orleans, New Orleans, Louisiana, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04344444</url>
  </study>
  <study rank="140">
    <nct_id>NCT04359264</nct_id>
    <title>Direct Income SupporT and Advice Negating Spread of Epidemic COVID-19: a Randomized Controlled Trial</title>
    <acronym>DISTANSE COVID</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Cash transfer</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Symptoms consisent with COVID-19</outcome_measure>
      <outcome_measure>Number of close contacts</outcome_measure>
      <outcome_measure>Number of participants with positive test for COVID-19</outcome_measure>
      <outcome_measure>Self-reported health based on the single question: &quot;In general, would you say your health is..&quot;</outcome_measure>
      <outcome_measure>Ability to make ends meet based on the single question: &quot;At the end of the month, are you able to make ends meet?&quot;</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>St. Michael's Hospital, Toronto</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>392</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>June 30, 2021</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Municipality of Assiginack Family Health Team, Assiginack, Ontario, Canada</location>
      <location>St Michael's Hospital Academic Family Health Team, Toronto, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04359264</url>
  </study>
  <study rank="141">
    <nct_id>NCT04344080</nct_id>
    <title>Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19</title>
    <acronym>CYTOCOV-19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Device">CytoSorb-Therapy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Percentage of patients with a significant stabilization of hemodynamics for at least 24 hours</outcome_measure>
      <outcome_measure>Change in organ dysfunction</outcome_measure>
      <outcome_measure>Lactate clearance</outcome_measure>
      <outcome_measure>Renal replacement therapy</outcome_measure>
      <outcome_measure>Extracorporeal Membrane Oxygenation</outcome_measure>
      <outcome_measure>ICU length of stay</outcome_measure>
      <outcome_measure>Time on mechanical ventilation</outcome_measure>
      <outcome_measure>Cumulative catecholamine dose</outcome_measure>
      <outcome_measure>Overall and ICU mortality</outcome_measure>
      <outcome_measure>Change of plasma Interleukin-6 (IL6) level</outcome_measure>
      <outcome_measure>Change of plasma Interleukin-10 (IL10) level</outcome_measure>
      <outcome_measure>Change of plasma Procalcitonin (PCT) level</outcome_measure>
      <outcome_measure>Change of HLA-DR level</outcome_measure>
      <outcome_measure>Change of TNF alpha level after ex-vivo stimulation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Universitätsklinikum Hamburg-Eppendorf</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>December 2020</primary_completion_date>
    <completion_date>February 2021</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>University Medical Center Hamburg-Eppendorf, Hamburg, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04344080</url>
  </study>
  <study rank="142">
    <nct_id>NCT04352465</nct_id>
    <title>Efficacy and Safety of MTX-loaded Nanoparticles to Treat Severe COVID-19 Patients</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Methotrexate</intervention>
      <intervention type="Drug">Methotrexate</intervention>
      <intervention type="Drug">Methotrexate</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in clinical conditions</outcome_measure>
      <outcome_measure>Change of Clinical symptoms - respiratory rate</outcome_measure>
      <outcome_measure>Hypoxia</outcome_measure>
      <outcome_measure>Changes of blood oxygen</outcome_measure>
      <outcome_measure>Inflammatory parameters</outcome_measure>
      <outcome_measure>Evolution of Acute Respiratory Syndrome</outcome_measure>
      <outcome_measure>Hospital discharge</outcome_measure>
      <outcome_measure>ICU discharge</outcome_measure>
      <outcome_measure>Rate of mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Azidus Brasil</lead_sponsor>
      <collaborator>InCor Heart Institute</collaborator>
      <collaborator>Hospital Santa Marcelina</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>42</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 1, 2020</start_date>
    <primary_completion_date>June 30, 2020</primary_completion_date>
    <completion_date>November 30, 2020</completion_date>
    <study_first_posted>April 20, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04352465</url>
  </study>
  <study rank="143">
    <nct_id>NCT04348448</nct_id>
    <title>Observational Study, Use of Canakinumab Administered Subcutaneously in the Treatment COVID-19 Pneumonia</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Canakinumab 150 MG/ML [Ilaris]</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>intensive care treatment</outcome_measure>
      <outcome_measure>ICU stay times</outcome_measure>
      <outcome_measure>% died after 1 month after treatment</outcome_measure>
      <outcome_measure>hospitalization</outcome_measure>
      <outcome_measure>adverse event</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>AUSL Romagna Rimini</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>100 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>September 2020</completion_date>
    <study_first_posted>April 16, 2020</study_first_posted>
    <last_update_posted>April 16, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04348448</url>
  </study>
  <study rank="144">
    <nct_id>NCT04354597</nct_id>
    <title>Hydroxychloroquine and Azithromycin as Prophylaxis for Healthcare Workers Dealing With COVID19 Patients</title>
    <acronym>MOPHYDA</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">HCQ &amp; AZ</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Effect of HCQ and AZ in preventing infection with COVID-19 among healthcare workers working with COVID-19 patients</outcome_measure>
      <outcome_measure>Safety of HCQ and AZ</outcome_measure>
      <outcome_measure>Oxygen requirement</outcome_measure>
      <outcome_measure>ICU admission</outcome_measure>
      <outcome_measure>Mortality rate</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Iyad Sultan</lead_sponsor>
      <collaborator>King Hussein Cancer Center</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>August 15, 2020</primary_completion_date>
    <completion_date>October 15, 2020</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>King Hussein Cancer Center, Amman, Jordan</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04354597</url>
  </study>
  <study rank="145">
    <nct_id>NCT04365634</nct_id>
    <title>A Single-center Retrospective Study to Find Prediction Factors Related to Mortality of COVID-19 Patients.</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Find the prediction factors associated with hospitalized death of patients with COVID-19 by univariate and multivariate analysis</outcome_measure>
      <outcome_measure>Demographics and clinical characteristics</outcome_measure>
      <outcome_measure>Laboratory parameters and radiography image features</outcome_measure>
      <outcome_measure>Treatment, complications and clinical outcomes</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tongji Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>306</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>February 2, 2020</start_date>
    <primary_completion_date>March 15, 2020</primary_completion_date>
    <completion_date>April 1, 2020</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Tongji Hospital, Wuhan, Hubei, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04365634</url>
  </study>
  <study rank="146">
    <nct_id>NCT04357535</nct_id>
    <title>Prognosis of Coronavirus Disease 2019 (COVID-19) Patients Receiving Receiving Antihypertensives</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Angiotensin-Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Blockers (ARB)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Assess the rate of requirement of invasive mechanical ventilation</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>Septic shock as defined by sepsis-3 criteria</outcome_measure>
      <outcome_measure>Degree of severity of respiratory disease</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hakeam Abdulaziz Hakeam</lead_sponsor>
      <collaborator>King Faisal Specialist Hospital &amp; Research Center</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>226</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 12, 2020</start_date>
    <primary_completion_date>July 31, 2020</primary_completion_date>
    <completion_date>September 30, 2020</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>King Faisal Specialist Hospital &amp; Research Centre, Riyadh, Saudi Arabia</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04357535</url>
  </study>
  <study rank="147">
    <nct_id>NCT04344236</nct_id>
    <title>Gargling and Nasal Rinses to Reduce Oro- and Nasopharyngeal Viral Load in Patients With COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Saline oral/nasal rinse</intervention>
      <intervention type="Drug">0.5% Povidone/Iodine oral/nasal rinse</intervention>
      <intervention type="Drug">0.12% Chlorhexidine oral/nasal rinse</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Viral load (and/or cycle time to PCR as a proxy for quantitative viral load) in the nasopharynx and oropharynx</outcome_measure>
      <outcome_measure>Oxygen requirement of the patient</outcome_measure>
      <outcome_measure>Oxygen saturation of the patient</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>NYU Langone Health</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>79 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>48</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 9, 2020</start_date>
    <primary_completion_date>May 1, 2020</primary_completion_date>
    <completion_date>May 9, 2020</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>NYU Langone Health, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04344236</url>
  </study>
  <study rank="148">
    <nct_id>NCT04307693</nct_id>
    <title>Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Lopinavir/ritonavir</intervention>
      <intervention type="Drug">Hydroxychloroquine sulfate</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Viral load</outcome_measure>
      <outcome_measure>Viral load change</outcome_measure>
      <outcome_measure>Time to clinical improvement (TTCI)</outcome_measure>
      <outcome_measure>Percentage of progression to supplemental oxygen requirement by day 7</outcome_measure>
      <outcome_measure>Time to NEWS2 (National Early Warning Score 2) of 3 or more maintained for 24 hours by day 7</outcome_measure>
      <outcome_measure>Time to clinical failure, defined as the time to death, mechanical ventilation, or ICU admission</outcome_measure>
      <outcome_measure>Rate of switch to Lopinavir/ritonavir or hydroxychloroquine by day 7</outcome_measure>
      <outcome_measure>adverse effects</outcome_measure>
      <outcome_measure>Concentration of Lopinavir/ritonavir and hydroxychloroquine</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Asan Medical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>16 Years</min_age>
    <max_age>99 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 11, 2020</start_date>
    <primary_completion_date>May 2020</primary_completion_date>
    <completion_date>May 2020</completion_date>
    <study_first_posted>March 13, 2020</study_first_posted>
    <last_update_posted>March 13, 2020</last_update_posted>
    <locations>
      <location>Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04307693</url>
  </study>
  <study rank="149">
    <nct_id>NCT04363814</nct_id>
    <title>Clinical Impact of BACTEK-R in Subject With Mild Pneumonia Due to COVID-19 Infection</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Bactek-R</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clinical recovery</outcome_measure>
      <outcome_measure>Clinical worsening</outcome_measure>
      <outcome_measure>Clinical severity</outcome_measure>
      <outcome_measure>Time to symptoms remission</outcome_measure>
      <outcome_measure>Medication Use</outcome_measure>
      <outcome_measure>Hospitalization time</outcome_measure>
      <outcome_measure>Blood routine test</outcome_measure>
      <outcome_measure>Heart rate</outcome_measure>
      <outcome_measure>Blood pressure</outcome_measure>
      <outcome_measure>Cardiac auscultation</outcome_measure>
      <outcome_measure>Oxygen saturation</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Inmunotek S.L.</lead_sponsor>
      <collaborator>BioClever 2005 S.L.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 10, 2020</start_date>
    <primary_completion_date>July 1, 2020</primary_completion_date>
    <completion_date>July 31, 2020</completion_date>
    <study_first_posted>April 27, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04363814</url>
  </study>
  <study rank="150">
    <nct_id>NCT04345692</nct_id>
    <title>A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients</title>
    <acronym>OAHU-COVID19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>i. Clinical status</outcome_measure>
      <outcome_measure>Oxygenation</outcome_measure>
      <outcome_measure>Mechanical Ventilation</outcome_measure>
      <outcome_measure>Hospitalization</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Queen's Medical Centre</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>95 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>350</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 26, 2020</start_date>
    <primary_completion_date>December 31, 2021</primary_completion_date>
    <completion_date>December 31, 2021</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>Queen's Medical Center, Honolulu, Hawaii, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04345692</url>
  </study>
  <study rank="151">
    <nct_id>NCT04331899</nct_id>
    <title>Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19</title>
    <acronym>COVID-Lambda</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon Lambda-1a</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Duration of Viral shedding of SARS-CoV-2 by qRT-PCR</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Stanford University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>64 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 24, 2020</start_date>
    <primary_completion_date>May 31, 2021</primary_completion_date>
    <completion_date>May 31, 2022</completion_date>
    <study_first_posted>April 2, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>Stanford University School of Medicine, Stanford, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04331899</url>
  </study>
  <study rank="152">
    <nct_id>NCT04362332</nct_id>
    <title>Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19</title>
    <acronym>ARCHAIC</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Chloroquine Sulfate</intervention>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Other">Standard supportive care</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Composite endpoint with disease progression defined as a NEWS2score ≥ 7 within 14 days or resulting in admission to Intensive/Medium Care unit or resulting in death within 14 days.</outcome_measure>
      <outcome_measure>Side effects</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>UMC Utrecht</lead_sponsor>
      <collaborator>ZonMw: The Netherlands Organisation for Health Research and Development</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>110 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>950</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 14, 2020</start_date>
    <primary_completion_date>April 14, 2021</primary_completion_date>
    <completion_date>May 14, 2021</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>UMCU, Utrecht, Netherlands</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04362332</url>
  </study>
  <study rank="153">
    <nct_id>NCT04323631</nct_id>
    <title>Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Other">The control group will not receive hydroxychloroquine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number patients developing severe infection or death</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Rambam Health Care Campus</lead_sponsor>
      <collaborator>Rabin Medical Center</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Early Phase 1</phase>
    </phases>
    <enrollment>1116</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 2020</start_date>
    <primary_completion_date>December 2020</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>March 26, 2020</study_first_posted>
    <last_update_posted>March 26, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04323631</url>
  </study>
  <study rank="154">
    <nct_id>NCT04331834</nct_id>
    <title>Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic</title>
    <acronym>PrEP_COVID</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Drug">Placebos</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Confirmed cases of a COVID-19</outcome_measure>
      <outcome_measure>SARS-CoV-2 seroconversion</outcome_measure>
      <outcome_measure>Occurrence of any adverse event related with hydroxychloroquine treatment</outcome_measure>
      <outcome_measure>Incidence of SARS-CoV-2 infection and COVID-19 among healthcare workers</outcome_measure>
      <outcome_measure>Risk ratio for the different clinical, analytical and microbiological conditions to develop COVID-19</outcome_measure>
      <outcome_measure>COVID-19 Biobank</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Barcelona Institute for Global Health</lead_sponsor>
      <collaborator>Hospital Clinic of Barcelona</collaborator>
      <collaborator>Laboratorios Rubió</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>440</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 3, 2020</start_date>
    <primary_completion_date>October 3, 2020</primary_completion_date>
    <completion_date>October 30, 2020</completion_date>
    <study_first_posted>April 2, 2020</study_first_posted>
    <last_update_posted>April 7, 2020</last_update_posted>
    <locations>
      <location>ISGlobal, Barcelona, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04331834</url>
  </study>
  <study rank="155">
    <nct_id>NCT04336254</nct_id>
    <title>Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">allogeneic human dental pulp stem cells (BSH BTC &amp; Utooth BTC)</intervention>
      <intervention type="Other">Intravenous saline injection (Placebo)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>TTCI</outcome_measure>
      <outcome_measure>Lung lesion</outcome_measure>
      <outcome_measure>Immune function</outcome_measure>
      <outcome_measure>Time of SARS-CoV-2 clearance</outcome_measure>
      <outcome_measure>Blood test</outcome_measure>
      <outcome_measure>SPO2</outcome_measure>
      <outcome_measure>RR</outcome_measure>
      <outcome_measure>Body temperature</outcome_measure>
      <outcome_measure>Side effects in the treatment group</outcome_measure>
      <outcome_measure>C-reactive protein (mg/L)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Renmin Hospital of Wuhan University</lead_sponsor>
      <collaborator>Beijing SH Bio-Tech Corporation, Beijing (CN)</collaborator>
      <collaborator>Utooth Biological Technology Co., Ltd. Hubei (CN)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 6, 2020</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>March 31, 2021</completion_date>
    <study_first_posted>April 7, 2020</study_first_posted>
    <last_update_posted>April 7, 2020</last_update_posted>
    <locations>
      <location>Renmin Hospital of Wuhan University (East Campus), Wuhan, Hubei, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04336254</url>
  </study>
  <study rank="156">
    <nct_id>NCT04313023</nct_id>
    <title>The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PUL-042 Inhalation Solution</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Severity of COVID-19</outcome_measure>
      <outcome_measure>Incidence of SARS-CoV-2 infection</outcome_measure>
      <outcome_measure>ICU admission</outcome_measure>
      <outcome_measure>Mechanical ventilation</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Pulmotect, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>September 2020</primary_completion_date>
    <completion_date>October 2020</completion_date>
    <study_first_posted>March 18, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04313023</url>
  </study>
  <study rank="157">
    <nct_id>NCT04332094</nct_id>
    <title>Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19</title>
    <acronym>TOCOVID</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tocilizumab</intervention>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Drug">Azithromycin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>In-hospital mortality</outcome_measure>
      <outcome_measure>Need for mechanical ventilation in the Intensive Care Unit</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</lead_sponsor>
      <collaborator>Instituto de Salud Carlos III</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>276</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2, 2020</start_date>
    <primary_completion_date>September 2020</primary_completion_date>
    <completion_date>October 2020</completion_date>
    <study_first_posted>April 2, 2020</study_first_posted>
    <last_update_posted>April 7, 2020</last_update_posted>
    <locations>
      <location>Hospital de la Santa Creu i Sant Pau, Barcelona, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04332094</url>
  </study>
  <study rank="158">
    <nct_id>NCT04292899</nct_id>
    <title>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Remdesivir</intervention>
      <intervention type="Drug">Standard of Care</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 14</outcome_measure>
      <outcome_measure>Proportion of Participants Experiencing any Treatment-Emergent Adverse Events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>12 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>6000</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 6, 2020</start_date>
    <primary_completion_date>May 2020</primary_completion_date>
    <completion_date>May 2020</completion_date>
    <study_first_posted>March 3, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States</location>
      <location>Mills-Peninsula Medical Center, Burlingame, California, United States</location>
      <location>Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States</location>
      <location>Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States</location>
      <location>St Joseph Hospital Eureka, Fortuna, California, United States</location>
      <location>Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States</location>
      <location>Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States</location>
      <location>Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States</location>
      <location>Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue, Los Angeles, California, United States</location>
      <location>Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue, Los Angeles, California, United States</location>
      <location>Mission Hospital Regional Medical Center, Mission Viejo, California, United States</location>
      <location>Kaiser Permanente Los Angeles Medical Center, 27300 Iris Avenue, Moreno Valley, California, United States</location>
      <location>El Camino Hospital, Mountain View, California, United States</location>
      <location>Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States</location>
      <location>Kaiser Permanente Oakland Medical Center, Oakland, California, United States</location>
      <location>Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue, Ontario, California, United States</location>
      <location>The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California, United States</location>
      <location>Kaiser Permanente Los Angeles Medical Center, 13651 Willard Street, Panorama City, California, United States</location>
      <location>Sutter Medical Center Sacramento, One Medical Plaza, Roseville, California, United States</location>
      <location>Sutter Medical Center Sacramento, Sacramento, California, United States</location>
      <location>Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd, San Diego, California, United States</location>
      <location>Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue, San Diego, California, United States</location>
      <location>Kaiser Permanente Oakland Medical Center, 1200 El Camino Real, San Francisco, California, United States</location>
      <location>California Pacific Medical Center-Infectious Disease Associates Medical Group, San Francisco, California, United States</location>
      <location>Kaiser Permanente-Oakland, 2425 Geary Blvd, San Francisco, California, United States</location>
      <location>Kaiser Permanente Oakland Medical Center, 250 Hospital Parkway, Suite 850, San Jose, California, United States</location>
      <location>Kaiser Permanente Oakland Medical Center, 2500 Merced St, San Leandro, California, United States</location>
      <location>Kaiser Permanente Oakland Medical Center, 700 Lawrence Expressway, Santa Clara, California, United States</location>
      <location>Providence St. Johns Medical Center, Santa Monica, California, United States</location>
      <location>Sutter Santa Rosa Regional Hospital, Santa Rosa, California, United States</location>
      <location>Stanford Hospital, Stanford, California, United States</location>
      <location>University of Colorado Denver, University of Colorado Hospital, Aurora, Colorado, United States</location>
      <location>SCL Health St. Joseph Hospital, 1375 East 19th Ave, Denver, Colorado, United States</location>
      <location>SCL Health St. Joseph Hospital, Denver, Colorado, United States</location>
      <location>Rose Medical Center, Denver, Colorado, United States</location>
      <location>SCL Health St. Joseph Hospital, 200 Exempla Circle., Lafayette, Colorado, United States</location>
      <location>Yale-New Haven Hospital, New Haven, Connecticut, United States</location>
      <location>Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii, United States</location>
      <location>John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States</location>
      <location>Rush University Medical Center, Chicago, Illinois, United States</location>
      <location>University of Chicago, Chicago, Illinois, United States</location>
      <location>IU Health Methodist Hospital, Indianapolis, Indiana, United States</location>
      <location>University of Iowa Hospitals &amp; Clinics, Iowa City, Iowa, United States</location>
      <location>Tulane University, New Orleans, Louisiana, United States</location>
      <location>Maine Medical Center, Portland, Maine, United States</location>
      <location>Holy Cross Hospital, Silver Spring, Maryland, United States</location>
      <location>Tufts Medical Center, Boston, Massachusetts, United States</location>
      <location>Brigham &amp; Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States</location>
      <location>Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States</location>
      <location>The University of Michigan Hospitals and Health Systems, Ann Arbor, Michigan, United States</location>
      <location>Henry Ford Health System, Detroit, Michigan, United States</location>
      <location>Hennepin Healthcare, Minneapolis, Minnesota, United States</location>
      <location>Mayo Clinic, Rochester, Minnesota, United States</location>
      <location>Providence St Patrick Hospital and International Heart Institute of MT Foundation, Missoula, Montana, United States</location>
      <location>Darmouth-Hitchhock Medical Center, Lebanon, New Hampshire, United States</location>
      <location>Hackensack University Medical Center, Hackensack, New Jersey, United States</location>
      <location>Robert Wood Johnson University Hospital Somerset, Hillsborough, New Jersey, United States</location>
      <location>Robert Wood Johnson University Hospital Somerset, 1 RWJ Place, New Brunswick, New Jersey, United States</location>
      <location>Robert Wood Johnson University Hospital Somerset, 201 Lyons Avenue, Newark, New Jersey, United States</location>
      <location>St. Joseph's University Medical Center, Paterson, New Jersey, United States</location>
      <location>Jacobi Medical Center, Bronx, New York, United States</location>
      <location>James J. Peters Veterans Administration Medical Center, Bronx, New York, United States</location>
      <location>Jamaica Hospital Medical Center, Jamaica, New York, United States</location>
      <location>Danbury Hospital, Lagrangeville, New York, United States</location>
      <location>North Shore University Hospital, 270-05 76th Ave, Manhasset, New York, United States</location>
      <location>North Shore University Hospital, Manhasset, New York, United States</location>
      <location>Icahn School of Medicine at Mount Sinai, 350 East 17th Street, New York, New York, United States</location>
      <location>Icahn School of Medicine at Mount Sinai, 440 West 114th St., New York, New York, United States</location>
      <location>Icahn School of Medicine at Mount Sinai, 1000 10th Avenue, New York, New York, United States</location>
      <location>Icahn School of Medicine at Mount Sinai, New York, New York, United States</location>
      <location>Columbia University Medical Center-New York Presbyterian Hospital, New York, New York, United States</location>
      <location>New York Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, United States</location>
      <location>Duke University Medical Center, Durham, North Carolina, United States</location>
      <location>University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States</location>
      <location>Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave, Hillsboro, Oregon, United States</location>
      <location>Providence Portland Medical Center, Portland, Oregon, United States</location>
      <location>Providence St. Vincent Medical Center, Portland, Oregon, United States</location>
      <location>Kaiser Sunnyside Medical Center, Portland, Oregon, United States</location>
      <location>Hospital of the University of Pennsylvania, 51 N. 31st Street, Philadelphia, Pennsylvania, United States</location>
      <location>Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States</location>
      <location>Temple University Hospital, Philadelphia, Pennsylvania, United States</location>
      <location>The Miriam Hospital, Providence, Rhode Island, United States</location>
      <location>Prisma Health Richland Hospital, Columbia, South Carolina, United States</location>
      <location>Prisma Health Richland Hospital, 701 Grove Road, Greenville, South Carolina, United States</location>
      <location>The Liver Institute of Methodist Dallas Medical Center, Dallas, Texas, United States</location>
      <location>UT Southwestern Medical Center Amelia Court, HIV Research Clinic, Dallas, Texas, United States</location>
      <location>Baylor University Medical Center, Dallas, Texas, United States</location>
      <location>UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States</location>
      <location>UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd, Dallas, Texas, United States</location>
      <location>Baylor University Medical Center, 1400 8th Ave, Fort Worth, Texas, United States</location>
      <location>Houston Methodist Hospital, Houston, Texas, United States</location>
      <location>Baylor University Medical Center, 2401 S. 31st St., Temple, Texas, United States</location>
      <location>University of Utah Health, Salt Lake City, Utah, United States</location>
      <location>Virginia Hospital Center, Arlington, Virginia, United States</location>
      <location>Inova Fairfax Medical Campus, Falls Church, Virginia, United States</location>
      <location>VCU Health Medical Center, Richmond, Virginia, United States</location>
      <location>Providence Regional Medical Center Everett, Everett, Washington, United States</location>
      <location>Kadlec Regional Medical Center, Kennewick, Washington, United States</location>
      <location>Providence St. Peter Hospital, Olympia, Washington, United States</location>
      <location>Virginia Mason Medical Center, Seattle, Washington, United States</location>
      <location>Swedish Center for Comprehensive Care, Seattle, Washington, United States</location>
      <location>MultiCare Deaconess Hospital, Spokane, Washington, United States</location>
      <location>MultiCare Tacoma General Hospital, Tacoma, Washington, United States</location>
      <location>St Joseph Medical Center, Tacoma, Washington, United States</location>
      <location>The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China</location>
      <location>CHU Pellegrin, Bordeaux, France</location>
      <location>CHU de Montpellier-Hopital Gui de Chauliac, Montpelier Cedex 5, France</location>
      <location>CHU de Nantes-Hotel Dieu, Nantes, France</location>
      <location>Hopital Saint-Louis, Paris, France</location>
      <location>Hopital Saint Antoine, Paris, France</location>
      <location>Universitatsklinikum Dusseldorf, Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Düsseldorf, WA, Germany</location>
      <location>Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik Infektiologie Pneumologie, Berlin, Germany</location>
      <location>Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany</location>
      <location>Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany</location>
      <location>Klinikum St. Georg gGmbH Klinik fur Infektiologie, Tropenmedizin, Nephrologie und Rheumatologie, Leipzig, Germany</location>
      <location>Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2, Munich, Germany</location>
      <location>Klinik für Hämatologie, Onkologie, Immunologie, München, Germany</location>
      <location>Robert-Bosch-Krankenhaus (RBK), Klinik Schillerhohe (KSH) und Dr. Margarete Fischer-Bosch-Institut fur klinische Pharmakologie (IKP), Stuttgart, Germany</location>
      <location>Prince of Wales Hospital, Hong Kong, Hong Kong</location>
      <location>Princess Margaret Hospital, Hong Kong, Hong Kong</location>
      <location>Queen Mary Hospital, Hong Kong, Hong Kong</location>
      <location>UOC Malattie Infettive, ASST Papa Giovanni XXIII, Bergamo, Italy</location>
      <location>ASST degli Spedali Civili di Brescia, Brescia, Italy</location>
      <location>ASST di Cremona - Azienda Socio Sanitaria Territor, Cremona, Italy</location>
      <location>UOC Malattie Infettive, IRCCS Ospedale San Raffaele, Milano, Italy</location>
      <location>Dipartimento di Malattie Infettive, Malattie Infettive I- Malattie Infettive III, AssT Fatebenefratelli Sacco Ospedale Luigi Sacco, Milano, Italy</location>
      <location>UO Malattie Infettive, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy</location>
      <location>UOC Medicina Di Laboratorio, Azienda Ospedaliera di Padova, Padova PD, Italy</location>
      <location>Azienda Ospedaliero Universitaria di Parma, Parma, Italy</location>
      <location>UOC Malattie Infettive I, Fondazione IRCCS Policlinio San Matteo, Pavia, Italy</location>
      <location>Ospedale Guglielmo da Saliceto AUSL di Piacenza, Piacenza, Italy</location>
      <location>UOC Malattie Infettive ad Alta Intensita di Cure, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S., Roma, Italy</location>
      <location>Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italy</location>
      <location>Yokohama Municipal Citizen's Hospital, Kanagawa, Japan</location>
      <location>Nagoya City East Medical Center, Nagoya, Japan</location>
      <location>Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan</location>
      <location>Kyungpook National University Hospital, Daegu, Korea, Republic of</location>
      <location>Seoul Medical Center, Seoul, Korea, Republic of</location>
      <location>National Medical Center, Seoul, Korea, Republic of</location>
      <location>Amsterdam University Medical Centre - Location AMC, Amsterdam, Netherlands</location>
      <location>Leiden University Medical Center, Leiden, Netherlands</location>
      <location>Erasmus Medical Centre, Rotterdam, Netherlands</location>
      <location>National University Hospital, Singapore, Singapore</location>
      <location>Singapore General Hospital, Singapore, Singapore</location>
      <location>National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore</location>
      <location>Hospital Principe de Asturias, Alcalá De Henares, Madrid, Spain</location>
      <location>Complejo Hospitalario Universitario A Coruña, A Coruña, Spain</location>
      <location>Hospital Universitari Vall d'Hebron, Barcelona, Spain</location>
      <location>Hospital Clinic de Barcelona, Barcelona, Spain</location>
      <location>Hospital Universitario Cruces, Bizkaia, Spain</location>
      <location>Hospital Universitario Ramón y Cajal, Madrid, Spain</location>
      <location>Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain</location>
      <location>Hospital Universitario 12 de Octubre, Madrid, Spain</location>
      <location>Hospital Universitario La Paz, Madrid, Spain</location>
      <location>Hospital Regional Universitario de Málaga, Málaga, Spain</location>
      <location>Hospital Universitario Virgen del Rocio, Sevilla, Spain</location>
      <location>Sahlgrenska University Hospital, Ostra, Gothenburg, Sweden</location>
      <location>SUS (Skanes University Hospital), Malmo, Sweden</location>
      <location>Karolinska University Hospital, Stockholm, Sweden</location>
      <location>Hopitaux Universitaires de Genève, Genève 14, Switzerland</location>
      <location>Ospedale Regionale di Locarno La Carità, Lugano, Switzerland</location>
      <location>Universitätsspital Zürich, Zürich, Switzerland</location>
      <location>Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan</location>
      <location>China Medical University Hospital, Taichung, Taiwan</location>
      <location>National Taiwan University Hospital, Taipei City, Taiwan</location>
      <location>Royal Infirmary of Edinburgh, Edinburgh, United Kingdom</location>
      <location>Queen Elizabeth University Hospital, Glasgow, United Kingdom</location>
      <location>Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom</location>
      <location>Royal Lancaster Hospital, Lancaster, United Kingdom</location>
      <location>Liverpool University Hospital, Liverpool, United Kingdom</location>
      <location>Northwick Park Hospital, London, United Kingdom</location>
      <location>Royal Free London NHS Foundation Trust, London, United Kingdom</location>
      <location>King's College Hospital NHS Trust, London, United Kingdom</location>
      <location>Imperial College Healthcare NHS Trust, London, United Kingdom</location>
      <location>University College London, London, United Kingdom</location>
      <location>Manchester University NHS Foundation Trust, Manchester, United Kingdom</location>
      <location>Manchester University NHS Foundation Trust, Manchester, United Kingdom</location>
      <location>Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom</location>
      <location>Derriford Hospital, Plymouth, United Kingdom</location>
      <location>Sheffield Teaching Hospitals, Sheffield, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04292899</url>
  </study>
  <study rank="159">
    <nct_id>NCT04312997</nct_id>
    <title>The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PUL-042 Inhalation Solution</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Severity of COVID-19</outcome_measure>
      <outcome_measure>SARS-CoV-2 infection</outcome_measure>
      <outcome_measure>Severity of COVID-19 over 28 days</outcome_measure>
      <outcome_measure>ICU admission</outcome_measure>
      <outcome_measure>Mechanical Ventilation</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Pulmotect, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>September 2020</primary_completion_date>
    <completion_date>October 2020</completion_date>
    <study_first_posted>March 18, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04312997</url>
  </study>
  <study rank="160">
    <nct_id>NCT04334980</nct_id>
    <title>Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">bacTRL-Spike</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Frequency of Adverse Events</outcome_measure>
      <outcome_measure>SARS-CoV-2 antibodies</outcome_measure>
      <outcome_measure>Incidence of COVID-19 infection</outcome_measure>
      <outcome_measure>bacTRL-Spike in stool post-vaccination</outcome_measure>
      <outcome_measure>Seroconversion of circulating anti-Spike IgG antibodies &amp; stability of serum IgG titers</outcome_measure>
      <outcome_measure>Effectiveness of intestinal colonization of the probiotic-based bacTRL-Spike oral vaccine</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Symvivo Corporation</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>19 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>84</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 30, 2020</start_date>
    <primary_completion_date>August 31, 2021</primary_completion_date>
    <completion_date>December 31, 2021</completion_date>
    <study_first_posted>April 6, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Vaccine Evaluation Center, BC Children's Hospital Research Institute, University of British Columbia., Vancouver, British Columbia, Canada</location>
      <location>Canadian Center for Vaccinology Dalhousie University, IWK Health Centre, Halifax, Nova Scotia, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04334980</url>
  </study>
  <study rank="161">
    <nct_id>NCT04348409</nct_id>
    <title>Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nitazoxanide Tablets</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Viral load</outcome_measure>
      <outcome_measure>Evolution of acute respiratory syndrome</outcome_measure>
      <outcome_measure>Change in Clinical Condition</outcome_measure>
      <outcome_measure>Hospital discharge</outcome_measure>
      <outcome_measure>Rate of mortality within 21-days</outcome_measure>
      <outcome_measure>Need of mechanical ventilation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Azidus Brasil</lead_sponsor>
      <collaborator>Farmoquimica S.A.</collaborator>
      <collaborator>Hospital Vera Cruz</collaborator>
      <collaborator>Hospital Casa de Saúde - Vera Cruz - Campinas - SP - Brazil</collaborator>
      <collaborator>Centro de Genomas - UNIFESP</collaborator>
      <collaborator>Emilio Ribas Institute of Infectious Diseases</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 12, 2020</start_date>
    <primary_completion_date>May 31, 2020</primary_completion_date>
    <completion_date>June 30, 2020</completion_date>
    <study_first_posted>April 16, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Hospital Vera Cruz, Campinas, São Paulo, Brazil</location>
      <location>Centro de Genomas, São Paulo, Brazil</location>
      <location>Hospital Emílio Ribas, São Paulo, Brazil</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04348409</url>
  </study>
  <study rank="162">
    <nct_id>NCT04353518</nct_id>
    <title>Clinical Trial to Evaluate Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Suspension of heat killed (autoclaved) Mycobacterium w</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of subject acquiring COVID-19 infection</outcome_measure>
      <outcome_measure>Incidence of Adverse Event and Serious Adverse Event (safety and tolerability)</outcome_measure>
      <outcome_measure>Number of subject developing Upper Respiratory Tract Infection (URTI) symptoms</outcome_measure>
      <outcome_measure>Number of subject developing severe COVID-19 infection based on ordinal scale</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Cadila Pharnmaceuticals</lead_sponsor>
      <collaborator>Council of Scientific and Industrial Research, India</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>4000</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 30, 2020</start_date>
    <primary_completion_date>March 30, 2021</primary_completion_date>
    <completion_date>May 30, 2021</completion_date>
    <study_first_posted>April 20, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04353518</url>
  </study>
  <study rank="163">
    <nct_id>NCT04360551</nct_id>
    <title>Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Telmisartan 40mg</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Maximum clinical severity of disease</outcome_measure>
      <outcome_measure>Incidence of treatment emergent adverse events</outcome_measure>
      <outcome_measure>Renin angiotensin system peptides</outcome_measure>
      <outcome_measure>Plasma biomarkers</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Hawaii</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>July 1, 2020</start_date>
    <primary_completion_date>June 30, 2021</primary_completion_date>
    <completion_date>June 30, 2021</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>University of Hawaii - Manoa, John A Burns School of Medicine UH Clinics at Kakaako, Honolulu, Hawaii, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04360551</url>
  </study>
  <study rank="164">
    <nct_id>NCT04347954</nct_id>
    <title>PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19)</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Povidone-Iodine 2%</intervention>
      <intervention type="Drug">Povidone-Iodine 0.5%</intervention>
      <intervention type="Drug">Isotonic saline 0.9%</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mean change in viral titers of SARS-CoV-2</outcome_measure>
      <outcome_measure>Frequency of adverse effects of interest after nasal sprays</outcome_measure>
      <outcome_measure>Frequency of symptoms related to SARS-CoV-2</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Stanford University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>45</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 2020</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>August 2020</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>Stanford Health Care, Stanford, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04347954</url>
  </study>
  <study rank="165">
    <nct_id>NCT04343989</nct_id>
    <title>A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Clazakizumab 12.5 mg</intervention>
      <intervention type="Drug">Clazakizumab 25 mg</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Incidence of serious adverse events associated with clazakizumab or placebo</outcome_measure>
      <outcome_measure>Incidence of intubation</outcome_measure>
      <outcome_measure>Time to extubation</outcome_measure>
      <outcome_measure>Length of ICU stay</outcome_measure>
      <outcome_measure>Number of patients who present a decrease in C-reactive protein</outcome_measure>
      <outcome_measure>Patient survival</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>NYU Langone Health</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 31, 2020</start_date>
    <primary_completion_date>July 1, 2020</primary_completion_date>
    <completion_date>July 1, 2020</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations>
      <location>New York University School of Medicine, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04343989</url>
  </study>
  <study rank="166">
    <nct_id>NCT04348435</nct_id>
    <title>A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19</title>
    <acronym/>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">HB-adMSCs</intervention>
      <intervention type="Drug">Placebos</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Incidence of hospitalization for COVID-19</outcome_measure>
      <outcome_measure>Incidence of symptoms associated with COVID-19</outcome_measure>
      <outcome_measure>Absence of upper/lower respiratory infection</outcome_measure>
      <outcome_measure>Leukocyte differential</outcome_measure>
      <outcome_measure>C Reactive protein</outcome_measure>
      <outcome_measure>TNF alpha</outcome_measure>
      <outcome_measure>IL-6</outcome_measure>
      <outcome_measure>IL-10</outcome_measure>
      <outcome_measure>Glucose</outcome_measure>
      <outcome_measure>Calcium</outcome_measure>
      <outcome_measure>Albumin</outcome_measure>
      <outcome_measure>Total protein</outcome_measure>
      <outcome_measure>Sodium</outcome_measure>
      <outcome_measure>Total carbon dioxide</outcome_measure>
      <outcome_measure>Potassium</outcome_measure>
      <outcome_measure>Chloride</outcome_measure>
      <outcome_measure>BUN</outcome_measure>
      <outcome_measure>Creatinine</outcome_measure>
      <outcome_measure>Alkaline phosphatase</outcome_measure>
      <outcome_measure>Alanine aminotransferase</outcome_measure>
      <outcome_measure>Total bilirubin</outcome_measure>
      <outcome_measure>white blood cells</outcome_measure>
      <outcome_measure>red blood cells</outcome_measure>
      <outcome_measure>hemoglobin</outcome_measure>
      <outcome_measure>hematocrit</outcome_measure>
      <outcome_measure>mean corpuscular volume</outcome_measure>
      <outcome_measure>mean corpuscular hemoglobin</outcome_measure>
      <outcome_measure>mean corpuscular hemoglobin concentration</outcome_measure>
      <outcome_measure>red cell distribution width</outcome_measure>
      <outcome_measure>neutrophils</outcome_measure>
      <outcome_measure>Lymphs</outcome_measure>
      <outcome_measure>Monocytes</outcome_measure>
      <outcome_measure>Eosinophils</outcome_measure>
      <outcome_measure>Basophils</outcome_measure>
      <outcome_measure>Absolute neutrophils</outcome_measure>
      <outcome_measure>Absolute lymphs</outcome_measure>
      <outcome_measure>Absolute monocytes</outcome_measure>
      <outcome_measure>Absolute eosinophils</outcome_measure>
      <outcome_measure>Absolute basophils</outcome_measure>
      <outcome_measure>Immature granulocytes</outcome_measure>
      <outcome_measure>Platelets</outcome_measure>
      <outcome_measure>Prothrombin time</outcome_measure>
      <outcome_measure>INR</outcome_measure>
      <outcome_measure>SF-36</outcome_measure>
      <outcome_measure>PHQ-9</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hope Biosciences</lead_sponsor>
      <collaborator>Hope Biosciences Stem Cell Research Foundation</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 23, 2020</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>April 30, 2021</completion_date>
    <study_first_posted>April 16, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04348435</url>
  </study>
  <study rank="167">
    <nct_id>NCT04329572</nct_id>
    <title>Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19</title>
    <acronym/>
    <status open="N">Suspended</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine Sulfate</intervention>
      <intervention type="Drug">Azithromycin Tablets</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Evolution of acute respiratory syndrome, oxygen saturation hemodynamic stability</outcome_measure>
      <outcome_measure>Viral load</outcome_measure>
      <outcome_measure>Change in Clinical Condition</outcome_measure>
      <outcome_measure>Evolution of Acute Respiratory Syndrome</outcome_measure>
      <outcome_measure>Hospital discharge</outcome_measure>
      <outcome_measure>Rate of mortality within 28-days</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Azidus Brasil</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Early Phase 1</phase>
    </phases>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 23, 2020</start_date>
    <primary_completion_date>May 31, 2020</primary_completion_date>
    <completion_date>June 30, 2020</completion_date>
    <study_first_posted>April 1, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04329572</url>
  </study>
  <study rank="168">
    <nct_id>NCT04341506</nct_id>
    <title>Non-contact ECG Sensor System for COVID19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Non-contact ECG</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>ECG changes associated with COVID-19</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Northwestern Medicine</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>July 15, 2020</primary_completion_date>
    <completion_date>September 15, 2020</completion_date>
    <study_first_posted>April 10, 2020</study_first_posted>
    <last_update_posted>April 10, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04341506</url>
  </study>
  <study rank="169">
    <nct_id>NCT04292730</nct_id>
    <title>Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Remdesivir</intervention>
      <intervention type="Drug">Standard of Care</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The Odds of Ratio for Improvement on a 7-point Ordinal Scale on Day 11</outcome_measure>
      <outcome_measure>Proportion of Participants experiencing Treatment-Emergent Adverse Events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>12 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1600</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 15, 2020</start_date>
    <primary_completion_date>May 2020</primary_completion_date>
    <completion_date>May 2020</completion_date>
    <study_first_posted>March 3, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue, Anaheim, California, United States</location>
      <location>Mills-Peninsula Medical Center, Burlingame, California, United States</location>
      <location>Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway, Downey, California, United States</location>
      <location>Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave, Fontana, California, United States</location>
      <location>St Joseph Hospital Eureka, Fortuna, California, United States</location>
      <location>Kaiser Permanente Los Angeles Medical Center, 25825 S. Vermont Ave., Harbor City, California, United States</location>
      <location>Kaiser Permanente Los Angeles Medical Center, Los Angeles, California, United States</location>
      <location>Kaiser Permanente Los Angeles Medical Center, 6041 Cadillac Ave., Los Angeles, California, United States</location>
      <location>Kaiser Permanente Los Angeles Medical Center, 5601 De Soto Avenue, Los Angeles, California, United States</location>
      <location>Kaiser Permanente Los Angeles Medical Center, 10800 Magnolia Avenue, Los Angeles, California, United States</location>
      <location>Mission Hospital Regional Medical Center, Mission Viejo, California, United States</location>
      <location>Kaiser Permanente Los Angeles Medical Center,27300 Iris Avenue, Moreno Valley, California, United States</location>
      <location>El Camino Hospital, Mountain View, California, United States</location>
      <location>Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States</location>
      <location>Kaiser Permanente-Oakland/San Francisco, Oakland, California, United States</location>
      <location>Kaiser Permanente Los Angeles Medical Center, 2295 S. Vineyard Avenue, Ontario, California, United States</location>
      <location>The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange, Orange, California, United States</location>
      <location>Kaiser Permanente Los Angeles Medical Center,13651 Willard Street, Panorama City, California, United States</location>
      <location>Sutter Medical Center Sacramento, One Medical Plaza, Roseville, California, United States</location>
      <location>Sutter Medical Center Sacramento, Sacramento, California, United States</location>
      <location>Kaiser Permanente Los Angeles Medical Center, 9455 Clairemont Mesa Blvd, San Diego, California, United States</location>
      <location>Kaiser Permanente Los Angeles Medical Center, 4647 Zion Avenue, San Diego, California, United States</location>
      <location>Kaiser Permanente-Oakland/San Francisco, 1200 El Camino Real, San Francisco, California, United States</location>
      <location>California Pacific Medical Center-Infectious Disease Associates Medical Group, San Francisco, California, United States</location>
      <location>Kaiser Permanente-Oakland/San Francisco, 2425 Geary Blvd, San Francisco, California, United States</location>
      <location>Kaiser Permanente-Oakland/San Francisco, 250 Hospital Parkway, Suite 850, San Jose, California, United States</location>
      <location>Kaiser Permanente-Oakland/San Francisco, 2500 Merced St, San Leandro, California, United States</location>
      <location>Kaiser Permanente-Oakland/San Francisco, 700 Lawrence Expressway, Santa Clara, California, United States</location>
      <location>Providence St. Johns Medical Center, Santa Monica, California, United States</location>
      <location>Sutter Santa Rosa Regional Hospital, Santa Rosa, California, United States</location>
      <location>Stanford Hospital, Stanford, California, United States</location>
      <location>University of Colorado Denver, University of Colorado Hospital, Aurora, Colorado, United States</location>
      <location>SCL Health St. Joseph Hospital, 1375 East 19th Ave, Denver, Colorado, United States</location>
      <location>SCL Health St. Joseph Hospital, Denver, Colorado, United States</location>
      <location>Rose Medical Center, Denver, Colorado, United States</location>
      <location>SCL Health St. Joseph Hospital, 200 Exempla Circle., Lafayette, Colorado, United States</location>
      <location>Yale University, New Haven, Connecticut, United States</location>
      <location>Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii, United States</location>
      <location>Cook County General Hospital, Chicago, Illinois, United States</location>
      <location>Rush University Medical Center, Chicago, Illinois, United States</location>
      <location>University of Chicago, Chicago, Illinois, United States</location>
      <location>IU Health Methodist Hospital, Indianapolis, Indiana, United States</location>
      <location>University of Iowa Hospitals &amp; Clinics, Iowa City, Iowa, United States</location>
      <location>Tulane University, New Orleans, Louisiana, United States</location>
      <location>Maine Medical Center, Portland, Maine, United States</location>
      <location>Holy Cross Hospital, Silver Spring, Maryland, United States</location>
      <location>Tufts Medical Center, Boston, Massachusetts, United States</location>
      <location>Brigham &amp; Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States</location>
      <location>Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States</location>
      <location>The University of Michigan Hospitals and Health Systems, Ann Arbor, Michigan, United States</location>
      <location>Henry Ford Health System, Detroit, Michigan, United States</location>
      <location>Hennepin Healthcare, Minneapolis, Minnesota, United States</location>
      <location>Mayo Clinic, Rochester, Minnesota, United States</location>
      <location>Providence St Patrick Hospital and International Heart Institute of MT Foundation, Missoula, Montana, United States</location>
      <location>Darmouth-Hitchhock Medical Center, Lebanon, New Hampshire, United States</location>
      <location>Hackensack Medical Center, Hackensack, New Jersey, United States</location>
      <location>Robert Wood Johnson University Hospital Somerset, Hillsborough, New Jersey, United States</location>
      <location>Robert Wood Johnson University Hospital Somerset, 1 RWJ Place, New Brunswick, New Jersey, United States</location>
      <location>Robert Wood Johnson University Hospital Somerset, 201 Lyons Avenue, Newark, New Jersey, United States</location>
      <location>St. Joseph's University Medical Center, Paterson, New Jersey, United States</location>
      <location>Jacobi Medical Center, Bronx, New York, United States</location>
      <location>James J. Peters Veterans Administration Medical Center, Bronx, New York, United States</location>
      <location>Jamaica Hospital Medical Center, Jamaica, New York, United States</location>
      <location>Danbury Hospital, Lagrangeville, New York, United States</location>
      <location>North Shore University Hospital, Manhasset, New York, United States</location>
      <location>North Shore University Hospital, 270-05 76th Ave, New Hyde Park, New York, United States</location>
      <location>Icahn School of Medicine at Mount Sinai, 350 East 17th Street, New York, New York, United States</location>
      <location>Icahn School of Medicine at Mount Sinai, 440 West 114th St., New York, New York, United States</location>
      <location>Icahn School of Medicine at Mount Sinai, 1000 10th Avenue, New York, New York, United States</location>
      <location>Icahn School of Medicine at Mount Sinai, New York, New York, United States</location>
      <location>Columbia University Irving Medical Center, New York, New York, United States</location>
      <location>Weill Cornell Medical College/NYU Presbyterian Hospital, New York, New York, United States</location>
      <location>Duke University Medical Center, Durham, North Carolina, United States</location>
      <location>University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States</location>
      <location>Kaiser Sunnyside Medical Center, 2875 NW Stucki Ave, Hillsboro, Oregon, United States</location>
      <location>Providence Portland Medical Center, Portland, Oregon, United States</location>
      <location>Providence St. Vincent Medical Center, Portland, Oregon, United States</location>
      <location>Kaiser Sunnyside Medical Center, Portland, Oregon, United States</location>
      <location>Hospital of the University of Pennsylvania, 51 N. 31st Street, Philadelphia, Pennsylvania, United States</location>
      <location>Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States</location>
      <location>Temple University Hospital, Philadelphia, Pennsylvania, United States</location>
      <location>The Miriam Hospital, Providence, Rhode Island, United States</location>
      <location>Prisma Health Richland Hospital, Columbia, South Carolina, United States</location>
      <location>Prisma Health Richland Hospital, 701 Grove Road, Greenville, South Carolina, United States</location>
      <location>The Liver Institute of Methodist Dallas Medical Center, Dallas, Texas, United States</location>
      <location>UTSW Medical Center, Dallas, Texas, United States</location>
      <location>Baylor University Medical Center, Dallas, Texas, United States</location>
      <location>UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 5201 Harry Hines Blvd., Dallas, Texas, United States</location>
      <location>UT Southwestern Medical Center Amelia Court, HIV Research Clinic, 6201 Harry Hines Blvd, Dallas, Texas, United States</location>
      <location>Baylor University Medical Center, 1400 8th Ave, Fort Worth, Texas, United States</location>
      <location>Houston Methodist Hospital, Houston, Texas, United States</location>
      <location>Baylor University Medical Center, 2401 S. 31st St., Temple, Texas, United States</location>
      <location>University of Utah Health, Salt Lake City, Utah, United States</location>
      <location>Virginia Hospital Center, Arlington, Virginia, United States</location>
      <location>Inova Fairfax Hospital, Falls Church, Virginia, United States</location>
      <location>VCU Health Medical Center, Richmond, Virginia, United States</location>
      <location>Providence Medical Research Center, Everett, Washington, United States</location>
      <location>Kadlec Regional Medical Center, Kennewick, Washington, United States</location>
      <location>Providence St. Peter Hospital, Olympia, Washington, United States</location>
      <location>Virginia Mason Medical Center, Seattle, Washington, United States</location>
      <location>Swedish Center for Comprehensive Care, Seattle, Washington, United States</location>
      <location>MultiCare Deaconess Hospital, Spokane, Washington, United States</location>
      <location>MultiCare Tacoma General Hospital, Tacoma, Washington, United States</location>
      <location>St Joseph Medical Center, Tacoma, Washington, United States</location>
      <location>The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China</location>
      <location>CHU Pellegrin, Bordeaux, France</location>
      <location>CHU de Montpellier-Hopital Gui de Chauliac, Montpelier Cedex 5, France</location>
      <location>CHU de Nantes-Hotel Dieu, Nantes, France</location>
      <location>Hopital Saint-Louis, Paris, France</location>
      <location>Hopital Saint Antoine, Paris, France</location>
      <location>Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum, Medizinische Klinik Infektiologie Pneumologie, Berlin, Germany</location>
      <location>Universitatsklinikum Dusseldorf, Klinik fur Gastroenterologie, Hepatologie und Infektiologie, Düsseldorf, Germany</location>
      <location>Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany</location>
      <location>Universitätsklinikum Schleswig-Holstein Campus Kiel, Kiel, Germany</location>
      <location>Klinikum St. Georg gGmbH Klinik fur Infektiologie, Tropenmedizin, Nephrologie und Rheumatologie, Leipzig, Germany</location>
      <location>Klinikum rechts der Isar der TU Munchen, Klinik und Poliklinik Innere Medizin 2, Munich, Germany</location>
      <location>Klinik für Hämatologie, Onkologie, Immunologie, München, Germany</location>
      <location>Robert-Bosch-Krankenhaus (RBK), Klinik Schillerhohe (KSH) und Dr. Margarete Fischer-Bosch-Institut fur klinische Pharmakologie (IKP), Stuttgart, Germany</location>
      <location>Prince of Wales Hospital, Hong Kong, Hong Kong</location>
      <location>Princess Margaret Hospital, Hong Kong, Hong Kong</location>
      <location>Queen Mary Hospital, Hong Kong, Hong Kong</location>
      <location>UOC Malattie Infettive, ASST Papa Giovanni XXIII, Bergamo, Italy</location>
      <location>ASST degli Spedali Civili di Brescia, Brescia, Italy</location>
      <location>ASST di Cremona - Azienda Socio Sanitaria Territor, Cremona, Italy</location>
      <location>UOC Malattie Infettive, IRCCS Ospedale San Raffaele, Milano, Italy</location>
      <location>ASST Fatebenefratelli Sacco, Milano, Italy</location>
      <location>UO Malattie Infettive, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy</location>
      <location>UOC Malattie Infettive e Tropicali, Azienda Ospedaliera di Padova, Padova PD, Italy</location>
      <location>Azienda Ospedaliero Universitaria di Parma, Parma, Italy</location>
      <location>Malattie Infettive I, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy</location>
      <location>Ospedale Guglielmo da Saliceto AUSL di Piacenza, Piacenza, Italy</location>
      <location>UOC Malattie Infettive ad Alta Intensita di Cure, Istituto Nazionale Malattie Infettive Lazzaro Spallanzani I.R.C.C.S., Roma, Italy</location>
      <location>Clinica Universitaria Malattie Infettive, Ospedale Amedeo di Savoia, Torino, Italy</location>
      <location>Yokohama Municipal Citizen's Hospital, Kanagawa, Japan</location>
      <location>Nagoya City East Medical Center, Nagoya, Japan</location>
      <location>Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan</location>
      <location>Kyungpook National University Hospital, Daegu, Korea, Republic of</location>
      <location>Seoul Medical Center, Seoul, Korea, Republic of</location>
      <location>National Medical Center, Seoul, Korea, Republic of</location>
      <location>Amsterdam University Medical Centre - Location AMC, Amsterdam, Netherlands</location>
      <location>Leiden University Medical Center, Leiden, Netherlands</location>
      <location>Erasmus Medical Centre, Rotterdam, Netherlands</location>
      <location>National University Hospital, Singapore, Singapore</location>
      <location>Singapore General Hospital, Singapore, Singapore</location>
      <location>National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore</location>
      <location>Hospital Principe de Asturias, Alcalá De Henares, Madrid, Spain</location>
      <location>Complejo Hospitalario Universitario A Coruña, A Coruña, Spain</location>
      <location>Hospital Clinic de Barcelona, Barcelona, Spain</location>
      <location>Hospital Universitario Cruces, Bizkaia, Spain</location>
      <location>Hospital Universitario Ramón y Cajal, Madrid, Spain</location>
      <location>Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain</location>
      <location>Hospital Universitario 12 de Octubre, Madrid, Spain</location>
      <location>Hospital Universitario La Paz, Madrid, Spain</location>
      <location>Hospital Regional Universitario de Málaga, Málaga, Spain</location>
      <location>Hospital Universitario Virgen del Rocio, Sevilla, Spain</location>
      <location>Sahlgrenska University Hospital, Ostra, Gothenburg, Sweden</location>
      <location>SUS (Skanes University Hospital), Malmo, Sweden</location>
      <location>Karolinska University Hospital, Stockholm, Sweden</location>
      <location>Hopitaux Universitaires de Genève, Genève 14, Switzerland</location>
      <location>Ospedale Regionale di Locarno La Carità, Lugano, Switzerland</location>
      <location>Universitätsspital Zürich, Zürich, Switzerland</location>
      <location>Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan</location>
      <location>China Medical University Hospital, Taichung, Taiwan</location>
      <location>National Taiwan University Hospital, Taipei City, Taiwan</location>
      <location>Imperial College NHS Trust, London, Greater London, United Kingdom</location>
      <location>NHS Lothian, Royal lnfirmary of Edinburgh, Edinburgh, United Kingdom</location>
      <location>Queen Elizabeth University Hospital, Glasgow, United Kingdom</location>
      <location>Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom</location>
      <location>Royal Lancaster Hospital, Lancaster, United Kingdom</location>
      <location>Liverpool University Hospital, Liverpool, United Kingdom</location>
      <location>Northwick Park Hospital, London, United Kingdom</location>
      <location>Royal Free London NHS Foundation Trust, London, United Kingdom</location>
      <location>King's College Hospital NHS Trust, London, United Kingdom</location>
      <location>University College London, London, United Kingdom</location>
      <location>Manchester University NHS Foundation Trust, Manchester, United Kingdom</location>
      <location>Manchester University NHS Foundation Trust, Manchester, United Kingdom</location>
      <location>Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom</location>
      <location>Derriford Hospital, Plymouth, United Kingdom</location>
      <location>Sheffield Teaching Hospitals, Sheffield, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04292730</url>
  </study>
  <study rank="170">
    <nct_id>NCT04358549</nct_id>
    <title>Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Favipiravir + Standard of Care</intervention>
      <intervention type="Drug">Standard of Care</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to viral clearance</outcome_measure>
      <outcome_measure>Status of clinical recovery as measured by the study-specific 6-point ordinal scale on Day 15</outcome_measure>
      <outcome_measure>Clinical effect of favipiravir + SOC compared to SOC measured by the National Early Warning Score 2 (NEWS2)</outcome_measure>
      <outcome_measure>Characterize the pharmacokinetics (PK) of favipiravir in plasma: Cmax)</outcome_measure>
      <outcome_measure>Characterized the pharmacokinetics (PK) of favipiravir in plasma: Cmin</outcome_measure>
      <outcome_measure>Characterized the pharmacokinetics (PK) of favipiravir in plasma: AUC</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Fujifilm Pharmaceuticals U.S.A., Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 17, 2020</start_date>
    <primary_completion_date>August 2020</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Brigham and Women's Hospital, Boston, Massachusetts, United States</location>
      <location>Massachusetts General Hospital, Boston, Massachusetts, United States</location>
      <location>UMass Memorial Health Care, Worcester, Massachusetts, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04358549</url>
  </study>
  <study rank="171">
    <nct_id>NCT04341168</nct_id>
    <title>Clinical and Immunological Characterisation of COVID-19 in Children, Adolescents and Adults</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>SARS-CoV-2</condition>
    </conditions>
    <interventions>
      <intervention type="Other">this study is non- interventional</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clinical course of COVID-19</outcome_measure>
      <outcome_measure>Analysis of development of antibodies to SARS-CoV-2</outcome_measure>
      <outcome_measure>Estimation of viral load</outcome_measure>
      <outcome_measure>Detection of viral coinfections</outcome_measure>
      <outcome_measure>Measurement of cytokine and chemokine response</outcome_measure>
      <outcome_measure>Characterisation of virus-host-interaction</outcome_measure>
      <outcome_measure>Identification of disease patterns in proteome</outcome_measure>
      <outcome_measure>Analysis of change in lymphocyte subtypes</outcome_measure>
      <outcome_measure>Analysis of histological changes in severe lung disease</outcome_measure>
      <outcome_measure>Detection of bacterial coinfections</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital of Cologne</lead_sponsor>
      <collaborator>Clinic for Internal Medicine I, University Hospital Cologne, Germany</collaborator>
      <collaborator>Institute of Virology, University Hospital Cologne, Germany</collaborator>
      <collaborator>Center for Molecular Medicine Cologne (CMMC) Cologne, Germany</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>160</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>October 2020</primary_completion_date>
    <completion_date>October 2020</completion_date>
    <study_first_posted>April 10, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>University Hospital Cologne, Cologne, NRW, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04341168</url>
  </study>
  <study rank="172">
    <nct_id>NCT04345523</nct_id>
    <title>Convalescent Plasma Therapy vs. SOC for the Treatment of COVID19 in Hospitalized Patients</title>
    <acronym>ConPlas-19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Blood and derivatives.</intervention>
      <intervention type="Drug">Standard of Care</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Category Changes in Ordinal Scale</outcome_measure>
      <outcome_measure>Time to category 5, 6 or 7 of the ordinal scale</outcome_measure>
      <outcome_measure>Mortality of any cause at 15 days</outcome_measure>
      <outcome_measure>Mortality of any cause at 29 days</outcome_measure>
      <outcome_measure>Oxygenation free days</outcome_measure>
      <outcome_measure>Ventilator free days</outcome_measure>
      <outcome_measure>Incidence of Treatment-Emergent Adverse Events</outcome_measure>
      <outcome_measure>Antibodies levels in CP donors recovered from COVID-19</outcome_measure>
      <outcome_measure>Viral load</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Cristina Avendaño Solá</lead_sponsor>
      <collaborator>Puerta de Hierro University Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>278</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 3, 2020</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>July 2020</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>Hospital Clínico Universitario Lozano Blesa, Zaragoza, Aragón, Spain</location>
      <location>Hospital Universitario Severo Ochoa, Leganés, Madrid, Spain</location>
      <location>Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Madrid, Spain</location>
      <location>Hospital Universitario Príncipe de Asturias, Meco, Madrid, Spain</location>
      <location>Hospital Universitario La Princesa, Madrid, Spain</location>
      <location>Hospital General Universitario Gregorio Marañón, Madrid, Spain</location>
      <location>Hospital Universitario Ramón y Cajal, Madrid, Spain</location>
      <location>Hospital Clínico San Carlos, Madrid, Spain</location>
      <location>Hospital Universitario 12 de Octubre, Madrid, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04345523</url>
  </study>
  <study rank="173">
    <nct_id>NCT04345510</nct_id>
    <title>Testing for COVID-19 Infection in Asymptomatic Persons</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19 Infection</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>COVID-19 infection</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>German Cancer Research Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>May 31, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04345510</url>
  </study>
  <study rank="174">
    <nct_id>NCT04347850</nct_id>
    <title>A Cohort of Patients With Possible or Confirmed SARS-CoV-2 (COVID-19)</title>
    <acronym>COVIDothèque</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV-2</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">blood sample</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of confirmed COVID-19</outcome_measure>
      <outcome_measure>Number of severe COVID-19</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Montpellier</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>February 1, 2020</start_date>
    <primary_completion_date>December 1, 2022</primary_completion_date>
    <completion_date>December 30, 2022</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 16, 2020</last_update_posted>
    <locations>
      <location>Uh Montpellier, Montpellier, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04347850</url>
  </study>
  <study rank="175">
    <nct_id>NCT04359992</nct_id>
    <title>Study of Hemostasis in Case of Severe COVID-19</title>
    <acronym>THROMBOVID</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19 Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Extra blood sample</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Platelet activation intensity with the occurrence of clinical thrombotic complications</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Strasbourg, France</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 17, 2020</start_date>
    <primary_completion_date>April 17, 2021</primary_completion_date>
    <completion_date>May 1, 2021</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04359992</url>
  </study>
  <study rank="176">
    <nct_id>NCT04313322</nct_id>
    <title>Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Use of Stem Cells for COVID-19 Treatment</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">WJ-MSCs</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clinical outcome</outcome_measure>
      <outcome_measure>CT Scan</outcome_measure>
      <outcome_measure>RT-PCR results</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Stem Cells Arabia</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>5</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 16, 2020</start_date>
    <primary_completion_date>June 30, 2020</primary_completion_date>
    <completion_date>September 30, 2020</completion_date>
    <study_first_posted>March 18, 2020</study_first_posted>
    <last_update_posted>March 18, 2020</last_update_posted>
    <locations>
      <location>Stem Cells Arabia, Amman, Jordan</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04313322</url>
  </study>
  <study rank="177">
    <nct_id>NCT04344171</nct_id>
    <title>CovidDB: The Covid-19 Inpatient Database</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Outcome comparison between different antiviral therapies</outcome_measure>
      <outcome_measure>Outcome comparisons between ventilation types</outcome_measure>
      <outcome_measure>Identification of risk factors</outcome_measure>
      <outcome_measure>Number of days in hospital vs. clinical classification</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>ClarData</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>5000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 30, 2020</start_date>
    <primary_completion_date>December 31, 2022</primary_completion_date>
    <completion_date>June 30, 2023</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>RoMed - Klinikum Bad Aibling, Bad Aibling, Germany</location>
      <location>DONAUISAR Klinikum Deggendorf, Deggendorf, Germany</location>
      <location>DONAUISAR Klinikum Dingolfing, Dingolfing, Germany</location>
      <location>RoMed - Klinikum Prien am Chiemsee, Prien, Germany</location>
      <location>RoMed - Klinikum Rosenheim, Rosenheim, Germany</location>
      <location>Universitätsklinikum Ulm, Ulm, Germany</location>
      <location>RoMed - Klinikum Wasserburg Am Inn, Wasserburg Am Inn, Germany</location>
      <location>Klinikum Altmühlfranken, Weißenburg, Germany</location>
      <location>Timiş County Emergency Clinical Hospital, Timisoara, Romania</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04344171</url>
  </study>
  <study rank="178">
    <nct_id>NCT04346615</nct_id>
    <title>Safety and Efficacy Trial of Vazegepant Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19 Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Vazegepant (BHV-3500)</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>To evaluate the safety and efficacy of vazegepant compared with placebo in patients hospitalized with COVID-19 infection requiring supplemental oxygen.</outcome_measure>
      <outcome_measure>The number of unique subjects alive and off of oxygen. These are subjects in categories 5 or 6 of the 6-point ordinal scale being used as the primary endpoint.</outcome_measure>
      <outcome_measure>A subject requiring initiation of mechanical ventilation, non-invasive ventilation, or a high flow nasal cannula is a subject that has any eCRF showing the use of any such device on any day.</outcome_measure>
      <outcome_measure>The number of unique subjects admitted to an ICU verse those not admitted.</outcome_measure>
      <outcome_measure>Subjects are alive and respiratory-failure free if they are categorized as being in categories 3, 4, 5 or 6 of the 6-point ordinal scale being used as the primary endpoint.</outcome_measure>
      <outcome_measure>Subjects are alive and free of either mechanical ventilation or non-invasive ventilation if they are categorized as being in categories 4, 5 or 6 of the 6-point ordinal scale being used as the primary endpoint.</outcome_measure>
      <outcome_measure>Efficacy on Day 29 will be evaluated using the same 6-point severity scales that is used at Day 15.</outcome_measure>
      <outcome_measure>Time to improvement of one category on the 6-point severity scale will be determined as the number of days from baseline to the first day that an eCRF indicates a one category improvement in the scale.</outcome_measure>
      <outcome_measure>A 48-hour improvement in SpO2/FiO2 consists of two consecutive days where the case report forms show a clinically meaningful increase from baseline.</outcome_measure>
      <outcome_measure>The time to improvement in the in the NEWS2 scale will be determined as the number of days from baseline to the first eCRF that shows an improvement.</outcome_measure>
      <outcome_measure>A score &lt; 2 for 24 hours on the NEWS2 scale consists of a day where all of the reported NEWS2 scores are &lt; 2.</outcome_measure>
      <outcome_measure>The change in NEWS2 scores will be determined as the change from baseline at Day 15 and at Day 29.</outcome_measure>
      <outcome_measure>The number of unique subjects alive and off of oxygen.</outcome_measure>
      <outcome_measure>A day with a resting respiratory rate &gt; 24 is a day in which all eCRFs collected for a subject indicate observed respiratory rates &gt; 24 breaths per minute.</outcome_measure>
      <outcome_measure>A day with supplemental oxygen is one in which any case report form collected on that day indicates the use of any amount of supplemental oxygen.</outcome_measure>
      <outcome_measure>Time to saturation greater than or equal to 90% on room air is measured by the number of days from baseline to the first day on which an eCRF indicates saturation greater than or equal to 90% without any supplemental oxygenation.</outcome_measure>
      <outcome_measure>A ventilator free day is a day in which all of the eCRFs collected indicate that the subject was not using a ventilator.</outcome_measure>
      <outcome_measure>SOFA scores will be determined from eCRFs. Values will be determined for subjects at admission to an ICU and for all subjects still in an ICU at the end of the study (Day 29).</outcome_measure>
      <outcome_measure>The number of days of hospitalization will be determined from eCRFs. A hospitalization day is any day that it is shown that a subject spent at least spent part of the day in a hospital.</outcome_measure>
      <outcome_measure>Time to fever resolution, without antipyretics, during two contiguous days .</outcome_measure>
      <outcome_measure>The number of deaths, SAEs, severe AEs and Grade 3 or 4 laboratory abnormalities will be tabulated as the number of unique subjects meeting those criteria.</outcome_measure>
      <outcome_measure>The incidence of severe or life-threatening bacterial, invasive fungal, or opportunistic infections will be tabulated as the number of unique subjects, reported in eCRFs, as having these conditions at any point in the study</outcome_measure>
      <outcome_measure>The incidence of intranasal administration reactions will be tabulated, from eCRFs, as the number of unique subjects having such a condition at any point in the study.</outcome_measure>
      <outcome_measure>The percentage of subjects who develop significant renal disease.</outcome_measure>
      <outcome_measure>The percentage of subjects discharged to home on supplemental oxygen will determined from the unique number of subjects have eCRF pages indicating they were discharged to home while still on supplemental oxygen.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Biohaven Pharmaceuticals, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>July 2020</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04346615</url>
  </study>
  <study rank="179">
    <nct_id>NCT04308317</nct_id>
    <title>Tetrandrine Tablets Used in the Treatment of COVID-19</title>
    <acronym>TT-NPC</acronym>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Corona Virus Disease 2019,COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tetrandrine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Survival rate</outcome_measure>
      <outcome_measure>body temperature</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Henan Provincial People's Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 5, 2020</start_date>
    <primary_completion_date>March 1, 2021</primary_completion_date>
    <completion_date>May 1, 2021</completion_date>
    <study_first_posted>March 16, 2020</study_first_posted>
    <last_update_posted>March 16, 2020</last_update_posted>
    <locations>
      <location>Tetrandrine Tablets, Jinhua, Zhejiang, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04308317</url>
  </study>
  <study rank="180">
    <nct_id>NCT04347369</nct_id>
    <title>A Retrospective Study of Neural Network Model to Dynamically Quantificate the Severity in COVID-19 Disease</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19 Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Other">other</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>discrimination</outcome_measure>
      <outcome_measure>Calibration</outcome_measure>
      <outcome_measure>Net benefit</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Xinqiao Hospital of Chongqing</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>January 17, 2020</start_date>
    <primary_completion_date>April 30, 2020</primary_completion_date>
    <completion_date>May 31, 2020</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>Xinqiao Hospital of Chongqing, Chongqing, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04347369</url>
  </study>
  <study rank="181">
    <nct_id>NCT04336956</nct_id>
    <title>Covid-19 Pediatric Observatory</title>
    <acronym>PANDOR</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">hospitalized children with Covid19</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Percentage of children with severe or critical form.</outcome_measure>
      <outcome_measure>Percentage of children requiring intensive care support</outcome_measure>
      <outcome_measure>Clinical symptoms of children</outcome_measure>
      <outcome_measure>Biological results of children</outcome_measure>
      <outcome_measure>CT chest of children</outcome_measure>
      <outcome_measure>Pulmonary echography</outcome_measure>
      <outcome_measure>nasopharynx SARScov2 PCR</outcome_measure>
      <outcome_measure>nasopharynx sarscov2 load</outcome_measure>
      <outcome_measure>nasopharynx multiplex PCR</outcome_measure>
      <outcome_measure>number of hospital days</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier Intercommunal Creteil</lead_sponsor>
      <collaborator>ACTIV</collaborator>
      <collaborator>GPIP</collaborator>
      <collaborator>Société Française de Pédiatrie</collaborator>
      <collaborator>GFRUP</collaborator>
    </sponsors>
    <gender>All</gender>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>250</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Other</study_design>
    </study_designs>
    <start_date>April 7, 2020</start_date>
    <primary_completion_date>June 30, 2021</primary_completion_date>
    <completion_date>June 30, 2021</completion_date>
    <study_first_posted>April 7, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>Chu Felix Guyon, Saint Denis, La Réunion, France</location>
      <location>Ch St Esprit, Agen, France</location>
      <location>Ch General Aix En Provence -, Aix-en-Provence, France</location>
      <location>CHU Angers, Angers, France</location>
      <location>CH d'ANGOULEME, Angoulème, France</location>
      <location>Pringy - Ch D'Annecy, Annecy, France</location>
      <location>Ch Armentieres, Armentières, France</location>
      <location>CH Arpajon, Arpajon, France</location>
      <location>Ch Auxerre, Auxerre, France</location>
      <location>CH GENERAL Henri Duffaut, Avignon, France</location>
      <location>CHU de BESANCON, Besançon, France</location>
      <location>Hopital Femme Enfant, Caen, France</location>
      <location>Ch de Pontoise, Cergy-Pontoise, France</location>
      <location>Ch W. Morey, Chalon-sur-Saône, France</location>
      <location>CH de CHAMBERY, Chambéry, France</location>
      <location>Ch Hotel Dieu, Chartres, France</location>
      <location>Centre Hospitalier intercommunal de Creteil, Creteil, France</location>
      <location>Ch de Dax, Dax, France</location>
      <location>Hopital D'Enfants Chu Dijon, Dijon, France</location>
      <location>CH Louviers Val de Reuil, Elbeuf, France</location>
      <location>CH Gonesse, Gonesse, France</location>
      <location>CH d'HYERES, Hyères, France</location>
      <location>Ch de Marne La Vallee, Jossigny, France</location>
      <location>Chru de Grenoble, La Tronche, France</location>
      <location>CHGénéral du HAVRE, Le Havre, France</location>
      <location>Hopital Saint Vincent de Paul, Lille, France</location>
      <location>Ch de Longjumeau, Longjumeau, France</location>
      <location>Hopital Femme Mere Enfant-Bron, Lyon, France</location>
      <location>Hopital Nord Enfants, Marseille, France</location>
      <location>Hopital de Meaux, Meaux, France</location>
      <location>CH de Montargis, Montargis, France</location>
      <location>CH de MONTBRISON, Montbrison, France</location>
      <location>CHRU de Nancy, Nancy, France</location>
      <location>Nantes - Hopital Mere Enfant, Nantes, France</location>
      <location>Ch de Neuilly Sur Seine, Neuilly-sur-Seine, France</location>
      <location>Hopital Lenval, Nice, France</location>
      <location>Assistance Publique Hôpitaux de Paris, Paris, France</location>
      <location>POISSY - CH de POISSY, Poissy, France</location>
      <location>QUIMPER - CH de Cornouaille, Quimper, France</location>
      <location>RANG du FLIERS - C.H.A.M., RANG du FLIERS, France</location>
      <location>Hopital Américain CHU REIMS, Reims, France</location>
      <location>CH RODEZ, Rodez, France</location>
      <location>Chu Rouen, Rouen, France</location>
      <location>Hopital Charles-Nicolle, Rouen, France</location>
      <location>Chu St Etienne, Saint Etienne, France</location>
      <location>Ch de Saint Malo, Saint-Malo, France</location>
      <location>Ch Du Pays Du Mont Blanc, Sallanches, France</location>
      <location>Chg Salon de Provence, Salon de Provence, France</location>
      <location>CH Bel Air, Thionville, France</location>
      <location>Hopital Sainte Musse, Toulon, France</location>
      <location>CHU Toulouse-hôpital des Enfants, Toulouse, France</location>
      <location>CH de TROYES, Troyes, France</location>
      <location>Ch Le Chesnay, Versailles, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04336956</url>
  </study>
  <study rank="182">
    <nct_id>NCT04346355</nct_id>
    <title>Efficacy of Early Administration of Tocilizumab in COVID-19 Patients</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19 Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tocilizumab</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Entry into Intensive Care with invasive mechanical ventilation or death from any cause or clinical aggravation</outcome_measure>
      <outcome_measure>Death from any cause</outcome_measure>
      <outcome_measure>Tocilizumab toxicity</outcome_measure>
      <outcome_measure>Levels of interleukin-6 and C-reactive protein (CRP) and their correlation with the effectiveness of the treatment</outcome_measure>
      <outcome_measure>Evaluate the progress of the PaO2 / FiO2 ratio</outcome_measure>
      <outcome_measure>Evaluate the trend over time of the lymphocyte count</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Azienda Unità Sanitaria Locale Reggio Emilia</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>398</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 31, 2020</start_date>
    <primary_completion_date>May 30, 2020</primary_completion_date>
    <completion_date>May 30, 2020</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>Ospedale di Guastalla, Guastalla, RE, Italy</location>
      <location>Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, RE, Italy</location>
      <location>Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy</location>
      <location>ASST Cremona, Cremona, Italy</location>
      <location>Azienda Ospedaliera S. Croce e Carle, Cuneo, Italy</location>
      <location>Azienda Ospedaliero Universitaria Ferrara, Ferrara, Italy</location>
      <location>Azienda Ospedaliero Universitaria Careggi, Firenze, Italy</location>
      <location>Ospedale Evangelico Internazionale di Genova, Genova, Italy</location>
      <location>Azienda Sociosanitaria ASL 1 ,Imperia, Imperia, Italy</location>
      <location>Azienda Sociosanitaria ASL 5 La Spezia, La Spezia, Italy</location>
      <location>ASST Mantova - Ospedale Carlo Poma, Mantova, Italy</location>
      <location>IRCCS Istituto Auxologico Italiano Milano, Milano, Italy</location>
      <location>Azienda Ospedaliero-Universitaria &quot;Maggiore della Carità&quot; di Novara, Novara, Italy</location>
      <location>Ospedali Riuniti Padova Sud - ULSS 6 Euganea, Padova, Italy</location>
      <location>Azienda Ospedaliero-Universitaria Parma, Parma, Italy</location>
      <location>Azienda Unità Sanitaria Locale di Piacenza, Piacenza, Italy</location>
      <location>Azienda Ospedaliera Universitaria Pisana, Pisa, Italy</location>
      <location>AO Ordine Mauriziano di Torino, Torino, Italy</location>
      <location>ASST Bergamo Ovest -Treviglio, Treviglio, Italy</location>
      <location>AULSS 2 Marca Trevigiana, Treviso, Italy</location>
      <location>AULSS2 Marca Trevigiana - Ospedale Vittorio Veneto, Treviso, Italy</location>
      <location>AULSS 3 Serenissima Ospedale &quot;Dell'Angelo&quot;, Venezia, Italy</location>
      <location>Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy</location>
      <location>IRCCS Sacro Cuore Don Calabria, Verona, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04346355</url>
  </study>
  <study rank="183">
    <nct_id>NCT04305106</nct_id>
    <title>Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT</title>
    <acronym>BEST-RCT</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19 Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Bevacizumab</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The time from randomization to clinical improvement</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Qilu Hospital of Shandong University</lead_sponsor>
      <collaborator>Renmin Hospital of Wuhan University</collaborator>
      <collaborator>Ialy Moriggia Pelascini Gravedona Hospital S.p.A</collaborator>
      <collaborator>Wuhan University</collaborator>
      <collaborator>Jiangbei Union Hospital of Huazhong University of science and technology</collaborator>
      <collaborator>Shandong Provincial Chest Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>140</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 17, 2020</start_date>
    <primary_completion_date>June 30, 2020</primary_completion_date>
    <completion_date>July 31, 2020</completion_date>
    <study_first_posted>March 12, 2020</study_first_posted>
    <last_update_posted>March 26, 2020</last_update_posted>
    <locations>
      <location>Qilu Hospital of Shandong University, Jinan, Shandong, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04305106</url>
  </study>
  <study rank="184">
    <nct_id>NCT04315987</nct_id>
    <title>NestCell® Mesenchymal Stem Cell to Treat Patients With Severe COVID-19 Pneumonia</title>
    <acronym>HOPE</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19 Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">NestCell®</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in Clinical Condition</outcome_measure>
      <outcome_measure>Rate of mortality within 10-days</outcome_measure>
      <outcome_measure>Change of Clinical symptoms - respiratory rate</outcome_measure>
      <outcome_measure>Hypoxia</outcome_measure>
      <outcome_measure>PaO2 / FiO2 ratio</outcome_measure>
      <outcome_measure>CD4+ and CD8+ T cell count</outcome_measure>
      <outcome_measure>Changes of blood oxygen</outcome_measure>
      <outcome_measure>Side effects in the treatment group</outcome_measure>
      <outcome_measure>Complete blood count, cardiac, hepatic and renal profiles;</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Azidus Brasil</lead_sponsor>
      <collaborator>Cellavita Pesquisa Científica Ltda</collaborator>
      <collaborator>Hospital Vera Cruz</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>66</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>May 2020</primary_completion_date>
    <completion_date>June 2020</completion_date>
    <study_first_posted>March 20, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>Hospital Vera Cruz, Campina Grande, São Paulo, Brazil</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04315987</url>
  </study>
  <study rank="185">
    <nct_id>NCT04329650</nct_id>
    <title>Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Siltuximab</intervention>
      <intervention type="Drug">Methylprednisolone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Proportion of patients requiring ICU admission at any time within the study period.</outcome_measure>
      <outcome_measure>Days of stay in the ICU during the study period.</outcome_measure>
      <outcome_measure>Days until resolution of fever defined as body temperature (axillary ≤ 36.6 ° C, oral ≤ 37.2 ° C, or rectal or tympanic ≤ 37.8 ° C) for at least 48 hours, without administration of antipyretics or until hospital discharge.</outcome_measure>
      <outcome_measure>Proportion of patients with a worsening requirement of supplemental oxygen at 29 days. days.</outcome_measure>
      <outcome_measure>Days with hypoxemia (SpO2 &lt;93% in ambient air or requiring oxygen supplemental or mechanical ventilation support) at 29 days.</outcome_measure>
      <outcome_measure>Proportion of patients using mechanical ventilation at 29 days.</outcome_measure>
      <outcome_measure>Days with use of mechanical ventilation at 29 days.</outcome_measure>
      <outcome_measure>Days until the start of use of mechanical ventilation, non-invasive ventilation or use of high flow nasal cannula (if the patient have not previously required these interventions at the inclusion of the study) at 29 days.</outcome_measure>
      <outcome_measure>Days of hospitalization among survivors at 29 days.</outcome_measure>
      <outcome_measure>Mortality rate from any cause at 29 days.</outcome_measure>
      <outcome_measure>Proportion of patients with serious adverse events at 29 days.</outcome_measure>
      <outcome_measure>Proportion of patients with invasive bacterial or fungal infections clinically significant or opportunistic with grade 4 neutropenia (count neutrophil absolute &lt;500 / mm3) at 29 days.</outcome_measure>
      <outcome_measure>Proportion of patients with invasive bacterial or fungal infections clinically significant or opportunistic at 29 days.</outcome_measure>
      <outcome_measure>Proportion of patients with grade 2 or higher adverse reactions related to the infusion of the sudy treatments at 29 days.</outcome_measure>
      <outcome_measure>Proportion of patients with hypersensitivity reactions of grade 2 or higher related to the administration of the study treatments at 29 days.</outcome_measure>
      <outcome_measure>Proportion of patients with gastrointestinal perforation at 29 days.</outcome_measure>
      <outcome_measure>Proportion of patients with secondary severe infections confirmed by laboratory or worsening of existing infections at 29 days.</outcome_measure>
      <outcome_measure>Changes from baseline in plasma leukocyte levels at days 1, 3, 5, 7 and 9.</outcome_measure>
      <outcome_measure>Changes from baseline in plasma hemoglobin levels at days 1, 3, 5, 7 and 9.</outcome_measure>
      <outcome_measure>Changes from baseline in plasma platelet at days 1, 3, 5, 7 and 9.</outcome_measure>
      <outcome_measure>Changes from baseline in plasma creatinine levels at days 1, 3, 5, 7 and 9.</outcome_measure>
      <outcome_measure>Changes from baseline in plasma total bilirubin levels at days 1, 3, 5, 7 and 9.</outcome_measure>
      <outcome_measure>Proportion of patients with ALT≥ 3 times ULN (for patients with initial values normal) or&gt; 3 times ULN AND at least 2 times more than the initial value (for patients with abnormal initial values) at days 1, 3, 5, 7 and 9.</outcome_measure>
      <outcome_measure>Changes from baseline in plasma biomarkers (PCR, lymphocytes, ferritin, d-dimer and LDH) at days 1, 3, 5, 7 and 9.</outcome_measure>
      <outcome_measure>Changes from baseline in chest Rx at days 1, 3 and 5.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Judit Pich Martínez</lead_sponsor>
      <collaborator>Fundacion Clinic per a la Recerca Biomédica</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>May 20, 2020</primary_completion_date>
    <completion_date>May 20, 2020</completion_date>
    <study_first_posted>April 1, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations>
      <location>Hospital Germans Trias i Pujol, Badalona, Spain</location>
      <location>Hospital Clínic de Barcelona, Barcelona, Spain</location>
      <location>Hospital Universitario de Salamanca, Salamanca, Spain</location>
      <location>Hospital Universitari Mútua de Terrassa, Terrassa, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04329650</url>
  </study>
  <study rank="186">
    <nct_id>NCT04331470</nct_id>
    <title>Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Levamisole Pill + Budesonide+Formoterol inhaler</intervention>
      <intervention type="Drug">Lopinavir/Ritonavir + hydoxychloroquine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clear chest CT-scan</outcome_measure>
      <outcome_measure>PCR test</outcome_measure>
      <outcome_measure>Physical statues of patient</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Fasa University of Medical Sciences</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>15 Years</min_age>
    <max_age>100 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 4, 2020</start_date>
    <primary_completion_date>April 20, 2020</primary_completion_date>
    <completion_date>May 20, 2020</completion_date>
    <study_first_posted>April 2, 2020</study_first_posted>
    <last_update_posted>April 13, 2020</last_update_posted>
    <locations>
      <location>Vali-Asr Hospital, Fasa, Fars, Iran, Islamic Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04331470</url>
  </study>
  <study rank="187">
    <nct_id>NCT04244591</nct_id>
    <title>Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19 Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">methylprednisolone therapy</intervention>
      <intervention type="Other">Standard care</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Lower Murray lung injury score</outcome_measure>
      <outcome_measure>The difference of PaO2/FiO2 between two groups</outcome_measure>
      <outcome_measure>Lower Sequential Organ Failure Assessment (SOFA) score</outcome_measure>
      <outcome_measure>Mechanical ventilation support</outcome_measure>
      <outcome_measure>Clearance of noval coronavirus</outcome_measure>
      <outcome_measure>All-cause mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Peking Union Medical College Hospital</lead_sponsor>
      <collaborator>Zhongda Hospital</collaborator>
      <collaborator>Zhongnan Hospital</collaborator>
      <collaborator>Renmin Hospital of Wuhan University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>January 26, 2020</start_date>
    <primary_completion_date>April 13, 2020</primary_completion_date>
    <completion_date>April 13, 2020</completion_date>
    <study_first_posted>January 28, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>Medical ICU,Peking Union Medical College Hospital, Beijing, Beijing, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04244591</url>
  </study>
  <study rank="188">
    <nct_id>NCT04320615</nct_id>
    <title>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia</title>
    <acronym>COVACTA</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19 Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tocilizumab (TCZ)</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clinical Status Assessed Using a 7-Category Ordinal Scale</outcome_measure>
      <outcome_measure>Time to Clinical Improvement (TTCI), Defined as a National Early Warning Score 2 (NEWS2) of &lt;/= 2 Maintained for 24 Hours</outcome_measure>
      <outcome_measure>Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status</outcome_measure>
      <outcome_measure>Incidence of Mechanical Ventilation</outcome_measure>
      <outcome_measure>Ventilator-Free Days to Day 28</outcome_measure>
      <outcome_measure>Incidence of Intensive Care Unit (ICU) Stay</outcome_measure>
      <outcome_measure>Duration of ICU Stay</outcome_measure>
      <outcome_measure>Time to Clinical Failure</outcome_measure>
      <outcome_measure>Mortality Rate</outcome_measure>
      <outcome_measure>Time to Hospital Discharge</outcome_measure>
      <outcome_measure>Duration of Time on Supplemental Oxygen</outcome_measure>
      <outcome_measure>Percentage of Participants with Adverse Events</outcome_measure>
      <outcome_measure>COVID-19 (SARS-CoV-2) Viral Load Over Time</outcome_measure>
      <outcome_measure>Time to Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) Virus Negativity</outcome_measure>
      <outcome_measure>Proportion of Participants with Post-Treatment Infection</outcome_measure>
      <outcome_measure>Serum Concentration of IL-6</outcome_measure>
      <outcome_measure>Serum Concentration of sIL-6R</outcome_measure>
      <outcome_measure>Serum Concentration of Ferritin</outcome_measure>
      <outcome_measure>Serum Concentration of C-Reactive Protein (CRP)</outcome_measure>
      <outcome_measure>Serum Concentration of TCZ</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>330</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 3, 2020</start_date>
    <primary_completion_date>August 31, 2020</primary_completion_date>
    <completion_date>September 30, 2020</completion_date>
    <study_first_posted>March 25, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>University of California San Diego, La Jolla, California, United States</location>
      <location>eStudySite, La Mesa, California, United States</location>
      <location>David Geffen School of Medicine UCLA, Los Angeles, California, United States</location>
      <location>Stanford University, Stanford, California, United States</location>
      <location>Denver Health Medical Center, Denver, Colorado, United States</location>
      <location>University of Miami Miller School of Medicine, Miami, Florida, United States</location>
      <location>Rush University Medical Center, Chicago, Illinois, United States</location>
      <location>University of Chicago, Chicago, Illinois, United States</location>
      <location>Ochsner Clinic Foundation, Baton Rouge, Louisiana, United States</location>
      <location>Baystate Health System, Springfield, Massachusetts, United States</location>
      <location>Mayo Clinic - PPDS, Rochester, Minnesota, United States</location>
      <location>Hackensack University Medical Center, Hackensack, New Jersey, United States</location>
      <location>Robert Wood Johnson University Hospital/Rutgers, New Brunswick, New Jersey, United States</location>
      <location>James J Peters Veterans Administration Medical Center - NAVREF, Bronx, New York, United States</location>
      <location>New York University Langone Medical Center, New York, New York, United States</location>
      <location>NYU-Langone Medical Center, New York, New York, United States</location>
      <location>Duke University Medical Center, Durham, North Carolina, United States</location>
      <location>Cleveland Clinic Foundation; Pulmonary, Allergy &amp; Critical Care Medicine, Cleveland, Ohio, United States</location>
      <location>Thomas Jefferson University, Philadelphia, Pennsylvania, United States</location>
      <location>Baylor St. Luke's Medical Center, Houston, Texas, United States</location>
      <location>Ben Taub General Hospital - HCHD, Houston, Texas, United States</location>
      <location>Smith Clinic-Harris County Hospital, Houston, Texas, United States</location>
      <location>Intermountain Medical Group, Saint George, Utah, United States</location>
      <location>Intermountain LDS Hospital, Salt Lake City, Utah, United States</location>
      <location>Evergreen Health Infectious Disease, Kirkland, Washington, United States</location>
      <location>Swedish Hospital Medical Center, Seattle, Washington, United States</location>
      <location>McMaster University Medical Centre, Hamilton, Ontario, Canada</location>
      <location>University Health Network, Toronto, Ontario, Canada</location>
      <location>Toronto Western Hospital, Toronto, Ontario, Canada</location>
      <location>Clinical Research Institute of Montreal, Montreal, Quebec, Canada</location>
      <location>Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark</location>
      <location>Hvidovre Hospital, Hvidovre, Denmark</location>
      <location>Odense Universitetshospital, Odense C, Denmark</location>
      <location>Sjællands Universitetshospital, Roskilde, Roskilde, Denmark</location>
      <location>Centre Hospitalier Departemental de Vendee, La Roche Sur Yon, France</location>
      <location>Centre Hospitalier et Universitaire de Limoges, Limoges, France</location>
      <location>Hôpital de La Croix Rousse, Lyon, France</location>
      <location>Hotel Dieu - Nantes, Nantes, France</location>
      <location>Hopital de la Pitie Salpetriere, Paris, France</location>
      <location>HOPITAL COCHIN university hospital, Paris, France</location>
      <location>CHRU de Tours, Pharmacie, Tours, France</location>
      <location>Universitatsklinikum Dusseldorf, Dusseldorf, Germany</location>
      <location>Medizinische Hochschule Hannover, Hannover, Germany</location>
      <location>Universitatsklinikum Schleswig Holstein; Klinik fur Allgemeine Innere Medizin, Kiel, Germany</location>
      <location>Uniklinik Köln, Köln, Germany</location>
      <location>LMU Klinikum der Universitat Munchen, Munchen, Germany</location>
      <location>Azienda Ospedaliera Dei Colli, Napoli, Campania, Italy</location>
      <location>Istituto Nazionale Malattie Infettive Lazzaro Spallanzani IRCCS, Roma, Lazio, Italy</location>
      <location>ASST Papa Giovanni XXIII; Dipartimento Interaziendale di Farmacia Clinica, Bergamo, Lombardia, Italy</location>
      <location>ASST Fatebenefratelli Sacco - Ospedale Luigi Sacco, Milano, Lombardia, Italy</location>
      <location>Azienda Ospedaliera San Gerardo di Monza, Monza MI, Lombardia, Italy</location>
      <location>Fondazione IRCCS Policlinico San Matteo di Pavia; S.S. Fisiopatologia Respiratoria, Pavia, Lombardia, Italy</location>
      <location>Amphia Ziekenhuis, Breda, Netherlands</location>
      <location>St. Antonius Ziekenhuis Nieuwegein, Nieuwegein, Netherlands</location>
      <location>Erasmus MC, Rotterdam, Netherlands</location>
      <location>Universitair Medisch Centrum Utrecht, Utrecht, Netherlands</location>
      <location>Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain</location>
      <location>Hospital Universitari Vall d'Hebron, Barcelona, Spain</location>
      <location>Hospital Clinic de Barcelona, Barcelona, Spain</location>
      <location>Hospital Universitario La Paz, Madrid, Spain</location>
      <location>Hospital Universitario Ramon y Cajal, Madrid, Spain</location>
      <location>Hospital General Universitario Gregorio Maranon, Madrid, Spain</location>
      <location>Hospital Universitario HM Sanchinarro-CIOCC, Madrid, Spain</location>
      <location>Greater Glasgow and Clyde Health Board, Glasgow, United Kingdom</location>
      <location>Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom</location>
      <location>Royal Free Hospital, London, United Kingdom</location>
      <location>Imperial College London, London, United Kingdom</location>
      <location>North Manchester General Hospital, Manchester, United Kingdom</location>
      <location>Salford Royal Hospital, Salford, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04320615</url>
  </study>
  <study rank="189">
    <nct_id>NCT04355884</nct_id>
    <title>Opportunistic Screening for Asymptomatic Left Ventricular Dysfunction in Coronavirus Disease 2019 (COVID19) Survivors</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Standard 12-lead ECG, NT-proBNP, echocardiography</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>New-onset cardiac arrhythmia</outcome_measure>
      <outcome_measure>Elevation of NT-proBNP</outcome_measure>
      <outcome_measure>Left ventricular dysfunction</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>The University of Hong Kong</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>May 1, 2020</primary_completion_date>
    <completion_date>May 1, 2020</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04355884</url>
  </study>
  <study rank="190">
    <nct_id>NCT04358809</nct_id>
    <title>Clinical Trial of Mycobacterium w in COVID-19 Positive Patients, Hospitalized But Not Critically Ill</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Suspension of heat killed (autoclaved) Mycobacterium w</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of patients with increased disease severity</outcome_measure>
      <outcome_measure>Incidence of adverse events and serious adverse events (Safety)</outcome_measure>
      <outcome_measure>Number of COVID-19 patients discharged from hospital</outcome_measure>
      <outcome_measure>Number of COVID-19 patients transfer to ICU</outcome_measure>
      <outcome_measure>Number of COVID-19 patients with reduction in disease severity by 1 ordinal scale</outcome_measure>
      <outcome_measure>Number of of symptom free patients</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Cadila Pharnmaceuticals</lead_sponsor>
      <collaborator>Council of Scientific and Industrial Research, India</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>480</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 30, 2020</start_date>
    <primary_completion_date>February 28, 2021</primary_completion_date>
    <completion_date>April 30, 2021</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04358809</url>
  </study>
  <study rank="191">
    <nct_id>NCT04363736</nct_id>
    <title>A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia</title>
    <acronym>MARIPOSA</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19 Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tociliuzumab</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Concentration of C-Reactive Protein (CRP)</outcome_measure>
      <outcome_measure>Serum Concentration of Interleukin-6 (IL-6)</outcome_measure>
      <outcome_measure>Serum Concentration of Soluble Interleukin Receptor (sIL-6R)</outcome_measure>
      <outcome_measure>Serum Concentration of Ferritin</outcome_measure>
      <outcome_measure>Serum Concentration of TCZ Following Administration of 8 mg/kg IV TCZ</outcome_measure>
      <outcome_measure>Serum Concentration of TCZ Following Administration of 4 mg/kg IV TCZ</outcome_measure>
      <outcome_measure>Clinical Status, as Assessed Using a 7-Category Ordinal Scale</outcome_measure>
      <outcome_measure>Time to Clinical Improvement, Defined as a National Early Warning Score 2 (NEWS2) of &lt;/=2 Maintained for 24 Hours</outcome_measure>
      <outcome_measure>Time to Improvement in at Least Two Categories Relative to Baseline on a 7-Category Ordinal Scale of Clinical Status</outcome_measure>
      <outcome_measure>Duration of Supplemental Oxygen Use</outcome_measure>
      <outcome_measure>Incidence of Intensive Care Unit (ICU) Stays</outcome_measure>
      <outcome_measure>Incidence of Mechanical Ventilation</outcome_measure>
      <outcome_measure>Duration of ICU Stay</outcome_measure>
      <outcome_measure>Time to Clinical Failure, Defined as the Time to Death, Mechanical Ventilation, ICU Admission, or Withdrawal (whichever occurs first)</outcome_measure>
      <outcome_measure>Mortality Rate</outcome_measure>
      <outcome_measure>Time to Hospital Discharge or &quot;Ready for Discharge&quot;</outcome_measure>
      <outcome_measure>Frequency of Addition of a Second Dose of TCZ</outcome_measure>
      <outcome_measure>Pecentage of Participants with Adverse Events</outcome_measure>
      <outcome_measure>SARS-CoV-2 (COVID-19) Viral Load Over Time</outcome_measure>
      <outcome_measure>Time to Real-Time Polymerase Chain Reaction (PCR) Virus Negativity</outcome_measure>
      <outcome_measure>Proportion of Participants with any Post-Treatment Infection</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hoffmann-La Roche</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 4, 2020</start_date>
    <primary_completion_date>June 11, 2020</primary_completion_date>
    <completion_date>August 3, 2020</completion_date>
    <study_first_posted>April 27, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04363736</url>
  </study>
  <study rank="192">
    <nct_id>NCT04344925</nct_id>
    <title>Non Invasive Positive Pressure Ventilation to Minimize Aerosolization for COVID 19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Aerosol-reducing Mask</intervention>
      <intervention type="Device">Standard Mask</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Total Leak Volume of Non Invasive Ventilation Mask</outcome_measure>
      <outcome_measure>Glasgow Coma Scale(GCS)</outcome_measure>
      <outcome_measure>Respiratory Rate</outcome_measure>
      <outcome_measure>Heart Rate</outcome_measure>
      <outcome_measure>Metabolic Data: Blood Gas Measurements</outcome_measure>
      <outcome_measure>Metabolic Data: Bicarbonate (HC03)</outcome_measure>
      <outcome_measure>Metabolic Data: Partial Pressure of Carbon Dioxide (PaC02)</outcome_measure>
      <outcome_measure>Metabolic Data: Partial Pressure of Oxygen (Pa02)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Lawson Health Research Institute</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>June 2020</primary_completion_date>
    <completion_date>August 2020</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04344925</url>
  </study>
  <study rank="193">
    <nct_id>NCT04273529</nct_id>
    <title>The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19 Thalidomide</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">thalidomide</intervention>
      <intervention type="Drug">placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to Clinical recoveryTime to Clinical Recovery (TTCR)</outcome_measure>
      <outcome_measure>All cause mortality</outcome_measure>
      <outcome_measure>Frequency of respiratory progression</outcome_measure>
      <outcome_measure>Time to defervescence</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>First Affiliated Hospital of Wenzhou Medical University</lead_sponsor>
      <collaborator>Second Affiliated Hospital of Wenzhou Medical University</collaborator>
      <collaborator>Wenzhou Central Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>February 20, 2020</start_date>
    <primary_completion_date>May 30, 2020</primary_completion_date>
    <completion_date>June 30, 2020</completion_date>
    <study_first_posted>February 18, 2020</study_first_posted>
    <last_update_posted>February 21, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04273529</url>
  </study>
  <study rank="194">
    <nct_id>NCT04273581</nct_id>
    <title>The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19 Thalidomide</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">placebo</intervention>
      <intervention type="Drug">Thalidomide</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to Clinical Improvement (TTCI)</outcome_measure>
      <outcome_measure>Clinical status</outcome_measure>
      <outcome_measure>Time to Hospital Discharge OR NEWS2 (National Early Warning Score 2) of ≤ 2 maintained for 24 hours</outcome_measure>
      <outcome_measure>All cause mortality</outcome_measure>
      <outcome_measure>Duration (days) of mechanical ventilation</outcome_measure>
      <outcome_measure>Duration (days) of extracorporeal membrane oxygenation</outcome_measure>
      <outcome_measure>Duration (days) of supplemental oxygenation</outcome_measure>
      <outcome_measure>Length of hospital stay (days)</outcome_measure>
      <outcome_measure>Time to 2019-nCoV RT-PCR negativity in upper and lower respiratory tract specimens</outcome_measure>
      <outcome_measure>Change (reduction) in 2019-nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve.</outcome_measure>
      <outcome_measure>Frequency of serious adverse drug events</outcome_measure>
      <outcome_measure>Serum TNF-α, IL-1β, IL-2, IL-6, IL-7, IL-10, GSCF, IP10#MCP1, MIP1α and other cytokine expression levels before and after treatment</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>First Affiliated Hospital of Wenzhou Medical University</lead_sponsor>
      <collaborator>Second Affiliated Hospital of Wenzhou Medical University</collaborator>
      <collaborator>Wenzhou Central Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>February 18, 2020</start_date>
    <primary_completion_date>April 30, 2020</primary_completion_date>
    <completion_date>May 30, 2020</completion_date>
    <study_first_posted>February 18, 2020</study_first_posted>
    <last_update_posted>February 21, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04273581</url>
  </study>
  <study rank="195">
    <nct_id>NCT04354870</nct_id>
    <title>COVID-19 PrEP HCW HCQ Study</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine (HCQ)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Frequency of seroconversion to SARS-CoV-2</outcome_measure>
      <outcome_measure>Incidence of COVID-19 symptoms in the 4 weeks preceding seroconversion</outcome_measure>
      <outcome_measure>Hospital admission rate</outcome_measure>
      <outcome_measure>ICU admission rate</outcome_measure>
      <outcome_measure>Mortality rate</outcome_measure>
      <outcome_measure>Incidents of AEs or SAEs related to HCQ upon study termination time</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>NYU Langone Health</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>350</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 3, 2020</start_date>
    <primary_completion_date>August 1, 2020</primary_completion_date>
    <completion_date>September 1, 2020</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>NYU Langone Health, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04354870</url>
  </study>
  <study rank="196">
    <nct_id>NCT04359602</nct_id>
    <title>COVID-19 Recovered Volunteer Research Participant Pool Registry</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Recovered From COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Serological testing of COVID patients</outcome_measure>
      <outcome_measure>Immune response</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of California, Los Angeles</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>10000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 8, 2020</start_date>
    <primary_completion_date>April 20, 2022</primary_completion_date>
    <completion_date>April 20, 2042</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>Ronald Reagan UCLA Medical Center, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04359602</url>
  </study>
  <study rank="197">
    <nct_id>NCT04312464</nct_id>
    <title>Myocardial Damage in COVID-19</title>
    <acronym/>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Cardiovascular Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Other">non</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The myocardial injury incidence</outcome_measure>
      <outcome_measure>The risk factors analysis for the death</outcome_measure>
      <outcome_measure>Clinical characteristics</outcome_measure>
      <outcome_measure>Clinical course</outcome_measure>
      <outcome_measure>Cardiovascular comorbidity</outcome_measure>
      <outcome_measure>Analysis of causes of death</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Wuhan Union Hospital, China</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>January 1, 2020</start_date>
    <primary_completion_date>March 15, 2020</primary_completion_date>
    <completion_date>March 18, 2020</completion_date>
    <study_first_posted>March 18, 2020</study_first_posted>
    <last_update_posted>March 18, 2020</last_update_posted>
    <locations>
      <location>Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04312464</url>
  </study>
  <study rank="198">
    <nct_id>NCT04363866</nct_id>
    <title>A Pilot Study to Assess Hydroxychloroquine in Patients With SARS-CoV-2 (COVID-19)</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>SARS-CoV-2</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clinical Status at Day 5 Assessed by a 6-Point Ordinal Scale</outcome_measure>
      <outcome_measure>Number of Participants with Detectable SARS-CoV-2 Virus from Day 0 to Day 28 and at Day 5</outcome_measure>
      <outcome_measure>Toxicity of Study Drug Assessed by Incidence of Adverse Events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Oregon Health and Science University</lead_sponsor>
      <collaborator>OHSU Knight Cancer Institute</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 2020</start_date>
    <primary_completion_date>December 2020</primary_completion_date>
    <completion_date>June 2021</completion_date>
    <study_first_posted>April 27, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>Oregon Health and Science University, Portland, Oregon, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04363866</url>
  </study>
  <study rank="199">
    <nct_id>NCT04339608</nct_id>
    <title>Max COVID19- Study</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>COVID-19 positive case</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Max Healthcare Insititute Limited</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>10000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 2, 2020</start_date>
    <primary_completion_date>May 30, 2020</primary_completion_date>
    <completion_date>June 30, 2020</completion_date>
    <study_first_posted>April 9, 2020</study_first_posted>
    <last_update_posted>April 9, 2020</last_update_posted>
    <locations>
      <location>Max Super Speciality Hospital, A Unit of Devki Devi Foundation, New Delhi, Delhi, India</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04339608</url>
  </study>
  <study rank="200">
    <nct_id>NCT04356560</nct_id>
    <title>COVID-19 Surveillance of Patients and Healthcare Workers in a Hospital Department</title>
    <acronym/>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">COVID-19 test, polymerase chain reaction for SARS-CoV-2</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Incidence of healthcare workers with SARS-CoV-2</outcome_measure>
      <outcome_measure>Incidence of ENT patients with SARS-CoV-2</outcome_measure>
      <outcome_measure>Development of SARS-CoV-2 antibodies among healthcare workers</outcome_measure>
      <outcome_measure>Sensitivity and specificity of a COVID-19 screening symptom questionnaire among healthcare workers</outcome_measure>
      <outcome_measure>SARS CoV-2 and bacterial super infections in upper respiratory airways</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Rigshospitalet, Denmark</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 23, 2020</start_date>
    <primary_completion_date>September 30, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Rigshospitalet University Hospital of Copenhagen, Copenhagen, Denmark</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04356560</url>
  </study>
  <study rank="201">
    <nct_id>NCT04353596</nct_id>
    <title>Stopping ACE-inhibitors in COVID-19</title>
    <acronym>ACEI-COVID</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV-2</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ACE inhibitor, angiotensin receptor blocker</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Combination of maximum Sequential Organ Failure Assessment (SOFA) Score and death</outcome_measure>
      <outcome_measure>Composite of admission to an intensive care unit (ICU), the use of mechanical ventilation, or all-cause death</outcome_measure>
      <outcome_measure>Maximum and median maximum Sequential Organ Failure Assessment (SOFA) Score</outcome_measure>
      <outcome_measure>Rates of non-invasive ventilation</outcome_measure>
      <outcome_measure>Rates of renal replacement therapies</outcome_measure>
      <outcome_measure>Change of viral burden</outcome_measure>
      <outcome_measure>Change of C-reactive protein (CRP), interleukin 6 (IL-6), D-Dimer, IL-6, hochsensitives Troponin (hsTN), NT-pro-brain natriuretic peptide (NT-pro BNP)</outcome_measure>
      <outcome_measure>Number of patients with systolic/diastolic blood pressure &gt; 180/120 mmHg</outcome_measure>
      <outcome_measure>Hospitalisation due to cardiac decompensation</outcome_measure>
      <outcome_measure>Rates of mechanical ventilation</outcome_measure>
      <outcome_measure>Rates of clonal hematopoiesis of indeterminate potential (CHIP)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Medical University Innsbruck</lead_sponsor>
      <collaborator>Ludwig-Maximilians - University of Munich</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>208</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>May 15, 2021</primary_completion_date>
    <completion_date>May 15, 2022</completion_date>
    <study_first_posted>April 20, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Medical University Innsbruck, University Hospital of Internal Medicine III, Innsbruck, Tyrol, Austria</location>
      <location>Landeskrankenhaus Hall, Hall In Tirol, Austria</location>
      <location>Medical University Innsbruck, Intensive Care and Emergency Medicine Department, Innsbruck, Austria</location>
      <location>Medical University Innsbruck, University Hospital of Internal Medicine II, Innsbruck, Austria</location>
      <location>Medical University Innsbruck, University Hospital of Internal Medicine IV, Innsbruck, Austria</location>
      <location>Medical University Innsbruck, University Hospital of Internal Medicine I, Innsbruck, Austria</location>
      <location>Medical University Innsbruck, University Hospital of Internal Medicine V, Innsbruck, Austria</location>
      <location>Klinikum Klagenfurt, Klagenfurt, Austria</location>
      <location>Bezirkskrankenhaus Kufstein, Kufstein, Austria</location>
      <location>Bezirkskrankenhaus St. Johann, Sankt Johann In Tirol, Austria</location>
      <location>Bezirkskrankenhaus Schwaz, Schwaz, Austria</location>
      <location>Krankenhaus St. Vinzenz Zams, Zams, Austria</location>
      <location>LMU Klinikum, Medizinische Klinik I, Munich, Bavaria, Germany</location>
      <location>Asklepios Stadtklinik Bad Tölz, Bad Tölz, Germany</location>
      <location>Klinikum Landkreis Erding, Erding, Germany</location>
      <location>Klinikum Memmingen, Memmingen, Germany</location>
      <location>Deutsches Herzzentrum München, Munich, Germany</location>
      <location>Klinikum rechts der Isar, Medizinische Klinik und Poliklinik I, Munich, Germany</location>
      <location>LMU Klinikum, Medizinische Klinik III, Munich, Germany</location>
      <location>LMU Klinikum, Medizinische Klinik II, Munich, Germany</location>
      <location>LMU Klinikum, Medizinische Klinik IV, Munich, Germany</location>
      <location>München Klinik Bogenhausen und Schwabing, Munich, Germany</location>
      <location>Universitätsklinik der Paracelsus Medizinischen Privatuniversität, Nürnberg, Germany</location>
      <location>Klinikum Starnberg, Starnberg, Germany</location>
      <location>Klinik für Innere Medizin Weilheim, Weilheim, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04353596</url>
  </study>
  <study rank="202">
    <nct_id>NCT04342221</nct_id>
    <title>Hydroxychloroquine for COVID-19</title>
    <acronym>COV-HCQ</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19, Hydroxychloroquine Sulfate</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine Sulfate</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Effect of HCQ on in vivo viral clearance</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital Tuebingen</lead_sponsor>
      <collaborator>Robert Bosch Medical Center</collaborator>
      <collaborator>Universitätsklinikum Hamburg-Eppendorf</collaborator>
      <collaborator>Bernhard Nocht Institute for Tropical Medicine</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>99 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>220</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 29, 2020</start_date>
    <primary_completion_date>March 2021</primary_completion_date>
    <completion_date>February 2022</completion_date>
    <study_first_posted>April 10, 2020</study_first_posted>
    <last_update_posted>April 10, 2020</last_update_posted>
    <locations>
      <location>Institute for Tropical Medicine, Tübingen, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04342221</url>
  </study>
  <study rank="203">
    <nct_id>NCT04355533</nct_id>
    <title>Immunity Against SARS-CoV2 in Children and Their Parents / COVID-19</title>
    <acronym>PED-COVID</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19 Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">serology test</intervention>
      <intervention type="Diagnostic Test">NG Biotech</intervention>
      <intervention type="Biological">nasopharyngeal swab</intervention>
      <intervention type="Biological">rectal swab</intervention>
      <intervention type="Biological">saliva sample</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Seroconversion against SARS-CoV2 in children of the Parisian area</outcome_measure>
      <outcome_measure>Protective immunity</outcome_measure>
      <outcome_measure>Measure of Ab antiN and Ab anti-S1</outcome_measure>
      <outcome_measure>Neutralization activity</outcome_measure>
      <outcome_measure>Positive qPCR</outcome_measure>
      <outcome_measure>correlation between different Ab and qPCR and neutralization activity</outcome_measure>
      <outcome_measure>correlation of the NGBiotech rapid test with the classical serological result</outcome_measure>
      <outcome_measure>correlation of the NGBiotech rapid test with qPCR results</outcome_measure>
      <outcome_measure>duration of viral carriage in stool, saliva and or nasopharynx</outcome_measure>
      <outcome_measure>correlation between antibody profile and viral clearance</outcome_measure>
      <outcome_measure>Ab profile and memory of immunity</outcome_measure>
      <outcome_measure>saliva biofluid characteristics of COVID-19 infected</outcome_measure>
      <outcome_measure>correlation of LIPS, the NGBiotech rapid test with the classical serological result</outcome_measure>
      <outcome_measure>Presence of COVID-19 Symptom</outcome_measure>
      <outcome_measure>seroconversion against SARS-CoV2 in parents of the Parisian area</outcome_measure>
      <outcome_measure>Intra-family correlation of serological results</outcome_measure>
      <outcome_measure>Measure of Ab antiN and Ab anti-S1 and neutralization activity</outcome_measure>
      <outcome_measure>correlation between different Ab and qPCR</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
      <collaborator>Institut National de la Santé Et de la Recherche Médicale, France</collaborator>
      <collaborator>NG Biotech</collaborator>
      <collaborator>Commissariat a l’energie atomique et aux energies alternatives</collaborator>
      <collaborator>Institut Pasteur</collaborator>
    </sponsors>
    <gender>All</gender>
    <max_age>17 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>1920</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>April 2020</primary_completion_date>
    <completion_date>July 2021</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>Hôpital necker Enfants-Malades, ¨Paris, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04355533</url>
  </study>
  <study rank="204">
    <nct_id>NCT04347070</nct_id>
    <title>Implementation of Physiotherapy on COVID-19 Patients in ICU</title>
    <acronym>PHYSIO-COVID</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sars-CoV2</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Phsyiotherapy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time of physiotherapy</outcome_measure>
      <outcome_measure>Type of physiotherapy implemented</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Montpellier</lead_sponsor>
      <collaborator>Société espagnole de pneumologie (SEPAR)</collaborator>
      <collaborator>Societe française de kinésithérapie en réanimation (SKR)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>April 1, 2017</start_date>
    <primary_completion_date>September 1, 2020</primary_completion_date>
    <completion_date>December 1, 2022</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 16, 2020</last_update_posted>
    <locations>
      <location>Uhmontpellier, Montpellier, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04347070</url>
  </study>
  <study rank="205">
    <nct_id>NCT04345679</nct_id>
    <title>Anti COVID-19 Convalescent Plasma Therapy</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID 19</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">anti-SARS-CoV-2 convalescent plasma</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Changing of viral load of SARS-CoV2</outcome_measure>
      <outcome_measure>Changes in immunglobulin G COVID-19 antibody titer</outcome_measure>
      <outcome_measure>Changes at the cytokine pattern</outcome_measure>
      <outcome_measure>Intensive Care Unit Admission</outcome_measure>
      <outcome_measure>Length of hospital stay</outcome_measure>
      <outcome_measure>Duration of mechanical ventilation</outcome_measure>
      <outcome_measure>Clinical Status</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Orthosera Kft.</lead_sponsor>
      <collaborator>Semmelweis University</collaborator>
      <collaborator>University of Pécs</collaborator>
      <collaborator>Hungarian National Blood Service</collaborator>
      <collaborator>Humán Bioplazma Kft - Kedrion</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Early Phase 1</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 14, 2020</start_date>
    <primary_completion_date>June 1, 2020</primary_completion_date>
    <completion_date>April 1, 2021</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04345679</url>
  </study>
  <study rank="206">
    <nct_id>NCT04355767</nct_id>
    <title>Convalescent Plasma vs. Placebo in Emergency Room Patients With COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Convalescent Plasma</intervention>
      <intervention type="Biological">Standard Plasma</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to disease progression</outcome_measure>
      <outcome_measure>Change in symptom severity over time</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Stanford University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>206</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 2020</start_date>
    <primary_completion_date>December 2022</primary_completion_date>
    <completion_date>December 2022</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>Stanford University, Stanford, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04355767</url>
  </study>
  <study rank="207">
    <nct_id>NCT04352608</nct_id>
    <title>Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19)</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule</intervention>
      <intervention type="Biological">Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule</intervention>
      <intervention type="Biological">Two doses of placebo at the emergency vaccination schedule</intervention>
      <intervention type="Biological">Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule</intervention>
      <intervention type="Biological">Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule</intervention>
      <intervention type="Biological">Two doses of placebo at the routine vaccination schedule</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Safety indexes of adverse reactions</outcome_measure>
      <outcome_measure>Immunogenicity indexes of neutralizing-antibody seroconversion rates for the emergency vaccination schedule （day 0,14）</outcome_measure>
      <outcome_measure>Immunogenicity indexes of neutralizing-antibody seroconversion rates for the routine vaccination schedule (day 0,28)</outcome_measure>
      <outcome_measure>Occurrence of abnormal changes of laboratory safety examinations (hemoglobin,WBCs, platelets, ALT, AST, total bilirubin, creatinine, creatine phosphokinase, urine protein, urine sugar, urinary erythrocyte)</outcome_measure>
      <outcome_measure>Safety indexes of serious adverse events (SAEs）</outcome_measure>
      <outcome_measure>Immunogenicity indexes of neutralizing-antibody seroconversion rates</outcome_measure>
      <outcome_measure>Immunogenicity indexes of IgG antibody seropositivity rates</outcome_measure>
      <outcome_measure>Immunogenicity indexes IgM antibody seropositivity rates</outcome_measure>
      <outcome_measure>Immunogenicity indexes of GMT of neutralizing-antibody</outcome_measure>
      <outcome_measure>Immunogenicity indexes of GMR of neutralizing-antibody</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sinovac Research and Development Co., Ltd.</lead_sponsor>
      <collaborator>Sinovac Biotech Co., Ltd</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>59 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>744</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 16, 2020</start_date>
    <primary_completion_date>August 13, 2020</primary_completion_date>
    <completion_date>December 13, 2020</completion_date>
    <study_first_posted>April 20, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Suining County Center for Disease Control and Prevention, Xuzhou, Jiangsu, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04352608</url>
  </study>
  <study rank="208">
    <nct_id>NCT04325061</nct_id>
    <title>Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19</title>
    <acronym>DEXA-COVID19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Acute Respiratory Distress Syndrome Caused by COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Dexamethasone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>60-day mortality</outcome_measure>
      <outcome_measure>Ventilator-free days</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Dr. Negrin University Hospital</lead_sponsor>
      <collaborator>Li Ka Shing Knowledge Institute</collaborator>
      <collaborator>Consorcio Centro de Investigación Biomédica en Red, M.P.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 3, 2020</start_date>
    <primary_completion_date>October 30, 2020</primary_completion_date>
    <completion_date>October 30, 2020</completion_date>
    <study_first_posted>March 27, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations>
      <location>ICU, Hospital Universitari Mutua Terrassa, Terrassa, Barcelona, Spain</location>
      <location>Hospital Universitario Dr. Negrin, Las Palmas de Gran Canaria, Las Palmas, Spain</location>
      <location>Department of Anesthesia, Hospital Universitario de Cruces, Barakaldo, Vizcaya, Spain</location>
      <location>Intensive Care Unit, Hospital Universitario de Cruces, Barakaldo, Vizcaya, Spain</location>
      <location>AVI, Hospital Clinic, Barcelona, Spain</location>
      <location>Cardiac ICU, Hospital Clinic, Barcelona, Spain</location>
      <location>Department of Anesthesia, Hospital Clinic, Barcelona, Spain</location>
      <location>Hepatic ICU, Hospital Clínic, Barcelona, Spain</location>
      <location>UVIR, Hospital Clinic, Barcelona, Spain</location>
      <location>Intensive Care Unit, Hospital General de Ciudad Real, Ciudad Real, Spain</location>
      <location>Department of Anesthesia, Hospital Universitario La Princesa, Madrid, Spain</location>
      <location>Intensive Care Unit, Hospital Universitario La Princesa, Madrid, Spain</location>
      <location>Intensive Care Unit, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain</location>
      <location>Department of Anesthesia, Hospital Universitario La Paz, Madrid, Spain</location>
      <location>Intensive Care Unit, Hospital Universitario La Paz, Madrid, Spain</location>
      <location>Department of Anesthesia, Hospital Universitario Virgen de Arrixaca, Murcia, Spain</location>
      <location>Intensive Care Unit, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain</location>
      <location>Department of Anesthesia, Hospital Unversitario Montecelo, Pontevedra, Spain</location>
      <location>Anesthesia, Hospital General Universitario de Valencia, Valencia, Spain</location>
      <location>Department of Anesthesia, Hospital Clinico Universitario, Valencia, Spain</location>
      <location>Intensive Care Unit, Hospital Clinico Universitario, Valencia, Spain</location>
      <location>Department of Anesthesia, Hospital Clínico Universitario, Valladolid, Spain</location>
      <location>Anesthesia, Hospital Universitario Río Hortega, Valladolid, Spain</location>
      <location>Intensive Care Unit, Hospital Universitario Río Hortega, Valladolid, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04325061</url>
  </study>
  <study rank="209">
    <nct_id>NCT04315896</nct_id>
    <title>Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial)</title>
    <acronym>HYDRA</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Severe Acute Respiratory Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Drug">Placebo oral tablet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>All-cause hospital mortality</outcome_measure>
      <outcome_measure>Length of hospital stay</outcome_measure>
      <outcome_measure>Need of mechanical ventilation</outcome_measure>
      <outcome_measure>Ventilator free days</outcome_measure>
      <outcome_measure>Grade 3-4 adverse reaction</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute of Respiratory Diseases, Mexico</lead_sponsor>
      <collaborator>Sanofi</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 14, 2020</start_date>
    <primary_completion_date>October 31, 2020</primary_completion_date>
    <completion_date>March 22, 2021</completion_date>
    <study_first_posted>March 20, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations>
      <location>Instituto Nacional de Enfermedades Respiratorias, &quot;Ismael Cosío Villegas&quot;, Mexico, City, Mexico</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04315896</url>
  </study>
  <study rank="210">
    <nct_id>NCT04338074</nct_id>
    <title>TXA and Corona Virus 2019 (COVID19) in Outpatients</title>
    <acronym>TCOutpatient</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tranexamic acid tablets</intervention>
      <intervention type="Drug">Placebo oral tablet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Hospitalization</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Alabama at Birmingham</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>19 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>October 15, 2020</primary_completion_date>
    <completion_date>October 30, 2020</completion_date>
    <study_first_posted>April 8, 2020</study_first_posted>
    <last_update_posted>April 8, 2020</last_update_posted>
    <locations>
      <location>University of Alabama at Birmingham, Birmingham, Alabama, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04338074</url>
  </study>
  <study rank="211">
    <nct_id>NCT04346017</nct_id>
    <title>Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in COVID-19 Patients With a Systemic Inflammatory Response Syndrome</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Cytokines dosage</intervention>
      <intervention type="Diagnostic Test">Complement dosage</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>IL6 concentration</outcome_measure>
      <outcome_measure>IL6 concentration change from baseline value</outcome_measure>
      <outcome_measure>Complement parameters</outcome_measure>
      <outcome_measure>Complement parameters change from baseline values</outcome_measure>
      <outcome_measure>Inflammatory cytokines baseline concentrations</outcome_measure>
      <outcome_measure>Inflammatory cytokines change from baseline values</outcome_measure>
      <outcome_measure>Concentration of markers of macrophage activation</outcome_measure>
      <outcome_measure>Markers of macrophage activation change from baseline values</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Francis Corazza</lead_sponsor>
      <collaborator>Brugmann University Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <start_date>March 20, 2020</start_date>
    <primary_completion_date>December 2020</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>CHU Brugmann, Brussels, Belgium</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04346017</url>
  </study>
  <study rank="212">
    <nct_id>NCT04344457</nct_id>
    <title>Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19</title>
    <acronym>COVID-19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Drug">Indomethacin</intervention>
      <intervention type="Drug">Zithromax Oral Product</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Improvement of clinical status</outcome_measure>
      <outcome_measure>Time of clinical recovery of fever</outcome_measure>
      <outcome_measure>Time of clinical recovery of cough</outcome_measure>
      <outcome_measure>Safety as determined by changes in QTC intervals measured by ECG</outcome_measure>
      <outcome_measure>Safety as determined by presence of side effects</outcome_measure>
      <outcome_measure>Time to improvement</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Perseverance Research Center, LLC</lead_sponsor>
      <collaborator>Athena Medical Group</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 16, 2020</start_date>
    <primary_completion_date>June 20, 2020</primary_completion_date>
    <completion_date>September 30, 2020</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 16, 2020</last_update_posted>
    <locations>
      <location>Perseverance Research Center, Scottsdale, Arizona, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04344457</url>
  </study>
  <study rank="213">
    <nct_id>NCT04343742</nct_id>
    <title>Determination of the Effectiveness of Oral Chlorine Dioxide in the Treatment of COVID 19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">chlorine dioxide 3000 ppm</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>negative testing of covid19</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Genesis Foundation</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>April 7, 2020</primary_completion_date>
    <completion_date>June 1, 2020</completion_date>
    <study_first_posted>April 13, 2020</study_first_posted>
    <last_update_posted>April 13, 2020</last_update_posted>
    <locations>
      <location>San Carlos Hospital, Bogota, Cundinamarca, Colombia</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04343742</url>
  </study>
  <study rank="214">
    <nct_id>NCT04345536</nct_id>
    <title>Prospective Quality Register of Patients With Confirmed Covid-19 at Oslo University Hospital</title>
    <acronym>CovidRegOUH</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>Severe disease</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Oslo University Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 15, 2020</start_date>
    <primary_completion_date>January 1, 2021</primary_completion_date>
    <completion_date>May 1, 2021</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>Oslo University Hospital, Oslo, Norway</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04345536</url>
  </study>
  <study rank="215">
    <nct_id>NCT04342182</nct_id>
    <title>Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study)</title>
    <acronym>ConCoVid-19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Convalescent plasma</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Overall mortality until discharge from the hospital or a maximum of 60 days after admission whichever comes first</outcome_measure>
      <outcome_measure>Impact of 300ml convP therapy on hospital days</outcome_measure>
      <outcome_measure>Impact of 300ml convP on weaning from oxygen therapy</outcome_measure>
      <outcome_measure>Impact of 300ml convP on overall mortality in patients admitted to the ICU within 24 hours after admission</outcome_measure>
      <outcome_measure>Difference in the effect of convP on mortality in patients with a duration of symptoms less or more the median duration of symptoms in the study population</outcome_measure>
      <outcome_measure>Impact of 300ml convP therapy on ICU days in patients admitted to the ICU within 24 hours after admission</outcome_measure>
      <outcome_measure>Impact of plasma therapy on the decrease in SARS-CoV2 shedding from airways</outcome_measure>
      <outcome_measure>Impact of CTL and NK cell immunity on the likelihood of being protected from immune serum transfer</outcome_measure>
      <outcome_measure>Safety of convP therapy</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Erasmus Medical Center</lead_sponsor>
      <collaborator>Maasstad Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>426</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 8, 2020</start_date>
    <primary_completion_date>July 1, 2020</primary_completion_date>
    <completion_date>July 1, 2020</completion_date>
    <study_first_posted>April 10, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands</location>
      <location>Maasstad Ziekenhuis, Rotterdam, Netherlands</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04342182</url>
  </study>
  <study rank="216">
    <nct_id>NCT04347174</nct_id>
    <title>A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Suspension of heat killed (autoclaved) Mycobacterium w</intervention>
      <intervention type="Drug">Standard therapy of COVID-19</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Sequential Organ Failure Assessment (SOFA) scores</outcome_measure>
      <outcome_measure>7-category ordinal scale that ranges from 1 (not hospitalized with resumption of normal activities) to 7 (death)</outcome_measure>
      <outcome_measure>All-cause mortality</outcome_measure>
      <outcome_measure>Incidence of AE / SAE or event of clinical significance</outcome_measure>
      <outcome_measure>SARS-CoV-2 detectable in nasal or oropharyngeal (OP) sample</outcome_measure>
      <outcome_measure>ICU length of stay</outcome_measure>
      <outcome_measure>Duration of mechanical ventilation</outcome_measure>
      <outcome_measure>Duration of hospitalization</outcome_measure>
      <outcome_measure>Clinical improvement</outcome_measure>
      <outcome_measure>Time (in days) from treatment initiation to death</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Cadila Pharnmaceuticals</lead_sponsor>
      <collaborator>Council of Scientific and Industrial Research, India</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>June 30, 2020</primary_completion_date>
    <completion_date>July 30, 2020</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations>
      <location>Postgraduate Institute of Medical Education and Research, Chandigarh, India</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04347174</url>
  </study>
  <study rank="217">
    <nct_id>NCT04360980</nct_id>
    <title>The Effects of Standard Protocol With or Without Colchicine in Covid-19 Infection</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Colchicine Tablets</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>CRPxN/R ratio change</outcome_measure>
      <outcome_measure>Clinical deterioration by the WHO definition</outcome_measure>
      <outcome_measure>PCR Viral Load</outcome_measure>
      <outcome_measure>CT severity involvement index</outcome_measure>
      <outcome_measure>LDH change</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Shahid Beheshti University of Medical Sciences</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 20, 2020</start_date>
    <primary_completion_date>May 20, 2020</primary_completion_date>
    <completion_date>May 30, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>SBMU, Tehran, Iran, Islamic Republic of</location>
      <location>Nooshin Dalili, Tehran, Iran, Islamic Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04360980</url>
  </study>
  <study rank="218">
    <nct_id>NCT04331600</nct_id>
    <title>ChloroQUine As antiviRal treAtmeNT In coroNavirus infEction 2020</title>
    <acronym>QUARANTINE2020</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Chloroquine phosphate</intervention>
      <intervention type="Other">Telemedicine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>COVID-19-related hospitalization or all-cause death</outcome_measure>
      <outcome_measure>Decrease in COVID-19 symptoms</outcome_measure>
      <outcome_measure>Development of pneumonia</outcome_measure>
      <outcome_measure>Development of coronavirus infection-related complications</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Wroclaw Medical University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 6, 2020</start_date>
    <primary_completion_date>September 30, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>April 2, 2020</study_first_posted>
    <last_update_posted>April 2, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04331600</url>
  </study>
  <study rank="219">
    <nct_id>NCT04335201</nct_id>
    <title>Defibrotide in COVID-19 Pneumonia</title>
    <acronym>DEFI-VID19</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Patients With COVID-19 Pneumonia Will Allow to Detect an Absolute Reduction in the Rate of Respiratory-failure</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Defibrotide Injection</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>to able to reduce the progression of acute respiratory failure</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
      <outcome_measure>duration of hospitalization</outcome_measure>
      <outcome_measure>systemic inflammation</outcome_measure>
      <outcome_measure>overall survival</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>IRCCS San Raffaele</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 6, 2020</start_date>
    <primary_completion_date>September 30, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>April 6, 2020</study_first_posted>
    <last_update_posted>April 6, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04335201</url>
  </study>
  <study rank="220">
    <nct_id>NCT04280588</nct_id>
    <title>Fingolimod in COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Disease (COVID-19)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Fingolimod 0.5 mg</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The change of pneumonia severity on X-ray images</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>First Affiliated Hospital of Fujian Medical University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>February 22, 2020</start_date>
    <primary_completion_date>July 1, 2020</primary_completion_date>
    <completion_date>July 1, 2020</completion_date>
    <study_first_posted>February 21, 2020</study_first_posted>
    <last_update_posted>February 21, 2020</last_update_posted>
    <locations>
      <location>Wan-Jin Chen, Fuzhou, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04280588</url>
  </study>
  <study rank="221">
    <nct_id>NCT04365816</nct_id>
    <title>NutriCovid30 : Nutritional Evaluation for Covid-19 Infection at D30</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Interview</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clinical signs impacting food intake and therefore the nutritional status</outcome_measure>
      <outcome_measure>Clinical signs limiting food intake</outcome_measure>
      <outcome_measure>Weight variation during the infection</outcome_measure>
      <outcome_measure>Factors limiting food intake</outcome_measure>
      <outcome_measure>Implemented nutritional strategy</outcome_measure>
      <outcome_measure>Pre-existing chronic disorders</outcome_measure>
      <outcome_measure>Covid-19 repercussions</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Grenoble</lead_sponsor>
      <collaborator>University Grenoble Alps</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>600</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>May 2020</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>October 2020</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04365816</url>
  </study>
  <study rank="222">
    <nct_id>NCT04350476</nct_id>
    <title>COVID-19 Remote Monitoring</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Cardiac Arrhythmias</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">VitalConnect Vital Sign Patch</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of different arrhythmias</outcome_measure>
      <outcome_measure>Temperature</outcome_measure>
      <outcome_measure>Oxygen Saturation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Vivek Reddy</lead_sponsor>
      <collaborator>Icahn School of Medicine at Mount Sinai</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>April 2021</primary_completion_date>
    <completion_date>April 2021</completion_date>
    <study_first_posted>April 17, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations>
      <location>Icahn School of Medicine at Mount Sinai, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04350476</url>
  </study>
  <study rank="223">
    <nct_id>NCT04363060</nct_id>
    <title>Azithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID19 Patients With Pneumonia in Non-intensive Unit</title>
    <acronym>AziA</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19 Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Combination Product">Azithromycin with amoxicillin/clavulanate</intervention>
      <intervention type="Drug">amoxicillin/clavulanate</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Rate of positive SARS-CoV-2 RT-PCR</outcome_measure>
      <outcome_measure>Clinical evolution on the WHO Ordinal Scale for Clinical Improvement for COVID-19</outcome_measure>
      <outcome_measure>Total duration of antibiotic treatment during the 30 days following inclusion</outcome_measure>
      <outcome_measure>Number of all-cause mortality during the 30 days following inclusion</outcome_measure>
      <outcome_measure>Number of in-hospital mortality during the 30 days following inclusion</outcome_measure>
      <outcome_measure>Number of patients transferred to intensive care unit during the 30-day follow-up</outcome_measure>
      <outcome_measure>Number of days without mechanical ventilation during the 30 days following inclusion</outcome_measure>
      <outcome_measure>adverse events attributable to antibiotic treatment during the 30 days following inclusion</outcome_measure>
      <outcome_measure>Hospital length of stay during the 30 days following inclusion</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Nantes University Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>99 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>104</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 30, 2020</start_date>
    <primary_completion_date>July 30, 2020</primary_completion_date>
    <completion_date>July 30, 2020</completion_date>
    <study_first_posted>April 27, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>Chu Angers, Angers, France</location>
      <location>CHD Vendée, La Roche-sur-Yon, France</location>
      <location>CHU Poitiers, Poitiers, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04363060</url>
  </study>
  <study rank="224">
    <nct_id>NCT04346056</nct_id>
    <title>Retrospective Study on Severe Respiratory Illness to Access the Presence of COVID-19</title>
    <acronym>Explore</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Disease (COVID-19)</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Exploring the presence of COVID-19</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ain Shams University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>1 Year</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>April 14, 2020</start_date>
    <primary_completion_date>October 1, 2020</primary_completion_date>
    <completion_date>December 1, 2020</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations>
      <location>Faculty of Medicine Ain Shams University, Cairo, Non-US, Egypt</location>
      <location>Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04346056</url>
  </study>
  <study rank="225">
    <nct_id>NCT04359680</nct_id>
    <title>Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- or Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Viral Respiratory Illnesses</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nitazoxanide</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The proportion of subjects with symptomatic laboratory-confirmed COVID-19 identified after start of treatment and before the end of the 6-week treatment period.</outcome_measure>
      <outcome_measure>The proportion of subjects with symptomatic laboratory-confirmed VRI identified after the start of treatment and before the end of the 6-week treatment period.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Romark Laboratories L.C.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>64 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>800</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 30, 2020</start_date>
    <primary_completion_date>August 31, 2020</primary_completion_date>
    <completion_date>August 31, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04359680</url>
  </study>
  <study rank="226">
    <nct_id>NCT04341389</nct_id>
    <title>A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector)</title>
    <acronym>CTII-nCoV</acronym>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Recombinant novel coronavirus vaccine (Adenovirus type 5 vector)</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Occurrence of adverse reactions</outcome_measure>
      <outcome_measure>Anti SARS-CoV-2 S antibody response(ELISA)</outcome_measure>
      <outcome_measure>Neutralizing antibody response to SARS-CoV-2</outcome_measure>
      <outcome_measure>Occurrence of adverse events</outcome_measure>
      <outcome_measure>Occurrence of serious adverse reaction</outcome_measure>
      <outcome_measure>Neutralizing antibody response to Ad5-vector</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Insitute of Biotechnology, Academy of Military Medical Sciences, PLA of China</lead_sponsor>
      <collaborator>CanSino Biologics Inc.</collaborator>
      <collaborator>Jiangsu Province Centers for Disease Control and Prevention</collaborator>
      <collaborator>Hubei Provincial Center for Disease Control and Prevention</collaborator>
      <collaborator>Zhongnan Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 12, 2020</start_date>
    <primary_completion_date>January 31, 2021</primary_completion_date>
    <completion_date>January 31, 2021</completion_date>
    <study_first_posted>April 10, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>Hubei Provincial Center for Disease Control and Prevention, Wuhan, Hubei, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04341389</url>
  </study>
  <study rank="227">
    <nct_id>NCT04343248</nct_id>
    <title>Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Viral Respiratory Illnesses</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nitazoxanide</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Symptomatic laboratory-confirmed COVID-19</outcome_measure>
      <outcome_measure>Symptomatic laboratory-confirmed VRI</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Romark Laboratories L.C.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>65 Years</min_age>
    <max_age>120 Years</max_age>
    <age_groups>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>600</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 30, 2020</start_date>
    <primary_completion_date>August 31, 2020</primary_completion_date>
    <completion_date>August 31, 2020</completion_date>
    <study_first_posted>April 13, 2020</study_first_posted>
    <last_update_posted>April 16, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04343248</url>
  </study>
  <study rank="228">
    <nct_id>NCT04329559</nct_id>
    <title>COVID-19 in Patients With Pre-existing Cirrhosis (COVID-Cirrhosis-CHESS2002): A Multicentre Observational Study</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Liver Cirrhosis</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>All-cause mortality of COVID-19 patients with liver cirrhosis</outcome_measure>
      <outcome_measure>Liver-related mortality of COVID-19 patients with liver cirrhosis</outcome_measure>
      <outcome_measure>Risk factors associated with specific outcomes of COVID-19 patients with liver cirrhosis</outcome_measure>
      <outcome_measure>Baseline characteristics of COVID-19 patients with liver cirrhosis</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hepatopancreatobiliary Surgery Institute of Gansu Province</lead_sponsor>
      <collaborator>Renmin Hospital of Wuhan University</collaborator>
      <collaborator>LanZhou University</collaborator>
      <collaborator>Minda Hospital Affiliated to Hubei University for Nationalities</collaborator>
      <collaborator>Wuhan Union Hospital, China</collaborator>
      <collaborator>The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture</collaborator>
      <collaborator>Tianjin Second People's Hospital</collaborator>
      <collaborator>Sixth People’s Hospital of Shenyang</collaborator>
      <collaborator>Guangxi Zhuang Autonomous Region</collaborator>
      <collaborator>Shenzhen Third People's Hospital</collaborator>
      <collaborator>Ankang Central Hospital</collaborator>
      <collaborator>Xingtai People's Hospital</collaborator>
      <collaborator>Dalian Sixth People’s Hospital</collaborator>
      <collaborator>The Central Hospital of Lishui City</collaborator>
      <collaborator>The Affiliated Third Hospital of Jiangsu University</collaborator>
      <collaborator>Suizhou Hospital, Hubei University of Medicine</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <start_date>March 30, 2020</start_date>
    <primary_completion_date>June 29, 2020</primary_completion_date>
    <completion_date>June 29, 2021</completion_date>
    <study_first_posted>April 1, 2020</study_first_posted>
    <last_update_posted>April 1, 2020</last_update_posted>
    <locations>
      <location>Dalian Sixth People's Hospital, Dalian, China</location>
      <location>Minda Hospital Affiliated to Hubei University for Nationalities, Enshi, China</location>
      <location>The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture, Enshi, China</location>
      <location>The First Hospital of Lanzhou University, Lanzhou, China</location>
      <location>The Central Hospital of Lishui City, Lishui, China</location>
      <location>Guangxi Zhuang Autonomous Region, Nanning, China</location>
      <location>The Sixth Peoples Hospital of Shenyang, Shenyang, China</location>
      <location>Shenzhen Third People's Hospital, Shenzhen, China</location>
      <location>Suizhou Hospital, Hubei University of Medicine, Suizhou, China</location>
      <location>Tianjin Second People's Hospital, Tianjin, China</location>
      <location>Ankang Central Hospital, Wuhan, China</location>
      <location>Renmin Hospital of Wuhan University, Wuhan, China</location>
      <location>Wuhan Union Hospital, Wuhan, China</location>
      <location>Xingtai People's Hospital, Xingtai, China</location>
      <location>The Affiliated Third Hospital of Jiangsu University, Zhenjiang, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04329559</url>
  </study>
  <study rank="229">
    <nct_id>NCT04318301</nct_id>
    <title>Hypertension in Patients Hospitalized With COVID-19</title>
    <acronym>HT-COVID19</acronym>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Hypertension</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Rate of Death</outcome_measure>
      <outcome_measure>the severity of pneumonia</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Zhenhua Zen</lead_sponsor>
      <collaborator>Nanfang Hospital of Southern Medical University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>100 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>275</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>March 21, 2020</start_date>
    <primary_completion_date>March 28, 2020</primary_completion_date>
    <completion_date>March 30, 2020</completion_date>
    <study_first_posted>March 23, 2020</study_first_posted>
    <last_update_posted>April 7, 2020</last_update_posted>
    <locations>
      <location>Hankou Hospital, Hankou, Hubei, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04318301</url>
  </study>
  <study rank="230">
    <nct_id>NCT04332107</nct_id>
    <title>Azithromycin for COVID-19 Treatment in Outpatients Nationwide</title>
    <acronym>ACTION</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>SARS-CoV-2</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Azithromycin</intervention>
      <intervention type="Drug">Placebos</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Hospitalization</outcome_measure>
      <outcome_measure>Viral load</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
      <outcome_measure>Positive SARS-CoV-2 test - nasal swab</outcome_measure>
      <outcome_measure>Positive SARS-CoV-2 test - saliva swab</outcome_measure>
      <outcome_measure>Positive SARS-CoV-2 test - rectal swab</outcome_measure>
      <outcome_measure>Genetic macrolide resistance determinants</outcome_measure>
      <outcome_measure>COVID-19 symptoms</outcome_measure>
      <outcome_measure>Number of emergency room visits</outcome_measure>
      <outcome_measure>Number of household members with COVID-19 (confirmed or symptomatic)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of California, San Francisco</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>2271</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 1, 2020</start_date>
    <primary_completion_date>August 30, 2020</primary_completion_date>
    <completion_date>August 30, 2021</completion_date>
    <study_first_posted>April 2, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>University of California San Francisco, San Francisco, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04332107</url>
  </study>
  <study rank="231">
    <nct_id>NCT04273646</nct_id>
    <title>Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>2019 Novel Coronavirus Pneumonia</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">UC-MSCs</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Pneumonia severity index</outcome_measure>
      <outcome_measure>Oxygenation index (PaO2/FiO2)</outcome_measure>
      <outcome_measure>Side effects in the UC-MSCs treatment group</outcome_measure>
      <outcome_measure>28-days survival</outcome_measure>
      <outcome_measure>Sequential organ failure assessment</outcome_measure>
      <outcome_measure>C-reactive protein</outcome_measure>
      <outcome_measure>Procalcitonin</outcome_measure>
      <outcome_measure>Lymphocyte count</outcome_measure>
      <outcome_measure>CD3+, CD4+ and CD8+ T celll count</outcome_measure>
      <outcome_measure>CD4+/CD8+ratio</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Wuhan Union Hospital, China</lead_sponsor>
      <collaborator>Wuhan Hamilton Bio-technology Co., Ltd, China.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>48</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>June 30, 2020</primary_completion_date>
    <completion_date>February 15, 2022</completion_date>
    <study_first_posted>February 18, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04273646</url>
  </study>
  <study rank="232">
    <nct_id>NCT04355871</nct_id>
    <title>Characteristics and Outcomes of Hospitalized Patients With COVID-19 in Spain</title>
    <acronym>COVID19@Spain</acronym>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Overall mortality</outcome_measure>
      <outcome_measure>Mechanical ventilation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Fundacion SEIMC-GESIDA</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>3000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>March 18, 2020</start_date>
    <primary_completion_date>April 15, 2020</primary_completion_date>
    <completion_date>April 17, 2020</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>H. Univ. de Bellvitge, Barcelona, Spain</location>
      <location>H. Univ. Gregorio Marañon, Madrid, Spain</location>
      <location>H. Univ. INfanta Leonor, Madrid, Spain</location>
      <location>H. Univ. La Paz, Madrid, Spain</location>
      <location>H. Univ. Virgen del Rocio, Sevilla, Spain</location>
      <location>H. Univ. Virgen Macarena, Sevilla, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04355871</url>
  </study>
  <study rank="233">
    <nct_id>NCT04337359</nct_id>
    <title>Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness</title>
    <acronym/>
    <status open="Y">Available</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Severe/Very Severe COVID-19 Illness</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ruxolitinib</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>6 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Expanded Access</study_types>
    <exp_acc_types>
      <exp_acc_type>Intermediate-size Population</exp_acc_type>
    </exp_acc_types>
    <study_designs/>
    <study_first_posted>April 7, 2020</study_first_posted>
    <last_update_posted>April 7, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04337359</url>
  </study>
  <study rank="234">
    <nct_id>NCT04349241</nct_id>
    <title>Efficacy and Safety of Favipiravir in Management of COVID-19</title>
    <acronym>FAV-001</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Disease (COVID-19)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">favipiravir</intervention>
      <intervention type="Drug">Standard of care therapy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Viral clearance</outcome_measure>
      <outcome_measure>Clinical improvement</outcome_measure>
      <outcome_measure>Radiological Improvement</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ain Shams University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>October 1, 2020</primary_completion_date>
    <completion_date>December 1, 2020</completion_date>
    <study_first_posted>April 16, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations>
      <location>Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04349241</url>
  </study>
  <study rank="235">
    <nct_id>NCT04345991</nct_id>
    <title>Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort</title>
    <acronym>CORIPLASM</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Transfusion of COVID-19 convalescent plasma</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Survival without needs of ventilator utilization or use of immunomodulatory drugs</outcome_measure>
      <outcome_measure>WHO progression scale ≥6</outcome_measure>
      <outcome_measure>Severe adverse events</outcome_measure>
      <outcome_measure>WHO progression scale</outcome_measure>
      <outcome_measure>Overall survival</outcome_measure>
      <outcome_measure>Time from randomization to discharge</outcome_measure>
      <outcome_measure>Time to oxygen supply independency</outcome_measure>
      <outcome_measure>Survival without needs of ventilator utilization</outcome_measure>
      <outcome_measure>Survival without use of immunomodulatory drugs</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
      <collaborator>Etablissement Français du Sang</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 14, 2020</start_date>
    <primary_completion_date>May 15, 2020</primary_completion_date>
    <completion_date>June 1, 2020</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>SMIT, Saint Antoine hospital, Paris, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04345991</url>
  </study>
  <study rank="236">
    <nct_id>NCT04355507</nct_id>
    <title>Computed Tomography for COVID-19 Diagnosis</title>
    <acronym>STOIC</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Chest computed tomography (CT)</intervention>
      <intervention type="Diagnostic Test">Reverse-transcription polymerase chain reaction (RT-PCR)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Predictive values of CT criteria</outcome_measure>
      <outcome_measure>Accuracy of CT composite severity score</outcome_measure>
      <outcome_measure>Accuracy of deep-learning based score</outcome_measure>
      <outcome_measure>Predictive values of deep-learning based diagnostic algorithms</outcome_measure>
      <outcome_measure>Dice similarity coefficient between manual and automated segmentation of lung disease abnormalities</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
      <collaborator>Institut National de la Santé Et de la Recherche Médicale, France</collaborator>
      <collaborator>GE Healthcare</collaborator>
      <collaborator>Orange healthcare</collaborator>
      <collaborator>TheraPanacea</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>10000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>May 2020</primary_completion_date>
    <completion_date>July 2020</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Cochin Hospital, Paris, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04355507</url>
  </study>
  <study rank="237">
    <nct_id>NCT04334044</nct_id>
    <title>Treatment of SARS Caused by COVID-19 With Ruxolitinib</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Severe Acute Respiratory Syndrome Coronavirus 2</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ruxolitinib Oral Tablet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Recovery of Pneumonia</outcome_measure>
      <outcome_measure>Response of C-reactive protein</outcome_measure>
      <outcome_measure>Response of Ferritin</outcome_measure>
      <outcome_measure>Response of D-dimer</outcome_measure>
      <outcome_measure>Rate of ICU admission</outcome_measure>
      <outcome_measure>Rate of mechanical ventilation</outcome_measure>
      <outcome_measure>Overall Survival</outcome_measure>
      <outcome_measure>Toxicity Rate</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Grupo Cooperativo de Hemopatías Malignas</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>June 1, 2020</primary_completion_date>
    <completion_date>June 1, 2020</completion_date>
    <study_first_posted>April 3, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations>
      <location>Grupo Cooperativo de Hemopatías Malignas, Huixquilucan, Estado De México, Mexico</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04334044</url>
  </study>
  <study rank="238">
    <nct_id>NCT04363489</nct_id>
    <title>The CEDiD Study (COVID-19 Early Diagnosis in Doctors)</title>
    <acronym>CEDiD</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid19</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Wearable Medical Device (Empatica E4)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>COVID-19</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>King's College London</lead_sponsor>
      <collaborator>Empatica, Inc.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 27, 2020</start_date>
    <primary_completion_date>May 27, 2020</primary_completion_date>
    <completion_date>May 27, 2020</completion_date>
    <study_first_posted>April 27, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04363489</url>
  </study>
  <study rank="239">
    <nct_id>NCT04331106</nct_id>
    <title>Survey of the Anxiety Associated With the COVID-19 Pandemic</title>
    <acronym>CORA</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Anxiety Related to the COVID-19 Pandemic</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Online Questionnaire</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Characteristics of COVID-19-related anxiety</outcome_measure>
      <outcome_measure>COVID-19-related anxiety symptoms</outcome_measure>
      <outcome_measure>Self-efficacy and coping with COVID-19</outcome_measure>
      <outcome_measure>Consequences of COVID-19 in the last three weeks.</outcome_measure>
      <outcome_measure>General Illness Attitude</outcome_measure>
      <outcome_measure>Media reporting</outcome_measure>
      <outcome_measure>Ultra-brief screening scale for anxiety and depression</outcome_measure>
      <outcome_measure>Change in characteristics of COVID-19-related anxiety</outcome_measure>
      <outcome_measure>Change in COVID-19-related anxiety symptoms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Charite University, Berlin, Germany</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>6000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 27, 2020</start_date>
    <primary_completion_date>September 2020</primary_completion_date>
    <completion_date>September 2021</completion_date>
    <study_first_posted>April 2, 2020</study_first_posted>
    <last_update_posted>April 13, 2020</last_update_posted>
    <locations>
      <location>Charité-Universitätsmedizin Berlin - Department of Psychiatry and Psychotherapy, Berlin, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04331106</url>
  </study>
  <study rank="240">
    <nct_id>NCT04362124</nct_id>
    <title>Performance Evaluation of BCG Vaccination in Healthcare Personnel to Reduce the Severity of SARS-COV-2 Infection</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">vaccine BCG</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Primary outcome</outcome_measure>
      <outcome_measure>Secondary outcome</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Universidad de Antioquia</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>June 2021</primary_completion_date>
    <completion_date>November 2021</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Program for Research and Control in Tropical Diseases - PECET, Medellín, Antioquia, Colombia</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04362124</url>
  </study>
  <study rank="241">
    <nct_id>NCT04365127</nct_id>
    <title>Progesterone for the Treatment of COVID-19 in Hospitalized Men</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Sars-CoV2</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Progesterone 100 MG</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in clinical status of subjects at Day 15 based on the following 7-point ordinal scale</outcome_measure>
      <outcome_measure>Change in clinical status of subjects assessed daily while hospitalized and on Day 29</outcome_measure>
      <outcome_measure>Duration of supplemental oxygen, mechanical ventilation (if applicable), and hospitalization</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sara Ghandehari</lead_sponsor>
      <collaborator>IBSA Institut Biochimique SA</collaborator>
      <collaborator>Cedars-Sinai Medical Center</collaborator>
    </sponsors>
    <gender>Male</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 27, 2020</start_date>
    <primary_completion_date>September 1, 2020</primary_completion_date>
    <completion_date>April 17, 2021</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Cedars Sinai Medical Center, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04365127</url>
  </study>
  <study rank="242">
    <nct_id>NCT04363203</nct_id>
    <title>VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL)</title>
    <acronym>VA-REACH</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV-2</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Drug">Azithromycin</intervention>
      <intervention type="Drug">Placebo oral tablet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Days to resolution of cough, fever and shortness of breath</outcome_measure>
      <outcome_measure>Days to resolution of all COVID-19 symptoms</outcome_measure>
      <outcome_measure>All cause hospitalization</outcome_measure>
      <outcome_measure>All cause mortality</outcome_measure>
      <outcome_measure>COVID-19 specific mortality</outcome_measure>
      <outcome_measure>COVID-19 specific hospitalization</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Salomeh Keyhani MD</lead_sponsor>
      <collaborator>San Francisco VA Health Care System</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>216 Months</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>600</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>March 2021</primary_completion_date>
    <completion_date>August 2021</completion_date>
    <study_first_posted>April 27, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04363203</url>
  </study>
  <study rank="243">
    <nct_id>NCT04343781</nct_id>
    <title>National Survey of Symptoms of People Aged 70 and Overs Diagnosed With COVID-19</title>
    <acronym>COVID19PUGG2</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV-2</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">observation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>symptoms of COVID-19 in older patients</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Angers</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>70 Years</min_age>
    <age_groups>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>353</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <start_date>March 22, 2020</start_date>
    <primary_completion_date>April 5, 2020</primary_completion_date>
    <completion_date>April 5, 2020</completion_date>
    <study_first_posted>April 13, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>Angers University Hospital, Angers, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04343781</url>
  </study>
  <study rank="244">
    <nct_id>NCT04341116</nct_id>
    <title>Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Disease 2019 COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TJ003234</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Proportion (%) of subjects experiencing deterioration in clinical status</outcome_measure>
      <outcome_measure>Treatment Emergent Adverse Events</outcome_measure>
      <outcome_measure>Clinical status</outcome_measure>
      <outcome_measure>Improvement in clinical status</outcome_measure>
      <outcome_measure>Sequential Organ Failure Assessment (SOFA) score</outcome_measure>
      <outcome_measure>Change from baseline in PaO2/ FiO2</outcome_measure>
      <outcome_measure>Length of time to normalization of oxygen saturation</outcome_measure>
      <outcome_measure>Change from baseline in percentage of subjects requiring mechanical ventilation</outcome_measure>
      <outcome_measure>Change from baseline in Glucocorticoid use</outcome_measure>
      <outcome_measure>Mortality rate from any cause</outcome_measure>
      <outcome_measure>Length of hospitalization</outcome_measure>
      <outcome_measure>Change from baseline in D-dimer</outcome_measure>
      <outcome_measure>Serum concentration of TJ003234</outcome_measure>
      <outcome_measure>Incidence and titer of anti-drug antibodies (ADA)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>I-Mab Biopharma Co. Ltd.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>144</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 11, 2020</start_date>
    <primary_completion_date>September 2020</primary_completion_date>
    <completion_date>September 2020</completion_date>
    <study_first_posted>April 10, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>OSF Healthcare Saint Francis Medical Center, Peoria, Illinois, United States</location>
      <location>Indiana University Health, Indianapolis, Indiana, United States</location>
      <location>Medpharmics, LLC, Metairie, Louisiana, United States</location>
      <location>Ochsner Medical Center, New Orleans, Louisiana, United States</location>
      <location>University of Mississippi Medical Center, Jackson, Mississippi, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04341116</url>
  </study>
  <study rank="245">
    <nct_id>NCT04252664</nct_id>
    <title>A Trial of Remdesivir in Adults With Mild and Moderate COVID-19</title>
    <acronym/>
    <status open="N">Suspended</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>SARS-CoV-2</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Remdesivir</intervention>
      <intervention type="Drug">Remdesivir placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to Clinical recoveryTime to Clinical Recovery (TTCR)</outcome_measure>
      <outcome_measure>All cause mortality</outcome_measure>
      <outcome_measure>Frequency of respiratory progression</outcome_measure>
      <outcome_measure>Time to defervescence (in those with fever at enrolment)</outcome_measure>
      <outcome_measure>Time to cough reported as mild or absent (in those with cough at enrolment rated severe or moderate)</outcome_measure>
      <outcome_measure>Time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnoea at enrolment rated as severe or moderate,)</outcome_measure>
      <outcome_measure>Frequency of requirement for supplemental oxygen or non-invasive ventilation</outcome_measure>
      <outcome_measure>Time to 2019-nCoV RT-PCR negative in upper respiratory tract specimen</outcome_measure>
      <outcome_measure>Change (reduction) in 2019-nCoV viral load in upper respiratory tract specimen as assessed by area under viral load curve.</outcome_measure>
      <outcome_measure>Frequency of requirement for mechanical ventilation</outcome_measure>
      <outcome_measure>Frequency of serious adverse events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Capital Medical University</lead_sponsor>
      <collaborator>Chinese Academy of Medical Sciences</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>308</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>February 12, 2020</start_date>
    <primary_completion_date>April 10, 2020</primary_completion_date>
    <completion_date>April 27, 2020</completion_date>
    <study_first_posted>February 5, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>Jin Yin-tan hospital, Wuhan, Hubei, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04252664</url>
  </study>
  <study rank="246">
    <nct_id>NCT04364802</nct_id>
    <title>COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients</title>
    <acronym>PIIPPI</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>SARS-CoV 2</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Povidone-Iodine Nasal Spray and Gargle</intervention>
      <intervention type="Drug">Povidone-Iodine Nasal Spray and Gargle</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Percent of healthcare workers testing positive for COVID-19.</outcome_measure>
      <outcome_measure>Percent of patients testing positive for COVID-9.</outcome_measure>
      <outcome_measure>PVP-I Ease of Use</outcome_measure>
      <outcome_measure>PVP-I Comfort</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Alexandra Kejner</lead_sponsor>
      <collaborator>University of Kentucky</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>99 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>250</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>May 2020</start_date>
    <primary_completion_date>May 2021</primary_completion_date>
    <completion_date>May 2021</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>University of Kentucky, Lexington, Kentucky, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04364802</url>
  </study>
  <study rank="247">
    <nct_id>NCT04360122</nct_id>
    <title>Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Disease (COVID-19)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Levamisole</intervention>
      <intervention type="Drug">Isoprinosine</intervention>
      <intervention type="Drug">Levamisole and Isoprinosine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Decrease the incidence of COVID-19 infection or its severity</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ain Shams University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>October 1, 2020</primary_completion_date>
    <completion_date>December 1, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04360122</url>
  </study>
  <study rank="248">
    <nct_id>NCT04351152</nct_id>
    <title>Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Disease 2019 (COVID-19) Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Lenzilumab</intervention>
      <intervention type="Drug">Standard of Care</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Incidence of invasive mechanical ventilation (IMV) and/or Mortality</outcome_measure>
      <outcome_measure>Incidence of acute respiratory distress syndrome (ARDS)</outcome_measure>
      <outcome_measure>Duration of Hospitalization</outcome_measure>
      <outcome_measure>Duration of Intensive Care Unit (ICU) Stay</outcome_measure>
      <outcome_measure>Ventilator-free Days</outcome_measure>
      <outcome_measure>Incidence of Non-invasive Ventilation</outcome_measure>
      <outcome_measure>Proportion of Participants Alive and Off Oxygen</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing Adverse Events</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing Serious Adverse Events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Humanigen, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>238</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>May 2020</start_date>
    <primary_completion_date>September 2020</primary_completion_date>
    <completion_date>September 2020</completion_date>
    <study_first_posted>April 17, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04351152</url>
  </study>
  <study rank="249">
    <nct_id>NCT04328493</nct_id>
    <title>The Vietnam Chloroquine Treatment on COVID-19</title>
    <acronym>VICO</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV-2 Infection</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Chloroquine phosphate</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Viral clearance time</outcome_measure>
      <outcome_measure>Lengh of hospital stay</outcome_measure>
      <outcome_measure>Ventilator free days</outcome_measure>
      <outcome_measure>Oxygene free days</outcome_measure>
      <outcome_measure>Time to death</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
      <outcome_measure>Time to viral PCR negative from rectal swab</outcome_measure>
      <outcome_measure>fever clearance time</outcome_measure>
      <outcome_measure>Ordinal outcome scale</outcome_measure>
      <outcome_measure>Development of ARDS</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Oxford University Clinical Research Unit, Vietnam</lead_sponsor>
      <collaborator>Ministry of Health, Vietnam</collaborator>
      <collaborator>Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam</collaborator>
      <collaborator>Cu Chi COVID Hospital, Vietnam</collaborator>
      <collaborator>Can Gio COVID Hospital, Vietnam</collaborator>
      <collaborator>Cho Ray Hospital, Vietnam</collaborator>
      <collaborator>National Hospital for Tropical Diseases, Hanoi, Vietnam</collaborator>
      <collaborator>Department of Health, Ho Chi Minh city</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>250</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 7, 2020</start_date>
    <primary_completion_date>April 1, 2021</primary_completion_date>
    <completion_date>April 1, 2022</completion_date>
    <study_first_posted>March 31, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>National Hospital for Tropical Diseases, Hanoi, Vietnam</location>
      <location>Can Gio COVID Hospital, Ho Chi Minh City, Vietnam</location>
      <location>Cho Ray Hospital, Ho Chi Minh City, Vietnam</location>
      <location>Cu Chi COVID Hospital, Ho Chi Minh City, Vietnam</location>
      <location>Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04328493</url>
  </study>
  <study rank="250">
    <nct_id>NCT04346147</nct_id>
    <title>Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19</title>
    <acronym>Covid-19HUF</acronym>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19 Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hidroxicloroquine</intervention>
      <intervention type="Drug">Lopinavir/ritonavir</intervention>
      <intervention type="Drug">Imatinib tablets</intervention>
      <intervention type="Drug">Baricitinib Oral Tablet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>time to clinical improvement</outcome_measure>
      <outcome_measure>Safety of treatments</outcome_measure>
      <outcome_measure>Tolerability of treatments</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hospital Universitario de Fuenlabrada</lead_sponsor>
      <collaborator>Centro Nacional de Investigaciones Oncologicas CARLOS III</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>165</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 13, 2020</start_date>
    <primary_completion_date>August 2020</primary_completion_date>
    <completion_date>September 2020</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 16, 2020</last_update_posted>
    <locations>
      <location>Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04346147</url>
  </study>
  <study rank="251">
    <nct_id>NCT04350931</nct_id>
    <title>Application of BCG Vaccine for Immune-prophylaxis Among Egyptian Healthcare Workers During the Pandemic of COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Disease (COVID-19)</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">intradermal injection of BCG Vaccine</intervention>
      <intervention type="Other">placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>incidence of confirmed COVID-19</outcome_measure>
      <outcome_measure>Effectiveness of BCG vaccine</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ain Shams University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>900</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>October 1, 2020</primary_completion_date>
    <completion_date>December 1, 2020</completion_date>
    <study_first_posted>April 17, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations>
      <location>Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04350931</url>
  </study>
  <study rank="252">
    <nct_id>NCT04346043</nct_id>
    <title>To Access the Egyptian COVID-19 Whole Genome by NGS and Compare to the International Worldwide Database</title>
    <acronym>Strain</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Disease (COVID-19)</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Dominant viral genome strain</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ain Shams University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Other</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>October 1, 2020</primary_completion_date>
    <completion_date>December 1, 2020</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations>
      <location>Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04346043</url>
  </study>
  <study rank="253">
    <nct_id>NCT04358068</nct_id>
    <title>Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>SARS-CoV 2</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine (HCQ)</intervention>
      <intervention type="Drug">Azithromycin (Azithro)</intervention>
      <intervention type="Drug">Placebo for Hydroxychloroquine</intervention>
      <intervention type="Drug">Placebo for Azithromycin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Proportion of participants who died from any cause or were hospitalized</outcome_measure>
      <outcome_measure>Proportion of participants who died from any cause</outcome_measure>
      <outcome_measure>Proportion of participants who died from any cause, or were hospitalized, or had an urgent visit to emergency room or clinic</outcome_measure>
      <outcome_measure>Proportion of participants who died from any cause or were hospitalized through the end of follow-up</outcome_measure>
      <outcome_measure>Proportion of participants who prematurely discontinue study treatment due to an adverse event</outcome_measure>
      <outcome_measure>Proportion of participants who had any cardiac adverse events</outcome_measure>
      <outcome_measure>Duration of fever</outcome_measure>
      <outcome_measure>Duration of symptoms associated with COVID-19 disease</outcome_measure>
      <outcome_measure>Participant-specific area under the curve of total symptom score associated with COVID-19 disease over time</outcome_measure>
      <outcome_measure>Time to self-reported return to usual (pre-COVID) health.</outcome_measure>
      <outcome_measure>SARS-CoV-2 RNA detection status from self-collected nasal and site-collected NP swabs among subset</outcome_measure>
      <outcome_measure>SARS-CoV-2 RNA level (continuous) from self-collected nasal and site-collected NP swabs among subset</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
      <collaborator>Teva Pharmaceuticals Industries LTD</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>2000</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 1, 2020</start_date>
    <primary_completion_date>October 9, 2020</primary_completion_date>
    <completion_date>March 5, 2021</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04358068</url>
  </study>
  <study rank="254">
    <nct_id>NCT04347889</nct_id>
    <title>Preventing COVID-19 in Healthcare Workers With HCQ: A RCT</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Other">Vitamin C</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>COVID-19 Seroconversion rate</outcome_measure>
      <outcome_measure>Admission for Covid-19</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Stony Brook University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>1212</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>December 30, 2020</primary_completion_date>
    <completion_date>December 30, 2020</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04347889</url>
  </study>
  <study rank="255">
    <nct_id>NCT04328441</nct_id>
    <title>Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine</title>
    <acronym>BCG-CORONA</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BCG Vaccine</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Health Care Workers absenteeism</outcome_measure>
      <outcome_measure>The cumulative incidence of documented SARS-CoV-2 infection</outcome_measure>
      <outcome_measure>The number of days of unplanned absenteeism, because of documented SARS-CoV-2 infection</outcome_measure>
      <outcome_measure>The number of days of absenteeism, because of imposed quarantine as a result of exposure to SARS-CoV-2 infection</outcome_measure>
      <outcome_measure>The number of days of absenteeism, because of imposed quarantine as a result of having acute respiratory symptoms, fever or documented SARS-CoV-2 infection</outcome_measure>
      <outcome_measure>The number of days of unplanned absenteeism because of self-reported acute respiratory symptoms</outcome_measure>
      <outcome_measure>The number of days of self-reported fever (≥38 gr C)</outcome_measure>
      <outcome_measure>The number of days of self-reported acute respiratory symptoms</outcome_measure>
      <outcome_measure>The cumulative incidence of self-reported acute respiratory symptoms</outcome_measure>
      <outcome_measure>The cumulative incidence of death for any reason</outcome_measure>
      <outcome_measure>The cumulative incidence of death due to documented SARS-CoV-2 infection</outcome_measure>
      <outcome_measure>The cumulative incidence of Intensive Care Admission for any reason</outcome_measure>
      <outcome_measure>The cumulative incidence of Intensive Care Admission due to documented SARS-CoV-2 infection</outcome_measure>
      <outcome_measure>The cumulative incidence of Hospital Admission for any reason</outcome_measure>
      <outcome_measure>The cumulative incidence of Hospital Admission due to documented SARS-CoV-2 infection</outcome_measure>
      <outcome_measure>The incidence and magnitude of SARS-CoV-2 antibodies at the end of the study period</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>UMC Utrecht</lead_sponsor>
      <collaborator>Radboud University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>March 25, 2020</start_date>
    <primary_completion_date>October 25, 2020</primary_completion_date>
    <completion_date>December 25, 2020</completion_date>
    <study_first_posted>March 31, 2020</study_first_posted>
    <last_update_posted>April 3, 2020</last_update_posted>
    <locations>
      <location>Jeroen Bosch ziekenhuis, Den Bosch, Brabant, Netherlands</location>
      <location>Canisius Wilhelmina Ziekenhuis, Nijmegen, Gelderland, Netherlands</location>
      <location>Radboud UMC, Nijmegen, Gelderland, Netherlands</location>
      <location>Sint Maartenskliniek, Nijmegen, Gelderland, Netherlands</location>
      <location>Noordwest Ziekenhuisgroep locatie Alkmaar, Alkmaar, Noord Holland, Netherlands</location>
      <location>Hagaziekenhuis, Den Haag, Zuid-Holland, Netherlands</location>
      <location>Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands</location>
      <location>Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands</location>
      <location>University Medical Center Utrecht, Utrecht, Netherlands</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04328441</url>
  </study>
  <study rank="256">
    <nct_id>NCT04330521</nct_id>
    <title>Impact of the Coronavirus (COVID-19) on Patients With Cancer</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cancer</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Number of participants who fill out the survey and participate in the semi-structured interviews.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Stanford University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>99 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>May 2022</primary_completion_date>
    <completion_date>May 2022</completion_date>
    <study_first_posted>April 1, 2020</study_first_posted>
    <last_update_posted>April 1, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04330521</url>
  </study>
  <study rank="257">
    <nct_id>NCT04366180</nct_id>
    <title>Evaluation of the Probiotic Lactobacillus Coryniformis K8 on COVID-19 Prevention in Healthcare Workers</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid-19</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Probiotic</intervention>
      <intervention type="Dietary Supplement">Control</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Incidence of SARS CoV-2 infection in healthcare workers</outcome_measure>
      <outcome_measure>Incidence of hospital admissions caused by SARS-CoV-2 infection</outcome_measure>
      <outcome_measure>Incidence of ICU admissions caused by SARS-CoV-2 infection</outcome_measure>
      <outcome_measure>Incidence of pneumonia caused by SARS-CoV-2 infection</outcome_measure>
      <outcome_measure>Incidence of oxygen support requirement caused by SARS-CoV-2 infection</outcome_measure>
      <outcome_measure>Incidence of gastrointestinal symptoms caused by SARS-CoV-2 infection</outcome_measure>
      <outcome_measure>Days with body's temperature &gt; 37.5 ºC</outcome_measure>
      <outcome_measure>Days with cough</outcome_measure>
      <outcome_measure>Days with fatigue</outcome_measure>
      <outcome_measure>Medical treatment</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Biosearch S.A.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>314</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 24, 2020</start_date>
    <primary_completion_date>June 2020</primary_completion_date>
    <completion_date>October 2020</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Raquel Rodriguez Blanque, Granada, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04366180</url>
  </study>
  <study rank="258">
    <nct_id>NCT04348214</nct_id>
    <title>Screening &amp; Risk Assessment of Healthcare Workers &amp; Infection Control in University &amp; COVID-19 Quarantine Hospitals</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Disease (COVID-19)</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Risk categorization of healthcare workers</outcome_measure>
      <outcome_measure>COVID-19 infection rate among health care workers</outcome_measure>
      <outcome_measure>Risk factors for COVID-19 among health care workers</outcome_measure>
      <outcome_measure>Adherence of health care workers to infection prevention</outcome_measure>
      <outcome_measure>Validity of the available rapid serological test for detecting COVID-19 virus infection</outcome_measure>
      <outcome_measure>Clinical spectrum of COVID-19</outcome_measure>
      <outcome_measure>Effectiveness of infection prevention in the health care facility</outcome_measure>
      <outcome_measure>Emergency infection prevention and control needs</outcome_measure>
      <outcome_measure>Isolation rate and emergency health care worker replacement needs</outcome_measure>
      <outcome_measure>Rate of seroconversion</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ain Shams University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>3000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>October 1, 2020</primary_completion_date>
    <completion_date>December 1, 2020</completion_date>
    <study_first_posted>April 16, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations>
      <location>Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04348214</url>
  </study>
  <study rank="259">
    <nct_id>NCT04348240</nct_id>
    <title>Transmissibility and Viral Load of SARS-CoV-2 in Oral Secretions</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>To determine SARS-CoV-2 viral load and infectivity in saliva that may contribute to asymptomatic transmission</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute of Dental and Craniofacial Research (NIDCR)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 16, 2020</start_date>
    <primary_completion_date>July 1, 2020</primary_completion_date>
    <completion_date>July 1, 2020</completion_date>
    <study_first_posted>April 16, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>National Institutes of Health Clinical Center, Bethesda, Maryland, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04348240</url>
  </study>
  <study rank="260">
    <nct_id>NCT04360876</nct_id>
    <title>Targeted Steroids for ARDS Due to COVID-19 Pneumonia: A Pilot Randomized Clinical Trial</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>ARDS</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Dexamethasone injection</intervention>
      <intervention type="Drug">Placebos</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Ventilator Free Days (VFD) at Day 28</outcome_measure>
      <outcome_measure>Clinical Status at day 14 as measured by World Health Organization (WHO) 7-point ordinal scale.</outcome_measure>
      <outcome_measure>Clinical Status at day 28 as measured by WHO 7-point ordinal scale</outcome_measure>
      <outcome_measure>In-Hospital Mortality at day 28</outcome_measure>
      <outcome_measure>In-Hospital Mortality at day 90</outcome_measure>
      <outcome_measure>Time to Mortality to day 28</outcome_measure>
      <outcome_measure>ICU-free days to day 28</outcome_measure>
      <outcome_measure>Hospital Length of Stay among survivors to day 90</outcome_measure>
      <outcome_measure>Severity of ARDS to day 10</outcome_measure>
      <outcome_measure>Days to resolution of fever</outcome_measure>
      <outcome_measure>Change in C-Reactive Protein (CRP) level from baseline to day 10</outcome_measure>
      <outcome_measure>Vasopressor-free days to day 28</outcome_measure>
      <outcome_measure>Renal replacement-free days to day 28</outcome_measure>
      <outcome_measure>Duration of mechanical ventilation to day 28</outcome_measure>
      <outcome_measure>Oxygenation-free days to day 28</outcome_measure>
      <outcome_measure>Incidence of New Mechanical Ventilation to day 28</outcome_measure>
      <outcome_measure>Change in sequential organ failure assessment (SOFA) score from baseline to day 10</outcome_measure>
      <outcome_measure>In-hospital adverse events to day 28</outcome_measure>
      <outcome_measure>Discontinuation of study drug infusion</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Colorado, Denver</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Care Provider)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 1, 2020</start_date>
    <primary_completion_date>September 30, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04360876</url>
  </study>
  <study rank="261">
    <nct_id>NCT04336332</nct_id>
    <title>Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV-2</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Combination Product">Hydroxychloroquine Sulfate + Azithromycin</intervention>
      <intervention type="Drug">Hydroxychloroquine Sulfate</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Changes in patients viral load</outcome_measure>
      <outcome_measure>Second evaluation of changes in patients viral load</outcome_measure>
      <outcome_measure>Symptom questionnaire</outcome_measure>
      <outcome_measure>Fever assessment</outcome_measure>
      <outcome_measure>Vital Signs - Body Temperature</outcome_measure>
      <outcome_measure>Discharge</outcome_measure>
      <outcome_measure>Recovery</outcome_measure>
      <outcome_measure>Assessment of agent toxicity</outcome_measure>
      <outcome_measure>Oropharynx swab sample collections</outcome_measure>
      <outcome_measure>Blood Sample collections</outcome_measure>
      <outcome_measure>Viral shedding assessment - nasopharyngeal secretions</outcome_measure>
      <outcome_measure>Viral shedding assessment - serology</outcome_measure>
      <outcome_measure>Cytokines in blood</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Rutgers, The State University of New Jersey</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>160</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>April 30, 2021</primary_completion_date>
    <completion_date>April 30, 2021</completion_date>
    <study_first_posted>April 7, 2020</study_first_posted>
    <last_update_posted>April 13, 2020</last_update_posted>
    <locations>
      <location>Robert Wood Johnson University Hopsital, New Brunswick, New Jersey, United States</location>
      <location>Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States</location>
      <location>The University Hospital, Newark, New Jersey, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04336332</url>
  </study>
  <study rank="262">
    <nct_id>NCT04357444</nct_id>
    <title>Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19</title>
    <acronym>LILIADE-COVID</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID 19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">1: ILT101</intervention>
      <intervention type="Drug">2: Placebo Comparator</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The PaO2/FiO2 ratio at D7</outcome_measure>
      <outcome_measure>Changes in Tregs between Baseline and Day 7 (expressed in %)</outcome_measure>
      <outcome_measure>Number of days alive with oxygen therapy within 28 days</outcome_measure>
      <outcome_measure>Maximal oxygen rate within 28 days</outcome_measure>
      <outcome_measure>Number of days alive free of invasive or non-invasive ventilation within 28 days</outcome_measure>
      <outcome_measure>Number of days alive outside ICU within 28 days</outcome_measure>
      <outcome_measure>Number of days alive outside hospital within 28 days</outcome_measure>
      <outcome_measure>Time (in days) from randomization to death</outcome_measure>
      <outcome_measure>Mortality rate at D28</outcome_measure>
      <outcome_measure>Difference between CRP levels at randomization and at Day 7 (or at the time of discharge if occurs before Day 7)</outcome_measure>
      <outcome_measure>Use of antibiotics for respiratory (proved or suspected) infection within 28 days</outcome_measure>
      <outcome_measure>Number of prone positioning sessions</outcome_measure>
      <outcome_measure>Changes in Tregs during the different visits between baseline and day 28</outcome_measure>
      <outcome_measure>Cytokines analysis on plasma samples at Day 0, 7 and 14</outcome_measure>
      <outcome_measure>Tregs numbers during induction period and throughout the follow up period at day 5, 7, 11, 14 and 28 compared to baseline before the first IL-2 injection.</outcome_measure>
      <outcome_measure>Tregs percentages during induction period and throughout the follow up period at day 5, 7, 11, 14 and 28 compared to baseline before the first IL-2 injection.</outcome_measure>
      <outcome_measure>Deep Immunophenotyping of Cellular components in blood samples at Day 0, 7, and 14</outcome_measure>
      <outcome_measure>T cell repertoire on Treg, after sorting from blood at Day 7 and Day 14 and compared to baseline</outcome_measure>
      <outcome_measure>T cell repertoire on Teff (CD4 and CD8) after sorting from blood at Day 7 and Day 14 and compared to baseline</outcome_measure>
      <outcome_measure>Single cells sequencing will be performed in BAL at Day 7 and Day 14 and compared to baseline.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
      <collaborator>Iltoo Pharma</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>May 2020</primary_completion_date>
    <completion_date>July 2020</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Service Anesthésie Réanimation - Groupe Hospitalier Pitié-Salpêtrière, Paris, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04357444</url>
  </study>
  <study rank="263">
    <nct_id>NCT04332913</nct_id>
    <title>Efficacy and Safety of Tocilizumab in the Treatment of SARS-Cov-2 Related Pneumonia</title>
    <acronym>TOSCA</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19 Pneumonia</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Percentage of patients with complete recovery defined as fever disappearance and return to normal peripheral oxygen saturation values (SpO2) after 14 days from the end of treatment with tocilizumab.</outcome_measure>
      <outcome_measure>Percentage of patients achieving a score &lt;3 on the Brescia-COVID respiratory severity scale (BCRSS) after the last tocilizumab administration.</outcome_measure>
      <outcome_measure>Percentage of patients with partial recovery defined as the disappearance of fever 14 days after the end of treatment with tocilizumab.</outcome_measure>
      <outcome_measure>Duration of hospitalization</outcome_measure>
      <outcome_measure>Time to the first negative SARS-CoV-2 negative RT-PCR test</outcome_measure>
      <outcome_measure>Changes from the baseline in the white blood cell count</outcome_measure>
      <outcome_measure>Changes from the baseline in the lymphocyte populations (cluster of differentiation (CD)3+CD4+, CD3+CD8+, CD19+, Th17)</outcome_measure>
      <outcome_measure>Changes from the baseline of c-reactive protein (CRP) values</outcome_measure>
      <outcome_measure>Changes from the baseline of Ferritin values</outcome_measure>
      <outcome_measure>Changes from the baseline of BNP values</outcome_measure>
      <outcome_measure>Changes from the baseline of CK-MB values</outcome_measure>
      <outcome_measure>Changes from the baseline of Troponin values</outcome_measure>
      <outcome_measure>Changes from the baseline of LDH values</outcome_measure>
      <outcome_measure>Changes from the baseline of myoglobulin values</outcome_measure>
      <outcome_measure>Changes in myocardial ischemia signs at the electrocardiographic trace (YES or NO)</outcome_measure>
      <outcome_measure>Rate of adverse events report during and after tocilizumab</outcome_measure>
      <outcome_measure>Mortality (number of Partecipants, cause and timing)</outcome_measure>
      <outcome_measure>Percentage of patients who develop autoimmune diseases</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of L'Aquila</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>March 31, 2021</completion_date>
    <study_first_posted>April 3, 2020</study_first_posted>
    <last_update_posted>April 13, 2020</last_update_posted>
    <locations>
      <location>Ospedale San Salvatore, L'Aquila, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04332913</url>
  </study>
  <study rank="264">
    <nct_id>NCT04356417</nct_id>
    <title>Long-term Use of Drugs That Could Prevent the Risk of Serious COVID-19 Infections or Make it Worse</title>
    <acronym>TRAPSAH</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>AMD, ACEi's/ARB Prevent/Worsen Risk of COVID-19 Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Other">- Synthetic anti-malarial drugs</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Identification of serious COVID-19 infections</outcome_measure>
      <outcome_measure>Pneumonia infections</outcome_measure>
      <outcome_measure>ICU stay</outcome_measure>
      <outcome_measure>Oro-tracheal intubation</outcome_measure>
      <outcome_measure>Death</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
      <collaborator>GIS EPI-PHARE</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>6000000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Other</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>June 2020</primary_completion_date>
    <completion_date>June 2020</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Assistance Publique Hôpitaux de Paris - CHU Henri Mondor, Créteil, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04356417</url>
  </study>
  <study rank="265">
    <nct_id>NCT04317040</nct_id>
    <title>CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment</title>
    <acronym>SAC-COVID</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Severe Coronavirus Disease (COVID-19)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">CD24Fc</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Improvement of COVID-19 disease status</outcome_measure>
      <outcome_measure>Disease progression of COVID-19</outcome_measure>
      <outcome_measure>All cause of death</outcome_measure>
      <outcome_measure>Conversion rate of clinical status at Day 8</outcome_measure>
      <outcome_measure>Conversion rate of clinical status at Day 15</outcome_measure>
      <outcome_measure>Hospital discharge time</outcome_measure>
      <outcome_measure>Duration of mechanical ventilation</outcome_measure>
      <outcome_measure>Duration of pressors</outcome_measure>
      <outcome_measure>Duration of ECMO</outcome_measure>
      <outcome_measure>Duration of oxygen therapy</outcome_measure>
      <outcome_measure>Length of hospital stay</outcome_measure>
      <outcome_measure>Absolute lymphocyte count</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>OncoImmune, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>230</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 8, 2020</start_date>
    <primary_completion_date>May 2021</primary_completion_date>
    <completion_date>May 2022</completion_date>
    <study_first_posted>March 20, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Baptist Health Research Institute, Jacksonville, Florida, United States</location>
      <location>Martin Army Community Hospital, Fort Benning, Georgia, United States</location>
      <location>Anne Anundel Medical Center, Annapolis, Maryland, United States</location>
      <location>Institute of Human Virology, University of Maryland Baltimore, Baltimore, Maryland, United States</location>
      <location>White Oak Medical Center, Silver Spring, Maryland, United States</location>
      <location>Cooper University Hospital, Camden, New Jersey, United States</location>
      <location>University Hospitals of Cleveland, Cleveland, Ohio, United States</location>
      <location>The Ohio State University Medical Center, Columbus, Ohio, United States</location>
      <location>Thomas Jefferson University Medical Center, Philadelphia, Pennsylvania, United States</location>
      <location>University of Vermont Medical Center, Burlington, Vermont, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04317040</url>
  </study>
  <study rank="266">
    <nct_id>NCT04359667</nct_id>
    <title>Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab</title>
    <acronym>UHID-COVID19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Severe Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>serum interleukin-6 and soluble interleukin-6 receptor as biomarkers of clinical outcomes in patients with severe coronavirus disease (COVID-19) pneumonia treated with tocilizumab</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital for Infectious Diseases, Croatia</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 16, 2020</start_date>
    <primary_completion_date>April 16, 2020</primary_completion_date>
    <completion_date>April 15, 2021</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>University Hospital for Infectious Diseases &quot;Dr Fran Mihaljevic&quot;, Zagreb, Croatia</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04359667</url>
  </study>
  <study rank="267">
    <nct_id>NCT04347876</nct_id>
    <title>Outcome of COVID-19 Cases Based on Tuberculin Test: Can Previous BCG Alter the Prognosis?</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>BCG Vaccination</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Tuberculin test</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Pneumonia severity index</outcome_measure>
      <outcome_measure>Need for ICU admission</outcome_measure>
      <outcome_measure>COVID -19 test conversion</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assiut University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>12 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 11, 2020</start_date>
    <primary_completion_date>June 16, 2020</primary_completion_date>
    <completion_date>June 30, 2020</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>AssiutU, Assiut, Egypt</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04347876</url>
  </study>
  <study rank="268">
    <nct_id>NCT04351529</nct_id>
    <title>Austrian COVID-19 Registry</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Infectious Disease</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Documentation of natural course and the therapeutic landscape of patients with COVID-19.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Arbeitsgemeinschaft medikamentoese Tumortherapie</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Other</study_design>
    </study_designs>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>December 2021</primary_completion_date>
    <completion_date>December 2021</completion_date>
    <study_first_posted>April 17, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations>
      <location>IIIrd Medical Department, Private Medical University Hospital Salzburg, Salzburg, Austria</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04351529</url>
  </study>
  <study rank="269">
    <nct_id>NCT04342897</nct_id>
    <title>A Study of LY3127804 in Participants With COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">LY3127804</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of Ventilator Free Days</outcome_measure>
      <outcome_measure>Number of Participants Reporting Each Severity Rating on the National Institute of Allergy and Infectious Diseases (NIAID) Ordinal Assessment</outcome_measure>
      <outcome_measure>Oxygen Saturation (SpO₂)</outcome_measure>
      <outcome_measure>Oxygen Flow Rate</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>Length of Hospitalization</outcome_measure>
      <outcome_measure>Number of Participants with any Serious Adverse Event (SAE)</outcome_measure>
      <outcome_measure>Number of Participants with any Treatment Emergent Adverse Event (TEAE)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Eli Lilly and Company</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>July 10, 2020</primary_completion_date>
    <completion_date>July 10, 2020</completion_date>
    <study_first_posted>April 13, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Franciscan St. Francis Health, Indianapolis, Indiana, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04342897</url>
  </study>
  <study rank="270">
    <nct_id>NCT04338932</nct_id>
    <title>COVID-19 and Deep Venous Thrombosis</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Deep Vein Thrombosis (DVT)/Thrombophlebitis</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>the prevalence of a DVT in patients at the ICU.</outcome_measure>
      <outcome_measure>Oxygen partial pressure and Carbon dioxide partial pressure levels in the blood</outcome_measure>
      <outcome_measure>Potassium, Sodium, Calcium, Bicarbonate, Base excess, Lactate levels in the blood</outcome_measure>
      <outcome_measure>glucose, haemoglobin, ureum, creatinine, total bilirubin levels in the blood</outcome_measure>
      <outcome_measure>oxygen saturation, basophils, eosinophils, monocytes, neutrophils, haematocrit and prothrombine levels in the blood</outcome_measure>
      <outcome_measure>white blood cells, red blood cells and platelets in the blood</outcome_measure>
      <outcome_measure>PT (%)aPTT (sec)Fibrinogen (g/L)D-dimers (mg/L) PT (INR) (ratio) AST (U/L)ALT (U/L)Lactate dehydrogenase (U/L)Troponin T (ng/L)CRP (mg/L)Ferritin (mg/L)in the blood</outcome_measure>
      <outcome_measure>prevalence of co-morbidities</outcome_measure>
      <outcome_measure>prevalence of vital signs at icu admission</outcome_measure>
      <outcome_measure>prevalence of complications during icu stay</outcome_measure>
      <outcome_measure>evaluation of treatment</outcome_measure>
      <outcome_measure>evaluation of the oxygen therapy</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Jessa Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>April 17, 2020</start_date>
    <primary_completion_date>September 30, 2020</primary_completion_date>
    <completion_date>December 30, 2020</completion_date>
    <study_first_posted>April 8, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04338932</url>
  </study>
  <study rank="271">
    <nct_id>NCT04365231</nct_id>
    <title>Hydroxychloroquine Azithromycin COVID-19 Pregnancy Trial</title>
    <acronym>HASCOPT</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine and azithromycin treatment</intervention>
      <intervention type="Other">conventional management of patients</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Percentage of patients with a negative RT-PCR test result to COVID-19</outcome_measure>
      <outcome_measure>Maternal outcomes: Percentage of severe forms of the disease</outcome_measure>
      <outcome_measure>Newborn outcomes: Rate of newborns hospitalized in intensive care or transferred to resuscitation unit</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hospital St. Joseph, Marseille, France</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>June 2020</primary_completion_date>
    <completion_date>January 2021</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Hopital Saint Joseph, Marseille, Paca, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04365231</url>
  </study>
  <study rank="272">
    <nct_id>NCT04354701</nct_id>
    <title>COVID-19 and Cancer Consortium Registry</title>
    <acronym>CCC19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Invasive Malignancy (Any Type)</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Web-based REDCap survey</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Web-based REDCap survey</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Vanderbilt-Ingram Cancer Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 17, 2020</start_date>
    <primary_completion_date>December 2021</primary_completion_date>
    <completion_date>December 2022</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>Vanderbilt University Medical Center, Nashville, Tennessee, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04354701</url>
  </study>
  <study rank="273">
    <nct_id>NCT04346368</nct_id>
    <title>Bone Marrow-Derived Mesenchymal Stem Cell Treatment for Severe Patients With Coronavirus Disease 2019 (COVID-19)</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Disease 2019 (COVID-19)</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">BM-MSCs</intervention>
      <intervention type="Biological">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Changes of oxygenation index (PaO2/FiO2)</outcome_measure>
      <outcome_measure>Side effects in the BM-MSCs treatment group</outcome_measure>
      <outcome_measure>Clinical outcome</outcome_measure>
      <outcome_measure>Hospital stay</outcome_measure>
      <outcome_measure>CT Scan</outcome_measure>
      <outcome_measure>Changes in viral load</outcome_measure>
      <outcome_measure>Changes of CD4+, CD8+ cells count and concentration of cytokines</outcome_measure>
      <outcome_measure>Rate of mortality within 28-days</outcome_measure>
      <outcome_measure>Changes of C-reactive protein</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Guangzhou Institute of Respiratory Disease</lead_sponsor>
      <collaborator>Guangzhou Eighth People's Hospital</collaborator>
      <collaborator>Tongji Hospital, Huazhong University of Science &amp; Technology</collaborator>
      <collaborator>Guangzhou Cellgenes Biotechnology Co.,Ltd</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>December 2020</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04346368</url>
  </study>
  <study rank="274">
    <nct_id>NCT04359121</nct_id>
    <title>COVID-19 and the Developement of Phobic Fears of Disease</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Questionnaires</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Development of phobias</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Medical University of Graz</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>600</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>April 15, 2023</primary_completion_date>
    <completion_date>April 15, 2024</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Medical University of Graz, Graz, Styria, Austria</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04359121</url>
  </study>
  <study rank="275">
    <nct_id>NCT04334005</nct_id>
    <title>Vitamin D on Prevention and Treatment of COVID-19</title>
    <acronym>COVITD-19</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Patients Infected With COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Vitamin D</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Composite of cumulative death (i.e. mortality) for all causes and for specific causes.</outcome_measure>
      <outcome_measure>Necessity of invasive assisted ventilation</outcome_measure>
      <outcome_measure>Necessity of non-invasive assisted ventilation</outcome_measure>
      <outcome_measure>Intensive care unit admission</outcome_measure>
      <outcome_measure>Post-anesthesia care unit admission</outcome_measure>
      <outcome_measure>Hospital admission</outcome_measure>
      <outcome_measure>Medical consultation</outcome_measure>
      <outcome_measure>Home care and isolation time</outcome_measure>
      <outcome_measure>Bed rest time</outcome_measure>
      <outcome_measure>symptoms' duration (i.e. cough, fever, nasal congestion, gastrointestinal symptoms, fatigue, anosmia, ageusia, diarrhea or alternative signs of COVID-19)</outcome_measure>
      <outcome_measure>Subjective perception of recovery</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Universidad de Granada</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>40 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 10, 2020</start_date>
    <primary_completion_date>June 30, 2020</primary_completion_date>
    <completion_date>June 30, 2020</completion_date>
    <study_first_posted>April 3, 2020</study_first_posted>
    <last_update_posted>April 7, 2020</last_update_posted>
    <locations>
      <location>Universidad de Granada, Granada, Andalucia, Spain</location>
      <location>Medicine Faculty, Granada, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04334005</url>
  </study>
  <study rank="276">
    <nct_id>NCT04303299</nct_id>
    <title>Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Hydroxychloroquine for Treatment of COVID-19 : A Randomized Control Trial</title>
    <acronym>THDMS-COVID-19</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-COV-2 Infections</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Oral</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>SARS-CoV-2 eradication time</outcome_measure>
      <outcome_measure>Number of patient with Death</outcome_measure>
      <outcome_measure>Number of patient with Recovery adjusted by initial severity in each arm</outcome_measure>
      <outcome_measure>Number of day With ventilator dependent adjusted by initial severity in each arm</outcome_measure>
      <outcome_measure>Number of patient developed Acute Respiratory Distress Syndrome After treatment</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Rajavithi Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>16 Years</min_age>
    <max_age>100 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>320</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>October 31, 2020</primary_completion_date>
    <completion_date>November 30, 2020</completion_date>
    <study_first_posted>March 11, 2020</study_first_posted>
    <last_update_posted>April 10, 2020</last_update_posted>
    <locations>
      <location>Assistant Professor Subsai Kongsaengdao, Bangkok, Thailand</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04303299</url>
  </study>
  <study rank="277">
    <nct_id>NCT04353323</nct_id>
    <title>COVID 19-Caregivers IGg Seroconversion</title>
    <acronym>CoSigS</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Infection, COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Blood sampling</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Seroconversion</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Limoges</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>130</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 25, 2020</start_date>
    <primary_completion_date>June 25, 2020</primary_completion_date>
    <completion_date>December 25, 2020</completion_date>
    <study_first_posted>April 20, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations>
      <location>CHU de Limoges, Limoges, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04353323</url>
  </study>
  <study rank="278">
    <nct_id>NCT04288102</nct_id>
    <title>Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19)</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Corona Virus Disease 2019(COVID-19)</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">MSCs</intervention>
      <intervention type="Biological">Saline containing 1% Human serum albumin（solution of MSC）</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Size of lesion area and severity of pulmonary fibrosis by chest CT</outcome_measure>
      <outcome_measure>mMRC (Modified Medical Research Council) dyspnea scale</outcome_measure>
      <outcome_measure>Oxygenation index( PaO2/FiO2)</outcome_measure>
      <outcome_measure>Duration of oxygen therapy(days)</outcome_measure>
      <outcome_measure>Duration of hospitalization(days)</outcome_measure>
      <outcome_measure>Blood oxygen saturation</outcome_measure>
      <outcome_measure>CD4+ T cell count and cytokine level</outcome_measure>
      <outcome_measure>Side effects in the MSCs treatment group</outcome_measure>
      <outcome_measure>6-minute walk test</outcome_measure>
      <outcome_measure>Maximum vital capacity (VCmax)</outcome_measure>
      <outcome_measure>Diffusing Capacity (DLCO)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Beijing 302 Hospital</lead_sponsor>
      <collaborator>Huoshenshan Hospital</collaborator>
      <collaborator>Maternal and Child Health Hospital of Hubei Province</collaborator>
      <collaborator>General Hospital of Central Theater Command, Wuhan, China</collaborator>
      <collaborator>VCANBIO CELL &amp; GENE ENGINEERING CORP.,LTD, China</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 5, 2020</start_date>
    <primary_completion_date>July 15, 2020</primary_completion_date>
    <completion_date>July 31, 2020</completion_date>
    <study_first_posted>February 28, 2020</study_first_posted>
    <last_update_posted>April 7, 2020</last_update_posted>
    <locations>
      <location>Maternal and Child Hospital of Hubei Province, Wuhan, Hubei, China</location>
      <location>Wuhan Huoshenshan Hospital, Wuhan, Hubei, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04288102</url>
  </study>
  <study rank="279">
    <nct_id>NCT04358939</nct_id>
    <title>Prone Position in Patients on High-flow Nasal Oxygen Therapy for COVID-19 (HIGH-PRONE-COVID-19)</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Acute Respiratory Distress Syndrome</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Prone decubitus</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Therapeutic failure within 14 days of randomization</outcome_measure>
      <outcome_measure>Evolution of oxygenation (PaO2/FiO2 ratio or SpO2/FiO2 surrogate) over the 14 days following randomization</outcome_measure>
      <outcome_measure>Evolution of the SpO2/FiO2 ratio during the first prone session</outcome_measure>
      <outcome_measure>Evolution of the ROX index during the first prone session</outcome_measure>
      <outcome_measure>Evolution of the World Health Organization disease severity score of COVID</outcome_measure>
      <outcome_measure>Patient comfort before, during and after the first prone position session</outcome_measure>
      <outcome_measure>Occurrence of skin lesions on the anterior surface of the body</outcome_measure>
      <outcome_measure>Displacement of invasive devices during reversals</outcome_measure>
      <outcome_measure>Days of nasal High-Flow therapy use</outcome_measure>
      <outcome_measure>Days spent in the intensive care unit and in the hospital</outcome_measure>
      <outcome_measure>Mortality in the intensive care unit and in the hospital</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Tours</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>248</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>November 2020</primary_completion_date>
    <completion_date>November 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Intensive Care Unit, Hospital, Argenteuil, Argenteuil, France</location>
      <location>Medical Intensive Care Unit, University Hospital, Brest, Brest, France</location>
      <location>Intensive Care Unit, Louis Mourier-APHP, Colombes, France</location>
      <location>Intensive Care Unit, Hospital, Le Mans, Le Mans, France</location>
      <location>Intensive Care Unit, University Hospital, Lille, Lille, France</location>
      <location>Medical Intensive Care Unit, University Hospital, Nantes, Nantes, France</location>
      <location>Medical Intensive Care Unit, University Hospital, Nice, NIce, France</location>
      <location>Medical Intensive Care Unit, Hospital, Orléans, Orléans, France</location>
      <location>Medical Intensive Care Unit, Tenon-APHP, Paris, France</location>
      <location>Medical Intensive Care Unit, University Hospital, Poitiers, Poitiers, France</location>
      <location>Medical Intensive Care Unit, University Hospital, Tours, Tours, France</location>
      <location>Surgical Intensive Care Unit, University Hospital, Tours, Tours, France</location>
      <location>Intensive Care Unit, Hospital, Vannes, Vannes, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04358939</url>
  </study>
  <study rank="280">
    <nct_id>NCT04286503</nct_id>
    <title>The Clinical Study of Carrimycin on Treatment Patients With COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Novel Coronavirus Infectious Disease (COVID-19)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Carrimycin</intervention>
      <intervention type="Drug">lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate</intervention>
      <intervention type="Drug">basic treatment</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Fever to normal time (day)</outcome_measure>
      <outcome_measure>Pulmonary inflammation resolution time (HRCT) (day)</outcome_measure>
      <outcome_measure>Negative conversion (%) of 2019-nCOVRNA in gargle (throat swabs) at the end of treatment</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Beijing YouAn Hospital</lead_sponsor>
      <collaborator>Shenyang Tonglian Group Co., Ltd.</collaborator>
      <collaborator>Institute of Medicine and Biotechnology, Chinese Academy of Medical Sciences</collaborator>
      <collaborator>Huangshi Central Hospital</collaborator>
      <collaborator>Shenyang Pharmaceutical University</collaborator>
      <collaborator>First Affiliated Hospital of Chongqing Medical University</collaborator>
      <collaborator>The Second Affiliated Hospital of Harbin Medical University</collaborator>
      <collaborator>No.2 People's Hospital of Fuyang City</collaborator>
      <collaborator>First Affiliated Hospital Bengbu Medical College</collaborator>
      <collaborator>Renmin Hospital of Wuhan University</collaborator>
      <collaborator>The sixth people's hospital of Shenyang</collaborator>
      <collaborator>Nanyang Central Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>520</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>February 23, 2020</start_date>
    <primary_completion_date>February 28, 2021</primary_completion_date>
    <completion_date>February 28, 2021</completion_date>
    <study_first_posted>February 27, 2020</study_first_posted>
    <last_update_posted>February 27, 2020</last_update_posted>
    <locations/>
    <study_documents>
      <study_document>
        <label>Study Protocol</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT04286503/Prot_000.pdf</url>
      </study_document>
      <study_document>
        <label>Informed Consent Form</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT04286503/ICF_001.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT04286503</url>
  </study>
  <study rank="281">
    <nct_id>NCT04329507</nct_id>
    <title>Non-invasive Detection of Pneumonia in Context of Covid-19 Using Gas Chromatography - Ion Mobility Spectrometry (GC-IMS)</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Respiratory Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Breath test</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>To perform a study in patients with clinical features of pneumonia/chest infection to identify a signature of Covid-19 pneumonia in patients exposed to SARS-CoV-2, compared to unexposed patients or those without.</outcome_measure>
      <outcome_measure>Detection of markers of Covid-19 pneumonia in non-invasive breath samples.</outcome_measure>
      <outcome_measure>Relationship of this biomarker signature to the presence of SARS-CoV-2 in nasal and throat swabs.</outcome_measure>
      <outcome_measure>Subsequently, the signature's relationship to other biomarkers of SARS-CoV-2 infection which are currently being explored</outcome_measure>
      <outcome_measure>In a smaller group of participants, ideally daily non-invasive breath samples will be collected to determine if there are changes between SARS-CoV-2 positive patients and those that are negative until hospital discharge or undue participant burden .</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>NHS Lothian</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 25, 2020</start_date>
    <primary_completion_date>March 25, 2020</primary_completion_date>
    <completion_date>March 25, 2020</completion_date>
    <study_first_posted>April 1, 2020</study_first_posted>
    <last_update_posted>April 1, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04329507</url>
  </study>
  <study rank="282">
    <nct_id>NCT04313127</nct_id>
    <title>Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults</title>
    <acronym>CTCOVID-19</acronym>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Safety indexes of adverse reactions</outcome_measure>
      <outcome_measure>Safety indexes of adverse events</outcome_measure>
      <outcome_measure>Safety indexes of SAE</outcome_measure>
      <outcome_measure>Safety indexes of lab measures</outcome_measure>
      <outcome_measure>Immunogencity indexes of GMT(ELISA)</outcome_measure>
      <outcome_measure>Immunogencity indexes of GMT(pseudoviral neutralization test method)</outcome_measure>
      <outcome_measure>Immunogencity indexes of seropositivity rates(ELISA)</outcome_measure>
      <outcome_measure>Immunogencity indexes of seropositivity rates(pseudoviral neutralization test method)</outcome_measure>
      <outcome_measure>Immunogencity indexes of GMI(ELISA)</outcome_measure>
      <outcome_measure>Immunogencity indexes of GMI(pseudoviral neutralization test method)</outcome_measure>
      <outcome_measure>Immunogencity indexes of GMC(Ad5 vector)</outcome_measure>
      <outcome_measure>Immunogencity indexes of GMI(Ad5 vector)</outcome_measure>
      <outcome_measure>Immunogencity indexes of cellular immune</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>CanSino Biologics Inc.</lead_sponsor>
      <collaborator>Institute of Biotechnology, Academy of Military Medical Sciences. PLA of China</collaborator>
      <collaborator>Jiangsu Province Centers for Disease Control and Prevention</collaborator>
      <collaborator>Hubei Provincial Center for Disease Control and Prevention</collaborator>
      <collaborator>Tongji Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>108</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>March 16, 2020</start_date>
    <primary_completion_date>December 30, 2020</primary_completion_date>
    <completion_date>December 20, 2022</completion_date>
    <study_first_posted>March 18, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>Hubei Provincial Center for Disease Control and Prevention, Wuhan, Hubei, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04313127</url>
  </study>
  <study rank="283">
    <nct_id>NCT04336657</nct_id>
    <title>Corona-Like Illness: Did we Got it Before WHO Announcement of the Disease?</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Questionnaire</intervention>
      <intervention type="Diagnostic Test">IgG</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Measure frequency of people suffered from unusual flu-like symptoms before December 2019</outcome_measure>
      <outcome_measure>Measure remote immunity for COVID-19 in subject with past history of severe flu before WHO announcement date- if possible</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assiut University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>8 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Ecologic or Community</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>May 2020</primary_completion_date>
    <completion_date>May 2020</completion_date>
    <study_first_posted>April 7, 2020</study_first_posted>
    <last_update_posted>April 7, 2020</last_update_posted>
    <locations>
      <location>AssiutU, Assiut, Egypt</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04336657</url>
  </study>
  <study rank="284">
    <nct_id>NCT04351581</nct_id>
    <title>Effects of Discontinuing Renin-angiotensin System Inhibitors in Patients With COVID-19</title>
    <acronym>RASCOVID-19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Discontinuation of ACEi/ARB</intervention>
      <intervention type="Other">Continuation of ACEi/ARB</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Days alive and out of hospital within 14 days after recruitment</outcome_measure>
      <outcome_measure>Key-secondary composite endpoint: Occurrence of worsening of COVID-19</outcome_measure>
      <outcome_measure>Occurrence and time to occurrence of each of the components of the key-secondary composite endpoint</outcome_measure>
      <outcome_measure>Kidney function assessed by plasma creatinine</outcome_measure>
      <outcome_measure>Duration of index hospitalisation</outcome_measure>
      <outcome_measure>30-day mortality</outcome_measure>
      <outcome_measure>Number of days alive during the intervention period</outcome_measure>
      <outcome_measure>Number of participants not yet discharged at day 30</outcome_measure>
      <outcome_measure>Number of readmissions after 30 days.</outcome_measure>
      <outcome_measure>Kidney function as assessed by eGFR</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Gentofte, Copenhagen</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>215</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>December 2020</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>April 17, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Department of Medicine, Gentofte Hospital, University of Copenhagen, Hellerup, Capital Region Of Denmark, Denmark</location>
      <location>Department of Medicine, Herlev Hospital, University of Copenhagen, Herlev, Capital Region Of Denmark, Denmark</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04351581</url>
  </study>
  <study rank="285">
    <nct_id>NCT04351243</nct_id>
    <title>A Study to Assess the Efficacy and Safety of of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19.</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Respiratory Distress Syndrome Due to COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Gimsilumab</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Primary endpoint</outcome_measure>
      <outcome_measure>Secondary endpoint</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Kinevant Sciences GmbH</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>79 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>270</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>October 2020</completion_date>
    <study_first_posted>April 17, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>Mount Sinai, New York, New York, United States</location>
      <location>Temple, Philadelphia, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04351243</url>
  </study>
  <study rank="286">
    <nct_id>NCT04347512</nct_id>
    <title>EVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRA</title>
    <acronym>TEACHCOVID</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sars-CoV-2, Community-Acquired Pneumonia,COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine and azithromycin treatment arm.</intervention>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Drug">Control arm</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Rate of patients reaching a significant hypoxemia, in each arms.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Strasbourg, France</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>405</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 1, 2020</start_date>
    <primary_completion_date>August 1, 2021</primary_completion_date>
    <completion_date>August 1, 2021</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04347512</url>
  </study>
  <study rank="287">
    <nct_id>NCT04339816</nct_id>
    <title>Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial</title>
    <acronym>AZIQUINE-ICU</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Respiratory Failure</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Azithromycin</intervention>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Proportion of alive patients free off mechanical ventilation</outcome_measure>
      <outcome_measure>Proportion of patients who avoided the need of mechanical ventilation</outcome_measure>
      <outcome_measure>ICU LOS</outcome_measure>
      <outcome_measure>Mortality28</outcome_measure>
      <outcome_measure>Mortality90</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Frantisek Duska, MD, PhD</lead_sponsor>
      <collaborator>Masaryk Hospital Usti nad Labem</collaborator>
      <collaborator>University Hospital Pilsen</collaborator>
      <collaborator>The Faculty Hospital Na Bulovce</collaborator>
      <collaborator>St. Anne's University Hospital Brno, Czech Republic</collaborator>
      <collaborator>University Hospital, Motol</collaborator>
      <collaborator>General University Hospital, Prague</collaborator>
      <collaborator>University Hospital Olomouc</collaborator>
      <collaborator>Charles University, Czech Republic</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>240</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>December 31, 2021</primary_completion_date>
    <completion_date>June 30, 2022</completion_date>
    <study_first_posted>April 9, 2020</study_first_posted>
    <last_update_posted>April 13, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04339816</url>
  </study>
  <study rank="288">
    <nct_id>NCT04347980</nct_id>
    <title>Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19</title>
    <acronym>DHYSCO</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Respiratory Distress Syndrome, Adult</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Dexamethasone and Hydroxychloroquine</intervention>
      <intervention type="Drug">Hydroxychloroquine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Day-28 mortality</outcome_measure>
      <outcome_measure>Ventilator-free days</outcome_measure>
      <outcome_measure>Intensive Care Unit mortality</outcome_measure>
      <outcome_measure>Day-60 mortality</outcome_measure>
      <outcome_measure>Nosocomial pneumonia</outcome_measure>
      <outcome_measure>Bacteremia</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Chirurgical Marie Lannelongue</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>122</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>June 2020</primary_completion_date>
    <completion_date>August 2020</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations>
      <location>Reanimation adulte. Hopital Marie Lannelongue, Le Plessis-Robinson, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04347980</url>
  </study>
  <study rank="289">
    <nct_id>NCT04359212</nct_id>
    <title>Increased Risk of VTE and Higher Hypercoagulability in Patients Recovered in ICU and in Medical Ward for COVID-19</title>
    <acronym>VTE-COVID</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19 Disease</condition>
      <condition>Thromboembolism, Venous</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">thromboprophylaxis with low-molecular-weight heparin or fondaparinux</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>the cumulative proportion of any distal or proximal deep venous thrombosis or of symptomatic pulmonary embolism</outcome_measure>
      <outcome_measure>the cumulative proportion of any distal or proximal deep venous thrombosis or of symptomatic pulmonary embolism plus the asymptomatic incidentally detected pulmonary embolism</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Quovadis Associazione</lead_sponsor>
      <collaborator>Azienda Ospedaliera di Padova</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>May 2020</start_date>
    <primary_completion_date>June 2020</primary_completion_date>
    <completion_date>June 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04359212</url>
  </study>
  <study rank="290">
    <nct_id>NCT04350736</nct_id>
    <title>First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Acute Lung Injury (ALI) Associated With COVID-19</condition>
      <condition>Inflammatory Lung Conditions Associated With COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TD-0903</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Safety and Tolerability of SAD of TD-0903: Adverse Events</outcome_measure>
      <outcome_measure>Safety and Tolerability of MAD of TD-0903: Adverse Events</outcome_measure>
      <outcome_measure>Pharmacokinetics (PK) of TD-0903 when given as a Single Ascending Dose (SAD): AUC</outcome_measure>
      <outcome_measure>Pharmacokinetics (PK) of TD-0903 when given as a Single Ascending Dose (SAD): Cmax</outcome_measure>
      <outcome_measure>Pharmacokinetics (PK) of TD-0903 when given as a Single Ascending Dose (SAD): Tmax</outcome_measure>
      <outcome_measure>Pharmacokinetics (PK) of TD-0903 when given as a Multiple Ascending Dose (MAD): AUC</outcome_measure>
      <outcome_measure>Pharmacokinetics (PK) of TD-0903 when given as a Multiple Ascending Dose (MAD): Cmax</outcome_measure>
      <outcome_measure>Pharmacokinetics (PK) of TD-0903 when given as a Multiple Ascending Dose (MAD): Tmax</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Theravance Biopharma</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>54</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>June 2020</primary_completion_date>
    <completion_date>June 2020</completion_date>
    <study_first_posted>April 17, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations>
      <location>Theravance Biopharma Investigational Site, Manchester, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04350736</url>
  </study>
  <study rank="291">
    <nct_id>NCT04343339</nct_id>
    <title>Evolution of Psychoactive Substances Consumption in Connection With COVID-19 Containment</title>
    <acronym>EPILOGUE</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Addiction, Substance</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Evolution of consumption</outcome_measure>
      <outcome_measure>health care access</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Montpellier</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 8, 2020</start_date>
    <primary_completion_date>July 30, 2020</primary_completion_date>
    <completion_date>September 30, 2020</completion_date>
    <study_first_posted>April 13, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>Uhmontpellier, Montpellier, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04343339</url>
  </study>
  <study rank="292">
    <nct_id>NCT04333472</nct_id>
    <title>Piclidenoson for Treatment of COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Coronavirus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Piclidenoson</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Duration of viral shedding in days</outcome_measure>
      <outcome_measure>Time to clinical recovery (TTCR) in days</outcome_measure>
      <outcome_measure>Treatment-emergent adverse events (AEs)</outcome_measure>
      <outcome_measure>Requirement for non-invasive or mechanical ventilation</outcome_measure>
      <outcome_measure>Length of hospital stay in days</outcome_measure>
      <outcome_measure>Estimated PaO2/FiO2 ratio on day of discharge</outcome_measure>
      <outcome_measure>All-cause mortality</outcome_measure>
      <outcome_measure>Patients reaching undetectable COVID-19 virus levels in respiratory secretions</outcome_measure>
      <outcome_measure>Duration of symptoms and signs of respiratory infection in days</outcome_measure>
      <outcome_measure>Need for supportive respiratory management</outcome_measure>
      <outcome_measure>Viral load</outcome_measure>
      <outcome_measure>Treatment-emergent serious AEs (SAEs)</outcome_measure>
      <outcome_measure>AEs leading to withdrawal</outcome_measure>
      <outcome_measure>Treatment-emergent abnormalities in clinical laboratory parameters</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Can-Fite BioPharma</lead_sponsor>
      <collaborator>Rabin Medical Center</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 6, 2020</start_date>
    <primary_completion_date>June 6, 2020</primary_completion_date>
    <completion_date>July 6, 2020</completion_date>
    <study_first_posted>April 3, 2020</study_first_posted>
    <last_update_posted>April 3, 2020</last_update_posted>
    <locations>
      <location>Rabin Medical Center, Petah tikva, Israel</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04333472</url>
  </study>
  <study rank="293">
    <nct_id>NCT04357808</nct_id>
    <title>Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID)</title>
    <acronym>SARCOVID</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sarilumab</intervention>
      <intervention type="Other">Standar of care</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mean change in clinical status assessment using the 7-point ordinal scale at day 7 after randomisation</outcome_measure>
      <outcome_measure>Duration of hospitalisation (days)</outcome_measure>
      <outcome_measure>Death</outcome_measure>
      <outcome_measure>Time to become afebrile (days)</outcome_measure>
      <outcome_measure>Time to non-invasive mechanical ventilation (days)</outcome_measure>
      <outcome_measure>Time to invasive mechanical ventilation (days)</outcome_measure>
      <outcome_measure>Time to independence from supplementary oxygen therapy (days)</outcome_measure>
      <outcome_measure>Mean change in clinical status assessment using the 7-point ordinal scale at day 14 after randomisation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Maria del Rosario Garcia de Vicuña Pinedo</lead_sponsor>
      <collaborator>Instituto de Investigación Sanitaria Hospital Universitario de la Princesa</collaborator>
      <collaborator>Fundación de Investigación Biomédica - Hospital Universitario de La Princesa</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 13, 2020</start_date>
    <primary_completion_date>June 2020</primary_completion_date>
    <completion_date>June 2020</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Hospital Universitario de la Princesa, Madrid, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04357808</url>
  </study>
  <study rank="294">
    <nct_id>NCT04345315</nct_id>
    <title>Correlative Study on Cancer Patients and Healthcare Professionals Exposed to Infection by Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-Cov-2), COVID-19 Causative Agent.</title>
    <acronym>CORSA</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>SARS-CoV-2</condition>
    </conditions>
    <interventions>
      <intervention type="Other">serological test</intervention>
      <intervention type="Other">Rapid molecular test</intervention>
      <intervention type="Genetic">Next generation Sequencing (NGS) analysis</intervention>
      <intervention type="Other">serum chemistry analysis</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>epidemiology</outcome_measure>
      <outcome_measure>Immunoglobulin G (IgG) and Immunoglobulin M (IgM) antibodies evaluation</outcome_measure>
      <outcome_measure>methods comparison</outcome_measure>
      <outcome_measure>correlation between biochemical and coagulative factors with SARS-CoV-2 positivity.</outcome_measure>
      <outcome_measure>phylogenetic map</outcome_measure>
      <outcome_measure>interactions between the virus and host cells</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori</lead_sponsor>
      <collaborator>AUSL Romagna</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Other</study_design>
    </study_designs>
    <start_date>March 27, 2020</start_date>
    <primary_completion_date>March 2021</primary_completion_date>
    <completion_date>March 2022</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>UO Microbiologia,Centro Servizi Pievesestina, AUSL Romagna, Cesena, FC, Italy</location>
      <location>Irst Irccs, Meldola, FC, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04345315</url>
  </study>
  <study rank="295">
    <nct_id>NCT04364984</nct_id>
    <title>ARB, ACEi, DRi in COVID-19</title>
    <acronym>BIRCOV</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hypertension</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Angiotensin converting enzyme inhibitor</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>BP (hypertensive efficacy)</outcome_measure>
      <outcome_measure>COVID-19 course</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Medical Practice Prof D. Ivanov</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>April 1, 2021</primary_completion_date>
    <completion_date>August 1, 2021</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Medical Practice Prof D.Ivanov, Kiev, Please Select, Ukraine</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04364984</url>
  </study>
  <study rank="296">
    <nct_id>NCT04366141</nct_id>
    <title>COVID-19 (Coronavirus Disease 2019) Intubation Barrier Box Randomized Controlled Trial</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Device">COVID-19 barrier box</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to tracheal intubation (TTI)</outcome_measure>
      <outcome_measure>First pass success rate</outcome_measure>
      <outcome_measure>Total time of airway manipulation</outcome_measure>
      <outcome_measure>Anesthesiologist perception of intubation difficulty</outcome_measure>
      <outcome_measure>Patient satisfaction</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of British Columbia</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>May 2020</start_date>
    <primary_completion_date>April 2021</primary_completion_date>
    <completion_date>April 2021</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04366141</url>
  </study>
  <study rank="297">
    <nct_id>NCT04353674</nct_id>
    <title>Modulation of Hyperinflammation in COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>SARS</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Control group</intervention>
      <intervention type="Device">SLEDD with a L-MOD</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Efficacy of a L-MOD against controls receiving supportive care in ICU.</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>Hospital Discharge</outcome_measure>
      <outcome_measure>Leukocyte Monitoring</outcome_measure>
      <outcome_measure>Sequential Organ Failure Assessment (SOFA) Score</outcome_measure>
      <outcome_measure>Intubation length</outcome_measure>
      <outcome_measure>Markers of Inflammation</outcome_measure>
      <outcome_measure>Leukocytes and Macrophages</outcome_measure>
      <outcome_measure>Myocardial damage</outcome_measure>
      <outcome_measure>Renal recovery</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Lawson Health Research Institute</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 28, 2020</start_date>
    <primary_completion_date>July 28, 2020</primary_completion_date>
    <completion_date>January 1, 2021</completion_date>
    <study_first_posted>April 20, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04353674</url>
  </study>
  <study rank="298">
    <nct_id>NCT04344431</nct_id>
    <title>Management by Hyperbaric Oxygen Therapy of Patients With Hypoxaemic Pneumonia With SARS-CoV-2 (COVID-19)</title>
    <acronym>OHB10cov</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid-19</condition>
    </conditions>
    <interventions>
      <intervention type="Combination Product">Hyperbaric oxygen treatment (HBOT) i.e. inhalation of pressurized oxygen delivered by a hyperbaric chamber (drug/device)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to normalize the oxygen requirement (oxygeno-dependence)</outcome_measure>
      <outcome_measure>Days of hospitalization between the HBO group and the control group.</outcome_measure>
      <outcome_measure>Oxygen flow values to obtain a saturation by pulse oximetry greater than or equal to 92% values between the HBO group and the control group.</outcome_measure>
      <outcome_measure>Days on invasive mechanical ventilation</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Direction Centrale du Service de Santé des Armées</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 14, 2020</start_date>
    <primary_completion_date>April 2021</primary_completion_date>
    <completion_date>May 2021</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>Sainte Anne Military Teaching Hospital, Toulon, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04344431</url>
  </study>
  <study rank="299">
    <nct_id>NCT04353336</nct_id>
    <title>Efficacay of Chloroquine in COVID-19 Treatment</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Coronavirus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Chloroquine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of patients with virological cure</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tanta University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 17, 2020</start_date>
    <primary_completion_date>December 1, 2030</primary_completion_date>
    <completion_date>December 1, 2030</completion_date>
    <study_first_posted>April 20, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations>
      <location>Tanta University, Tanta, Egypt</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04353336</url>
  </study>
  <study rank="300">
    <nct_id>NCT04293692</nct_id>
    <title>Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">UC-MSCs</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Size of lesion area by chest imaging</outcome_measure>
      <outcome_measure>Blood oxygen saturation</outcome_measure>
      <outcome_measure>Rate of mortality within 28-days</outcome_measure>
      <outcome_measure>Sequential organ failure assessment</outcome_measure>
      <outcome_measure>Side effects in the UC-MSCs treatment group</outcome_measure>
      <outcome_measure>Electrocardiogram, the changes of ST-T interval mostly</outcome_measure>
      <outcome_measure>Concentration of C-reactive protein C-reactive protein, immunoglobulin</outcome_measure>
      <outcome_measure>CD4+ and CD8+ T cells count</outcome_measure>
      <outcome_measure>Concentration of the blood cytokine (IL-1β, IL-6, IL-8,IL-10,TNF-α)</outcome_measure>
      <outcome_measure>Concentration of the myocardial enzymes</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Puren Hospital Affiliated to Wuhan University of Science and Technology</lead_sponsor>
      <collaborator>Wuhan Hamilton Bio-technology Co., Ltd</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>February 24, 2020</start_date>
    <primary_completion_date>February 25, 2020</primary_completion_date>
    <completion_date>February 25, 2020</completion_date>
    <study_first_posted>March 3, 2020</study_first_posted>
    <last_update_posted>March 18, 2020</last_update_posted>
    <locations>
      <location>Puren Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, Hubei, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04293692</url>
  </study>
  <study rank="301">
    <nct_id>NCT04341688</nct_id>
    <title>A Clinical Trial of Gargling Agents in Reducing Intraoral Viral Load Among COVID-19 Patients</title>
    <acronym>GARGLES</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Gargle/Mouthwash</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Intraoral viral load</outcome_measure>
      <outcome_measure>Salivary cytokine profile</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Aga Khan University</lead_sponsor>
      <collaborator>University of Karachi</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <start_date>July 1, 2020</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>March 31, 2021</completion_date>
    <study_first_posted>April 10, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04341688</url>
  </study>
  <study rank="302">
    <nct_id>NCT04355247</nct_id>
    <title>Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">MethylPREDNISolone 80 Mg/mL Injectable Suspension</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clinical complete response criteria</outcome_measure>
      <outcome_measure>Clinical Partial Response criteria</outcome_measure>
      <outcome_measure>Secondary response criteria</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Auxilio Mutuo Cancer Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 14, 2020</start_date>
    <primary_completion_date>July 31, 2020</primary_completion_date>
    <completion_date>April 30, 2021</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>San Juan City Hospital / Puerto Rico Medical Center, San Juan, Puerto Rico</location>
      <location>Hospital Auxilio Mutuo Cancer Center, San Juan, Puerto Rico</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04355247</url>
  </study>
  <study rank="303">
    <nct_id>NCT04361435</nct_id>
    <title>Lung Recruitment Device for COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Physiotherapy</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Chest physiotherapy using a non-invasive oscillating device</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>SpO2/FIO2 Ratio</outcome_measure>
      <outcome_measure>Blood pressures</outcome_measure>
      <outcome_measure>Heart rates</outcome_measure>
      <outcome_measure>Respiratory rate</outcome_measure>
      <outcome_measure>Body temperature</outcome_measure>
      <outcome_measure>Modified Wood Clinical Asthma Score (m-WCAS)</outcome_measure>
      <outcome_measure>Expiratory tidal lung volume.</outcome_measure>
      <outcome_measure>End-tidal CO2</outcome_measure>
      <outcome_measure>Clinical Respiratory severity scores.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>St. Justine's Hospital</lead_sponsor>
      <collaborator>Dymedso Inc.</collaborator>
      <collaborator>Réseau de Recherche en Santé Respiratoire du Québec</collaborator>
      <collaborator>Fonds de la Recherche en Santé du Québec</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <start_date>May 1, 2020</start_date>
    <primary_completion_date>July 31, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04361435</url>
  </study>
  <study rank="304">
    <nct_id>NCT04345276</nct_id>
    <title>Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Danoprevir+Ritonavir</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Rate of composite adverse outcomes</outcome_measure>
      <outcome_measure>Time to recovery</outcome_measure>
      <outcome_measure>Rate of no fever</outcome_measure>
      <outcome_measure>Rate of no cough</outcome_measure>
      <outcome_measure>Rate of no dyspnea</outcome_measure>
      <outcome_measure>Rate of no requiring supplemental oxygen</outcome_measure>
      <outcome_measure>Rate of undetectable New coronavirus pathogen nucleic acid</outcome_measure>
      <outcome_measure>Rate of mechanical ventilation</outcome_measure>
      <outcome_measure>Rate of ICU admission</outcome_measure>
      <outcome_measure>Rate of serious adverse event</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Huoshenshan Hospital</lead_sponsor>
      <collaborator>Ascletis Pharmaceuticals Co., Ltd.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 18, 2020</start_date>
    <primary_completion_date>April 30, 2020</primary_completion_date>
    <completion_date>May 31, 2020</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>Huoshenshan Hostipal, Wuhan, Hubei, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04345276</url>
  </study>
  <study rank="305">
    <nct_id>NCT04358926</nct_id>
    <title>Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19)</title>
    <acronym>HBOTCOVID19</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Desaturation of Blood</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Hyperbaric oxygen therapy</intervention>
      <intervention type="Device">Normobaric oxygen therapy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>PaO2/FiO2</outcome_measure>
      <outcome_measure>SpO2</outcome_measure>
      <outcome_measure>NEWS Score</outcome_measure>
      <outcome_measure>Inflammation level</outcome_measure>
      <outcome_measure>Symptoms level</outcome_measure>
      <outcome_measure>Average oxygen supply per day</outcome_measure>
      <outcome_measure>Viral load</outcome_measure>
      <outcome_measure>Chest Xray changes</outcome_measure>
      <outcome_measure>Number of patients with IgG seroconverstion</outcome_measure>
      <outcome_measure>Number of patients with IgM seroconverstion</outcome_measure>
      <outcome_measure>FEV1/FVC</outcome_measure>
      <outcome_measure>Time to symptoms recovery</outcome_measure>
      <outcome_measure>Number of patients who required invasive ventilation</outcome_measure>
      <outcome_measure>Time to negative virus PCR</outcome_measure>
      <outcome_measure>Mortality rate</outcome_measure>
      <outcome_measure>Number of barotrauma events (safety)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assaf-Harofeh Medical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 26, 2020</start_date>
    <primary_completion_date>June 30, 2020</primary_completion_date>
    <completion_date>July 30, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04358926</url>
  </study>
  <study rank="306">
    <nct_id>NCT04291729</nct_id>
    <title>Evaluation of Ganovo （Danoprevir ） Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ganovo+ritonavir+/-Interferon nebulization</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Rate of composite adverse outcomes</outcome_measure>
      <outcome_measure>Time to recovery</outcome_measure>
      <outcome_measure>Rate of no fever</outcome_measure>
      <outcome_measure>Rate of no cough</outcome_measure>
      <outcome_measure>Rate of no dyspnea</outcome_measure>
      <outcome_measure>Rate of no requiring supplemental oxygen</outcome_measure>
      <outcome_measure>Rate of undetectable New coronavirus pathogen nucleic acid</outcome_measure>
      <outcome_measure>Rate of mechanical ventilation</outcome_measure>
      <outcome_measure>Rate of ICU admission</outcome_measure>
      <outcome_measure>Rate of serious adverse event</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>The Ninth Hospital of Nanchang</lead_sponsor>
      <collaborator>Ascletis Pharmaceuticals Co., Ltd.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>11</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>February 17, 2020</start_date>
    <primary_completion_date>March 19, 2020</primary_completion_date>
    <completion_date>March 19, 2020</completion_date>
    <study_first_posted>March 2, 2020</study_first_posted>
    <last_update_posted>April 13, 2020</last_update_posted>
    <locations>
      <location>The Ninth Hospital of Nanchang, Nanchang, Jiangxi, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04291729</url>
  </study>
  <study rank="307">
    <nct_id>NCT04359459</nct_id>
    <title>Nasal Epithelial Genetic and Single Cell RNA COVID-19 Study</title>
    <acronym>CIPOLLINI</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Nasal epithelial transcriptional response to SARS-CoV2</outcome_measure>
      <outcome_measure>ACE2-AngII system</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Medical Center Groningen</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>June 2020</start_date>
    <primary_completion_date>June 2022</primary_completion_date>
    <completion_date>June 2022</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04359459</url>
  </study>
  <study rank="308">
    <nct_id>NCT04338828</nct_id>
    <title>Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED</title>
    <acronym>NO COV-ED</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nitric Oxide Gas</intervention>
      <intervention type="Other">Inhaled Supplemental Oxygen</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Rates of return visits to the ED</outcome_measure>
      <outcome_measure>Inpatient hospitalizations required</outcome_measure>
      <outcome_measure>Rates of intubation</outcome_measure>
      <outcome_measure>Rates of mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Massachusetts General Hospital</lead_sponsor>
      <collaborator>Department of Anesthesia, Critical Care and Pain Medicine (DACCPM), Massachusetts General Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>260</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>April 2021</primary_completion_date>
    <completion_date>April 2022</completion_date>
    <study_first_posted>April 8, 2020</study_first_posted>
    <last_update_posted>April 8, 2020</last_update_posted>
    <locations>
      <location>Massachusetts General Hospital, Boston, Massachusetts, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04338828</url>
  </study>
  <study rank="309">
    <nct_id>NCT04335305</nct_id>
    <title>Checkpoint Blockade in COVID-19 Pandemic</title>
    <acronym>COPERNICO</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Pneumonia, Viral</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tocilizumab</intervention>
      <intervention type="Biological">Pembrolizumab (MK-3475)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Percentage of patients with normalization of oxygen saturation by pulse oximetry (SpO2) ≥96%</outcome_measure>
      <outcome_measure>Proportion of patients with temperature &lt; 37,5 °C armpit.</outcome_measure>
      <outcome_measure>Proportion of patients discharged from the emergency department and classified as low risk</outcome_measure>
      <outcome_measure>Change from baseline in organ failure parameters</outcome_measure>
      <outcome_measure>Proportion of mortality rate</outcome_measure>
      <outcome_measure>Analysis of the remission of respiratory symptoms</outcome_measure>
      <outcome_measure>Evaluation of the radiological response</outcome_measure>
      <outcome_measure>Time to first negative in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RT-PCR test</outcome_measure>
      <outcome_measure>Change from baseline of absolute lymphocyte count (ALC),white blood cell count and white blood cell differential count</outcome_measure>
      <outcome_measure>Change from baseline of hemoglobin</outcome_measure>
      <outcome_measure>Change from baseline of platelets</outcome_measure>
      <outcome_measure>Change from baseline of activated partial thromboplastin time (aPTT)</outcome_measure>
      <outcome_measure>Change from baseline of Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)</outcome_measure>
      <outcome_measure>Change from baseline of creatinine</outcome_measure>
      <outcome_measure>Change from baseline of glucose</outcome_measure>
      <outcome_measure>Change from baseline of total bilirubin</outcome_measure>
      <outcome_measure>Change from baseline of albumin</outcome_measure>
      <outcome_measure>Incidence of adverse events (AEs), incidence of prespecified AEs (safety and tolerability)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>MedSIR</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 14, 2020</start_date>
    <primary_completion_date>May 15, 2020</primary_completion_date>
    <completion_date>May 15, 2020</completion_date>
    <study_first_posted>April 6, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Hospital Quirónsalud Barcelona, Barcelona, Spain</location>
      <location>Hospital de la Santa Creu i Sant Pau, Barcelona, Spain</location>
      <location>Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain</location>
      <location>Hospital Ruber Juan Bravo, Madrid, Spain</location>
      <location>Hospital Ruber Internacional, Madrid, Spain</location>
      <location>Hospital Arnau de Vilanova-Lliria, Valencia, Spain</location>
      <location>Hospital Universitario Doctor Peset, Valencia, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04335305</url>
  </study>
  <study rank="310">
    <nct_id>NCT04355715</nct_id>
    <title>Combination of Chest Scanography and Nasal Viral Detection Test to Detect COVID-19 Positive Patients Before Surgical Intervention in a University Hospital During Coronavirus Pandemia</title>
    <acronym>COVID-Scan</acronym>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID 19</condition>
      <condition>SARS-Cov-2</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Confirmed diagnosis of COVID-19 infection</outcome_measure>
      <outcome_measure>Incidence of unexpected COVID-19 positive patients admitted to the hospital</outcome_measure>
      <outcome_measure>Number of contaminating events avoided by the early detection of COVID-19 patients</outcome_measure>
      <outcome_measure>Incidence of SARS-Cov-2 seroconversion</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Montpellier</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>99 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 1, 2019</start_date>
    <primary_completion_date>October 1, 2020</primary_completion_date>
    <completion_date>October 20, 2020</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>Uh Montpellier, Montpellier, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04355715</url>
  </study>
  <study rank="311">
    <nct_id>NCT04273321</nct_id>
    <title>Efficacy and Safety of Corticosteroids in COVID-19</title>
    <acronym/>
    <status open="N">Suspended</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Novel Coronavirus Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Methylprednisolone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>the incidence of treatment failure in 14 days</outcome_measure>
      <outcome_measure>clinical cure incidence in 14 days</outcome_measure>
      <outcome_measure>the duration of virus change to negative</outcome_measure>
      <outcome_measure>mortality at day 30</outcome_measure>
      <outcome_measure>ICU admission rate in 30 days</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Beijing Chao Yang Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>February 14, 2020</start_date>
    <primary_completion_date>May 1, 2020</primary_completion_date>
    <completion_date>May 30, 2020</completion_date>
    <study_first_posted>February 18, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations>
      <location>Hubei province hospital of integrated Chinese &amp; Western Medicine, Wuhan, Hubei, China</location>
      <location>Yichang first people's Hospital, Yichang, Hubei, China</location>
      <location>Beijing YouAn Hospital, Beijing, China</location>
      <location>Renmin Hospital of Wuhan University, Wuhan, China</location>
      <location>Tianyou Hospital Affiliated to Wuhan University of science and technology, Wuhan, China</location>
      <location>Union Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology, Wuhan, China</location>
      <location>the first peopel hospital of Xiangyang, Xiangyang, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04273321</url>
  </study>
  <study rank="312">
    <nct_id>NCT04347538</nct_id>
    <title>Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID 19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Saline Nasal Irrigation</intervention>
      <intervention type="Other">Saline with Baby Shampoo Nasal Irrigation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in SARS-CoV-2 mucosal immune response in the nasopharynx</outcome_measure>
      <outcome_measure>Change in microbial load in the nasopharynx</outcome_measure>
      <outcome_measure>Change in Viral Load in the nasopharynx over the course of COVID-19 infection</outcome_measure>
      <outcome_measure>Symptom assessment</outcome_measure>
      <outcome_measure>Temperature assessment</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Vanderbilt University Medical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 2020</start_date>
    <primary_completion_date>June 2021</primary_completion_date>
    <completion_date>June 2022</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations>
      <location>Vanderblt University Medical Center, Nashville, Tennessee, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04347538</url>
  </study>
  <study rank="313">
    <nct_id>NCT04355026</nct_id>
    <title>Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Bromhexine Oral Tablet and/or hydroxychloroquine tablet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Duration of hospitalization</outcome_measure>
      <outcome_measure>Duration of disease</outcome_measure>
      <outcome_measure>Hospital-aquired pneumonia</outcome_measure>
      <outcome_measure>ICU stay duration</outcome_measure>
      <outcome_measure>Oxygene therapy duration</outcome_measure>
      <outcome_measure>Mechanical ventilatory support duration</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>General and Teaching Hospital Celje</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>19 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 10, 2020</start_date>
    <primary_completion_date>June 30, 2020</primary_completion_date>
    <completion_date>July 31, 2020</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>SB Celje, Celje, Slovenia</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04355026</url>
  </study>
  <study rank="314">
    <nct_id>NCT04338360</nct_id>
    <title>Expanded Access to Convalescent Plasma for the Treatment of Patients With COVID-19</title>
    <acronym/>
    <status open="Y">Available</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID19</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">COVID-19 convalescent plasma</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Mayo Clinic</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Expanded Access</study_types>
    <exp_acc_types>
      <exp_acc_type>Intermediate-size Population</exp_acc_type>
    </exp_acc_types>
    <study_designs/>
    <study_first_posted>April 8, 2020</study_first_posted>
    <last_update_posted>April 8, 2020</last_update_posted>
    <locations>
      <location>Mayo Clinic in Arizona, Scottsdale, Arizona, United States</location>
      <location>Mayo Clinic in Florida, Jacksonville, Florida, United States</location>
      <location>Mayo Clinic Health System in Albert Lea, Albert Lea, Minnesota, United States</location>
      <location>Mayo Clinic Health System in Austin, Austin, Minnesota, United States</location>
      <location>Mayo Clinic Health System in Cannon Falls, Cannon Falls, Minnesota, United States</location>
      <location>Mayo Clinic Health System in Lake City, Lake City, Minnesota, United States</location>
      <location>Mayo Clinic Health System in Mankato, Mankato, Minnesota, United States</location>
      <location>Mayo Clinic Health System in Owatonna, Owatonna, Minnesota, United States</location>
      <location>Mayo Clinic Health System in Red Wing, Red Wing, Minnesota, United States</location>
      <location>Mayo Clinic in Rochester, Rochester, Minnesota, United States</location>
      <location>Mayo Clinic Health System - Eau Claire, Eau Claire, Wisconsin, United States</location>
      <location>Mayo Clinic Health System - Franciscan Healthcare, La Crosse, Wisconsin, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04338360</url>
  </study>
  <study rank="315">
    <nct_id>NCT04363541</nct_id>
    <title>Local Thermotherapy for Patients With Moderate Symptoms of COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Thermotherapy</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Electric pad for human external pain therapy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Hospitalization time</outcome_measure>
      <outcome_measure>Patients needing intensive care</outcome_measure>
      <outcome_measure>Symptoms after hospitalization release</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Instituto Nacional de Perinatologia</lead_sponsor>
      <collaborator>Hospital Juarez de Mexico</collaborator>
      <collaborator>Direccion General de Calidad y Educacion en Salud</collaborator>
      <collaborator>Laboratorios Silanes S.A. de C.V.</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>298</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>September 2020</primary_completion_date>
    <completion_date>November 2020</completion_date>
    <study_first_posted>April 27, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04363541</url>
  </study>
  <study rank="316">
    <nct_id>NCT04343976</nct_id>
    <title>Pegylated Interferon Lambda Treatment for COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>COVID</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pegylated interferon lambda</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Undetectable COVID PCR at day 7</outcome_measure>
      <outcome_measure>Undetectable COVID PCR at day 3, 10 and 14</outcome_measure>
      <outcome_measure>Percentage of subjects on Lambda vs standard of care with symptomatic improvement</outcome_measure>
      <outcome_measure>Percentage of subjects on Lambda vs standard of care with improved clinical outcomes</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Raymond Chung</lead_sponsor>
      <collaborator>Eiger BioPharmaceuticals</collaborator>
      <collaborator>Massachusetts General Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 15, 2020</start_date>
    <primary_completion_date>October 1, 2020</primary_completion_date>
    <completion_date>December 31, 2021</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Massachusetts General Hospital, Boston, Massachusetts, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04343976</url>
  </study>
  <study rank="317">
    <nct_id>NCT04341142</nct_id>
    <title>Assessment of Serological Techniques for Screening Patients Regarding COVID-19-COVID-SER</title>
    <acronym>COVID-SER</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid19</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Serological tests will be applied on patients blood sampling</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The positivity (Yes/No) of the serological test.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hospices Civils de Lyon</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <start_date>April 9, 2020</start_date>
    <primary_completion_date>September 9, 2020</primary_completion_date>
    <completion_date>September 9, 2020</completion_date>
    <study_first_posted>April 10, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations>
      <location>Hôpital Lyon Sud,Sainte Eugénie bat 4M,5, Chemin du Grand Revoyet, Pierre-Bénite cedex, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04341142</url>
  </study>
  <study rank="318">
    <nct_id>NCT04353206</nct_id>
    <title>Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid-19</condition>
      <condition>Sars-CoV2</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Multiple Doses of Anti-SARS-CoV-2 convalescent plasma</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Proportion of subjects who consent to the study and receive at least one dose of convalescent plasma.</outcome_measure>
      <outcome_measure>Overall survival of patients in the ICU receiving at least once dose of convalescent plasma for Covid-19-induced respiratory failure.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Noah Merin</lead_sponsor>
      <collaborator>Johns Hopkins University</collaborator>
      <collaborator>University of Pittsburgh Medical Center</collaborator>
      <collaborator>Cedars-Sinai Medical Center</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Early Phase 1</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 2020</start_date>
    <primary_completion_date>May 2021</primary_completion_date>
    <completion_date>May 2021</completion_date>
    <study_first_posted>April 20, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>8700 Beverly Blvd., Los Angeles, California, United States</location>
      <location>Johns Hopkins University, Baltimore, Maryland, United States</location>
      <location>University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04353206</url>
  </study>
  <study rank="319">
    <nct_id>NCT04334252</nct_id>
    <title>Descriptive Study Regarding Ambulant Screening During COVID-19 Pandemia</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID 19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Questionnaire</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Prevalence of symptoms</outcome_measure>
      <outcome_measure>Prevalence of positive Sars CoV-2 PCR</outcome_measure>
      <outcome_measure>Prevalence of positive radiological findings</outcome_measure>
      <outcome_measure>Prediction of symptoms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Jessa Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>5000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 17, 2020</start_date>
    <primary_completion_date>December 20, 2022</primary_completion_date>
    <completion_date>December 20, 2023</completion_date>
    <study_first_posted>April 6, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04334252</url>
  </study>
  <study rank="320">
    <nct_id>NCT04353180</nct_id>
    <title>Assessment the Activity Value of 13- Cis-Retinoic Acid(Isotretinoin) in the Treatment of COVID-19</title>
    <acronym>Isotretinoin</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment</intervention>
      <intervention type="Drug">Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment</intervention>
      <intervention type="Drug">Standard treatment</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>lung injury score</outcome_measure>
      <outcome_measure>Absolute lymphocyte counts</outcome_measure>
      <outcome_measure>Serum levels of CRP, ESR ,IL-1,IL-6,TNF and Type I interferon</outcome_measure>
      <outcome_measure>Serum level of COVID19 RNA</outcome_measure>
      <outcome_measure>All cause mortality rate</outcome_measure>
      <outcome_measure>Ventilation free days</outcome_measure>
      <outcome_measure>ICU free days</outcome_measure>
      <outcome_measure>d-dimers</outcome_measure>
      <outcome_measure>Time to first negative SARS-CoV-2 PCR in NP swap</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Kafrelsheikh University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>45</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>May 2020</primary_completion_date>
    <completion_date>June 2020</completion_date>
    <study_first_posted>April 20, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Faculty of Medicine, Kafr El-sheikh University, Cairo, Kafr El-sheikh, Egypt</location>
      <location>Faculty of Medicine, Kafr El-sheikh University, Cairo, Egypt</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04353180</url>
  </study>
  <study rank="321">
    <nct_id>NCT04339426</nct_id>
    <title>Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Atovaquone/Azithromycin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Virology Cure Rate</outcome_measure>
      <outcome_measure>Incidence of GI adverse events</outcome_measure>
      <outcome_measure>Cardiac Toxicity</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>HonorHealth Research Institute</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>95 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>October 2020</primary_completion_date>
    <completion_date>April 2021</completion_date>
    <study_first_posted>April 9, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>HonorHealth, Scottsdale, Arizona, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04339426</url>
  </study>
  <study rank="322">
    <nct_id>NCT04364763</nct_id>
    <title>Effect of RBT-9 on Preventing Progression of COVID-19 in High-Risk Individuals</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Stannous protoporphyrin (90mg)</intervention>
      <intervention type="Drug">0.9% sodium chloride (normal saline)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Evaluate the effect of RBT-9(stannous protoporphyrin) versus placebo on clinical status of Covid-19 patients as measured using the 8-point World Health Organization (WHO) Ordinal Clinical Scale</outcome_measure>
      <outcome_measure>Time to first occurrence of death from any cause or new/worsened organ dysfunction</outcome_measure>
      <outcome_measure>All-cause survival</outcome_measure>
      <outcome_measure>Respiratory distress rate</outcome_measure>
      <outcome_measure>Fever incidence</outcome_measure>
      <outcome_measure>Acute kidney injury (AKI) incidence</outcome_measure>
      <outcome_measure>New or worsening congestive heart failure (HF)</outcome_measure>
      <outcome_measure>Hospitalization status</outcome_measure>
      <outcome_measure>Ventricular tachycardia or fibrillation lasting at least 30 seconds and/or associated with hemodynamic instability or pulseless electrical activity, or resuscitated cardiac arrest</outcome_measure>
      <outcome_measure>Oxygen-free days</outcome_measure>
      <outcome_measure>Intensive care unit (ICU) status</outcome_measure>
      <outcome_measure>Days on ventilator</outcome_measure>
      <outcome_measure>Time to and duration of vasopressor or inotrope utilization</outcome_measure>
      <outcome_measure>Dialysis status</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Renibus Therapuetics, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>252</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>June 1, 2020</start_date>
    <primary_completion_date>June 30, 2021</primary_completion_date>
    <completion_date>December 31, 2021</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04364763</url>
  </study>
  <study rank="323">
    <nct_id>NCT04354584</nct_id>
    <title>Compartmental Inflammation in Mechanically Ventilated Patients With COVID-19</title>
    <acronym>COV2ICU-DK</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Respiratory Failure</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>White blood cell counts</outcome_measure>
      <outcome_measure>Lymphocyte populations</outcome_measure>
      <outcome_measure>Cytokines</outcome_measure>
      <outcome_measure>Lectin complement pathway</outcome_measure>
      <outcome_measure>Microorganisms</outcome_measure>
      <outcome_measure>Respiratory pathogens</outcome_measure>
      <outcome_measure>Ribosomal RNA in the airways</outcome_measure>
      <outcome_measure>Levels of SARS-CoV-2 in the airways</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hvidovre University Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 6, 2020</start_date>
    <primary_completion_date>April 6, 2021</primary_completion_date>
    <completion_date>April 6, 2021</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>Dept. of Intensive Care 542, University Hospital Hvidovre, Hvidovre, Copenhagen, Denmark</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04354584</url>
  </study>
  <study rank="324">
    <nct_id>NCT04343794</nct_id>
    <title>Using Biovitals® Sentinel to Monitor Disease Progression in Subjects Quarantined for Suspected COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID19</condition>
    </conditions>
    <interventions>
      <intervention type="Device">BIOVITALS</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to diagnosis of COVID-19 by RT-PCR in subjects</outcome_measure>
      <outcome_measure>Compliance to complete the study</outcome_measure>
      <outcome_measure>Sensitivity and specificity of Biovitals® Sentinel</outcome_measure>
      <outcome_measure>Cross infection rate within the family cluster</outcome_measure>
      <outcome_measure>Length of hospital stay of positive subjects</outcome_measure>
      <outcome_measure>Length of ICU stay of positive patients</outcome_measure>
      <outcome_measure>National Early Warning Score 2 rating of positive patients</outcome_measure>
      <outcome_measure>Viral load of positive patients</outcome_measure>
      <outcome_measure>Worsening of comorbidities</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>The University of Hong Kong</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>December 31, 2021</primary_completion_date>
    <completion_date>January 31, 2022</completion_date>
    <study_first_posted>April 13, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04343794</url>
  </study>
  <study rank="325">
    <nct_id>NCT04341103</nct_id>
    <title>AlloSure Guided Immuno-Optimization for COVID-19: An Early Experience</title>
    <acronym>Al-COVE</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Solid Organ Transplant Rejection</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Assessing the utility of AlloSure dd-cfDNA to guide clinical immune-optimization for transplant patients with COVID-19</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>CareDx</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>December 1, 2020</primary_completion_date>
    <completion_date>March 1, 2021</completion_date>
    <study_first_posted>April 10, 2020</study_first_posted>
    <last_update_posted>April 10, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04341103</url>
  </study>
  <study rank="326">
    <nct_id>NCT04341285</nct_id>
    <title>Early Versus Late ECMO Therapy in COVID-19 Induced ARDS (ECMO-VID)</title>
    <acronym>ECMO-VID</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>ARDS, Human</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">ECMO Implantation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>28 day all cause mortality</outcome_measure>
      <outcome_measure>90 day all cause mortality</outcome_measure>
      <outcome_measure>Sepsis-related organ failure assessment score at day 1-14, 28 and 90 days</outcome_measure>
      <outcome_measure>duration of mechanical ventilation support</outcome_measure>
      <outcome_measure>Ventilator Associated Pneumonia</outcome_measure>
      <outcome_measure>Bleeding complications</outcome_measure>
      <outcome_measure>Acute Renal Failure</outcome_measure>
      <outcome_measure>Discharge Location</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital Tuebingen</lead_sponsor>
      <collaborator>University Hospital Freiburg</collaborator>
      <collaborator>RWTH Aachen University</collaborator>
      <collaborator>University Hospital Muenster</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>June 1, 2020</start_date>
    <primary_completion_date>June 1, 2024</primary_completion_date>
    <completion_date>December 1, 2025</completion_date>
    <study_first_posted>April 10, 2020</study_first_posted>
    <last_update_posted>April 16, 2020</last_update_posted>
    <locations>
      <location>University Hospital Tuebingen, Tuebingen, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04341285</url>
  </study>
  <study rank="327">
    <nct_id>NCT04331665</nct_id>
    <title>Study of the Efficacy and Safety of Ruxolitinib to Treat COVID-19 Pneumonia</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ruxolitinib</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Proportion of patients with COVID-19 pneumonia who become critically ill (defined as requiring mechanical ventilation and/or FiO2 of 60% of more)</outcome_measure>
      <outcome_measure>Number of adverse events</outcome_measure>
      <outcome_measure>All cause mortality rate</outcome_measure>
      <outcome_measure>Average duration of hospital stay</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Health Network, Toronto</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>12 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>64</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>October 30, 2020</primary_completion_date>
    <completion_date>January 31, 2021</completion_date>
    <study_first_posted>April 2, 2020</study_first_posted>
    <last_update_posted>April 13, 2020</last_update_posted>
    <locations>
      <location>Princess Margaret Cancer Centre, Toronto, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04331665</url>
  </study>
  <study rank="328">
    <nct_id>NCT04344730</nct_id>
    <title>Dexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 Pneumonia</title>
    <acronym>COVIDICUS</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Acute Hypoxemic Respiratory Failure</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Dexamethasone injection</intervention>
      <intervention type="Drug">placebo</intervention>
      <intervention type="Procedure">conventional oxygen</intervention>
      <intervention type="Procedure">CPAP</intervention>
      <intervention type="Procedure">HFNO</intervention>
      <intervention type="Procedure">mechanical ventilation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The time-to-death from all causes</outcome_measure>
      <outcome_measure>The time to need for mechanical ventilation (MV)</outcome_measure>
      <outcome_measure>The viral load in the respiratory tract</outcome_measure>
      <outcome_measure>Number of patient with at least one episode of healthcare-associated infections</outcome_measure>
      <outcome_measure>Number of days alive without mechanical ventilation</outcome_measure>
      <outcome_measure>Measure of SOFA score</outcome_measure>
      <outcome_measure>Number of days alive without renal replacement therapy</outcome_measure>
      <outcome_measure>Lengths of ICU-stay</outcome_measure>
      <outcome_measure>Lengths of hospital-stay</outcome_measure>
      <outcome_measure>Number of patients with severe hypoxemia,</outcome_measure>
      <outcome_measure>Number of patients with cardiac arrest within 1 hour after intubation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>550</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 10, 2020</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>Hopital Bichat - Aphp, Paris, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04344730</url>
  </study>
  <study rank="329">
    <nct_id>NCT04352491</nct_id>
    <title>An Online Survey to Understand Feelings Related to COVID-19 Among ILBS Patients With Liver Disease</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID 19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">No intervention</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Assessment of the fear levels during the COVID-19 disease pandemic among patients with Liver disease (currently under treatment from ILBS)</outcome_measure>
      <outcome_measure>Assessment of the anxiety levels during the COVID-19 disease pandemic among patients with Liver disease (currently under treatment from ILBS)</outcome_measure>
      <outcome_measure>Assessment of the stress levels during the COVID-19 disease pandemic among patients with Liver disease (currently under treatment from ILBS)</outcome_measure>
      <outcome_measure>Association between presence of Liver disease and fear levels</outcome_measure>
      <outcome_measure>Association between presence of Liver disease and anxiety levels</outcome_measure>
      <outcome_measure>Association between presence of Liver disease and stress levels</outcome_measure>
      <outcome_measure>Correlation between Fear and Child-Turcotte-Pugh Score</outcome_measure>
      <outcome_measure>Correlation between anxiety and Child-Turcotte-Pugh Score</outcome_measure>
      <outcome_measure>Correlation between stress and Child-Turcotte-Pugh Score</outcome_measure>
      <outcome_measure>Correlation between fear and Model for End Stage Liver Disease Score</outcome_measure>
      <outcome_measure>Correlation between anxiety and Model for End Stage Liver Disease Score</outcome_measure>
      <outcome_measure>Correlation between stress and Model for End Stage Liver Disease Score</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Institute of Liver and Biliary Sciences, India</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <start_date>April 22, 2020</start_date>
    <primary_completion_date>April 30, 2020</primary_completion_date>
    <completion_date>April 30, 2020</completion_date>
    <study_first_posted>April 20, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Institute of Liver and Biliary Sciences, New Delhi, Delhi, India</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04352491</url>
  </study>
  <study rank="330">
    <nct_id>NCT04318444</nct_id>
    <title>Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Corona Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Drug">Placebo oral tablet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of participants with symptomatic, lab-confirmed COVID-19.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Columbia University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1600</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>March 29, 2020</start_date>
    <primary_completion_date>March 2021</primary_completion_date>
    <completion_date>March 2022</completion_date>
    <study_first_posted>March 24, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>Columbia University Irving Medical Center, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04318444</url>
  </study>
  <study rank="331">
    <nct_id>NCT04349631</nct_id>
    <title>A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19</title>
    <acronym/>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">HB-adMSCs</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Incidence of hospitalization for COVID-19</outcome_measure>
      <outcome_measure>Incidence of symptoms for COVID-19</outcome_measure>
      <outcome_measure>absence of upper/lower respiratory infection</outcome_measure>
      <outcome_measure>Glucose</outcome_measure>
      <outcome_measure>Calcium</outcome_measure>
      <outcome_measure>Albumin</outcome_measure>
      <outcome_measure>Total Protein</outcome_measure>
      <outcome_measure>Sodium</outcome_measure>
      <outcome_measure>Total carbon dioxide</outcome_measure>
      <outcome_measure>Potassium</outcome_measure>
      <outcome_measure>Chloride</outcome_measure>
      <outcome_measure>BUN</outcome_measure>
      <outcome_measure>Creatinine</outcome_measure>
      <outcome_measure>Alkaline phosphatase</outcome_measure>
      <outcome_measure>Alanine aminotransferase</outcome_measure>
      <outcome_measure>Aspartate aminotransferase</outcome_measure>
      <outcome_measure>Total bilirubin</outcome_measure>
      <outcome_measure>White blood cells</outcome_measure>
      <outcome_measure>Red blood cells</outcome_measure>
      <outcome_measure>Hemoglobin</outcome_measure>
      <outcome_measure>Hematocrit</outcome_measure>
      <outcome_measure>Mean corpuscular volume</outcome_measure>
      <outcome_measure>Mean corpuscular hemoglobin</outcome_measure>
      <outcome_measure>Mean corpuscular hemoglobin concentration</outcome_measure>
      <outcome_measure>Red cell distribution width</outcome_measure>
      <outcome_measure>Neutrophils</outcome_measure>
      <outcome_measure>Lymphs</outcome_measure>
      <outcome_measure>Monocytes</outcome_measure>
      <outcome_measure>Eos</outcome_measure>
      <outcome_measure>Basophils</outcome_measure>
      <outcome_measure>Absolute neutrophils</outcome_measure>
      <outcome_measure>Absolute lymphs</outcome_measure>
      <outcome_measure>Absolute monocytes</outcome_measure>
      <outcome_measure>Absolute eosinophils</outcome_measure>
      <outcome_measure>Absolute basophils</outcome_measure>
      <outcome_measure>Immature granulocytes</outcome_measure>
      <outcome_measure>Absolute Immature granulocytes</outcome_measure>
      <outcome_measure>Platelets</outcome_measure>
      <outcome_measure>Prothrombin time</outcome_measure>
      <outcome_measure>INR</outcome_measure>
      <outcome_measure>TNFalpha</outcome_measure>
      <outcome_measure>Interleukin-6</outcome_measure>
      <outcome_measure>Interleukin-10</outcome_measure>
      <outcome_measure>C-reactive protein</outcome_measure>
      <outcome_measure>SF-36</outcome_measure>
      <outcome_measure>PHQ-9</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hope Biosciences</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>56</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 16, 2020</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>April 16, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations>
      <location>Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04349631</url>
  </study>
  <study rank="332">
    <nct_id>NCT04357574</nct_id>
    <title>Assessing the System for High-Intensity Evaluation During Radiotherapy During Changes in Response to COVID-19</title>
    <acronym>CORONA-SHIELD</acronym>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Telehealth</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Radiation Oncology providers perception of of telehealth for on treatment patients in lieu of in person on treatment visits during COVID-19</outcome_measure>
      <outcome_measure>Number of missed telehealth clinical evaluation visits during COVID-19</outcome_measure>
      <outcome_measure>Number of unplanned emergency department visits or hospital admissions during COVID-19</outcome_measure>
      <outcome_measure>Number of acute care visits with listed reason as anemia, nutrition (including dehydration), diarrhea, emesis, infectious (including fever, pneumonia, and sepsis), nausea, neutropenia, pain category during COVID-19</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Duke University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 14, 2020</start_date>
    <primary_completion_date>April 2021</primary_completion_date>
    <completion_date>April 2021</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Duke Cancer Center, Durham, North Carolina, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04357574</url>
  </study>
  <study rank="333">
    <nct_id>NCT04352751</nct_id>
    <title>Experimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">convalescent plasma</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in COVID-19 severity status</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hilton Pharma</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>2000</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>April 2021</primary_completion_date>
    <completion_date>April 2021</completion_date>
    <study_first_posted>April 20, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations>
      <location>Hilton Pharma Pvt. Ltd., Karachi, Sindh, Pakistan</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04352751</url>
  </study>
  <study rank="334">
    <nct_id>NCT04366154</nct_id>
    <title>Impact of the COVID-19 Infectious Epidemic on the Management of Oncology and Onco-hematology Patients and on the Psychological Consequences for Patients and Caregivers</title>
    <acronym>COVIPACT</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Questionnaire</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>To assess the impact of the COVID-19 pandemic on the adaptations of medical oncology treatments administered in hospital (day units) to patients with cancer or malignant hemopathy</outcome_measure>
      <outcome_measure>Evaluate the psychological impact of the pandemic on cancer patients treated in unit day of hospital</outcome_measure>
      <outcome_measure>Evaluate the psychological impact of the pandemic on caregivers (perceived stress, post-traumatic stress, burnout, feeling of personal effectiveness)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Francois Baclesse</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>385</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Centre François Baclesse, Caen, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04366154</url>
  </study>
  <study rank="335">
    <nct_id>NCT04318015</nct_id>
    <title>Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial)</title>
    <acronym>PHYDRA</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Severe Acute Respiratory Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Drug">Placebo oral tablet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Symptomatic COVID-19 infection rate</outcome_measure>
      <outcome_measure>Symptomatic non-COVID viral infection rate</outcome_measure>
      <outcome_measure>Days of labor absenteeism</outcome_measure>
      <outcome_measure>Rate of labor absenteeism</outcome_measure>
      <outcome_measure>Rate of severe respiratory COVID-19 disease in healthcare personnel</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute of Respiratory Diseases, Mexico</lead_sponsor>
      <collaborator>Sanofi</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 14, 2020</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>March 31, 2021</completion_date>
    <study_first_posted>March 23, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations>
      <location>Instituto Nacional de Enfermedades Respiratorias, &quot;Ismael Cosío Villegas&quot;, Mexico, City, Mexico</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04318015</url>
  </study>
  <study rank="336">
    <nct_id>NCT04341038</nct_id>
    <title>Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury</title>
    <acronym>TACROVID</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Lung Injury</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tacrolimus</intervention>
      <intervention type="Drug">Methylprednisolone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to reach clinical stability</outcome_measure>
      <outcome_measure>Time to reach an afebrile state for 48 hours.</outcome_measure>
      <outcome_measure>Time to reach PaO2 / FiO2&gt; 400 and / or SatO2 / FiO2&gt; 300</outcome_measure>
      <outcome_measure>Time to reach FR ≤ 24 rpm for 48 hours</outcome_measure>
      <outcome_measure>Time to normalization of D-dimer (&lt;250 ug / L)</outcome_measure>
      <outcome_measure>Time until PCR normalization (&lt;5mg / L).</outcome_measure>
      <outcome_measure>Time until normalization of ferritin (&lt;400ug / L)</outcome_measure>
      <outcome_measure>Study the impact of immunosuppressive treatment on viral load using quantitative PCR</outcome_measure>
      <outcome_measure>Time until hospital discharge</outcome_measure>
      <outcome_measure>Need for ventilatory support devices</outcome_measure>
      <outcome_measure>Duration that it is necessary to maintain ventilatory support.</outcome_measure>
      <outcome_measure>COVID-19 mortality</outcome_measure>
      <outcome_measure>all-cause mortality</outcome_measure>
      <outcome_measure>Analyze the expanded cytokine profile before the start of treatment and their evolution every 7 days after admission</outcome_measure>
      <outcome_measure>Describe the side effects and their severity attributed to tacrolimus and / or methylprednisolone.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hospital Universitari de Bellvitge</lead_sponsor>
      <collaborator>Institut d'Investigació Biomèdica de Bellvitge</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>84</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>June 1, 2020</primary_completion_date>
    <completion_date>July 1, 2020</completion_date>
    <study_first_posted>April 10, 2020</study_first_posted>
    <last_update_posted>April 10, 2020</last_update_posted>
    <locations>
      <location>Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04341038</url>
  </study>
  <study rank="337">
    <nct_id>NCT04363008</nct_id>
    <title>COVID 19 Biomarkers</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID 19</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">serum inflammatory biomarkers</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Interleukin 1b, 6, 10 and tumor necrosis factor alpha</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of British Columbia</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 30, 2020</start_date>
    <primary_completion_date>April 16, 2020</primary_completion_date>
    <completion_date>September 30, 2021</completion_date>
    <study_first_posted>April 27, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>Vancouver General Hospital, Vancouver, British Columbia, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04363008</url>
  </study>
  <study rank="338">
    <nct_id>NCT04361565</nct_id>
    <title>Frequency and Clinical Evolution of Olfactory and Taste Disorders in COVID-19 Patients</title>
    <acronym/>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19 by SARS-CoV-2 Infection</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Anosmia</outcome_measure>
      <outcome_measure>Ageusia</outcome_measure>
      <outcome_measure>Duration of the loss of anosmia ageusia</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier Universitaire de Nice</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>March 20, 2020</start_date>
    <primary_completion_date>April 10, 2020</primary_completion_date>
    <completion_date>May 31, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>CHU de Nice, Nice, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04361565</url>
  </study>
  <study rank="339">
    <nct_id>NCT04328272</nct_id>
    <title>Effectiveness of Hydroxychloroquine in Covid-19 Patients</title>
    <acronym>Covid</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine 200 Mg Oral Tablet</intervention>
      <intervention type="Drug">Azithromycin 500Mg Oral Tablet</intervention>
      <intervention type="Dietary Supplement">Glucose tablets</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>National Early Warning Score equal to zero</outcome_measure>
      <outcome_measure>C-reactive proteins</outcome_measure>
      <outcome_measure>Lymphocyte Count</outcome_measure>
      <outcome_measure>d-dimers</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Prof. Dr. Umar Farooq</lead_sponsor>
      <collaborator>Ayub Medical College, Abbottabad</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>75</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 28, 2020</start_date>
    <primary_completion_date>May 28, 2020</primary_completion_date>
    <completion_date>June 28, 2020</completion_date>
    <study_first_posted>March 31, 2020</study_first_posted>
    <last_update_posted>April 2, 2020</last_update_posted>
    <locations>
      <location>Ayub Teaching Institution, Abbottābād, K.p.k, Pakistan</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04328272</url>
  </study>
  <study rank="340">
    <nct_id>NCT04356677</nct_id>
    <title>Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">50 mg/mL Virazole</intervention>
      <intervention type="Drug">100 mg/mL Virazole</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in the clinical status severity (CSS) rating from the first dose date up to the completion of treatment</outcome_measure>
      <outcome_measure>Time to recover gas exchange to a PaO2/FiO2 ≥300 for at least 24 hours.</outcome_measure>
      <outcome_measure>Time to reach peripheral capillary oxygen saturation (Sp02) &gt;94% for at least 24 hours.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Bausch Health Americas, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>April 2021</primary_completion_date>
    <completion_date>April 2021</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04356677</url>
  </study>
  <study rank="341">
    <nct_id>NCT04350320</nct_id>
    <title>Randomized Open-blind Controlled Trial to Study the Benefit of Colchicine in Patients With COVID-19</title>
    <acronym>COL-COVID</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Colchicine Tablets</intervention>
      <intervention type="Drug">Standard therapy for COVID-19 according to the stablished hospital protocols.</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Changes in the patients' clinical status through the 7 points ordinal scale WHO</outcome_measure>
      <outcome_measure>Changes in IL-6 concentrations</outcome_measure>
      <outcome_measure>Improvement in the clinical status</outcome_measure>
      <outcome_measure>Changes in the score for the Sequential Organ Failure Assessment</outcome_measure>
      <outcome_measure>Changes in the punctuation in the National Early Warning Score</outcome_measure>
      <outcome_measure>Number of days with invasive mechanical ventilation</outcome_measure>
      <outcome_measure>Number of days with high flow oxygen therapy</outcome_measure>
      <outcome_measure>Changes in other inflammatory markers</outcome_measure>
      <outcome_measure>Changes in severity markers</outcome_measure>
      <outcome_measure>Changes in myocardial damage</outcome_measure>
      <outcome_measure>Time until reaching a virus negative status</outcome_measure>
      <outcome_measure>Length of hospital stay</outcome_measure>
      <outcome_measure>Number of days in the intensive care unit.</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>102</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>October 20, 2020</primary_completion_date>
    <completion_date>November 20, 2020</completion_date>
    <study_first_posted>April 17, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04350320</url>
  </study>
  <study rank="342">
    <nct_id>NCT04366024</nct_id>
    <title>A Novel Nomogram to Predict Severity of COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19 Disease</condition>
      <condition>Nomogram Model</condition>
    </conditions>
    <interventions>
      <intervention type="Other">other</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>the consistency of predicted severe rate and observed severe rate of COVID-19 patients</outcome_measure>
      <outcome_measure>Duration of severe illness</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Xinqiao Hospital of Chongqing</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>January 17, 2020</start_date>
    <primary_completion_date>May 30, 2020</primary_completion_date>
    <completion_date>December 31, 2021</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Xinqiao Hospital of Chongqing, Chongqing, Chongqing, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04366024</url>
  </study>
  <study rank="343">
    <nct_id>NCT04352764</nct_id>
    <title>ANTIBODY BASED TESTS FOR SARSCoV-2 COVID-19) - Evaluation of Patients and Healthcare Providers in the Confines of Healthcare Settings</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid19</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">CoronaCideTM COVID-19 IgM/IgG Rapid Test and Premier Biotech COVID-19 IgM/IgG Rapid Test</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>prevalence of COVID-19 exposure</outcome_measure>
      <outcome_measure>correlation between the test results with the presence or lack of COVID-19 symptoms or illness</outcome_measure>
      <outcome_measure>correlate pre-existing risk factors with test results and baseline symptoms</outcome_measure>
      <outcome_measure>correlate subsequent healthcare utilization with test results and baseline symptoms</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Texas Cardiac Arrhythmia Research Foundation</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>5000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 27, 2020</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>January 31, 2021</completion_date>
    <study_first_posted>April 20, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>St. David's Medical Center, Austin, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04352764</url>
  </study>
  <study rank="344">
    <nct_id>NCT04327531</nct_id>
    <title>Evaluation of Covid 19 Knowledge Anxiety and Expectation Levels of Turkish Physicians, Survey Study</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Physician-Patient Relations</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">turkish physicians</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Evaluation of covid-19 knowledge level of turkish physicians</outcome_measure>
      <outcome_measure>what they think about the future</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Kanuni Sultan Suleyman Training and Research Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>25 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Ecologic or Community</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 26, 2020</start_date>
    <primary_completion_date>April 26, 2020</primary_completion_date>
    <completion_date>April 28, 2020</completion_date>
    <study_first_posted>March 31, 2020</study_first_posted>
    <last_update_posted>April 2, 2020</last_update_posted>
    <locations>
      <location>Pinar Yalcin Bahat, Istanbul, İ̇stanbul, Turkey</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04327531</url>
  </study>
  <study rank="345">
    <nct_id>NCT04348474</nct_id>
    <title>Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19</title>
    <acronym/>
    <status open="N">Suspended</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine Sulfate</intervention>
      <intervention type="Drug">Azithromycin Tablets</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in Clinical Condition</outcome_measure>
      <outcome_measure>Hospitalization</outcome_measure>
      <outcome_measure>Rate of mortality within 28-days</outcome_measure>
      <outcome_measure>Change in Clinical Condition related to comorbidity</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Azidus Brasil</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Early Phase 1</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>June 30, 2020</primary_completion_date>
    <completion_date>July 31, 2020</completion_date>
    <study_first_posted>April 16, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04348474</url>
  </study>
  <study rank="346">
    <nct_id>NCT04338568</nct_id>
    <title>Screening COVID-19 by Point-of-care Lung Ultrasound: a Validation Study</title>
    <acronym>SCOUT</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19 Pneumonia</condition>
      <condition>Lung Ultrasound</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Lung ultrasound</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Accuracy of the diagnosis of interstitial syndrome by lung ultrasound</outcome_measure>
      <outcome_measure>Inter-observer variability</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hasselt University</lead_sponsor>
      <collaborator>Ziekenhuis Oost-Limburg</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <start_date>April 13, 2020</start_date>
    <primary_completion_date>April 30, 2020</primary_completion_date>
    <completion_date>April 30, 2020</completion_date>
    <study_first_posted>April 8, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>Ziekenhuis Oost Limburg, Genk, Limburg, Belgium</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04338568</url>
  </study>
  <study rank="347">
    <nct_id>NCT03891420</nct_id>
    <title>A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Yellow Fever</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Galidesivir</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>number of subjects with treatment emergent adverse events and serious adverse events</outcome_measure>
      <outcome_measure>number of subjects with change in laboratory parameters</outcome_measure>
      <outcome_measure>exposure of galidesivir as measured by plasma concentrations</outcome_measure>
      <outcome_measure>yellow fever virus (YFV) titer (Group A)</outcome_measure>
      <outcome_measure>antiviral effect on SARS-CoV-2 in the respiratory tract - COVID-19 (Group B)</outcome_measure>
      <outcome_measure>changes in clinical status using 8-point ordinal scale in COVID-19 (Group B)</outcome_measure>
      <outcome_measure>changes from baseline and time to improvement using NEWS in COVID-19 (Group B)</outcome_measure>
      <outcome_measure>mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>BioCryst Pharmaceuticals</lead_sponsor>
      <collaborator>National Institute of Allergy and Infectious Diseases (NIAID)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>66</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 9, 2020</start_date>
    <primary_completion_date>May 31, 2021</primary_completion_date>
    <completion_date>May 31, 2021</completion_date>
    <study_first_posted>March 27, 2019</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>Clinical Research Unit and Department of Infectious and Parasitic Diseases Hospital das Clínicas, School of Medicine, USP, São Paulo, SP, Brazil</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03891420</url>
  </study>
  <study rank="348">
    <nct_id>NCT04349202</nct_id>
    <title>Beaumont Health Large-scale Automated Serologic Testing for COVID-19</title>
    <acronym>BLAST COVID-19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Coronavirus Infection</condition>
      <condition>Severe Acute Respiratory Syndrome Coronavirus 2</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">EUROIMMUN assay</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Prevalence COVID antibodies in employees of Beaumont Health</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>William Beaumont Hospitals</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>50000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 10, 2020</start_date>
    <primary_completion_date>June 2021</primary_completion_date>
    <completion_date>June 2021</completion_date>
    <study_first_posted>April 16, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Beaumont Health System, Royal Oak, Michigan, United States</location>
      <location>Beaumont Health, Royal Oak, Michigan, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04349202</url>
  </study>
  <study rank="349">
    <nct_id>NCT04336774</nct_id>
    <title>CAPTION AI to Minimize Risk of COVID Exposure</title>
    <acronym>CAPTION AI</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Caption AI</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Percent of patient echos that are not interpretable</outcome_measure>
      <outcome_measure>Percent of patient echos that provide an automated (AI) LVEF (left ventricular ejection fraction)</outcome_measure>
      <outcome_measure>Time to acquire images as measured by time stamps</outcome_measure>
      <outcome_measure>Percent of agreement between AI calculate LVEF and LVEF read by physician</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Duke University</lead_sponsor>
      <collaborator>Caption Health, Inc.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>November 1, 2020</primary_completion_date>
    <completion_date>November 9, 2020</completion_date>
    <study_first_posted>April 7, 2020</study_first_posted>
    <last_update_posted>April 7, 2020</last_update_posted>
    <locations>
      <location>Duke University Medical Center, Durham, North Carolina, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04336774</url>
  </study>
  <study rank="350">
    <nct_id>NCT04350580</nct_id>
    <title>Polyvalent Immunoglobulin in COVID-19 Related ARds</title>
    <acronym>ICAR</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Acute Respiratory Distress Syndrome</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Human immunoglobulin</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Ventilator-free days</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>Sequential Organ Failure Assessment Score</outcome_measure>
      <outcome_measure>P/F ratio</outcome_measure>
      <outcome_measure>Lung compliance</outcome_measure>
      <outcome_measure>Radiological score</outcome_measure>
      <outcome_measure>Biological efficacy endpoints - C-reactive protein</outcome_measure>
      <outcome_measure>Biological efficacy endpoints - Procalcitonin</outcome_measure>
      <outcome_measure>Immunological profile</outcome_measure>
      <outcome_measure>Number of patients using other treatments for COVID-19 related ARDS</outcome_measure>
      <outcome_measure>Occurrence of deep vein thrombosis or pulmonary embolism</outcome_measure>
      <outcome_measure>Total duration of mechanical ventilation, ventilatory weaning and curarisation</outcome_measure>
      <outcome_measure>Kidney Disease: Improving Global Outcomes (KDIGO) score and need for dialysis</outcome_measure>
      <outcome_measure>Occurrence of adverse event related to immunoglobulins</outcome_measure>
      <outcome_measure>Occurrence of critical illness neuromyopathy</outcome_measure>
      <outcome_measure>Occurrence of ventilator-acquired pneumonia</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier St Anne</lead_sponsor>
      <collaborator>Groupe Hospitalier Universitaire Paris psychiatrie &amp; neurosciences</collaborator>
      <collaborator>Laboratoire français de Fractionnement et de Biotechnologies</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>138</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Care Provider)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 11, 2020</start_date>
    <primary_completion_date>June 2020</primary_completion_date>
    <completion_date>August 2020</completion_date>
    <study_first_posted>April 17, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Centre Hospitalier Sainte-Anne, Paris, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04350580</url>
  </study>
  <study rank="351">
    <nct_id>NCT04323345</nct_id>
    <title>Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Natural Honey</intervention>
      <intervention type="Other">Standard Care</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Rate of recovery from positive to negative swaps</outcome_measure>
      <outcome_measure>Fever to normal temperature in days</outcome_measure>
      <outcome_measure>Resolution of lung inflammation in CT or X ray</outcome_measure>
      <outcome_measure>30 days mortality rate</outcome_measure>
      <outcome_measure>Number of days till reaching negative swab results</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Misr University for Science and Technology</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>5 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>December 15, 2020</primary_completion_date>
    <completion_date>January 15, 2021</completion_date>
    <study_first_posted>March 26, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>Mahmoud Tantawy, Cairo, Egypt</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04323345</url>
  </study>
  <study rank="352">
    <nct_id>NCT04348877</nct_id>
    <title>Plasma Rich Antibodies From Recovered Patients From COVID19</title>
    <acronym>PRA-001</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Disease (COVID-19)</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Antibody-Rich Plasma from COVID-19 recovered patients</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>viral COVID-19 clearance</outcome_measure>
      <outcome_measure>Decrease of radiological abnormalities</outcome_measure>
      <outcome_measure>Clinical improvement</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ain Shams University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>October 2020</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>April 16, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations>
      <location>Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04348877</url>
  </study>
  <study rank="353">
    <nct_id>NCT04355897</nct_id>
    <title>CoVID-19 Plasma in Treatment of COVID-19 Patients</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID 19</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Convalescent COVID 19 Plasma</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Reduce mortality</outcome_measure>
      <outcome_measure>Reduce requirement for mechanical ventilation.</outcome_measure>
      <outcome_measure>Reduce the duration of mechanical ventilation.</outcome_measure>
      <outcome_measure>Review of treatment related adverse events.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>The Christ Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Early Phase 1</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>August 2020</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>The Christ Hospital, Cincinnati, Ohio, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04355897</url>
  </study>
  <study rank="354">
    <nct_id>NCT04344756</nct_id>
    <title>Trial Evaluating Efficacy and Safety of Anticoagulation in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort</title>
    <acronym>CORIMMUNO-COAG</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID19 Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tinzaparin or unfractionated heparin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Survival without ventilation (VNI or mechanical ventilation)</outcome_measure>
      <outcome_measure>ventilator free survival</outcome_measure>
      <outcome_measure>World Health Organisation(WHO) progression scale ≤5</outcome_measure>
      <outcome_measure>World Health Organisation(WHO) progression scale</outcome_measure>
      <outcome_measure>overall survival</outcome_measure>
      <outcome_measure>Length of hospital stay</outcome_measure>
      <outcome_measure>Length of ICU stay</outcome_measure>
      <outcome_measure>time to oxygenation supply independency</outcome_measure>
      <outcome_measure>time to ventilator (non invasive or invasive)</outcome_measure>
      <outcome_measure>rate of acute kidney injury</outcome_measure>
      <outcome_measure>time to Renal Replacement Therapy (RRT) initiation</outcome_measure>
      <outcome_measure>rate of clinically overt pulmonary embolism or proximal deep vein thrombosis</outcome_measure>
      <outcome_measure>Rate of clinically overt arterial thrombosis</outcome_measure>
      <outcome_measure>Rate of unscheduled central venous catheter replacement for catheter dysfunction</outcome_measure>
      <outcome_measure>Rate of central venous catheter-related deep vein thrombosis (CVC-DVT)</outcome_measure>
      <outcome_measure>Rate of unscheduled indwelling arterial catheter replacement for catheter dysfunction</outcome_measure>
      <outcome_measure>Rate of acute clotting leading to the replacement the renal replacement therapy circuit stratified by regional citrate anticoagulation or not</outcome_measure>
      <outcome_measure>Time to acute clot formation within the oxygenator (acute oxygenator thrombosis, AOT) leading to the exchange of an extracorporeal membrane oxygenation (ECMO) system</outcome_measure>
      <outcome_measure>Time to acute clot formation within the pump head (pump head thrombosis, PHT) leading to the exchange of an extracorporeal membrane oxygenation (ECMO) system</outcome_measure>
      <outcome_measure>Incidence of adverse events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>808</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>July 31, 2020</primary_completion_date>
    <completion_date>September 30, 2020</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>Réanimation hôpital Louis Mourier, Colombes, Hauts De Seine, France</location>
      <location>réanimation hôpital Cochin, Paris, France</location>
      <location>Médecine vasculaire, Hôpital Européen Georges Pompidou, Paris, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04344756</url>
  </study>
  <study rank="355">
    <nct_id>NCT04366232</nct_id>
    <title>Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation (JAKINCOV)</title>
    <acronym>JAKINKOV</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Anakinra alone (stages 2b/3)</intervention>
      <intervention type="Drug">Anakinra and Ruxolitinib (overcome stage 3)</intervention>
      <intervention type="Other">Standard of care</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Biological criteria</outcome_measure>
      <outcome_measure>Time to become afebrile</outcome_measure>
      <outcome_measure>Duration of oxygen therapy (days)</outcome_measure>
      <outcome_measure>Number of days without mechanical ventilation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer</lead_sponsor>
      <collaborator>Hôpital d'instruction des armées Sainte-Anne</collaborator>
      <collaborator>Assistance Publique Hopitaux De Marseille</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 1, 2020</start_date>
    <primary_completion_date>August 31, 2020</primary_completion_date>
    <completion_date>August 31, 2020</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>AP-HM, Hôpital de la Conception, Marseille, Bouches-du-Rhône, France</location>
      <location>Hôpital Sainte-Musse, Toulon, VAR, France</location>
      <location>Sainte Anne Teaching Military Hospital, Toulon, Var, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04366232</url>
  </study>
  <study rank="356">
    <nct_id>NCT04344782</nct_id>
    <title>Trial Evaluating Efficacy and Safety of Bevacizumab (Avastin®/Zeribev®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort</title>
    <acronym>CORIMMUNO-BEVA</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID19 Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Bevacizumab Injection</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Proportion of surviving patients without need for intubation for respiratory support</outcome_measure>
      <outcome_measure>Saturation of Oxygen in the blood (SaO2)</outcome_measure>
      <outcome_measure>Arterial oxygen partial pressure (paO2)</outcome_measure>
      <outcome_measure>Ratio of arterial oxygen partial pressure to fractional inspired oxygen (paO2/FiO2)</outcome_measure>
      <outcome_measure>CT-scan score</outcome_measure>
      <outcome_measure>dyspnea</outcome_measure>
      <outcome_measure>overall survival</outcome_measure>
      <outcome_measure>admissionn to the intensive care unit (ICU)</outcome_measure>
      <outcome_measure>incidence of mechanical ventilation</outcome_measure>
      <outcome_measure>hospital length of stay</outcome_measure>
      <outcome_measure>incidence of adverse event</outcome_measure>
      <outcome_measure>VEGF plasma concentration</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>130</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>September 30, 2020</primary_completion_date>
    <completion_date>November 30, 2020</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04344782</url>
  </study>
  <study rank="357">
    <nct_id>NCT04364893</nct_id>
    <title>Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Patients With COVID19</title>
    <acronym>BRACE-CORONA</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Corona Virus Infection</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Suspension or Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Median days alive and out of the hospital</outcome_measure>
      <outcome_measure>Number of participants with adverse cardiovascular outcomes and new worsening heart failure</outcome_measure>
      <outcome_measure>Cardiovascular biomarkers related to COVID-19</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>D'Or Institute for Research and Education</lead_sponsor>
      <collaborator>Brazilian Clinical Research Institute</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 6, 2020</start_date>
    <primary_completion_date>October 1, 2020</primary_completion_date>
    <completion_date>December 1, 2020</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Idor, São Paulo, Brazil</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04364893</url>
  </study>
  <study rank="358">
    <nct_id>NCT04357327</nct_id>
    <title>Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19)</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>SARS-CoV 2</condition>
      <condition>Corona Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">rapid salivary test</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Sensibility</outcome_measure>
      <outcome_measure>Specificity</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Università degli Studi dell'Insubria</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <start_date>April 16, 2020</start_date>
    <primary_completion_date>May 31, 2020</primary_completion_date>
    <completion_date>July 31, 2020</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>ASST dei Sette Laghi, Varese, VA, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04357327</url>
  </study>
  <study rank="359">
    <nct_id>NCT04335019</nct_id>
    <title>Interest of the Use of Pulmonary Ultrasound in the Referral of Patients With or Suspected COVID-19 +</title>
    <acronym>eChoVid</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>2019-nCoV (COVID-19)</condition>
      <condition>Interstitial Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Pulmonary ultrasound</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Association of pulmonary lesions on ultrasound on D0 classified according to three stages of severity</outcome_measure>
      <outcome_measure>Assessment of the agreement between a newly trained operator and an experienced operator of classification in one of the three stages of ultrasound gravity, by Cohen's kappa coefficient.</outcome_measure>
      <outcome_measure>Estimate in patients who had a CT-scan on D0, the agreement in the evaluation of the severity of lung lesions via ultrasound vs. CT-scan, by Cohen's kappa coefficient</outcome_measure>
      <outcome_measure>Measurement of the cumulative incidence of invasive mechanical ventilation and measurement of survival</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>April 2020</primary_completion_date>
    <completion_date>May 2020</completion_date>
    <study_first_posted>April 6, 2020</study_first_posted>
    <last_update_posted>April 6, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04335019</url>
  </study>
  <study rank="360">
    <nct_id>NCT04342663</nct_id>
    <title>A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection</title>
    <acronym>STOP COVID</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID 19</condition>
      <condition>Coronavirus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Fluvoxamine</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to clinical worsening</outcome_measure>
      <outcome_measure>clinical deterioration on a Likert-type scale (1-6)</outcome_measure>
      <outcome_measure>clinical deterioration measured by number of days</outcome_measure>
      <outcome_measure>Symptomatic severity on a likert scale (0-10 where 0= none and 10=very severe)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Washington University School of Medicine</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>152</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 10, 2020</start_date>
    <primary_completion_date>June 1, 2020</primary_completion_date>
    <completion_date>July 1, 2020</completion_date>
    <study_first_posted>April 13, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>BJC, Belleville, Illinois, United States</location>
      <location>Washington University School of Medicine, Saint Louis, Missouri, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04342663</url>
  </study>
  <study rank="361">
    <nct_id>NCT04363749</nct_id>
    <title>COVID-19 Infection: Exploration of Respiratory Control Center Abnormalities</title>
    <acronym>CRC-COVID</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid19</condition>
      <condition>Neurological Complication</condition>
    </conditions>
    <interventions>
      <intervention type="Other">hypoxia : 14.3 and 12.7% FIO2, hypercapnia 7% CO2, inspiratory mechanical constraint</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Intensity of the emotional response to hypoxic exposure (14.3 et 12.7% FIO2)</outcome_measure>
      <outcome_measure>Perception of a hypoxic stimulus induced dyspnea (14.3 et 12.7% FIO2)</outcome_measure>
      <outcome_measure>Perception of a hypercapnic stimulus induced dyspnea (7% CO2)</outcome_measure>
      <outcome_measure>Perception of a inspiratory mechanical constraint induced dyspnea</outcome_measure>
      <outcome_measure>brain MRI</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <start_date>April 27, 2020</start_date>
    <primary_completion_date>April 27, 2021</primary_completion_date>
    <completion_date>November 27, 2021</completion_date>
    <study_first_posted>April 27, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04363749</url>
  </study>
  <study rank="362">
    <nct_id>NCT04347278</nct_id>
    <title>Observational Study of Follow-up of Hospitalized Patients Diagnosed With COVID-19 to Evaluate the Effectiveness of the Drug Treatment Used to Treat This Disease. COVID-19 Registry</title>
    <acronym>RegCOVID19</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV-2</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Patients with the treatment agains COVID19</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Effectiveness of current drug treatments for hospitalized patients with SARS-CoV-2 infection (COVID-19 patients) in routine clinical practice</outcome_measure>
      <outcome_measure>Risk factors or modifiers of pharmacological effect such as demographic characteristics, comorbidity or underlying pathology, concomitant medication.</outcome_measure>
      <outcome_measure>Information on the patterns of use of these drugs (dose, duration of treatment,</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
      <outcome_measure>Time of hospital admission and/or stay in ICU and maximum severity reached.</outcome_measure>
      <outcome_measure>Treatments for SARS-CoV-2 positive patients not described in the protocol</outcome_measure>
      <outcome_measure>healthy survey for patients after their recovery/discharge from hospital.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Instituto de Investigación Marqués de Valdecilla</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>1 Year</min_age>
    <max_age>100 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Other</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>October 15, 2020</primary_completion_date>
    <completion_date>January 1, 2021</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04347278</url>
  </study>
  <study rank="363">
    <nct_id>NCT04354519</nct_id>
    <title>The United Kingdom Multiple Sclerosis Register Covid-19 Substudy</title>
    <acronym>UKMSRCV19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Multiple Sclerosis</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Incidence of COVID-19 Infections within an MS Cohort in the UK</outcome_measure>
      <outcome_measure>Hospitalisations in MS Patients with COVID-19</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>Patient Reported Expanded Disability Status Score</outcome_measure>
      <outcome_measure>Hospital Anxiety and Depression Scale</outcome_measure>
      <outcome_measure>Multiple Sclerosis Impact Scale 29 V2</outcome_measure>
      <outcome_measure>Multiple Sclerosis Walking Scale 12 V2</outcome_measure>
      <outcome_measure>Fatigue Severity Scale</outcome_measure>
      <outcome_measure>EuroQol 5D (3l)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Swansea University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>3000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 14, 2020</start_date>
    <primary_completion_date>July 14, 2021</primary_completion_date>
    <completion_date>July 14, 2022</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>Swansea Univeristy, Swansea, United Kingdom</location>
    </locations>
    <study_documents>
      <study_document>
        <label>Study Protocol</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/19/NCT04354519/Prot_000.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT04354519</url>
  </study>
  <study rank="364">
    <nct_id>NCT04351711</nct_id>
    <title>Immunological Profiling of Patients With COVID-19 in Respiratory Distress</title>
    <acronym>ACTICOV-2</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV-2</condition>
      <condition>Covid-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Immunological profiling</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Membrane expression of Human Leukocyte Antigen -DR isotype compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Membrane expression of cluster of differentiation 38 compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Membrane expression of Programmed cell death 1 protein compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Membrane expression of cluster of differentiation 45RA compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Membrane expression of cluster of differentiation 27 (naïve/central memory/effector memory) compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Membrane expression of CD57 on T CD4+ and T CD8+ cells compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Membrane expression of cluster of differentiation 27 on T CD4+ and T CD8+ cells compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Membrane expression of cluster of differentiation 28 on T CD4+ and T CD8+ cells compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Membrane expression of Human Leukocyte Antigen -DR isotype on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Membrane expression of cluster of differentiation 69 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Membrane expression of cluster of differentiation 56 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Membrane expression of cluster of differentiation 57 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Membrane expression of cluster of differentiation 14 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Membrane expression of cluster of differentiation 16 on Naturel Killer cells compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Number of regulatory T cells (CD4+CD25hiCD127loFoxP3+).</outcome_measure>
      <outcome_measure>Percentage of regulatory T cells (CD4+CD25hiCD127loFoxP3+).</outcome_measure>
      <outcome_measure>Rate of circulating Immunoglobulin A compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Rate of circulating Immunoglobulin G compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Rate of circulating Immunoglobulin M compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Rate of circulating Soluble cluster of differentiation 14 compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Rate of circulating Soluble cluster of differentiation 163 compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Rate of circulating Ultrasensitive C-Reactive Protein compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Rate of circulating Soluble tumor necrosis factor alpha receptor type I compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Rate of circulating E-selectin (cluster of differentiation 62E) compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Rate of circulating Granulocyte Macrophage Colony-Stimulating Factor compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Rate of circulating InterCellular Adhesion Molecule-1 compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Rate of circulating Interferon alpha compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Rate of circulating Interferon beta compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Rate of circulating Interferon gamma compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Rate of circulating Interleukin-1 alpha compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Rate of circulating Interleukin-1 beta compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Rate of circulating Interleukin-4 compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Rate of circulating Interleukin-6 compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Rate of circulating Interleukin-8 compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Rate of circulating Interleukin-10 compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Rate of circulating Interleukin-12p70 compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Rate of circulating Interleukin-13 compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Rate of circulating Interleukin-17A compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Rate of circulating Induced Protein 10 (C-X-C motif chemokine 10) compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Rate of circulating Monocyte Chemoattractant Protein-1 (C-C Motif Chemokine Ligand 2) compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Rate of circulating Macrophage inflammatory protein-1 alpha (C-C Motif Chemokine Ligand 3) compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Rate of circulating Macrophage inflammatory protein-1 beta (C-C Motif Chemokine Ligand 4) compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Rate of circulating P-selectin compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Rate of tumor necrosis factor alpha compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Rate of tissue plasminogen activator compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Rate of soluble form of endothelial protein C receptor compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Rate of D-Dimers compared to normal values (based on 150 healthy volunteers previously sampled)</outcome_measure>
      <outcome_measure>Compare the immune activation phenotype (defined in primary outcome) of patients affected by COVID-19 before any respiratory distress against that of 150 volunteers from the general population (data already existing).</outcome_measure>
      <outcome_measure>Compare the immune activation phenotype (defined in primary outcome) of patients affected by COVID-19 with respiratory failure against versus those without respiratory failure</outcome_measure>
      <outcome_measure>Mortality rate</outcome_measure>
      <outcome_measure>Comparison of E-selectin levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects</outcome_measure>
      <outcome_measure>Comparison of Granulocyte Macrophage Colony-Stimulating Factor levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects</outcome_measure>
      <outcome_measure>Comparison of InterCellular Adhesion Molecule levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects</outcome_measure>
      <outcome_measure>Comparison of Interferon alpha levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects</outcome_measure>
      <outcome_measure>Comparison of Interferon gamma levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects</outcome_measure>
      <outcome_measure>Comparison of Interleukin-1alpha levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects</outcome_measure>
      <outcome_measure>Comparison of Interleukin-1beta levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects</outcome_measure>
      <outcome_measure>Comparison of Interleukin-4 levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects</outcome_measure>
      <outcome_measure>Comparison of Interleukin-6 levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects</outcome_measure>
      <outcome_measure>Comparison of Interleukin-8 (C-X-C motif ligand 8) levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects</outcome_measure>
      <outcome_measure>Comparison of Interleukin-10 levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects</outcome_measure>
      <outcome_measure>Comparison of Interleukin-12p70 levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects</outcome_measure>
      <outcome_measure>Comparison of Interleukin-13 levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects</outcome_measure>
      <outcome_measure>Comparison of Interleukin-17A levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects</outcome_measure>
      <outcome_measure>Comparison of Induced Protein -10 (C-X-C motif chemokine 10) levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects</outcome_measure>
      <outcome_measure>Comparison of Monocyte Chemoattractant Protein-1 levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects</outcome_measure>
      <outcome_measure>Comparison of Macrophage Inflammatory Protein-1alpha levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects</outcome_measure>
      <outcome_measure>Comparison of Macrophage Inflammatory Protein -1beta levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects</outcome_measure>
      <outcome_measure>Comparison of P-Selectin levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects</outcome_measure>
      <outcome_measure>Comparison of Tumor necrosis factor alpha levels from plasma and the supernatant of PBMC activated or not by lipopolysaccharide and Staphylococcal enterotoxin B against norms previously established from 16 healthy subjects</outcome_measure>
      <outcome_measure>Identify inflammatory mediators over-produced by the PBMC of patients with COVID-19 before respiratory distress</outcome_measure>
      <outcome_measure>Compare the inflammatory mediators over-produced by the peripheral blood mononuclear cells of patients with COVID-19 with versus without respiratory failure</outcome_measure>
      <outcome_measure>Comparison of transcriptome from peripheral blood mononuclear cells from 12 patients with respiratory failure (from intensive care ward) and 10 without (normal hospitalization)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier Universitaire de Nīmes</lead_sponsor>
      <collaborator>Institute of Human Genetics, Montpellier</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>October 2020</primary_completion_date>
    <completion_date>October 2020</completion_date>
    <study_first_posted>April 17, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations>
      <location>CHU de Nimes, Nîmes, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04351711</url>
  </study>
  <study rank="365">
    <nct_id>NCT04355351</nct_id>
    <title>Study of Immune Response During SARS-CoV-2 Infection - (COVID-19)</title>
    <acronym>CovImmune</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>New Coronavirus Disease (COVID-19), Infection With SARS-CoV-2</condition>
    </conditions>
    <interventions>
      <intervention type="Other">blood sampling</intervention>
      <intervention type="Other">additional blood tubes</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Level of IFN-gamma after a non-specific stimulation of T lymphocytes</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier Universitaire de Nice</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <start_date>April 22, 2020</start_date>
    <primary_completion_date>October 22, 2020</primary_completion_date>
    <completion_date>October 22, 2020</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Antibes Hospital, Antibes, France</location>
      <location>Cannes Hospital, Cannes, France</location>
      <location>Nice Hospital, Nice, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04355351</url>
  </study>
  <study rank="366">
    <nct_id>NCT04343001</nct_id>
    <title>Coronavirus Response - Active Support for Hospitalised Covid-19 Patients</title>
    <acronym>CRASH-19</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Aspirin</intervention>
      <intervention type="Drug">Losartan</intervention>
      <intervention type="Drug">Simvastatin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Death</outcome_measure>
      <outcome_measure>Myocardial infarction</outcome_measure>
      <outcome_measure>Congestive cardiac failure</outcome_measure>
      <outcome_measure>Severe cardiac arrythmia</outcome_measure>
      <outcome_measure>Myocarditis</outcome_measure>
      <outcome_measure>Respiratory failure including ARDS</outcome_measure>
      <outcome_measure>Viral pneumonitis</outcome_measure>
      <outcome_measure>Acute renal failure</outcome_measure>
      <outcome_measure>Sepsis</outcome_measure>
      <outcome_measure>Stroke</outcome_measure>
      <outcome_measure>Gastrointestinal bleeding</outcome_measure>
      <outcome_measure>Receipt of non invasive or mechanical ventilation</outcome_measure>
      <outcome_measure>Ability to self care at hospital discharge</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>London School of Hygiene and Tropical Medicine</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>40 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>10000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>April 2021</primary_completion_date>
    <completion_date>August 2021</completion_date>
    <study_first_posted>April 13, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations>
      <location>University College Hospital, Ibadan, Oyo, Nigeria</location>
      <location>Shifa Tameer-e-Millat University, Rawalpindi, Pakistan</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04343001</url>
  </study>
  <study rank="367">
    <nct_id>NCT04348500</nct_id>
    <title>Clazakizumab (Anti-IL- 6 Monoclonal) Compared to Placebo for COVID19 Disease</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Clazakizumab</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Evaluate the safety and efficacy of clazakizumab for the treatment of patients with COVID-19 disease and signs of pulmonary involvement</outcome_measure>
      <outcome_measure>Patient survival at 28 days</outcome_measure>
      <outcome_measure>Patient survival at 60 days</outcome_measure>
      <outcome_measure>Number of patients requiring the dose of open-label clazakizumab</outcome_measure>
      <outcome_measure>Reduced duration of intensive care unit stay</outcome_measure>
      <outcome_measure>Reduced duration of hospital stay</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Cedars-Sinai Medical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>100 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 21, 2020</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>March 31, 2021</completion_date>
    <study_first_posted>April 16, 2020</study_first_posted>
    <last_update_posted>April 16, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04348500</url>
  </study>
  <study rank="368">
    <nct_id>NCT04363099</nct_id>
    <title>Multicentre Observational Study on Management COVID 19 Positive Outpatients in a French Cluster.</title>
    <acronym>COVID AMBU 60</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">observational</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>clinical description of covid 19 ambulatory cases.</outcome_measure>
      <outcome_measure>Biological and radiological description of ambulatory cases</outcome_measure>
      <outcome_measure>Prevalence of positive cases (PCR and/or serological positive)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Maison de Sante Pluridisciplinaire de Creil</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <max_age>99 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Other</study_design>
    </study_designs>
    <start_date>March 1, 2020</start_date>
    <primary_completion_date>June 30, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>April 27, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>Msp de Creil, Creil, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04363099</url>
  </study>
  <study rank="369">
    <nct_id>NCT04356534</nct_id>
    <title>Convalescent Plasma Trial in COVID -19 Patients</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV 2</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">plasma therapy using convalescent plasma with antibody against SARS-CoV-2</intervention>
      <intervention type="Other">Routine care for COVID-19 patients</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Requirement for invasive ventilation</outcome_measure>
      <outcome_measure>Time to viral clearance</outcome_measure>
      <outcome_measure>Radiological Improvement</outcome_measure>
      <outcome_measure>Reduction in white cell count</outcome_measure>
      <outcome_measure>C reactive protein measurement</outcome_measure>
      <outcome_measure>lactate dehydrogenase measurement</outcome_measure>
      <outcome_measure>Procalcitonin measurement</outcome_measure>
      <outcome_measure>D Dimer measurement</outcome_measure>
      <outcome_measure>Ferritin measurement</outcome_measure>
      <outcome_measure>Troponin T measurement</outcome_measure>
      <outcome_measure>Brain naturetic peptide measurement</outcome_measure>
      <outcome_measure>Mortality rate</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Royal College of Surgeons in Ireland - Medical University of Bahrain</lead_sponsor>
      <collaborator>Salmaniya Medical Complex</collaborator>
      <collaborator>Bahrain Defence Force Royal Medical Services, Military Hospital</collaborator>
      <collaborator>Mohammed Bin Khalifa Bin Sulman Al Khalifa Cardiac Centre, Awali</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 19, 2020</start_date>
    <primary_completion_date>May 3, 2020</primary_completion_date>
    <completion_date>June 30, 2020</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Royal College of Surgeons in Ireland - Bahrain, Manama, Bahrain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04356534</url>
  </study>
  <study rank="370">
    <nct_id>NCT04344288</nct_id>
    <title>Corticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 Infection</title>
    <acronym>CORTI-Covid</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Viral Pneumonia Human Coronavirus</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Prednisone</intervention>
      <intervention type="Other">Control group</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of patients with a theoretical respiratory indication for transfer to intensive care unit evaluated by a SpO2 &lt;90% stabilized at rest and under not more than 5 L / min of supplemental oxygen using medium concentration mask.</outcome_measure>
      <outcome_measure>disease severity assessed on a 7-level ordinal scale</outcome_measure>
      <outcome_measure>number of patients with a supplemental oxygen use</outcome_measure>
      <outcome_measure>radiological signs on chest imaging</outcome_measure>
      <outcome_measure>number of patients transferred to intensive care unit</outcome_measure>
      <outcome_measure>number of patients requiring invasive ventilation</outcome_measure>
      <outcome_measure>Duration of oxygen therapy</outcome_measure>
      <outcome_measure>number of adverse events induced by corticosteroid treatment</outcome_measure>
      <outcome_measure>number of patients with infections other than SARS-CoV-2</outcome_measure>
      <outcome_measure>number of deaths</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hospices Civils de Lyon</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>304</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>November 2020</primary_completion_date>
    <completion_date>November 2020</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations>
      <location>Hôpital Pneumologique et Cardiovasculaire Louis Pradel, Bron, France</location>
      <location>Groupement Hospitalier Nord, Lyon, France</location>
      <location>Groupement Hospitalier Nord, Lyon, France</location>
      <location>Hôpital Edouard Herriot, Lyon, France</location>
      <location>Hôpital St Joseph Saint Luc, Lyon, France</location>
      <location>Hôpital St Joseph, Marseille, France</location>
      <location>Centre hospitalier Lyon Sud, Pierre-Bénite, France</location>
      <location>Centre hospitalier Lyon Sud, Pierre-Bénite, France</location>
      <location>CHU St Etienne, Saint-Étienne, France</location>
      <location>Clinique Charcot, Sainte-Foy-lès-Lyon, France</location>
      <location>CHG Vienne, Vienne, France</location>
      <location>Médipôle, Villeurbanne, France</location>
      <location>Clinique des Portes du Sud, Vénissieux, France</location>
      <location>CH Annecy-Genevois, Épagny, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04344288</url>
  </study>
  <study rank="371">
    <nct_id>NCT04361786</nct_id>
    <title>Acral Cutaneous Thrombotic Vasculopathy and Covid-19 Infection</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID 19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Biological acquired thrombophilia</outcome_measure>
      <outcome_measure>Overexpression of interferon type I</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Montpellier</lead_sponsor>
      <collaborator>Lyon Civil Hospitals - Lyon Sud Hospital Center</collaborator>
      <collaborator>Marseille University Hospital - Assistance-Publique Hôpitaux de Marseille.</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>June 30, 2020</primary_completion_date>
    <completion_date>October 30, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Uh Montpellier, Montpellier, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04361786</url>
  </study>
  <study rank="372">
    <nct_id>NCT04348383</nct_id>
    <title>Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.</title>
    <acronym>DEFACOVID</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Defibrotide 25 mg/kg 24 hours continuous infusion for 15 days</intervention>
      <intervention type="Drug">Placebo 250 cc 24 hours continuous infusion for 15 days</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>1. Mortality rate</outcome_measure>
      <outcome_measure>Clinical improvement by WHO</outcome_measure>
      <outcome_measure>Clinical improvement by NEWS2 scales</outcome_measure>
      <outcome_measure>Biologic response</outcome_measure>
      <outcome_measure>Radiological response</outcome_measure>
      <outcome_measure>Collection and storage of biological samples</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 8, 2020</start_date>
    <primary_completion_date>July 8, 2020</primary_completion_date>
    <completion_date>August 8, 2020</completion_date>
    <study_first_posted>April 16, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations>
      <location>Virgen de la Arrixaca University Clinical Hospital, Murcia, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04348383</url>
  </study>
  <study rank="373">
    <nct_id>NCT04323644</nct_id>
    <title>Outcomes of Surgery in COVID-19 Infection: International Cohort Study (CovidSurg)</title>
    <acronym>CovidSurg</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Coronavirus</condition>
      <condition>Surgery</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Surgery</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>30-day mortality</outcome_measure>
      <outcome_measure>7-day mortality</outcome_measure>
      <outcome_measure>30-day reoperation</outcome_measure>
      <outcome_measure>Postoperative ICU admission</outcome_measure>
      <outcome_measure>Postoperative respiratory failure</outcome_measure>
      <outcome_measure>Postoperative acute respiratory distress syndrome (ARDS)</outcome_measure>
      <outcome_measure>Postoperative sepsis</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Birmingham</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Other</study_design>
    </study_designs>
    <start_date>March 31, 2020</start_date>
    <primary_completion_date>September 30, 2020</primary_completion_date>
    <completion_date>September 30, 2020</completion_date>
    <study_first_posted>March 26, 2020</study_first_posted>
    <last_update_posted>March 26, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04323644</url>
  </study>
  <study rank="374">
    <nct_id>NCT04334291</nct_id>
    <title>International COVID19 Clinical Evaluation Registry,</title>
    <acronym>HOPE COVID 19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID 19</condition>
    </conditions>
    <interventions>
      <intervention type="Combination Product">Observational (registry)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Death</outcome_measure>
      <outcome_measure>In hospital stay.</outcome_measure>
      <outcome_measure>Heart failure</outcome_measure>
      <outcome_measure>Renal failure</outcome_measure>
      <outcome_measure>Respiratory Insufficiency.</outcome_measure>
      <outcome_measure>Upper respiratory tract involvement</outcome_measure>
      <outcome_measure>Pneumonia</outcome_measure>
      <outcome_measure>Sepsis</outcome_measure>
      <outcome_measure>Systemic inflammatory response Syndrome.</outcome_measure>
      <outcome_measure>Clinically relevant bleeding</outcome_measure>
      <outcome_measure>Other complications.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>IVAN J NUÑEZ GIL</lead_sponsor>
      <collaborator>St Carlos Hospital, Madrid, Spain</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>6000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <start_date>March 23, 2020</start_date>
    <primary_completion_date>May 1, 2020</primary_completion_date>
    <completion_date>May 5, 2020</completion_date>
    <study_first_posted>April 6, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Hospital Lclinico San Carlos, Madrid, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04334291</url>
  </study>
  <study rank="375">
    <nct_id>NCT04341870</nct_id>
    <title>Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO</title>
    <acronym>CORIMUNO-VIRO</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID19</condition>
      <condition>SARS-CoV-2 Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sarilumab</intervention>
      <intervention type="Drug">Azithromycin</intervention>
      <intervention type="Drug">Hydroxychloroquine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Need for ventilation (including invasive and non invasive ventilation), intensive care or death</outcome_measure>
      <outcome_measure>Early improvement: OMS progression scale &lt;= 5</outcome_measure>
      <outcome_measure>OMS progression scale</outcome_measure>
      <outcome_measure>Survival</outcome_measure>
      <outcome_measure>ICU-free days alive</outcome_measure>
      <outcome_measure>Ventilation-free days alive</outcome_measure>
      <outcome_measure>Hospital-free days alive</outcome_measure>
      <outcome_measure>Oxygen therapy-free days alive</outcome_measure>
      <outcome_measure>Time to negative viral excretion</outcome_measure>
      <outcome_measure>Immunophenotyping and multiplex cytokines</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 11, 2020</start_date>
    <primary_completion_date>May 2020</primary_completion_date>
    <completion_date>July 2020</completion_date>
    <study_first_posted>April 10, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>AP-HP Hôpital Européen George Pompidou, Paris, France</location>
      <location>AP-HP Hôpital Lariboisière, Paris, France</location>
      <location>AP-HP Hôpital Pitié Salpétrière, Paris, France</location>
      <location>AP-HP Hôpital Saint Antoine, Paris, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04341870</url>
  </study>
  <study rank="376">
    <nct_id>NCT04352842</nct_id>
    <title>Echocardiographic Manifestation in Patient With Coronavirus Disease 2019 (COVID-19)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid19</condition>
      <condition>Echocardiography</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Echocardiography</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Major adverse cardiovascular events(MACEs)</outcome_measure>
      <outcome_measure>Death</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>RenJi Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>55</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>February 19, 2020</start_date>
    <primary_completion_date>April 4, 2020</primary_completion_date>
    <completion_date>April 6, 2020</completion_date>
    <study_first_posted>April 20, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>Ren Ji Hospital Affliated to School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04352842</url>
  </study>
  <study rank="377">
    <nct_id>NCT04352400</nct_id>
    <title>Efficacy of Nafamostat in Covid-19 Patients (RACONA Study)</title>
    <acronym>RACONA</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nafamostat Mesilate</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time-to-clinical improvement</outcome_measure>
      <outcome_measure>Responders</outcome_measure>
      <outcome_measure>Critical or dead patients</outcome_measure>
      <outcome_measure>pO2/FiO2 ratio</outcome_measure>
      <outcome_measure>SOFA score over time</outcome_measure>
      <outcome_measure>Hospitalization</outcome_measure>
      <outcome_measure>Mechanical ventilation</outcome_measure>
      <outcome_measure>Mechanical ventilation duration</outcome_measure>
      <outcome_measure>Cardiovascular disease</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital Padova</lead_sponsor>
      <collaborator>Yokohama City University</collaborator>
      <collaborator>University of Zurich</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>256</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>December 2021</primary_completion_date>
    <completion_date>December 2021</completion_date>
    <study_first_posted>April 20, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04352400</url>
  </study>
  <study rank="378">
    <nct_id>NCT04360824</nct_id>
    <title>Covid-19 Associated Coagulopathy</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID 19 Associated Coagulopathy</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Intermediate dose thromboprophylaxis</intervention>
      <intervention type="Drug">Standard of Care thromboprophylaxis</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>Major Bleeding</outcome_measure>
      <outcome_measure>Arterial Thrombosis</outcome_measure>
      <outcome_measure>Venous Thromboembolism</outcome_measure>
      <outcome_measure>ICU admission, intubation/ventilation</outcome_measure>
      <outcome_measure>Packed Red Blood Cell Transfusions</outcome_measure>
      <outcome_measure>Platelet Transfusions</outcome_measure>
      <outcome_measure>Fresh Frozen Plasma Transfusions</outcome_measure>
      <outcome_measure>Cryoprecipitate Transfusions</outcome_measure>
      <outcome_measure>Prothrombin Complex Concentrate Transfusions</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Iowa</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>100 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>170</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 16, 2020</start_date>
    <primary_completion_date>April 16, 2021</primary_completion_date>
    <completion_date>April 16, 2021</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04360824</url>
  </study>
  <study rank="379">
    <nct_id>NCT04344951</nct_id>
    <title>Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial</title>
    <acronym>HOPE</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pneumonia, Viral</condition>
      <condition>Covid-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">UNIKINON (Chloroquine phosphate) 200mg tablets</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>50% reduction in symptom score for patients with lower respiratory tract infection</outcome_measure>
      <outcome_measure>Lack of progression for patients with upper respiratory tract infection</outcome_measure>
      <outcome_measure>Comparison of the primary endpoint with respective patients not receiving the treatment</outcome_measure>
      <outcome_measure>Serious respiratory failure until day 14. This will be compared with respective patients not receiving the treatment.</outcome_measure>
      <outcome_measure>Frequency of AEs and SAEs</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.</lead_sponsor>
      <collaborator>Athens General Hospital Hippokrateio</collaborator>
      <collaborator>Athens General Hospital of Thoracic Diseases SOTIRIA</collaborator>
      <collaborator>General Hospital of Athens Sismanoglio</collaborator>
      <collaborator>Divine Providence Hospital Pammakaristos</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 6, 2020</start_date>
    <primary_completion_date>April 1, 2021</primary_completion_date>
    <completion_date>April 30, 2021</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>Divine Providence Hospital &quot;Pammakaristos&quot;, Athens, Greece</location>
      <location>Athens General Hospital &quot;Hippokrateio&quot;, Athens, Greece</location>
      <location>Athens General Hospital of Thoracic Diseases &quot;SOTIRIA&quot;, 1st University Pulmonary Clinic, Athens, Greece</location>
      <location>Athens General Hospital of Thoracic Diseases &quot;SOTIRIA&quot;, 3rd University Pathology Clinic, Athens, Greece</location>
      <location>General Hospital of Athens &quot;Sismanoglio&quot;, Maroúsi, Greece</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04344951</url>
  </study>
  <study rank="380">
    <nct_id>NCT04358029</nct_id>
    <title>Cardiac Arrhythmias In Patients With Coronavirus Disease (COVID-19)</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID 19 Cardiac</condition>
      <condition>COVID 16 Arrhythmia</condition>
      <condition>COVID 19 Death</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Frequency of cardiac arrhythmias</outcome_measure>
      <outcome_measure>Mode of death</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Vivek Reddy</lead_sponsor>
      <collaborator>Icahn School of Medicine at Mount Sinai</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>10000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Other</study_design>
    </study_designs>
    <start_date>April 9, 2020</start_date>
    <primary_completion_date>May 2021</primary_completion_date>
    <completion_date>December 2021</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Icahn School of Medicine at Mount Sinai, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04358029</url>
  </study>
  <study rank="381">
    <nct_id>NCT04261517</nct_id>
    <title>Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pneumonia, Pneumocystis</condition>
      <condition>Coronavirus</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3</outcome_measure>
      <outcome_measure>The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5</outcome_measure>
      <outcome_measure>The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7</outcome_measure>
      <outcome_measure>The mortality rate of subjects at weeks 2</outcome_measure>
      <outcome_measure>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0</outcome_measure>
      <outcome_measure>The critical illness rate of subjects at weeks 2</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Shanghai Public Health Clinical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>February 6, 2020</start_date>
    <primary_completion_date>February 25, 2020</primary_completion_date>
    <completion_date>February 25, 2020</completion_date>
    <study_first_posted>February 7, 2020</study_first_posted>
    <last_update_posted>April 13, 2020</last_update_posted>
    <locations>
      <location>Shanghai Public Health Clinical Center, Shanghai, Shanghai, China</location>
      <location>Shanghai Public Health Clinical Center, Shanghai, Shanghai, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04261517</url>
  </study>
  <study rank="382">
    <nct_id>NCT04359251</nct_id>
    <title>Different PEEP Settings of COVID-19 Induced ARDS</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Mechanical Ventilation Pressure High</condition>
      <condition>Acute Respiratory Distress Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Gas exchanges at different PEEP</intervention>
      <intervention type="Other">lung mechanics at different PEEP</intervention>
      <intervention type="Other">Hemodynamics changes at different PEEP</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Respiratory system compliance improvement</outcome_measure>
      <outcome_measure>Gas echanges improvement</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Southeast University, China</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 5, 2020</start_date>
    <primary_completion_date>March 25, 2020</primary_completion_date>
    <completion_date>March 25, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Zhongda Hospital, Southeast University, Nanjing, Jiangsu, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04359251</url>
  </study>
  <study rank="383">
    <nct_id>NCT04251767</nct_id>
    <title>Washed Microbiota Transplantation for Patients With 2019-nCoV Infection</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19 Complicated With Refractory Intestinal Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Other">washed microbiota transplantation</intervention>
      <intervention type="Other">placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of participants with improvement from severe type to common type</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>The Second Hospital of Nanjing Medical University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>14 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>February 5, 2020</start_date>
    <primary_completion_date>April 30, 2020</primary_completion_date>
    <completion_date>April 30, 2020</completion_date>
    <study_first_posted>February 5, 2020</study_first_posted>
    <last_update_posted>March 17, 2020</last_update_posted>
    <locations>
      <location>Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04251767</url>
  </study>
  <study rank="384">
    <nct_id>NCT04330144</nct_id>
    <title>Hydroxychloroquine as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial)</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Contact Person From COVID-19 Confirmed Patient</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine as post exposure prophylaxis</intervention>
      <intervention type="Other">Others(No intervention)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The rate of COVID-19</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Gangnam Severance Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>99 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>2486</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>March 30, 2021</primary_completion_date>
    <completion_date>March 30, 2022</completion_date>
    <study_first_posted>April 1, 2020</study_first_posted>
    <last_update_posted>April 1, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04330144</url>
  </study>
  <study rank="385">
    <nct_id>NCT04362345</nct_id>
    <title>Clinical Features and Risk Factors Associated With Worse Outcome in Patients Hospitalized for Covid-19 Pneumonia</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Identification of risk factors for severity (death or transfer to resuscitation) of Covid-19 infection</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Strasbourg, France</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>April 9, 2020</start_date>
    <primary_completion_date>April 17, 2020</primary_completion_date>
    <completion_date>April 17, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Service des Maladies Infectieuses et Tropicales, Strasbourg, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04362345</url>
  </study>
  <study rank="386">
    <nct_id>NCT04347824</nct_id>
    <title>Predict Adverse Events by Covid-19 Nephritis</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Disease-Aggrevation</outcome_measure>
      <outcome_measure>Complications</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital Goettingen</lead_sponsor>
      <collaborator>Universitätsklinikum Hamburg-Eppendorf</collaborator>
      <collaborator>University Hospital, Aachen</collaborator>
      <collaborator>Transplantationszentrum Köln-Merheim</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>April 27, 2020</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>December 31, 2021</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>University Medical Center Goettingen, Göttingen, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04347824</url>
  </study>
  <study rank="387">
    <nct_id>NCT04347681</nct_id>
    <title>Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Convalescent Plasma for COVID 19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">convalescent plasma from recovered COVID 19 donor</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>ICU length of stay</outcome_measure>
      <outcome_measure>Safety of convalescent plasma &amp; Serious adverse reactions.</outcome_measure>
      <outcome_measure>Number of days on mechanical ventilation</outcome_measure>
      <outcome_measure>30 days of mortality</outcome_measure>
      <outcome_measure>Days to clinical recovery .</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>King Fahad Specialist Hospital Dammam</lead_sponsor>
      <collaborator>King Fahad Medical City</collaborator>
      <collaborator>King Faisal Specialist Hospital And Research Center</collaborator>
      <collaborator>King Abdulaziz Medical City</collaborator>
      <collaborator>King Fahad University Hospital</collaborator>
      <collaborator>John Hopkins Aramco Healthcare</collaborator>
      <collaborator>Taibah University</collaborator>
      <collaborator>King Saud University</collaborator>
      <collaborator>King Khaled University Hospital</collaborator>
      <collaborator>King Fahad Military Medical Complex</collaborator>
      <collaborator>Qatif Central Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 12, 2020</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>April 11, 2021</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>John Hopkins Aramco Healthcare, Dhahran, Eastern Provence, Saudi Arabia</location>
      <location>Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia</location>
      <location>king Fahad specialist hospital, Dammam, Saudi Arabia</location>
      <location>DHahran Military Medical Complex, Dhahran, Saudi Arabia</location>
      <location>Taibah University, Madinah, Saudi Arabia</location>
      <location>Qatif Central Hospital, Qatif, Saudi Arabia</location>
      <location>King Abdulaziz Medical City, Riyadh, Saudi Arabia</location>
      <location>King Fahad Medical City, Riyadh, Saudi Arabia</location>
      <location>King Faisal Specialist Hospital &amp; Research Center, Riyadh, Saudi Arabia</location>
      <location>King Khalid University Hospital, Riyadh, Saudi Arabia</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04347681</url>
  </study>
  <study rank="388">
    <nct_id>NCT04354753</nct_id>
    <title>AiM COVID for Covid 19 Tracking and Prediction</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID 19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">No Intervention</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Physical symptoms</outcome_measure>
      <outcome_measure>Contact History</outcome_measure>
      <outcome_measure>Travel History</outcome_measure>
      <outcome_measure>Fever</outcome_measure>
      <outcome_measure>Headache</outcome_measure>
      <outcome_measure>Soar Throat</outcome_measure>
      <outcome_measure>Runny nose</outcome_measure>
      <outcome_measure>Cough</outcome_measure>
      <outcome_measure>Shortness of breath</outcome_measure>
      <outcome_measure>Nausea</outcome_measure>
      <outcome_measure>Vomiting</outcome_measure>
      <outcome_measure>Muscle pain</outcome_measure>
      <outcome_measure>Joint pain</outcome_measure>
      <outcome_measure>Diarrhoea</outcome_measure>
      <outcome_measure>Other</outcome_measure>
      <outcome_measure>Hospitalisation history</outcome_measure>
      <outcome_measure>Co-morbid conditions</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Aarogyam UK</lead_sponsor>
      <collaborator>University of Warwick</collaborator>
      <collaborator>Igor Sikorsky Kyiv Polytechnic Institute</collaborator>
      <collaborator>ClickMedix LLC</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>March 28, 2020</start_date>
    <primary_completion_date>April 14, 2020</primary_completion_date>
    <completion_date>April 17, 2020</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>Aarogyam (UK), Leicester, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04354753</url>
  </study>
  <study rank="389">
    <nct_id>NCT04361344</nct_id>
    <title>Neurodegeneration Markers and Neurological Course in Severe Covid-19 Infection</title>
    <acronym>MARNEVO-Covid</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19 Infection</condition>
      <condition>Encephalitis</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">blood samples</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change of neurodegeneration markers level</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier de PAU</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <start_date>May 5, 2020</start_date>
    <primary_completion_date>January 5, 2021</primary_completion_date>
    <completion_date>January 5, 2021</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04361344</url>
  </study>
  <study rank="390">
    <nct_id>NCT04343144</nct_id>
    <title>Trial Evaluating Efficacy and Safety of Nivolumab (Optivo®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort.</title>
    <acronym>CORIMUNO-NIVO</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID19- Infection With SARS-CoV-2 Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nivolumab Injection</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to clinical improvement</outcome_measure>
      <outcome_measure>Overall survival</outcome_measure>
      <outcome_measure>Cumulative incidence of ICU admission</outcome_measure>
      <outcome_measure>Length of hospital stay</outcome_measure>
      <outcome_measure>Positive nasal PCR</outcome_measure>
      <outcome_measure>Incidence of adverse events</outcome_measure>
      <outcome_measure>Incidence of grade 3-4 adverse events</outcome_measure>
      <outcome_measure>World Health Organisation (WHO) progression scale</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>92</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>July 31, 2020</primary_completion_date>
    <completion_date>September 30, 2020</completion_date>
    <study_first_posted>April 13, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>Pneumologie hôpital Tenon, Paris, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04343144</url>
  </study>
  <study rank="391">
    <nct_id>NCT04348513</nct_id>
    <title>Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection</title>
    <acronym>Thy-Support</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pulmonary Infection</condition>
      <condition>Covid-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">T3 solution for injection</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Assessment of weaning from cardiorespiratory support</outcome_measure>
      <outcome_measure>Assessment of hemodynamic status</outcome_measure>
      <outcome_measure>Assessment of pulmonary function</outcome_measure>
      <outcome_measure>Assessment of hepatic function</outcome_measure>
      <outcome_measure>Assessment of renal function</outcome_measure>
      <outcome_measure>Assessment of cardiac function</outcome_measure>
      <outcome_measure>Assessment of cardiac injury</outcome_measure>
      <outcome_measure>Assessment of the course of COVID-19 infection</outcome_measure>
      <outcome_measure>Assessment of clinical outcome and safety</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.</lead_sponsor>
      <collaborator>ATTIKON University Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 2, 2020</start_date>
    <primary_completion_date>May 2, 2021</primary_completion_date>
    <completion_date>May 31, 2021</completion_date>
    <study_first_posted>April 16, 2020</study_first_posted>
    <last_update_posted>April 16, 2020</last_update_posted>
    <locations>
      <location>Attikon University General Hospital, Haidari/Athens, Greece</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04348513</url>
  </study>
  <study rank="392">
    <nct_id>NCT04358510</nct_id>
    <title>COVID-19 Mortality Prediction Model</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Pneumonia</condition>
      <condition>Mechanical Ventilation</condition>
    </conditions>
    <interventions>
      <intervention type="Device">COViage</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mortality outcome in COVID-19 ICU patients</outcome_measure>
      <outcome_measure>Mortality outcome in mechanically ventilated ICU patients</outcome_measure>
      <outcome_measure>Mortality outcome in pneumonia ICU patients</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Dascena</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>114</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>April 17, 2020</primary_completion_date>
    <completion_date>April 17, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Dascena, Oakland, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04358510</url>
  </study>
  <study rank="393">
    <nct_id>NCT04299724</nct_id>
    <title>Safety and Immunity of Covid-19 aAPC Vaccine</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Treat and Prevent Covid-19 Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Pathogen-specific aAPC</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Frequency of vaccine events</outcome_measure>
      <outcome_measure>Frequency of serious vaccine events</outcome_measure>
      <outcome_measure>Proportion of subjects with positive T cell response</outcome_measure>
      <outcome_measure>28-day mortality</outcome_measure>
      <outcome_measure>Duration of mechanical ventilation if applicable</outcome_measure>
      <outcome_measure>Proportion of patients in each category of the 7-point scale</outcome_measure>
      <outcome_measure>Proportion of patients with normalized inflammation factors</outcome_measure>
      <outcome_measure>Clinical improvement based on the 7-point scale if applicable</outcome_measure>
      <outcome_measure>Lower Murray lung injury score if applicable</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Shenzhen Geno-Immune Medical Institute</lead_sponsor>
      <collaborator>Shenzhen Third People's Hospital</collaborator>
      <collaborator>Shenzhen Second People's Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>6 Months</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>February 15, 2020</start_date>
    <primary_completion_date>July 31, 2023</primary_completion_date>
    <completion_date>December 31, 2024</completion_date>
    <study_first_posted>March 9, 2020</study_first_posted>
    <last_update_posted>March 9, 2020</last_update_posted>
    <locations>
      <location>Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04299724</url>
  </study>
  <study rank="394">
    <nct_id>NCT04344977</nct_id>
    <title>Collection of Anti-SARS-CoV-2 Immune Plasma</title>
    <acronym>NIAID</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Disease 2019 (COVID-19)</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Identification of eligible donors and collection of anti-SARS-CoV-2 immune plasma</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1500</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>May 15, 2020</start_date>
    <primary_completion_date>July 1, 2024</primary_completion_date>
    <completion_date>April 1, 2025</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Bloodworks Northwest, Seattle, Washington, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04344977</url>
  </study>
  <study rank="395">
    <nct_id>NCT04342104</nct_id>
    <title>NIV and CPAP Failure Predictors in COVID-19 Associated Respiratory Failure</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Respiratory Failure</condition>
      <condition>Covid-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Monitoring for aggravation</intervention>
      <intervention type="Other">Evaluate HACOR score effectivity in this patients</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>HACOR score efficacy</outcome_measure>
      <outcome_measure>HACOR score addaptation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hospital General Universitario Morales Meseguer</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>June 1, 2020</primary_completion_date>
    <completion_date>July 1, 2020</completion_date>
    <study_first_posted>April 10, 2020</study_first_posted>
    <last_update_posted>April 13, 2020</last_update_posted>
    <locations>
      <location>Hospital General Universitario Morales Meseguer, Murcia, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04342104</url>
  </study>
  <study rank="396">
    <nct_id>NCT04346264</nct_id>
    <title>CoVid-19 - Infection and Antibody Formation in the Viennese Population</title>
    <acronym/>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Virus Diseases</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">NO intervention planned due to the observational study design only a diagnostic testing</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Prevalence of SARS-CoV-2 antibody titres</outcome_measure>
      <outcome_measure>Prevalence of SARS-CoV-2 antibody titres after 3 Months</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ludwig Boltzmann Institute for Lung Health</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>6 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>5500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 27, 2020</start_date>
    <primary_completion_date>June 1, 2020</primary_completion_date>
    <completion_date>September 30, 2020</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 16, 2020</last_update_posted>
    <locations>
      <location>The LEAD Study Center, Vienna, Austria</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04346264</url>
  </study>
  <study rank="397">
    <nct_id>NCT04356586</nct_id>
    <title>Immune Response to Covid-19 in 300 Health Care Workers With Mild Symptoms</title>
    <acronym/>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Serology</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Percentage of serological positive healthcare workers</outcome_measure>
      <outcome_measure>Percentage of HCW with positive Saliva-sabs</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sciensano</lead_sponsor>
      <collaborator>Jessa Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 30, 2020</start_date>
    <primary_completion_date>July 30, 2020</primary_completion_date>
    <completion_date>July 30, 2020</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Sciensano, Brussels, Belgium</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04356586</url>
  </study>
  <study rank="398">
    <nct_id>NCT04346797</nct_id>
    <title>CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort</title>
    <acronym>CORIMUNO19-ECU</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV-2</condition>
      <condition>COVID19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Eculizumab</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Survival without needs of intubation at day 14</outcome_measure>
      <outcome_measure>Change in organ failure at day 3</outcome_measure>
      <outcome_measure>Intubation free survival at day 14</outcome_measure>
      <outcome_measure>WHO progression scale at days 4, 7 and 14</outcome_measure>
      <outcome_measure>Survival at 14, 28 and 90 days</outcome_measure>
      <outcome_measure>Time to discharge</outcome_measure>
      <outcome_measure>Time to oxygen supply independency</outcome_measure>
      <outcome_measure>Time to negative viral excretion</outcome_measure>
      <outcome_measure>Incidence of secondary infections</outcome_measure>
      <outcome_measure>Vasopressor-free survival</outcome_measure>
      <outcome_measure>Ventilator-free survival</outcome_measure>
      <outcome_measure>28-day ventilator-free days</outcome_measure>
      <outcome_measure>Incidence of dialysis</outcome_measure>
      <outcome_measure>PaO2/FiO2 ratio</outcome_measure>
      <outcome_measure>Rate of respiratory acidosis at day 4</outcome_measure>
      <outcome_measure>Time to ICU discharge</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 16, 2020</start_date>
    <primary_completion_date>September 30, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>Saint Louis, Paris, Ile De France, France</location>
      <location>Réanimation médicale, Paris, France</location>
      <location>saint Louis, Paris, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04346797</url>
  </study>
  <study rank="399">
    <nct_id>NCT04347928</nct_id>
    <title>Respiratory and Hemodynamic Changes Induced in Mechanically Ventilated Patients for COVID-19</title>
    <acronym>PHYSIO-COVID</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>ARDS</condition>
      <condition>Sars-CoV2</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>intrapulmonary shunt ratio</outcome_measure>
      <outcome_measure>Evolution of respiratory variables</outcome_measure>
      <outcome_measure>Evolution of hemodynamic stability variables</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Lille</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>September 2020</primary_completion_date>
    <completion_date>September 2020</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04347928</url>
  </study>
  <study rank="400">
    <nct_id>NCT04338958</nct_id>
    <title>Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation</title>
    <acronym>RuxCoFlam</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ruxolitinib</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>overall response rate in reversal of hyperinflammation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Jena</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 1, 2020</start_date>
    <primary_completion_date>January 31, 2021</primary_completion_date>
    <completion_date>August 31, 2021</completion_date>
    <study_first_posted>April 8, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>University Hospital Jena, Jena, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04338958</url>
  </study>
  <study rank="401">
    <nct_id>NCT04257656</nct_id>
    <title>A Trial of Remdesivir in Adults With Severe COVID-19</title>
    <acronym/>
    <status open="N">Terminated</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Remdesivir</condition>
      <condition>SARS-CoV-2</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Remdesivir</intervention>
      <intervention type="Drug">Remdesivir placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to Clinical Improvement (TTCI) [Censored at Day 28]</outcome_measure>
      <outcome_measure>Clinical status</outcome_measure>
      <outcome_measure>Time to Hospital Discharge OR NEWS2 (National Early Warning Score 2) of ≤ 2 maintained for 24 hours.</outcome_measure>
      <outcome_measure>All cause mortality</outcome_measure>
      <outcome_measure>Duration (days) of mechanical ventilation</outcome_measure>
      <outcome_measure>Duration (days) of extracorporeal membrane oxygenation</outcome_measure>
      <outcome_measure>Duration (days) of supplemental oxygenation</outcome_measure>
      <outcome_measure>Length of hospital stay (days)</outcome_measure>
      <outcome_measure>Time to 2019-nCoV RT-PCR negativity in upper and lower respiratory tract specimens</outcome_measure>
      <outcome_measure>Change (reduction) in 2019-nCoV viral load in upper and lower respiratory tract specimens as assessed by area under viral load curve.</outcome_measure>
      <outcome_measure>Frequency of serious adverse drug events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Capital Medical University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>237</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>February 6, 2020</start_date>
    <primary_completion_date>March 30, 2020</primary_completion_date>
    <completion_date>April 10, 2020</completion_date>
    <study_first_posted>February 6, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>Bin Cao, Beijing, Beijing, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04257656</url>
  </study>
  <study rank="402">
    <nct_id>NCT04359654</nct_id>
    <title>Nebulised Dornase Alfa for Treatment of COVID-19</title>
    <acronym>COVASE</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID19</condition>
      <condition>Hypoxia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Dornase Alfa Inhalation Solution [Pulmozyme]</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Reduction in inflammation</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>Oxygen requirement</outcome_measure>
      <outcome_measure>Length of hospital admission</outcome_measure>
      <outcome_measure>Need of mechanical ventilation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University College, London</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>100 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 1, 2020</start_date>
    <primary_completion_date>August 1, 2020</primary_completion_date>
    <completion_date>November 1, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>University College London Hospital, London, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04359654</url>
  </study>
  <study rank="403">
    <nct_id>NCT04338126</nct_id>
    <title>Tranexamic Acid (TXA) and Corona Virus 2019 (COVID19) in Inpatients</title>
    <acronym>TCInpatient</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tranexamic acid</intervention>
      <intervention type="Drug">Placebo oral tablet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Admission to Intensive Care Unit</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Alabama at Birmingham</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>19 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>October 15, 2020</primary_completion_date>
    <completion_date>December 15, 2020</completion_date>
    <study_first_posted>April 8, 2020</study_first_posted>
    <last_update_posted>April 8, 2020</last_update_posted>
    <locations>
      <location>University of Alabama at Birmingham, Birmingham, Alabama, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04338126</url>
  </study>
  <study rank="404">
    <nct_id>NCT04361903</nct_id>
    <title>Ruxolitinib for the Treatment of Acute Respiratory Distress Syndrome in Patients With COVID-19 Infection</title>
    <acronym>RESPIRE</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Severe Acute Respiratory Syndrome Coronavirus 2</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ruxolitinib Oral Tablet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of patients who avoid mechanical assisted ventilation in acute respiratory distress syndrome in patients with SARS-CoV-2 COVID-19</outcome_measure>
      <outcome_measure>Improvement of respiratory performance - Arterial Blood Gas Analisys - pH</outcome_measure>
      <outcome_measure>Improvement of respiratory performance - Arterial Blood Gas Analisys - pO2</outcome_measure>
      <outcome_measure>Improvement of respiratory performance - Arterial Blood Gas Analisys - pCO2</outcome_measure>
      <outcome_measure>Improvement of respiratory performance - ratio values</outcome_measure>
      <outcome_measure>Evaluation of known adverse events related to the use of the drug - D-Dimer</outcome_measure>
      <outcome_measure>Evaluation of known adverse events related to the use of the drug - fibrinogen</outcome_measure>
      <outcome_measure>Evaluation of known adverse events related to the use of the drug - transaminases</outcome_measure>
      <outcome_measure>Evaluation of known adverse events related to the use of the drug - aPTT</outcome_measure>
      <outcome_measure>Evaluation of known adverse events related to the use of the drug - INR</outcome_measure>
      <outcome_measure>Evaluation of known adverse events related to the use of the drug - glycemia</outcome_measure>
      <outcome_measure>Evaluation of known adverse events related to the use of the drug - creatinine</outcome_measure>
      <outcome_measure>Evaluation of known adverse events related to the use of the drug - Leucocytes count</outcome_measure>
      <outcome_measure>Evaluation of known adverse events related to the use of the drug - Leucocytes formula</outcome_measure>
      <outcome_measure>Evaluation of the epidemiological parameters: Chest CT</outcome_measure>
      <outcome_measure>Evaluation of the epidemiological parameters: Eco Chest</outcome_measure>
      <outcome_measure>Evaluation of the epidemiological parameters: CHEST X-ray</outcome_measure>
      <outcome_measure>Monitoring of Serum levels of cytokines before and every 48 h from start to to end of treatment</outcome_measure>
      <outcome_measure>Monitoring incidence of treatment Emergent Adverse Events of ruxolitinib therapy</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Azienda USL Toscana Nord Ovest</lead_sponsor>
      <collaborator>Fondazione C.N.R./Regione Toscana &quot;G. Monasterio&quot;, Pisa, Italy</collaborator>
      <collaborator>Azienda Ospedaliera Universitaria Senese</collaborator>
      <collaborator>Azienda Ospedaliero, Universitaria Pisana</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>13</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>April 25, 2020</start_date>
    <primary_completion_date>May 24, 2020</primary_completion_date>
    <completion_date>May 31, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04361903</url>
  </study>
  <study rank="405">
    <nct_id>NCT04363385</nct_id>
    <title>Collection of Biological Samples With Clinical Characterization of Covid-19 Patients</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid-19</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Biological test</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Phenotype/genotype correlation research modulating the severity of Covid-19 disease</outcome_measure>
      <outcome_measure>Phenotype/transcriptomic correlation research modulating the severity of Covid-19 disease</outcome_measure>
      <outcome_measure>Phenotype/biomarker correlation research modulating the severity of Covid-19 disease</outcome_measure>
      <outcome_measure>Development of clinical-biological scores in the severity of Covid-19 disease</outcome_measure>
      <outcome_measure>Development of predictive imaging scores in the severity of Covid-19 disease</outcome_measure>
      <outcome_measure>Identification of pathophysiological pathways to susceptibility to Covid-19 disease</outcome_measure>
      <outcome_measure>Identification of genetic markers for treatment response</outcome_measure>
      <outcome_measure>Identification of transcriptomic markers for treatment response</outcome_measure>
      <outcome_measure>Identification of proteomic for treatment response</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier Intercommunal Creteil</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>May 1, 2020</start_date>
    <primary_completion_date>December 1, 2020</primary_completion_date>
    <completion_date>December 1, 2020</completion_date>
    <study_first_posted>April 27, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Centre hospitalier intercommunal de Créteil, Créteil, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04363385</url>
  </study>
  <study rank="406">
    <nct_id>NCT04298814</nct_id>
    <title>Safety Related Factors of Endotracheal Intubation in Patients With Severe Covid-19 Pneumonia</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Endotracheal Intubation</condition>
    </conditions>
    <interventions>
      <intervention type="Other">severe covid-19 pneumonia with ET</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Success rate of intubation</outcome_measure>
      <outcome_measure>Infection rate of Anesthesiologist</outcome_measure>
      <outcome_measure>Extubation time</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tongji Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 7, 2020</start_date>
    <primary_completion_date>May 30, 2020</primary_completion_date>
    <completion_date>July 30, 2020</completion_date>
    <study_first_posted>March 6, 2020</study_first_posted>
    <last_update_posted>March 6, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04298814</url>
  </study>
  <study rank="407">
    <nct_id>NCT04359537</nct_id>
    <title>Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19</title>
    <acronym>CHEER</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID 19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine Sulfate 200 MG</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>COVID-19-free survival in experimental arms compared to placebo</outcome_measure>
      <outcome_measure>Incidence of confirmed SARS-COV-2 detection</outcome_measure>
      <outcome_measure>Incidence of possible COVID-19 symptoms</outcome_measure>
      <outcome_measure>Incidence of all-cause study medicine discontinuation</outcome_measure>
      <outcome_measure>Ordinal Scale of COVID-19 Disease maximum severity if COVID-19 diagnosed at study end</outcome_measure>
      <outcome_measure>Incidence of Hospitalization for COVID-19 or death</outcome_measure>
      <outcome_measure>Incidence of study medication-related adverse events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Shaheed Zulfiqar Ali Bhutto Medical University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 25, 2020</start_date>
    <primary_completion_date>August 25, 2020</primary_completion_date>
    <completion_date>September 25, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04359537</url>
  </study>
  <study rank="408">
    <nct_id>NCT04343092</nct_id>
    <title>Ivermectin Adjuvant to Hydroxychloroquin and Azithromycine in COVID19 Patients</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID 19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ivermectine</intervention>
      <intervention type="Drug">Hydroxychloroquine Sulfate</intervention>
      <intervention type="Drug">Placebos</intervention>
      <intervention type="Drug">Azithromycin 500 mg</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of cured patients</outcome_measure>
      <outcome_measure>Number of participants with treatment-related adverse events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Baghdad</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 18, 2020</start_date>
    <primary_completion_date>August 1, 2020</primary_completion_date>
    <completion_date>August 1, 2020</completion_date>
    <study_first_posted>April 13, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>General Directorate of Medical City, Bagdad, Baghdad, Iraq</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04343092</url>
  </study>
  <study rank="409">
    <nct_id>NCT04335097</nct_id>
    <title>Sensor Based Vital Signs Monitoring of Covid 19 Patients During Home Isolation</title>
    <acronym>HSC19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID 19</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Biosensors</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Stop home isolation</outcome_measure>
      <outcome_measure>NEWS score</outcome_measure>
      <outcome_measure>Clinic at hospitalization</outcome_measure>
      <outcome_measure>Symptoms developed</outcome_measure>
      <outcome_measure>Relative/peers evaluation of the patient</outcome_measure>
      <outcome_measure>Serious of symptoms at admittance hospital</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Lars Wik</lead_sponsor>
      <collaborator>University of Stavanger</collaborator>
      <collaborator>Oslo University Hospital</collaborator>
      <collaborator>Norwegian Telemedicine</collaborator>
      <collaborator>Basque Country University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>214</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <start_date>April 22, 2020</start_date>
    <primary_completion_date>April 8, 2021</primary_completion_date>
    <completion_date>December 20, 2025</completion_date>
    <study_first_posted>April 6, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Lillestrom legevakt, Lillestrom, Norway</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04335097</url>
  </study>
  <study rank="410">
    <nct_id>NCT04324190</nct_id>
    <title>DIgital Online SuPport for COVID-19 StrEss</title>
    <acronym>DISPOSE</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Psychosocial Stress</condition>
      <condition>Mental Health</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Guided online support program</intervention>
      <intervention type="Behavioral">WHO recommendations (waiting condition)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in Short-Form-36 (SF-36) Health Survey - Mental Health Component Summary score</outcome_measure>
      <outcome_measure>Short-Form-36 (SF-36) Health Survey - Mental Health Component Summary score</outcome_measure>
      <outcome_measure>Chronic stress items (9 items)</outcome_measure>
      <outcome_measure>Generalized Anxiety Disorder Scale (GAD-7)</outcome_measure>
      <outcome_measure>Patient Health Questionnaire (PHQ8)</outcome_measure>
      <outcome_measure>Somatic Symptom Disorder (SSD-12)</outcome_measure>
      <outcome_measure>Somatic Symptom Scale (SSS-8)</outcome_measure>
      <outcome_measure>Allgemeine Selbstwirksamkeit Kurzskala (ASKU)</outcome_measure>
      <outcome_measure>Screening Tool for Psychological Distress (STOP-D) - selected items</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Gunther Meinlschmidt</lead_sponsor>
      <collaborator>Selfapy GmbH</collaborator>
      <collaborator>International Psychoanalytic University Berlin</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>600</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: Single (Care Provider)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 8, 2020</start_date>
    <primary_completion_date>June 2020</primary_completion_date>
    <completion_date>December 2021</completion_date>
    <study_first_posted>March 27, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>Selfapy GmbH, Berlin, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04324190</url>
  </study>
  <study rank="411">
    <nct_id>NCT04334850</nct_id>
    <title>Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia</title>
    <acronym>MultiCov</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid19</condition>
      <condition>Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Combined use of a respiratory broad panel multiplex PCR and procalcitonin</intervention>
      <intervention type="Other">Usual antibiotic treatment</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of antibiotic free days</outcome_measure>
      <outcome_measure>Mortality rates</outcome_measure>
      <outcome_measure>Number of defined daily dose (DDD) per 100 patient-days of broad- and narrow-spectrum antibiotics.</outcome_measure>
      <outcome_measure>Antibiotics duration at D28</outcome_measure>
      <outcome_measure>Number of organ-failure free days (based on SOFA)</outcome_measure>
      <outcome_measure>Incidence rates of bacterial super-infections</outcome_measure>
      <outcome_measure>Incidence rates of colonization/infection with multidrug resistant bacteria and Clostridium difficile infections</outcome_measure>
      <outcome_measure>ICU and hospital lengths of stay</outcome_measure>
      <outcome_measure>Quality of life Quality of life</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
      <collaborator>BioMérieux</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>194</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>August 2020</completion_date>
    <study_first_posted>April 6, 2020</study_first_posted>
    <last_update_posted>April 6, 2020</last_update_posted>
    <locations>
      <location>Intensive care department-Hospital Tenon, Paris, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04334850</url>
  </study>
  <study rank="412">
    <nct_id>NCT04348305</nct_id>
    <title>Hydrocortisone for COVID-19 and Severe Hypoxia</title>
    <acronym>COVID STEROID</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid-19</condition>
      <condition>Hypoxia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydrocortisone</intervention>
      <intervention type="Drug">Sodium Chloride 9mg/mL</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Days alive without life support at day 28</outcome_measure>
      <outcome_measure>All-cause mortality at day 28</outcome_measure>
      <outcome_measure>Days alive without life support at day 90</outcome_measure>
      <outcome_measure>All-cause mortality at day 90</outcome_measure>
      <outcome_measure>Number of participants with one or more serious adverse reactions</outcome_measure>
      <outcome_measure>Days alive and out of hospital at day 90</outcome_measure>
      <outcome_measure>All-cause mortality at 1 year after randomisation</outcome_measure>
      <outcome_measure>Health-related quality of life at 1 year</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Scandinavian Critical Care Trials Group</lead_sponsor>
      <collaborator>Rigshospitalet, Denmark</collaborator>
      <collaborator>Copenhagen Trial Unit, Center for Clinical Intervention Research</collaborator>
      <collaborator>University of Copenhagen</collaborator>
      <collaborator>Aarhus University Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 17, 2020</start_date>
    <primary_completion_date>March 30, 2021</primary_completion_date>
    <completion_date>December 30, 2021</completion_date>
    <study_first_posted>April 16, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Rigshospitalet, Copenhagen, Denmark</location>
      <location>Hvidovre Hospital - Dept of Pulmonary Medicine, Hvidovre, Denmark</location>
      <location>Kolding Hospital, Kolding, Denmark</location>
      <location>Slagelse Hospital, Slagelse, Denmark</location>
      <location>Viborg Hospital, Viborg, Denmark</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04348305</url>
  </study>
  <study rank="413">
    <nct_id>NCT04354610</nct_id>
    <title>Cardiovascular and Renal Biomarkers to Predict Acute Heart or Kidney Injury in Severe Covid-19 Infection</title>
    <acronym>Nancy-CovH-AKI</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID 19</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Biological samples specific to research</intervention>
      <intervention type="Procedure">Clinical examination</intervention>
      <intervention type="Procedure">Telephone follow-up</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Worsening of renal function by at least KDIGO grade 1 during hospitalization for Covid-19 infection</outcome_measure>
      <outcome_measure>Troponin greater than 99th percentile during hospitalization for Covid-19 infection</outcome_measure>
      <outcome_measure>AKI KDIGO grade 1 or higher in hospitalisation (approach with AND without a priori)</outcome_measure>
      <outcome_measure>Elevation of troponin&gt; 99th percentile in hospitalisation (approach with AND without a priori)</outcome_measure>
      <outcome_measure>AKI KDIGO grade 1 or higher</outcome_measure>
      <outcome_measure>Association with troponin elevation &gt;99th</outcome_measure>
      <outcome_measure>Association with elevation of serum creatinine &gt;30%</outcome_measure>
      <outcome_measure>With the onset of chronic renal failure (eDFG &lt;60 ml / min / 1.73m2)</outcome_measure>
      <outcome_measure>The occurrence of cardiovascular events (stroke, myocardial infarction, hospitalisation for heart failure, cardiovascular death) during hospitalisation and three months after discharge from hospital</outcome_measure>
      <outcome_measure>The occurrence of death from any cause during hospitalisation and three months after discharge from hospital</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Central Hospital, Nancy, France</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>57</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>July 18, 2020</primary_completion_date>
    <completion_date>October 18, 2020</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>CHRU de Nancy, Vandœuvre-lès-Nancy, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04354610</url>
  </study>
  <study rank="414">
    <nct_id>NCT04335071</nct_id>
    <title>Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19)</title>
    <acronym>CORON-ACT</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV-2 Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tocilizumab (TCZ)</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of patients with ICU admission</outcome_measure>
      <outcome_measure>Number of patients with intubation</outcome_measure>
      <outcome_measure>Number of patients with death</outcome_measure>
      <outcome_measure>Illness severity</outcome_measure>
      <outcome_measure>Number of patients with clinical improvement</outcome_measure>
      <outcome_measure>Time to clinical improvement (days)</outcome_measure>
      <outcome_measure>Duration of hospitalization (days)</outcome_measure>
      <outcome_measure>Time to ICU admission (days)</outcome_measure>
      <outcome_measure>Duration of ICU stay</outcome_measure>
      <outcome_measure>Time to intubation</outcome_measure>
      <outcome_measure>Duration of mechanical ventilation (days)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital Inselspital, Berne</lead_sponsor>
      <collaborator>Roche Pharma AG</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>30 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 26, 2020</start_date>
    <primary_completion_date>October 2020</primary_completion_date>
    <completion_date>October 2020</completion_date>
    <study_first_posted>April 6, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>University Hospital Bern (Inselspital), Bern, Switzerland</location>
      <location>Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland</location>
      <location>Ospedale Regionale di Lugano (EOC), Viganello, Switzerland</location>
      <location>University Hospital Zurich, Zurich, Switzerland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04335071</url>
  </study>
  <study rank="415">
    <nct_id>NCT04362111</nct_id>
    <title>Early Identification and Treatment of Cytokine Storm Syndrome in Covid-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cytokine Storm</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Anakinra</intervention>
      <intervention type="Drug">Normal saline</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>No increase in oxygen requirement and no increase in respiratory support measures</outcome_measure>
      <outcome_measure>Improvement in Cytokine Storm markers</outcome_measure>
      <outcome_measure>No requirement for mechanical ventilation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Alabama at Birmingham</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 2020</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04362111</url>
  </study>
  <study rank="416">
    <nct_id>NCT04355364</nct_id>
    <title>Efficacy and Safety of Aerosolized Intra-tracheal Dornase Alpha Administration in Patients With COVID19-induced ARDS (COVIDORNASE)</title>
    <acronym>COVIDORNASE</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Acute Respiratory Distress Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Dornase Alfa Inhalation Solution [Pulmozyme]</intervention>
      <intervention type="Procedure">standard procedure</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Efficacy of intratracheal administration: occurrence of at least one grade improvement</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Fondation Ophtalmologique Adolphe de Rothschild</lead_sponsor>
      <collaborator>University Hospital, Strasbourg, France</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>April 15, 2020</primary_completion_date>
    <completion_date>August 15, 2020</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Hôpital Fondation A. de Rotschhild, Paris, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04355364</url>
  </study>
  <study rank="417">
    <nct_id>NCT04333693</nct_id>
    <title>Outcomes of Vascular Surgery in COVID-19 Infection: National Cohort Study</title>
    <acronym>Covid-VAS</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Vascular Surgical Procedures</condition>
      <condition>COVID-19</condition>
      <condition>Postoperative Complications</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Vascular surgery</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>30-days mortality</outcome_measure>
      <outcome_measure>7-days mortality</outcome_measure>
      <outcome_measure>30-days reoperation</outcome_measure>
      <outcome_measure>Postoperative ICU admission</outcome_measure>
      <outcome_measure>Postoperative respiratory failure</outcome_measure>
      <outcome_measure>Postoperative acute respiratory distress syndrome (ARDS)</outcome_measure>
      <outcome_measure>Postoperative sepsis</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Vascular Investigation Network Spanish Society for Angiology and Vascular Surgery</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>October 1, 2020</primary_completion_date>
    <completion_date>November 1, 2020</completion_date>
    <study_first_posted>April 3, 2020</study_first_posted>
    <last_update_posted>April 3, 2020</last_update_posted>
    <locations>
      <location>Spanish Society for Angiology and Vascular Surgery, Madrid, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04333693</url>
  </study>
  <study rank="418">
    <nct_id>NCT04349540</nct_id>
    <title>Role of Immune and Inflammatory Response in Recipients of Allogeneic Haematopoietic Stem Cell Transplantation (SCT) Affected by Severe COVID19</title>
    <acronym>(COVID19_BMT)</acronym>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">no intervention</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Comparison of inflammatory/immunological biomarkers &lt;72 hours after development of oxygen requirement</outcome_measure>
      <outcome_measure>Overall survival at 30 and 100 days after development of oxygen requirement</outcome_measure>
      <outcome_measure>Comparison of 30 and 100 day survival in SCT patients who are vs are not ongoing immunosuppression</outcome_measure>
      <outcome_measure>Proportion of patients requiring mechanical ventilation</outcome_measure>
      <outcome_measure>Incidence of secondary HLH (as defined by HS score)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Great Ormond Street Hospital for Children NHS Foundation Trust</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>3 Months</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>October 15, 2020</primary_completion_date>
    <completion_date>January 15, 2021</completion_date>
    <study_first_posted>April 16, 2020</study_first_posted>
    <last_update_posted>April 16, 2020</last_update_posted>
    <locations>
      <location>Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04349540</url>
  </study>
  <study rank="419">
    <nct_id>NCT04352803</nct_id>
    <title>Adipose Mesenchymal Cells for Abatement of SARS-CoV-2 Respiratory Compromise in COVID-19 Disease</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid-19 Pneumonia</condition>
      <condition>Cyotokine Storm</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Autologous Adipose MSC's</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Safety - Incidence of unexpected adverse events</outcome_measure>
      <outcome_measure>Efficacy - Frequency of progression to mechanical ventilation</outcome_measure>
      <outcome_measure>Efficacy - Changes in length of mechanical ventilation</outcome_measure>
      <outcome_measure>Efficacy - Changes in length of weaning of mechanical ventilation</outcome_measure>
      <outcome_measure>Efficacy - Changes in length of hospital stay</outcome_measure>
      <outcome_measure>Efficacy - Changes in mortality rate</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Regeneris Medical</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>April 2024</primary_completion_date>
    <completion_date>April 2026</completion_date>
    <study_first_posted>April 20, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04352803</url>
  </study>
  <study rank="420">
    <nct_id>NCT04276896</nct_id>
    <title>Immunity and Safety of Covid-19 Synthetic Minigene Vaccine</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pathogen Infection Covid-19 Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clinical improvement based on the 7-point scale</outcome_measure>
      <outcome_measure>Lower Murray lung injury score</outcome_measure>
      <outcome_measure>28-day mortality</outcome_measure>
      <outcome_measure>Duration of mechanical ventilation</outcome_measure>
      <outcome_measure>Duration of hospitalization</outcome_measure>
      <outcome_measure>Proportion of patients with negative RT-PCR results</outcome_measure>
      <outcome_measure>Proportion of patients in each category of the 7-point scale</outcome_measure>
      <outcome_measure>Proportion of patients with normalized inflammation factors</outcome_measure>
      <outcome_measure>Frequency of vaccine/CTL Events</outcome_measure>
      <outcome_measure>Frequency of Serious vaccine/CTL Events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Shenzhen Geno-Immune Medical Institute</lead_sponsor>
      <collaborator>Shenzhen Third People's Hospital</collaborator>
      <collaborator>Shenzhen Second People's Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>6 Months</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 24, 2020</start_date>
    <primary_completion_date>July 31, 2023</primary_completion_date>
    <completion_date>December 31, 2024</completion_date>
    <study_first_posted>February 19, 2020</study_first_posted>
    <last_update_posted>March 19, 2020</last_update_posted>
    <locations>
      <location>Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China</location>
      <location>Shenzhen Second People's Hospital, Shenzhen, Guangdong, China</location>
      <location>Shenzhen Third People's Hospital, Shenzhen, Guangdong, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04276896</url>
  </study>
  <study rank="421">
    <nct_id>NCT04353011</nct_id>
    <title>Psychological Impact of Quarantine in Chronic Pain Patient During COVID-19 Outbreak</title>
    <acronym>DolPsyCOVID</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sars-CoV2</condition>
      <condition>Chronic Pain</condition>
    </conditions>
    <interventions>
      <intervention type="Other">questionnaire assesment</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Hospital Anxiety and Depression Scale questionnaire</outcome_measure>
      <outcome_measure>Quality of life (SF36)</outcome_measure>
      <outcome_measure>self-reported questionnaire for painful</outcome_measure>
      <outcome_measure>qualitive questionnaire</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Lille</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Family-Based</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>December 2020</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>April 20, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04353011</url>
  </study>
  <study rank="422">
    <nct_id>NCT04351633</nct_id>
    <title>Psychological Impact of Quarantine in Osteoporosis Patient During COVID-19 Outbreak</title>
    <acronym>OsPsyCOVID</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sars-CoV2</condition>
      <condition>Osteoporosis</condition>
    </conditions>
    <interventions>
      <intervention type="Other">questionnaire assesment</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>percentage of patient with feeling of disabilities</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Lille</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Family-Based</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>December 2020</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>April 17, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04351633</url>
  </study>
  <study rank="423">
    <nct_id>NCT04343963</nct_id>
    <title>Pyridostigmine in Severe SARS-CoV-2 Infection</title>
    <acronym>PISCO</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>SARS-CoV-2</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Pyridostigmine Bromide</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Critical condition or death</outcome_measure>
      <outcome_measure>IL-6</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>436</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 4, 2020</start_date>
    <primary_completion_date>September 30, 2020</primary_completion_date>
    <completion_date>April 30, 2021</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Tlalpan, Mexico</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04343963</url>
  </study>
  <study rank="424">
    <nct_id>NCT04349410</nct_id>
    <title>The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol</title>
    <acronym>FMTVDM</acronym>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>CoVid 19 Positive</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine, Azithromycin</intervention>
      <intervention type="Drug">Hydroxychloroquine, Doxycycline</intervention>
      <intervention type="Drug">Hydroxychloroquine, Clindamycin</intervention>
      <intervention type="Drug">Hydroxychloroquine, Clindamycin, Primaquine - low dose.</intervention>
      <intervention type="Drug">Hydroxychloroquine, Clindamycin, Primaquine - high dose.</intervention>
      <intervention type="Drug">Remdesivir</intervention>
      <intervention type="Drug">Tocilizumab</intervention>
      <intervention type="Drug">Methylprednisolone</intervention>
      <intervention type="Drug">Interferon-Alpha2B</intervention>
      <intervention type="Drug">Losartan</intervention>
      <intervention type="Drug">Convalescent Serum</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Improvement in FMTVDM Measurement with nuclear imaging.</outcome_measure>
      <outcome_measure>Ventilator status</outcome_measure>
      <outcome_measure>Survival status</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>The Camelot Foundation</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: Single (Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 11, 2020</start_date>
    <primary_completion_date>October 11, 2020</primary_completion_date>
    <completion_date>November 11, 2020</completion_date>
    <study_first_posted>April 16, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations>
      <location>FHHI-OI-Camelot; QME, Los Angeles, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04349410</url>
  </study>
  <study rank="425">
    <nct_id>NCT04354428</nct_id>
    <title>Treatment for SARS-CoV-2 in High-Risk Adult Outpatients</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>SARS-CoV-2</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ascorbic Acid and Folic Acid</intervention>
      <intervention type="Drug">Hydroxychloroquine Sulfate and Folic Acid</intervention>
      <intervention type="Drug">Hydroxychloroquine Sulfate and Azithromycin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Lower respiratory tract infection (LRTI) rates</outcome_measure>
      <outcome_measure>Incidence of hospitalization or mortality</outcome_measure>
      <outcome_measure>Change in upper respiratory viral shedding</outcome_measure>
      <outcome_measure>Rate of participant-reported adverse events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Washington</lead_sponsor>
      <collaborator>Bill and Melinda Gates Foundation</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>630</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 16, 2020</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>October 2020</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>University of Washington Coordinating Center, Seattle, Washington, United States</location>
      <location>UW Virology Research Clinic, Seattle, Washington, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04354428</url>
  </study>
  <study rank="426">
    <nct_id>NCT04351490</nct_id>
    <title>Impact of Zinc and Vitamin D3 Supplementation on the Survival of Aged Patients Infected With COVID-19</title>
    <acronym>ZnD3-CoVici</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV 2</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Zinc gluconate</intervention>
      <intervention type="Dietary Supplement">25-OH cholecalciferol</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Survival rate in asymptomatic subjects at inclusion</outcome_measure>
      <outcome_measure>Survival rate in symptomatic subjects at inclusion</outcome_measure>
      <outcome_measure>Survival rate in overall subjects</outcome_measure>
      <outcome_measure>Cumulative incidence of Covid-19 infection in asymptomatic subjects at inclusion</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Lille</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>60 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>3140</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>July 2020</completion_date>
    <study_first_posted>April 17, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04351490</url>
  </study>
  <study rank="427">
    <nct_id>NCT04358588</nct_id>
    <title>Pulsed Inhaled Nitric Oxide for the Treatment of Patients With Mild or Moderate COVID-19</title>
    <acronym/>
    <status open="Y">Available</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infection</condition>
      <condition>COVID-19</condition>
      <condition>Pneumonia, Viral</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">iNO (inhaled nitric oxide) delivered via the INOpulse Delivery System</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Bellerophon</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>95 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Expanded Access</study_types>
    <exp_acc_types>
      <exp_acc_type>Intermediate-size Population</exp_acc_type>
    </exp_acc_types>
    <study_designs/>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04358588</url>
  </study>
  <study rank="428">
    <nct_id>NCT04341415</nct_id>
    <title>Impact of Auricular Vagus Nerve Neuromodulation on COVID-19 Positive Inpatients Outcome</title>
    <acronym>SOS-COVID19</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid19</condition>
      <condition>SARS-CoV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Auricular neuromodulation</intervention>
      <intervention type="Procedure">Control</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Comparison of the percentage of clinically improved inpatients between D0 and D14</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Fondation Ophtalmologique Adolphe de Rothschild</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Care Provider)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>June 2020</primary_completion_date>
    <completion_date>June 2020</completion_date>
    <study_first_posted>April 10, 2020</study_first_posted>
    <last_update_posted>April 10, 2020</last_update_posted>
    <locations>
      <location>Fondation Adolphe de Rothschild, Paris, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04341415</url>
  </study>
  <study rank="429">
    <nct_id>NCT04333862</nct_id>
    <title>Assessment of Covid-19 Infection Rates in Healthcare Workers Using a Desynchronization Strategy</title>
    <acronym>Covid-19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV-2</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Fraction of healthcare workers infected with SARS-CoV-2</outcome_measure>
      <outcome_measure>Fraction of healthcare workers with COVID-19</outcome_measure>
      <outcome_measure>Number of patients infected in the hospital</outcome_measure>
      <outcome_measure>Development of SARS-CoV2 specific antibody repertoire</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital Inselspital, Berne</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 19, 2020</start_date>
    <primary_completion_date>June 30, 2020</primary_completion_date>
    <completion_date>December 31, 2021</completion_date>
    <study_first_posted>April 3, 2020</study_first_posted>
    <last_update_posted>April 3, 2020</last_update_posted>
    <locations>
      <location>Guido Beldi, Bern, Switzerland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04333862</url>
  </study>
  <study rank="430">
    <nct_id>NCT04364711</nct_id>
    <title>EuRopean Study of MAjor Infectious Disease Syndromes Related to COVID-19</title>
    <acronym>MERMAIDS 2</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>SARS-CoV 2</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Pneumonia Severity indexes</outcome_measure>
      <outcome_measure>Need for supplemental oxygen; non-invasive or invasive mechanical ventilation; extra-corporeal life support</outcome_measure>
      <outcome_measure>Hospital - and ICU/HCU length of stay</outcome_measure>
      <outcome_measure>In-hospital mortality</outcome_measure>
      <outcome_measure>Activities of daily life, quality of life, variations in home living status and employment status</outcome_measure>
      <outcome_measure>Proportion of SARS-CoV2 positive patients</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>UMC Utrecht</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>2000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>May 1, 2020</start_date>
    <primary_completion_date>April 30, 2022</primary_completion_date>
    <completion_date>April 30, 2022</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04364711</url>
  </study>
  <study rank="431">
    <nct_id>NCT04333953</nct_id>
    <title>COVID-19 in Patients With HIV</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV/AIDS</condition>
      <condition>COVID-19</condition>
      <condition>SARS-CoV-2</condition>
    </conditions>
    <interventions>
      <intervention type="Other">No intervention</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>Frequency of patients requiring hospital admissions</outcome_measure>
      <outcome_measure>Frequency of patients requiring ICU admissions</outcome_measure>
      <outcome_measure>Frequency of respiratory support use</outcome_measure>
      <outcome_measure>Frequency of kidney injury</outcome_measure>
      <outcome_measure>Frequency of liver injury</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Missouri-Columbia</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>October 1, 2020</primary_completion_date>
    <completion_date>October 1, 2020</completion_date>
    <study_first_posted>April 3, 2020</study_first_posted>
    <last_update_posted>April 7, 2020</last_update_posted>
    <locations>
      <location>University of Missouri-Columbia, Columbia, Missouri, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04333953</url>
  </study>
  <study rank="432">
    <nct_id>NCT04358042</nct_id>
    <title>PSYCHIATRIC Disorders and Covid-19</title>
    <acronym>PSYCHIC</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Psychiatric Disorder</condition>
      <condition>Covid19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Brief Psychiatric Rating Scale</intervention>
      <intervention type="Other">Depression, Anxiety and Stress Scale</intervention>
      <intervention type="Other">Impact of Event Scale-Revised</intervention>
      <intervention type="Other">Connor-Davidson Resilience Scale 10 items (CD-RISC 10)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>impact of the COVID-19 pandemic on psychiatric symptomatology</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Nantes University Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>15 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>250</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 25, 2020</start_date>
    <primary_completion_date>January 1, 2022</primary_completion_date>
    <completion_date>January 1, 2023</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Nantes University Hospital - IFAC, Nantes, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04358042</url>
  </study>
  <study rank="433">
    <nct_id>NCT04365153</nct_id>
    <title>Canakinumab to Reduce Deterioration of Cardiac and Respiratory Function Due to COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>SARS-CoV 2</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Canakinumab Injection 600mg</intervention>
      <intervention type="Drug">Canakinumab Injection 300mg</intervention>
      <intervention type="Drug">Placebos</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to clinical improvement up to day 14, defined as the time in days from randomization to either an improvement of two points on a seven-category ordinal scale or discharge from the hospital, whichever occurs first.</outcome_measure>
      <outcome_measure>Mortality at day 28</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>The Cleveland Clinic</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>45</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 24, 2020</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Cleveland Clinic, Cleveland, Ohio, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04365153</url>
  </study>
  <study rank="434">
    <nct_id>NCT04322188</nct_id>
    <title>An Observational Case-control Study of the Use of Siltuximab in ARDS Patients Diagnosed With COVID-19 Infection</title>
    <acronym>SISCO</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Severe Acute Respiratory Syndrome (ARDS) Secondary to SARS-COV-2 Infection</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Cohort A: reduction of the need of invasive ventilation or 30-day mortality</outcome_measure>
      <outcome_measure>Cohort B: reduction of mortality</outcome_measure>
      <outcome_measure>Cohort A Reduction of the need of time of ventilatory support</outcome_measure>
      <outcome_measure>Cohort B Percentage of patients that undergo to tracheostomy</outcome_measure>
      <outcome_measure>Cohort B Improvement of the lung function assessed by radiologic findings</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>A.O. Ospedale Papa Giovanni XXIII</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>March 19, 2020</start_date>
    <primary_completion_date>May 19, 2020</primary_completion_date>
    <completion_date>May 19, 2020</completion_date>
    <study_first_posted>March 26, 2020</study_first_posted>
    <last_update_posted>March 31, 2020</last_update_posted>
    <locations>
      <location>ASST - Papa Giovanni XXIII, Bergamo, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04322188</url>
  </study>
  <study rank="435">
    <nct_id>NCT04323514</nct_id>
    <title>Use of Ascorbic Acid in Patients With COVID 19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hospitalized Patients With Covid-19 Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Vitamin C</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>In-hospital mortality</outcome_measure>
      <outcome_measure>PCR levels</outcome_measure>
      <outcome_measure>Lactate clearance</outcome_measure>
      <outcome_measure>Hospital stay</outcome_measure>
      <outcome_measure>Symptoms</outcome_measure>
      <outcome_measure>Positive swab</outcome_measure>
      <outcome_measure>Tomography imaging</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Palermo</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 13, 2020</start_date>
    <primary_completion_date>March 13, 2021</primary_completion_date>
    <completion_date>March 13, 2021</completion_date>
    <study_first_posted>March 26, 2020</study_first_posted>
    <last_update_posted>March 26, 2020</last_update_posted>
    <locations>
      <location>A.R.N.A.S. Civico - Di Cristina - Benfratelli, Palermo, Italy</location>
    </locations>
    <study_documents>
      <study_document>
        <label>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT04323514/Prot_SAP_ICF_000.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT04323514</url>
  </study>
  <study rank="436">
    <nct_id>NCT04363853</nct_id>
    <title>Tocilizumab Treatment in Patients With COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sars-CoV2</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tocilizumab</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Hematic biometry</outcome_measure>
      <outcome_measure>Blood chemistry</outcome_measure>
      <outcome_measure>Blood gas</outcome_measure>
      <outcome_measure>blood gas</outcome_measure>
      <outcome_measure>thorax radiography</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Instituto Nacional de Cancerologia de Mexico</lead_sponsor>
      <collaborator>Roche Pharma AG</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>June 1, 2020</primary_completion_date>
    <completion_date>August 1, 2020</completion_date>
    <study_first_posted>April 27, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>National Cancer Institute of Mexico, Mexico city, Distrito Federal, Mexico</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04363853</url>
  </study>
  <study rank="437">
    <nct_id>NCT04345653</nct_id>
    <title>Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers</title>
    <acronym/>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine Sulfate (HCQ)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Recruitment Feasibility</outcome_measure>
      <outcome_measure>Recourse utilization</outcome_measure>
      <outcome_measure>Safety as reflected on the number and severity of adverse events and serious adverse events</outcome_measure>
      <outcome_measure>Early feasibility as reflected on the number of participants contracting COVID-19 (10% or less) in comparison to the expected 30% as per CDC.</outcome_measure>
      <outcome_measure>Effect of basic inflammatory regulation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hackensack Meridian Health</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>99 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>45</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 14, 2020</start_date>
    <primary_completion_date>April 8, 2021</primary_completion_date>
    <completion_date>April 8, 2022</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 16, 2020</last_update_posted>
    <locations>
      <location>Hackensack Meridian Health - JFK Medical Center, Edison, New Jersey, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04345653</url>
  </study>
  <study rank="438">
    <nct_id>NCT04304690</nct_id>
    <title>COVID-19 Seroconversion Among Front Line Medical and Paramedical Staff in Emergency, Intensive Care Units and Infectious Disease Departments During the 2020 Epidemic</title>
    <acronym>SEROCOV</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sars-CoV2</condition>
    </conditions>
    <interventions>
      <intervention type="Other">blood sample</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Quantify the proportion of patients with documented Sars-CoV2 infection among medical and paramedical staff</outcome_measure>
      <outcome_measure>Identification of risk factors for seroconversion</outcome_measure>
      <outcome_measure>Quantify the proportion of asymptomatic infections among staff who have seroconverted</outcome_measure>
      <outcome_measure>&quot; Describe symptomatic infections for personnel developing acute clinical (respiratory or digestive) viral syndrome &quot;</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <start_date>March 16, 2020</start_date>
    <primary_completion_date>July 16, 2020</primary_completion_date>
    <completion_date>October 16, 2020</completion_date>
    <study_first_posted>March 11, 2020</study_first_posted>
    <last_update_posted>April 13, 2020</last_update_posted>
    <locations>
      <location>Hopital Pitié Salpetrière, Paris, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04304690</url>
  </study>
  <study rank="439">
    <nct_id>NCT04363671</nct_id>
    <title>Adolescents and Health Professionals Faced With the Necessity for Changing to Remote Care During the COVID-19 Outbreak Quarantine (AdoPro-Cov19)</title>
    <acronym>AdoPro-Cov19</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Remote Consultation</condition>
      <condition>Covid-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Exploration of themes emerging from analysis of the content of the interview with the adolescents and therapists</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hôpital Cochin</lead_sponsor>
      <collaborator>Institut National de la Santé Et de la Recherche Médicale, France</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>11 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>May 2020</start_date>
    <primary_completion_date>June 2020</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>April 27, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>Maison de Solenn, Cochin Hospital, Paris, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04363671</url>
  </study>
  <study rank="440">
    <nct_id>NCT04356508</nct_id>
    <title>COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>SARS-CoV-2</condition>
      <condition>2019-nCoV</condition>
      <condition>Pneumonia, Viral</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nivolumab</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Viral clearance kinetics</outcome_measure>
      <outcome_measure>Treatment-related adverse events of nivolumab (Intervention arm only)</outcome_measure>
      <outcome_measure>Lymphocyte kinetics</outcome_measure>
      <outcome_measure>Cytokine kinetics</outcome_measure>
      <outcome_measure>Length of inpatient stay due to COVID-19</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Dr Gerry Gin Wai Kwok</lead_sponsor>
      <collaborator>The University of Hong Kong</collaborator>
      <collaborator>Queen Mary Hospital, Hong Kong</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 14, 2020</start_date>
    <primary_completion_date>June 30, 2020</primary_completion_date>
    <completion_date>August 31, 2021</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04356508</url>
  </study>
  <study rank="441">
    <nct_id>NCT04342195</nct_id>
    <title>Acquiring Convalescent Specimens for COVID-19 Antibodies</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Coronavirus Infection</condition>
      <condition>Corona Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Blood draw</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of antibodies against coronaviruses isolated and identified from patient samples</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Columbia University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <start_date>March 25, 2020</start_date>
    <primary_completion_date>March 2021</primary_completion_date>
    <completion_date>March 2021</completion_date>
    <study_first_posted>April 10, 2020</study_first_posted>
    <last_update_posted>April 13, 2020</last_update_posted>
    <locations>
      <location>Columbia University Irving Medical Center/NYP, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04342195</url>
  </study>
  <study rank="442">
    <nct_id>NCT04365959</nct_id>
    <title>The Prone Position in Covid-19 Affected Patients</title>
    <acronym>PRON-COVID</acronym>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sars-CoV2</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Prone position</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of patients in whom the prone position caused an increase in oxygenation</outcome_measure>
      <outcome_measure>The feasibility of prone position</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Milano Bicocca</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>56</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 20, 2020</start_date>
    <primary_completion_date>April 9, 2020</primary_completion_date>
    <completion_date>May 31, 2020</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>ASST Monza, Monza, MB, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04365959</url>
  </study>
  <study rank="443">
    <nct_id>NCT04356937</nct_id>
    <title>Efficacy of Tocilizumab on Patients With COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV 2</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tocilizumab</intervention>
      <intervention type="Drug">Placebos</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Proportion of patients that require mechanical ventilation</outcome_measure>
      <outcome_measure>Requirement for inotropes and/or vasopressors</outcome_measure>
      <outcome_measure>8-level Clinical improvement Scale</outcome_measure>
      <outcome_measure>Duration of mechanical ventalition</outcome_measure>
      <outcome_measure>Hospital discharge</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>Duration of ICU stay</outcome_measure>
      <outcome_measure>Duration of time on supplemental oxygen</outcome_measure>
      <outcome_measure>The proportion of patients who require renal replacement therapy or have doubling of creatinine</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Massachusetts General Hospital</lead_sponsor>
      <collaborator>Genentech, Inc.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 27, 2020</start_date>
    <primary_completion_date>June 30, 2020</primary_completion_date>
    <completion_date>August 30, 2020</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Massachusetts General Hospital, Boston, Massachusetts, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04356937</url>
  </study>
  <study rank="444">
    <nct_id>NCT04316299</nct_id>
    <title>Acute Kidney Injury in Patients Hospitalized With COVID-19</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Acute Kidney Injury</condition>
      <condition>Kidney Function</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Rate of Acute Kidney Injury</outcome_measure>
      <outcome_measure>Rate of Death</outcome_measure>
      <outcome_measure>the length of hospital stay</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Zhenhua Zen</lead_sponsor>
      <collaborator>Nanfang Hospital of Southern Medical University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>287</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>February 26, 2020</start_date>
    <primary_completion_date>February 28, 2020</primary_completion_date>
    <completion_date>March 8, 2020</completion_date>
    <study_first_posted>March 20, 2020</study_first_posted>
    <last_update_posted>March 30, 2020</last_update_posted>
    <locations>
      <location>Hankou Hospital, Wuhan, Hubei, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04316299</url>
  </study>
  <study rank="445">
    <nct_id>NCT04361032</nct_id>
    <title>Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia</title>
    <acronym>TRONCHER</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID19</condition>
      <condition>Intensive Care Unit</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tocilizumab Injection</intervention>
      <intervention type="Drug">Deferoxamine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>the mortality rate</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Abderrahmane Mami Hospital</lead_sponsor>
      <collaborator>Eshmoun Clinical Research Centre</collaborator>
      <collaborator>Datametrix</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>260</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 4, 2020</start_date>
    <primary_completion_date>September 4, 2020</primary_completion_date>
    <completion_date>October 4, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Eshmoun Clinical Research Centre/ Hôpital Abderrahmane Mami-Ariana, Ariana, Tunisia</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04361032</url>
  </study>
  <study rank="446">
    <nct_id>NCT04341207</nct_id>
    <title>Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients</title>
    <acronym>ONCOVID</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cancer &amp; COVID 19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Drug">Azithromycin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Prevalence and the 3-months incidence of SARS-CoV-2 in cancer patients</outcome_measure>
      <outcome_measure>Covid-19 disease-specific mortality rate in cancer patients treated by hydroxychloroquine and azithromycin</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Gustave Roussy, Cancer Campus, Grand Paris</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 3, 2020</start_date>
    <primary_completion_date>April 2022</primary_completion_date>
    <completion_date>April 2022</completion_date>
    <study_first_posted>April 10, 2020</study_first_posted>
    <last_update_posted>April 10, 2020</last_update_posted>
    <locations>
      <location>Gustave Roussy, Villejuif, Val De Marne, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04341207</url>
  </study>
  <study rank="447">
    <nct_id>NCT04336345</nct_id>
    <title>Outcomes of Patients With COVID-19 in the Intensive Care Unit</title>
    <acronym>MexCOVID-19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infections</condition>
      <condition>COVID-19</condition>
      <condition>Viral Pneumonia Human Coronavirus</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Hospital mortality</outcome_measure>
      <outcome_measure>Length of stay in the intensive care unit</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>April 30, 2020</primary_completion_date>
    <completion_date>May 30, 2020</completion_date>
    <study_first_posted>April 7, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico</location>
      <location>All centres from Mexico willing to contribute are Welcome., Mexico, Mexico</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04336345</url>
  </study>
  <study rank="448">
    <nct_id>NCT04318431</nct_id>
    <title>Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children</title>
    <acronym>COVILLE</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid19</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Data collection and rhinopharyngeal swab</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Proportion of asymptomatic children or children with mild respiratory symptoms</outcome_measure>
      <outcome_measure>Confirmed Cov2-SARS cases by age</outcome_measure>
      <outcome_measure>Confirmed Cov2-SARS cases by symptoms</outcome_measure>
      <outcome_measure>Viral load</outcome_measure>
      <outcome_measure>Other respiratory viruses</outcome_measure>
      <outcome_measure>Sars-Cov2 IgM</outcome_measure>
      <outcome_measure>Sars-Cov2 IgG</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier Intercommunal Creteil</lead_sponsor>
      <collaborator>ACTIV</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>6 Months</min_age>
    <max_age>15 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>600</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <start_date>April 14, 2020</start_date>
    <primary_completion_date>June 2020</primary_completion_date>
    <completion_date>June 2020</completion_date>
    <study_first_posted>March 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Cabinet du Dr Belaroussi, Boulogne, France</location>
      <location>Cabinet du Dr Derkx, Champigny-sur-Marne, France</location>
      <location>Cabinet du Dr Coicadan, Chennevières-sur-Marne, France</location>
      <location>14 Av rené Samuel, Clamart, France</location>
      <location>Cabinet du Dr Corrard, Combs-la-Ville, France</location>
      <location>10 rue Delambre, Lagny-sur-Marne, France</location>
      <location>157 Avenue du Général Leclerc, Maisons-Alfort, France</location>
      <location>21 Grande Rue Charles de Gaulle, Nogent-sur-Marne, France</location>
      <location>Cabinet du Dr Deberdt, Nogent-sur-Marne, France</location>
      <location>Cabinet du Dr Wollner, Nogent-sur-Marne, France</location>
      <location>4 allée des Norottes, Noisy-le-Grand, France</location>
      <location>Cabinet du Dr D'acremont, Paris, France</location>
      <location>146 Avenue Ledru Rollin, Paris, France</location>
      <location>132 Boulevard du Montparnasse, Paris, France</location>
      <location>Cabinet du Dr Romain, Paris, France</location>
      <location>Cabinet du Dr Turberg-Romain, Paris, France</location>
      <location>15 Quai Louis Blériot, Paris, France</location>
      <location>Cabinet du Dr Michot, Paris, France</location>
      <location>24 rue Volta, Puteaux, France</location>
      <location>Cabinet du Dr Cohen, Saint-Maur-des-Fossés, France</location>
      <location>Cabinet de Pédiatrie des Docteurs Ravilly et Bessa, Villejuif, France</location>
      <location>13 Villa Beauséjour, Vincennes, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04318431</url>
  </study>
  <study rank="449">
    <nct_id>NCT04364009</nct_id>
    <title>Anakinra for COVID-19 Respiratory Symptoms</title>
    <acronym>ANACONDA</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19 Infection</condition>
      <condition>ANAKINRA Treatment</condition>
      <condition>Optimized Standard of Care (oSOC)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Anakinra plus oSOC</intervention>
      <intervention type="Drug">oSOC</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Treatment success</outcome_measure>
      <outcome_measure>OMS progression scale (on a 7 point ordinal scale)</outcome_measure>
      <outcome_measure>Overall survival</outcome_measure>
      <outcome_measure>Time to ICU admission</outcome_measure>
      <outcome_measure>Time to ventilatory support</outcome_measure>
      <outcome_measure>Change in National Early Warning Score (NEW)from baseline to Day 3, Day 10, Day 14 and Day 28</outcome_measure>
      <outcome_measure>Change in inflammatory parameter</outcome_measure>
      <outcome_measure>Hospital length of stay</outcome_measure>
      <outcome_measure>ICU parameter</outcome_measure>
      <outcome_measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</outcome_measure>
      <outcome_measure>Predictors of efficacy of Anakinra</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Tours</lead_sponsor>
      <collaborator>INSERM CIC-P 1415, University Hospital Center of Tours</collaborator>
      <collaborator>Swedish Orphan Biovitrum (SOBI)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>240</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 27, 2020</start_date>
    <primary_completion_date>September 10, 2020</primary_completion_date>
    <completion_date>September 24, 2020</completion_date>
    <study_first_posted>April 27, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04364009</url>
  </study>
  <study rank="450">
    <nct_id>NCT04364594</nct_id>
    <title>COVID-19 Search in Conjunctival Cells</title>
    <acronym>COVID-T</acronym>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID 19</condition>
      <condition>Pulmonary Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">conjunctival swab</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Conjunctival swab results based on RT-PCR</outcome_measure>
      <outcome_measure>Conjunctival swab positivity in relation to Pulmonary and blood abnormalities</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <start_date>March 26, 2020</start_date>
    <primary_completion_date>April 30, 2020</primary_completion_date>
    <completion_date>May 30, 2020</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Maria Cristina Savastano, Roma, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04364594</url>
  </study>
  <study rank="451">
    <nct_id>NCT04329546</nct_id>
    <title>Understanding COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV-2 Viral Kinetics and Host Immune Responses</condition>
    </conditions>
    <interventions>
      <intervention type="Other">NA (no intervention)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Immunogenicity primary outcome: Geometric mean antibody concentration of total IgG antibodies to SARS-CoV-2 assessed by ELISA at 28 days</outcome_measure>
      <outcome_measure>Virologic primary outcome: Peak viral load in the 56 days following diagnosis/suspected diagnosis</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Geneva</lead_sponsor>
      <collaborator>University of Geneva, Switzerland</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>250</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 27, 2020</start_date>
    <primary_completion_date>January 31, 2022</primary_completion_date>
    <completion_date>March 31, 2022</completion_date>
    <study_first_posted>April 1, 2020</study_first_posted>
    <last_update_posted>April 13, 2020</last_update_posted>
    <locations>
      <location>University Hospitals of Geneva, Geneva, Switzerland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04329546</url>
  </study>
  <study rank="452">
    <nct_id>NCT04353271</nct_id>
    <title>Trial of Hydroxychloroquine In Covid-19 Kinetics</title>
    <acronym>THICK</acronym>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid 19</condition>
      <condition>Corona Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Percentage of virus free subjects</outcome_measure>
      <outcome_measure>Disease severity</outcome_measure>
      <outcome_measure>Incidence of hospitalization</outcome_measure>
      <outcome_measure>Incidence of Death</outcome_measure>
      <outcome_measure>Incidence of confirmed SARS-CoV-2 Detection</outcome_measure>
      <outcome_measure>Incidence of all-cause study medication discontinuation or withdrawal</outcome_measure>
      <outcome_measure>Immunity to Covid-19</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of South Alabama</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>19 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>58</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 17, 2020</start_date>
    <primary_completion_date>July 1, 2020</primary_completion_date>
    <completion_date>December 1, 2020</completion_date>
    <study_first_posted>April 20, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>University of South Alabama, Mobile, Alabama, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04353271</url>
  </study>
  <study rank="453">
    <nct_id>NCT04364737</nct_id>
    <title>Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Coronavirus</condition>
      <condition>Coronavirus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Convalescent Plasma</intervention>
      <intervention type="Biological">Lactated ringer's solution or sterile saline</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Percentage of subjects reporting each severity rating on WHO ordinal scale for clinical improvement</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Albert Einstein College of Medicine</lead_sponsor>
      <collaborator>New York University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 17, 2020</start_date>
    <primary_completion_date>January 31, 2023</primary_completion_date>
    <completion_date>April 30, 2023</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Montefiore Medical Center, Bronx, New York, United States</location>
      <location>New York University, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04364737</url>
  </study>
  <study rank="454">
    <nct_id>NCT04344002</nct_id>
    <title>LunG canceR pAtients coVId19 Disease (GRAVID)</title>
    <acronym>GRAVID</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid-19</condition>
      <condition>Lung Cancer</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Clinical data of lung cancer patients with COVID-19 diagnoses</outcome_measure>
      <outcome_measure>Diagnosis data</outcome_measure>
      <outcome_measure>Treatments received</outcome_measure>
      <outcome_measure>Prognostic factors</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Spanish Lung Cancer Group</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Other</study_design>
    </study_designs>
    <start_date>May 15, 2020</start_date>
    <primary_completion_date>May 15, 2021</primary_completion_date>
    <completion_date>May 15, 2022</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>H. Universitario Quirón Dexeus, Barcelona, Spain</location>
      <location>H.U. Puerta de Hierro, Madrid, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04344002</url>
  </study>
  <study rank="455">
    <nct_id>NCT04360837</nct_id>
    <title>PEEP Incremental and Decremental Alveolar Recruitment of Critically Ill Corona Virus Disease-19 (COVID-19) Patients</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Virus; Pneumonia</condition>
      <condition>Atelectasis</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">alveolar recruitment</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Changes in lung compliance</outcome_measure>
      <outcome_measure>Change in global impedance</outcome_measure>
      <outcome_measure>Change in recruitability</outcome_measure>
      <outcome_measure>Gas exchange</outcome_measure>
      <outcome_measure>Plateau pressure</outcome_measure>
      <outcome_measure>End expiratory lung impedance (EELI)</outcome_measure>
      <outcome_measure>Antero-to-posterior ventilation ratio</outcome_measure>
      <outcome_measure>Center of ventilation</outcome_measure>
      <outcome_measure>Global inhomogeneity index</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Szeged University</lead_sponsor>
      <collaborator>Furtwangen University</collaborator>
      <collaborator>BUDAPEST UNIVERSITY OF TECHNOLOGY AND ECONOMICS</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>99 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <start_date>May 1, 2020</start_date>
    <primary_completion_date>April 19, 2021</primary_completion_date>
    <completion_date>April 19, 2021</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04360837</url>
  </study>
  <study rank="456">
    <nct_id>NCT04334460</nct_id>
    <title>Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sars-CoV2</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BLD-2660</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Antiviral Activity</outcome_measure>
      <outcome_measure>Improvement of oxygenation</outcome_measure>
      <outcome_measure>Safety &amp; Tolerability: incidence of TEAEs and serious adverse events (SAEs)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Blade Therapeutics</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 2020</start_date>
    <primary_completion_date>August 2020</primary_completion_date>
    <completion_date>September 2020</completion_date>
    <study_first_posted>April 6, 2020</study_first_posted>
    <last_update_posted>April 6, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04334460</url>
  </study>
  <study rank="457">
    <nct_id>NCT04351919</nct_id>
    <title>Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+)</title>
    <acronym>COVID+PA</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Patients With COVID19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Drug">Azithromycin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>improvment or healing of clinical signs</outcome_measure>
      <outcome_measure>Evolution of clinical signs</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Abderrahmane Mami Hospital</lead_sponsor>
      <collaborator>Eshmoun Clinical Research Centre</collaborator>
      <collaborator>Dacima Consulting</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>July 15, 2020</primary_completion_date>
    <completion_date>July 15, 2020</completion_date>
    <study_first_posted>April 17, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>Eshmoun Clinical Research Centre/ Hôpital Abderrahmen Mami-Ariana, Tunis, Tunisia</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04351919</url>
  </study>
  <study rank="458">
    <nct_id>NCT04366245</nct_id>
    <title>Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV 2</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Hyperimmune plasma</intervention>
      <intervention type="Drug">Hidroxicloroquina + Azitromicina o Lopinavir/ritonavir + Interferon β-1b + Hidroxicloroquina</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Safety: Incidence of Adverse Events and Serious Adverse Events grade 3 and 4, related to the product under investigation or the administration procedure, graduated according to the common toxicity criteria scale (CTCAE).</outcome_measure>
      <outcome_measure>Efficacy: Death from any cause</outcome_measure>
      <outcome_measure>Efficacy: Need for mechanical ventilation</outcome_measure>
      <outcome_measure>Efficacy: Any of the following analytical data after 72h of randomization.</outcome_measure>
      <outcome_measure>Efficacy: SOFA scale ≥ 3 after 72 hours of randomization.</outcome_measure>
      <outcome_measure>Efficacy. Mortality on days 14 and 28.</outcome_measure>
      <outcome_measure>Efficacy: Proportion of patients who required mechanical ventilation</outcome_measure>
      <outcome_measure>Efficacy: Proportion of patients who develop analytical alterations.</outcome_measure>
      <outcome_measure>Efficacy: Cure / clinical improvement (disappearance or improvement of signs and symptoms of COVID-19) in the cure test.</outcome_measure>
      <outcome_measure>Efficacy: PCR negative for SARS-CoV-2</outcome_measure>
      <outcome_measure>Efficacy: Proportion of patients who required treatment with Tocilizumab</outcome_measure>
      <outcome_measure>Efficacy: Duration of hospitalization (days)</outcome_measure>
      <outcome_measure>Virology and immunological variables: Qualitative PCR for SARS-CoV-2 in naso-oropharyngeal exudate sample</outcome_measure>
      <outcome_measure>Virology and immunological variables: Total antibody quantification</outcome_measure>
      <outcome_measure>Virology and immunological variables: Quantification of total antibodies in PC donors recovered from COVID-19.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Andalusian Network for Design and Translation of Advanced Therapies</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>72</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>December 2021</primary_completion_date>
    <completion_date>December 2021</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Hospital Unversitario Virgen Macarena, Sevilla, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04366245</url>
  </study>
  <study rank="459">
    <nct_id>NCT04341441</nct_id>
    <title>Will Hydroxychloroquine Impede or Prevent COVID-19</title>
    <acronym>WHIP COVID-19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Coronavirus</condition>
      <condition>Coronavirus Infections</condition>
      <condition>SARS-CoV 2</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine - Daily Dosing</intervention>
      <intervention type="Drug">Hydroxychloroquine - Weekly Dosing</intervention>
      <intervention type="Other">Placebo oral tablet</intervention>
      <intervention type="Diagnostic Test">Monitoring Visit - Baseline</intervention>
      <intervention type="Diagnostic Test">Monitoring Visit - Week 4</intervention>
      <intervention type="Diagnostic Test">Monitoring Visit - Week 8</intervention>
      <intervention type="Other">Weekly Assessment</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Reduction in the number of COVID-19 infections in healthcare workers.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Henry Ford Health System</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>3000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 7, 2020</start_date>
    <primary_completion_date>June 30, 2020</primary_completion_date>
    <completion_date>April 30, 2021</completion_date>
    <study_first_posted>April 10, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>Henry Ford Hospital, Detroit, Michigan, United States</location>
      <location>Detroit Department of Transportation (DDOT), Detroit, Michigan, United States</location>
      <location>Detroit Fire Department &amp; Detroit EMS, Detroit, Michigan, United States</location>
      <location>Detroit Police Department, Detroit, Michigan, United States</location>
    </locations>
    <study_documents>
      <study_document>
        <label>Study Protocol</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/41/NCT04341441/Prot_000.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT04341441</url>
  </study>
  <study rank="460">
    <nct_id>NCT04355728</nct_id>
    <title>Use of UC-MSCs for COVID-19 Patients</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Corona Virus Infection</condition>
      <condition>ARDS</condition>
      <condition>ARDS, Human</condition>
      <condition>Acute Respiratory Distress Syndrome</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Umbilical Cord Mesenchymal Stem Cells</intervention>
      <intervention type="Other">Standard of Care</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Incidence of pre-specified infusion associated adverse events</outcome_measure>
      <outcome_measure>Incidence of Severe Adverse Events</outcome_measure>
      <outcome_measure>Survival rate after 90 days post first infusion</outcome_measure>
      <outcome_measure>Ventilator-Free Days</outcome_measure>
      <outcome_measure>Change in Oxygenation Index (OI)</outcome_measure>
      <outcome_measure>Plat-PEEP</outcome_measure>
      <outcome_measure>Sequential Organ Failure Assessment (SOFA) Scores</outcome_measure>
      <outcome_measure>Small Identification Test (SIT) scores</outcome_measure>
      <outcome_measure>Troponin I levels</outcome_measure>
      <outcome_measure>C-Reactive Protein levels</outcome_measure>
      <outcome_measure>Arachidonic Acid (AA)/Eicosapentaenoic Acid (EPA) Ratio</outcome_measure>
      <outcome_measure>D-dimer levels</outcome_measure>
      <outcome_measure>25-Hydroxy Vitamin D levels</outcome_measure>
      <outcome_measure>Alloantibodies levels</outcome_measure>
      <outcome_measure>Blood white cell count</outcome_measure>
      <outcome_measure>Platelets count</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Camillo Ricordi</lead_sponsor>
      <collaborator>University of Miami</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 25, 2020</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>May 1, 2021</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, Florida, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04355728</url>
  </study>
  <study rank="461">
    <nct_id>NCT04333914</nct_id>
    <title>Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection</title>
    <acronym>IMMUNONCOVID</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV-2 (COVID-19) Infection</condition>
      <condition>Advanced or Metastatic Hematological or Solid Tumor</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Chloroquine analog (GNS651)</intervention>
      <intervention type="Drug">Nivolumab</intervention>
      <intervention type="Drug">Tocilizumab</intervention>
      <intervention type="Other">Standard of care</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>28-day survival rate</outcome_measure>
      <outcome_measure>Time to clinical improvement</outcome_measure>
      <outcome_measure>Clinical status</outcome_measure>
      <outcome_measure>Mean change in clinical status from baseline to days</outcome_measure>
      <outcome_measure>Overall survival</outcome_measure>
      <outcome_measure>Length of stay in Intensive Care Unit</outcome_measure>
      <outcome_measure>Duration of mechanical ventilation or high flow oxygen devices</outcome_measure>
      <outcome_measure>Duration of hospitalization</outcome_measure>
      <outcome_measure>Rate of throat swab negativation</outcome_measure>
      <outcome_measure>Quantitative SARS-CoV-2 virus in throat swab and blood samples</outcome_measure>
      <outcome_measure>Rate of secondary infection by other documented pathogens</outcome_measure>
      <outcome_measure>Biological parameters</outcome_measure>
      <outcome_measure>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0</outcome_measure>
      <outcome_measure>Cost-Effectiveness Analyses (CEA)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Leon Berard</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>273</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>June 2020</primary_completion_date>
    <completion_date>August 2020</completion_date>
    <study_first_posted>April 3, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>Centre Léon Bérard, Lyon, Rhône, France</location>
      <location>AP-HP Hôpital Saint Antoine, Paris, France</location>
      <location>AP-HP La Pitié Salpétrière, Paris, France</location>
      <location>Hôpital Saint-Joseph, Paris, France</location>
      <location>AP-HP Tenon, Paris, France</location>
      <location>AP-HP Hôpital Bichat Claude Bernard, Paris, France</location>
      <location>Gustave Roussy, Villejuif, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04333914</url>
  </study>
  <study rank="462">
    <nct_id>NCT04357457</nct_id>
    <title>Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia</title>
    <acronym>AIRVM-COVID</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid 19</condition>
      <condition>Hypoxemic Respiratory Failure</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Almitrine</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Rate of endotracheal intubation</outcome_measure>
      <outcome_measure>28-day mortality</outcome_measure>
      <outcome_measure>In-hospital mortality</outcome_measure>
      <outcome_measure>Number of ventilator-free days</outcome_measure>
      <outcome_measure>Number of days in the ICU</outcome_measure>
      <outcome_measure>Number of days in the hospital</outcome_measure>
      <outcome_measure>Discontinuation rate of the treatment</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
      <collaborator>Centre Hospitalier de Chartres</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>212</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>June 2020</primary_completion_date>
    <completion_date>July 2020</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Hospital Pitié-Salpêtrière, Paris, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04357457</url>
  </study>
  <study rank="463">
    <nct_id>NCT04355494</nct_id>
    <title>SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19</title>
    <acronym/>
    <status open="Y">Available</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Pneumonia, Viral</condition>
      <condition>Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">eculizumab</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Alexion Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Expanded Access</study_types>
    <exp_acc_types>
      <exp_acc_type>Intermediate-size Population</exp_acc_type>
    </exp_acc_types>
    <study_designs/>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>Hôpital Henri Mondor, Creteil, France</location>
      <location>Hôpital Garches Raymond Poincaré, Garches, France</location>
      <location>Hôpital de Bicêtre, Le Kremlin Bicêtre, France</location>
      <location>Hôpital Saint Louis, Paris, France</location>
      <location>Hôpital Paul Brousse, Villejuif, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04355494</url>
  </study>
  <study rank="464">
    <nct_id>NCT04336384</nct_id>
    <title>Impact of Covid-19 in Congenital Heart Disease</title>
    <acronym>COVID-CHD</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Congenital Heart Disease</condition>
      <condition>Covid-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Prevalence of Covid-19 infection in the overall CHD population</outcome_measure>
      <outcome_measure>Prevalence of Covid-19 infection per CHD sub-group</outcome_measure>
      <outcome_measure>Cardiovascular complications</outcome_measure>
      <outcome_measure>Other complications</outcome_measure>
      <outcome_measure>Number of deaths</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Montpellier</lead_sponsor>
      <collaborator>Pr. Jean-Benoît THAMBO, Bordeaux (président)</collaborator>
      <collaborator>Dr. Céline GRUNENWALD GRONIER, Strasbourg</collaborator>
      <collaborator>Dr. Sébastien HASCOET, Le Plessis-Robinson</collaborator>
      <collaborator>Dr. Adeline BASQUIN, Rennes</collaborator>
      <collaborator>Dr. Nicolas COMBES, Toulouse</collaborator>
      <collaborator>Dr. Xavier IRIART, Bordeaux</collaborator>
      <collaborator>Dr. Daniela LAUX, Paris</collaborator>
      <collaborator>Dr. Magalie LADOUCEUR, Paris</collaborator>
      <collaborator>Pr. BERTRAND LEOBON, Toulouse</collaborator>
      <collaborator>Pr. Caroline OVAERT, Marseille</collaborator>
      <collaborator>Dr. Karine WARIN-FRESSE, Nantes</collaborator>
      <collaborator>Alexis BLANC, Montpellier</collaborator>
      <collaborator>Pr. Roland HENAINE, Lyon</collaborator>
      <collaborator>Hamouda ABASSI, Montpellier</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>5000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 1, 2020</start_date>
    <primary_completion_date>December 1, 2020</primary_completion_date>
    <completion_date>December 30, 2020</completion_date>
    <study_first_posted>April 7, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>Uh Montpellier, Montpellier, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04336384</url>
  </study>
  <study rank="465">
    <nct_id>NCT04320017</nct_id>
    <title>Joint Use of Electrocardiogram and Transthoracic Echocardiography With Other Clinico-biological Parameters in an Observational Study to Monitor Cardio-vascular Events and Predict Outcomes in Patients Diagnosed With COVID-19</title>
    <acronym>JOCOVID</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Myocardial Injury</condition>
      <condition>Myocarditis</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Electrocardiogram, transthoracic echocardiography and clinico-biological parameters in routine care</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Incidence of acute myocardial events in COVID-19 population at baseline and during hospital stay</outcome_measure>
      <outcome_measure>Description of cardiovascular outcomes in the cohort</outcome_measure>
      <outcome_measure>Prognosis role of baseline cardio-vascular caracteristics on patients survival</outcome_measure>
      <outcome_measure>Prediction of cardio-vascular events with baseline characteristics</outcome_measure>
      <outcome_measure>Characterization of inflammation on cardio-vascular outcomes</outcome_measure>
      <outcome_measure>Prognosis role of baseline clinico-biological caracteristics on patients transfer to ICU and survival</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Groupe Hospitalier Pitie-Salpetriere</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>16 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 20, 2020</start_date>
    <primary_completion_date>May 20, 2020</primary_completion_date>
    <completion_date>May 20, 2020</completion_date>
    <study_first_posted>March 24, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Clinical Investigation Center Pitié-Salpêtrière, Paris, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04320017</url>
  </study>
  <study rank="466">
    <nct_id>NCT04344938</nct_id>
    <title>Covid 19 Pandemic. Emerging Legal and Ehical Disputes Over Patient Confidentiality</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid 19 Pandemic From Ethical View</condition>
    </conditions>
    <interventions>
      <intervention type="Other">questionnair about Emerging Legal and Ehical Disputes Over Patient Confidentiality</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Evaluate the ethical requirement of controlled disrupts of patients In case of infectious disease pandemic</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assiut University</lead_sponsor>
      <collaborator>Doaa M.EL Shehaby</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>874</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Ecologic or Community</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>June 2020</primary_completion_date>
    <completion_date>July 2020</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04344938</url>
  </study>
  <study rank="467">
    <nct_id>NCT04366323</nct_id>
    <title>Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sars-CoV2</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Safety of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Adverse Event Rate</outcome_measure>
      <outcome_measure>Efficacy of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Survival Rate</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Andalusian Network for Design and Translation of Advanced Therapies</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>26</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>October 2021</primary_completion_date>
    <completion_date>October 2021</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04366323</url>
  </study>
  <study rank="468">
    <nct_id>NCT04352959</nct_id>
    <title>COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses</title>
    <acronym>BBCovid</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID19</condition>
      <condition>Mouthwash</condition>
      <condition>Saliva</condition>
    </conditions>
    <interventions>
      <intervention type="Device">mouthrinse with bêta-cyclodextrin and citrox</intervention>
      <intervention type="Device">mouthrinse without bêta-cyclodextrin and citrox</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change from Baseline amount of SARS-CoV-2 in salivary samples at 7 days</outcome_measure>
      <outcome_measure>Change from Baseline amount of SARS-CoV-2 virus in nasal samples at 7 days</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Claude Bernard University</lead_sponsor>
      <collaborator>University Hospital, Tours</collaborator>
      <collaborator>University Hospital, Montpellier</collaborator>
      <collaborator>Hospices Civils de Lyon</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>178</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 27, 2020</start_date>
    <primary_completion_date>May 20, 2020</primary_completion_date>
    <completion_date>June 20, 2020</completion_date>
    <study_first_posted>April 20, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04352959</url>
  </study>
  <study rank="469">
    <nct_id>NCT04355481</nct_id>
    <title>Dissemination of SARS-COV-2 (COVID-19) in the Environment of Infected Patients Admitted to Intensive Care Unit</title>
    <acronym>ENVIROREA</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid-19</condition>
      <condition>Viral Infection</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Estimate the proportion of patients hospitalized in intensive care for a SARS-Cov-2 viral lung infection and contaminating their environment at 1 meter.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 17, 2020</start_date>
    <primary_completion_date>October 17, 2020</primary_completion_date>
    <completion_date>December 17, 2020</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Service de réanimation Hôpital Avicenne, Bobigny, France</location>
      <location>Service de réanimation Hôpital Bichat, Paris, France</location>
      <location>Service de réanimation Hôpital Tenon, Paris, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04355481</url>
  </study>
  <study rank="470">
    <nct_id>NCT04357834</nct_id>
    <title>WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories</title>
    <acronym>WAVE</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
      <condition>COVID 19</condition>
      <condition>SARS-CoV 2</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Equipment with smartwatch throughout hospital stay on the general ward</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Diagnostic accuracy of smartwatch data in predicting ICU requirement in COVID-19 contracted inpatients quantified as the area under the receiver operator characteristics curve (AUC ROC &gt; 0.85).</outcome_measure>
      <outcome_measure>Diagnostic accuracy of routine physiological data in predicting ICU requirement in COVID-19 contracted in-patients quantified as the area under the receiver operator characteristics curve (AUC ROC &gt; 0.85).</outcome_measure>
      <outcome_measure>Diagnostic accuracy of predicting hospital discharge without ICU admission in COVID-19 contracted in-patients quantified as area under the receiver operator characteristics curve</outcome_measure>
      <outcome_measure>Change of heart rate from baseline (hospitalization) to ICU admission</outcome_measure>
      <outcome_measure>Change of heart rate variability from baseline (hospitalization) to ICU admission</outcome_measure>
      <outcome_measure>Change of skin temperature from baseline (hospitalization) to ICU admission</outcome_measure>
      <outcome_measure>Change of blood oxygen saturation from baseline (hospitalization) to ICU admission</outcome_measure>
      <outcome_measure>Change of respiration rate from baseline (hospitalization) to ICU admission</outcome_measure>
      <outcome_measure>Change of physical activity from baseline (hospitalization) to ICU admission</outcome_measure>
      <outcome_measure>Change of stress level from baseline (hospitalization) to ICU admission</outcome_measure>
      <outcome_measure>Change of sleep pattern from baseline (hospitalization) to ICU admission</outcome_measure>
      <outcome_measure>Change of steps per day from baseline (hospitalization) to ICU admission</outcome_measure>
      <outcome_measure>Change of systolic blood pressure from baseline (hospitalization) to ICU admission</outcome_measure>
      <outcome_measure>Change of diastolic blood pressure from baseline (hospitalization) to ICU admission</outcome_measure>
      <outcome_measure>Change of body temperature from baseline (hospitalization) to ICU admission</outcome_measure>
      <outcome_measure>Change of oxygen partial pressure (pO2) from baseline (hospitalization) to ICU admission</outcome_measure>
      <outcome_measure>Change of CO2 partial pressure (pCO2) from baseline (hospitalization) to ICU admission</outcome_measure>
      <outcome_measure>Change of blood pH from baseline (hospitalization) to ICU admission</outcome_measure>
      <outcome_measure>Change of bicarbonate from baseline (hospitalization) to ICU admission</outcome_measure>
      <outcome_measure>Change of base excess from baseline (hospitalization) to ICU admission</outcome_measure>
      <outcome_measure>Change of oxygen flow rate from baseline (hospitalization) to ICU admission</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital Inselspital, Berne</lead_sponsor>
      <collaborator>ETH Zurich</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>120 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>May 1, 2020</start_date>
    <primary_completion_date>July 31, 2020</primary_completion_date>
    <completion_date>July 31, 2020</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Emergency Department, University Hospital Bern, Inselspital, Bern, Switzerland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04357834</url>
  </study>
  <study rank="471">
    <nct_id>NCT04360486</nct_id>
    <title>Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)</title>
    <acronym/>
    <status open="Y">Available</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Severe Acute Respiratory Syndrome Coronavirus 2</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Anti-Sars-CoV-2 Convalescent Plasma</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>U.S. Army Medical Research and Development Command</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Expanded Access</study_types>
    <exp_acc_types>
      <exp_acc_type>Treatment IND/Protocol</exp_acc_type>
    </exp_acc_types>
    <study_designs/>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04360486</url>
  </study>
  <study rank="472">
    <nct_id>NCT04330300</nct_id>
    <title>Coronavirus (COVID-19) ACEi/ARB Investigation</title>
    <acronym>CORONACION</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hypertension</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Thiazide or Thiazide-like diuretics</intervention>
      <intervention type="Drug">Calcium Channel Blockers</intervention>
      <intervention type="Drug">ACE inhibitor</intervention>
      <intervention type="Drug">Angiotensin receptor blocker</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of Covid-19 positive participants who die, require intubation in ICU, or require hospitalization for non-invasive ventilation (NIV)</outcome_measure>
      <outcome_measure>Number of Covid-19 positive participants who die</outcome_measure>
      <outcome_measure>Number of Covid-19 positive participants who require intubation in intensive care unit (ICU)</outcome_measure>
      <outcome_measure>Number of Covid-19 positive participants who require hospitalization for non-invasive ventilation (NIV)</outcome_measure>
      <outcome_measure>Number of SARS-CoV-2 positive participants</outcome_measure>
      <outcome_measure>Maximum troponin T value (ng/L) among Covid-19 positive participants who require acute hospitalization</outcome_measure>
      <outcome_measure>24 hour mean systolic BP (mmHg) on ambulatory BP monitoring</outcome_measure>
      <outcome_measure>All-cause mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National University of Ireland, Galway, Ireland</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>60 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>2414</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>March 30, 2020</start_date>
    <primary_completion_date>January 31, 2021</primary_completion_date>
    <completion_date>March 1, 2021</completion_date>
    <study_first_posted>April 1, 2020</study_first_posted>
    <last_update_posted>April 13, 2020</last_update_posted>
    <locations>
      <location>University Hospital Galway, Galway, Ireland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04330300</url>
  </study>
  <study rank="473">
    <nct_id>NCT04350086</nct_id>
    <title>Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection</title>
    <acronym>PRODEX</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19 Infection</condition>
      <condition>Sars-cov-2</condition>
      <condition>Respiratory Failure</condition>
      <condition>Palliative Situation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Treatment with Dexmedetomidine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Efficacy of mild to moderate palliative sedation induced by Dexmedetomidine.</outcome_measure>
      <outcome_measure>Overall survival of patients on Dexmedetomidine</outcome_measure>
      <outcome_measure>Daily analgesic effect of Dexmedetomidine</outcome_measure>
      <outcome_measure>Other sedative pharmacological agents</outcome_measure>
      <outcome_measure>Average dosage required for Dexmedetomidine to achieve mild to moderate sedation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Limoges</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>November 20, 2020</primary_completion_date>
    <completion_date>November 20, 2020</completion_date>
    <study_first_posted>April 16, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations>
      <location>University Hospital, Limoges, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04350086</url>
  </study>
  <study rank="474">
    <nct_id>NCT04351191</nct_id>
    <title>PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds</title>
    <acronym>PRECISE</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sars-CoV2</condition>
      <condition>Symptomatic Condition</condition>
      <condition>Covid-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine Sulfate Regular dose</intervention>
      <intervention type="Drug">Hydroxychloroquine Sulfate Loading Dose</intervention>
      <intervention type="Drug">Chloroquine</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>RT-PCR negative status</outcome_measure>
      <outcome_measure>Progression of symptoms</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Government of Punjab, Specialized Healthcare and Medical Education Department</lead_sponsor>
      <collaborator>Mayo Hospital Lahore</collaborator>
      <collaborator>Services Hospital, Lahore</collaborator>
      <collaborator>Pakistan Kidney and Liver Institute</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>April 30, 2020</primary_completion_date>
    <completion_date>May 30, 2020</completion_date>
    <study_first_posted>April 17, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04351191</url>
  </study>
  <study rank="475">
    <nct_id>NCT04347694</nct_id>
    <title>Study to Determine the Immunization Status Among Nephrological Health Care Personnel Against SARS-CoV-2 in a Single Center Over the Course of 12 Months During the Worldwide COVID-19 Pandemic.</title>
    <acronym>CONEC</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV 2</condition>
      <condition>Immunization; Infection</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Status of Immunization</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Medical University of Vienna</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>100 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 11, 2020</start_date>
    <primary_completion_date>April 11, 2021</primary_completion_date>
    <completion_date>April 11, 2021</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Medical University of Vienna, Division for Nephrology and Dialysis, Vienna, Austria</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04347694</url>
  </study>
  <study rank="476">
    <nct_id>NCT04361591</nct_id>
    <title>COVID-19 in Liver Transplant Recipients</title>
    <acronym>COVID19-SETH</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Liver Transplant; Complications</condition>
      <condition>COVID19</condition>
      <condition>Respiratory Failure</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Observational only</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Incidence of COVID19 in LT recipients</outcome_measure>
      <outcome_measure>Clinical characteristics of COVID19 in LT recipients</outcome_measure>
      <outcome_measure>Survival and Mechanical ventilation / respiratory support</outcome_measure>
      <outcome_measure>Observed treatments and immunosuppression management</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hospital Clinic of Barcelona</lead_sponsor>
      <collaborator>Sociedad Española de Trasplante Hepático</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 1, 2020</start_date>
    <primary_completion_date>March 1, 2021</primary_completion_date>
    <completion_date>March 2021</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>SETH-affiliated Liver Transplant Programs in Spain, Barcelona, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04361591</url>
  </study>
  <study rank="477">
    <nct_id>NCT04331574</nct_id>
    <title>Renin-Angiotensin System Inhibitors and COVID-19</title>
    <acronym>SARS-RAS</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Hypertension</condition>
      <condition>Cardiovascular Diseases</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Numbers of COVID-19 patients enrolled that use ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents</outcome_measure>
      <outcome_measure>Numbers of COVID-19 patients enrolled with no symptoms, with moderate symptoms or with severe symptoms of pneumoni based on the WHO specification for ARDS that also used ACE inhibitors and/or Angiotensin Receptor Blockers (ARB) as antihypertensive agents</outcome_measure>
      <outcome_measure>Number and type of anthropometric and clinical parameters that associate with COVID19 and COVID-19 severity</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Societa Italiana dell'Ipertensione Arteriosa</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>120 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>2000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <start_date>March 10, 2020</start_date>
    <primary_completion_date>April 10, 2020</primary_completion_date>
    <completion_date>April 30, 2020</completion_date>
    <study_first_posted>April 2, 2020</study_first_posted>
    <last_update_posted>April 2, 2020</last_update_posted>
    <locations>
      <location>Spedali Civili di Brescia, Brescia, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04331574</url>
  </study>
  <study rank="478">
    <nct_id>NCT04321265</nct_id>
    <title>Outcomes and Prognostic Factors in COVID-19</title>
    <acronym>COVIP</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Elderly Patients</condition>
      <condition>Critical Illness</condition>
      <condition>Survival</condition>
      <condition>Old Age</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Survival</outcome_measure>
      <outcome_measure>Fragilty</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Heinrich-Heine University, Duesseldorf</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>70 Years</min_age>
    <age_groups>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>4000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 19, 2020</start_date>
    <primary_completion_date>September 2020</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>March 25, 2020</study_first_posted>
    <last_update_posted>April 8, 2020</last_update_posted>
    <locations>
      <location>Department of Intensive Care, Aarhus University Hospital, Aarhus, Denmark</location>
      <location>Hôpitaux de Paris, Hôpital Saint-Antoine, service de réanimation médicale, Paris, France</location>
      <location>INSERM, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France</location>
      <location>Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France</location>
      <location>Division of Cardiology, Pulmonary Disease and Vascular Medicine, Duesseldorf, Germany</location>
      <location>Department of Anaestesia and Intensive Care, Haukeland University Hospital, Bergen, Norway</location>
      <location>Department of Clinical Medecine,University of Bergen, Bergen, Norway</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04321265</url>
  </study>
  <study rank="479">
    <nct_id>NCT04328961</nct_id>
    <title>Hydroxychloroquine for COVID-19 PEP</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Corona Virus Infection</condition>
      <condition>SARS (Severe Acute Respiratory Syndrome)</condition>
      <condition>SARS-CoV-2</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine Sulfate</intervention>
      <intervention type="Drug">Ascorbic Acid</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Polymerase chain reaction (PCR) confirmed SARS-CoV-2 infection</outcome_measure>
      <outcome_measure>Rate of participant-reported adverse events</outcome_measure>
      <outcome_measure>Incidence rates of COVID-19 through study completion</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Washington</lead_sponsor>
      <collaborator>Bill and Melinda Gates Foundation</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>2000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>March 31, 2020</start_date>
    <primary_completion_date>September 30, 2020</primary_completion_date>
    <completion_date>October 31, 2020</completion_date>
    <study_first_posted>April 1, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations>
      <location>University of California Los Angeles, Los Angeles, California, United States</location>
      <location>Tulane, New Orleans, Louisiana, United States</location>
      <location>University of Maryland, Baltimore, Baltimore, Maryland, United States</location>
      <location>Boston University, Boston, Massachusetts, United States</location>
      <location>NYU Langone Health, New York, New York, United States</location>
      <location>SUNY Upstate Medical University, Syracuse, New York, United States</location>
      <location>University of Washington, Coordinating Center, Seattle, Washington, United States</location>
      <location>UW Virology Research Clinic, Seattle, Washington, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04328961</url>
  </study>
  <study rank="480">
    <nct_id>NCT04327206</nct_id>
    <title>BCG Vaccination to Protect Healthcare Workers Against COVID-19</title>
    <acronym>BRACE</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Disease 2019 (COVID-19)</condition>
      <condition>Febrile Respiratory Illness</condition>
      <condition>Corona Virus Infection</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BCG Vaccine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>COVID-19 disease incidence</outcome_measure>
      <outcome_measure>Severe COVID-19 disease incidence</outcome_measure>
      <outcome_measure>COVID-19 incidence by 12 months</outcome_measure>
      <outcome_measure>Severe COVID-19 incidence by 12 months</outcome_measure>
      <outcome_measure>Time to first symptom of COVID-19</outcome_measure>
      <outcome_measure>Episodes of COVID-19</outcome_measure>
      <outcome_measure>Asymptomatic SARS-CoV-2 infection</outcome_measure>
      <outcome_measure>Work absenteeism due to COVID-19</outcome_measure>
      <outcome_measure>Bed confinement due to COVID-19</outcome_measure>
      <outcome_measure>Symptom duration of COVID-19</outcome_measure>
      <outcome_measure>SARS-CoV-2 pneumonia</outcome_measure>
      <outcome_measure>Oxygen therapy with SARS-CoV-2</outcome_measure>
      <outcome_measure>Critical care admissions with SARS-CoV-2</outcome_measure>
      <outcome_measure>Critical care admission duration with SARS-CoV-2</outcome_measure>
      <outcome_measure>Mechanical ventilation with SARS-CoV-2</outcome_measure>
      <outcome_measure>Mechanical ventilation duration with SARS-CoV-2</outcome_measure>
      <outcome_measure>Hospitalisation duration with COVID-19</outcome_measure>
      <outcome_measure>Mortality with SARS-CoV-2</outcome_measure>
      <outcome_measure>Febrile respiratory illness</outcome_measure>
      <outcome_measure>Episodes of febrile respiratory illness</outcome_measure>
      <outcome_measure>Work absenteeism due to febrile respiratory illness</outcome_measure>
      <outcome_measure>Bed confinement due to febrile respiratory illness</outcome_measure>
      <outcome_measure>Symptom duration of febrile respiratory illness</outcome_measure>
      <outcome_measure>Pneumonia</outcome_measure>
      <outcome_measure>Oxygen therapy</outcome_measure>
      <outcome_measure>Critical care admissions</outcome_measure>
      <outcome_measure>Mechanical ventilation</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>Hospitalisation duration with febrile respiratory illness</outcome_measure>
      <outcome_measure>Unplanned work absenteeism</outcome_measure>
      <outcome_measure>Hospitalisation cost to treat COVID-19</outcome_measure>
      <outcome_measure>Local and systemic adverse events to BCG vaccination in healthcare workers</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Murdoch Childrens Research Institute</lead_sponsor>
      <collaborator>Royal Children's Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>4170</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>March 30, 2020</start_date>
    <primary_completion_date>October 30, 2020</primary_completion_date>
    <completion_date>March 30, 2022</completion_date>
    <study_first_posted>March 31, 2020</study_first_posted>
    <last_update_posted>April 7, 2020</last_update_posted>
    <locations>
      <location>Epworth Victoria Parade, Melbourne, Victoria, Australia</location>
      <location>Royal Children's Hospital, Melbourne, Victoria, Australia</location>
      <location>Epworth Richmond, Melbourne, Victoria, Australia</location>
      <location>Epworth Eastern, Melbourne, Victoria, Australia</location>
      <location>Monash Health- Monash Medical Centre, Melbourne, Victoria, Australia</location>
      <location>Fiona Stanley Hospital, Murdoch, Western Australia, Australia</location>
      <location>Perth Children's Hospital, Perth, Western Australia, Australia</location>
      <location>Sir Charles Gairdner Hospital, Perth, Western Australia, Australia</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04327206</url>
  </study>
  <study rank="481">
    <nct_id>NCT04358406</nct_id>
    <title>Rhu-pGSN for Severe Covid-19 Pneumonia</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sars-CoV2</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Recombinant human plasma gelsolin (Rhu-pGSN)</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Efficacy: Proportion of subjects alive not on vasopressors, mechanical ventilator, and dialysis</outcome_measure>
      <outcome_measure>Safety and Tolerability: Proportion of subjects with serious adverse events (SAEs)</outcome_measure>
      <outcome_measure>Efficacy: All cause mortality rate though Day 28</outcome_measure>
      <outcome_measure>Efficacy: Change in World Health Organisation (WHO) 9-point severity score</outcome_measure>
      <outcome_measure>Efficacy: Proportion of subjects discharged to home or immediate prior residence</outcome_measure>
      <outcome_measure>Efficacy: Number of days alive and off the ventilator</outcome_measure>
      <outcome_measure>Efficacy: Length of stay (LOS) of surviving subjects in the hospital</outcome_measure>
      <outcome_measure>Efficacy: Proportion of subjects readmitted to the hospital</outcome_measure>
      <outcome_measure>Safety and Tolerability: Proportion of subjects with Grade 3-4 clinically significant laboratory abnormalities.</outcome_measure>
      <outcome_measure>Safety and Tolerability: Proportion of subjects with non-serious adverse events (AEs)</outcome_measure>
      <outcome_measure>Immunogenicity: Proportion of subjects with anti-pGSN antibodies</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>BioAegis Therapeutics Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>June 2020</start_date>
    <primary_completion_date>August 2020</primary_completion_date>
    <completion_date>September 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04358406</url>
  </study>
  <study rank="482">
    <nct_id>NCT04357782</nct_id>
    <title>Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation</title>
    <acronym>AVoCaDO</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Hypoxia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">L-ascorbic acid</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Incidence of adverse events</outcome_measure>
      <outcome_measure>Incidence of serious adverse reactions</outcome_measure>
      <outcome_measure>Incidence of adverse reactions</outcome_measure>
      <outcome_measure>Ventilator-free days</outcome_measure>
      <outcome_measure>ICU-free days</outcome_measure>
      <outcome_measure>Hospital-free days</outcome_measure>
      <outcome_measure>All-cause mortality</outcome_measure>
      <outcome_measure>Change in S/F ratio during HDIVC infusion</outcome_measure>
      <outcome_measure>C-reactive protein (CRP)</outcome_measure>
      <outcome_measure>Lactate dehydrogenase (LDH)</outcome_measure>
      <outcome_measure>D-dimer</outcome_measure>
      <outcome_measure>Lymphocyte count</outcome_measure>
      <outcome_measure>Neutrophil to Lymphocyte ratio (NLR)</outcome_measure>
      <outcome_measure>Serum Ferritin</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hunter Holmes Mcguire Veteran Affairs Medical Center</lead_sponsor>
      <collaborator>McGuire Research Institute</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>99 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 16, 2020</start_date>
    <primary_completion_date>June 1, 2020</primary_completion_date>
    <completion_date>August 1, 2020</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Hunter Holmes Mcguire Veteran Affairs Medical Center, Richmond, Virginia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04357782</url>
  </study>
  <study rank="483">
    <nct_id>NCT04333732</nct_id>
    <title>CROWN CORONATION: Chloroquine RepurpOsing to healthWorkers for Novel CORONAvirus mitigaTION</title>
    <acronym>CROWN CORONA</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID 19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Low-dose chloroquine/hydroxychloroquine</intervention>
      <intervention type="Drug">Mid dose chloroquine or hydroxychloroquine</intervention>
      <intervention type="Drug">High does chloroquine or hydroxychloroquine</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Symptomatic COVID-19</outcome_measure>
      <outcome_measure>Peak severity of COVID-19 over the study period</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Washington University School of Medicine</lead_sponsor>
      <collaborator>Bill and Melinda Gates Foundation</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>55000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>February 2021</primary_completion_date>
    <completion_date>February 2021</completion_date>
    <study_first_posted>April 3, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>Washington University School of Medicine, Saint Louis, Missouri, United States</location>
      <location>Melbourne Medical School, Melbourne, Victoria, Australia</location>
      <location>Population Health Resarch Institute, Hamilton, Ontario, Canada</location>
      <location>University of Toronto, Toronto, Ontario, Canada</location>
      <location>St James's Hospital, Dublin, Leinster, Ireland</location>
      <location>Universitas Academic Hospital, Bloemfontein, Free State, South Africa</location>
      <location>Wits RHI, University of the Witwatersrand, Johannesburg, Gauteng, South Africa</location>
      <location>Steve Biko Academic Hospital, Pretoria, Gauteng, South Africa</location>
      <location>Tygerberg Hospital, Cape Town, Western Cape, South Africa</location>
      <location>Groote Schuur Hospital, Cape Town, Western Cape, South Africa</location>
      <location>University College London, London, United Kingdom</location>
      <location>Centre for Infectious Disease Research in Zambia [CIDRZ], Lusaka, Zambia</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04333732</url>
  </study>
  <study rank="484">
    <nct_id>NCT04326790</nct_id>
    <title>The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention</title>
    <acronym>GRECCO-19</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Corona Virus Disease 19 (Covid 19)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Colchicine</intervention>
      <intervention type="Drug">Standard treatment</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>CRP increase to 3 x upper limit of normal</outcome_measure>
      <outcome_measure>Clinical deterioration in the semiquantitative ordinal scale suggested by the WHO R&amp;D committee</outcome_measure>
      <outcome_measure>Maximal concentration of cardiac troponin</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National and Kapodistrian University of Athens</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>180</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 6, 2020</start_date>
    <primary_completion_date>August 31, 2020</primary_completion_date>
    <completion_date>September 30, 2020</completion_date>
    <study_first_posted>March 30, 2020</study_first_posted>
    <last_update_posted>April 2, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04326790</url>
  </study>
  <study rank="485">
    <nct_id>NCT04345601</nct_id>
    <title>Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sars-CoV2</condition>
      <condition>Acute Respiratory Distress Syndrome</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Genetic">Mesenchymal Stromal Cells</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Incidence of unexpected adverse events</outcome_measure>
      <outcome_measure>Improved oxygen saturations ≥93%</outcome_measure>
      <outcome_measure>Decrease in oxygen supplementation by non-invasive or invasive interventions</outcome_measure>
      <outcome_measure>Frequency of progression to mechanical ventilation or ECMO</outcome_measure>
      <outcome_measure>Duration of mechanical ventilation</outcome_measure>
      <outcome_measure>Duration of ICU stay</outcome_measure>
      <outcome_measure>Duration of hospital stay</outcome_measure>
      <outcome_measure>All-cause mortality at day 28</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Baylor College of Medicine</lead_sponsor>
      <collaborator>Center for Cell and Gene Therapy, Baylor College of Medicine</collaborator>
      <collaborator>The Methodist Hospital System</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Early Phase 1</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 2020</start_date>
    <primary_completion_date>February 2022</primary_completion_date>
    <completion_date>February 2022</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>Houston Methodist Hospital, Houston, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04345601</url>
  </study>
  <study rank="486">
    <nct_id>NCT04355702</nct_id>
    <title>Covid-19 in Lupus Patients</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Systemic Lupus Erythematosus</condition>
      <condition>Covid-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>prevalence and severity of Covid-19 infection in patients with SLE</outcome_measure>
      <outcome_measure>prevalence and severity of Covid-19 infection in patients treated by hydroxychloroquine</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Montpellier</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>130</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>March 1, 2020</start_date>
    <primary_completion_date>May 1, 2020</primary_completion_date>
    <completion_date>May 30, 2020</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>Uhmontpellier, Montpellier, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04355702</url>
  </study>
  <study rank="487">
    <nct_id>NCT04339712</nct_id>
    <title>Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction</title>
    <acronym>ESCAPE</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Virus Diseases</condition>
      <condition>Macrophage Activation Syndrome</condition>
      <condition>Corona Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Anakinra</intervention>
      <intervention type="Drug">Tocilizumab</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change of baseline total sequential organ failure assessment (SOFA) score</outcome_measure>
      <outcome_measure>Improvement of lung involvement measurements</outcome_measure>
      <outcome_measure>Increase of pO2/FiO2 ratio</outcome_measure>
      <outcome_measure>Comparison of change of baseline total sequential organ failure assessment (SOFA) score in enrolled subjects towards historical comparators</outcome_measure>
      <outcome_measure>Comparison of change of lung involvement measurements in enrolled subjects towards historical comparators</outcome_measure>
      <outcome_measure>Comparison of pO2/FiO2 ratio in enrolled subjects towards historical comparators</outcome_measure>
      <outcome_measure>Change of sequential organ failure assessment (SOFA) score</outcome_measure>
      <outcome_measure>Rate of Mortality</outcome_measure>
      <outcome_measure>Cytokine stimulation</outcome_measure>
      <outcome_measure>Gene expression</outcome_measure>
      <outcome_measure>Serum/plasma proteins</outcome_measure>
      <outcome_measure>Classification of the immune function</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hellenic Institute for the Study of Sepsis</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2, 2020</start_date>
    <primary_completion_date>April 1, 2022</primary_completion_date>
    <completion_date>April 1, 2022</completion_date>
    <study_first_posted>April 9, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>2nd Department of Critical Care Medicine, ATTIKON University Hospital, Athens, Haidari, Greece</location>
      <location>Intensive Care Unit, Ioannina University Hospital, Ioánnina, Ioannina, Greece</location>
      <location>Department of Internal Medicine, Patras University Hospital, Patras, Rion, Greece</location>
      <location>Department of Internal Medicine, I PAMMAKARISTOS Hospital, Athens, Greece</location>
      <location>Intensive Care Unit, General Hospital of Athens KORGIALENIO-BENAKIO E.E.S., Athens, Greece</location>
      <location>1st Department of Pulmonary Medicine and Intensive Care Unit, Athens, Greece</location>
      <location>Intensive Care Unit, General Hospital of Athens IPPOKRATEIO, Athens, Greece</location>
      <location>4th Department of Internal Medicine, Attikon University Hospital, Athens, Greece</location>
      <location>Intensive Care Unit, General Hospital ASKLEPIEIO Voulas, Athens, Greece</location>
      <location>Intensive Care Unit, &quot;Latsio&quot;, Thriasio Elefsis General Hospital, Elefsína, Greece</location>
      <location>Intensive Care Unit, &quot;Koutlimbaneio &amp; Triantafylleio&quot; Larissa General Hospital, Larissa, Greece</location>
      <location>Department of Internal Medicine, Larissa University Hospital, Larissa, Greece</location>
      <location>Intensive Care Unit, AGIOS DIMITRIOS General Hospital of Thessaloniki, Thessaloniki, Greece</location>
      <location>Intensive Care Unit, G. GENNIMATAS General Hospital of Thessaloniki, Thessaloniki, Greece</location>
      <location>Intensive Care Unit, Theageneio Oncological Hospital of Thessaloniki, Thessaloniki, Greece</location>
      <location>Intensive Care Unit, General Hospital of Thessaloniki IPPOKRATEIO, Thessaloniki, Greece</location>
      <location>Department of Anesthesiology and Intensive Care Medicine, University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04339712</url>
  </study>
  <study rank="488">
    <nct_id>NCT04331054</nct_id>
    <title>Protective Role of Inhaled Steroids for Covid-19 Infection</title>
    <acronym>INHASCO</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid-19 Infection</condition>
      <condition>Hospitalization in Respiratory Disease Department</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">2: Usual practice + SYMBICORT RAPIHALER</intervention>
      <intervention type="Other">1: Usual practice</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time (in days) to clinical improvement within 30 days after randomization</outcome_measure>
      <outcome_measure>Mortality rate at D30</outcome_measure>
      <outcome_measure>Time (in days) from randomization to death</outcome_measure>
      <outcome_measure>Number of days alive outside ICU within 30 days</outcome_measure>
      <outcome_measure>Number of days alive free of invasive or non-invasive ventilation within 30 days</outcome_measure>
      <outcome_measure>Number of days alive with oxygen therapy within 30 days</outcome_measure>
      <outcome_measure>Maximal oxygen rate within 30 days</outcome_measure>
      <outcome_measure>Difference between PaO2/FiO2 ratio at randomization and at Day 7 (or at the time of stopping oxygen therapy or discharge if occurs before Day 7)</outcome_measure>
      <outcome_measure>Number of days alive outside hospital within 30 days</outcome_measure>
      <outcome_measure>Use of antibiotics for respiratory (proved or suspected) infection within 30 days</outcome_measure>
      <outcome_measure>Difference between CRP levels at randomization and at Day 7 (or at the time of discharge if occurs before Day 7)</outcome_measure>
      <outcome_measure>Safety outcomes included events that occurred during treatment, serious adverse events, and premature discontinuation of treatment.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>436</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 13, 2020</start_date>
    <primary_completion_date>July 13, 2020</primary_completion_date>
    <completion_date>July 13, 2020</completion_date>
    <study_first_posted>April 2, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations>
      <location>Hôpital Bichat - Service de Pneumologie, Paris, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04331054</url>
  </study>
  <study rank="489">
    <nct_id>NCT04292964</nct_id>
    <title>Prognostic Factors of Patients With COVID-19</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV-2</condition>
      <condition>Outcome, Fatal</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>all-cause mortality</outcome_measure>
      <outcome_measure>Severe state</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Chongqing Medical University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>201</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>March 1, 2020</start_date>
    <primary_completion_date>March 13, 2020</primary_completion_date>
    <completion_date>March 13, 2020</completion_date>
    <study_first_posted>March 3, 2020</study_first_posted>
    <last_update_posted>March 17, 2020</last_update_posted>
    <locations>
      <location>The First Affiliated Hospital of Chongqing Medical University, Chongqing, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04292964</url>
  </study>
  <study rank="490">
    <nct_id>NCT04362995</nct_id>
    <title>St. Jude Tracking of Viral and Host Factors Associated With COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Coronavirus Infection</condition>
      <condition>Coronavirus</condition>
      <condition>SARS-CoV-2</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Proportion of asymptomatic subjects</outcome_measure>
      <outcome_measure>Positive CD4 and CD8 cell epitope positive response</outcome_measure>
      <outcome_measure>Proportion of seroprevalence</outcome_measure>
      <outcome_measure>T-cell response</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>St. Jude Children's Research Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1517</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 23, 2020</start_date>
    <primary_completion_date>April 20, 2021</primary_completion_date>
    <completion_date>March 20, 2025</completion_date>
    <study_first_posted>April 27, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>St. Jude Children's Research Hospital, Memphis, Tennessee, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04362995</url>
  </study>
  <study rank="491">
    <nct_id>NCT04337346</nct_id>
    <title>Evaluation of Covid 19 Anxiety in Endometriosis Patients</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Endometriosis</condition>
      <condition>Covid19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Covid 19 Anxiety levels in Endometriosis Patients</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Kanuni Sultan Suleyman Training and Research Hospital</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 5, 2020</start_date>
    <primary_completion_date>April 20, 2020</primary_completion_date>
    <completion_date>April 25, 2020</completion_date>
    <study_first_posted>April 7, 2020</study_first_posted>
    <last_update_posted>April 7, 2020</last_update_posted>
    <locations>
      <location>Pinar Yalcin Bahat, Istanbul, İ̇stanbul, Turkey</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04337346</url>
  </study>
  <study rank="492">
    <nct_id>NCT04346212</nct_id>
    <title>Oropharyngeal Dysphagia in Patients With COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Oropharyngeal Dysphagia</condition>
      <condition>COVID-19</condition>
      <condition>Sars-CoV2</condition>
      <condition>Nutrition</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Swallowing evaluation with the EAT-10 and the volume-viscosity swallowing test (V-VST)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Prevalence of oropharyngeal dysphagia</outcome_measure>
      <outcome_measure>Swallowing screening</outcome_measure>
      <outcome_measure>Swallowing status.</outcome_measure>
      <outcome_measure>Nutritonal status of study patient's.</outcome_measure>
      <outcome_measure>Needs of compensatory treatments in those patients with oropharyngeal dysphagia (fluid adaptation).</outcome_measure>
      <outcome_measure>Needs of compensatory treatments in those patients with oropharyngeal dysphagia (nutritional adaptation).</outcome_measure>
      <outcome_measure>Clinical complications at 6 months follow up from patient's medical history (incidence of readmissions).</outcome_measure>
      <outcome_measure>Clinical complications at 6 months follow up from patient's medical history (prevalence of readmissions).</outcome_measure>
      <outcome_measure>Clinical complications at 6 months follow up from patient's medical history (number of visits to emergency department).</outcome_measure>
      <outcome_measure>Clinical complications at 6 months follow up from patient's medical history (percentage of visits to emergency department).</outcome_measure>
      <outcome_measure>Clinical complications at 6 months follow up from patient's medical history (respiratory complications).</outcome_measure>
      <outcome_measure>Clinical complications at 6 months follow up from patient's medical history (mortality).</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hospital de Mataró</lead_sponsor>
      <collaborator>Centro Investigación Biomédica en Red de Enfermedades Hepáticas Digestivas</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 14, 2020</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>August 2020</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Consorci Sanitari del Maresme (Hospital de Mataró), Mataró, Barcelona, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04346212</url>
  </study>
  <study rank="493">
    <nct_id>NCT04344184</nct_id>
    <title>Early Infusion of Vitamin C for Treatment of Novel COVID-19 Acute Lung Injury (EVICT-CORONA-ALI)</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Lung Injury, Acute</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">L-ascorbic acid</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of ventilator-free days</outcome_measure>
      <outcome_measure>All-cause-mortality</outcome_measure>
      <outcome_measure>Acute-inflammation-free days</outcome_measure>
      <outcome_measure>Organ-failure-free days</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Virginia Commonwealth University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>June 2020</start_date>
    <primary_completion_date>May 2021</primary_completion_date>
    <completion_date>May 2021</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Hunter Holmes McGuire VA Medical Center, Richmond, Virginia, United States</location>
      <location>Virginia Commonwealth University, Richmond, Virginia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04344184</url>
  </study>
  <study rank="494">
    <nct_id>NCT04338698</nct_id>
    <title>Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT</title>
    <acronym>PROTECT</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID 19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Drug">Oseltamivir</intervention>
      <intervention type="Drug">Azithromycin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Laboratory Result</outcome_measure>
      <outcome_measure>Clinical Outcome</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Shehnoor Azhar</lead_sponsor>
      <collaborator>Federal Task Force on Science &amp; Technology notified by Government of Pakistan</collaborator>
      <collaborator>University of Health Sciences Lahore</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 7, 2020</start_date>
    <primary_completion_date>September 1, 2020</primary_completion_date>
    <completion_date>November 30, 2020</completion_date>
    <study_first_posted>April 8, 2020</study_first_posted>
    <last_update_posted>April 10, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04338698</url>
  </study>
  <study rank="495">
    <nct_id>NCT04325646</nct_id>
    <title>Sero-epidemiological Study of the SARS-CoV-2 Virus in France: Constitution of a Collection of Human Biological Samples</title>
    <acronym>CORSER</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS (Severe Acute Respiratory Syndrome)</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Human Biological samples</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Presence of specific anti-SARS-CoV-2 antibodies in the different study groups.</outcome_measure>
      <outcome_measure>Percentage of asymptomatic forms in individuals with anti-SARS-CoV-2 antibodies</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Institut Pasteur</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>5 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 13, 2020</start_date>
    <primary_completion_date>February 28, 2021</primary_completion_date>
    <completion_date>February 28, 2023</completion_date>
    <study_first_posted>March 27, 2020</study_first_posted>
    <last_update_posted>March 31, 2020</last_update_posted>
    <locations>
      <location>CHU Amiens-Picardie, Amiens, France</location>
      <location>CHU François Mitterand, Dijon, France</location>
      <location>CHU Limoges, Limoges, France</location>
      <location>Hôpital de la Croix Rousse, Lyon, France</location>
      <location>Hôpitaux de Brabois, Nancy, France</location>
      <location>CHR Orléans, Orléans, France</location>
      <location>Institut Pasteur, Paris, France</location>
      <location>CHU Poitiers, Poitiers, France</location>
      <location>Hôpital Pontchaillou, Rennes, France</location>
      <location>CHU Saint-Etienne, Saint-Étienne, France</location>
      <location>CH de Tourcoing, Tourcoing, France</location>
      <location>Hôpital Bretonneau, Tours, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04325646</url>
  </study>
  <study rank="496">
    <nct_id>NCT04351503</nct_id>
    <title>A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City; COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS Coronavirus (SARS-CoV-2) Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Study A</intervention>
      <intervention type="Other">Study B</intervention>
      <intervention type="Other">Study C</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Identification of factors associated with (i) infection (binary, yes/no), (ii) hospitalization (binary, yes/no), (iii) requirement for ICU treatment (binary, yes/no)</outcome_measure>
      <outcome_measure>duration of hospitalization (in days)</outcome_measure>
      <outcome_measure>duration of Intensive Care Unit (ICU) stay (in days)</outcome_measure>
      <outcome_measure>in-hospital mortality (binary, yes/no)</outcome_measure>
      <outcome_measure>Number of infected cases within the city of Basel</outcome_measure>
      <outcome_measure>whole genome sequencing to study pathogen evolution (number, type, and complexity of viral genome)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Basel, Switzerland</lead_sponsor>
      <collaborator>sciCORE University of Basel</collaborator>
      <collaborator>Leonhard Med IT ETH Zurich</collaborator>
      <collaborator>Swiss Institute of Bioinformatics</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>10000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>April 9, 2020</start_date>
    <primary_completion_date>April 2022</primary_completion_date>
    <completion_date>April 2022</completion_date>
    <study_first_posted>April 17, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Viollier AG, Allschwil, Switzerland</location>
      <location>University Hospital Basel, Basel, Switzerland</location>
      <location>Biozentrum University of Basel, Basel, Switzerland</location>
      <location>sciCore University of Basel, Basel, Switzerland</location>
      <location>Department of Biosystems Science and Engineering ETH Zurich, Basel, Switzerland</location>
      <location>Swiss Institute of Bioinformatics, Geneva, Switzerland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04351503</url>
  </study>
  <study rank="497">
    <nct_id>NCT04335786</nct_id>
    <title>Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Respiratory Distress Syndrome, Adult</condition>
      <condition>SARS-CoV-2</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Valsartan (Diovan)</intervention>
      <intervention type="Drug">Placebo oral tablet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>first occurrence of intensive care unit admission, mechanical ventilation or death</outcome_measure>
      <outcome_measure>Death</outcome_measure>
      <outcome_measure>Mechanical ventilation</outcome_measure>
      <outcome_measure>Intensive care unit admission</outcome_measure>
      <outcome_measure>Occurrence of acute kidney injury</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Radboud University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>651</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>August 2021</completion_date>
    <study_first_posted>April 6, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands</location>
      <location>Rijnstate, Arnhem, Netherlands</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04335786</url>
  </study>
  <study rank="498">
    <nct_id>NCT04361604</nct_id>
    <title>Clinical Characterisation Protocol for COVID-19 in People Living With HIV</title>
    <acronym>COVIDHIV</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Adult Patients Living With HIV (PLWHIV) With Confirmed Infection With SARS-CoV-2 Since 1st January 2020</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Biological collection (patients co infected HIV Sras-CoV-2)</intervention>
      <intervention type="Other">Auto-questionnaires (patients co infected HIV Sras-CoV-2)</intervention>
      <intervention type="Other">Qualitative interviews (in 40 patients : 20 with COVID-19 and 20 without COVID-19)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Describe the course of COVID-19 disease in patients infected with HIV,</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>270</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Other</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>October 2020</primary_completion_date>
    <completion_date>October 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Department of Internal Medicine and Clinical Immunology of Professor Cécile Goujard, Le Kremlin-Bicêtre, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04361604</url>
  </study>
  <study rank="499">
    <nct_id>NCT04335552</nct_id>
    <title>Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV-2</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Standard of care</intervention>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Drug">Azithromycin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>World Health Organization (WHO) ordinal scale measured at 14 days after enrollment</outcome_measure>
      <outcome_measure>Rates of death during the index hospitalization</outcome_measure>
      <outcome_measure>Number of days on mechanical ventilation for patients who were on mechanical ventilation at baseline</outcome_measure>
      <outcome_measure>Proportion of patients not receiving mechanical ventilation at baseline who progress to requiring mechanical ventilation during the index hospitalization</outcome_measure>
      <outcome_measure>WHO ordinal scale measured at 28 days after enrollment</outcome_measure>
      <outcome_measure>Hospital length of stay in days for the index hospitalization</outcome_measure>
      <outcome_measure>Rates of all-cause study medication discontinuation</outcome_measure>
      <outcome_measure>Rates of severe adverse events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Duke University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>12 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 17, 2020</start_date>
    <primary_completion_date>August 1, 2020</primary_completion_date>
    <completion_date>August 1, 2020</completion_date>
    <study_first_posted>April 6, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Duke Regional Hospital, Durham, North Carolina, United States</location>
      <location>Duke University Hospital, Durham, North Carolina, United States</location>
      <location>Durham VA Medical Center, Durham, North Carolina, United States</location>
      <location>Duke Raleigh Hospital, Raleigh, North Carolina, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04335552</url>
  </study>
  <study rank="500">
    <nct_id>NCT04345848</nct_id>
    <title>Preventing COVID-19 Complications With Low- and High-dose Anticoagulation</title>
    <acronym>COVID-HEP</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
      <condition>Sars-CoV2</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Enoxaparin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Composite outcome of arterial or venous thrombosis, disseminated intravascular coagulation and all-cause mortality</outcome_measure>
      <outcome_measure>Arterial thrombosis</outcome_measure>
      <outcome_measure>Venous thromboembolism</outcome_measure>
      <outcome_measure>Disseminated intravascular coagulation</outcome_measure>
      <outcome_measure>All-cause mortality</outcome_measure>
      <outcome_measure>Sepsis-induced coagulopathy</outcome_measure>
      <outcome_measure>Acute respiratory distress syndrome</outcome_measure>
      <outcome_measure>Durations of hospital stay, ICU stay, ventilation</outcome_measure>
      <outcome_measure>Sequential organ failure assessment score</outcome_measure>
      <outcome_measure>Clinical deterioration</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Geneva</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 14, 2020</start_date>
    <primary_completion_date>November 30, 2020</primary_completion_date>
    <completion_date>November 30, 2020</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>Geneva University Hospitals, Geneva, Switzerland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04345848</url>
  </study>
  <study rank="501">
    <nct_id>NCT04342806</nct_id>
    <title>Healthcare Worker Exposure Response and Outcomes (HERO) Registry Study, COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Health Care Worker (HCW)</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Number and percent of participants who enroll in the HERO Registry Study by geographic region, age, COVID-19 risk factors, and past COVID-19 diagnosis</outcome_measure>
      <outcome_measure>Distribution of COVID-19 risk factors by participant characteristics</outcome_measure>
      <outcome_measure>Proportion of participants undergoing changes in health status (e.g. new diagnosis of COVID-19, ER visits, hospitalization)</outcome_measure>
      <outcome_measure>Proportion of all participants enrolled in the HERO Registry who participate in an ancillary research study</outcome_measure>
      <outcome_measure>Proportion of participants who continue to supple information about their health to the HERO Registry at various time points after their enrollment</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Duke University</lead_sponsor>
      <collaborator>Patient-Centered Outcomes Research Institute</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>89 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 10, 2020</start_date>
    <primary_completion_date>December 31, 2099</primary_completion_date>
    <completion_date>December 31, 2099</completion_date>
    <study_first_posted>April 13, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>Duke Clinical Research Institute, Durham, North Carolina, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04342806</url>
  </study>
  <study rank="502">
    <nct_id>NCT04337320</nct_id>
    <title>Evaluation of Postnatal Outcomes of Covid 19 Positive Mothers Newborns</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid19</condition>
      <condition>Newborn Morbidity</condition>
    </conditions>
    <interventions>
      <intervention type="Other">newborns from covid 19 positive mothers</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Evaluation of apgar status of newborns from covid 19 positive mothers</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Kanuni Sultan Suleyman Training and Research Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <max_age>15 Minutes</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases/>
    <enrollment>70</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>June 15, 2020</primary_completion_date>
    <completion_date>June 20, 2020</completion_date>
    <study_first_posted>April 7, 2020</study_first_posted>
    <last_update_posted>April 7, 2020</last_update_posted>
    <locations>
      <location>Pinar Yalcin Bahat, Istanbul, İ̇stanbul, Turkey</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04337320</url>
  </study>
  <study rank="503">
    <nct_id>NCT04365517</nct_id>
    <title>The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients</title>
    <acronym>SIDIACO</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid19</condition>
      <condition>Diabetes Mellitus, Type 2</condition>
      <condition>CKD</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sitagliptin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time for clinical improvement</outcome_measure>
      <outcome_measure>Clinical parameter of acute lung disease</outcome_measure>
      <outcome_measure>Biochemical parameter of acute lung disease</outcome_measure>
      <outcome_measure>Clinical parameters of acute lung disease</outcome_measure>
      <outcome_measure>Dipeptilpeptidase 4 expression in biological samples</outcome_measure>
      <outcome_measure>Cytokine-inflammatory profile</outcome_measure>
      <outcome_measure>Glycemic variability</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Milan</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>170</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 30, 2020</start_date>
    <primary_completion_date>May 30, 2020</primary_completion_date>
    <completion_date>December 30, 2020</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>ASST FBF Sacco, Milan, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04365517</url>
  </study>
  <study rank="504">
    <nct_id>NCT04359927</nct_id>
    <title>Long-term Effects of Coronavirus Disease 2019 on the Cardiovascular System: CV COVID-19 Registry</title>
    <acronym>CV-COVID-19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sars-CoV2</condition>
      <condition>Covid19</condition>
      <condition>Cardiovascular Diseases</condition>
      <condition>Cardiovascular Risk Factor</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Cardiovascular mortality</outcome_measure>
      <outcome_measure>Acute myocardial infarction</outcome_measure>
      <outcome_measure>Stroke</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hospital Clinic of Barcelona</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>10000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>August 31, 2021</primary_completion_date>
    <completion_date>August 31, 2025</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>Hospital Clínic of Barcelona, Barcelona, Catalonia, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04359927</url>
  </study>
  <study rank="505">
    <nct_id>NCT04357860</nct_id>
    <title>Clinical Trial of Sarilumab in Adults With COVID-19</title>
    <acronym>SARICOR</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV 2</condition>
      <condition>SARS</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]</intervention>
      <intervention type="Drug">Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA]</intervention>
      <intervention type="Drug">Best available treatment</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Ventilation requirements</outcome_measure>
      <outcome_measure>Crude mortality</outcome_measure>
      <outcome_measure>Time to clinical improvement</outcome_measure>
      <outcome_measure>Time until improvement in oxygenation</outcome_measure>
      <outcome_measure>Proportion of patients requiring invasive mechanical ventilation</outcome_measure>
      <outcome_measure>Proportion of patients having negative COVID-19 CRP at each visit</outcome_measure>
      <outcome_measure>Mean of serum cytokine levels</outcome_measure>
      <outcome_measure>Adverse events related to medication and its administration</outcome_measure>
      <outcome_measure>Incidence in the appearance of serious bacterial, fungal or opportunistic infections</outcome_measure>
      <outcome_measure>Incidence of perforation of the gastrointestinal tract</outcome_measure>
      <outcome_measure>Leukocyte and neutrophil count</outcome_measure>
      <outcome_measure>Hemoglobin levels</outcome_measure>
      <outcome_measure>Platelet count</outcome_measure>
      <outcome_measure>Levels of creatinemia</outcome_measure>
      <outcome_measure>Bilirubin levels</outcome_measure>
      <outcome_measure>ALT and AST levels</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Maimónides Biomedical Research Institute of Córdoba</lead_sponsor>
      <collaborator>Consejería de Salud y Familias - Junta de Andalucía</collaborator>
      <collaborator>Red Andaluza de Ensayos Clínicos en Enfermedades Infecciosas (Red ANCRAID)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 27, 2020</start_date>
    <primary_completion_date>July 27, 2020</primary_completion_date>
    <completion_date>July 27, 2020</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>Hospital Universitario Reina Sofía, Córdoba, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04357860</url>
  </study>
  <study rank="506">
    <nct_id>NCT04357366</nct_id>
    <title>suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE)</title>
    <acronym>SAVE</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Virus Diseases</condition>
      <condition>Corona Virus Infection</condition>
      <condition>Lower Respiratory Tract Infection Viral</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Anakinra</intervention>
      <intervention type="Drug">trimethoprim/sulfamethoxazole</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The ratio of patients who will not develop serious respiratory failure (SRF)</outcome_measure>
      <outcome_measure>Comparison of the rate of patients who will not develop serious respiratory failure (SRF) until day 14 with historical comparators from Hellenic Sepsis Study Group Database</outcome_measure>
      <outcome_measure>Change of scoring for respiratory symptoms in enrolled subjects between days 1 and 7</outcome_measure>
      <outcome_measure>Change of scoring for respiratory symptoms in enrolled subjects between days 1 and 14</outcome_measure>
      <outcome_measure>Change of SOFA score in enrolled subjects between days 1 and 7</outcome_measure>
      <outcome_measure>Change of Sequential organ failure assessment (SOFA) score in enrolled subjects between days 1 and 14</outcome_measure>
      <outcome_measure>Change of cytokine production between days 1 and 7</outcome_measure>
      <outcome_measure>Change of plasma inflammatory mediators levels between days 1 and 7</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hellenic Institute for the Study of Sepsis</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>April 15, 2022</primary_completion_date>
    <completion_date>April 15, 2022</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>COVID-19 Department, General Hospital of Attica SISMANOGLEIO-AMALIA FLEMING, Marousi, Athens, Greece</location>
      <location>2nd Department of Internal Medicine, University General Hospital of Alexandroupolis, Alexandroupolis, Greece</location>
      <location>Department of Internal Medicine, I PAMMAKARISTOS Hospital, Athens, Greece</location>
      <location>1st Department of Internal Medicine, General Hospital of Athens G. GENNIMATAS, Athens, Greece</location>
      <location>1st University Department of Internal Medicine, General Hospital of Athens LAIKO, Athens, Greece</location>
      <location>2nd University Department of Internal Medicine, IPPOKRATEION General Hospital of Athens, Athens, Greece</location>
      <location>3rd University Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA, Athens, Greece</location>
      <location>Department of Internal Medicine, General Hospital of Chest Diseases of Athens I SOTIRIA, Athens, Greece</location>
      <location>Department of Clinical Therapeutics, ALEXANDRA General Hospital of Athens, Athens, Greece</location>
      <location>Department of Infectious Diseases, General Hospital of Kerkira, Corfu, Greece</location>
      <location>1st Department of Internal Medicine, General University Hospital of Ioannina, Ioánnina, Greece</location>
      <location>Department of Internal Medicine, University General Hospital of Larissa, Larissa, Greece</location>
      <location>Department of Internal Medicine, University General Hospital of Patras PANAGIA I VOITHIA, Patra, Greece</location>
      <location>1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki, Thessaloníki, Greece</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04357366</url>
  </study>
  <study rank="507">
    <nct_id>NCT04341792</nct_id>
    <title>Predictive Biomarkers of Secondary Aggravation in Covid-19 Suspect Patient</title>
    <acronym>BIOCOVU</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Infection Viral</condition>
      <condition>Coronavirus</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Rate of secondary aggravation</outcome_measure>
      <outcome_measure>Change of standart biological parameters</outcome_measure>
      <outcome_measure>Change of Von willebrand factor (vWF) changes over time</outcome_measure>
      <outcome_measure>Change of the Factor VIII (FVIII)</outcome_measure>
      <outcome_measure>Prevalence of positivity of COVID-19 virus measured by PCR or serology</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Lille</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>August 2020</primary_completion_date>
    <completion_date>August 2020</completion_date>
    <study_first_posted>April 10, 2020</study_first_posted>
    <last_update_posted>April 10, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04341792</url>
  </study>
  <study rank="508">
    <nct_id>NCT04366063</nct_id>
    <title>Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid-19</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Cell therapy protocol 1</intervention>
      <intervention type="Biological">Cell therapy protocol 2</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Adverse events assessment</outcome_measure>
      <outcome_measure>Blood oxygen saturation</outcome_measure>
      <outcome_measure>Intensive care unit-free days</outcome_measure>
      <outcome_measure>Clinical symptoms</outcome_measure>
      <outcome_measure>Respiratory efficacy</outcome_measure>
      <outcome_measure>Biomarkers concentrations in plasma</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Royan Institute</lead_sponsor>
      <collaborator>Tehran University of Medical Sciences</collaborator>
      <collaborator>Shahid Beheshti University of Medical Sciences</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 5, 2020</start_date>
    <primary_completion_date>June 6, 2020</primary_completion_date>
    <completion_date>December 10, 2020</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Masoumeh Nouri, Tehran, Iran, Islamic Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04366063</url>
  </study>
  <study rank="509">
    <nct_id>NCT04356495</nct_id>
    <title>Treatments to Decrease the Risk of Hospitalization or Death in Elderly Outpatients With Symptomatic SARS-CoV-2 Infection (COVID-19)</title>
    <acronym>COVERAGE</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Corona Virus Infection</condition>
      <condition>Sars-CoV2</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Vitamins</intervention>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Drug">Imatinib</intervention>
      <intervention type="Drug">Favipiravir</intervention>
      <intervention type="Drug">Telmisartan</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Proportion of participants with an occurrence of hospitalization</outcome_measure>
      <outcome_measure>Death</outcome_measure>
      <outcome_measure>Proportion of hospitalizations, overall and by cause, in each group</outcome_measure>
      <outcome_measure>Death and causes of death</outcome_measure>
      <outcome_measure>Proportion of intensive care hospitalizations, overall and by cause, in each group</outcome_measure>
      <outcome_measure>Proportion of participants with negative nasopharyngeal SARS-CoV-2 RT-PCR</outcome_measure>
      <outcome_measure>Proportion of participants with a loss of autonomy evaluated by the ADL and IADL scale</outcome_measure>
      <outcome_measure>Haematological markers evolution</outcome_measure>
      <outcome_measure>Biochemical markers evolution</outcome_measure>
      <outcome_measure>Inflammatory markers evolution</outcome_measure>
      <outcome_measure>Immunological markers evolution</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
      <outcome_measure>Adverse reactions</outcome_measure>
      <outcome_measure>Plasma concentration</outcome_measure>
      <outcome_measure>Acceptability of the treatment</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Bordeaux</lead_sponsor>
      <collaborator>University of Bordeaux</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>65 Years</min_age>
    <age_groups>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1057</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>July 31, 2020</primary_completion_date>
    <completion_date>August 15, 2020</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Bordeaux university Hospital, Bordeaux, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04356495</url>
  </study>
  <study rank="510">
    <nct_id>NCT04365764</nct_id>
    <title>Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid-19</condition>
      <condition>ARDS</condition>
      <condition>Pneumonia</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Composite of death and mechanical ventilation</outcome_measure>
      <outcome_measure>Death</outcome_measure>
      <outcome_measure>Mechanical ventilation</outcome_measure>
      <outcome_measure>World Health Organization score</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Groupe Hospitalier Pitie-Salpetriere</lead_sponsor>
      <collaborator>Centre Hospitalier Intercommunal Robert Ballanger</collaborator>
      <collaborator>Centre Hospitalier Intercommunal Montfermeil-Le Raincy</collaborator>
      <collaborator>CMC Ambroise Paré</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <start_date>March 14, 2020</start_date>
    <primary_completion_date>May 31, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Centre Hospitalier Intercommunal Robert Ballanger, Aulnay-sous-Bois, France</location>
      <location>Centre Hospitalier Intercommunal Le Raincy-Montfermeil, Montfermeil, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04365764</url>
  </study>
  <study rank="511">
    <nct_id>NCT04346667</nct_id>
    <title>Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds</title>
    <acronym>PEACE</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV-2</condition>
      <condition>Coronavirus Infection</condition>
      <condition>Asymptomatic Condition</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine Sulfate Regular dose</intervention>
      <intervention type="Drug">Hydroxychloroquine Sulfate Loading Dose</intervention>
      <intervention type="Drug">Chloroquine</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>RT-PCR negative status</outcome_measure>
      <outcome_measure>Progression of symptoms</outcome_measure>
      <outcome_measure>Development of Symptoms</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Government of Punjab, Specialized Healthcare and Medical Education Department</lead_sponsor>
      <collaborator>Mayo Hospital Lahore</collaborator>
      <collaborator>Services Institute of Medical Sciences, Pakistan</collaborator>
      <collaborator>Pakistan Kidney and Liver Institute</collaborator>
      <collaborator>Forman Christian College</collaborator>
      <collaborator>Harvard School of Public Health</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 14, 2020</start_date>
    <primary_completion_date>April 28, 2020</primary_completion_date>
    <completion_date>May 28, 2021</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04346667</url>
  </study>
  <study rank="512">
    <nct_id>NCT04360759</nct_id>
    <title>Chloroquine Outpatient Treatment Evaluation for HIV-Covid-19</title>
    <acronym>CQOTE</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid-19</condition>
      <condition>HIV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Chloroquine or hydroxychloroquine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Event-free survival at 28 days post-randomization between experimental group and standard of care group</outcome_measure>
      <outcome_measure>Incidence of serious adverse events</outcome_measure>
      <outcome_measure>Incidence of adverse events of special interest related to investigational product at time of hospitalisation</outcome_measure>
      <outcome_measure>Premature discontinuation of treatment</outcome_measure>
      <outcome_measure>Time from treatment initiation to death, ARDS (PF/SF ratio &lt; 300), or mechanical ventilation</outcome_measure>
      <outcome_measure>Proportion with moderate and severe ARDS</outcome_measure>
      <outcome_measure>Duration of hospitalisation and ICU stay in survivors</outcome_measure>
      <outcome_measure>Incidence of Covid-19 in household contacts</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Cape Town</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>560</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 1, 2020</start_date>
    <primary_completion_date>May 31, 2021</primary_completion_date>
    <completion_date>July 31, 2021</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>Khayelitsha Hospital, Cape Town, Western Cape, South Africa</location>
      <location>Groote Schuur Hospital, Cape Town, Western Cape, South Africa</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04360759</url>
  </study>
  <study rank="513">
    <nct_id>NCT04357106</nct_id>
    <title>COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma</title>
    <acronym>COPLA</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Convalescent plasma</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Lung injury</outcome_measure>
      <outcome_measure>Overall survival</outcome_measure>
      <outcome_measure>Adverse reactions to plasma</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centro de Hematología y Medicina Interna</lead_sponsor>
      <collaborator>Laboratorios Clínicos de Puebla (Laboratorios Ruiz)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 13, 2020</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>August 2020</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Centro de Hematología y Medicina Interna, Puebla, Mexico</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04357106</url>
  </study>
  <study rank="514">
    <nct_id>NCT04338009</nct_id>
    <title>Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019</title>
    <acronym>REPLACECOVID</acronym>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Discontinuation of ARB/ACEI</intervention>
      <intervention type="Other">Continuation of ARB/ACEI</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Hierarchical composite endpoint</outcome_measure>
      <outcome_measure>All-Cause Death</outcome_measure>
      <outcome_measure>Length of Hospital Stay</outcome_measure>
      <outcome_measure>Length of ICU Stay, invasive mechanical ventilation or extracorporeal membrane oxygenation</outcome_measure>
      <outcome_measure>AUC SOFA</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Pennsylvania</lead_sponsor>
      <collaborator>Jordana B. Cohen, MD, MSCE</collaborator>
      <collaborator>Thomas C. Hanff, MD, MPH</collaborator>
      <collaborator>Vicente Corrales-Medina, MD, PhD</collaborator>
      <collaborator>James Brian Byrd, MD</collaborator>
      <collaborator>Roberto Viau Colindres</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>152</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 31, 2020</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>April 8, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04338009</url>
  </study>
  <study rank="515">
    <nct_id>NCT04334265</nct_id>
    <title>Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Anluohuaxian</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Changes in high-resolution computer tomography of the lung</outcome_measure>
      <outcome_measure>Change in 6-minute walking distance</outcome_measure>
      <outcome_measure>Changes in compound physiological index</outcome_measure>
      <outcome_measure>Changes in the scores of the St. George's Hospital Respiratory Questionnaire</outcome_measure>
      <outcome_measure>Changes in modified British Medical Research Council Dyspnea Scale (mMRC) scores</outcome_measure>
      <outcome_measure>Changes in vital capacity of the lung</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Peking University First Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>750</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>June 1, 2020</primary_completion_date>
    <completion_date>December 1, 2020</completion_date>
    <study_first_posted>April 6, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>The Second People's Hospital of Fuyang, Fuyang, Anhui, China</location>
      <location>Ezhou Central Hospital, Wuhan, Hubei, China</location>
      <location>Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China</location>
      <location>Jinyintan Hospital of Wuhan, Wuhan, Hubei, China</location>
      <location>Tongji Hospital of Huazhong University of Science and Technology, Wuhan, Hubei, China</location>
      <location>West Hospital Union Hospital Huazhong University of Science and Technology, Wuhan, Hubei, China</location>
      <location>Wuhan Pulmonary Hospital, Wuhan, Hubei, China</location>
      <location>Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China</location>
      <location>Wenzhou Medical University Affiliated First Hospital, Wenzhou, Zhejiang, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04334265</url>
  </study>
  <study rank="516">
    <nct_id>NCT04334148</nct_id>
    <title>Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine</title>
    <acronym>HERO-HCQ</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Drug">Placebo oral tablet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of participants with clinical infection with COVID-19 infection</outcome_measure>
      <outcome_measure>Number of participants with COVID-19 viral shedding</outcome_measure>
      <outcome_measure>Safety as measured by number of adverse events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Duke University</lead_sponsor>
      <collaborator>Patient-Centered Outcomes Research Institute</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>15000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>July 2020</completion_date>
    <study_first_posted>April 6, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04334148</url>
  </study>
  <study rank="517">
    <nct_id>NCT04333589</nct_id>
    <title>Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Favipiravir</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Viral nucleic acid test negative conversion rate</outcome_measure>
      <outcome_measure>Clinical cure rate</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Peking University First Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>210</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>June 1, 2020</primary_completion_date>
    <completion_date>September 15, 2020</completion_date>
    <study_first_posted>April 3, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>The Second People's Hospital of Fuyang, Fuyang, Anhui, China</location>
      <location>Ezhou Hospital of Traditional Chinese Medicine, Ezhou, Hubei, China</location>
      <location>Ezhou Central Hospital, Wuhan, Hubei, China</location>
      <location>Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China</location>
      <location>Jinyintan Hospital of Wuhan, Wuhan, Hubei, China</location>
      <location>Wuhan Pulmonary Hospital, Wuhan, Hubei, China</location>
      <location>Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China</location>
      <location>Wenzhou Medical University Affiliated First Hospital, Wenzhou, Zhejiang, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04333589</url>
  </study>
  <study rank="518">
    <nct_id>NCT04328480</nct_id>
    <title>The ECLA PHRI COLCOVID Trial</title>
    <acronym>COLCOVID</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Colchicine</intervention>
      <intervention type="Other">Local standard of care</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>All-cause mortality</outcome_measure>
      <outcome_measure>Composite outcome:composite of intubation for mechanical ventilation or death.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Estudios Clínicos Latino América</lead_sponsor>
      <collaborator>Population Health Research Institute</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>2500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 2020</start_date>
    <primary_completion_date>May 30, 2020</primary_completion_date>
    <completion_date>June 30, 2020</completion_date>
    <study_first_posted>March 31, 2020</study_first_posted>
    <last_update_posted>March 31, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04328480</url>
  </study>
  <study rank="519">
    <nct_id>NCT04311398</nct_id>
    <title>Development and Verification of a New Coronavirus Multiplex Nucleic Acid Detection System</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">New QIAstat-Dx fully automatic multiple PCR detection platform</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Sensitivity， spectivity turnaround time of the New QIAstat-Dx fully automatic multiple PCR detection platform</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Huashan Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>16 Years</min_age>
    <max_age>100 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>March 14, 2020</start_date>
    <primary_completion_date>June 1, 2020</primary_completion_date>
    <completion_date>December 1, 2020</completion_date>
    <study_first_posted>March 17, 2020</study_first_posted>
    <last_update_posted>March 17, 2020</last_update_posted>
    <locations>
      <location>Huashan Hospital of Fudan University, Shanghai, Shanghai, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04311398</url>
  </study>
  <study rank="520">
    <nct_id>NCT04310228</nct_id>
    <title>Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Favipiravir Combined With Tocilizumab</intervention>
      <intervention type="Drug">Favipiravir</intervention>
      <intervention type="Drug">Tocilizumab</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clinical cure rate</outcome_measure>
      <outcome_measure>Viral nucleic acid test negative conversion rate and days from positive to negative</outcome_measure>
      <outcome_measure>Duration of fever</outcome_measure>
      <outcome_measure>Lung imaging improvement time</outcome_measure>
      <outcome_measure>Mortality rate because of Corona Virus Disease 2019</outcome_measure>
      <outcome_measure>Rate of non-invasive or invasive mechanical ventilation when respiratory failure occurs</outcome_measure>
      <outcome_measure>Mean in-hospital time</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Peking University First Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 8, 2020</start_date>
    <primary_completion_date>May 2020</primary_completion_date>
    <completion_date>May 2020</completion_date>
    <study_first_posted>March 17, 2020</study_first_posted>
    <last_update_posted>April 10, 2020</last_update_posted>
    <locations>
      <location>Guiqiang Wang, Beijing, Beijing, China</location>
      <location>Peking University First Hospital, Beijing, Beijing, China</location>
      <location>Ezhou Central Hospital, Wuhan, Hubei, China</location>
      <location>Huoshenshan Hospital of Wuhan, Wuhan, Hubei, China</location>
      <location>Jinyintan Hospital of Wuhan, Wuhan, Hubei, China</location>
      <location>Wuhan Pulmonary Hospital, Wuhan, Hubei, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04310228</url>
  </study>
  <study rank="521">
    <nct_id>NCT04278963</nct_id>
    <title>Yinhu Qingwen Decoction for the Treatment of Mild / Common CoVID-19</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>CoVID-19</condition>
      <condition>Chinese Medicine</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">YinHu QingWen Decoction</intervention>
      <intervention type="Drug">YinHu QingWen Decoction(low dose)</intervention>
      <intervention type="Other">Chinese medicine treatment</intervention>
      <intervention type="Other">standard western medicine treatment</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mean clinical recovery time (hours)</outcome_measure>
      <outcome_measure>Time to CoVID-19 RT-PCR negative in upper respiratory tract specimen</outcome_measure>
      <outcome_measure>Change (reduction) in CoVID-19 viral load in upper respiratory tract specimen as assessed by area under viral load curve.</outcome_measure>
      <outcome_measure>Time to defervescence (in those with fever at enrolment)</outcome_measure>
      <outcome_measure>Time to cough reported as mild or absent (in those with cough at enrolment rated severe or moderate)</outcome_measure>
      <outcome_measure>Time to dyspnea reported as mild or absent (on a scale of severe, moderate, mild absent, in those with dyspnea at enrollment rated as severe or moderate)</outcome_measure>
      <outcome_measure>Frequency of requirement for supplemental oxygen or non-invasive ventilation</outcome_measure>
      <outcome_measure>Frequency of respiratory progression</outcome_measure>
      <outcome_measure>Severe case incidence</outcome_measure>
      <outcome_measure>Proportion of re-hospitalization or admission to ICU</outcome_measure>
      <outcome_measure>All-cause mortality</outcome_measure>
      <outcome_measure>Frequency of serious adverse events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>China Academy of Chinese Medical Sciences</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>February 27, 2020</start_date>
    <primary_completion_date>January 2021</primary_completion_date>
    <completion_date>January 2021</completion_date>
    <study_first_posted>February 20, 2020</study_first_posted>
    <last_update_posted>March 17, 2020</last_update_posted>
    <locations>
      <location>Jingzhou Hospital of Traditional Chinese Medicine, Jingzhou, Hubei, China</location>
      <location>Wuhan Leishenshan (Thunder God Mountain) Hospital/The First Affiliated Hospital of Dalian Medical University, Wuhan, Hubei, China</location>
      <location>Xiangyang Hospital of Traditional Chinese Medicine, Xiangyang, Hubei, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04278963</url>
  </study>
  <study rank="522">
    <nct_id>NCT04302519</nct_id>
    <title>Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Dental pulp mesenchymal stem cells</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Disppear time of ground-glass shadow in the lungs</outcome_measure>
      <outcome_measure>Absorption of Lung shadow absorption by CT Scan-Chest</outcome_measure>
      <outcome_measure>Changes of blood oxygen</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>CAR-T (Shanghai) Biotechnology Co., Ltd.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Early Phase 1</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 5, 2020</start_date>
    <primary_completion_date>June 30, 2021</primary_completion_date>
    <completion_date>July 30, 2021</completion_date>
    <study_first_posted>March 10, 2020</study_first_posted>
    <last_update_posted>March 10, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04302519</url>
  </study>
  <study rank="523">
    <nct_id>NCT04295551</nct_id>
    <title>Multicenter Clinical Study on the Efficacy and Safety of Xiyanping Injection in the Treatment of New Coronavirus Infection Pneumonia (General and Severe)</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Lopinavir / ritonavir tablets combined with Xiyanping injection</intervention>
      <intervention type="Drug">Lopinavir/ritonavir treatment</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clinical recovery time</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Jiangxi Qingfeng Pharmaceutical Co. Ltd.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>100 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 14, 2020</start_date>
    <primary_completion_date>July 14, 2020</primary_completion_date>
    <completion_date>April 14, 2021</completion_date>
    <study_first_posted>March 4, 2020</study_first_posted>
    <last_update_posted>March 4, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04295551</url>
  </study>
  <study rank="524">
    <nct_id>NCT04354441</nct_id>
    <title>Effect of Hydroxychloroquine in COVID-19 Positive Pregnant Women</title>
    <acronym>HyPreC</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>SARS-CoV-2</condition>
      <condition>Pregnant Women</condition>
      <condition>Hydroxychloroquine</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">hydroxychloroquine sulfate 200 MG</intervention>
      <intervention type="Drug">Placebo oral tablet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>COVID-19-related hospital admissions</outcome_measure>
      <outcome_measure>Symptoms related to COVID-19 infection</outcome_measure>
      <outcome_measure>Adverse Events</outcome_measure>
      <outcome_measure>Maternal outcomes</outcome_measure>
      <outcome_measure>Newborn outcomes</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sir Mortimer B. Davis - Jewish General Hospital</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>600</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 2020</start_date>
    <primary_completion_date>November 2020</primary_completion_date>
    <completion_date>November 2020</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04354441</url>
  </study>
  <study rank="525">
    <nct_id>NCT04360707</nct_id>
    <title>Solid Organ Transplant Recipients With Covid-19 French Registry</title>
    <acronym>TX-COVID</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV-2</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Clinical Presentation and Incidence of Covid-19 Infection in Different Cohorts of Solid Organ Transplant Patients</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Strasbourg, France</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>1 Year</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 8, 2020</start_date>
    <primary_completion_date>April 8, 2021</primary_completion_date>
    <completion_date>April 8, 2021</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Service de Néphrologie et Transplantation, Strasbourg, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04360707</url>
  </study>
  <study rank="526">
    <nct_id>NCT04351854</nct_id>
    <title>Registry for Clinical Presentation and Management of Patients With COVID-19 in the Emergency Room</title>
    <acronym>ReCovER</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Corona Virus Infection</condition>
      <condition>SARS-CoV 2</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Retrospective data collection</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Identification of risk factors present at the earliest stage of hospital care (i.e. in the ED) that warrant hospital admission.</outcome_measure>
      <outcome_measure>Determination of the course of the disease (days since onset of symptoms, nature of symptoms, e.g. fever, chills, headache) and the state at which patients present to the ED</outcome_measure>
      <outcome_measure>Identification of the ratio of patients with mild or moderate to severe disease</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Cologne</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>December 31, 2025</primary_completion_date>
    <completion_date>August 31, 2026</completion_date>
    <study_first_posted>April 17, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>University Hospital of Cologne, Cologne, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04351854</url>
  </study>
  <study rank="527">
    <nct_id>NCT04303507</nct_id>
    <title>Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting</title>
    <acronym>COPCOV</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID19</condition>
      <condition>Coronavirus</condition>
      <condition>Acute Respiratory Illnesses</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Chloroquine or Hydroxychloroquine</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of symptomatic COVID-19 infections</outcome_measure>
      <outcome_measure>Symptoms severity of COVID-19</outcome_measure>
      <outcome_measure>Number of asymptomatic cases of COVID-19</outcome_measure>
      <outcome_measure>Number of symptomatic acute respiratory illnesses</outcome_measure>
      <outcome_measure>Severity of symptomatic acute respiratory illnesses</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Oxford</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>16 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>40000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>April 2021</primary_completion_date>
    <completion_date>April 2021</completion_date>
    <study_first_posted>March 11, 2020</study_first_posted>
    <last_update_posted>March 27, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04303507</url>
  </study>
  <study rank="528">
    <nct_id>NCT04357028</nct_id>
    <title>Measles Vaccine in HCW</title>
    <acronym>MV-COVID19</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Measles-Mumps-Rubella Vaccine</intervention>
      <intervention type="Drug">Placebos</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>COVID-19 disease incidence</outcome_measure>
      <outcome_measure>SARS-CoV-2 pneumonia</outcome_measure>
      <outcome_measure>Critical care admission duration with SARS-CoV-2</outcome_measure>
      <outcome_measure>Oxygen therapy with SARS-CoV-2</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Kasr El Aini Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>May 1, 2020</start_date>
    <primary_completion_date>October 1, 2020</primary_completion_date>
    <completion_date>November 1, 2020</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Cairo University Hospital, Cairo, Egypt</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04357028</url>
  </study>
  <study rank="529">
    <nct_id>NCT04347941</nct_id>
    <title>Awake Prone Positioning to Reduce Invasive VEntilation in COVID-19 Induced Acute Respiratory failurE</title>
    <acronym>APPROVE-CARE</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>ARDS, Human</condition>
      <condition>Mechanical Ventilation Complication</condition>
      <condition>COVID19</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Prone Positioning</intervention>
      <intervention type="Procedure">Standard of care.</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The effect of prone positioning on requirement for invasive mechanical ventilation in patients with COVID 19 induced respiratory failure.</outcome_measure>
      <outcome_measure>Length of time tolerating prone positioning</outcome_measure>
      <outcome_measure>PaO2/FiO2 measured before prone positioning</outcome_measure>
      <outcome_measure>PaO2/FiO2 ratio after 1 hours of prone positioning</outcome_measure>
      <outcome_measure>SpO2/FiO2 ratio measured before prone positioning</outcome_measure>
      <outcome_measure>SpO2/FiO2 ratio after 1 hours of prone positioning</outcome_measure>
      <outcome_measure>Number requiring increase in ventilatory assistance (CPAP+BIPAP+IMV etc)</outcome_measure>
      <outcome_measure>Work of breathing assessment (Respiratory distress scale)</outcome_measure>
      <outcome_measure>Changes in bioimpedance measures of lung edema in patients in PP</outcome_measure>
      <outcome_measure>Use of awake prone positioning as a rescue intervention in control patients</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University College Hospital Galway</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 11, 2020</start_date>
    <primary_completion_date>March 11, 2021</primary_completion_date>
    <completion_date>May 11, 2021</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>Galway University Hospital, Galway, Ireland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04347941</url>
  </study>
  <study rank="530">
    <nct_id>NCT04362176</nct_id>
    <title>Passive Immunity Trial of Nashville II</title>
    <acronym>PassItOn II</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Coronavirus</condition>
      <condition>SARS-CoV-2</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">pathogen reduced SARS-CoV-2 convalescent plasma</intervention>
      <intervention type="Biological">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>COVID Ordinal Outcomes Scale:Day 15</outcome_measure>
      <outcome_measure>All-location, all-cause 14-day mortality</outcome_measure>
      <outcome_measure>All-location, all-cause 28-day mortality</outcome_measure>
      <outcome_measure>COVID Ordinal Outcomes Scale Day 3</outcome_measure>
      <outcome_measure>COVID Ordinal Outcomes Scale Day 8</outcome_measure>
      <outcome_measure>COVID Ordinal Outcomes Scale Day 29</outcome_measure>
      <outcome_measure>Composite of death or receipt of ECMO through Day 28</outcome_measure>
      <outcome_measure>Oxygen-free days through Day 28</outcome_measure>
      <outcome_measure>Vasopressor-free days through Day 28</outcome_measure>
      <outcome_measure>Ventilator-free days through Day 28</outcome_measure>
      <outcome_measure>ICU-free days through Day 28</outcome_measure>
      <outcome_measure>Hospital-free days through Day 28</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Vanderbilt University Medical Center</lead_sponsor>
      <collaborator>Dolly Parton</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 24, 2020</start_date>
    <primary_completion_date>April 2021</primary_completion_date>
    <completion_date>April 2021</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Vanderbilt University Medical Center, Nashville, Tennessee, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04362176</url>
  </study>
  <study rank="531">
    <nct_id>NCT04366206</nct_id>
    <title>Factors Associated With Clinical Outcomes in Patients Hospitalized for Covid-19 in GHT-93 Est</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
      <condition>SARS-CoV 2</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Composite of death and mechanical ventilation</outcome_measure>
      <outcome_measure>Need for mechanical ventilation</outcome_measure>
      <outcome_measure>Death</outcome_measure>
      <outcome_measure>Acute kidney injury</outcome_measure>
      <outcome_measure>Acute respiratory distress syndrome</outcome_measure>
      <outcome_measure>Cardiac arrhythmia and conduction disorder</outcome_measure>
      <outcome_measure>60-days mortality</outcome_measure>
      <outcome_measure>60-days mechanical ventilation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier Intercommunal Robert Ballanger</lead_sponsor>
      <collaborator>Groupe Hospitalier Pitie-Salpetriere</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>143</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 14, 2020</start_date>
    <primary_completion_date>July 31, 2020</primary_completion_date>
    <completion_date>July 31, 2020</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Centre Hospitalier Intercommunal Robert Ballanger, Aulnay-sous-Bois, France</location>
      <location>Groupe Hospitalier Pitie Salpetriere, Paris, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04366206</url>
  </study>
  <study rank="532">
    <nct_id>NCT04347226</nct_id>
    <title>Anti-Interleukin-8 (Anti-IL-8) for Cancer Patients With COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Solid Tumor</condition>
      <condition>Sars-CoV2</condition>
      <condition>Hematological Malignancy</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">BMS-986253</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to Improvement in the 7-point ordinal scale</outcome_measure>
      <outcome_measure>Time to Death</outcome_measure>
      <outcome_measure>Time to Intubation</outcome_measure>
      <outcome_measure>Proportion of patients requiring ICU admission</outcome_measure>
      <outcome_measure>Mortality at 1 month</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Matthew Dallos</lead_sponsor>
      <collaborator>Bristol-Myers Squibb</collaborator>
      <collaborator>Columbia University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>138</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 16, 2020</start_date>
    <primary_completion_date>September 2021</primary_completion_date>
    <completion_date>September 2022</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations>
      <location>Columbia University Irving Medical Center, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04347226</url>
  </study>
  <study rank="533">
    <nct_id>NCT04356482</nct_id>
    <title>CONVALESCENT PLASMA FOR ILL PATIENTS BY COVID-19</title>
    <acronym>COPLASCOV19</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>SARS-CoV 2</condition>
      <condition>Convalescence</condition>
      <condition>Plasma</condition>
      <condition>Doses</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">convalescent plasma</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clinical improvement</outcome_measure>
      <outcome_measure>improvement in tomographic image</outcome_measure>
      <outcome_measure>test positivity for COVID-19</outcome_measure>
      <outcome_measure>early and late complications associated to convalescent plasma</outcome_measure>
      <outcome_measure>days at ICU</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado</lead_sponsor>
      <collaborator>SECRETARIA DE SALUD DEL ESTADO DE SONORA</collaborator>
      <collaborator>CENTRO ESTATAL DE LA TRANSFUSION SANGUINEA</collaborator>
      <collaborator>HOSPITAL CENTRAL NACIONAL PEMEX NORTE</collaborator>
      <collaborator>HOSPITAL DE ZONA No. 2 IMSS</collaborator>
      <collaborator>HOSPITAL DE ZONA No.14 IMSS</collaborator>
      <collaborator>HOSPITAL ANGELES DE CHIHUAHUA</collaborator>
      <collaborator>HOSPITAL GENERAL DEL ESTADO DE SONORA</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>16 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 2020</start_date>
    <primary_completion_date>November 2020</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Hospital Del Issste Regional En Guadalajara Jalisco, Guadalajara, Jalisco, Mexico</location>
      <location>Secretaria de Salud Del Estado de Sonora, Hospital General Del Estado, Hermosillo, Sonora, Mexico</location>
      <location>Hospital Central Norte Pemex, Mexico City, Mexico</location>
      <location>hospital general de Mexico, Mexico City, Mexico</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04356482</url>
  </study>
  <study rank="534">
    <nct_id>NCT04328012</nct_id>
    <title>COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2</title>
    <acronym>COVIDMED</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV-2 Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">lopinavir/ritonavir</intervention>
      <intervention type="Drug">Hydroxychloroquine Sulfate</intervention>
      <intervention type="Drug">Losartan</intervention>
      <intervention type="Drug">Placebos</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>National Institute of Allergy and Infectious Diseases COVID-19 Ordinal Severity Scale (NCOSS)</outcome_measure>
      <outcome_measure>Hospital length of stay (LOS)</outcome_measure>
      <outcome_measure>Intensive care unit level LOS</outcome_measure>
      <outcome_measure>Mechanical ventilation</outcome_measure>
      <outcome_measure>survival</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Bassett Healthcare</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>4000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 6, 2020</start_date>
    <primary_completion_date>January 1, 2021</primary_completion_date>
    <completion_date>April 1, 2021</completion_date>
    <study_first_posted>March 31, 2020</study_first_posted>
    <last_update_posted>April 8, 2020</last_update_posted>
    <locations>
      <location>Bassett Medical Center, Cooperstown, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04328012</url>
  </study>
  <study rank="535">
    <nct_id>NCT04320472</nct_id>
    <title>Acute Encephalopathy in Critically Ill Patients With COVID-19</title>
    <acronym>NeuroCOVID19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Encephalopathy</condition>
      <condition>Critically Ill</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Follow up</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>prevalence</outcome_measure>
      <outcome_measure>Favorable outcome</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ictal Group</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>250</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 23, 2020</start_date>
    <primary_completion_date>December 2020</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>March 25, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Jackson Memorial Health System; University of Miami, Miller School of Medicine, Miami, Florida, United States</location>
      <location>Centre Hospitalier d'Argenteuil, Argenteuil, France</location>
      <location>Centre Hospitalier de Beauvais, Beauvais, France</location>
      <location>Centre Hospitalier Universitaire Ambroise Paré, Boulogne, France</location>
      <location>Centre Hospitalier de Bourg en Bresse, Bourg-en-Bresse, France</location>
      <location>Centre Hospitalier Régional Universitaire de Brest, Brest, France</location>
      <location>Centre Hospitalier de Brives, Brive-la-Gaillarde, France</location>
      <location>Centre Hospitalier Universitaire Beaujon, Clichy, France</location>
      <location>Centre Hospitalier Universitaire Louis Mourier, Colombes, France</location>
      <location>Centre Hospitalier Universitaire Henri Mondor, Créteil, France</location>
      <location>Centre hospitalier de Dieppe, Dieppe, France</location>
      <location>Centre Hospitalier Universitaire de Dijon, Dijon, France</location>
      <location>Centre Hospitalier d'Etampes, Etampes, France</location>
      <location>Grand Hôpital de l'Est Francilien - Site de Marne-la-Vallée, Jossigny, France</location>
      <location>Centre Hospitalier de la Roche-sur-Yon, La Roche-sur-Yon, France</location>
      <location>Centre Hospitalier de La Rochelle, La Rochelle, France</location>
      <location>Centre Hospitalier de Versailles, Le Chesnay, France</location>
      <location>Centre Hospitalier Universitaire de Lille, Lille, France</location>
      <location>Centre Hospitalier Universitaire Hôpital Edouard Herriot, Lyon, France</location>
      <location>Hôpital privé Jacques Cartier, Massy, France</location>
      <location>Groupe Hospitalier Sud Ile-de-France, Melun, France</location>
      <location>Centre Hospitalier Universitaire de Nantes, Nantes, France</location>
      <location>Centre Hospitalier Régional d'Orléans, Orléans, France</location>
      <location>Centre Hospitalier Universitaire Cochin, Paris, France</location>
      <location>Groupe hospitalier Paris Saint-Joseph, Paris, France</location>
      <location>Hôpital Fondation Adolphe de Rothschild, Paris, France</location>
      <location>Hopital Privé Claude Galien, Quincy-sous-Sénart, France</location>
      <location>Centre Hospitalier Universitaire de Rennes, Rennes, France</location>
      <location>Centre Hospitalier de Roanne, Roanne, France</location>
      <location>Hopital Foch, Suresnes, France</location>
      <location>Centre Hospitalier de Toulon, Toulon, France</location>
      <location>Centre Hospitalier Universitaire de Toulouse, Toulouse, France</location>
      <location>Centre Hospitalier Universitaire de Tours, Tours, France</location>
      <location>Gustave-Roussy, Villejuif, France</location>
      <location>Hospital Clinic Universitari, Valencia, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04320472</url>
  </study>
  <study rank="536">
    <nct_id>NCT04365985</nct_id>
    <title>Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19</title>
    <acronym>SINK COVID-19</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Acute Respiratory Distress Syndrome</condition>
      <condition>Severe Acute Respiratory Syndrome (SARS)</condition>
      <condition>Coronavirus Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Naltrexone</intervention>
      <intervention type="Drug">Ketamine</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Progression of oxygenation needs</outcome_measure>
      <outcome_measure>Renal failure</outcome_measure>
      <outcome_measure>Liver failure</outcome_measure>
      <outcome_measure>Cytokine Storm</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>Length of hospital stay</outcome_measure>
      <outcome_measure>Intensive Care Unit (ICU) admission</outcome_measure>
      <outcome_measure>Intensive Care Unit (ICU) duration</outcome_measure>
      <outcome_measure>Intubation</outcome_measure>
      <outcome_measure>Intubation duration</outcome_measure>
      <outcome_measure>Time until recovery</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>William Beaumont Hospitals</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>May 2020</primary_completion_date>
    <completion_date>August 2020</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>William Beaumont Hospital, Royal Oak, Michigan, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04365985</url>
  </study>
  <study rank="537">
    <nct_id>NCT04272710</nct_id>
    <title>Prognositc Factors in COVID-19 Patients Complicated With Hypertension</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>2019-nCoV</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Occupancy rate in the intensive care unit (ICU)</outcome_measure>
      <outcome_measure>Mechanical Ventilation</outcome_measure>
      <outcome_measure>Death</outcome_measure>
      <outcome_measure>All cause mortality</outcome_measure>
      <outcome_measure>Time from onset of symptoms to main outcome and its components</outcome_measure>
      <outcome_measure>Time to Clinical Recovery</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Chongqing Medical University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>100 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>January 25, 2020</start_date>
    <primary_completion_date>March 31, 2020</primary_completion_date>
    <completion_date>April 30, 2020</completion_date>
    <study_first_posted>February 17, 2020</study_first_posted>
    <last_update_posted>March 17, 2020</last_update_posted>
    <locations>
      <location>The First Affiliated Hospital of Chongqing Medical University, Chongqing, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04272710</url>
  </study>
  <study rank="538">
    <nct_id>NCT04362930</nct_id>
    <title>Cohort of Patients With Covid-19 Presenting Neurological or Psychiatric Disorders (CoCo-Neurosciences)</title>
    <acronym>CoCo-Neuro</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Neurologic Manifestations</condition>
      <condition>Psychiatric Disorders</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Central or peripheral neurological symptoms or psychiatric symptoms observed in patients with Covid-19</outcome_measure>
      <outcome_measure>Progression of pre-existing neurological or psychiatric pathologies</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>2000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>April 24, 2020</start_date>
    <primary_completion_date>April 24, 2022</primary_completion_date>
    <completion_date>April 24, 2022</completion_date>
    <study_first_posted>April 27, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04362930</url>
  </study>
  <study rank="539">
    <nct_id>NCT04357418</nct_id>
    <title>Psychological Outcome of COVID-19 Lockdown on Psychiatric Hospital Staff and Close Relatives</title>
    <acronym>ICOS</acronym>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Anxiety State</condition>
      <condition>COVID-19</condition>
      <condition>Isolation, Social</condition>
      <condition>Health Personnel Attitude</condition>
    </conditions>
    <interventions>
      <intervention type="Other">it is a survey</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>State Anxiety assessed by the State-Trait Anxiety Inventory (STAI)</outcome_measure>
      <outcome_measure>Visual numeric scales assessing anger and stress the ongoing week.</outcome_measure>
      <outcome_measure>Beck Depression Inventory</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre hospitalier de Ville-Evrard, France</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1320</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>June 30, 2020</primary_completion_date>
    <completion_date>June 30, 2020</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>URC Ville Evrard, Neuilly-sur-Marne, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04357418</url>
  </study>
  <study rank="540">
    <nct_id>NCT04335032</nct_id>
    <title>EPA-FFA to Treat Hospitalised Patients With COVID-19 (SARS-CoV-2)</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV-2</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Eicosapentaenoic acid gastro-resistant capsules</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Evaluation of EPA-FFA efficacy compared to standard of care</outcome_measure>
      <outcome_measure>Increase in oxygen saturation</outcome_measure>
      <outcome_measure>PaO2/FiO2 &gt;300mmHg increase</outcome_measure>
      <outcome_measure>Reduction of IL-6</outcome_measure>
      <outcome_measure>Mortality rate reduction</outcome_measure>
      <outcome_measure>Reduction in ICU stays</outcome_measure>
      <outcome_measure>Reducing hospitalisation days</outcome_measure>
      <outcome_measure>reduction in need for mechanical ventilation</outcome_measure>
      <outcome_measure>Fever reduction</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>S.L.A. Pharma AG</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>240</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 13, 2020</start_date>
    <primary_completion_date>July 13, 2020</primary_completion_date>
    <completion_date>July 31, 2020</completion_date>
    <study_first_posted>April 6, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04335032</url>
  </study>
  <study rank="541">
    <nct_id>NCT04273763</nct_id>
    <title>Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)</title>
    <acronym/>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Novel Coronavirus Pneumonia</condition>
      <condition>2019-nCoV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Bromhexine Hydrochloride Tablets</intervention>
      <intervention type="Drug">Arbidol Hydrochloride Granules</intervention>
      <intervention type="Drug">Recombinant Human Interferon α2b Spray</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to clinical recovery after treatment</outcome_measure>
      <outcome_measure>Rate of aggravation</outcome_measure>
      <outcome_measure>Clinical remission rate</outcome_measure>
      <outcome_measure>Dynamic changes of oxygenation index</outcome_measure>
      <outcome_measure>Time to cure</outcome_measure>
      <outcome_measure>rate to cure</outcome_measure>
      <outcome_measure>Time to defervescence</outcome_measure>
      <outcome_measure>Time to cough remission</outcome_measure>
      <outcome_measure>Time to dyspnea remission</outcome_measure>
      <outcome_measure>Days of supplemental oxygenation</outcome_measure>
      <outcome_measure>Rate of patients with requring supplemental oxygen</outcome_measure>
      <outcome_measure>Rate of patients with mechanical ventilation</outcome_measure>
      <outcome_measure>Time of negative COVID-19 nucleic acid results</outcome_measure>
      <outcome_measure>Rate of negative COVID-19 nucleic acid results</outcome_measure>
      <outcome_measure>Rate of ICU admission</outcome_measure>
      <outcome_measure>28-day mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Second Affiliated Hospital of Wenzhou Medical University</lead_sponsor>
      <collaborator>WanBangDe Pharmaceutical Group Co.,Ltd.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>February 16, 2020</start_date>
    <primary_completion_date>April 15, 2020</primary_completion_date>
    <completion_date>April 30, 2020</completion_date>
    <study_first_posted>February 18, 2020</study_first_posted>
    <last_update_posted>March 23, 2020</last_update_posted>
    <locations>
      <location>The Second AffIliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04273763</url>
  </study>
  <study rank="542">
    <nct_id>NCT04352946</nct_id>
    <title>HEalth Care Worker pROphylaxis Against COVID-19: The HERO Trial</title>
    <acronym>HERO</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Prophylaxis</condition>
      <condition>COVID-19</condition>
      <condition>Health Care Worker</condition>
      <condition>Hydroxychloroquine</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine Pre-Exposure Prophylaxis</intervention>
      <intervention type="Drug">Placebo oral tablet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Cumulative Incidence of COVID-19 Infection</outcome_measure>
      <outcome_measure>Adverse events incidence</outcome_measure>
      <outcome_measure>Duration of symptomatic COVID-19 disease</outcome_measure>
      <outcome_measure>Days hospitalized attributed to COVID-19</outcome_measure>
      <outcome_measure>Number or respiratory failure attributable to COVID-19 disease</outcome_measure>
      <outcome_measure>Mortality Incidence</outcome_measure>
      <outcome_measure>Days of work lost</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>GeoSentinel Foundation</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>374</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 24, 2020</start_date>
    <primary_completion_date>June 24, 2020</primary_completion_date>
    <completion_date>August 24, 2020</completion_date>
    <study_first_posted>April 20, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>The New York Center for Travel and Tropical Medicine, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04352946</url>
  </study>
  <study rank="543">
    <nct_id>NCT04355611</nct_id>
    <title>Epidemiological Characteristics of COVID-19 in Patients With MS or NMO</title>
    <acronym>COVISEP</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Multiple Sclerosis</condition>
      <condition>NMO Spectrum Disorder</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Evaluation of the epidemiological characteristics of coronavirus infection (SARS-CoV-2)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clinical severity</outcome_measure>
      <outcome_measure>EDSS (Expanded Disability Status Scale)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>2000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>April 20, 2022</primary_completion_date>
    <completion_date>April 20, 2022</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04355611</url>
  </study>
  <study rank="544">
    <nct_id>NCT04331613</nct_id>
    <title>Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Acute Respiratory Distress Syndrome</condition>
      <condition>Virus; Pneumonia</condition>
      <condition>Acute Lung Injury</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">CAStem</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Adverse reaction (AE) and severe adverse reaction (SAE)</outcome_measure>
      <outcome_measure>Changes of lung imaging examinations</outcome_measure>
      <outcome_measure>Time to SARS-CoV-2 RT-PCR negative</outcome_measure>
      <outcome_measure>Duration of fever (Celsius)</outcome_measure>
      <outcome_measure>Changes of blood oxygen (%)</outcome_measure>
      <outcome_measure>Rate of all-cause mortality within 28 days</outcome_measure>
      <outcome_measure>Lymphocyte count (*10^9/L)</outcome_measure>
      <outcome_measure>Alanine aminotransferase (U/L)</outcome_measure>
      <outcome_measure>Creatinine (umol/L)</outcome_measure>
      <outcome_measure>Creatine kinase (U/L)</outcome_measure>
      <outcome_measure>C-reactive protein (mg/L)</outcome_measure>
      <outcome_measure>Procalcitonin (ng/L)</outcome_measure>
      <outcome_measure>Lactate (mmol/L)</outcome_measure>
      <outcome_measure>IL-1beta (pg/mL)</outcome_measure>
      <outcome_measure>IL-2 (pg/mL)</outcome_measure>
      <outcome_measure>IL-6 (pg/mL)</outcome_measure>
      <outcome_measure>IL-8 (pg/mL)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Chinese Academy of Sciences</lead_sponsor>
      <collaborator>Beijing YouAn Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>9</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>January 27, 2020</start_date>
    <primary_completion_date>December 2020</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>April 2, 2020</study_first_posted>
    <last_update_posted>April 2, 2020</last_update_posted>
    <locations>
      <location>Beijing YouAn Hospital, Capital Medical University, Beijing, Beijing, China, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04331613</url>
  </study>
  <study rank="545">
    <nct_id>NCT04346810</nct_id>
    <title>Burnout Among Caregivers Facing COVID-19 Health Crisis at a Non-conventional Intensive Care Unit Compared to a Conventional Intensive Care Unit</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Burnout, Caregiver</condition>
      <condition>Intensive Care Unit</condition>
      <condition>Stress, Psychological</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Patient management suffering of coronavirus infection</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Stress in a recovery room transformed into an intensive care unit versus a conventional intensive care unit</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hôpital Raymond Poincaré</lead_sponsor>
      <collaborator>Dominique FLETCHER MD-PhD</collaborator>
      <collaborator>Guillaume GERI MD-PhD</collaborator>
      <collaborator>Clement DURET MD</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Ecologic or Community</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>August 15, 2020</primary_completion_date>
    <completion_date>September 1, 2020</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04346810</url>
  </study>
  <study rank="546">
    <nct_id>NCT04359862</nct_id>
    <title>Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection</title>
    <acronym>SEVO-COVID19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Acute Respiratory Distress Syndrome</condition>
      <condition>COVID19 Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sevoflurane</intervention>
      <intervention type="Drug">Propofol</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>PaO2/FiO2</outcome_measure>
      <outcome_measure>TNFα</outcome_measure>
      <outcome_measure>IL-1b</outcome_measure>
      <outcome_measure>IL-6</outcome_measure>
      <outcome_measure>IL-8</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Fundación para la Investigación del Hospital Clínico de Valencia</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>99 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 16, 2020</start_date>
    <primary_completion_date>August 16, 2020</primary_completion_date>
    <completion_date>September 16, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>Hospital Universitario Ramón y Cajal, Madrid, Spain</location>
      <location>Hospital Universitario La Paz, Madrid, Spain</location>
      <location>Hospital Clínico Universitario de Valencia, Valencia, Spain</location>
      <location>Hospital Clínico Universitario de Valencia, Valencia, Spain</location>
      <location>Hospital General Universitario de Valencia, Valencia, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04359862</url>
  </study>
  <study rank="547">
    <nct_id>NCT04310865</nct_id>
    <title>Yinhu Qingwen Granula for the Treatment of Severe CoVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Severe Pneumonia</condition>
      <condition>Chinese Medicine</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Yinhu Qingwen Granula</intervention>
      <intervention type="Drug">Yin Hu Qing Wen Granula(low does)</intervention>
      <intervention type="Other">standard medical treatment</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>changes in the ratio of PaO2 to FiO2 from baseline</outcome_measure>
      <outcome_measure>PaO2</outcome_measure>
      <outcome_measure>blood oxygen saturation (SpO2)</outcome_measure>
      <outcome_measure>clinical status rating on the 7-point ordinal scale</outcome_measure>
      <outcome_measure>Time to Clinical Improvement (TTCI)</outcome_measure>
      <outcome_measure>Duration (hours) of non-invasive mechanical ventilation or high-flow nasal catheter oxygen inhalation use</outcome_measure>
      <outcome_measure>Duration (hours) of invasive mechanical ventilation use</outcome_measure>
      <outcome_measure>Duration (hours) of extracorporeal membrane oxygenation (ECMO) use</outcome_measure>
      <outcome_measure>Duration (days) of Oxygen use</outcome_measure>
      <outcome_measure>The proportion of the patients reporting 2019-nCoV RT-PCR negativity at Day 10 after treatment</outcome_measure>
      <outcome_measure>The counts/percentage of Lymphocyte</outcome_measure>
      <outcome_measure>Time to hospital discharge with clinical recovery from the randomisation</outcome_measure>
      <outcome_measure>The incidence of critical status conversion in 30 days</outcome_measure>
      <outcome_measure>All-cause mortality within 30 days</outcome_measure>
      <outcome_measure>Frequency of severe adverse drug events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Zhong Wang</lead_sponsor>
      <collaborator>Wuhan Leishenshan Hospital</collaborator>
      <collaborator>The First Affiliated Hospital of Dalian Medical University</collaborator>
      <collaborator>Tanshan People's Hospital</collaborator>
      <collaborator>North China University of Science and Technology Affiliated Hospital</collaborator>
      <collaborator>Jizhong Energy Fengfeng Group Hospital</collaborator>
      <collaborator>China Academy of Chinese Medical Sciences</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>116</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>March 20, 2020</start_date>
    <primary_completion_date>March 30, 2021</primary_completion_date>
    <completion_date>June 30, 2021</completion_date>
    <study_first_posted>March 17, 2020</study_first_posted>
    <last_update_posted>March 17, 2020</last_update_posted>
    <locations>
      <location>Wuhan No.7 Hospital/Jizhong Energy Fengfeng Group Hospital, Wuhan, Hubei, China</location>
      <location>Wuhan No.7 Hospital/North China University of Science and Technology Affiliated Hospital, Wuhan, Hubei, China</location>
      <location>Zhongnan Hospital of Wuhan University/Tanshan People's Hospital, Wuhan, Hubei, China</location>
      <location>Wuhan Leishenshan (Thunder God Mountain) Hospital/The First Affiliated Hospital of Dalian Medical University, Wuhan, Hubei, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04310865</url>
  </study>
  <study rank="548">
    <nct_id>NCT04351789</nct_id>
    <title>Impact of a Minimal Psychoeducational Intervention on Anxiety Among Hospitalized COVID-19 Patients in Denmark</title>
    <acronym>PISCA</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Mental Health</condition>
      <condition>Psychoeducation</condition>
      <condition>Anxiety</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Psychoeducational intervention</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Anxiety 1 month</outcome_measure>
      <outcome_measure>Anxiety 3 months</outcome_measure>
      <outcome_measure>Depression 3 months</outcome_measure>
      <outcome_measure>Post Traumatic Stress Disorder (PTSD) symptoms 3 months</outcome_measure>
      <outcome_measure>Anxiety 12 months</outcome_measure>
      <outcome_measure>Post Traumatic Stress Disorder (PTSD) symptoms 12 months</outcome_measure>
      <outcome_measure>Depression 12 months</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Copenhagen University Hospital, Hvidovre</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>66</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>April 2023</primary_completion_date>
    <completion_date>April 2023</completion_date>
    <study_first_posted>April 17, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04351789</url>
  </study>
  <study rank="549">
    <nct_id>NCT04351399</nct_id>
    <title>Psychological Impact of Quarantine in Rheumatoid Arthritis Patient During COVID-19 Outbreak</title>
    <acronym>PRPsyCOVID</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sars-CoV2</condition>
      <condition>Rheumatic Diseases</condition>
      <condition>Rheumatoid Arthritis</condition>
      <condition>Chronic Pain</condition>
    </conditions>
    <interventions>
      <intervention type="Other">questionnaire assesment</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Frequency of RA patients with emotional impact (feeling of isolation)</outcome_measure>
      <outcome_measure>self-reported questionnaire for painful</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Lille</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Family-Based</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>December 2020</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>April 17, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04351399</url>
  </study>
  <study rank="550">
    <nct_id>NCT04344600</nct_id>
    <title>Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 Infection</title>
    <acronym>PROTECT</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sars-CoV2</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon lambda alfa-1a subcutaneous injection</intervention>
      <intervention type="Other">Saline</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Proportion of participants with no evidence of SARS-CoV-2 infection</outcome_measure>
      <outcome_measure>Time (days) to no detection of SARS-CoV-2 in two upper respiratory samples</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Johns Hopkins University</lead_sponsor>
      <collaborator>Eiger BioPharmaceuticals</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>164</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>December 2020</primary_completion_date>
    <completion_date>June 2021</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>Johns Hopkins Hospital, Baltimore, Maryland, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04344600</url>
  </study>
  <study rank="551">
    <nct_id>NCT04324021</nct_id>
    <title>Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV-2</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Emapalumab</intervention>
      <intervention type="Biological">Anakinra</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Treatment success</outcome_measure>
      <outcome_measure>Time to mechanical ventilation</outcome_measure>
      <outcome_measure>Change from baseline in Modified Early Warning system score</outcome_measure>
      <outcome_measure>Change from baseline in resting peripheral capillary oxygen saturation (SpO2)</outcome_measure>
      <outcome_measure>Change from baseline in partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2)</outcome_measure>
      <outcome_measure>Change of pH in hemogasanalysis from baseline</outcome_measure>
      <outcome_measure>Change of carbon dioxide tension (pCO2) in hemogasanalysis from baseline</outcome_measure>
      <outcome_measure>Change of oxygen tension (pO2) in hemogasanalysis from baseline</outcome_measure>
      <outcome_measure>Change of potassium in hemogasanalysis from baseline</outcome_measure>
      <outcome_measure>Change of sodium in hemogasanalysis from baseline</outcome_measure>
      <outcome_measure>Change of chloride in hemogasanalysis from baseline</outcome_measure>
      <outcome_measure>Change of lactic acid in hemogasanalysis from baseline</outcome_measure>
      <outcome_measure>Change of hemoglobin in hemogasanalysis from baseline</outcome_measure>
      <outcome_measure>Change from baseline in oxygen supplementation</outcome_measure>
      <outcome_measure>Change of findings of high-resolution computed tomography (CT) scan of the chest</outcome_measure>
      <outcome_measure>Change from baseline in Ferritin</outcome_measure>
      <outcome_measure>Change from baseline in lactate dehydrogenase (LDH)</outcome_measure>
      <outcome_measure>Change from baseline in D-dimers</outcome_measure>
      <outcome_measure>Change from baseline in White Blood Cells with differential counts</outcome_measure>
      <outcome_measure>Change from baseline in Red Blood Counts</outcome_measure>
      <outcome_measure>Change from baseline in Hemoglobin</outcome_measure>
      <outcome_measure>Change from baseline in Platelet count</outcome_measure>
      <outcome_measure>Change from baseline in Fibrinogen</outcome_measure>
      <outcome_measure>Change from baseline in Complement factors C3/C4</outcome_measure>
      <outcome_measure>Change from baseline in Prothrombin time</outcome_measure>
      <outcome_measure>Change from baseline in Cardiac troponin</outcome_measure>
      <outcome_measure>Change from baseline in aspartate aminotransferase (AST)</outcome_measure>
      <outcome_measure>Change from baseline in alanine aminotransferase (ALT)</outcome_measure>
      <outcome_measure>Change from baseline in total bilirubin levels</outcome_measure>
      <outcome_measure>Change from baseline in C-Reactive Protein</outcome_measure>
      <outcome_measure>Change from baseline in Creatinine</outcome_measure>
      <outcome_measure>Overall survival</outcome_measure>
      <outcome_measure>Time to hospital discharge</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Swedish Orphan Biovitrum</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>30 Years</min_age>
    <max_age>79 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>54</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2, 2020</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>September 2020</completion_date>
    <study_first_posted>March 27, 2020</study_first_posted>
    <last_update_posted>April 9, 2020</last_update_posted>
    <locations>
      <location>ASST Spedali Civili di Brescia Dipartimento di Reumatologia e Immunologia Clinica, Brescia, Italy</location>
      <location>Ospedale Maggiore Policlinico, Dipartimento di Anestesia-Rianimazione e Medicina di Urgenza, Milano, Italy</location>
      <location>Azienda Ospedaliero-Universitaria di Parma, Dipartimento di Malattie infettive ed epatologia, Parma, Italy</location>
      <location>Ospedale Lazzaro Spallanzani, Dipartimento di Malattie Infettive ad alta Intensità di cura ed altamente contagiose,Ospedale Lazzaro Spallanzani, Roma, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04324021</url>
  </study>
  <study rank="552">
    <nct_id>NCT04361448</nct_id>
    <title>Performance of 3 Sampling Methods for the Detection of SARS-CoV-2 (COVID-19) With Real-time Reverse Transcriptase PCR</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid-19</condition>
      <condition>SARS-CoV-2</condition>
      <condition>Diagnosis</condition>
      <condition>Polymerase Chain Reaction</condition>
    </conditions>
    <interventions>
      <intervention type="Other">samling of oropharynx and nasopharynx</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>sensitivity</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Jessa Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>May 20, 2020</primary_completion_date>
    <completion_date>May 20, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Jessa Hospital, Hasselt, Belgium</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04361448</url>
  </study>
  <study rank="553">
    <nct_id>NCT04319445</nct_id>
    <title>Mindfulness During COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Migraine Disorders</condition>
      <condition>Stress</condition>
      <condition>Anxiety</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Mindfulness session(s)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Helpfulness of the session</outcome_measure>
      <outcome_measure>Platform effectiveness</outcome_measure>
      <outcome_measure>Change in Anxiety Level</outcome_measure>
      <outcome_measure>Change in Stress Level</outcome_measure>
      <outcome_measure>Value of the session</outcome_measure>
      <outcome_measure>Satisfaction with the session</outcome_measure>
      <outcome_measure>Percentage of participants that showed interest in a future session</outcome_measure>
      <outcome_measure>Percentage of participants that would recommend this session to a family member</outcome_measure>
      <outcome_measure>Percentage of participants by session frequency preference</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Wake Forest University Health Sciences</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <start_date>March 22, 2020</start_date>
    <primary_completion_date>December 2020</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>March 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Wake Forest Health Sciences, Winston-Salem, North Carolina, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04319445</url>
  </study>
  <study rank="554">
    <nct_id>NCT04357496</nct_id>
    <title>COVID-19 Epidemic Response Study</title>
    <acronym>COVeR</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Fever</condition>
      <condition>Pneumonia</condition>
      <condition>Cough</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Identification of prognostic parameters for SARS-CoV-2 infected participants.</outcome_measure>
      <outcome_measure>Investigation of the kinetics of immune activation and antibody production against SARS-CoV-2 and correlation with clinical course</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centogene AG Rostock</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>60 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>October 30, 2020</primary_completion_date>
    <completion_date>October 30, 2020</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04357496</url>
  </study>
  <study rank="555">
    <nct_id>NCT04339998</nct_id>
    <title>Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS)</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infection</condition>
      <condition>COVID</condition>
      <condition>Covid-19</condition>
      <condition>SARS-CoV-2</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Point-of-Care Ultrasonography (POCUS)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>POCUS Score - Lungs</outcome_measure>
      <outcome_measure>POCUS Score - Heart</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Minnesota</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>October 2020</primary_completion_date>
    <completion_date>October 2020</completion_date>
    <study_first_posted>April 9, 2020</study_first_posted>
    <last_update_posted>April 9, 2020</last_update_posted>
    <locations>
      <location>University of Minnesota Medical Center (UMMC), Minneapolis, Minnesota, United States</location>
      <location>M Health Fairview Bethesda Hospital, Saint Paul, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04339998</url>
  </study>
  <study rank="556">
    <nct_id>NCT04323761</nct_id>
    <title>Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)</title>
    <acronym/>
    <status open="Y">Available</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV2 Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Remdesivir</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>12 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Expanded Access</study_types>
    <exp_acc_types>
      <exp_acc_type>Treatment IND/Protocol</exp_acc_type>
    </exp_acc_types>
    <study_designs/>
    <study_first_posted>March 27, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Banner Health, Phoenix, Arizona, United States</location>
      <location>Community Medical Centers, Fresno, California, United States</location>
      <location>St. Jude Medical Center, Fullerton, California, United States</location>
      <location>Scripps Memorial Hospital La Jolla, La Jolla, California, United States</location>
      <location>MemorialCare Medical Group Long Beach, Long Beach, California, United States</location>
      <location>Huntington Hospital, Pasadena, California, United States</location>
      <location>California Pacific Medical Center, San Francisco, California, United States</location>
      <location>The Regents of the University of California, on behalf of its San Francisco campus, San Francisco, California, United States</location>
      <location>Regional Medical Center, San Jose, California, United States</location>
      <location>San Mateo County Medical Center Foundation, San Mateo, California, United States</location>
      <location>Santa Rosa Memorial Hospital, Santa Rosa, California, United States</location>
      <location>Los Robles Regional Medical Center, Thousand Oaks, California, United States</location>
      <location>PIH Health Whittier Hospital, Whittier, California, United States</location>
      <location>The Medical Center Of Aurora, Aurora, Colorado, United States</location>
      <location>Rose Medical Center, Boulder, Colorado, United States</location>
      <location>Greenwich Hospital, Greenwich, Connecticut, United States</location>
      <location>Stamford Infectious Diseases LLC, Stamford, Connecticut, United States</location>
      <location>George Washington University Hospital, Washington, District of Columbia, United States</location>
      <location>Lawnwood Regional Medical Center, Fort Pierce, Florida, United States</location>
      <location>Memorial Healthcare System, Hollywood, Florida, United States</location>
      <location>Mount Sinai Medical Center, Miami Beach, Florida, United States</location>
      <location>AdventHealth Orlando, Orlando, Florida, United States</location>
      <location>Sarasota Memorial Hospital Clinical Research Center, Sarasota, Florida, United States</location>
      <location>Piedmont Atlanta Hospital, Atlanta, Georgia, United States</location>
      <location>Piedmont Fayette Hospital, Fayetteville, Georgia, United States</location>
      <location>Northwestern Lake Forest Hospital, Lake Forest, Illinois, United States</location>
      <location>Northwestern Medicine Central DuPage Hospital, Winfield, Illinois, United States</location>
      <location>St. Vincent Hospital and Health Care Center, Inc., Carmel, Indiana, United States</location>
      <location>Touro Infirmary, New Orleans, Louisiana, United States</location>
      <location>Ochsner Medical Center, New Orleans, Louisiana, United States</location>
      <location>Slidell Memorial Hospital, Slidell, Louisiana, United States</location>
      <location>Steward St. Elizabeth Medical Center of Boston, Boston, Massachusetts, United States</location>
      <location>Cambridge Health Alliance, Cambridge, Massachusetts, United States</location>
      <location>University of Massachusetts, Worcester, Massachusetts, United States</location>
      <location>St. Joseph Mercy Hospital Health System, Ann Arbor, Michigan, United States</location>
      <location>Huron Valley-Sinai Hospital, Commerce, Michigan, United States</location>
      <location>Henry Ford Health System, Detroit, Michigan, United States</location>
      <location>Bronson Methodist Hospital, Kalamazoo, Michigan, United States</location>
      <location>Clara Maass Medical Center, Belleville, New Jersey, United States</location>
      <location>Hackensack Meridian Health - JFK Medical Center, Edison, New Jersey, United States</location>
      <location>Englewood Health, Englewood, New Jersey, United States</location>
      <location>Hunterdon Medical Center, Flemington, New Jersey, United States</location>
      <location>CentraState Medical Center, Freehold, New Jersey, United States</location>
      <location>Jersey City Medical Center, Jersey City, New Jersey, United States</location>
      <location>Christ Hospital, Jersey City, New Jersey, United States</location>
      <location>Monmouth Medical Center, Long Branch, New Jersey, United States</location>
      <location>Atlantic Health System/ Morristown Medical Center, Morristown, New Jersey, United States</location>
      <location>St. Michael's Medical Center, Newark, New Jersey, United States</location>
      <location>Ocean Medical Center, Oakhurst, New Jersey, United States</location>
      <location>The Valley Hospital, Ridgewood, New Jersey, United States</location>
      <location>Atlantic Health System/Overlook Medical Center, Summit, New Jersey, United States</location>
      <location>Holy Name Medical Center, Teaneck, New Jersey, United States</location>
      <location>Capital Health System, Trenton, New Jersey, United States</location>
      <location>Virtua Voorhees, Voorhees, New Jersey, United States</location>
      <location>St. Peter's Hospital, Albany, New York, United States</location>
      <location>Good Samaritan Hospital Medical Center, Bay Shore, New York, United States</location>
      <location>Lincoln Medical Center, Bronx, New York, United States</location>
      <location>St Barnabus Hospital, Bronx, New York, United States</location>
      <location>Kingsbrook Jewish Medical Center, Brooklyn, New York, United States</location>
      <location>Kings County Hospital, Brooklyn, New York, United States</location>
      <location>New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States</location>
      <location>Maimonides Medical Center, Brooklyn, New York, United States</location>
      <location>New York City Health and Hospitals - Coney Island, Brooklyn, New York, United States</location>
      <location>New York Presbyterian Hospital, Flushing, New York, United States</location>
      <location>Glens Falls Hospital, Glens Falls, New York, United States</location>
      <location>Hospital for Special Surgery, New York, New York, United States</location>
      <location>New York City Health and Hospitals/Harlem, New York, New York, United States</location>
      <location>Memorial Sloan-Kettering Cancer Center, New York, New York, United States</location>
      <location>Mount Sinai South Nassau, Oceanside, New York, United States</location>
      <location>St. Francis Hospital, Roslyn, New York, United States</location>
      <location>Ellis Hospital, Schenectady, New York, United States</location>
      <location>Staten Island University Hopsital- Northwell Health (North Campus), Staten Island, New York, United States</location>
      <location>Stony Brook University Hospital/ Stony Brook Children's, Stony Brook, New York, United States</location>
      <location>MetroHealth Medical Center, Cleveland, Ohio, United States</location>
      <location>Saint Francis Hospital, Tulsa, Oklahoma, United States</location>
      <location>Einstein Medical Center Philadelphia, Philadelphia, Pennsylvania, United States</location>
      <location>Lexington Medical Center, West Columbia, South Carolina, United States</location>
      <location>TriStar Centennial Medical Center, Nashville, Tennessee, United States</location>
      <location>St. David's Medical Center, Austin, Texas, United States</location>
      <location>Texas Health Presbyterian Hospital Dallas, Dallas, Texas, United States</location>
      <location>HCA Houston Healthcare West, Houston, Texas, United States</location>
      <location>Covenant Medical Group - Covenant Medical Center Lubbock, Lubbock, Texas, United States</location>
      <location>Methodist Mansfield Medical, Mansfield, Texas, United States</location>
      <location>Methodist Healthcare System of San Antonio, San Antonio, Texas, United States</location>
      <location>Saint Mark's Hospital, Salt Lake City, Utah, United States</location>
      <location>Inova Fairfax Medical Campus, Fairfax, Virginia, United States</location>
      <location>Henrico Doctors Hospital, Richmond, Virginia, United States</location>
      <location>Jessa Ziekenhuis, Hasselt, Belgium</location>
      <location>AZ Groeninge, Kortrijk, Belgium</location>
      <location>Universitair Ziekenhuis Leuven, Leuven, Belgium</location>
      <location>Hopital Avicenne, Bobigny, France</location>
      <location>Centre Hospitalier Regional Universitaire Brest Hôpital de la Cavale Blanche à Brest, Brest Cedex, France</location>
      <location>Hôpitaux Civils de Colmar, Colmar, France</location>
      <location>Centre Hospitalier Sud Francilien, Corbeil Essonnes, France</location>
      <location>Hôpital Raymond Poincaré, Garches, France</location>
      <location>Centre Hospitalier Régional d'Orléans, Orléans, France</location>
      <location>Centre Hospitalier Universitaire de Poitiers, Poitiers, France</location>
      <location>Hôpital Charles-Nicolle, Rouen, France</location>
      <location>Saint Josef Hospital Ruhr Universitaet Bochum, Bochum, Germany</location>
      <location>Universitatsklinikum, Essen, Germany</location>
      <location>Universitätsklinikum Freiburg, Freiburg, Germany</location>
      <location>Universitätsmedizin Göttingen, Göttingen, Germany</location>
      <location>Medizinische Hochschule Hannover, Hannover, Germany</location>
      <location>Universitatsklinikum Regensburg, Regensburg, Germany</location>
      <location>Klinikum Würzburg Mitte, Würzburg, Germany</location>
      <location>Shaare Zedek Medical Center, Jerusalem, Israel</location>
      <location>Hasharon Hospital, Petah Tikva, Israel</location>
      <location>Sheba Medical Center at Tel Hashomer, Ramat Gan, Israel</location>
      <location>Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona, Ancona, Italy</location>
      <location>Azienda Ospedaliero Universitaria, Bologna, Italy</location>
      <location>Azienda Ospedaliero - Universitaria Careggi, Florence, Italy</location>
      <location>Ospedale San Gerardo di Monza, Monza, Italy</location>
      <location>Azienda Ospedaliera dei Colli, Napoli, Italy</location>
      <location>Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy</location>
      <location>Azienda Ospedaliero Universitaria, Turin, Italy</location>
      <location>Radboud Universitair Medisch Centrum, Nijmegen, Netherlands</location>
      <location>HagaZiekenhuis, The Hague, Netherlands</location>
      <location>Institutul National de Boli Infectioase Prof. Dr. Matei Bals, Bucharest, Romania</location>
      <location>Hospital Universitari Germans Trias i Pujol, Badalona, Spain</location>
      <location>Hospital General Universitario Gregorio Maranon, Madrid, Spain</location>
      <location>Hospital Universitario Central de Asturias, Oviedo, Spain</location>
      <location>Hospital Universitario Son Espases, Palma de Mallorca, Spain</location>
      <location>Hospital Clinico Universitario de Salamanca, Salamanca, Spain</location>
      <location>Hospital Universitario Donostia, San Sebastian, Spain</location>
      <location>Hospital Virgen De La Salud, Santa Cruz de Tenerife, Spain</location>
      <location>Hospital Virgen De La Salud, Toledo, Spain</location>
      <location>Hospital Clinico Universitario de Valladolid, Valladolid, Spain</location>
      <location>Hospital Universitario Miguel Servet, Zaragoza, Spain</location>
      <location>Kantonsspital Aarau, Aarau, Switzerland</location>
      <location>University Hospital Basel, Basel, Switzerland</location>
      <location>Spitalzentrum Biel, Biel, Switzerland</location>
      <location>Kantonsspital Graubünden, Chur, Switzerland</location>
      <location>Centre Hospitalier Universitaire Vaudois Lausanne, Lausanne, Switzerland</location>
      <location>Luzerner Kantonsspital, Luzern, Switzerland</location>
      <location>University Hospital of Wales, Cardiff and Vale NHS Trust, Cardiff, United Kingdom</location>
      <location>Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom</location>
      <location>St. George's Hospital, London, United Kingdom</location>
      <location>Southampton University Hospital, Southampton, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04323761</url>
  </study>
  <study rank="557">
    <nct_id>NCT04350450</nct_id>
    <title>Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
      <condition>Coronavirus</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to resolution of symptoms</outcome_measure>
      <outcome_measure>Number of days from onset of illness to symptom resolution</outcome_measure>
      <outcome_measure>Number of days to return to work</outcome_measure>
      <outcome_measure>Rate of hospital admission in treated and untreated healthcare workers</outcome_measure>
      <outcome_measure>Adverse effect of HCQ during treatment</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Montefiore Medical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>99 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>August 2020</primary_completion_date>
    <completion_date>August 2020</completion_date>
    <study_first_posted>April 17, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations>
      <location>Montefiore Medical Center, Bronx, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04350450</url>
  </study>
  <study rank="558">
    <nct_id>NCT04319731</nct_id>
    <title>A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS CoV-2 Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Human Amniotic Fluid</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Ventilator Free Days</outcome_measure>
      <outcome_measure>Duration of supplemental oxygen use</outcome_measure>
      <outcome_measure>All cause mortality</outcome_measure>
      <outcome_measure>Systemic inflammation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Utah</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Early Phase 1</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 20, 2020</start_date>
    <primary_completion_date>March 20, 2021</primary_completion_date>
    <completion_date>March 20, 2021</completion_date>
    <study_first_posted>March 24, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations>
      <location>University of Utah Health, Salt Lake City, Utah, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04319731</url>
  </study>
  <study rank="559">
    <nct_id>NCT04334967</nct_id>
    <title>Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care</title>
    <acronym/>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Corona Virus Infection</condition>
      <condition>SARS-CoV-2</condition>
      <condition>2019-nCoV</condition>
      <condition>2019 Novel Coronavirus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Dietary Supplement">Vitamin C</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Total Hospitalization</outcome_measure>
      <outcome_measure>Total Mechanical Ventilation</outcome_measure>
      <outcome_measure>Fever intensity measure</outcome_measure>
      <outcome_measure>Shortness of breath measure</outcome_measure>
      <outcome_measure>Changes in daytime cough measure</outcome_measure>
      <outcome_measure>Changes in nighttime cough measure</outcome_measure>
      <outcome_measure>Total mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Providence Health &amp; Services</lead_sponsor>
      <collaborator>Center for Outcomes Research and Education</collaborator>
      <collaborator>Providence Cancer Center, Earle A. Chiles Research Institute</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>45 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>1250</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 30, 2020</start_date>
    <primary_completion_date>September 30, 2021</primary_completion_date>
    <completion_date>September 30, 2023</completion_date>
    <study_first_posted>April 6, 2020</study_first_posted>
    <last_update_posted>April 6, 2020</last_update_posted>
    <locations>
      <location>Portland Providence Medical Center, Portland, Oregon, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04334967</url>
  </study>
  <study rank="560">
    <nct_id>NCT04321928</nct_id>
    <title>Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary</title>
    <acronym>PROACTIVE-19</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV-2</condition>
      <condition>Coronavirus</condition>
      <condition>COVID-19</condition>
      <condition>2019-nCoV</condition>
      <condition>2019nCoV</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Personalized health education</intervention>
      <intervention type="Behavioral">General health education</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Primary composite rate of intensive care unit (ICU) admission, 48 hours of hospital admission, death in COVID-19 positive cases</outcome_measure>
      <outcome_measure>The number of general practitioner visits</outcome_measure>
      <outcome_measure>The number of emergency, hospital admission and intensive care admission</outcome_measure>
      <outcome_measure>Length of hospitalization and intensive care unit stay</outcome_measure>
      <outcome_measure>Organ dysfunction</outcome_measure>
      <outcome_measure>Lifestyle changes</outcome_measure>
      <outcome_measure>The cost of care</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Pecs</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>60 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>7576</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>April 21, 2021</primary_completion_date>
    <completion_date>August 21, 2021</completion_date>
    <study_first_posted>March 25, 2020</study_first_posted>
    <last_update_posted>March 27, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04321928</url>
  </study>
  <study rank="561">
    <nct_id>NCT04355429</nct_id>
    <title>Efficacy of Captopril in Covid-19 Patients With Severe Acute Respiratory Syndrome (SARS) CoV-2 Pneumonia (CAPTOCOVID)</title>
    <acronym>CAPTOCOVID</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pneumonia</condition>
      <condition>Coronavirus Infection</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">captopril 25mg</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Efficacy of captopril nebulization addition to standard of care compared to standard of care.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>230</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 5, 2020</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>August 2020</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>CH Victor Dupuy- Argenteuil, Argenteuil, France</location>
      <location>Hôpital Avicenne,, Bobigny, France</location>
      <location>Hôpital Avicenne, Bobigny, France</location>
      <location>Hôpital Avicenne, Bobigny, France</location>
      <location>Hôpital Antoine Béclère, Clamart, France</location>
      <location>CH de Compiègne-Noyon, Compiègne, France</location>
      <location>Groupe hospitalier Sud Ile de France, Melun, France</location>
      <location>Hôpital de la Pitié- Salpêtrière, Paris, France</location>
      <location>Hôpital Tenon, Paris, France</location>
      <location>CHRU de Tours, Hôpital Bretonneau, Tours, France</location>
      <location>Hôpital de Tours, Tours, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04355429</url>
  </study>
  <study rank="562">
    <nct_id>NCT04363450</nct_id>
    <title>Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP)</title>
    <acronym>HCQPreP</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Corona Virus Infection</condition>
      <condition>Wuhan Coronavirus</condition>
      <condition>Prophylaxis</condition>
      <condition>Healthcare Worker</condition>
      <condition>Sars-CoV2</condition>
      <condition>Hydroxychloroquine</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Incidence of symptomatic COVID-19 infection in healthcare workers</outcome_measure>
      <outcome_measure>Absenteeism from work due to COVID-19</outcome_measure>
      <outcome_measure>Severity of COVID-19 infection</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Louisiana State University Health Sciences Center in New Orleans</lead_sponsor>
      <collaborator>Lafayette General Medical Center</collaborator>
      <collaborator>University of Louisiana Lafayette</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1700</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>May 4, 2020</start_date>
    <primary_completion_date>July 6, 2020</primary_completion_date>
    <completion_date>August 3, 2020</completion_date>
    <study_first_posted>April 27, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04363450</url>
  </study>
  <study rank="563">
    <nct_id>NCT04363268</nct_id>
    <title>ACCESS A Master Digital Surveillance Protocol for COVID-19</title>
    <acronym>ACCESS</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
      <condition>COVID</condition>
      <condition>COVID-19</condition>
      <condition>COVID19</condition>
      <condition>Corona Virus Infection</condition>
      <condition>Coronavirus Infection</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Development of population-based models of disease risk</outcome_measure>
      <outcome_measure>Relation between disease burden and geolocation</outcome_measure>
      <outcome_measure>Effect of medications on symptoms of COVID19</outcome_measure>
      <outcome_measure>Effect of medications on disease severity of COVID19</outcome_measure>
      <outcome_measure>Rate of COVID19 infection and disease outcomes</outcome_measure>
      <outcome_measure>Effect of COVID19 on health outcomes</outcome_measure>
      <outcome_measure>Long-term follow up and recontact</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Medable Inc.</lead_sponsor>
      <collaborator>Datavant</collaborator>
      <collaborator>American Heart Association</collaborator>
      <collaborator>BioIntelliSense</collaborator>
      <collaborator>PWNHealth</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>April 20, 2030</primary_completion_date>
    <completion_date>October 1, 2031</completion_date>
    <study_first_posted>April 27, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Medable Inc., Palo Alto, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04363268</url>
  </study>
  <study rank="564">
    <nct_id>NCT04342884</nct_id>
    <title>COVID-19 Community Research Partnership</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
      <condition>COVID</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Seroprevalence of SARS-CoV-2 infection in the general population of North Carolina</outcome_measure>
      <outcome_measure>Seroprevalence of SARS-CoV-2 infection among health care workers of North Carolina</outcome_measure>
      <outcome_measure>Cumulative incidence of SARS-CoV-2 infection</outcome_measure>
      <outcome_measure>Monthly incidence of SARS-CoV-2 infection</outcome_measure>
      <outcome_measure>Stratified incidence of SARS-CoV-2 infection by age group</outcome_measure>
      <outcome_measure>Stratified incidence of SARS-CoV-2 infection by sex</outcome_measure>
      <outcome_measure>Stratified incidence of SARS-CoV-2 by season</outcome_measure>
      <outcome_measure>Stratified incidence of SARS-CoV-2 infection by geographic area (zip code)</outcome_measure>
      <outcome_measure>Stratified incidence of SARS-CoV-2 infection by preexisting comorbidities</outcome_measure>
      <outcome_measure>Stratified incidence of SARS-CoV-2 infection by COVID-2 contacts</outcome_measure>
      <outcome_measure>Stratified incidence of SARS-CoV-2 infection by use of personal protective equipment (PPE) by health workers</outcome_measure>
      <outcome_measure>Relative risk of SARS-CoV-2 infection by age group</outcome_measure>
      <outcome_measure>Relative risk of SARS-CoV-2 infection by sex</outcome_measure>
      <outcome_measure>Relative risk of SARS-CoV-2 infection by season</outcome_measure>
      <outcome_measure>Relative risk of SARS-CoV-2 infection by geographic area (zip code)</outcome_measure>
      <outcome_measure>Relative risk of SARS-CoV-2 infection by preexisting comorbidities</outcome_measure>
      <outcome_measure>Relative risk of SARS-CoV-2 infection by COVID-2 contacts</outcome_measure>
      <outcome_measure>Relative risk of SARS-CoV-2 infection by use of PPE by health workers</outcome_measure>
      <outcome_measure>Incidence of sequelae</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Wake Forest University Health Sciences</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>150000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 8, 2020</start_date>
    <primary_completion_date>December 2021</primary_completion_date>
    <completion_date>December 2021</completion_date>
    <study_first_posted>April 13, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04342884</url>
  </study>
  <study rank="565">
    <nct_id>NCT04360538</nct_id>
    <title>Long Term Outcomes of Patients With COVID-19</title>
    <acronym>COVID19 LTFU</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Critical Illness</condition>
      <condition>Corona Virus Infection</condition>
      <condition>Respiratory Failure</condition>
      <condition>Covid-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Quality of Life</intervention>
      <intervention type="Other">Impact Event Score</intervention>
      <intervention type="Other">Hospital anxiety and depression scale</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Quality of Life score</outcome_measure>
      <outcome_measure>cognitive dysfunction</outcome_measure>
      <outcome_measure>Functional Status Score</outcome_measure>
      <outcome_measure>Physical Disability</outcome_measure>
      <outcome_measure>Psychological Sequelae</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 8, 2020</start_date>
    <primary_completion_date>July 1, 2021</primary_completion_date>
    <completion_date>December 30, 2021</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>University of Chicago Medical Center, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04360538</url>
  </study>
  <study rank="566">
    <nct_id>NCT04327505</nct_id>
    <title>Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19</title>
    <acronym>COVID-19-HBO</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS (Severe Acute Respiratory Syndrome)</condition>
      <condition>Cytokine Storm</condition>
      <condition>ARDS, Human</condition>
      <condition>COVID-19</condition>
      <condition>Sars-CoV2</condition>
      <condition>Acute Respiratory Failure</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hyperbaric oxygen</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>ICU admission</outcome_measure>
      <outcome_measure>30-day mortality</outcome_measure>
      <outcome_measure>Time-to-intubation</outcome_measure>
      <outcome_measure>Time-to-ICU</outcome_measure>
      <outcome_measure>Inflammatory response</outcome_measure>
      <outcome_measure>Overall survival</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Karolinska Institutet</lead_sponsor>
      <collaborator>Karolinska Trial Alliance</collaborator>
      <collaborator>University of California, San Diego</collaborator>
      <collaborator>Blekinge County Council Hospital</collaborator>
      <collaborator>JK Biostatistics AB</collaborator>
      <collaborator>The Swedish Research Council</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 8, 2020</start_date>
    <primary_completion_date>November 30, 2021</primary_completion_date>
    <completion_date>December 31, 2022</completion_date>
    <study_first_posted>March 31, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04327505</url>
  </study>
  <study rank="567">
    <nct_id>NCT04349982</nct_id>
    <title>ICU Trial in Critical Ill COVID‐19 Patients</title>
    <acronym>POINT-C</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Risk Factor, Cardiovascular</condition>
      <condition>Covid19</condition>
      <condition>Critical Illness</condition>
      <condition>Course Illness</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Biomarker (TropT, Myoglobin, CK, CK-MB, LDH, D-dimer, CRP, PCT)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>ICU CV risk and Biomarker (e.g. Troponin)</outcome_measure>
      <outcome_measure>CV risk and Outcome during ICU stay</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Medical University of Graz</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 8, 2020</start_date>
    <primary_completion_date>June 30, 2020</primary_completion_date>
    <completion_date>July 31, 2020</completion_date>
    <study_first_posted>April 16, 2020</study_first_posted>
    <last_update_posted>April 16, 2020</last_update_posted>
    <locations>
      <location>Medical University of Graz, Graz, Styria, Austria</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04349982</url>
  </study>
  <study rank="568">
    <nct_id>NCT04336215</nct_id>
    <title>Rutgers COVID-19 Cohort Study</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
      <condition>SARS-CoV-2</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Non-Interventional</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Prevalence</outcome_measure>
      <outcome_measure>Incidence</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Rutgers, The State University of New Jersey</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>750</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 7, 2020</start_date>
    <primary_completion_date>September 1, 2020</primary_completion_date>
    <completion_date>October 21, 2021</completion_date>
    <study_first_posted>April 7, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>Clinical Research Center Rutgers-Robert Wood Johnson Medical School RWJUH East Tower -, New Brunswick, New Jersey, United States</location>
      <location>Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States</location>
      <location>Clinical Research Unit Rutgers New Jersey Medical School, Newark, New Jersey, United States</location>
      <location>Rutgers School of Dental Medicine, Newark, New Jersey, United States</location>
      <location>University Hospital, Newark, New Jersey, United States</location>
      <location>Environmental and Occupational Health Sciences Institute, Piscataway, New Jersey, United States</location>
      <location>RUCDR Infinite Biologics, Piscataway, New Jersey, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04336215</url>
  </study>
  <study rank="569">
    <nct_id>NCT04341766</nct_id>
    <title>Evolution of Pulmonary Ultrasound in Patients Hospitalized for Covid (Coronavirus Disease) 19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pneumonia, Viral</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">No special intervention</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Characteristics of pulmonary ultrasound for Covid-19 patients</outcome_measure>
      <outcome_measure>Charateristics of pulmonary CT-scan for Covid-19 patients</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier Intercommunal Creteil</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>105 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 31, 2020</start_date>
    <primary_completion_date>May 1, 2020</primary_completion_date>
    <completion_date>September 30, 2020</completion_date>
    <study_first_posted>April 10, 2020</study_first_posted>
    <last_update_posted>April 10, 2020</last_update_posted>
    <locations>
      <location>CHG de Chambery, Chambéry, France</location>
      <location>Centre Hospitalier Intercommunal de Créteil, Créteil, France</location>
      <location>CHU de Limoges, Limoges, France</location>
      <location>APHM - Hopital Nord, Marseille, France</location>
      <location>CHU de Nancy, Nancy, France</location>
      <location>Hopital privé de la Loire, Saint-Étienne, France</location>
      <location>CHU de Tours, Tours, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04341766</url>
  </study>
  <study rank="570">
    <nct_id>NCT04362267</nct_id>
    <title>Longitudinal Study of Covid-19 Infection Among HCW in a French University Hospital</title>
    <acronym>PRECOVIA</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sars-CoV2</condition>
    </conditions>
    <interventions>
      <intervention type="Other">self-administered questionnaire</intervention>
      <intervention type="Diagnostic Test">SARS-Cov2 testing</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>the incidence of SARS- Cov2 infection Heath Care Worker diagnosed by the positivity of SARS-Cov2 RT-PCT and serological testing</outcome_measure>
      <outcome_measure>Occupational exposures associated with the SARS-Cov2 infection</outcome_measure>
      <outcome_measure>Environmental exposures associated with the SARS-Cov2 infection</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Lille</lead_sponsor>
      <collaborator>Fondation Santé Roquette</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>September 2020</primary_completion_date>
    <completion_date>September 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04362267</url>
  </study>
  <study rank="571">
    <nct_id>NCT04270383</nct_id>
    <title>Clinical Characteristics and Long-term Prognosis of 2019-nCoV Infection in Children</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>2019-nCoV</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>The cure rate of 2019-nCoV.</outcome_measure>
      <outcome_measure>The improvement rate of 2019-nCoV.</outcome_measure>
      <outcome_measure>The incidence of long-term adverse outcomes.</outcome_measure>
      <outcome_measure>Duration of fever</outcome_measure>
      <outcome_measure>Duration of respiratory symptoms</outcome_measure>
      <outcome_measure>Duration of hospitalization</outcome_measure>
      <outcome_measure>Number of participant(s) need intensive care</outcome_measure>
      <outcome_measure>Number of participant(s) with acute respiratory distress syndrome</outcome_measure>
      <outcome_measure>Number of participant(s) with extra-pulmonary complications, including shock, renal failure, multiple organ failure, hemophagocytosis syndrome, et al.</outcome_measure>
      <outcome_measure>Number of participant(s) who died during the trial</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Beijing Children's Hospital</lead_sponsor>
      <collaborator>Capital Institute of Pediatrics, China</collaborator>
      <collaborator>The First Affiliated Hospital of Anhui Medical University</collaborator>
      <collaborator>China-Japan Friendship Hospital</collaborator>
      <collaborator>The First Affiliated Hospital of Xiamen University</collaborator>
      <collaborator>Guangzhou Women and Children's Medical Center</collaborator>
      <collaborator>Shenzhen Children's Hospital</collaborator>
      <collaborator>First Affiliated Hospital of Guangxi Medical University</collaborator>
      <collaborator>The Affiliated Hospital Of Guizhou Medical University</collaborator>
      <collaborator>Hainan People's Hospital</collaborator>
      <collaborator>Children's Hospital of Hebei Province</collaborator>
      <collaborator>Wuhan Women and Children's Medical Center</collaborator>
      <collaborator>Changchun Children's Hospital</collaborator>
      <collaborator>Children’s Hospital of Nanjing Medical University</collaborator>
      <collaborator>Jiangxi Province Children's Hospital</collaborator>
      <collaborator>Shengjing Hospital</collaborator>
      <collaborator>Shanxi Provincial Maternity and Children's Hospital</collaborator>
      <collaborator>Xian Children's Hospital</collaborator>
      <collaborator>Children's Hospital of Chongqing Medical University</collaborator>
      <collaborator>Tianjin Children's Hospital</collaborator>
      <collaborator>Tianjin Medical University Second Hospital</collaborator>
      <collaborator>Kunming Children's Hospital</collaborator>
      <collaborator>Second Affiliated Hospital of Wenzhou Medical University</collaborator>
    </sponsors>
    <gender>All</gender>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>February 15, 2020</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>February 17, 2020</study_first_posted>
    <last_update_posted>February 17, 2020</last_update_posted>
    <locations>
      <location>Beijing Children's Hospital,, Beijing, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04270383</url>
  </study>
  <study rank="572">
    <nct_id>NCT04363632</nct_id>
    <title>Prospective Analysis of Morbi-mortality of Patients With Cancers in Active Phase of Treatment Suspected or Diagnosed of a SARS-CoV-2 Infection</title>
    <acronym>ONCOVID-19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV-2 (COVID-19) Suspicion</condition>
      <condition>Cancer</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Mortality of cancer patients under active anticancer treatment</outcome_measure>
      <outcome_measure>Overall survival</outcome_measure>
      <outcome_measure>Duration of hospitalization</outcome_measure>
      <outcome_measure>Death cause</outcome_measure>
      <outcome_measure>Associated complications</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Leon Berard</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Other</study_design>
    </study_designs>
    <start_date>April 2, 2020</start_date>
    <primary_completion_date>June 2020</primary_completion_date>
    <completion_date>June 2020</completion_date>
    <study_first_posted>April 27, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>Centre Leon Berard, Lyon, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04363632</url>
  </study>
  <study rank="573">
    <nct_id>NCT04298060</nct_id>
    <title>DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)</title>
    <acronym>STOP-Flu</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Influenza Infection</condition>
      <condition>SAD-RV Infection and COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DAS181</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Percent of subjects who have returned to room air</outcome_measure>
      <outcome_measure>Percent change of subjects return to baseline oxygen requirement</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ansun Biopharma, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>280</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>March 2021</primary_completion_date>
    <completion_date>September 2022</completion_date>
    <study_first_posted>March 6, 2020</study_first_posted>
    <last_update_posted>April 2, 2020</last_update_posted>
    <locations>
      <location>Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04298060</url>
  </study>
  <study rank="574">
    <nct_id>NCT04348864</nct_id>
    <title>COVID-19 Antibody Self-testing Using Virtual Point-of-care</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Communicable Disease</condition>
      <condition>COVID-19</condition>
      <condition>Sars-CoV2</condition>
      <condition>Infectious Disease</condition>
      <condition>Coronavirus</condition>
      <condition>Virus Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">COVID-19 IgM/IgG Rapid Testing, mobile device image capture and telemedicine support</intervention>
      <intervention type="Other">Telemedicine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clinical accuracy of the antibody-based rapid tests compared to PCR-based test result</outcome_measure>
      <outcome_measure>Clinical accuracy of the rapid tests based on Clinical diagnosis</outcome_measure>
      <outcome_measure>Self-test interpretation of result vs expert clinical image interpretation of result</outcome_measure>
      <outcome_measure>Ease of self-testing procedure</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Neuroganics LLC</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>99 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <start_date>April 16, 2020</start_date>
    <primary_completion_date>April 2021</primary_completion_date>
    <completion_date>April 2021</completion_date>
    <study_first_posted>April 16, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations>
      <location>Neuroganics, Northglenn, Colorado, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04348864</url>
  </study>
  <study rank="575">
    <nct_id>NCT04334954</nct_id>
    <title>SARS-COV2 Pandemic Serosurvey and Blood Sampling</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-COV2 Virus</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Number of people with detectable antibodies to SARS-COV2</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>15000</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <start_date>May 1, 2020</start_date>
    <primary_completion_date>March 31, 2022</primary_completion_date>
    <completion_date>March 31, 2022</completion_date>
    <study_first_posted>April 6, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>National Institutes of Health Clinical Center, Bethesda, Maryland, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04334954</url>
  </study>
  <study rank="576">
    <nct_id>NCT04332991</nct_id>
    <title>Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease</title>
    <acronym>ORCHID</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
      <condition>Acute Respiratory Infection</condition>
      <condition>SARS-CoV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>COVID Ordinal Outcomes Scale on Day 15</outcome_measure>
      <outcome_measure>all-location, all-cause mortality assessed on day 15</outcome_measure>
      <outcome_measure>all-location, all-cause mortality assessed on day 29</outcome_measure>
      <outcome_measure>COVID Ordinal Outcomes Scale on Study Day 3</outcome_measure>
      <outcome_measure>COVID Ordinal Outcomes Scale on Study Day 8</outcome_measure>
      <outcome_measure>COVID Ordinal Outcomes Scale on Study Day 29</outcome_measure>
      <outcome_measure>Number of patients dead or with receipt of ECMO between enrollment and Day 28</outcome_measure>
      <outcome_measure>Oxygen-free days through Day 28</outcome_measure>
      <outcome_measure>Ventilator-free days through Day 28</outcome_measure>
      <outcome_measure>Vasopressor-free days through Day 28</outcome_measure>
      <outcome_measure>ICU-free days to Day 28</outcome_measure>
      <outcome_measure>Hospital-free days to Day 28</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Massachusetts General Hospital</lead_sponsor>
      <collaborator>National Heart, Lung, and Blood Institute (NHLBI)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>510</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2, 2020</start_date>
    <primary_completion_date>April 2021</primary_completion_date>
    <completion_date>July 2021</completion_date>
    <study_first_posted>April 3, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>University of Arizona, Tucson, Arizona, United States</location>
      <location>UCSF Fresno, Fresno, California, United States</location>
      <location>Cedars-Sinai Medical Center, Los Angeles, California, United States</location>
      <location>Ronald Reagan UCLA Medical Center, Los Angeles, California, United States</location>
      <location>UC Davis Medical Center, Sacramento, California, United States</location>
      <location>UCSF Medical Center, San Francisco, California, United States</location>
      <location>Stanford University, Stanford, California, United States</location>
      <location>Medical Center of Aurora, Aurora, Colorado, United States</location>
      <location>University of Colorado Hospital, Aurora, Colorado, United States</location>
      <location>Denver Health Medical Center, Denver, Colorado, United States</location>
      <location>St. Joseph Hospital, Denver, Colorado, United States</location>
      <location>University of Florida, Gainesville, Florida, United States</location>
      <location>University of Kentucky, Lexington, Kentucky, United States</location>
      <location>University Medical Center, New Orleans, Louisiana, United States</location>
      <location>Maine Medical Center, Portland, Maine, United States</location>
      <location>Massachusetts General Hospital, Boston, Massachusetts, United States</location>
      <location>Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States</location>
      <location>Brigham and Women's Hospital, Boston, Massachusetts, United States</location>
      <location>Baystate Medical Center, Springfield, Massachusetts, United States</location>
      <location>St. Vincent's Hospital, Worcester, Massachusetts, United States</location>
      <location>University of Michigan Medical Center, Ann Arbor, Michigan, United States</location>
      <location>Henry Ford Medical Center, Detroit, Michigan, United States</location>
      <location>University of Mississippi Medical Center, Jackson, Mississippi, United States</location>
      <location>Montefiore Medical Center-Weiler, Bronx, New York, United States</location>
      <location>Montefiore Medical Center-Moses, Bronx, New York, United States</location>
      <location>University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States</location>
      <location>Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States</location>
      <location>University of Cincinnati Medical Center, Cincinnati, Ohio, United States</location>
      <location>Cleveland Clinic Foundation, Cleveland, Ohio, United States</location>
      <location>Ohio State University Wexner Medical Center, Columbus, Ohio, United States</location>
      <location>Oregon Health and Science University, Portland, Oregon, United States</location>
      <location>Penn State Hershey Medical Center, Hershey, Pennsylvania, United States</location>
      <location>Temple University Hospital, Philadelphia, Pennsylvania, United States</location>
      <location>UPMC Presbyterian/Mercy/Shadyside, Pittsburgh, Pennsylvania, United States</location>
      <location>Medical University of South Carolina, Charleston, South Carolina, United States</location>
      <location>Vanderbilt University Medical Center, Nashville, Tennessee, United States</location>
      <location>University of Texas Health Science Center, Houston, Texas, United States</location>
      <location>Intermountain Medical Center, Murray, Utah, United States</location>
      <location>University of Utah Hospital, Salt Lake City, Utah, United States</location>
      <location>University of Virginia Health System, Charlottesville, Virginia, United States</location>
      <location>VCU Medical Center, Richmond, Virginia, United States</location>
      <location>Harborview Medical Center, Seattle, Washington, United States</location>
      <location>Swedish Hospital First Hill, Seattle, Washington, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04332991</url>
  </study>
  <study rank="577">
    <nct_id>NCT04357275</nct_id>
    <title>The RIsk Stratification in COVID-19 Patients in the ICU Registry</title>
    <acronym>RISC-19-ICU</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Critical Illness</condition>
      <condition>ARDS</condition>
      <condition>Inflammatory Response</condition>
      <condition>COVID-19</condition>
      <condition>Circulatory Shock</condition>
    </conditions>
    <interventions>
      <intervention type="Other">ICU treatment</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>ICU mortality</outcome_measure>
      <outcome_measure>Hospital mortality</outcome_measure>
      <outcome_measure>ICU length of stay</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Zurich</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>10000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 13, 2020</start_date>
    <primary_completion_date>March 2021</primary_completion_date>
    <completion_date>March 2022</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>University Hospital of Zurich, Zurich, Switzerland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04357275</url>
  </study>
  <study rank="578">
    <nct_id>NCT04320511</nct_id>
    <title>Beaumont Quantitative Lung Function Imaging to Characterize Patients With SARS-COV 2</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-COV2</condition>
      <condition>Severe Acute Respiratory Syndrome</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Device">CT-V</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Predictive association between CT-V, PBM score and disease progression</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>William Beaumont Hospitals</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>March 2021</primary_completion_date>
    <completion_date>March 2022</completion_date>
    <study_first_posted>March 25, 2020</study_first_posted>
    <last_update_posted>March 31, 2020</last_update_posted>
    <locations>
      <location>Beaumont Health, Royal Oak, Michigan, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04320511</url>
  </study>
  <study rank="579">
    <nct_id>NCT04340050</nct_id>
    <title>COVID-19 Convalescent Plasma</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">anti-SARS-CoV-2 convalescent plasma</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Feasibility of performing study pathway consisting of consenting convalescent donors, harvesting convalescent plasma, application for FDA eIND and administering convalescent plasma to the patients</outcome_measure>
      <outcome_measure>Type of respiratory support</outcome_measure>
      <outcome_measure>Cardiac arrest</outcome_measure>
      <outcome_measure>Transfer to ICU</outcome_measure>
      <outcome_measure>ICU mortality</outcome_measure>
      <outcome_measure>ICU length of stay</outcome_measure>
      <outcome_measure>Hospital mortality</outcome_measure>
      <outcome_measure>Hospital length of stay</outcome_measure>
      <outcome_measure>Ventilator-free days</outcome_measure>
      <outcome_measure>Overall survival (28-day mortality)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Chicago</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Early Phase 1</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 10, 2020</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>December 31, 2021</completion_date>
    <study_first_posted>April 9, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>University of Chicago Medicine, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04340050</url>
  </study>
  <study rank="580">
    <nct_id>NCT04359914</nct_id>
    <title>Neurocognitive Impairment in Patients With COVID-19</title>
    <acronym>NCoV</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Critical Illness</condition>
      <condition>COVID-19</condition>
      <condition>Central Nervous System Injury</condition>
      <condition>Delirium</condition>
      <condition>Encephalopathy</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Incidence of delirium/neurocognitive impairment in adult and pediatric patients with COVID-19 compared to patients without COVID-19</outcome_measure>
      <outcome_measure>Change in neuroaxonal injury biomarker levels in patients with COVID-19 compared to patients without COVID-19</outcome_measure>
      <outcome_measure>Neurocognitive 3-months outcome in patients with COVID-19 compared to patients without COVID-19</outcome_measure>
      <outcome_measure>Quality of life in patients with COVID-19 compared to patients without COVID-19 after hospital discharge</outcome_measure>
      <outcome_measure>Length of hospital stay in patients with COVID-19 compared to patients without COVID-19</outcome_measure>
      <outcome_measure>90-day survival in patients with COVID-19 compared to patients without COVID-19</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Rostock</lead_sponsor>
      <collaborator>Ludwig-Maximilians - University of Munich</collaborator>
      <collaborator>University College, London</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>April 1, 2021</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Department of Anesthesiology and Intensive Care Medicine, University Medical Center Rostock, Rostock, Mecklenburg-Vorpommern, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04359914</url>
  </study>
  <study rank="581">
    <nct_id>NCT04352517</nct_id>
    <title>Influence Physical Activity Psychological Responses COVID-19 Pandemic</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sedentary Behavior</condition>
      <condition>Mental Health Wellness 1</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Online Survey</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Impact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on avoidance impact of COVID-19 through IES-R</outcome_measure>
      <outcome_measure>Impact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on intrusion impact of COVID-19 through IES-R</outcome_measure>
      <outcome_measure>Impact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on hyperarousal impact of COVID-19 through IES-R</outcome_measure>
      <outcome_measure>Impact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on depression health status through DASS-21</outcome_measure>
      <outcome_measure>IImpact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on anxiety health status through DASS-21</outcome_measure>
      <outcome_measure>Impact of International Physical Activity Questionnaire-score (high, moderate, low level;higher scores mean a better outcome) on stress health status through DASS-21</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Extremadura</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>3500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Ecologic or Community</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <start_date>March 16, 2020</start_date>
    <primary_completion_date>August 31, 2020</primary_completion_date>
    <completion_date>September 30, 2020</completion_date>
    <study_first_posted>April 20, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>Universidade da Sao Paulo, Ribeirão Preto, Sao Paulo, Brazil</location>
      <location>Universidad Autonoma de Chile, Santiago, Región Metropolitana, Chile</location>
      <location>Universidad de la República, Rivera, Uruguay</location>
    </locations>
    <study_documents>
      <study_document>
        <label>Study Protocol and Statistical Analysis Plan</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT04352517/Prot_SAP_000.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT04352517</url>
  </study>
  <study rank="582">
    <nct_id>NCT04324528</nct_id>
    <title>Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation</title>
    <acronym>CYCOV</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
      <condition>COVID-19</condition>
      <condition>SARS-CoV Infection</condition>
      <condition>Respiratory Failure</condition>
      <condition>Cytokine Storm</condition>
    </conditions>
    <interventions>
      <intervention type="Device">vv-ECMO + cytokine adsorption (Cytosorb adsorber)</intervention>
      <intervention type="Device">vv-ECMO only (no cytokine adsorption)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>interleukin-6 (IL-6) level after 72 hours</outcome_measure>
      <outcome_measure>30-day-survival</outcome_measure>
      <outcome_measure>vasopressor dosage</outcome_measure>
      <outcome_measure>fluid balance</outcome_measure>
      <outcome_measure>lactate</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Dr. Alexander Supady</lead_sponsor>
      <collaborator>University Hospital Freiburg</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>100 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 27, 2020</start_date>
    <primary_completion_date>September 26, 2020</primary_completion_date>
    <completion_date>November 26, 2020</completion_date>
    <study_first_posted>March 27, 2020</study_first_posted>
    <last_update_posted>March 31, 2020</last_update_posted>
    <locations>
      <location>University Clinic Freiburg, Freiburg, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04324528</url>
  </study>
  <study rank="583">
    <nct_id>NCT04336787</nct_id>
    <title>Physical Activity Level, Stress Level, Sleep Quality in Pregnant Women During Covid-19 Quarantine</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid-19</condition>
      <condition>Coronavirus Infection</condition>
      <condition>Pregnancy Related</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Survey</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>International Physical Activity Questionnaire</outcome_measure>
      <outcome_measure>Pittsburgh Sleep Quality Index</outcome_measure>
      <outcome_measure>Perceived Stress Scale</outcome_measure>
      <outcome_measure>Numerical Pain Rating Scale</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Istanbul Kültür University</lead_sponsor>
      <collaborator>Istanbul University-Cerrahpasa</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>45 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Ecologic or Community</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 12, 2020</start_date>
    <primary_completion_date>May 10, 2020</primary_completion_date>
    <completion_date>June 10, 2020</completion_date>
    <study_first_posted>April 7, 2020</study_first_posted>
    <last_update_posted>April 13, 2020</last_update_posted>
    <locations>
      <location>Istanbul University - Cerrahpaşa, Istanbul, Turkey</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04336787</url>
  </study>
  <study rank="584">
    <nct_id>NCT04359836</nct_id>
    <title>A Study to Explore the Role of Gut Flora in COVID-19 Infection</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Gut Microbiome</condition>
      <condition>Gastrointestinal Microbiome</condition>
      <condition>COVID</condition>
      <condition>COVID-19</condition>
      <condition>Corona Virus Infection</condition>
      <condition>Coronavirus</condition>
      <condition>Coronaviridae Infections</condition>
      <condition>Coronavirus 19</condition>
      <condition>Coronavirus-19</condition>
      <condition>COVID 19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">There is no intervention in this study</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Correlation of Microbiome to Disease via Relative Abundance Found in Microbiome Sequencing</outcome_measure>
      <outcome_measure>Validation of Sequencing Methods</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>ProgenaBiome</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>250</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Other</study_design>
    </study_designs>
    <start_date>April 16, 2020</start_date>
    <primary_completion_date>April 30, 2021</primary_completion_date>
    <completion_date>July 31, 2021</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>ProgenaBiome, Ventura, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04359836</url>
  </study>
  <study rank="585">
    <nct_id>NCT04343651</nct_id>
    <title>Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Disease 2019</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Placebos</intervention>
      <intervention type="Drug">Leronlimab (700mg)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clinical Improvement as assessed by change in total symptom score (for fever, myalgia, dyspnea and cough)</outcome_measure>
      <outcome_measure>Time to clinical resolution (TTCR)</outcome_measure>
      <outcome_measure>Change from baseline in National Early Warning Score 2 (NEWS2)</outcome_measure>
      <outcome_measure>Change from baseline in pulse oxygen saturation (SpO2)</outcome_measure>
      <outcome_measure>Change from baseline in the patient's health status on a 7-category ordinal scale</outcome_measure>
      <outcome_measure>Incidence of hospitalization</outcome_measure>
      <outcome_measure>Duration (days) of hospitalization</outcome_measure>
      <outcome_measure>Incidence of mechanical ventilation supply</outcome_measure>
      <outcome_measure>Duration (days) of mechanical ventilation supply</outcome_measure>
      <outcome_measure>Incidence of oxygen use</outcome_measure>
      <outcome_measure>Duration (days) of oxygen use</outcome_measure>
      <outcome_measure>Mortality rate</outcome_measure>
      <outcome_measure>Time to return to normal activity</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>CytoDyn, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>99 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>75</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>December 4, 2020</primary_completion_date>
    <completion_date>April 4, 2021</completion_date>
    <study_first_posted>April 13, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>Montefiore Medical Center, Bronx, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04343651</url>
  </study>
  <study rank="586">
    <nct_id>NCT04363827</nct_id>
    <title>Protect: A Randomized Study With Hydroxychloroquine Versus Observational Support for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19)</title>
    <acronym>PROTECT</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID19</condition>
      <condition>Hydroxychloroquine</condition>
      <condition>Prophylaxis</condition>
      <condition>Treatment</condition>
      <condition>SARS-CoV-2</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>the proportion of subjects of Group 1 who become symptomatic and/or swab positive in each arm within 1 month from randomization.</outcome_measure>
      <outcome_measure>the proportion of subjects of Group 2 who become swab negative in each arm within 14 days from randomization.</outcome_measure>
      <outcome_measure>The proportion of subjects with positive swabs in Group 1 within 1 month from randomization in both arms</outcome_measure>
      <outcome_measure>The proportion of subjects of Group 1 who become symptomatic in each arm within 1 month from randomization</outcome_measure>
      <outcome_measure>The proportion of subjects of Group 2 who become swab negative in each arm within within 14 days from randomization.</outcome_measure>
      <outcome_measure>The proportion of subjects of Group 2 who become swab negative in each arm within 1 month from randomization in overall population and in subgroup population</outcome_measure>
      <outcome_measure>Absolute and relative frequencies of Serious Adverse Events</outcome_measure>
      <outcome_measure>Variation in Quality of Life scores in different time points</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori</lead_sponsor>
      <collaborator>University of Bologna</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>2300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 2020</start_date>
    <primary_completion_date>September 2020</primary_completion_date>
    <completion_date>March 2021</completion_date>
    <study_first_posted>April 27, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>Irst Irccs, Meldola, FC, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04363827</url>
  </study>
  <study rank="587">
    <nct_id>NCT04285190</nct_id>
    <title>The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Disease 2019</condition>
      <condition>Novel Coronavirus Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">T89</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The time to oxygen saturation recovery to normal level (≥97%)</outcome_measure>
      <outcome_measure>The proportion of patients with normal level of oxygen saturation(≥97%)</outcome_measure>
      <outcome_measure>The degree of remission of symptoms of patients, including: fatigue, nausea, vomiting, chest tightness, shortness of breath, etc.</outcome_measure>
      <outcome_measure>The time to the myocardial enzyme spectrum recovery to normal after treatment</outcome_measure>
      <outcome_measure>The proportion of the patients with normal myocardial enzyme spectrum after treatment</outcome_measure>
      <outcome_measure>The time to the electrocardiogram recovery to normal level after treatment</outcome_measure>
      <outcome_measure>The proportion of the patients with normal electrocardiogram after treatment</outcome_measure>
      <outcome_measure>The time to the hemodynamics recovery to normal after treatment</outcome_measure>
      <outcome_measure>The proportion of the patients with normal hemodynamics after treatment</outcome_measure>
      <outcome_measure>The time to exacerbation or remission of the disease after treatment;</outcome_measure>
      <outcome_measure>The proportion of the patients with exacerbation or remission of disease after treatment</outcome_measure>
      <outcome_measure>The proportion of patients who need other treatment (e.g. heparin, anticoagulants) due to microcirculation disorders</outcome_measure>
      <outcome_measure>The all-cause mortality rate</outcome_measure>
      <outcome_measure>The proportion of patients with acidosis</outcome_measure>
      <outcome_measure>The total duration of the patients in-hospital</outcome_measure>
      <outcome_measure>The total duration of oxygen inhalation during treatment</outcome_measure>
      <outcome_measure>The oxygen flow rate during treatment</outcome_measure>
      <outcome_measure>The oxygen concentration during treatment</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tasly Pharmaceuticals, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>February 26, 2020</start_date>
    <primary_completion_date>June 15, 2020</primary_completion_date>
    <completion_date>September 15, 2020</completion_date>
    <study_first_posted>February 26, 2020</study_first_posted>
    <last_update_posted>February 26, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04285190</url>
  </study>
  <study rank="588">
    <nct_id>NCT04365595</nct_id>
    <title>SARS-CoV-2 Associated Respiratory Failure Recovery (COVID-19 CAir)</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV 2</condition>
      <condition>COVID</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Questionnaires, spirometry</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Health-related quality-of-life</outcome_measure>
      <outcome_measure>Anxiety and depression</outcome_measure>
      <outcome_measure>Symptom burden</outcome_measure>
      <outcome_measure>Spirometry</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Zurich</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>May 2020</start_date>
    <primary_completion_date>December 2020</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>University Hospital Zurich, Zurich, Switzerland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04365595</url>
  </study>
  <study rank="589">
    <nct_id>NCT04324606</nct_id>
    <title>A Study of a Candidate COVID-19 Vaccine (COV001)</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">ChAdOx1 nCoV-19</intervention>
      <intervention type="Biological">MenACWY</intervention>
      <intervention type="Biological">ChAdOx1 nCoV-19 boost</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Assess efficacy of the candidate ChAdOx1 nCoV-19 against COVID-19: Number of virologically confirmed (PCR positive) symptomatic cases</outcome_measure>
      <outcome_measure>Assess the safety of the candidate vaccine ChAdOx1 nCoV: Occurrence of serious adverse events (SAEs)</outcome_measure>
      <outcome_measure>Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV: Occurrence of solicited local reactogenicity signs and symptoms</outcome_measure>
      <outcome_measure>Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV: Occurrence of solicited systemic reactogenicity signs and symptoms</outcome_measure>
      <outcome_measure>Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV: Occurrence of unsolicited adverse events (AEs)</outcome_measure>
      <outcome_measure>Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV through standard blood tests</outcome_measure>
      <outcome_measure>Assess the safety, tolerability and reactogenicity profile of the candidate vaccine ChAdOx1 nCoV by measuring the number of disease enhancement episodes</outcome_measure>
      <outcome_measure>Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19</outcome_measure>
      <outcome_measure>Assess efficacy of the candidate ChAdOx1 nCoV-19 against severe and non-severe COVID-19 by measuring seroconversion rates</outcome_measure>
      <outcome_measure>Assess cellular and humoral immunogenicity of ChAdOx1 nCoV-19 through ELISpot assays</outcome_measure>
      <outcome_measure>Assess cellular and humoral immunogenicity of ChAdOx1 nCoV-19</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Oxford</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>1112</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>May 2021</primary_completion_date>
    <completion_date>May 2021</completion_date>
    <study_first_posted>March 27, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>NIHR WTCRF, University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom</location>
      <location>St Georges University Hospital NHS Foundation Trust, London, Tooting, United Kingdom</location>
      <location>University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom</location>
      <location>Imperial College Healthcare NHS Trust, London, United Kingdom</location>
      <location>CCVTM, University of Oxford, Churchill Hospital, Oxford, United Kingdom</location>
      <location>John Radcliffe Hospital, Oxford, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04324606</url>
  </study>
  <study rank="590">
    <nct_id>NCT04325048</nct_id>
    <title>Clinical Evaluation of Cordio Application in Adult COVID-19 Virus Positive Patients</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Cordio App</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Voice anaysis</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Cordio Medical</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>5000</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>June 2021</primary_completion_date>
    <completion_date>September 2021</completion_date>
    <study_first_posted>March 27, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04325048</url>
  </study>
  <study rank="591">
    <nct_id>NCT04358003</nct_id>
    <title>Plasma Adsorption in Patients With Confirmed COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Respiratory Failure</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Plasma Adsorption Cartridge</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>All-cause mortality</outcome_measure>
      <outcome_measure>Change in Sequential Organ Failure Assessment [SOFA] scores</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Marker Therapeutics AG</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>2000</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 27, 2020</start_date>
    <primary_completion_date>August 1, 2020</primary_completion_date>
    <completion_date>December 1, 2020</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04358003</url>
  </study>
  <study rank="592">
    <nct_id>NCT04362956</nct_id>
    <title>Clinical and Immunologic Impact of Perinatal SARS-CoV-2 (COVID-19) Infection</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid19</condition>
      <condition>Pregnancy Related</condition>
      <condition>Neonatal Infection</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Vertical transmission</outcome_measure>
      <outcome_measure>Neonatal protection due to maternal antibodies</outcome_measure>
      <outcome_measure>Increase risk of neonatal morbidity</outcome_measure>
      <outcome_measure>Increase risk of obstetric complications</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Fundacion Infant</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>May 1, 2020</start_date>
    <primary_completion_date>September 30, 2020</primary_completion_date>
    <completion_date>September 30, 2020</completion_date>
    <study_first_posted>April 27, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04362956</url>
  </study>
  <study rank="593">
    <nct_id>NCT04356950</nct_id>
    <title>Analysis of the Coagulopathy Developed by COVID-19 Infected Patients</title>
    <acronym>COVID-TGT</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sepsis</condition>
      <condition>Blood Coagulation Disorders</condition>
      <condition>Thrombin</condition>
      <condition>Disseminated Intravascular Coagulation</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Thrombin generation test assay</intervention>
      <intervention type="Other">Fibrin generation markers assays</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Survival rate during hospitalization</outcome_measure>
      <outcome_measure>Absolute thrombin generation test latent period</outcome_measure>
      <outcome_measure>Relative thrombin generation test latent period compared to reference plasma</outcome_measure>
      <outcome_measure>Absolute thrombin generation test initial velocity</outcome_measure>
      <outcome_measure>Relative thrombin generation test initial velocity compared to reference plasma</outcome_measure>
      <outcome_measure>Relative thrombin generation test peak thrombin compared to reference plasma</outcome_measure>
      <outcome_measure>Absolute thrombin generation test peak thrombin</outcome_measure>
      <outcome_measure>Absolute thrombin generation test peak thrombin time</outcome_measure>
      <outcome_measure>Relative thrombin generation test peak thrombin time compared to reference plasma</outcome_measure>
      <outcome_measure>Absolute thrombin generation test total thrombin generation time</outcome_measure>
      <outcome_measure>Relative thrombin generation test total thrombin generation time compared to reference plasma</outcome_measure>
      <outcome_measure>Absolute thrombin generation test endogenous thrombin potential</outcome_measure>
      <outcome_measure>Relative thrombin generation test endogenous thrombin potential compared to reference plasma</outcome_measure>
      <outcome_measure>Transfer to intensive care unit during hospitalization</outcome_measure>
      <outcome_measure>Thrombotic complication during hospitalization</outcome_measure>
      <outcome_measure>Plasma concentrations of D-dimers</outcome_measure>
      <outcome_measure>Plasma concentrations of soluble fibrin monomers</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier Universitaire de Nīmes</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>175</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>January 2021</primary_completion_date>
    <completion_date>January 2021</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>CHU de Bordeaux, Bordeaux, France</location>
      <location>CHU de Limoges, Limoges, France</location>
      <location>CHU de Montpellier, Montpellier, France</location>
      <location>CHU de Nimes, Nîmes, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04356950</url>
  </study>
  <study rank="594">
    <nct_id>NCT04344379</nct_id>
    <title>Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus</title>
    <acronym>PREP-COVID</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV-2 Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">hydroxychloroquine</intervention>
      <intervention type="Drug">azithromycin</intervention>
      <intervention type="Drug">hydroxychloroquine placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>To assess the impact of hydroxychloroquine and azithromycin on the prevention of SARS-CoV-2 contamination in hospital workers exposed to 40 days of treatment.</outcome_measure>
      <outcome_measure>Reducing clinical episodes due to suspected SARS-2 CoV infection confirmed by PCR</outcome_measure>
      <outcome_measure>Reducing seroconversion for SARS-CoV-2 without any clinical sign</outcome_measure>
      <outcome_measure>Evaluation of drug tolerance in the study</outcome_measure>
      <outcome_measure>Evaluation on work stopping of hospital workers</outcome_measure>
      <outcome_measure>Observance of treatment measured by plasmatic concentrations of hydroxychloroquine or azythromycine</outcome_measure>
      <outcome_measure>Incidence of cardiologic events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>900</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>July 31, 2020</primary_completion_date>
    <completion_date>August 31, 2020</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Hopial Avicenne, Bobigny, France</location>
      <location>Hôpital GHU Paris Saclay, Le Kremlin-Bicêtre, France</location>
      <location>Hôpital Saint Antoine, Paris, France</location>
      <location>Hôpital Broca, Paris, France</location>
      <location>Hôpital La Pitié-Salpétrière, Paris, France</location>
      <location>Hôpital Cochin, Paris, France</location>
      <location>Hôpital européen Georges Pompidou, Paris, France</location>
      <location>Hôpital Necker, Paris, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04344379</url>
  </study>
  <study rank="595">
    <nct_id>NCT04356443</nct_id>
    <title>Non-Invasive Monitoring of Respiratory Function in Spontaneously Breathing Patients With COVID-19 Infection</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Respiratory Failure</condition>
      <condition>Ventilatory Failure</condition>
      <condition>COVID-19</condition>
      <condition>Pneumonia</condition>
      <condition>ARDS, Human</condition>
    </conditions>
    <interventions>
      <intervention type="Device">AirGo Respiratory Monitor</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Endotracheal intubation during present hospitalization, recorded through chart review</outcome_measure>
      <outcome_measure>Improvement in hypoxemia as indicated by oxygen saturation and requirement for supplemental oxygen, recorded through chart review</outcome_measure>
      <outcome_measure>Premature need for removal of the band, recorded through investigator report</outcome_measure>
      <outcome_measure>In-hospital mortality, recorded through chart review</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Massachusetts General Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Massachusetts General Hospital, Boston, Massachusetts, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04356443</url>
  </study>
  <study rank="596">
    <nct_id>NCT04323878</nct_id>
    <title>Early CPAP in COVID Patients With Respiratory Failure. A Prospective Cohort Study.</title>
    <acronym>EC-COVID-PCS</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Early CPAP Ventilation in COVID-19 Patients</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Death or need of intubation</outcome_measure>
      <outcome_measure>30-day mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Mario Negri Institute for Pharmacological Research</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>3000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 6, 2020</start_date>
    <primary_completion_date>October 5, 2020</primary_completion_date>
    <completion_date>November 9, 2020</completion_date>
    <study_first_posted>March 27, 2020</study_first_posted>
    <last_update_posted>March 31, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04323878</url>
  </study>
  <study rank="597">
    <nct_id>NCT04355962</nct_id>
    <title>Sevoflurane in COVID-19 ARDS (SevCov)</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>ARDS, Human</condition>
      <condition>Coronavirus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sevoflurane</intervention>
      <intervention type="Drug">Intravenous drug</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Composite outcome of death rate (rate of patients that did not survive) and organ failure rate (rate of patients surviving with persistent organ dysfunction) at day 28</outcome_measure>
      <outcome_measure>Length of stay ICU</outcome_measure>
      <outcome_measure>Plasma Inflammatory markers</outcome_measure>
      <outcome_measure>Length of stay at hospital</outcome_measure>
      <outcome_measure>Sex-related differences in complications</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Zurich</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>64</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 23, 2020</start_date>
    <primary_completion_date>March 31, 2021</primary_completion_date>
    <completion_date>March 31, 2021</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>University Hospital Zuirch, Zurich, Switzerland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04355962</url>
  </study>
  <study rank="598">
    <nct_id>NCT04349618</nct_id>
    <title>Ultraprotective Ventilation Without Extracorporeal Circulation During COVID 19 Pneumonia</title>
    <acronym>VT4COVID</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Acute Respiratory Distress Syndrome</condition>
      <condition>COVID19</condition>
      <condition>Sars-CoV2</condition>
      <condition>Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Other">PROTECTIVE VENTILATION</intervention>
      <intervention type="Other">ULTRAPROTECTIVE VENTILATION</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>A composite score based on all-cause mortality and the number of ventilator free-days (VFD)</outcome_measure>
      <outcome_measure>All-cause mortality (intention to treat)</outcome_measure>
      <outcome_measure>Ventilator-free days (VFD)</outcome_measure>
      <outcome_measure>All-cause mortality with per protocol analysis</outcome_measure>
      <outcome_measure>Time to successful extubation</outcome_measure>
      <outcome_measure>Length of hospital stay</outcome_measure>
      <outcome_measure>Respiratory parameters assessed daily from inclusion to weaning of deep sedation or 14 days whichever comes first</outcome_measure>
      <outcome_measure>Daily sedation dose during the first 14 days of the study</outcome_measure>
      <outcome_measure>Rate of use of rescue therapies</outcome_measure>
      <outcome_measure>Incidence density rate of severe mixed acidosis</outcome_measure>
      <outcome_measure>Incidence density rate of ventilator associated pneumonia</outcome_measure>
      <outcome_measure>Incidence density rate of acute cor pulmonale</outcome_measure>
      <outcome_measure>Incidence density rate of barotrauma</outcome_measure>
      <outcome_measure>Incidence density rate of any serious adverse events</outcome_measure>
      <outcome_measure>Cognitive impairment assessed by phone call using the Telephone Montreal Cognitive Assessment (T-MoCA) test</outcome_measure>
      <outcome_measure>Quality of life assessed by the RAND 36-Item Health Survey (SF-36) score</outcome_measure>
      <outcome_measure>Post-traumatic stress disorder assessed by the Impact of Event Scale - revised (IES-R) score by phone call</outcome_measure>
      <outcome_measure>Cost-efficacy ratio of the innovative strategy compared to the reference strategy</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hospices Civils de Lyon</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 14, 2020</start_date>
    <primary_completion_date>July 14, 2021</primary_completion_date>
    <completion_date>April 14, 2022</completion_date>
    <study_first_posted>April 16, 2020</study_first_posted>
    <last_update_posted>April 16, 2020</last_update_posted>
    <locations>
      <location>Service de Médecine Intensive Réanimation CHU Gabriel Montpied, Clermont-Ferrand, France</location>
      <location>Service de Médecine Intensive Réanimation Hôpital Michallon - CHU Grenoble Alpes, La Tronche, France</location>
      <location>Service de Médecine Intensive Réanimation Hôpital Edouard Herriot Hospices Civils de Lyon, Lyon, France</location>
      <location>Service de Réanimation Chirurgicale Hôpital Edouard Herriot Hospices Civils de Lyon, Lyon, France</location>
      <location>Service de Médecine Intensive Réanimation Hôpital de la Croix Rousse Hospices Civils de Lyon, Lyon, France</location>
      <location>Service de Réanimation Chirurgicale Hôpital de la Croix Rousse Hospices Civils de Lyon, Lyon, France</location>
      <location>Service de réanimation Polyvalente Centre Hospitalier Saint Joseph-Saint Luc, Lyon, France</location>
      <location>Service de Réanimation Clinique de la Sauvegarde, Lyon, France</location>
      <location>Service de Réanimation Polyvalente Centre Hospitalier Lyon Sud Hospices Civils de Lyon, Pierre-Bénite, France</location>
      <location>Service de Réanimation Centre hospitalier Annecy Genevois, Pringy, France</location>
      <location>Service de Médecine Intensive Réanimation Hôpital Nord - CHU Saint-Etienne, Saint-Priest-en-Jarez, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04349618</url>
  </study>
  <study rank="599">
    <nct_id>NCT04354818</nct_id>
    <title>Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia (CORIA)</title>
    <acronym>CORIA</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV-1-infection</condition>
      <condition>Cancer</condition>
      <condition>Primary Immune Deficiency Disorder</condition>
      <condition>Immunosuppression Disorders</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>percentage of patients who required hospitalisation, developed severe illness (ICU admission) or died</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Kirby Institute</lead_sponsor>
      <collaborator>St Vincent's Hospital, Sydney</collaborator>
      <collaborator>Garvan Institute of Medical Research</collaborator>
      <collaborator>Westmead Hospital, Sydney, Australia</collaborator>
      <collaborator>Blacktown Hospital, Sydney, Australia</collaborator>
      <collaborator>Holdsworth House Medical Practice</collaborator>
      <collaborator>Royal North Shore Hospital</collaborator>
      <collaborator>Melanoma Institute Australia</collaborator>
      <collaborator>Prince of Wales Hospital, Sydney</collaborator>
      <collaborator>Gilead Sciences</collaborator>
      <collaborator>Cancer Institute NSW</collaborator>
      <collaborator>Cancer Council New South Wales</collaborator>
      <collaborator>Positive Life NSW</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 27, 2020</start_date>
    <primary_completion_date>April 27, 2022</primary_completion_date>
    <completion_date>April 27, 2022</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04354818</url>
  </study>
  <study rank="600">
    <nct_id>NCT04360733</nct_id>
    <title>Precision Immunology to Determine the Immune Response in Patients With COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV 2</condition>
      <condition>COVID</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Blood draw</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Immune response</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Bonn</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>April 2022</primary_completion_date>
    <completion_date>September 2022</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>University Hospital Bonn, Bonn, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04360733</url>
  </study>
  <study rank="601">
    <nct_id>NCT04347239</nct_id>
    <title>Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19)</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Disease 2019</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Placebos</intervention>
      <intervention type="Drug">Leronlimab (700mg)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>All-cause mortality at Day 28</outcome_measure>
      <outcome_measure>All-cause mortality at Day 14</outcome_measure>
      <outcome_measure>Change in clinical status of subject at Day 14 (on a 7 point ordinal scale)</outcome_measure>
      <outcome_measure>Change in clinical status of subject at Day 28 (on a 7 point ordinal scale)</outcome_measure>
      <outcome_measure>Change from baseline in Sequential Organ Failure Assessment (SOFA) score at Day 14.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>CytoDyn, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>390</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>April 1, 2021</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>Montefiore Medical Center, Bronx, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04347239</url>
  </study>
  <study rank="602">
    <nct_id>NCT04323800</nct_id>
    <title>Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19</title>
    <acronym>CSSC-001</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
      <condition>Convalescence</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Anti- SARS-CoV-2 Plasma</intervention>
      <intervention type="Biological">SARS-CoV-2 non-immune Plasma</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Cumulative incidence of composite outcome of disease severity</outcome_measure>
      <outcome_measure>Anti-SARS-CoV-2 titers</outcome_measure>
      <outcome_measure>Rates of SARS-CoV-2 PCR positivity</outcome_measure>
      <outcome_measure>Duration of SARS-CoV-2 PCR positivity</outcome_measure>
      <outcome_measure>Peak quantity levels of SARS-CoV-2 RNA</outcome_measure>
      <outcome_measure>Cumulative incidence of disease severity</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Johns Hopkins University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 1, 2020</start_date>
    <primary_completion_date>December 31, 2022</primary_completion_date>
    <completion_date>January 2023</completion_date>
    <study_first_posted>March 27, 2020</study_first_posted>
    <last_update_posted>April 8, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04323800</url>
  </study>
  <study rank="603">
    <nct_id>NCT04363463</nct_id>
    <title>Impact of Prone Position in Patients Under Spontaneous Breathing on Intubation or Non-invasive Ventilation or Death Incidence During COVID-19 Acute Respiratory Distress</title>
    <acronym>PROVID-19</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID19</condition>
      <condition>Oxygen Therapy</condition>
      <condition>Prone Position</condition>
      <condition>Spontaneous Ventilation</condition>
      <condition>Respiratory Distress Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Other">prone position</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Percent age of patients who will have endotracheal intubation or non-invasive ventilation at two pressure levels and/or die, in each of the 2 randomization groups.</outcome_measure>
      <outcome_measure>Duration in days for the change of 2 points on the WHO ordinal scale</outcome_measure>
      <outcome_measure>Rate (%) of intubation and invasive ventilation in the 2 randomization groups.</outcome_measure>
      <outcome_measure>Rate (%) of non-invasive ventilation at two pressure levels in the 2 randomization groups</outcome_measure>
      <outcome_measure>Duration of oxygen therapy in the 2 randomization groups.</outcome_measure>
      <outcome_measure>Duration of hospitalization in the 2 randomization groups.</outcome_measure>
      <outcome_measure>Hospital mortality and mortality at D28 in the 2 randomization groups</outcome_measure>
      <outcome_measure>Rate (%) of need for transfer to intensive care unit</outcome_measure>
      <outcome_measure>Rate (%) of use of non-invasive ventilation at two pressure levels, intubation throughout the entire stay when the stay is longer than 28 days.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier Régional d'Orléans</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <start_date>May 2020</start_date>
    <primary_completion_date>May 2022</primary_completion_date>
    <completion_date>May 2022</completion_date>
    <study_first_posted>April 27, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>CH de DAX, Dax, France</location>
      <location>CHD de VENDEE, La Roche sur Yon, France</location>
      <location>CH de LA ROCHELLE, La Rochelle, France</location>
      <location>CHR d'Orléans - Service Pneumologie, Orléans, France</location>
      <location>CHR d'Orleans - Service Maladies Infectieuses, Orléans, France</location>
      <location>HOPITAL LARIBOISIERE - Service diabétologie, endocrinologie, nutrition, Paris, France</location>
      <location>Hopital Lariboisiere - Medecine Interne, Paris, France</location>
      <location>Hopital Lariboisiere, Paris, France</location>
      <location>CH de PERPIGNAN - Service Maladies infectieuses, Perpignan, France</location>
      <location>CH de Perpignan - pneumologie, Perpignan, France</location>
      <location>Centre Hospitalier Intercommunal de Cornouaille - Quimper Concarneau, Quimper, France</location>
      <location>CHRU de Tours - Service Médecine interne et immunologie Clinique, Tours, France</location>
      <location>CHRU de Tours - Service Pneumologie, Tours, France</location>
      <location>CHRU DE TOURS - Service Médecine interne et maladies infectieuses, Tours, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04363463</url>
  </study>
  <study rank="604">
    <nct_id>NCT04321096</nct_id>
    <title>The Impact of Camostat Mesilate on COVID-19 Infection</title>
    <acronym>CamoCO-19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Corona Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Camostat Mesilate</intervention>
      <intervention type="Drug">Placebo oral tablet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Days to clinical improvement from study enrolment</outcome_measure>
      <outcome_measure>Safety evaluation, as measured by AEs, Adverse Reactions (ARs), SAEs, Serious ARs (SARs)</outcome_measure>
      <outcome_measure>Clinical status as assessed by the 7-point ordinal scale at day 7, 14 and 30</outcome_measure>
      <outcome_measure>Day 30 mortality</outcome_measure>
      <outcome_measure>Change in NEW(2) score from baseline to day 30</outcome_measure>
      <outcome_measure>Admission to ICU</outcome_measure>
      <outcome_measure>Use of invasive mechanical ventilation or ECMO</outcome_measure>
      <outcome_measure>Duration of supplemental oxygen (days)</outcome_measure>
      <outcome_measure>Days to self-reported recovery (e.g. limitations in daily life activities) during telephone interviews conducted at day 30</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Aarhus</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>110 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>180</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 31, 2020</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>May 1, 2021</completion_date>
    <study_first_posted>March 25, 2020</study_first_posted>
    <last_update_posted>April 6, 2020</last_update_posted>
    <locations>
      <location>Department of Infectious Diseases, Aalborg, Denmark</location>
      <location>Department for Infectious Diseases, Aarhus University Hospital, Aarhus N, Denmark</location>
      <location>Herning Regional Hospital, Herning, Denmark</location>
      <location>Northzealands hospital - Hillerød, Hillerød, Denmark</location>
      <location>Horsens Regional Hospital, Horsens, Denmark</location>
      <location>Bispebjerg hospital, København, Denmark</location>
      <location>Dept. of Infectious Diseases, Odense University Hospital, Odense, Denmark</location>
      <location>Randers Regional Hospital, Randers, Denmark</location>
      <location>Silkeborg Hospital, Silkeborg, Denmark</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04321096</url>
  </study>
  <study rank="605">
    <nct_id>NCT04351139</nct_id>
    <title>Impact of the COVID-19 Pandemic in Gynecological Oncology</title>
    <acronym>COVID-GYN</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Gynecologic Cancer</condition>
      <condition>Breast Neoplasm Female</condition>
      <condition>Uterine Neoplasms</condition>
      <condition>Ovarian Neoplasms</condition>
      <condition>Uterine Cervical Neoplasms</condition>
      <condition>Vulvar Neoplasms</condition>
      <condition>Vaginal Neoplasms</condition>
    </conditions>
    <interventions>
      <intervention type="Other">modification of the planned therapeutic management</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>percentage of patients with a change in the planned therapeutic management (surgery, chemotherapy, radiotherapy, hormone therapy)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hospices Civils de Lyon</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Other</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>May 2020</primary_completion_date>
    <completion_date>May 2020</completion_date>
    <study_first_posted>April 17, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Service de Gynécologie, HFME, Hospices Civils de Lyon, Bron, France</location>
      <location>Service de Gynécologie, Croix-Rousse, Hospices Civils de Lyon, Lyon, France</location>
      <location>Service Gynécologie, CHLS, Hospices Civils de Lyon, Pierre-Bénite, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04351139</url>
  </study>
  <study rank="606">
    <nct_id>NCT04332380</nct_id>
    <title>Convalescent Plasma for Patients With COVID-19: A Pilot Study</title>
    <acronym>CP-COVID-19</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
      <condition>Coronavirus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Plasma</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in Viral Load</outcome_measure>
      <outcome_measure>Change in Immunoglobulin M COVID-19 antibodies Titers</outcome_measure>
      <outcome_measure>Change in Immunoglobulin G COVID-19 antibodies Titers</outcome_measure>
      <outcome_measure>Intensive Care Unit Admission</outcome_measure>
      <outcome_measure>Length of Intensive Care Unit stay</outcome_measure>
      <outcome_measure>Length of hospital stay (days)</outcome_measure>
      <outcome_measure>Requirement of mechanical ventilation</outcome_measure>
      <outcome_measure>Duration (days) of mechanical ventilation</outcome_measure>
      <outcome_measure>Clinical status assessed according to the World Health Organization guideline</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Universidad del Rosario</lead_sponsor>
      <collaborator>CES University</collaborator>
      <collaborator>Instituto Distrital de Ciencia Biotecnologia e Innovacion en salud</collaborator>
      <collaborator>Fundación Universitaria de Ciencias de la Salud</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 1, 2020</start_date>
    <primary_completion_date>August 31, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>April 2, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Universidad del Rosario, Bogota, Cundinamarca, Colombia</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04332380</url>
  </study>
  <study rank="607">
    <nct_id>NCT04358380</nct_id>
    <title>Liver Injury in Patients With COVID-19</title>
    <acronym/>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Liver Injury</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Liver injury</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Liver injury in patients with COVID-19</outcome_measure>
      <outcome_measure>Prognostic factors associated with death</outcome_measure>
      <outcome_measure>Clinical characteristics of patients who developed liver injury</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Austral University, Argentina</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>17 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>34</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Universidad Austral, Pilar, Buenos Aires, Argentina</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04358380</url>
  </study>
  <study rank="608">
    <nct_id>NCT04268537</nct_id>
    <title>Immunoregulatory Therapy for 2019-nCoV</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>2019 nCoV, PD-1</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">PD-1 blocking antibody+standard treatment</intervention>
      <intervention type="Drug">Thymosin+standard treatment</intervention>
      <intervention type="Other">standard treatment</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>lung injury score</outcome_measure>
      <outcome_measure>absolute lymphocyte counts</outcome_measure>
      <outcome_measure>serum level of CRP, PCT and IL-6</outcome_measure>
      <outcome_measure>SOFA score</outcome_measure>
      <outcome_measure>all cause mortality rate</outcome_measure>
      <outcome_measure>ventilation free days</outcome_measure>
      <outcome_measure>ICU free days</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Southeast University, China</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>February 10, 2020</start_date>
    <primary_completion_date>April 30, 2020</primary_completion_date>
    <completion_date>October 31, 2020</completion_date>
    <study_first_posted>February 13, 2020</study_first_posted>
    <last_update_posted>February 13, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04268537</url>
  </study>
  <study rank="609">
    <nct_id>NCT04332666</nct_id>
    <title>Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial</title>
    <acronym>ATCO</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
      <condition>Respiratory Failure</condition>
      <condition>Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere</condition>
      <condition>SARS-CoV-2</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Angiotensin 1-7</intervention>
      <intervention type="Drug">Placebos</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>ventilator free days</outcome_measure>
      <outcome_measure>ICU free days</outcome_measure>
      <outcome_measure>Hospital length of stay</outcome_measure>
      <outcome_measure>Time to wean from mechanical ventilation</outcome_measure>
      <outcome_measure>PaO2/FiO2 changes during drug administration</outcome_measure>
      <outcome_measure>Deep vein thrombosis incidence</outcome_measure>
      <outcome_measure>Changes in inflammatory markers</outcome_measure>
      <outcome_measure>RAS effectors levels</outcome_measure>
      <outcome_measure>Radiological findings</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Erasme University Hospital</lead_sponsor>
      <collaborator>Fonds Erasme pour la Recherche Médicale</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 31, 2020</start_date>
    <primary_completion_date>May 30, 2020</primary_completion_date>
    <completion_date>June 15, 2020</completion_date>
    <study_first_posted>April 3, 2020</study_first_posted>
    <last_update_posted>April 6, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04332666</url>
  </study>
  <study rank="610">
    <nct_id>NCT04349098</nct_id>
    <title>Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection</title>
    <acronym>Coronavirus</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Selinexor</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Percentage of Participants with at Least a 2 Point Improvement in the Ordinal Scale</outcome_measure>
      <outcome_measure>Time to Clinical Improvement (TTCI)</outcome_measure>
      <outcome_measure>Number of Participants with Overall Death Rate</outcome_measure>
      <outcome_measure>Number of Participants With Rate of Mechanical Ventilation</outcome_measure>
      <outcome_measure>Time to Mechanical Ventilation</outcome_measure>
      <outcome_measure>Overall survival</outcome_measure>
      <outcome_measure>Time to Improvement (2 points) in Clinical Measures Using the Ordinal Scale</outcome_measure>
      <outcome_measure>Time to Intensive Care Unit (ICU) Admission</outcome_measure>
      <outcome_measure>Rate of Intensive Care Unit (ICU) Admission</outcome_measure>
      <outcome_measure>Length of Stay in Hospital</outcome_measure>
      <outcome_measure>Percentage of Participants Discharged from Hospital</outcome_measure>
      <outcome_measure>Length of Stay in Intensive Care Unit (ICU)</outcome_measure>
      <outcome_measure>Duration of Oxygen Supplementation</outcome_measure>
      <outcome_measure>Duration of Mechanical Ventilation</outcome_measure>
      <outcome_measure>Change in Vienna Vaccine Safety Initiative (ViVI) Disease Severity Score</outcome_measure>
      <outcome_measure>Time to Clinical Improvement in Participants ≤ 70 Years Old</outcome_measure>
      <outcome_measure>Time to Clinical Improvement in Participants &gt; 70 Years Old</outcome_measure>
      <outcome_measure>Time to Clinical Improvement in Participants with Pre-existing Diseases</outcome_measure>
      <outcome_measure>Change in Oxygenation Index</outcome_measure>
      <outcome_measure>Time to Improvement of One Point Using WHO Ordinal Scale Improvement</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing WHO Ordinal Scale Improvement of &gt;1 point</outcome_measure>
      <outcome_measure>Change from Baseline in C-reactive protein (CRP) Levels</outcome_measure>
      <outcome_measure>Change from Baseline in Ferritin Levels</outcome_measure>
      <outcome_measure>Change from Baseline in Lactate Dehydrogenase (LDH) Levels</outcome_measure>
      <outcome_measure>Changes from Baseline in Blood Plasma Cytokines Levels</outcome_measure>
      <outcome_measure>Number of Participants with Adverse Events (AE)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Karyopharm Therapeutics Inc</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>230</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 17, 2020</start_date>
    <primary_completion_date>August 31, 2020</primary_completion_date>
    <completion_date>August 31, 2020</completion_date>
    <study_first_posted>April 16, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>UCLA, Los Angeles, California, United States</location>
      <location>Norton Healthcare, Louisville, Kentucky, United States</location>
      <location>Lehigh Valley Hospital, Allentown, Pennsylvania, United States</location>
      <location>Baylor Scott &amp; White Dallas, Dallas, Texas, United States</location>
      <location>Hospital Hietzing, 2. Medical department - Center for Diagnosis and Therapy of Rheumatic Diseases, Vienna, Austria</location>
      <location>Hadassah MC, Jerusalem, Israel</location>
      <location>Servicio de Medicina Interna, Hospital Universitario de Salamanca, Universidad de Salamanca, Salamanca, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04349098</url>
  </study>
  <study rank="611">
    <nct_id>NCT04330495</nct_id>
    <title>Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With Hydroxychloroquine in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID 19</condition>
      <condition>Immunomediated Inflammatory Disease in Treatment With Biological Agents and / or Jak Inhibitors</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hidroxicloroquina</intervention>
      <intervention type="Drug">Control group</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Incidence rate of new COVID-19 cases in both arms</outcome_measure>
      <outcome_measure>Prevalence of COVID-19 cases in both arms</outcome_measure>
      <outcome_measure>Mortality rate secondary to COVID-19 cases in both groups</outcome_measure>
      <outcome_measure>Intensive Care Unit (CU) admission rate secondary to COVID-19 cases in both groups</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Instituto de Investigación Marqués de Valdecilla</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>800</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 6, 2020</start_date>
    <primary_completion_date>November 6, 2020</primary_completion_date>
    <completion_date>November 6, 2020</completion_date>
    <study_first_posted>April 1, 2020</study_first_posted>
    <last_update_posted>April 13, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04330495</url>
  </study>
  <study rank="612">
    <nct_id>NCT04339881</nct_id>
    <title>NOsocomial Dissemination Risk of SARS-Cov2</title>
    <acronym>NODS-Cov2</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sars-CoV2</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Understanding the dissemination of SARS Cov2 in hospital</outcome_measure>
      <outcome_measure>Optimizing hospital strategies to prevent transmission to caregivers and not infected hospitalized patients with SARSCov2</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 13, 2020</start_date>
    <primary_completion_date>May 15, 2020</primary_completion_date>
    <completion_date>June 15, 2020</completion_date>
    <study_first_posted>April 9, 2020</study_first_posted>
    <last_update_posted>April 9, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04339881</url>
  </study>
  <study rank="613">
    <nct_id>NCT04334928</nct_id>
    <title>Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel</title>
    <acronym>EPICOS</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Emtricitabine/tenofovir disoproxil</intervention>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Drug">Placebo: Emtricitabine/tenofovir disoproxil Placebo</intervention>
      <intervention type="Drug">Placebo: Hydroxychloroquine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of confirmed symptomatic infections of SARS-CoV-2 (COVID-19)</outcome_measure>
      <outcome_measure>Severity of disease in confirmed infected participants of SARS-CoV-2 (COVID-19)</outcome_measure>
      <outcome_measure>Duration of symptoms in confirmed infected participants of SARS-CoV-2 (COVID-19) measured in days</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Plan Nacional sobre el Sida (PNS)</lead_sponsor>
      <collaborator>Effice Servicios Para la Investigacion S.L.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>4000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>June 30, 2020</primary_completion_date>
    <completion_date>July 31, 2020</completion_date>
    <study_first_posted>April 6, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Hospital Universitario de Ferrol, Ferrol, A Coruña, Spain</location>
      <location>Hospital Clínico Universitario de Santiago, Santiago De Compostela, A Coruña, Spain</location>
      <location>Hospital General de Elche, Elche, Alicante, Spain</location>
      <location>Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain</location>
      <location>Hospital Sant Joan de Deu de Esplugues, Esplugues De Llobregat, Barcelona, Spain</location>
      <location>Parc Sanitari Sant Joan de Déu de Sant Boi, Sant Boi De Llobregat, Barcelona, Spain</location>
      <location>Hospital Infanta Margarita, Cabra, Córdoba, Spain</location>
      <location>Hospital Insular de Las Palmas, Las Palmas De Gran Canaria, Gran Canaria, Spain</location>
      <location>Hospital Universitario de Canarias, Las Palmas De Gran Canaria, Gran Canaria, Spain</location>
      <location>Hospital de Donostia, San Sebastián, Guipuzcoa, Spain</location>
      <location>Hospital San Pedro, Logroño, La Rioja, Spain</location>
      <location>Hospital Principe de Asturias, Alcalá De Henares, Madrid, Spain</location>
      <location>Hospital Fundación de Alcorcón, Alcorcón, Madrid, Spain</location>
      <location>Hospital Colllado Villalba, Collado-Villalba, Madrid, Spain</location>
      <location>Hospital Severo Ochoa, Leganés, Madrid, Spain</location>
      <location>Hospital Rey Juan Carlos, Móstoles, Madrid, Spain</location>
      <location>Hospital Quirón Pozuelo, Pozuelo De Alarcón, Madrid, Spain</location>
      <location>Hospital de Torrejón, Torrejón De Ardoz, Madrid, Spain</location>
      <location>Hospital Infanta Elena, Valdemoro, Madrid, Spain</location>
      <location>Hospital Virgen del Castillo, Yecla, Murcia, Spain</location>
      <location>Hospital Costa del Sol, Marbella, Málaga, Spain</location>
      <location>Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain</location>
      <location>Hospital Arnau de Vilanova, Llíria, Valencia, Spain</location>
      <location>Hospital de Araba, Alava, Vitoria, Spain</location>
      <location>Hospital General Universitario de Albacete, Albacete, Spain</location>
      <location>Centro Médico Teknon, Barcelona, Spain</location>
      <location>Hospital Clinic, Barcelona, Spain</location>
      <location>Hospital del Mar, Barcelona, Spain</location>
      <location>Hospital Dexeus, Barcelona, Spain</location>
      <location>Hospital Quirón Barcelona, Barcelona, Spain</location>
      <location>Hospital Sant Pau, Barcelona, Spain</location>
      <location>Hospital Universitario Sagrat Cor, Barcelona, Spain</location>
      <location>Hospital Universitario de Burgos, Burgos, Spain</location>
      <location>Hospital Virgen de la Luz, Cuenca, Spain</location>
      <location>Hospital Clínico San Cecilio, Granada, Spain</location>
      <location>Hospital Universitario de León, León, Spain</location>
      <location>Hospital Universitario Ramón y Cajal, Madrid, Spain</location>
      <location>Fundación Jiménez Díaz, Madrid, Spain</location>
      <location>Hospital Clinico San Carlos, Madrid, Spain</location>
      <location>Hospital Infanta Leonor, Madrid, Spain</location>
      <location>Hospital La Princesa, Madrid, Spain</location>
      <location>Hospital Universitario 12 de Octubre, Madrid, Spain</location>
      <location>Hospital Universitario Gregorio Marañon, Madrid, Spain</location>
      <location>Hospital Universitario La Paz, Madrid, Spain</location>
      <location>Hospital Universitario Puerta de Hierro, Madrid, Spain</location>
      <location>Hospital Reina Sofía, Murcia, Spain</location>
      <location>Hospital Universitario Virgen de la Arrixaca, Murcia, Spain</location>
      <location>Hospital Virgen de la Victoria, Málaga, Spain</location>
      <location>Complejo Asistencial de Palencia, Palencia, Spain</location>
      <location>Hospital Universitario de Salamanca, Salamanca, Spain</location>
      <location>Hospital General de Segovia, Segovia, Spain</location>
      <location>Hospital Virgen del Rocio, Sevilla, Spain</location>
      <location>Hospital Virgen Macarena, Sevilla, Spain</location>
      <location>Hospital Clinico Universitario, Valencia, Spain</location>
      <location>Hospital Dr. Peset, Valencia, Spain</location>
      <location>Hospital General de Valencia, Valencia, Spain</location>
      <location>Hospital La Fe, Valencia, Spain</location>
      <location>Hospital de Valladolid, Valladolid, Spain</location>
      <location>Hospital Rio Hortega, Valladolid, Spain</location>
      <location>Hospital Lozano Blesa, Zaragoza, Spain</location>
      <location>Hospital Miguel Servet, Zaragoza, Spain</location>
      <location>Hospital Nuestra Señora de Sonsoles, Ávila, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04334928</url>
  </study>
  <study rank="614">
    <nct_id>NCT04355676</nct_id>
    <title>Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Selinexor</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Percentage of Participants with at Least a 2 Point Improvement in the Ordinal Scale</outcome_measure>
      <outcome_measure>Time to Clinical Improvement (TTCI)</outcome_measure>
      <outcome_measure>Overall Death Rate</outcome_measure>
      <outcome_measure>Rate of Mechanical Ventilation</outcome_measure>
      <outcome_measure>Time to Mechanical Ventilation</outcome_measure>
      <outcome_measure>Overall Survival</outcome_measure>
      <outcome_measure>Time to Improvement (2 points) in Clinical Measures Using the Ordinal Scale</outcome_measure>
      <outcome_measure>Time to Intensive Care Unit (ICU) Admission</outcome_measure>
      <outcome_measure>Rate of Intensive Care Unit (ICU) Admission</outcome_measure>
      <outcome_measure>Length of Stay in Hospital</outcome_measure>
      <outcome_measure>Percentage of Participants Discharged From Hospital</outcome_measure>
      <outcome_measure>Length of Stay in Intensive Care Unit (ICU)</outcome_measure>
      <outcome_measure>Duration of Oxygen Supplementation</outcome_measure>
      <outcome_measure>Duration of Mechanical Ventilation</outcome_measure>
      <outcome_measure>Time to Clinical Improvement in Participants ≤ 70 Years Old</outcome_measure>
      <outcome_measure>Time to Clinical Improvement in Participants &gt; 70 Years Old</outcome_measure>
      <outcome_measure>Time to Clinical Improvement in Participants with Pre-existing Diseases</outcome_measure>
      <outcome_measure>Change in Oxygenation Index</outcome_measure>
      <outcome_measure>Time to Improvement of One Point Using WHO Ordinal Scale Improvement</outcome_measure>
      <outcome_measure>Percentage of Participants Experiencing WHO Ordinal Scale Improvement of &gt;1 point</outcome_measure>
      <outcome_measure>Change from Baseline in C-reactive protein (CRP) Levels</outcome_measure>
      <outcome_measure>Change from Baseline in Ferritin Levels</outcome_measure>
      <outcome_measure>Change from Baseline in Lactate Dehydrogenase (LDH) Levels</outcome_measure>
      <outcome_measure>Number of Participants with Adverse Events (AE)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Karyopharm Therapeutics Inc</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 30, 2020</start_date>
    <primary_completion_date>August 30, 2020</primary_completion_date>
    <completion_date>August 30, 2020</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04355676</url>
  </study>
  <study rank="615">
    <nct_id>NCT04358614</nct_id>
    <title>Baricitinib Therapy in COVID-19</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
      <condition>Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Baricitinib 4 MG Oral Tablet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>To assess the safety of baricitinib combined with antiviral (lopinavir-ritonavir) in terms of serious or non-serious adverse events incidence rate.</outcome_measure>
      <outcome_measure>To evaluate the impact of baricitinib in terms of clinical, laboratory, respiratory parameters.</outcome_measure>
      <outcome_measure>ICU admission rate</outcome_measure>
      <outcome_measure>Discharge rate.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Fabrizio Cantini</lead_sponsor>
      <collaborator>Hospital of Prato</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>12</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 16, 2020</start_date>
    <primary_completion_date>April 5, 2020</primary_completion_date>
    <completion_date>April 7, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Fabrizio Cantini, Prato, Tuscany, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04358614</url>
  </study>
  <study rank="616">
    <nct_id>NCT04357639</nct_id>
    <title>Impact of Long-term Protease Inhibitors in Patients Living With HIV on the Incidence of COVID-19 ( COVIP )</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>HIV Patients</condition>
    </conditions>
    <interventions>
      <intervention type="Other">No intervention</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Comparison of the incidence of COVID-19 infection in PLWHIV treated with long-term antiretroviral drugs including a protease inhibitor and those without a protease inhibitor</outcome_measure>
      <outcome_measure>Determination of the seroprevalence of COVID-19 infection in both groups of the study</outcome_measure>
      <outcome_measure>Comparison of the severity of COVID-19 infection symptoms in both groups of the study.</outcome_measure>
      <outcome_measure>Identification of potential risk factors for COVID-19 infection in HIV patients treated with protease inhibitor or without protease inhibitor</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier Intercommunal Creteil</lead_sponsor>
      <collaborator>Centre Hospitalier Intercommunal Villeneuve St Georges</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>794</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 30, 2020</start_date>
    <primary_completion_date>May 31, 2020</primary_completion_date>
    <completion_date>October 31, 2020</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>CHI Créteil, Créteil, France</location>
      <location>CHU Henri Mondor, Créteil, France</location>
      <location>Centre hospitalier de Melun (GHSIF), Melun, France</location>
      <location>Hôpital universitaire de Hôtel Dieu, Paris, France</location>
      <location>CHI Villeneuve St Georges, Villeneuve-Saint-Georges, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04357639</url>
  </study>
  <study rank="617">
    <nct_id>NCT04361396</nct_id>
    <title>Assessment of the Presence of the SARS-COV-2 Virus in the Peritoneum of COVID-19 Patients</title>
    <acronym>LAPTRANSCOV</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Assessment of the presence of the SARS-COV-2 virus</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Assessment of the presence of the SARS-COV-2 virus at T4</outcome_measure>
      <outcome_measure>Assessment of the presence of the SARS-COV-2 virus at T1</outcome_measure>
      <outcome_measure>Assessment of the presence of the SARS-COV-2 virus in the peritoneal effusion at T2 or T4</outcome_measure>
      <outcome_measure>Assessment of the presence of the SARS-COV-2 virus at T3</outcome_measure>
      <outcome_measure>Assessment of the presence of the SARS-COV-2 virus at T5</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier René Dubos</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <start_date>April 23, 2020</start_date>
    <primary_completion_date>October 2020</primary_completion_date>
    <completion_date>October 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Department of General and Digestive Surgery, Hospital René Dubos, Pontoise, France</location>
      <location>Department of Gynecology-Obstetrics, Hospital René Dubos, Pontoise, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04361396</url>
  </study>
  <study rank="618">
    <nct_id>NCT04325412</nct_id>
    <title>Cardiac complicAtions in Patients With SARS Corona vIrus 2 regisTrY</title>
    <acronym>CAPACITY-COVID</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19; Cardiovascular Diseases</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>The incidence of cardiovascular complications in patients with COVID-19</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>UMC Utrecht</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 23, 2020</start_date>
    <primary_completion_date>March 23, 2021</primary_completion_date>
    <completion_date>June 23, 2021</completion_date>
    <study_first_posted>March 27, 2020</study_first_posted>
    <last_update_posted>March 27, 2020</last_update_posted>
    <locations>
      <location>University Medical Center Utrecht, Utrecht, Netherlands</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04325412</url>
  </study>
  <study rank="619">
    <nct_id>NCT04365881</nct_id>
    <title>Loneliness During the NPIs for the COVID-19 Pandemic in Norway: Risk Factors and Associations With Psychopathology</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Loneliness, Worry, Rumination, Health Anxiety, Depression, Anxiety</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Cross-sectional observational study</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>UCLA Loneliness Scale-8 (ULS-8)</outcome_measure>
      <outcome_measure>Patient Health Questionnaire-9 (PHQ-9)</outcome_measure>
      <outcome_measure>Generalized Anxiety Disorder-7 (GAD-7)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Modum Bad</lead_sponsor>
      <collaborator>University of Oslo</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>10084</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <start_date>March 31, 2020</start_date>
    <primary_completion_date>April 7, 2020</primary_completion_date>
    <completion_date>April 7, 2020</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>University of Oslo, Oslo, Norway</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04365881</url>
  </study>
  <study rank="620">
    <nct_id>NCT04353128</nct_id>
    <title>Efficacy of Melatonin in the Prophylaxis of Coronavirus Disease 2019 (COVID-19) Among Healthcare Workers.</title>
    <acronym>MeCOVID</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid19</condition>
      <condition>SARS-CoV 2</condition>
      <condition>Coronavirus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Melatonin 2mg</intervention>
      <intervention type="Drug">Placebo oral tablet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>SARS-CoV 2 infection rate</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Instituto de Investigación Hospital Universitario La Paz</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>450</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>April 2021</primary_completion_date>
    <completion_date>July 2021</completion_date>
    <study_first_posted>April 20, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04353128</url>
  </study>
  <study rank="621">
    <nct_id>NCT04346277</nct_id>
    <title>Compassionate Use Open-Label Anti-CD14 Treatment in Patients With SARS-CoV-2 (COVID-19)</title>
    <acronym/>
    <status open="Y">Available</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
      <condition>ARDS, Human</condition>
      <condition>Ards</condition>
      <condition>Sars-CoV2</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">IC14, a monoclonal antibody against CD14</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Implicit Bioscience</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Expanded Access</study_types>
    <exp_acc_types>
      <exp_acc_type>Intermediate-size Population</exp_acc_type>
    </exp_acc_types>
    <study_designs/>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 16, 2020</last_update_posted>
    <locations>
      <location>IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milano, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04346277</url>
  </study>
  <study rank="622">
    <nct_id>NCT04329533</nct_id>
    <title>Effects of Using Mobile App on Perceived Stress During COVID-19 Pandemic</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Perceived Stress</condition>
      <condition>Anxiety</condition>
      <condition>Sleep Disturbance</condition>
    </conditions>
    <interventions>
      <intervention type="Other">&quot;Calm&quot; is a mindfulness meditation mobile app</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Perceived Stress Scale</outcome_measure>
      <outcome_measure>Hospital Anxiety and Depression Scale</outcome_measure>
      <outcome_measure>PROMIS Sleep Disturbance Short Form Survey</outcome_measure>
      <outcome_measure>Adherence</outcome_measure>
      <outcome_measure>Participant Satisfaction</outcome_measure>
      <outcome_measure>Coronavirus Questionnaire</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Arizona</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>99 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <start_date>April 13, 2020</start_date>
    <primary_completion_date>June 30, 2020</primary_completion_date>
    <completion_date>July 30, 2020</completion_date>
    <study_first_posted>April 1, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>Banner University Medicine Women's Institute, Phoenix, Arizona, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04329533</url>
  </study>
  <study rank="623">
    <nct_id>NCT04323787</nct_id>
    <title>Viral Infection and Respiratory Illness Universal Study[VIRUS]: COVID-19 Registry</title>
    <acronym>COVID-19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
    </conditions>
    <interventions>
      <intervention type="Other">observational</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>ICU and hospital mortality of COVID-19 patients</outcome_measure>
      <outcome_measure>30 days mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Mayo Clinic</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>50000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Other</study_design>
    </study_designs>
    <start_date>March 30, 2020</start_date>
    <primary_completion_date>April 30, 2021</primary_completion_date>
    <completion_date>April 30, 2021</completion_date>
    <study_first_posted>March 27, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>Mayo Clinic in Arizona, Scottsdale, Arizona, United States</location>
      <location>Mayo Clinic in Florida, Jacksonville, Florida, United States</location>
      <location>Society of Critical Care Medicine (150+ sites), Chicago, Illinois, United States</location>
      <location>Rahul Kashyap, Rochester, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04323787</url>
  </study>
  <study rank="624">
    <nct_id>NCT04332835</nct_id>
    <title>Convalescent Plasma for Patients With COVID-19: A Randomized, Open Label, Parallel, Controlled Clinical Study</title>
    <acronym>CP-COVID-19</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
      <condition>Coronavirus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Plasma</intervention>
      <intervention type="Drug">Hydroxychloroquine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in Viral Load</outcome_measure>
      <outcome_measure>Change in Immunoglobulin M COVID-19 Titers</outcome_measure>
      <outcome_measure>Change in Immunoglobulin G COVID-19 Titers</outcome_measure>
      <outcome_measure>Intensive Care Unit Admission</outcome_measure>
      <outcome_measure>Length of Intensive Care Unit stay</outcome_measure>
      <outcome_measure>Length of hospital stay (days)</outcome_measure>
      <outcome_measure>Requirement of mechanical ventilation</outcome_measure>
      <outcome_measure>Duration (days) of mechanical ventilation</outcome_measure>
      <outcome_measure>Clinical status assessed according to the World Health Organization guideline</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Universidad del Rosario</lead_sponsor>
      <collaborator>Fundación Universitaria de Ciencias de la Salud</collaborator>
      <collaborator>CES University</collaborator>
      <collaborator>Instituto Distrital de Ciencia Biotecnología e Innovacion en Salud</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 1, 2020</start_date>
    <primary_completion_date>August 31, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>April 3, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Universidad del Rosario, Bogota, Cundinamarca, Colombia</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04332835</url>
  </study>
  <study rank="625">
    <nct_id>NCT04352556</nct_id>
    <title>COVID19-hematological Malignancies: the Italian Hematology Alliance</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV-2 Infection</condition>
      <condition>Hematological Malignancies</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>To evaluate admission to ICU requiring mechanical ventilation or death.</outcome_measure>
      <outcome_measure>To evaluate potential predictive biochemical parameters of mortality.</outcome_measure>
      <outcome_measure>To evaluate potential predictive HM-related parameters of mortality.</outcome_measure>
      <outcome_measure>To evaluate COVID severity as predictive parameter of mortality.</outcome_measure>
      <outcome_measure>Epidemiology of patients with HM infected by SARS-CoV-2with any spectrum of illness severity</outcome_measure>
      <outcome_measure>Definition of complete clinical picture of COVID-19 in HM</outcome_measure>
      <outcome_measure>Dynamic of HM evolution</outcome_measure>
      <outcome_measure>To evaluate admission to ICU requiring mechanical ventilation or death per characteristics</outcome_measure>
      <outcome_measure>Viral dynamics in infected HM patients</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ospedale di Circolo - Fondazione Macchi</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>250</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Other</study_design>
    </study_designs>
    <start_date>April 7, 2020</start_date>
    <primary_completion_date>April 30, 2021</primary_completion_date>
    <completion_date>April 30, 2021</completion_date>
    <study_first_posted>April 20, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations>
      <location>SC Ematologia Ospedale SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy</location>
      <location>UOC Ematologia, Ospedali Riuniti, Ancona, Italy</location>
      <location>UOC Ematologia e Terapia Cellulare, Ospedale Mazzoni, Ascoli Piceno, Italy</location>
      <location>SC Oncologia Medica, CRO, Aviano, Italy</location>
      <location>SC Ematologia, Policlinico Bari, Bari, Italy</location>
      <location>UOC Ematologia, I.R.C.C.S Istituto Tumori Giovanni Paolo II, Bari, Italy</location>
      <location>SSD Ematologia, Ospedale degli Infermi, Biella, Italy</location>
      <location>UOC Ematologia, Azienda Ospedaliero-Universitaria Policlinico S.Orsola-Malpighi,, Bologna, Italy</location>
      <location>Ematologia e Centro Trapianto Midollo Osseo, Ospedale di Bolzano, Bolzano, Italy</location>
      <location>UO Ematologia e CTMO, ASST Spedali Civili, Brescia, Italy</location>
      <location>UO Ematologia e CTMO, ASST Spedali Civili, Brescia, Italy</location>
      <location>UOC Onco-Ematologia ASST Valle Olona, Busto Arsizio, Italy</location>
      <location>SC Ematologia e CTMO AZIENDA OSPEDALIERA &quot;G. BROTZU&quot; - OSPEDALE ONCOLOGICO BUSINCO, Cagliari, Italy</location>
      <location>UOC Ematologia, AOU Policlinico Vittorio Emanuele, Catania, Italy</location>
      <location>Ematologia, Ospedale Valduce, Como, Italy</location>
      <location>UOC Ematologia, Azienda Ospedaliera di Cosenza, Cosenza, Italy</location>
      <location>UO Ematologia e CTMO, ASST Cremona, Cremona, Italy</location>
      <location>SC Ematologia Ospedale S. Croce, Cuneo, Italy</location>
      <location>UOC, Ematologia Azienda Ospedaliero Universitaria Arcispedale S. Anna, Ferrara, Italy</location>
      <location>S.O.D. Ematologia, Azienda Ospedaliero Universitaria Careggi, Firenze, Italy</location>
      <location>UOC Ematologia, Policlinico Ospedali Riuniti, Foggia, Italy</location>
      <location>UO Ematologia, Ospedale Policlinico S.Martino IRCCS, Genova, Italy</location>
      <location>UO Ematologia, Ospedale Policlinico San Martino, Genova, Italy</location>
      <location>UOC di Ematologia e Trapianto di Cellule Staminali, P.O. Vito Fazzi, Lecce, Italy</location>
      <location>UOC di Ematologia, Ospedale di Legnano, Legnano, Italy</location>
      <location>UOC Oncologia ASST Lodi, Lodi, Italy</location>
      <location>UOC Ematologia Azienda Ospedaliera Universitaria &quot;G.Martino&quot;, Messina, Italy</location>
      <location>UO Ematologia, Ospedale dell'Angelo di Mestre, Mestre, Italy</location>
      <location>Ematologia, IEO, Milano, Italy</location>
      <location>SC Ematologia, Istituto Nazionale dei Tumori, Milano, Italy</location>
      <location>SC Ematologia, Ospedale Niguarda, Milano, Italy</location>
      <location>UO Ematologia, IRCCS Ospedale San Raffaele, Milano, Italy</location>
      <location>UO Servizio di Ematologia e Medicina Trasfusionale, Ospedale Luigi Sacco, Milano, Italy</location>
      <location>UOC Ematologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy</location>
      <location>UO Ematologia Policlinico di Modena, Modena, Italy</location>
      <location>UOC Ematologia, Ospedale S. Gerardo, Monza, Italy</location>
      <location>SC Ematologia Istituto Nazionale Tumori - IRCCS &quot;Fondazione G. Pascale&quot;,, Napoli, Italy</location>
      <location>UOC Ematologia e Trapianti di Midollo, AOU Federico II, Napoli, Italy</location>
      <location>UOC Ematologia, Ospedale Antonio Cardarelli, Napoli, Italy</location>
      <location>UOC Ematologia, Azienda Ospedaliero-Universitaria Maggiore della Carità, Novara, Italy</location>
      <location>Ospedale san Luigi Gonzaga, Orbassano, Italy</location>
      <location>Ematologia Azienda Ospedaliera di Padova, Padova, Italy</location>
      <location>UO Ematologia, Policlinico Paolo Giaccone, Palermo, Italy</location>
      <location>UOC Ematologia e CTMO, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy</location>
      <location>SC Ematologia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy</location>
      <location>SC Ematologia e Trapianto di Midollo Osseo, Azienda Ospedaliera di Perugia, Perugia, Italy</location>
      <location>UO Ematologia e CTMO, Azienda Ospedaliera Ospedali Riuniti, Pesaro, Italy</location>
      <location>UOC di Ematologia, Ospedale Civile Spirito Santo, Pescara, Italy</location>
      <location>UO Ematologia e CTMO, Presidio Ospedaliero di Piacenza, Piacenza, Italy</location>
      <location>UO Ematologia, AOU Pisana- Santa Chiara, Pisa, Italy</location>
      <location>UO Ematologia dell'Ospedale Santa Maria delle Croci, Ravenna, Italy</location>
      <location>UOC Ematologia, Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli, Reggio Calabria, Italy</location>
      <location>SC Ematologia, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy</location>
      <location>UO Ematologia, Ospedale Infermi, Rimini, Italy</location>
      <location>SC Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy</location>
      <location>UO Ematologia e Trapianti di Cellule Staminali, A.O. S. Camillo-Forlanini, Roma, Italy</location>
      <location>UO Ematologia, Policlinico Tor Vergata, Roma, Italy</location>
      <location>UOC Ematologia e trapianto di cellule staminali, Policlinico Universitario Campus Bio-Medico, Roma, Italy</location>
      <location>UOC Ematologia Policlinico Umberto I, Roma, Italy</location>
      <location>UOC Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy</location>
      <location>UO Ematologia, Istituto Clinico Humanitas, Rozzano, Italy</location>
      <location>UOC Ematologia e centro trapianti cellule staminali emopoietiche, AOU San Giovanni Di Dio e Ruggi D'aragona, Salerno, Italy</location>
      <location>UOC Ematologia, Policlinico Santa Maria alle Scotte, Siena, Italy</location>
      <location>UOC Ematologia e Trapianto Midollo Osseo, Ospedale S. G. Moscati, Taranto, Italy</location>
      <location>SCDU Ematologia e terapie cellulari, Ospedale Mauriziano Umberto I, Torino, Italy</location>
      <location>UO Ematologia, Ospedale Universitario Molinette San Giovanni Battista, Torino, Italy</location>
      <location>UO Ematologia, Ospedale Universitario Molinette San Giovanni Battista, Torino, Italy</location>
      <location>UO Ematologia, Ospedale Civili Ca' Foncello, Treviso, Italy</location>
      <location>SC Ematologia, Azienda sanitaria universitaria Giuliano Isontina, Trieste, Italy</location>
      <location>Clinica Ematologia, Azienda Ospedaliera-Universitaria Santa Maria della Misericordia, Udine, Italy</location>
      <location>UOC Ematologia, ASST Sette Laghi, Osp. Di Circolo e Fondazione Macchi, Varese, Italy</location>
      <location>UOC Ematologia, Azienda Ospedaliera Integrata di Verona, Verona, Italy</location>
      <location>UOC Ematologia, Azienda Ospedaliera Integrata di Verona, Verona, Italy</location>
      <location>UOC Ematologia, Ospedale San Bortolo, Vicenza, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04352556</url>
  </study>
  <study rank="626">
    <nct_id>NCT04334876</nct_id>
    <title>Rapid SARS-CoV-2 IgG Antibody Testing in High Risk Healthcare Workers</title>
    <acronym>COVID-Antibody</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV-2</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">SARS-CoV-2 IgG Antibody Testing Kit</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Validation of SARS-CoV-2 IgG Antibody Test</outcome_measure>
      <outcome_measure>Incidence of Seroconversion</outcome_measure>
      <outcome_measure>Identify Candidacy</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Indiana University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>340</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Ecologic or Community</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>November 1, 2020</primary_completion_date>
    <completion_date>January 1, 2021</completion_date>
    <study_first_posted>April 6, 2020</study_first_posted>
    <last_update_posted>April 6, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04334876</url>
  </study>
  <study rank="627">
    <nct_id>NCT04361461</nct_id>
    <title>Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19)</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infections</condition>
      <condition>SARS-CoV 2</condition>
      <condition>SARS (Severe Acute Respiratory Syndrome)</condition>
      <condition>Pulmonary Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine Sulfate</intervention>
      <intervention type="Drug">Hydroxychloroquine Sulfate + Azythromycin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Individual response rate</outcome_measure>
      <outcome_measure>All-cause mortality</outcome_measure>
      <outcome_measure>Duration of mechanical ventilation</outcome_measure>
      <outcome_measure>Proportion of patients which needed mechanical ventilation during study</outcome_measure>
      <outcome_measure>World Health Organization (WHO) Ordinal scale</outcome_measure>
      <outcome_measure>Duration of hospitalization</outcome_measure>
      <outcome_measure>Rates of drug discontinuation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Apsen Farmaceutica S.A.</lead_sponsor>
      <collaborator>Hospital São Paulo</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 4, 2020</start_date>
    <primary_completion_date>November 4, 2020</primary_completion_date>
    <completion_date>November 4, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Apsen Farmacêutica S.A., São Paulo, Brazil</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04361461</url>
  </study>
  <study rank="628">
    <nct_id>NCT04306705</nct_id>
    <title>Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19</title>
    <acronym>TACOS</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid-19</condition>
      <condition>SARS</condition>
      <condition>Cytokine Storm</condition>
      <condition>Cytokine Release Syndrome</condition>
      <condition>Tocilizumab</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tocilizumab</intervention>
      <intervention type="Other">Standard of care</intervention>
      <intervention type="Procedure">Continuous renal replacement therapy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Proportion of Participants With Normalization of Fever and Oxygen Saturation Through Day 14</outcome_measure>
      <outcome_measure>Duration of hospitalization</outcome_measure>
      <outcome_measure>Proportion of Participants With Normalization of Fever Through Day 14</outcome_measure>
      <outcome_measure>Change from baseline in white blood cell and differential count</outcome_measure>
      <outcome_measure>Time to first negative in 2019 novel Corona virus RT-PCR test</outcome_measure>
      <outcome_measure>All-cause mortality</outcome_measure>
      <outcome_measure>Change from baseline in hsCRP</outcome_measure>
      <outcome_measure>Change from baseline in cytokines IL-1β, IL-10, sIL-2R, IL-6, IL-8 and TNF-α</outcome_measure>
      <outcome_measure>Change from baseline in proportion of CD4+CD3/CD8+CD3 T cells</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tongji Hospital</lead_sponsor>
      <collaborator>Hubei Xinhua Hospital</collaborator>
      <collaborator>Wuhan No.1 Hospital</collaborator>
      <collaborator>Wuhan central hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>February 20, 2020</start_date>
    <primary_completion_date>May 30, 2020</primary_completion_date>
    <completion_date>June 20, 2020</completion_date>
    <study_first_posted>March 13, 2020</study_first_posted>
    <last_update_posted>March 17, 2020</last_update_posted>
    <locations>
      <location>Tongji Hospital, Wuhan, Hubei, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04306705</url>
  </study>
  <study rank="629">
    <nct_id>NCT04359693</nct_id>
    <title>Impact of SARS-CoV-2 Infection on the Incidence of Ventilator-acquired Infections</title>
    <acronym>COVAPID</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV 2</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Cumulative incidence of ventilator-associated lower respiratory tract infection</outcome_measure>
      <outcome_measure>Cumulative incidence of ventilator-associated tracheobronchitis</outcome_measure>
      <outcome_measure>Cumulative incidence of ventilator-associated pneumonia</outcome_measure>
      <outcome_measure>the cumulative incidence of ICU acquired bacteremia diagnosed</outcome_measure>
      <outcome_measure>ICU mortality</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>the duration of mechanical ventilation</outcome_measure>
      <outcome_measure>Length of stay in Intensive Care Unit</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Lille</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1071</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>July 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04359693</url>
  </study>
  <study rank="630">
    <nct_id>NCT04366271</nct_id>
    <title>Clinical Trial of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With COVID-19</title>
    <acronym>MESCEL-COVID19</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Mesenchymal cells</intervention>
      <intervention type="Drug">Standard of care</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mortality due to lung involvement due to SARS-CoV-2 virus infection at 28 days of treatment</outcome_measure>
      <outcome_measure>Mortality due to lung involvement due to SARS-CoV-2 virus infection at 14 days of treatment</outcome_measure>
      <outcome_measure>Mortality from any cause at 28 days</outcome_measure>
      <outcome_measure>Days without mechanical respirator and without vasopressor treatment for 28 days</outcome_measure>
      <outcome_measure>Patients alive without mechanical ventilation and without vasopressors on day 28</outcome_measure>
      <outcome_measure>Patients alive and without mechanical ventilation on day 14</outcome_measure>
      <outcome_measure>Patients alive and without mechanical ventilation on day 28</outcome_measure>
      <outcome_measure>Patients alive and without vasopressors on day 28</outcome_measure>
      <outcome_measure>Days without vasopressors for 28 days</outcome_measure>
      <outcome_measure>Patients cured at 15 days</outcome_measure>
      <outcome_measure>Incidence of Treatment-Emergent Adverse Events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hospital Infantil Universitario Niño Jesús, Madrid, Spain</lead_sponsor>
      <collaborator>Apices Soluciones S.L.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>40 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>106</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 24, 2020</start_date>
    <primary_completion_date>July 31, 2020</primary_completion_date>
    <completion_date>May 31, 2021</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Hospital Universitario de Getafe, Getafe, Madrid, Spain</location>
      <location>Hospital Universitario de Cruces, Barakaldo, Spain</location>
      <location>Hospital Universitario de La Princesa, Madrid, Spain</location>
      <location>Hospital Infantil Universitario Niño Jesus, Madrid, Spain</location>
      <location>Hospital Ramón Y Cajal, Madrid, Spain</location>
      <location>Complejo Universitario La Paz, Madrid, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04366271</url>
  </study>
  <study rank="631">
    <nct_id>NCT04366089</nct_id>
    <title>Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora</title>
    <acronym>PROBIOZOVID</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
      <condition>SARS-CoV 2</condition>
      <condition>Pneumonia, Viral</condition>
      <condition>Coronavirus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Oxygen-ozone therapy, probiotic supplementation and Standard of care</intervention>
      <intervention type="Dietary Supplement">SivoMixx (200 billion)</intervention>
      <intervention type="Drug">Azithromycin</intervention>
      <intervention type="Drug">hydroxychloroquine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Delta in the number of patients requiring orotracheal intubation despite treatment</outcome_measure>
      <outcome_measure>Delta of crude mortality</outcome_measure>
      <outcome_measure>Delta of length of stay for patients in hospital</outcome_measure>
      <outcome_measure>delta in the value of interleukin (IL)-1</outcome_measure>
      <outcome_measure>delta in the value of IL-6</outcome_measure>
      <outcome_measure>delta in the value of IL-10</outcome_measure>
      <outcome_measure>delta in the value of Tumor Necrosis Factor (TNF)-alpha</outcome_measure>
      <outcome_measure>delta in the value of cluster of differentiation (CD)4+ CD38/ Human Leukocyte Antigen-DR isotype (HLA-DR)</outcome_measure>
      <outcome_measure>delta in the value of CD8+ CD38/ HLA-DR</outcome_measure>
      <outcome_measure>delta in the value of fecal calprotectin</outcome_measure>
      <outcome_measure>delta in the value of lipopolysaccharide (LPS)</outcome_measure>
      <outcome_measure>delta in the value of zonulin</outcome_measure>
      <outcome_measure>delta in the value of alpha1-antitrypsin</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Roberto Poscia MD, PhD</lead_sponsor>
      <collaborator>Azienda Policlinico Umberto I</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>152</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 26, 2020</start_date>
    <primary_completion_date>October 30, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Francesco Pugliese, Rome, RM, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04366089</url>
  </study>
  <study rank="632">
    <nct_id>NCT04337424</nct_id>
    <title>Evaluation of Quickly Diagnostic Saliva Tests for SARS-CoV-2</title>
    <acronym>EasyCoV</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV-2</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Sampling salivary</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Specific detection of SARS-CoV-2 specific RNA</outcome_measure>
      <outcome_measure>Analytical sensitivity of the LAMP test.</outcome_measure>
      <outcome_measure>The correlation between the measurement of the assayed viral load (CT value) by the standard method and by the LAMP developed by SYS2DIAG / SKILLCELL.</outcome_measure>
      <outcome_measure>Evaluation of the use of saliva samples compared to nasopharyngeal samples</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Montpellier</lead_sponsor>
      <collaborator>SkillCell</collaborator>
      <collaborator>Sys2Diag (CNRS-Alcediag UMR9005)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>180</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 7, 2020</start_date>
    <primary_completion_date>April 17, 2020</primary_completion_date>
    <completion_date>April 17, 2020</completion_date>
    <study_first_posted>April 7, 2020</study_first_posted>
    <last_update_posted>April 7, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04337424</url>
  </study>
  <study rank="633">
    <nct_id>NCT04312100</nct_id>
    <title>Sequential Oxygen Therapy Strategy for Patients With COVID-19</title>
    <acronym>SOTSPC</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Disease-2019</condition>
    </conditions>
    <interventions>
      <intervention type="Other">oxygen treatment</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Incidence of respiratory failure</outcome_measure>
      <outcome_measure>28 day mortality rate</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Henan Provincial People's Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>February 1, 2020</start_date>
    <primary_completion_date>October 2020</primary_completion_date>
    <completion_date>February 2021</completion_date>
    <study_first_posted>March 18, 2020</study_first_posted>
    <last_update_posted>March 18, 2020</last_update_posted>
    <locations>
      <location>Henan Provincial People's Hospital, Zhengzhou, Henan, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04312100</url>
  </study>
  <study rank="634">
    <nct_id>NCT04312009</nct_id>
    <title>Losartan for Patients With COVID-19 Requiring Hospitalization</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Corona Virus Infection</condition>
      <condition>Acute Respiratory Distress Syndrome</condition>
      <condition>SARS-CoV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Losartan</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Difference in Estimated (PEEP adjusted) P/F Ratio at 7 days</outcome_measure>
      <outcome_measure>Daily Hypotensive Episodes</outcome_measure>
      <outcome_measure>Hypotension Requiring Vasopressors</outcome_measure>
      <outcome_measure>Acute Kidney Injury</outcome_measure>
      <outcome_measure>Sequential Organ Failure Assessment (SOFA) Total Score</outcome_measure>
      <outcome_measure>Oxygen Saturation / Fractional Inhaled Oxygen (F/S)</outcome_measure>
      <outcome_measure>28-Day Mortality</outcome_measure>
      <outcome_measure>90-Day Mortality</outcome_measure>
      <outcome_measure>ICU Admission</outcome_measure>
      <outcome_measure>Number of Ventilator-Free Days</outcome_measure>
      <outcome_measure>Number of Therapeutic Oxygen-Free Days</outcome_measure>
      <outcome_measure>Number of Vasopressor-Free Days</outcome_measure>
      <outcome_measure>Length of ICU Stay</outcome_measure>
      <outcome_measure>Length of Hospital Stay</outcome_measure>
      <outcome_measure>Incidence of Respiratory Failure</outcome_measure>
      <outcome_measure>Change in PROMIS Dyspnea Functional Limitations</outcome_measure>
      <outcome_measure>Change in PROMIS Dyspnea Severity</outcome_measure>
      <outcome_measure>Disease Severity Rating</outcome_measure>
      <outcome_measure>Viral Load by Nasopharyngeal Swab Day 9</outcome_measure>
      <outcome_measure>Viral Load by Nasopharyngeal Swab Day 15</outcome_measure>
      <outcome_measure>Viral Load by Blood Day 9</outcome_measure>
      <outcome_measure>Viral Load by Blood Day 15</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Minnesota</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 13, 2020</start_date>
    <primary_completion_date>April 1, 2021</primary_completion_date>
    <completion_date>April 1, 2021</completion_date>
    <study_first_posted>March 17, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Hennepin County Medical Center, Minneapolis, Minnesota, United States</location>
      <location>M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States</location>
      <location>University of Minnesota, Minneapolis, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04312009</url>
  </study>
  <study rank="635">
    <nct_id>NCT04359706</nct_id>
    <title>Bacterial and Fungal Microbiota of Patients With Severe Viral Pneumonia With SARS-CoV2</title>
    <acronym>MICROVID</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sars-CoV2</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Composition of the fecal bacterial and fungal microbiota</outcome_measure>
      <outcome_measure>Analysis of the faecal microbiota from rectal swab</outcome_measure>
      <outcome_measure>Analysis of the respiratory microbiota from the bronchoalveolar lavage liquid</outcome_measure>
      <outcome_measure>Serum inflammatory markers changes</outcome_measure>
      <outcome_measure>Inflammatory markers changes</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>mechanical ventilation free days</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Lille</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>September 2020</primary_completion_date>
    <completion_date>September 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04359706</url>
  </study>
  <study rank="636">
    <nct_id>NCT04361474</nct_id>
    <title>Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity</title>
    <acronym>COVIDORL</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Budesonide</condition>
      <condition>Olfaction Disorders</condition>
      <condition>SARS-CoV-2</condition>
      <condition>Anosmia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Budesonide Nasal</intervention>
      <intervention type="Other">Physiological serum</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Patient with more than 2 points on the ODORATEST</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Fondation Ophtalmologique Adolphe de Rothschild</lead_sponsor>
      <collaborator>Hopital Lariboisière</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 25, 2020</start_date>
    <primary_completion_date>April 25, 2020</primary_completion_date>
    <completion_date>May 25, 2021</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04361474</url>
  </study>
  <study rank="637">
    <nct_id>NCT04313946</nct_id>
    <title>Artificial Intelligence Algorithms for Discriminating Between COVID-19 and Influenza Pneumonitis Using Chest X-Rays</title>
    <acronym>AI-COVID-Xr</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Pneumonia, Viral</condition>
      <condition>Influenza With Pneumonia</condition>
      <condition>Flu Symptom</condition>
      <condition>Flu Like Illness</condition>
      <condition>Pneumonia, Interstitial</condition>
      <condition>Pneumonia, Ventilator-Associated</condition>
      <condition>Pneumonia Atypical</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Scanning Chest X-rays and performing AI algorithms on images</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>COVID-19 positive X-Rays</outcome_measure>
      <outcome_measure>COVID-19 negative X-Rays</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Professor Adrian Covic</lead_sponsor>
      <collaborator>Falcon Trading Iasi</collaborator>
      <collaborator>Romanian Academy of Medical Sciences</collaborator>
      <collaborator>Grigore T. Popa University of Medicine and Pharmacy</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Ecologic or Community</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 18, 2020</start_date>
    <primary_completion_date>August 16, 2020</primary_completion_date>
    <completion_date>August 18, 2020</completion_date>
    <study_first_posted>March 18, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>U.O. Multidisciplinare di Patologia Mammaria e Ricerca Traslazionale; Dipartimento Universitario Clinico di Scienze Mediche, Chirurgiche e della Salute Università degli Studi di Trieste, Cremona, Italy</location>
      <location>University of Medicine and Pharmacy Gr T Popa, Iaşi, Romania</location>
      <location>Department of Cardiology at Chelsea and Westminster NHS hospital, London, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04313946</url>
  </study>
  <study rank="638">
    <nct_id>NCT04315948</nct_id>
    <title>Trial of Treatments for COVID-19 in Hospitalized Adults</title>
    <acronym>DisCoVeRy</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Corona Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Remdesivir</intervention>
      <intervention type="Drug">Lopinavir/ritonavir</intervention>
      <intervention type="Drug">Interferon Beta-1A</intervention>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Other">Standard of care</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Percentage of subjects reporting each severity rating on a 7-point ordinal scale</outcome_measure>
      <outcome_measure>Percentage of subjects reporting each severity rating on a 7-point on an ordinal scale</outcome_measure>
      <outcome_measure>The time to discharge or to a NEWS of ≤ 2 and maintained for 24 hours, whichever occurs first.</outcome_measure>
      <outcome_measure>Number of oxygenation free days in the first 28 days</outcome_measure>
      <outcome_measure>Incidence of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.</outcome_measure>
      <outcome_measure>Duration of new oxygen use, non-invasive ventilation or high flow oxygen devices during the trial.</outcome_measure>
      <outcome_measure>Ventilator free days in the first 28 days</outcome_measure>
      <outcome_measure>Incidence of new mechanical ventilation use during the trial.</outcome_measure>
      <outcome_measure>Hospitalization</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>Cumulative incidence of serious adverse events (SAEs)</outcome_measure>
      <outcome_measure>Cumulative incidence of Grade 3 and 4 adverse events (AEs)</outcome_measure>
      <outcome_measure>Number of participants with a discontinuation or temporary suspension of study drugs (for any reason)</outcome_measure>
      <outcome_measure>Changes from baseline in blood white cell count</outcome_measure>
      <outcome_measure>Changes from baseline in haemoglobin</outcome_measure>
      <outcome_measure>Changes from baseline in platelets</outcome_measure>
      <outcome_measure>Changes from baseline in creatinine</outcome_measure>
      <outcome_measure>Changes from baseline in blood electrolytes (including kaliemia)</outcome_measure>
      <outcome_measure>Changes from baseline in prothrombine time</outcome_measure>
      <outcome_measure>Changes from baseline in international normalized ratio (INR)</outcome_measure>
      <outcome_measure>Changes from baseline in glucose</outcome_measure>
      <outcome_measure>Changes from baseline in total bilirubin</outcome_measure>
      <outcome_measure>Changes from baseline in alanine aminotransferase (ALT)</outcome_measure>
      <outcome_measure>Changes from baseline in aspartate aminotransferase (AST)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Institut National de la Santé Et de la Recherche Médicale, France</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>3100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 22, 2020</start_date>
    <primary_completion_date>March 2023</primary_completion_date>
    <completion_date>March 2023</completion_date>
    <study_first_posted>March 20, 2020</study_first_posted>
    <last_update_posted>March 25, 2020</last_update_posted>
    <locations>
      <location>CHRU Lille, Lille, France</location>
      <location>CHU Nantes, Nantes, France</location>
      <location>APHP - Bichat Claude Bernard, Paris, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04315948</url>
  </study>
  <study rank="639">
    <nct_id>NCT04311177</nct_id>
    <title>Losartan for Patients With COVID-19 Not Requiring Hospitalization</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Corona Virus Infection</condition>
      <condition>Acute Respiratory Distress Syndrome</condition>
      <condition>SARS-CoV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Losartan</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Hospital Admission</outcome_measure>
      <outcome_measure>Change in PROMIS Dyspnea Functional Limitations</outcome_measure>
      <outcome_measure>Change in PROMIS Dyspnea Severity</outcome_measure>
      <outcome_measure>Daily Maximum Temperature</outcome_measure>
      <outcome_measure>Emergency Department/Clinic Presentations</outcome_measure>
      <outcome_measure>Disease Severity Rating Day 7</outcome_measure>
      <outcome_measure>Disease Severity Rating Day 15</outcome_measure>
      <outcome_measure>Disease Severity Rating Day 28</outcome_measure>
      <outcome_measure>Viral Load by Oropharyngeal Swab Day 9</outcome_measure>
      <outcome_measure>Viral Load by Oropharyngeal Swab Day 15</outcome_measure>
      <outcome_measure>Ventilator-Free Days</outcome_measure>
      <outcome_measure>Therapeutic Oxygen-Free Days</outcome_measure>
      <outcome_measure>Need for Hospital Admission at 15 Days</outcome_measure>
      <outcome_measure>Need for Oxygen Therapy at 15 Days</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Minnesota</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>580</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 9, 2020</start_date>
    <primary_completion_date>April 1, 2021</primary_completion_date>
    <completion_date>April 1, 2021</completion_date>
    <study_first_posted>March 17, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Hennepin County Medical Center, Minneapolis, Minnesota, United States</location>
      <location>M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States</location>
      <location>University of Minnesota, Minneapolis, Minnesota, United States</location>
      <location>Mayo Clinic Health System, Rochester, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04311177</url>
  </study>
  <study rank="640">
    <nct_id>NCT04323839</nct_id>
    <title>COVID-19 PRIORITY (Pregnancy CoRonavIrus Outcomes RegIsTrY)</title>
    <acronym>PRIORITY</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pregnancy</condition>
      <condition>Coronavirus</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Pregnant women under investigation for Coronavirus or diagnosed with COVID-19</intervention>
      <intervention type="Other">Postpartum women under investigation for Coronavirus or diagnosed with COVID-19</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clinical presentation</outcome_measure>
      <outcome_measure>Disease prognosis outcomes</outcome_measure>
      <outcome_measure>Pregnancy outcomes</outcome_measure>
      <outcome_measure>Obstetric outcomes</outcome_measure>
      <outcome_measure>Neonatal outcomes</outcome_measure>
      <outcome_measure>Modes of transmission of COVID-19</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of California, San Francisco</lead_sponsor>
      <collaborator>University of California, Los Angeles</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>13 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>2000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 20, 2020</start_date>
    <primary_completion_date>March 31, 2024</primary_completion_date>
    <completion_date>March 31, 2024</completion_date>
    <study_first_posted>March 27, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>University of California, San Francisco, San Francisco, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04323839</url>
  </study>
  <study rank="641">
    <nct_id>NCT04335084</nct_id>
    <title>A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection</title>
    <acronym>HELPCOVID-19</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Coronavirus Infection</condition>
      <condition>Sars-CoV2</condition>
      <condition>Corona Virus Infection</condition>
      <condition>COVID</condition>
      <condition>Coronavirus</condition>
      <condition>Coronavirus-19</condition>
      <condition>Coronavirus 19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Dietary Supplement">Vitamin C</intervention>
      <intervention type="Dietary Supplement">Vitamin D</intervention>
      <intervention type="Dietary Supplement">Zinc</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Prevention of COVID-19 symptoms as recorded in a daily diary</outcome_measure>
      <outcome_measure>Safety as determined by presence or absence of Adverse Events and Serious Adverse Events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>ProgenaBiome</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>600</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>April 2021</primary_completion_date>
    <completion_date>July 2021</completion_date>
    <study_first_posted>April 6, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>ProgenaBiome, Ventura, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04335084</url>
  </study>
  <study rank="642">
    <nct_id>NCT04353609</nct_id>
    <title>Covid-19 in Patients With Chronic Inflammatory Rheumatism, Auto-immune or Auto-inflammatory Rare and Non-rare Diseases</title>
    <acronym>covid19 fai2r</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sars-CoV2</condition>
      <condition>Chronic Inflammatory Rheumatism</condition>
      <condition>Autoimmune Diseases</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Proportion of patients presenting a severe form of covid-19 requiring an intensive care unit admission or leading to death</outcome_measure>
      <outcome_measure>Proportion of patients who die from a severe form of covid-19</outcome_measure>
      <outcome_measure>Proportion of patients who present an history of diabetes according to medical records</outcome_measure>
      <outcome_measure>Proportion of patients who present obesity (validated by Body Mass Index value &gt; 30 kg/cm2)</outcome_measure>
      <outcome_measure>Proportion of patients who present an history of Chronic Pulmonary Obstructive Disease according to medical records</outcome_measure>
      <outcome_measure>Proportion of patients who present an history of Asthma according to medical records</outcome_measure>
      <outcome_measure>Proportion of patients who present an history of Hypertension according to medical records</outcome_measure>
      <outcome_measure>Proportion of patients who present an history of cardiac disease according to medical records</outcome_measure>
      <outcome_measure>Proportion of patients who present an history of Pulmonary Interstitial Disease according to medical records</outcome_measure>
      <outcome_measure>Proportion of patients who present an history of stroke according to medical records</outcome_measure>
      <outcome_measure>Proportion of patients who present an history of angiotensin-converting-enzyme inhibitor according to medical records</outcome_measure>
      <outcome_measure>Proportion of patients who present an history of cancer according to medical records</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Lille</lead_sponsor>
      <collaborator>FAI²R (Auto-immune and auto-inflammatory rare diseases French network)</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>13770</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>April 18, 2020</start_date>
    <primary_completion_date>December 2020</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>April 20, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Hôpital Huriez, Lille, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04353609</url>
  </study>
  <study rank="643">
    <nct_id>NCT04337788</nct_id>
    <title>Gerontological Telemonitoring of Older Adults Living in Nursing Homes With COVID-19 Disease</title>
    <acronym>COVIDeHPAD</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Other">telehealth applications</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Impact of Gerontological telemonitoring on healthcare management for older adults living in Nursing Homes with symptoms of confirmed or probable COVID-19 disease (Death within 30 days).</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Limoges</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>75 Years</min_age>
    <age_groups>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>September 2020</completion_date>
    <study_first_posted>April 8, 2020</study_first_posted>
    <last_update_posted>April 8, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04337788</url>
  </study>
  <study rank="644">
    <nct_id>NCT04261426</nct_id>
    <title>The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>2019-nCoV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Intravenous Immunoglobulin</intervention>
      <intervention type="Other">Standard care</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clinical improvement based on the 7-point scale</outcome_measure>
      <outcome_measure>Lower Murray lung injury score</outcome_measure>
      <outcome_measure>28-day mortality</outcome_measure>
      <outcome_measure>Duration of mechanical ventilation</outcome_measure>
      <outcome_measure>Duration of hospitalization</outcome_measure>
      <outcome_measure>Proportion of patients with negative RT-PCR results</outcome_measure>
      <outcome_measure>Proportion of patients in each category of the 7-point scale</outcome_measure>
      <outcome_measure>Proportion of patients with normalized inflammation factors</outcome_measure>
      <outcome_measure>Frequency of Adverse Drug Events</outcome_measure>
      <outcome_measure>Frequency of Serious Adverse Drug Events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Peking Union Medical College Hospital</lead_sponsor>
      <collaborator>Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>February 10, 2020</start_date>
    <primary_completion_date>April 30, 2020</primary_completion_date>
    <completion_date>June 30, 2020</completion_date>
    <study_first_posted>February 7, 2020</study_first_posted>
    <last_update_posted>February 7, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04261426</url>
  </study>
  <study rank="645">
    <nct_id>NCT04354779</nct_id>
    <title>Antibody Seroprevalence and Rate of Asymptomatic Infections With SARS-CoV-2 in Austrian Hospital Personnel.</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Severe Acute Respiratory Syndrome Coronavirus 2</condition>
      <condition>SARS-CoV 2</condition>
      <condition>Coronavirus Infection</condition>
      <condition>Covid19</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">a specifically designed self-administered questionnaire</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Antibody status in HCW</outcome_measure>
      <outcome_measure>Active virus carriers in HCW</outcome_measure>
      <outcome_measure>Incubation time</outcome_measure>
      <outcome_measure>Background incidence rate</outcome_measure>
      <outcome_measure>Occupation associated infection risk</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>AUVA</lead_sponsor>
      <collaborator>Paracelsus Medical University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>15 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>4000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>October 2020</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04354779</url>
  </study>
  <study rank="646">
    <nct_id>NCT04255017</nct_id>
    <title>A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>2019-nCoV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Abidol hydrochloride</intervention>
      <intervention type="Drug">Oseltamivir</intervention>
      <intervention type="Drug">Lopinavir/ritonavir</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Rate of disease remission</outcome_measure>
      <outcome_measure>Time for lung recovery</outcome_measure>
      <outcome_measure>Rate of no fever</outcome_measure>
      <outcome_measure>Rate of respiratory symptom remission</outcome_measure>
      <outcome_measure>Rate of lung imaging recovery</outcome_measure>
      <outcome_measure>Rate of CRP,ES,Biochemical criterion(CK,ALT,Mb) recovery</outcome_measure>
      <outcome_measure>Rate of undetectable viral RNA</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tongji Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>February 1, 2020</start_date>
    <primary_completion_date>June 1, 2020</primary_completion_date>
    <completion_date>July 1, 2020</completion_date>
    <study_first_posted>February 5, 2020</study_first_posted>
    <last_update_posted>March 17, 2020</last_update_posted>
    <locations>
      <location>Department and Institute of Infectious Disease, Wuhan, Hubei, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04255017</url>
  </study>
  <study rank="647">
    <nct_id>NCT04332016</nct_id>
    <title>COVID-19 Biological Samples Collection</title>
    <acronym>COLCOV19-BX</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Infection Viral</condition>
    </conditions>
    <interventions>
      <intervention type="Other">biological samples collection</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>COVID-19 desease description</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Bordeaux</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <max_age>100 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>2000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 2, 2020</start_date>
    <primary_completion_date>March 2023</primary_completion_date>
    <completion_date>March 2023</completion_date>
    <study_first_posted>April 2, 2020</study_first_posted>
    <last_update_posted>April 3, 2020</last_update_posted>
    <locations>
      <location>Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04332016</url>
  </study>
  <study rank="648">
    <nct_id>NCT04254874</nct_id>
    <title>A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>2019-nCoV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Abidol hydrochloride</intervention>
      <intervention type="Drug">Abidol Hydrochloride combined with Interferon atomization</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Rate of disease remission</outcome_measure>
      <outcome_measure>Time for lung recovery</outcome_measure>
      <outcome_measure>Rate of no fever</outcome_measure>
      <outcome_measure>Rate of respiratory symptom remission</outcome_measure>
      <outcome_measure>Rate of lung imaging recovery</outcome_measure>
      <outcome_measure>Rate of CRP,ES,Biochemical criterion (CK,ALT,Mb)recovery</outcome_measure>
      <outcome_measure>Rate of undetectable viral RNA</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tongji Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>February 1, 2020</start_date>
    <primary_completion_date>June 1, 2020</primary_completion_date>
    <completion_date>July 1, 2020</completion_date>
    <study_first_posted>February 5, 2020</study_first_posted>
    <last_update_posted>March 17, 2020</last_update_posted>
    <locations>
      <location>Department and Institute of Infectious Disease, Wuhan, Hubei, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04254874</url>
  </study>
  <study rank="649">
    <nct_id>NCT04340466</nct_id>
    <title>French Multicentre Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management Study</title>
    <acronym>FRENCH CORONA</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pneumonia, Viral</condition>
      <condition>Critically Ill</condition>
      <condition>Corona Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Other">No intervention</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mortality at day 28</outcome_measure>
      <outcome_measure>severe complications</outcome_measure>
      <outcome_measure>Imaging</outcome_measure>
      <outcome_measure>Delay in Microbiological diagnosis</outcome_measure>
      <outcome_measure>Antiviral therapy</outcome_measure>
      <outcome_measure>Antibiotic therapy</outcome_measure>
      <outcome_measure>Covid-19 treatments</outcome_measure>
      <outcome_measure>Patients receiving renal replacement therapy</outcome_measure>
      <outcome_measure>Patients receiving mechanical ventilation</outcome_measure>
      <outcome_measure>Vital status</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier Universitaire de Nīmes</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>220</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 3, 2020</start_date>
    <primary_completion_date>June 30, 2020</primary_completion_date>
    <completion_date>April 30, 2021</completion_date>
    <study_first_posted>April 9, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>CHU Nimes, Nîmes, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04340466</url>
  </study>
  <study rank="650">
    <nct_id>NCT04350099</nct_id>
    <title>Emotional Burden of Healthcare Professionals and Covid Infection 19</title>
    <acronym>Emocovid</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Emotionnal Distress; COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">quetionnary</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>anxiety</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Limoges</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>December 15, 2020</primary_completion_date>
    <completion_date>June 15, 2021</completion_date>
    <study_first_posted>April 16, 2020</study_first_posted>
    <last_update_posted>April 16, 2020</last_update_posted>
    <locations>
      <location>CH Esquirol, Limoges, France</location>
      <location>CHU de Limoges, Limoges, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04350099</url>
  </study>
  <study rank="651">
    <nct_id>NCT04316949</nct_id>
    <title>Predictors of Respiratory Failure in SARS-Cov-2 Infection</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV-2 Pneumonia</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Respiratory failure</outcome_measure>
      <outcome_measure>Occurence of bacterial superinfection</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Bologna</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>99 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>350</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>March 20, 2020</start_date>
    <primary_completion_date>April 30, 2020</primary_completion_date>
    <completion_date>May 31, 2020</completion_date>
    <study_first_posted>March 20, 2020</study_first_posted>
    <last_update_posted>April 7, 2020</last_update_posted>
    <locations>
      <location>University of Bologna - Department of Medical and Surgical Sciences, Bologna, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04316949</url>
  </study>
  <study rank="652">
    <nct_id>NCT04275414</nct_id>
    <title>Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia</title>
    <acronym>BEST-CP</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Bevacizumab Injection</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Partial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratio</outcome_measure>
      <outcome_measure>Degree of dyspnea (Liker scale)</outcome_measure>
      <outcome_measure>Degree of dyspnea (VAS)</outcome_measure>
      <outcome_measure>The area of lung lesions on Chest CT</outcome_measure>
      <outcome_measure>The degree of lung exudation on Chest CT</outcome_measure>
      <outcome_measure>SpO2</outcome_measure>
      <outcome_measure>PaO2</outcome_measure>
      <outcome_measure>CRP</outcome_measure>
      <outcome_measure>hs-CRP</outcome_measure>
      <outcome_measure>All-cause mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Qilu Hospital of Shandong University</lead_sponsor>
      <collaborator>Renmin Hospital of Wuhan University</collaborator>
      <collaborator>Moriggia-Pelascini Gravedona Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>February 15, 2020</start_date>
    <primary_completion_date>April 2020</primary_completion_date>
    <completion_date>May 2020</completion_date>
    <study_first_posted>February 19, 2020</study_first_posted>
    <last_update_posted>April 3, 2020</last_update_posted>
    <locations>
      <location>Renmin Hospital of Wuhan University, Wuhan, Hubei, China</location>
      <location>Qilu Hospital of Shandong University, Jinan, Shandong, China</location>
      <location>Moriggia-Pelascini Gravedona Hospital, Gravedona, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04275414</url>
  </study>
  <study rank="653">
    <nct_id>NCT04348929</nct_id>
    <title>Birth Experience During COVID-19 Confinement</title>
    <acronym>CONFINE</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Postpartum Depression</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Self-administered questionnaires</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>&quot;Labor Agentry Scale questionnaire&quot; score in immediate post-partum (duration of hospital stay)</outcome_measure>
      <outcome_measure>&quot;Labor Agentry Scale questionnaire&quot; score at two months after birth</outcome_measure>
      <outcome_measure>Edinburg Postnatale Depression Scale questionnaire&quot; score at two months after birth</outcome_measure>
      <outcome_measure>&quot;Impact of Event Scale - Revised questionnaire&quot; score at two months after birth</outcome_measure>
      <outcome_measure>Breastfeeding statement at two months after birth</outcome_measure>
      <outcome_measure>&quot;SF-12 Quality of life questionnaire&quot; score at two months after birth</outcome_measure>
      <outcome_measure>&quot;SF-12 Quality of life questionnaire&quot; score in immediate post-partum</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Central Hospital, Nancy, France</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>600</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <start_date>April 16, 2020</start_date>
    <primary_completion_date>August 16, 2021</primary_completion_date>
    <completion_date>November 1, 2021</completion_date>
    <study_first_posted>April 16, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Centre Hospitalier Régional Universitaire de Nancy, Nancy, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04348929</url>
  </study>
  <study rank="654">
    <nct_id>NCT04357340</nct_id>
    <title>The Effects of Pulmonary Physiotherapy Treatments on Patients With COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid-19</condition>
      <condition>Pneumonia</condition>
      <condition>SARS Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Pulmonary Physiotherapy Techniques</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mixed venous O2 pressure (PVO2)</outcome_measure>
      <outcome_measure>Mixed venous CO2 pressure (PVCO2)</outcome_measure>
      <outcome_measure>PH</outcome_measure>
      <outcome_measure>HCO3</outcome_measure>
      <outcome_measure>Oxygen saturation (O2 Sat) from VBG</outcome_measure>
      <outcome_measure>Six minute walk test</outcome_measure>
      <outcome_measure>O2 Sat after one minute walking</outcome_measure>
      <outcome_measure>O2 Sat after two minutes use of Partial Rebreather</outcome_measure>
      <outcome_measure>O2 Sat after two minutes free air breathing</outcome_measure>
      <outcome_measure>O2 sat/ Fio2</outcome_measure>
      <outcome_measure>breathlessness</outcome_measure>
      <outcome_measure>Mortality rate</outcome_measure>
      <outcome_measure>Number of participants with Rehospitalization</outcome_measure>
      <outcome_measure>The Health-Related Quality of Life (HRQOL)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tehran University of Medical Sciences</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>June 20, 2020</primary_completion_date>
    <completion_date>August 1, 2020</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Imam Khomeini Hospital Complex, Tehran, Iran, Islamic Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04357340</url>
  </study>
  <study rank="655">
    <nct_id>NCT04341935</nct_id>
    <title>Effects of DPP4 Inhibition on COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infection</condition>
      <condition>Type 2 Diabetes</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Linagliptin</intervention>
      <intervention type="Drug">Insulin regimen</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Changes in Glucose Llevels</outcome_measure>
      <outcome_measure>Changes in SpO2 levels</outcome_measure>
      <outcome_measure>Changes in Interleukin 6 (IL6)</outcome_measure>
      <outcome_measure>Changes in chest structures</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Miami</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 30, 2020</start_date>
    <primary_completion_date>June 30, 2020</primary_completion_date>
    <completion_date>September 30, 2020</completion_date>
    <study_first_posted>April 10, 2020</study_first_posted>
    <last_update_posted>April 10, 2020</last_update_posted>
    <locations>
      <location>University of Miami, Miami, Florida, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04341935</url>
  </study>
  <study rank="656">
    <nct_id>NCT04343053</nct_id>
    <title>Pro-thrombotic Status in Patients With SARS-Cov-2 Infection</title>
    <acronym>ATTAC-Co</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Severe Acute Respiratory Syndrome Coronavirus 2</condition>
    </conditions>
    <interventions>
      <intervention type="Other">SARS-Cov-2 infection</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>on-treatment platelet reactivity</outcome_measure>
      <outcome_measure>apoptosis rate in human umbilical vein endothelial cells (HUVEC)</outcome_measure>
      <outcome_measure>Nitric oxide (NO) intracellular levels</outcome_measure>
      <outcome_measure>reactive oxygen species (ROS) levels</outcome_measure>
      <outcome_measure>coagulation factors levels</outcome_measure>
      <outcome_measure>respiratory function</outcome_measure>
      <outcome_measure>cardiac function</outcome_measure>
      <outcome_measure>clinical outcome</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital of Ferrara</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <start_date>April 8, 2020</start_date>
    <primary_completion_date>June 30, 2020</primary_completion_date>
    <completion_date>June 30, 2021</completion_date>
    <study_first_posted>April 13, 2020</study_first_posted>
    <last_update_posted>April 13, 2020</last_update_posted>
    <locations>
      <location>Azienda Ospedaliera Universitaria di Ferrara, Ferrara, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04343053</url>
  </study>
  <study rank="657">
    <nct_id>NCT04339387</nct_id>
    <title>COVID-19 Risk Stratification</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
      <condition>Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Suitable for discharge</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Brigham and Women's Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Other</study_design>
    </study_designs>
    <start_date>March 1, 2020</start_date>
    <primary_completion_date>April 15, 2020</primary_completion_date>
    <completion_date>April 15, 2020</completion_date>
    <study_first_posted>April 9, 2020</study_first_posted>
    <last_update_posted>April 9, 2020</last_update_posted>
    <locations>
      <location>Brigham and Women's Hospital, Boston, Massachusetts, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04339387</url>
  </study>
  <study rank="658">
    <nct_id>NCT04261270</nct_id>
    <title>A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>2019-nCoV Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ASC09F+Oseltamivir</intervention>
      <intervention type="Drug">Ritonavir+Oseltamivir</intervention>
      <intervention type="Drug">Oseltamivir</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Rate of comprehensive adverse outcome</outcome_measure>
      <outcome_measure>Time of clinical remission</outcome_measure>
      <outcome_measure>Rate of no fever</outcome_measure>
      <outcome_measure>Rate of no cough</outcome_measure>
      <outcome_measure>Rate of no dyspnea</outcome_measure>
      <outcome_measure>Rate of no need for oxygen inhalation</outcome_measure>
      <outcome_measure>Rate of undetectable viral RNA</outcome_measure>
      <outcome_measure>Rate of mechanical ventilation</outcome_measure>
      <outcome_measure>Rate of ICU admission</outcome_measure>
      <outcome_measure>Rate and time of CRP,ES,Biochemical criterion(CK,ALT,Mb)recovery</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tongji Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>February 1, 2020</start_date>
    <primary_completion_date>May 1, 2020</primary_completion_date>
    <completion_date>July 1, 2020</completion_date>
    <study_first_posted>February 7, 2020</study_first_posted>
    <last_update_posted>March 17, 2020</last_update_posted>
    <locations>
      <location>Department and Institute of Infectious Disease, Wuhan, Hubei, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04261270</url>
  </study>
  <study rank="659">
    <nct_id>NCT04357938</nct_id>
    <title>Risk Stratification With Chest CT to Rule-out Suspected SARS-CoV-2 Infections</title>
    <acronym>SCout</acronym>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Severe Acute Respiratory Syndrome Coronavirus 2</condition>
    </conditions>
    <interventions>
      <intervention type="Device">CT-imaging</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Sensitivity and specificity of chest CT in detecting pneumonia in unspecific symptomatic patients who are to be admitted to hospital and who are rt-PCR negative for SARS-CoV-2.</outcome_measure>
      <outcome_measure>Sensitivity and specificity of chest CT in patients with pulmonary comorbidities</outcome_measure>
      <outcome_measure>Sensitivity and specificity of chest CT in patients with cardiovascular comorbidities</outcome_measure>
      <outcome_measure>Sensitivity and specificity of chest CT in patients with malignancy</outcome_measure>
      <outcome_measure>Sensitivity and specificity of chest CT in patients with immunodeficiency</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Jena University Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>145</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>April 20, 2020</primary_completion_date>
    <completion_date>April 30, 2020</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Jena University Hospital, Jena, Thuringia, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04357938</url>
  </study>
  <study rank="660">
    <nct_id>NCT04342169</nct_id>
    <title>University of Utah COVID-19 Hydrochloroquine Trial</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infection</condition>
      <condition>Coronavirus</condition>
      <condition>Infectious Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Drug">Placebo oral tablet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Duration of viral shedding</outcome_measure>
      <outcome_measure>Duration of COVID-19-attributable symptoms</outcome_measure>
      <outcome_measure>Hospitalization</outcome_measure>
      <outcome_measure>Adult household contact viral acquisition</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Utah</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 14, 2020</start_date>
    <primary_completion_date>April 2022</primary_completion_date>
    <completion_date>April 2023</completion_date>
    <study_first_posted>April 10, 2020</study_first_posted>
    <last_update_posted>April 16, 2020</last_update_posted>
    <locations>
      <location>University of Utah, Salt Lake City, Utah, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04342169</url>
  </study>
  <study rank="661">
    <nct_id>NCT04360863</nct_id>
    <title>The Impact of COVID-19 Pandemic on the Smoking Behaviour of Young Smokers and the Youth Quitline Service in Hong Kong</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Smoking Cessation</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Telephone survey</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Smoking behaviors</outcome_measure>
      <outcome_measure>Knowledge</outcome_measure>
      <outcome_measure>Readiness to quit</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>The University of Hong Kong</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <max_age>25 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <start_date>April 24, 2020</start_date>
    <primary_completion_date>June 30, 2020</primary_completion_date>
    <completion_date>June 30, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>The University of Hong Kong, Hong Kong, Hong Kong</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04360863</url>
  </study>
  <study rank="662">
    <nct_id>NCT04332042</nct_id>
    <title>TOFAcitinib in SARS-CoV2 Pneumonia</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-COv2 Related Interstitial Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tofacitinib</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>need of mechanical ventilation</outcome_measure>
      <outcome_measure>need of admission in intensive care unit</outcome_measure>
      <outcome_measure>death</outcome_measure>
      <outcome_measure>rate of adverse events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Università Politecnica delle Marche</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 10, 2020</start_date>
    <primary_completion_date>June 20, 2020</primary_completion_date>
    <completion_date>July 10, 2020</completion_date>
    <study_first_posted>April 2, 2020</study_first_posted>
    <last_update_posted>April 2, 2020</last_update_posted>
    <locations>
      <location>Ospedali Riuniti di Ancona, Ancona, Marche, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04332042</url>
  </study>
  <study rank="663">
    <nct_id>NCT04353401</nct_id>
    <title>WGS ANALYSIS OF SARS-COV-2 POSITIVE PATIENTS</title>
    <acronym>CALYPSO</acronym>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infection</condition>
      <condition>SARS-CoV-2</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Associations with severity and outcomes</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Vanda Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>5000</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>November 2020</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>April 20, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations>
      <location>Vanda Pharmaceuticals, Inc., Washington, District of Columbia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04353401</url>
  </study>
  <study rank="664">
    <nct_id>NCT04329195</nct_id>
    <title>ACE Inhibitors or ARBs Discontinuation in Context of SARS-CoV-2 Pandemic</title>
    <acronym>ACORES-2</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>History of Cardiovascular Disease Treated With RAS Blockers and With SARS-CoV-2 Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">1: discontinuation of RAS blocker therapy</intervention>
      <intervention type="Drug">2: continuation of RAS blocker therapy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to clinical improvement from day 0 to day 28 (improvement of two points on a seven-category ordinal scale, or live discharge from the hospital, whichever comes first)</outcome_measure>
      <outcome_measure>Primary safety endpoint: major adverse cardiac events defined as the composite of cardiovascular death, myocardial infarction, stroke or acute heart failure at day 28</outcome_measure>
      <outcome_measure>Clinical status as assessed with the seven-category ordinal scale on days 7, 14 and 28.</outcome_measure>
      <outcome_measure>Number of days alive free of oxygen.</outcome_measure>
      <outcome_measure>Number of days alive outside hospital until day28</outcome_measure>
      <outcome_measure>Number of days alive free of intensive-care unit (ICU) admission or mechanical ventilation (invasive or non-invasive) until day28</outcome_measure>
      <outcome_measure>Number of days alive free of mechanical ventilation (invasive or non-invasive) until day28</outcome_measure>
      <outcome_measure>Number of days alive free of ICU admission until day28</outcome_measure>
      <outcome_measure>Rate of all-cause mortality at day 28</outcome_measure>
      <outcome_measure>Rate of cardiovascular death at day 28</outcome_measure>
      <outcome_measure>Number of days alive free of acute kidney injury until hospital discharge</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
      <collaborator>Groupe Hospitalier Pitié-Salpêtrière</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>554</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 9, 2020</start_date>
    <primary_completion_date>May 9, 2020</primary_completion_date>
    <completion_date>May 9, 2020</completion_date>
    <study_first_posted>April 1, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>Cardiologie, Groupe Hospitalier Pitié-Salpêtrière, Paris, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04329195</url>
  </study>
  <study rank="665">
    <nct_id>NCT04358640</nct_id>
    <title>Anxiety and Work Resilience Among Tertiary University Hospital Workers During the COVID-19 Outbreak: An Online Survey</title>
    <acronym>PSY_CO_CHU</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Critical Illness</condition>
      <condition>Sars-CoV2</condition>
      <condition>SARS Pneumonia</condition>
      <condition>Coronavirus Infection</condition>
      <condition>Stress Disorders, Post-Traumatic</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Anxiety</outcome_measure>
      <outcome_measure>Insomnia</outcome_measure>
      <outcome_measure>Catastrophism</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier Universitaire de Nīmes</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>2000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 9, 2020</start_date>
    <primary_completion_date>April 22, 2020</primary_completion_date>
    <completion_date>April 22, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Intensive care unit CHU Nimes, Nîmes, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04358640</url>
  </study>
  <study rank="666">
    <nct_id>NCT04316728</nct_id>
    <title>Clinical Performance of the VivaDiag ™ COVID-19 lgM / IgG Rapid Test in Early Detecting the Infection of COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Device">VivaDiag™ COVID-19 lgM/IgG Rapid Test</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of patients with constant negative results</outcome_measure>
      <outcome_measure>Number of patients with positive test with a positive PCR for COVID-19</outcome_measure>
      <outcome_measure>Overall Number of patients positive for COVID-19</outcome_measure>
      <outcome_measure>Overall Number of patients negative for COVID-19</outcome_measure>
      <outcome_measure>Number of patients with contrasting results</outcome_measure>
      <outcome_measure>Reliability of the test</outcome_measure>
      <outcome_measure>Positive HCW</outcome_measure>
      <outcome_measure>Number of Chronic Patients</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centro Studi Internazionali, Italy</lead_sponsor>
      <collaborator>VivaChek Laboratories, Inc.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <start_date>March 2020</start_date>
    <primary_completion_date>September 2020</primary_completion_date>
    <completion_date>November 2020</completion_date>
    <study_first_posted>March 20, 2020</study_first_posted>
    <last_update_posted>March 20, 2020</last_update_posted>
    <locations>
      <location>Unità' Complesse di cure primarie (UCCP), ASP Catanzaro, Catanzaro, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04316728</url>
  </study>
  <study rank="667">
    <nct_id>NCT04321616</nct_id>
    <title>The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV Infection</condition>
      <condition>COVID 19</condition>
      <condition>Acute Respiratory Distress Syndrome ARDS</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Drug">Remdesivir</intervention>
      <intervention type="Other">(Standard of Care) SoC</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>In-hospital mortality</outcome_measure>
      <outcome_measure>Occurrence and duration of mechanical ventilation</outcome_measure>
      <outcome_measure>Occurrence and duration of intensive care unit (ICU) treatment</outcome_measure>
      <outcome_measure>Duration of hospital admittance</outcome_measure>
      <outcome_measure>28 Day mortality</outcome_measure>
      <outcome_measure>Viral clearance as assessed by SARS-CoV-2 PCR in peripheral blood and nasopharyngeal airway speciemen</outcome_measure>
      <outcome_measure>Occurrence of co-infections</outcome_measure>
      <outcome_measure>Occurrence of organ dysfunction</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Oslo University Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>700</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 28, 2020</start_date>
    <primary_completion_date>August 2020</primary_completion_date>
    <completion_date>November 2020</completion_date>
    <study_first_posted>March 25, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>Andreas Barratt-Due, Oslo, Norway</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04321616</url>
  </study>
  <study rank="668">
    <nct_id>NCT04365101</nct_id>
    <title>Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 (CYNK-001-COVID-19)</title>
    <acronym>CYNK001COVID</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
      <condition>Coronavirus Infection</condition>
      <condition>Severe Acute Respiratory Syndrome Coronavirus 2</condition>
      <condition>Pneumonia</condition>
      <condition>Pneumonia, Viral</condition>
      <condition>Lung Diseases</condition>
      <condition>Respiratory Tract Disease</condition>
      <condition>Respiratory Tract Infections</condition>
      <condition>Coronaviridae Infections</condition>
      <condition>Nidovirales Infections</condition>
      <condition>RNA Virus Infections</condition>
      <condition>Virus Disease</condition>
      <condition>Immunologic Disease</condition>
      <condition>ARDS</condition>
      <condition>Immunologic Factors</condition>
      <condition>Physiological Effects of Drugs</condition>
      <condition>Antiviral Agents</condition>
      <condition>Anti-infective Agents</condition>
      <condition>Analgesics</condition>
      <condition>Antimetabolites, Antineoplastic</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">CYNK-001</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Phase 1: Frequency and Severity of Adverse Events (AE)</outcome_measure>
      <outcome_measure>Time to Clearance of SARS-CoV-2</outcome_measure>
      <outcome_measure>Rate of Clearance of SARS-CoV-2</outcome_measure>
      <outcome_measure>Time to Clinical Improvement of cough</outcome_measure>
      <outcome_measure>Time to Clinical Improvement of fever</outcome_measure>
      <outcome_measure>Time to Clinical Improvement in radiological evaluation of disease related chest x-ray</outcome_measure>
      <outcome_measure>Rate of Clinical Improvement of fever</outcome_measure>
      <outcome_measure>Rate of Clinical Improvement of cough</outcome_measure>
      <outcome_measure>Rate of Clinical Improvement of radiological evaluation of disease related chest x-ray</outcome_measure>
      <outcome_measure>Time to Pulmonary Clearance</outcome_measure>
      <outcome_measure>Rate of Pulmonary Clearance</outcome_measure>
      <outcome_measure>Impact of CYNK-001 on sequential organ failure assessment (SOFA) score</outcome_measure>
      <outcome_measure>Phase 2: Frequency and Severity of Adverse Events (AE)</outcome_measure>
      <outcome_measure>Overall Clinical Benefit by time to medical discharge</outcome_measure>
      <outcome_measure>Overall Clinical Benefit by hospital utilization</outcome_measure>
      <outcome_measure>Overall Clinical Benefit by measuring mortality rate</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Celularity Incorporated</lead_sponsor>
      <collaborator>IDRI</collaborator>
      <collaborator>Lung Biotechnology PBC</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>86</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 30, 2020</start_date>
    <primary_completion_date>November 30, 2020</primary_completion_date>
    <completion_date>November 30, 2021</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04365101</url>
  </study>
  <study rank="669">
    <nct_id>NCT04327349</nct_id>
    <title>Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial</title>
    <acronym/>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Convalescent Plasma</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mortality changes in day 10</outcome_measure>
      <outcome_measure>Mortality changes in day 30</outcome_measure>
      <outcome_measure>Changes of C-reactive protein</outcome_measure>
      <outcome_measure>Changes of Interleukin 6</outcome_measure>
      <outcome_measure>Changes of tumor necrosis factor-α</outcome_measure>
      <outcome_measure>Changes of PaO2/FiO2 Ratio</outcome_measure>
      <outcome_measure>Changes of CD3</outcome_measure>
      <outcome_measure>Changes of CD4</outcome_measure>
      <outcome_measure>Changes of CD8</outcome_measure>
      <outcome_measure>Changes of CD4/CD8 ratio</outcome_measure>
      <outcome_measure>Changes of lymphocyte count</outcome_measure>
      <outcome_measure>Changes of leukocyte count</outcome_measure>
      <outcome_measure>Changes of alanine transaminase (ALT)</outcome_measure>
      <outcome_measure>Changes of aspartate transaminase (AST)</outcome_measure>
      <outcome_measure>Changes of alkaline phosphatase (ALP)</outcome_measure>
      <outcome_measure>Changes of lactate dehydrogenase (LDH)</outcome_measure>
      <outcome_measure>Changes of creatine phosphokinase (CPK)</outcome_measure>
      <outcome_measure>Changes of Creatine kinase-MB (CK-MB)</outcome_measure>
      <outcome_measure>Changes of Specific IgG</outcome_measure>
      <outcome_measure>Radiological findings</outcome_measure>
      <outcome_measure>Number of days ventilated</outcome_measure>
      <outcome_measure>Length of hospitalization</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Mazandaran University of Medical Sciences</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>30 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 28, 2020</start_date>
    <primary_completion_date>May 20, 2020</primary_completion_date>
    <completion_date>September 30, 2020</completion_date>
    <study_first_posted>March 31, 2020</study_first_posted>
    <last_update_posted>March 31, 2020</last_update_posted>
    <locations>
      <location>Imam Khomeini Hospital, Mazandaran University of Medical Sciences, Sari, Mazandaran, Iran, Islamic Republic of</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04327349</url>
  </study>
  <study rank="670">
    <nct_id>NCT04311697</nct_id>
    <title>Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress</title>
    <acronym>COVID-AIV</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Acute Respiratory Distress Syndrome</condition>
      <condition>Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)</condition>
      <condition>Corona Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Aviptadil by intravenous infusion + maximal intensive care</intervention>
      <intervention type="Drug">Normal Saline Infusion + Maximal intensive care</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>PaO2:FiO2 ratio</outcome_measure>
      <outcome_measure>TNF alpha</outcome_measure>
      <outcome_measure>Multi-system organ failure free days</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>NeuroRx, Inc.</lead_sponsor>
      <collaborator>Relief Therapeutics Holding SA</collaborator>
      <collaborator>Target Health Inc.</collaborator>
      <collaborator>Lavin Consulting, LLC</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>100 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>August 2020</primary_completion_date>
    <completion_date>September 2020</completion_date>
    <study_first_posted>March 17, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Miller School of Medicine / University of Miami Medical Center, Miami, Florida, United States</location>
      <location>Robert I Grossman School of Medicine / NYU Langone Medical Center, New York, New York, United States</location>
      <location>Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States</location>
      <location>Rambam Health Care Campus, Haifa, Israel</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04311697</url>
  </study>
  <study rank="671">
    <nct_id>NCT04357730</nct_id>
    <title>STudy of Alteplase for Respiratory Failure in SARS-Cov2 (COVID-19)</title>
    <acronym>STARS</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Severe Acute Respiratory Syndrome</condition>
      <condition>Respiratory Failure</condition>
      <condition>Acute Respiratory Distress Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Alteplase 50 MG [Activase]</intervention>
      <intervention type="Drug">Alteplase 100 MG [Activase]</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>PaO2/FiO2 improvement from pre-to-post intervention</outcome_measure>
      <outcome_measure>Achievement of PaO2/FiO2 ≥ 200 or 50% increase in PaO2/FiO2</outcome_measure>
      <outcome_measure>48 hour in-hospital mortality</outcome_measure>
      <outcome_measure>14 days in-hospital mortality</outcome_measure>
      <outcome_measure>28 days in-hospital mortality</outcome_measure>
      <outcome_measure>ICU-free days</outcome_measure>
      <outcome_measure>In-hospital coagulation-related event-free (arterial and venous) days</outcome_measure>
      <outcome_measure>Ventilator-free days</outcome_measure>
      <outcome_measure>Successful extubation</outcome_measure>
      <outcome_measure>Successful weaning from paralysis</outcome_measure>
      <outcome_measure>Survival to discharge</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Denver Health and Hospital Authority</lead_sponsor>
      <collaborator>Genentech, Inc., University of Colorado Denver, National Jewish, Beth Israel Deaconess Medical Center, and Long Island Jewish Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>August 2020</primary_completion_date>
    <completion_date>October 2020</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04357730</url>
  </study>
  <study rank="672">
    <nct_id>NCT04328129</nct_id>
    <title>Household Transmission Investigation Study for COVID-19 in French Guiana</title>
    <acronym>EPI-COVID-19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infections</condition>
      <condition>Severe Acute Respiratory Syndrome</condition>
      <condition>SARS-CoV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Human biological samples</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Evaluation of the extent of the virus transmission within households</outcome_measure>
      <outcome_measure>Characterization of the secondary cases</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Institut Pasteur</lead_sponsor>
      <collaborator>Institut Pasteur de la Guyane</collaborator>
      <collaborator>Centre Hospitalier Andrée Rosemon de Cayenne</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>450</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <start_date>March 23, 2020</start_date>
    <primary_completion_date>March 23, 2022</primary_completion_date>
    <completion_date>March 23, 2022</completion_date>
    <study_first_posted>March 31, 2020</study_first_posted>
    <last_update_posted>April 16, 2020</last_update_posted>
    <locations>
      <location>Centre Hospitalier Andrée Rosemon, Cayenne, French Guiana</location>
      <location>Institut Pasteur de la Guyane, Cayenne, French Guiana</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04328129</url>
  </study>
  <study rank="673">
    <nct_id>NCT04263402</nct_id>
    <title>The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>2019-nCoV Severe Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Methylprednisolone</intervention>
      <intervention type="Drug">Methylprednisolone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Rate of disease remission</outcome_measure>
      <outcome_measure>Rate and time of entering the critical stage</outcome_measure>
      <outcome_measure>Rate of normal tempreture</outcome_measure>
      <outcome_measure>Rate of respiratory symptom remission</outcome_measure>
      <outcome_measure>Rate of lung imaging recovery</outcome_measure>
      <outcome_measure>Rate of laboratory indicator recovery</outcome_measure>
      <outcome_measure>Rate of undetectable viral RNA</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tongji Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>February 1, 2020</start_date>
    <primary_completion_date>June 1, 2020</primary_completion_date>
    <completion_date>July 1, 2020</completion_date>
    <study_first_posted>February 10, 2020</study_first_posted>
    <last_update_posted>March 17, 2020</last_update_posted>
    <locations>
      <location>Department and Institute of Infectious Disease, Wuhan, Hubei, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04263402</url>
  </study>
  <study rank="674">
    <nct_id>NCT04343261</nct_id>
    <title>Convalescent Plasma in the Treatment of COVID 19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV-2</condition>
      <condition>COVID</condition>
      <condition>Coronavirus</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Convalescent Plasma</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>Viral Load</outcome_measure>
      <outcome_measure>Serum Antibody Titers</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Saint Francis Care</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 10, 2020</start_date>
    <primary_completion_date>December 1, 2020</primary_completion_date>
    <completion_date>April 1, 2021</completion_date>
    <study_first_posted>April 13, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>Trinity Health Of New England, Hartford, Connecticut, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04343261</url>
  </study>
  <study rank="675">
    <nct_id>NCT04360096</nct_id>
    <title>Inhaled Aviptadil for the Treatment of Non-Acute Lung Injury in COVID-19</title>
    <acronym>AVINALI</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV 2</condition>
      <condition>COVID</condition>
      <condition>ARDS</condition>
      <condition>ALI</condition>
      <condition>Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)</condition>
      <condition>Dyspnea</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Aviptadil (VIP)</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Progression to ARDS</outcome_measure>
      <outcome_measure>Blood oxygenation</outcome_measure>
      <outcome_measure>RDP Dsypnea Scale</outcome_measure>
      <outcome_measure>Distance walked in six minutes</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>NeuroRx, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>144</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>June 1, 2020</start_date>
    <primary_completion_date>August 1, 2020</primary_completion_date>
    <completion_date>October 1, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04360096</url>
  </study>
  <study rank="676">
    <nct_id>NCT04359810</nct_id>
    <title>Plasma Therapy of COVID-19 in Critically Ill Patients</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Convalescent Plasma (anti-SARS-CoV-2 plasma)</intervention>
      <intervention type="Biological">Non-convalescent Plasma (control plasma)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to Improvement</outcome_measure>
      <outcome_measure>Rate of SARS-CoV-2 PCR Positivity</outcome_measure>
      <outcome_measure>Duration of SARS-CoV-2 PCR Positivity</outcome_measure>
      <outcome_measure>Duration of Need for Supplemental Oxygen</outcome_measure>
      <outcome_measure>Duration of Hospitalization</outcome_measure>
      <outcome_measure>In-hospital 28-day Mortality Rate</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Max R. O'Donnell</lead_sponsor>
      <collaborator>New York Blood Center</collaborator>
      <collaborator>Columbia University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>105</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>December 2020</primary_completion_date>
    <completion_date>April 2021</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Columbia University Irving Medical Center/NYP, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04359810</url>
  </study>
  <study rank="677">
    <nct_id>NCT04341480</nct_id>
    <title>The Safety of Chemotherapy for Patients With Gynecological Malignancy in High-risk Region of COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Gynecological Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Chemotherapy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>SARS-CoV-2 infection</outcome_measure>
      <outcome_measure>Tumor response</outcome_measure>
      <outcome_measure>Safety and tolerability</outcome_measure>
      <outcome_measure>Patient-reported outcomes</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tongji Hospital</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>207</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 10, 2020</start_date>
    <primary_completion_date>July 10, 2020</primary_completion_date>
    <completion_date>July 10, 2020</completion_date>
    <study_first_posted>April 10, 2020</study_first_posted>
    <last_update_posted>April 10, 2020</last_update_posted>
    <locations>
      <location>Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04341480</url>
  </study>
  <study rank="678">
    <nct_id>NCT04340349</nct_id>
    <title>Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals</title>
    <acronym>HCQINRLGII</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hydroxychloroquine</condition>
      <condition>Antimalarials</condition>
      <condition>Enzyme Inhibitors</condition>
      <condition>Antirheumatic Agents</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine Sulfate</intervention>
      <intervention type="Drug">Bromhexine 8 MG</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Polymerase chain reaction assay (PCR) negative at day 0 plus negative serological panel for COVID-19 antibodies at enrolment.</outcome_measure>
      <outcome_measure>Polymerase chain reaction assay (PCR) negative at day 30.</outcome_measure>
      <outcome_measure>Polymerase chain reaction assay (PCR) negative at day 60.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Instituto Nacional de Rehabilitacion</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Early Phase 1</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 10, 2020</start_date>
    <primary_completion_date>June 9, 2020</primary_completion_date>
    <completion_date>July 10, 2020</completion_date>
    <study_first_posted>April 9, 2020</study_first_posted>
    <last_update_posted>April 9, 2020</last_update_posted>
    <locations>
      <location>National Institute of Rehabilitation, Mexico City, Cdmx, Mexico</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04340349</url>
  </study>
  <study rank="679">
    <nct_id>NCT04252274</nct_id>
    <title>Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19</title>
    <acronym>DC-COVID-19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pneumonia, Pneumocystis</condition>
      <condition>Coronavirus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Darunavir and Cobicistat</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7</outcome_measure>
      <outcome_measure>The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3</outcome_measure>
      <outcome_measure>The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5</outcome_measure>
      <outcome_measure>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0</outcome_measure>
      <outcome_measure>The critical illness rate of subjects at weeks 2</outcome_measure>
      <outcome_measure>The mortality rate of subjects at weeks 2</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Shanghai Public Health Clinical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>January 30, 2020</start_date>
    <primary_completion_date>August 31, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>February 5, 2020</study_first_posted>
    <last_update_posted>April 13, 2020</last_update_posted>
    <locations>
      <location>Shanghai Public Health Clinical Center, Shanghai, Shanghai, China</location>
      <location>Shanghai Public Health Clinical Center, Shanghai, Shanghai, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04252274</url>
  </study>
  <study rank="680">
    <nct_id>NCT03042143</nct_id>
    <title>Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST) (COVID-19)</title>
    <acronym>REALIST</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Acute Respiratory Distress Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Human umbilical cord derived CD362 enriched MSCs</intervention>
      <intervention type="Biological">Placebo (Plasma-Lyte 148)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Oxygenation index (OI)</outcome_measure>
      <outcome_measure>Incidence of Serious Adverse Events (SAEs)</outcome_measure>
      <outcome_measure>Oxygenation index</outcome_measure>
      <outcome_measure>Sequential Organ Failure Assessment (SOFA) score</outcome_measure>
      <outcome_measure>Respiratory compliance (Crs)</outcome_measure>
      <outcome_measure>Partial pressure of arterial oxygen to the fraction of inspired oxygen ratio (P/F ratio)</outcome_measure>
      <outcome_measure>Driving Pressure</outcome_measure>
      <outcome_measure>Extubation and reintubation</outcome_measure>
      <outcome_measure>Ventilation free days at day 28</outcome_measure>
      <outcome_measure>Length of ICU and hospital stay</outcome_measure>
      <outcome_measure>28-day and 90-day mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Belfast Health and Social Care Trust</lead_sponsor>
      <collaborator>Queen's University, Belfast</collaborator>
      <collaborator>Northern Ireland Clinical Trials Unit</collaborator>
      <collaborator>NHS Blood and Transplant</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>16 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>75</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>January 7, 2019</start_date>
    <primary_completion_date>September 2020</primary_completion_date>
    <completion_date>October 2022</completion_date>
    <study_first_posted>February 3, 2017</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>Belfast Health and Social Care Trust, Royal Hospitals, Belfast, Northern Ireland, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03042143</url>
  </study>
  <study rank="681">
    <nct_id>NCT04256395</nct_id>
    <title>Efficacy of a Self-test and Self-alert Mobile Applet in Detecting Susceptible Infection of COVID-19</title>
    <acronym>COVID-19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Susceptibility to Viral and Mycobacterial Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Other">mobile internet survey on self-test</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>positive number diagnosed by national guideline in the evaluated population</outcome_measure>
      <outcome_measure>distribution map of evaluated people</outcome_measure>
      <outcome_measure>Effect of medical guidance by designated feedback questionnaire</outcome_measure>
      <outcome_measure>mental scale of relief the mental anxiety and avoid unnecessary outpatient</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Beijing Tsinghua Chang Gung Hospital</lead_sponsor>
      <collaborator>Institute for precision medicine of Tsinghua University</collaborator>
      <collaborator>Institute for artificial intelligent of Tsinghua University</collaborator>
      <collaborator>Chinese Medical Doctor Association</collaborator>
      <collaborator>Institute for network behavior of Tsinghua University</collaborator>
      <collaborator>school of clinical medicine of Tsinghua University</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>300000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>February 1, 2020</start_date>
    <primary_completion_date>July 31, 2020</primary_completion_date>
    <completion_date>July 31, 2020</completion_date>
    <study_first_posted>February 5, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Beijing Tsinghua Changgung Hospital, Beijing, Beijing, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04256395</url>
  </study>
  <study rank="682">
    <nct_id>NCT04325919</nct_id>
    <title>Coronavirus Disease 2019 (COVID-19) Study of Hospitalized Patients in Hong Kong</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Other">No intervention</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clinical</outcome_measure>
      <outcome_measure>Virological</outcome_measure>
      <outcome_measure>Microbiological</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Chinese University of Hong Kong</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>170</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>February 24, 2020</start_date>
    <primary_completion_date>February 28, 2021</primary_completion_date>
    <completion_date>June 17, 2021</completion_date>
    <study_first_posted>March 30, 2020</study_first_posted>
    <last_update_posted>March 30, 2020</last_update_posted>
    <locations>
      <location>Prince of Wales Hospital, Sha Tin, Hong Kong</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04325919</url>
  </study>
  <study rank="683">
    <nct_id>NCT04345159</nct_id>
    <title>Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease</title>
    <acronym>COVCALL</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV-2</condition>
      <condition>Systemic Lupus Erythematosus</condition>
      <condition>Rheumatoid Arthritis</condition>
      <condition>Sjogren's Syndrome</condition>
      <condition>Psoriatic Arthritis</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Questionnaire by phone call</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Adjusted Odds Ratio</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Fondation Ophtalmologique Adolphe de Rothschild</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>October 2020</primary_completion_date>
    <completion_date>October 2020</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>Fondation Adolphe de Rothschild, Paris, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04345159</url>
  </study>
  <study rank="684">
    <nct_id>NCT02735707</nct_id>
    <title>Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia</title>
    <acronym>REMAP-CAP</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Community-acquired Pneumonia, Influenza, COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Fixed-duration Hydrocortisone</intervention>
      <intervention type="Drug">Shock-dependent hydrocortisone</intervention>
      <intervention type="Drug">Ceftriaxone</intervention>
      <intervention type="Drug">Moxifloxacin or Levofloxacin</intervention>
      <intervention type="Drug">Piperacillin-tazobactam</intervention>
      <intervention type="Drug">Ceftaroline</intervention>
      <intervention type="Drug">Amoxicillin-clavulanate</intervention>
      <intervention type="Drug">Macrolide administered for 3-5 days</intervention>
      <intervention type="Drug">Macrolide administered for up to 14 days</intervention>
      <intervention type="Drug">Five-days oseltamivir</intervention>
      <intervention type="Drug">Ten-days oseltamivir</intervention>
      <intervention type="Drug">Lopinavir/ritonavir</intervention>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Drug">Hydroxychloroquine + lopinavir/ritonavir</intervention>
      <intervention type="Drug">Interferon-β1a</intervention>
      <intervention type="Drug">Anakinra</intervention>
      <intervention type="Drug">Fixed-duration higher dose Hydrocortisone</intervention>
      <intervention type="Drug">Tocilizumab</intervention>
      <intervention type="Drug">Sarilumab</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>All-cause mortality</outcome_measure>
      <outcome_measure>Days alive and outside of ICU</outcome_measure>
      <outcome_measure>ICU Mortality</outcome_measure>
      <outcome_measure>ICU length of stay</outcome_measure>
      <outcome_measure>Hospital length of stay</outcome_measure>
      <outcome_measure>Ventilator free days</outcome_measure>
      <outcome_measure>Organ failure free days</outcome_measure>
      <outcome_measure>Health-related Quality of life assessment</outcome_measure>
      <outcome_measure>Proportion of intubated patients who receive a tracheostomy</outcome_measure>
      <outcome_measure>Destination at time of hospital discharge</outcome_measure>
      <outcome_measure>Readmission to the index ICU during the index hospitalization</outcome_measure>
      <outcome_measure>World Health Organisation 8-point ordinal scale outcome</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>MJM Bonten</lead_sponsor>
      <collaborator>Australian and New Zealand Intensive Care Research Centre</collaborator>
      <collaborator>Medical Research Institute of New Zealand</collaborator>
      <collaborator>Unity Health</collaborator>
      <collaborator>Berry Consultants</collaborator>
      <collaborator>Global Coalition for Adaptive Research</collaborator>
      <collaborator>University of Pittsburgh Medical Center</collaborator>
      <collaborator>UMC Utrecht</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>7100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 11, 2016</start_date>
    <primary_completion_date>December 2021</primary_completion_date>
    <completion_date>December 2023</completion_date>
    <study_first_posted>April 13, 2016</study_first_posted>
    <last_update_posted>April 16, 2020</last_update_posted>
    <locations>
      <location>St Vincent's Hospital Sydney, Sydney, New South Wales, Australia</location>
      <location>Royal Prince Alfred Hospital, Sydney, New South Wales, Australia</location>
      <location>Royal North Shore Hospital, Sydney, New South Wales, Australia</location>
      <location>Nepean Hospital, Sydney, New South Wales, Australia</location>
      <location>Wollongong Hospital, Sydney, New South Wales, Australia</location>
      <location>Royal Darwin Hospital,, Darwin, Northern Territory, Australia</location>
      <location>Sunshine Coast University Hospital, Birtinya, Queensland, Australia</location>
      <location>Princess Alexandra Hospital, Brisbane, Queensland, Australia</location>
      <location>Logan Hospital, Brisbane, Queensland, Australia</location>
      <location>Toowoomba Hospital, Toowoomba, Queensland, Australia</location>
      <location>The Queen Elizabeth Hospital, Adelaide, South Australia, Australia</location>
      <location>Bendigo Hospital, Bendigo, Victoria, Australia</location>
      <location>University Hosptial Geelong, Geelong, Victoria, Australia</location>
      <location>The Alfred Hospital, Melbourne, Victoria, Australia</location>
      <location>Royal Melbourne Hospital, Melbourne, Victoria, Australia</location>
      <location>St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia</location>
      <location>Royal Perth Hospital, Perth, Western Australia, Australia</location>
      <location>Sir Charles Gairdner Hospital, Perth, Western Australia, Australia</location>
      <location>St John of God Hospital Midland, Perth, Western Australia, Australia</location>
      <location>Fiona Stanley Hospital, Perth, Western Australia, Australia</location>
      <location>St John of God Hospital Murdoch, Perth, Western Australia, Australia</location>
      <location>AZ Sint-Jan, Brugge, Belgium</location>
      <location>CHU de Charleroi - Hôpital Civil Marie Curie, Charleroi, Belgium</location>
      <location>Universitair Ziekenhuis Antwerp, Edegem, Belgium</location>
      <location>Universitair Ziekenhuis Gent, Gent, Belgium</location>
      <location>St. Joseph's Healthcare Hamilton, Hamilton, Canada</location>
      <location>Centre Hospitalier de l'Université de Sherbrooke, Sherbrooke, Canada</location>
      <location>St. Michael's Hospital Unity Health Toronto, Toronto, Canada</location>
      <location>General County Hospital Požega, Požega, Croatia</location>
      <location>University Hospital Centre Zagreb, Zagreb, Croatia</location>
      <location>University Hospital for Infectious Diseases, Zagreb, Croatia</location>
      <location>Charité - Universitätsmedizin Berlin - Infektiologie und Pneumologie, Berlin, Germany</location>
      <location>Charité - Universitätsmedizin Berlin - Nephrologie, Berlin, Germany</location>
      <location>Vivantes Klinikum Neukölln, Berlin, Germany</location>
      <location>Universitätsklinikum Köln, Cologne, Germany</location>
      <location>Universitätsklinikum Frankfurt, Frankfurt, Germany</location>
      <location>University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany</location>
      <location>Medizinische Hochschule Hannover, Hannover, Germany</location>
      <location>Universitätsklinikum Jena, Jena, Germany</location>
      <location>Universitätsklinikum Leipzig, Leipzig, Germany</location>
      <location>Universitäts Klinikum Tübingen, Tübingen, Germany</location>
      <location>Universitätsklinikum Würzburg, Würzburg, Germany</location>
      <location>Jósa András County Hospital, Nyíregyháza, Hungary</location>
      <location>Csolnoky Ferenc Kórház - Veszprem County Hospital, Veszprém, Hungary</location>
      <location>Almási Balogh Pál Kórház, Ózd, Hungary</location>
      <location>Beaumont Hospital, Dublin, Ireland</location>
      <location>St. Vincent's University Hospital, Dublin, Ireland</location>
      <location>University Hospital Galway, Galway, Ireland</location>
      <location>Meander Medisch Centrum, Amersfoort, Netherlands</location>
      <location>Jeroen Bosch Ziekenhuis, Den Bosch, Netherlands</location>
      <location>Martini Hospital Groningen, Groningen, Netherlands</location>
      <location>University Medical Center Groningen, Groningen, Netherlands</location>
      <location>Leiden University Medical Center, Leiden, Netherlands</location>
      <location>Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands</location>
      <location>Radboud University Medical Center, Nijmegen, Netherlands</location>
      <location>University Medical Center Utrecht, Utrecht, Netherlands</location>
      <location>North Shore Hospital, Auckland, New Zealand</location>
      <location>CVICU, Auckland City Hospital, Auckland, New Zealand</location>
      <location>DCCM, Auckland City Hospital, Auckland, New Zealand</location>
      <location>Middlemore Hospital, Auckland, New Zealand</location>
      <location>Christchurch Hospital, Christchurch, New Zealand</location>
      <location>Waikato Hospital, Hamilton, New Zealand</location>
      <location>Rotorua Hospital, Rotorua, New Zealand</location>
      <location>Tauranga Hospital, Tauranga, New Zealand</location>
      <location>Wellington Regional Hospital, Wellington, New Zealand</location>
      <location>Whangarei Hospital, Whangarei, New Zealand</location>
      <location>Centro Hospitalar do Medio Tejo, Abrantes, Portugal</location>
      <location>Hospital Lusíadas Lisbon, Lisboa, Portugal</location>
      <location>Clinical Hospital of Infectious and Tropical Diseases &quot;Dr. Victor Babes&quot;, Bucharest, Romania</location>
      <location>Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain</location>
      <location>Hospital Universitario Reina Sofia, Córdoba, Spain</location>
      <location>Basingstoke and North Hampshire Hospital, Basingstoke, United Kingdom</location>
      <location>Southmead Hospital, Bristol, United Kingdom</location>
      <location>University Hospital Coventry, Coventry, United Kingdom</location>
      <location>Darlington Memorial Hospital, Darlington, United Kingdom</location>
      <location>University Hospital of North Durham, Durham, United Kingdom</location>
      <location>Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom</location>
      <location>Maidstone Hospital - Maidstone and Tunbridge Wells NHS Trust, Maidstone, United Kingdom</location>
      <location>The James Cook University Hospital, Middlesbrough, United Kingdom</location>
      <location>Milton Keynes University Hospital, Milton Keynes, United Kingdom</location>
      <location>Northampton General Hospital, Northampton, United Kingdom</location>
      <location>Queen's Medical Centre - Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom</location>
      <location>Poole Hospital NHS Foundation Trust, Poole, United Kingdom</location>
      <location>Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust, Portsmouth, United Kingdom</location>
      <location>Royal Berkshire Hospital, Reading, United Kingdom</location>
      <location>University Hospital of North Tees, Stockton-on-Tees, United Kingdom</location>
      <location>Royal Cornwall Hospital, Truro, United Kingdom</location>
      <location>Tunbridge Wells Hospital - Maidstone and Tunbridge Wells NHS Trust, Tunbridge Wells, United Kingdom</location>
      <location>York Hospital, York, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT02735707</url>
  </study>
  <study rank="685">
    <nct_id>NCT04324866</nct_id>
    <title>Prevalence and Incidence of COVID-19 Infection in Patients With Chronic Plaque Psoriasis on Immunosuppressant Therapy</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Nasopharyngeal swab</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Point prevalence of COVID-19 infection</outcome_measure>
      <outcome_measure>Incidence of COVID-19 infection</outcome_measure>
      <outcome_measure>Percentage of subjects presenting fever or respiratory symptoms</outcome_measure>
      <outcome_measure>Evaluate the relationship between COVID-19 infection and chronic pharmacological treatments</outcome_measure>
      <outcome_measure>Evaluate the relationship between COVID-19 infection and comorbid medical conditions</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Universita di Verona</lead_sponsor>
      <collaborator>Azienda Ospedaliera Universitaria Integrata Verona</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>November 2020</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>March 27, 2020</study_first_posted>
    <last_update_posted>March 27, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04324866</url>
  </study>
  <study rank="686">
    <nct_id>NCT04305457</nct_id>
    <title>Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19</title>
    <acronym>NoCovid</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infections</condition>
      <condition>Pneumonia, Viral</condition>
      <condition>Acute Respiratory Distress Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nitric Oxide</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Reduction in the incidence of patients with mild/moderate COVID-19 requiring intubation and mechanical ventilation</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>Time to clinical recovery</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Massachusetts General Hospital</lead_sponsor>
      <collaborator>Xijing Hospital</collaborator>
      <collaborator>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>240</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 21, 2020</start_date>
    <primary_completion_date>April 1, 2021</primary_completion_date>
    <completion_date>April 1, 2022</completion_date>
    <study_first_posted>March 12, 2020</study_first_posted>
    <last_update_posted>April 9, 2020</last_update_posted>
    <locations>
      <location>Massachusetts General Hospital, Boston, Massachusetts, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04305457</url>
  </study>
  <study rank="687">
    <nct_id>NCT04333368</nct_id>
    <title>Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS</title>
    <acronym>STROMA-CoV2</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Severe Acute Respiratory Syndrome Coronavirus 2</condition>
      <condition>Severe Acute Respiratory Distress Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Umbilical cord Wharton's jelly-derived human</intervention>
      <intervention type="Other">NaCl 0.9%</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Respiratory efficacy evaluated by the increase in PaO2/FiO2 ratio from baseline to day 7 in the experimental group compared with the placebo group</outcome_measure>
      <outcome_measure>Lung injury score</outcome_measure>
      <outcome_measure>Oxygenation index</outcome_measure>
      <outcome_measure>In-hospital mortality</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>Ventilator-free days</outcome_measure>
      <outcome_measure>Number of days between randomization and the first day the patient meets weaning criteria o Number of days between randomization and the first day the patient meets PaO2/FiO2 &gt; 200 (out of a prone positioning session)</outcome_measure>
      <outcome_measure>Cumulative use of sedatives</outcome_measure>
      <outcome_measure>Cumulative duration of use of sedatives</outcome_measure>
      <outcome_measure>Cumulative duration of use of neuromuscular blocking agents (other than used for intubation)</outcome_measure>
      <outcome_measure>Cumulative use of neuromuscular blocking agents (other than used for intubation)</outcome_measure>
      <outcome_measure>ICU-acquired weakness and delirium</outcome_measure>
      <outcome_measure>Treatment-induced toxicity rate and adverse events up to day 28</outcome_measure>
      <outcome_measure>Quality of life at one year (EQ5D-3L quality of life questionnaire)</outcome_measure>
      <outcome_measure>Measurements of plasmatic cytokines (IL1, IL6, IL8, TNF-alpha, IL10, TGF-beta, sRAGE, Ang2) level</outcome_measure>
      <outcome_measure>Anti-HLA antibodies plasmatic dosage</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 6, 2020</start_date>
    <primary_completion_date>August 31, 2020</primary_completion_date>
    <completion_date>July 31, 2021</completion_date>
    <study_first_posted>April 3, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>Hôpital Pitié-Salpêtrière - APHP, Paris, France</location>
      <location>Hôpital Européen Georges Pompidou - APHP, Paris, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04333368</url>
  </study>
  <study rank="688">
    <nct_id>NCT04327570</nct_id>
    <title>In-depth Immunological Investigation of COVID-19.</title>
    <acronym>COntAGIouS</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Patient sampling</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clinical Features</outcome_measure>
      <outcome_measure>Immune host response at systemic level</outcome_measure>
      <outcome_measure>Immune host response at local level</outcome_measure>
      <outcome_measure>Host genetic variation</outcome_measure>
      <outcome_measure>Comparison severe and non-severe COVID-19 hospitalised patients</outcome_measure>
      <outcome_measure>Correlation of findings with outcome</outcome_measure>
      <outcome_measure>Correlation of immune profiling - microbiome</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Universitaire Ziekenhuizen Leuven</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 27, 2020</start_date>
    <primary_completion_date>September 30, 2020</primary_completion_date>
    <completion_date>September 30, 2020</completion_date>
    <study_first_posted>March 31, 2020</study_first_posted>
    <last_update_posted>March 31, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04327570</url>
  </study>
  <study rank="689">
    <nct_id>NCT04320277</nct_id>
    <title>Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study.</title>
    <acronym>BARI-COVID</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pharmacological Action</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Baricitinib</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The percentage of patients requiring transfer to ICU as compared with the rate of transfers observed in controls.</outcome_measure>
      <outcome_measure>The percentage of patients achieving the remission; CRP, IL-6 and TNFα values at baseline and during the treatment course; the number of AEs.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hospital of Prato</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 16, 2020</start_date>
    <primary_completion_date>June 30, 2020</primary_completion_date>
    <completion_date>July 30, 2020</completion_date>
    <study_first_posted>March 24, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Fabrizio Cantini, Prato, Tuscany, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04320277</url>
  </study>
  <study rank="690">
    <nct_id>NCT04348695</nct_id>
    <title>Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.</title>
    <acronym>Ruxo-Sim-20</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ruxolitinib plus simvastatin</intervention>
      <intervention type="Other">Standard of Care</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Percentage of patients who develop severe respiratory failure.</outcome_measure>
      <outcome_measure>Length of ICU stay.</outcome_measure>
      <outcome_measure>Length of hospital stay</outcome_measure>
      <outcome_measure>Survival rate at 6 months</outcome_measure>
      <outcome_measure>Survival rate at 12 months</outcome_measure>
      <outcome_measure>Survival rate at 28 days</outcome_measure>
      <outcome_measure>Percentage of patients with each AE by grade</outcome_measure>
      <outcome_measure>Percentage of patients who discontinued due to AEs</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Fundación de investigación HM</lead_sponsor>
      <collaborator>Apices Soluciones S.L.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>94</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 12, 2020</start_date>
    <primary_completion_date>May 13, 2020</primary_completion_date>
    <completion_date>May 13, 2020</completion_date>
    <study_first_posted>April 16, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations>
      <location>Hospital Universitario Madrid Sanchinarro, Madrid, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04348695</url>
  </study>
  <study rank="691">
    <nct_id>NCT04354259</nct_id>
    <title>Interferon Lambda for Immediate Antiviral Therapy at Diagnosis</title>
    <acronym>ILIAD</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sars-CoV2</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Peginterferon Lambda-1A</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Cohort A (Ambulatory) - Primary Efficacy Endpoint</outcome_measure>
      <outcome_measure>Cohort A (Ambulatory) - Primary Safety Endpoint</outcome_measure>
      <outcome_measure>Cohort B (Hospitalized) - Primary Efficacy Endpoint</outcome_measure>
      <outcome_measure>Cohort B (Hospitalized) - Primary Safety Endpoint</outcome_measure>
      <outcome_measure>Cohort A (Ambulatory) - Clinical Outcome #1</outcome_measure>
      <outcome_measure>Cohort A (Ambulatory) - Clinical Outcome #2</outcome_measure>
      <outcome_measure>Cohort A (Ambulatory) - Clinical Outcome #3</outcome_measure>
      <outcome_measure>Cohort A (Ambulatory) - Clinical Outcome #4</outcome_measure>
      <outcome_measure>Cohort A (Ambulatory) - Clinical Outcome #5</outcome_measure>
      <outcome_measure>Cohort A (Ambulatory) - Clinical Outcome #6</outcome_measure>
      <outcome_measure>Cohort A (Ambulatory) - Clinical Outcome #7</outcome_measure>
      <outcome_measure>Cohort A (Ambulatory) - Virologic/Immunological Outcome #1</outcome_measure>
      <outcome_measure>Cohort A (Ambulatory) - Virologic/Immunological Outcome #2</outcome_measure>
      <outcome_measure>Cohort A (Ambulatory) - Virologic/Immunological Outcome #3</outcome_measure>
      <outcome_measure>Cohort A (Ambulatory) - Virologic/Immunological Outcome #4</outcome_measure>
      <outcome_measure>Cohort A (Ambulatory) - Virologic/Immunological Outcome #5</outcome_measure>
      <outcome_measure>Cohort A (Ambulatory) - Virologic/Immunological Outcome #6</outcome_measure>
      <outcome_measure>Cohort A (Ambulatory) - Transmission Outcome #1</outcome_measure>
      <outcome_measure>Cohort A (Ambulatory) - Transmission Outcome #2</outcome_measure>
      <outcome_measure>Cohort B (Hospitalized) - Clinical Outcome #1</outcome_measure>
      <outcome_measure>Cohort B (Hospitalized) - Clinical Outcome #2</outcome_measure>
      <outcome_measure>Cohort B (Hospitalized) - Clinical Outcome #3</outcome_measure>
      <outcome_measure>Cohort B (Hospitalized) - Clinical Outcome #4</outcome_measure>
      <outcome_measure>Cohort B (Hospitalized) - Clinical Outcome #5</outcome_measure>
      <outcome_measure>Cohort B (Hospitalized) - Clinical Outcome #6</outcome_measure>
      <outcome_measure>Cohort B (Hospitalized) - Clinical Outcome #7</outcome_measure>
      <outcome_measure>Cohort B (Hospitalized) - Clinical Outcome #8</outcome_measure>
      <outcome_measure>Cohort B (Hospitalized) - Clinical Outcome #9</outcome_measure>
      <outcome_measure>Cohort B (Hospitalized) - Clinical Outcome #10</outcome_measure>
      <outcome_measure>Cohort B (Hospitalized) - Clinical Outcome #11</outcome_measure>
      <outcome_measure>Cohort B (Hospitalized) - Virologic/Immunological Outcome #1</outcome_measure>
      <outcome_measure>Cohort B (Hospitalized) - Virologic/Immunological Outcome #2</outcome_measure>
      <outcome_measure>Cohort B (Hospitalized) - Virologic/Immunological Outcome #3</outcome_measure>
      <outcome_measure>Cohort B (Hospitalized) - Virologic/Immunological Outcome #4</outcome_measure>
      <outcome_measure>Cohort B (Hospitalized) - Virologic/Immunological Outcome #5</outcome_measure>
      <outcome_measure>Cohort B (Hospitalized) - Virologic/Immunological Outcome #6</outcome_measure>
      <outcome_measure>Cohort B (Hospitalized) - Virologic/Immunological Outcome #7</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Health Network, Toronto</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>140</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 21, 2020</start_date>
    <primary_completion_date>August 1, 2020</primary_completion_date>
    <completion_date>November 30, 2020</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>Toronto General Hospital, Toronto, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04354259</url>
  </study>
  <study rank="692">
    <nct_id>NCT04339322</nct_id>
    <title>Characteristics and Outcome of Coronavirus Disease 2019 (COVID-19) in Egypt</title>
    <acronym>COVID-19</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Characteristics Diseases</condition>
      <condition>Outcome, Fatal</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Follow up</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Demographics of Coronavirus Disease 2019 (COVID-19) in the cohort group</outcome_measure>
      <outcome_measure>Clinical manifestations of Coronavirus Disease 2019 (COVID-19)</outcome_measure>
      <outcome_measure>Laboratory data of included Coronavirus Disease 2019 (COVID-19) cohort</outcome_measure>
      <outcome_measure>Radiological features of Coronavirus Disease 2019 (COVID-19) cohort</outcome_measure>
      <outcome_measure>outcomes of Coronavirus Disease 2019 (COVID-19) infection in the cohort group</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assiut University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>May 1, 2020</start_date>
    <primary_completion_date>July 30, 2020</primary_completion_date>
    <completion_date>July 30, 2020</completion_date>
    <study_first_posted>April 9, 2020</study_first_posted>
    <last_update_posted>April 9, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04339322</url>
  </study>
  <study rank="693">
    <nct_id>NCT04352634</nct_id>
    <title>The Covid-19 HEalth caRe wOrkErS (HEROES) Study</title>
    <acronym>HEROES</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid-19</condition>
      <condition>Mental Health Disorder</condition>
      <condition>Stress Disorder</condition>
      <condition>Anxiety</condition>
      <condition>Depression</condition>
      <condition>SARS-CoV-2</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Exposure to the SARS-CoV-2 and its consequences</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Anxiety and depressive symptoms</outcome_measure>
      <outcome_measure>Experiences, fears and concerns about the Covid-19</outcome_measure>
      <outcome_measure>Training and resource prioritization</outcome_measure>
      <outcome_measure>Suicide ideation (presence)</outcome_measure>
      <outcome_measure>Suicide ideation (frequency)</outcome_measure>
      <outcome_measure>Acute stress symptoms</outcome_measure>
      <outcome_measure>Psycho/social support and network</outcome_measure>
      <outcome_measure>Resilience</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Chile</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>2000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>April 14, 2021</primary_completion_date>
    <completion_date>April 14, 2021</completion_date>
    <study_first_posted>April 20, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations>
      <location>Columbia University, New York, New York, United States</location>
      <location>University of Chile, Santiago, Chile</location>
      <location>University of Cagliari, Cagliari, Italy</location>
      <location>Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04352634</url>
  </study>
  <study rank="694">
    <nct_id>NCT04325867</nct_id>
    <title>Integrated Distance Management Strategy for Patients With Cardiovascular Diseases in the Context of COVID-19</title>
    <acronym>eCardioCovid19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Angina Pectoris</condition>
      <condition>Acute Coronary Syndrome</condition>
      <condition>Coronary Syndrome</condition>
      <condition>Coronary Artery Disease</condition>
      <condition>Angioplasty</condition>
      <condition>Stent Restenosis</condition>
      <condition>Hypertension</condition>
      <condition>Heart Failure, Systolic</condition>
      <condition>Depression, Anxiety</condition>
      <condition>Covid-19</condition>
      <condition>Isolation, Social</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Tele-medicine platform</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Providing a special electronic platform (e-health) for remote managing cardiovascular outpatients</outcome_measure>
      <outcome_measure>Number of patients included in this platform</outcome_measure>
      <outcome_measure>Number of consultations/sessions given</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Professor Adrian Covic</lead_sponsor>
      <collaborator>Medical Sciences Academy - Romania</collaborator>
      <collaborator>Victor Babes Clinical Hospital of Infectious Diseases - Bucharest</collaborator>
      <collaborator>Grigore T. Popa University of Medicine and Pharmacy</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Health Services Research</study_design>
    </study_designs>
    <start_date>March 31, 2020</start_date>
    <primary_completion_date>October 1, 2020</primary_completion_date>
    <completion_date>October 1, 2020</completion_date>
    <study_first_posted>March 30, 2020</study_first_posted>
    <last_update_posted>April 1, 2020</last_update_posted>
    <locations>
      <location>Medical Sciences Academy, Bucharest, Romania</location>
      <location>University of Medicine and Pharmacy Gr T Popa, Iasi, Romania</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04325867</url>
  </study>
  <study rank="695">
    <nct_id>NCT04347382</nct_id>
    <title>Efficacy of Nigella Sativa and Natural Honey Against COVID-19</title>
    <acronym>WUHAN</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infection</condition>
      <condition>Sars-CoV2</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Honey</intervention>
      <intervention type="Drug">Nigella Sativa / Black Cumin</intervention>
      <intervention type="Drug">Placebos</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Days required to get a positive COVID-19 PCR to negative</outcome_measure>
      <outcome_measure>HRCT/ X-ray findings of disease progression</outcome_measure>
      <outcome_measure>Severity of symptoms progression</outcome_measure>
      <outcome_measure>Duration of Hospital Saty</outcome_measure>
      <outcome_measure>30 day mortality</outcome_measure>
      <outcome_measure>Oxygen Saturation at room air</outcome_measure>
      <outcome_measure>Incidence of viral myocarditis</outcome_measure>
      <outcome_measure>Incidence of Acute respiratory Distress Syndrome</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sohaib Ashraf</lead_sponsor>
      <collaborator>Sheikh Zayed Federal Postgraduate Medical Institute</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>5 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>May 25, 2020</primary_completion_date>
    <completion_date>May 30, 2020</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>Mayo Hospital, Kingedward Medical University, Lahore, Punjab, Pakistan</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04347382</url>
  </study>
  <study rank="696">
    <nct_id>NCT04342156</nct_id>
    <title>Safety And Efficacy Of Hydroxychloroquine For At Risk Population (SHARP) Against COVID-19</title>
    <acronym>SHARP COVID-19</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infection</condition>
      <condition>Hydroxychloroquine Adverse Reaction</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine Sulfate 200 milligram (mg) Tab</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>positive serology or reverse transcriptase (RT-PCR) for COVID-19 up until day 28.</outcome_measure>
      <outcome_measure>Positive serology at day 28.</outcome_measure>
      <outcome_measure>Symptoms of COVID-19.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tan Tock Seng Hospital</lead_sponsor>
      <collaborator>National Center for Infectious Diseases</collaborator>
      <collaborator>Singapore Clinical Research Institute</collaborator>
      <collaborator>Singapore Eye Research Institute</collaborator>
      <collaborator>Saw Swee Hock School of Public Health</collaborator>
      <collaborator>Duke-NUS Graduate Medical School</collaborator>
      <collaborator>Netherlands: Ministry of Health, Welfare and Sports</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>August 2020</primary_completion_date>
    <completion_date>October 2020</completion_date>
    <study_first_posted>April 10, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04342156</url>
  </study>
  <study rank="697">
    <nct_id>NCT04358081</nct_id>
    <title>Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">HCQ</intervention>
      <intervention type="Drug">HCQ+AZT</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Percentage of participants who achieve clinical response</outcome_measure>
      <outcome_measure>Percentage of Participants with Viral Clearance</outcome_measure>
      <outcome_measure>Number of participants receiving hydroxychloroquine or hydroxychloroquine and azithromycin with adverse events of hydroxychloroquin or hydroxychloroquine and azithromycin compared to placebo</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Novartis Pharmaceuticals</lead_sponsor>
      <collaborator>Novartis</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>444</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 30, 2020</start_date>
    <primary_completion_date>July 21, 2020</primary_completion_date>
    <completion_date>July 21, 2020</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04358081</url>
  </study>
  <study rank="698">
    <nct_id>NCT04355442</nct_id>
    <title>Evolution of Facial Trauma During COVID Containment Measures</title>
    <acronym>Traumax</acronym>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Maxillofacial Injuries</condition>
      <condition>Skull Fractures</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Facial fractures reduction or osteosynthesis</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>evolution of number of maxillofacial trauma</outcome_measure>
      <outcome_measure>variability in terms of type of trauma</outcome_measure>
      <outcome_measure>the inter-regional variability of maxillofacial trauma</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Montpellier</lead_sponsor>
      <collaborator>Unités de CMF des CHU de Paris (Dr Davrou - Pitié salpetrière)</collaborator>
      <collaborator>Amiens (Dr Dapke)</collaborator>
      <collaborator>Nantes (Pr Corre)</collaborator>
      <collaborator>Toulouse (Pr Lauwers - Purpan)</collaborator>
      <collaborator>Marseille (Dr Foletti – La conception)</collaborator>
      <collaborator>Nice (Dr Savoldelli)</collaborator>
      <collaborator>Clermont Ferrand (Dr Sesque)</collaborator>
      <collaborator>Perpignan (Dr Llobet)</collaborator>
      <collaborator>Lyon (Dr Bourlet – Croix Rousse)</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>May 1, 2020</primary_completion_date>
    <completion_date>May 30, 2020</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>Uh Montpellier, Montpellier, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04355442</url>
  </study>
  <study rank="699">
    <nct_id>NCT04361877</nct_id>
    <title>Cardiovascular Prevention During COVID-19 Pandemic Lockdown in Young Adults (COLA Trial)</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cardiovascular Prevention Behaviour</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Change of physical activity</outcome_measure>
      <outcome_measure>quantitative change of physical activity by activity tracker</outcome_measure>
      <outcome_measure>change of nutrition behaviour</outcome_measure>
      <outcome_measure>semiquantitative change of alcohol intake</outcome_measure>
      <outcome_measure>change of smoking behaviour</outcome_measure>
      <outcome_measure>change of stress level</outcome_measure>
      <outcome_measure>step count</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Klinikum der Universitaet Muenchen</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1900</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 30, 2020</start_date>
    <primary_completion_date>April 20, 2020</primary_completion_date>
    <completion_date>April 20, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>University Hospital Munich (LMU Klinikum), Munich, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04361877</url>
  </study>
  <study rank="700">
    <nct_id>NCT04349228</nct_id>
    <title>Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID19 for Health Professionals</title>
    <acronym>COVID_2Pro</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID19</condition>
      <condition>Sars-CoV2</condition>
      <condition>Hydroxychloroquine</condition>
      <condition>Prophylaxis</condition>
      <condition>Healthcare Worker</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine (HCQ)</intervention>
      <intervention type="Drug">Placebo oral tablet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Symptomatic COVID(+) infection rate</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Abderrahmane Mami Hospital</lead_sponsor>
      <collaborator>Eshmoun Clinical Research Centre</collaborator>
      <collaborator>Datametrix</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>530</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>July 15, 2020</primary_completion_date>
    <completion_date>July 15, 2020</completion_date>
    <study_first_posted>April 16, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>Eshmoun Clinical Research Centre/ Hôpital Abderrahmane Mami-Ariana, Tunis, Tunisia</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04349228</url>
  </study>
  <study rank="701">
    <nct_id>NCT04338100</nct_id>
    <title>Point Of Care UltraSonography for Risk-stratification of COVID-19 Patients</title>
    <acronym>POCUSCO</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
      <condition>Coronavirus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Follow-up at 14 days</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Risk of unfavourable outcome at D14</outcome_measure>
      <outcome_measure>Risk of unfavourable outcome over time</outcome_measure>
      <outcome_measure>Risk-stratification threshold values</outcome_measure>
      <outcome_measure>Adding value of POCUS score to previous risk-stratification clinical rules</outcome_measure>
      <outcome_measure>POCUS score and patient clinical status at D14</outcome_measure>
      <outcome_measure>POCUS and CT scan correlation</outcome_measure>
      <outcome_measure>POCUS versus CT scan risk-stratification performances</outcome_measure>
      <outcome_measure>POCUS score evolution performances</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Angers</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 6, 2020</start_date>
    <primary_completion_date>December 29, 2020</primary_completion_date>
    <completion_date>January 29, 2021</completion_date>
    <study_first_posted>April 8, 2020</study_first_posted>
    <last_update_posted>April 8, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04338100</url>
  </study>
  <study rank="702">
    <nct_id>NCT04342650</nct_id>
    <title>Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection</title>
    <acronym>CloroCOVID19II</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>SARS-CoV Infection</condition>
      <condition>Severe Acute Respiratory Syndrome (SARS) Pneumonia</condition>
      <condition>Clinical Trial</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Chloroquine Diphosphate</intervention>
      <intervention type="Drug">Placebo oral tablet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Proportion of patients with onset of severe acute respiratory syndrome (SARS)</outcome_measure>
      <outcome_measure>Mortality rate</outcome_measure>
      <outcome_measure>Number of participants in need of intensive care support</outcome_measure>
      <outcome_measure>Viral concentration</outcome_measure>
      <outcome_measure>Cumulative incidence of serious adverse events</outcome_measure>
      <outcome_measure>Cumulative incidence of grade 3 and 4 adverse events</outcome_measure>
      <outcome_measure>Proportion of patients with discontinued treatment</outcome_measure>
      <outcome_measure>Incidence of cardiac lesions</outcome_measure>
      <outcome_measure>Incidence of cardiac disfunctions</outcome_measure>
      <outcome_measure>Change in respiratory capacity</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Fundação de Medicina Tropical Dr. Heitor Vieira Dourado</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>210</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 8, 2020</start_date>
    <primary_completion_date>September 2020</primary_completion_date>
    <completion_date>September 2020</completion_date>
    <study_first_posted>April 13, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz, Manaus, Amazonas, Brazil</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04342650</url>
  </study>
  <study rank="703">
    <nct_id>NCT04339790</nct_id>
    <title>Mental Health Impact of COVID-19 Pandemic on NIMH Research Participants and Volunteers</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Healthy Volunteer</condition>
      <condition>Mood Disorder</condition>
      <condition>Anxiety Disorder</condition>
      <condition>Preexisting Medical Condition</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>NIMH COVID Study survey - adult responses</outcome_measure>
      <outcome_measure>DSM XC and KS survey</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute of Mental Health (NIMH)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>5000</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>May 1, 2020</start_date>
    <primary_completion_date>March 1, 2022</primary_completion_date>
    <completion_date>April 1, 2022</completion_date>
    <study_first_posted>April 9, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>National Institute of Mental Health (NIMH), Bethesda, Maryland, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04339790</url>
  </study>
  <study rank="704">
    <nct_id>NCT04356378</nct_id>
    <title>Long Term Physical Functional Limitations in Daily Living in SARS-CoV2 Infected Patients Hospitalized in the Acute Phase Then Requiring Rehabilitation</title>
    <acronym>CAPACoV19</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Infection With Coronavirus SARS-CoV2</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Data record</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Physical functional limitations</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>CHU de Reims</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>May 1, 2020</start_date>
    <primary_completion_date>September 1, 2021</primary_completion_date>
    <completion_date>February 1, 2022</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Damien JOLLY, Reims, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04356378</url>
  </study>
  <study rank="705">
    <nct_id>NCT04366297</nct_id>
    <title>Intravascular Access of COVID-19 Patient Under Personal Protective Equipment</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cardiac Arrest</condition>
      <condition>Emergencies</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Intravenous access</intervention>
      <intervention type="Device">Intraosseous access</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>successful rate of first intravascular access attempt</outcome_measure>
      <outcome_measure>time to successful access</outcome_measure>
      <outcome_measure>number of attempts to successful access</outcome_measure>
      <outcome_measure>time to infusion</outcome_measure>
      <outcome_measure>complication rates</outcome_measure>
      <outcome_measure>ease of use</outcome_measure>
      <outcome_measure>Preferred intravascular access method</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Lazarski University</lead_sponsor>
      <collaborator>Poznan University of Medical Sciences</collaborator>
      <collaborator>Medical University of Bialystok</collaborator>
      <collaborator>Wroclaw Medical University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>41</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>January 12, 2020</start_date>
    <primary_completion_date>February 25, 2020</primary_completion_date>
    <completion_date>February 25, 2020</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Lazarski Univeristy, Warsaw, Poland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04366297</url>
  </study>
  <study rank="706">
    <nct_id>NCT04279197</nct_id>
    <title>Treatment of Pulmonary Fibrosis Due to 2019-nCoV Pneumonia With Fuzheng Huayu</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pulmonary Fibrosis Due to 2019-nCoV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">N-acetylcysteine+ Fuzheng Huayu Tablet</intervention>
      <intervention type="Drug">N-acetylcysteine+Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>High-resolution computed tomography (HRCT) score</outcome_measure>
      <outcome_measure>Lung function including FVC, FVC as a percentage of projected value and DLco</outcome_measure>
      <outcome_measure>Times of acute exacerbation</outcome_measure>
      <outcome_measure>Six-minute walk distance</outcome_measure>
      <outcome_measure>Dyspnea Scores</outcome_measure>
      <outcome_measure>Composite physiological index</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>ShuGuang Hospital</lead_sponsor>
      <collaborator>Hubei Hospital of Traditional Chinese Medicine</collaborator>
      <collaborator>Jingmen No.1 People’s Hospital</collaborator>
      <collaborator>Tongji Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>136</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>February 15, 2020</start_date>
    <primary_completion_date>December 2022</primary_completion_date>
    <completion_date>December 2022</completion_date>
    <study_first_posted>February 21, 2020</study_first_posted>
    <last_update_posted>February 21, 2020</last_update_posted>
    <locations>
      <location>Shuguang Hospital, Shanghai, Shanghai, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04279197</url>
  </study>
  <study rank="707">
    <nct_id>NCT04327401</nct_id>
    <title>COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III</title>
    <acronym>CoDEX</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infection</condition>
      <condition>Pneumonia, Viral</condition>
      <condition>Acute Respiratory Distress Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Dexamethasone</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Ventilator-free days</outcome_measure>
      <outcome_measure>Evaluation of the clinical status</outcome_measure>
      <outcome_measure>All-cause mortality</outcome_measure>
      <outcome_measure>Mechanical ventilation duration</outcome_measure>
      <outcome_measure>Sequential Organ Failure Assessment (SOFA) Score</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Luiz F. L. Reis, Ph.D.</lead_sponsor>
      <collaborator>Hospital Israelita Albert Einstein</collaborator>
      <collaborator>Hospital do Coracao</collaborator>
      <collaborator>Brazilian Research In Intensive Care Network</collaborator>
      <collaborator>Ache Laboratorios Farmaceuticos S.A.</collaborator>
      <collaborator>Hospital Sirio-Libanes</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>290</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 13, 2020</start_date>
    <primary_completion_date>August 30, 2020</primary_completion_date>
    <completion_date>August 30, 2020</completion_date>
    <study_first_posted>March 31, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>Hospital Ana Nery, Salvador, Bahia, Brazil</location>
      <location>Instituto de Cardiologia do Distrito Federal, Brasília, Distrito Federal, Brazil</location>
      <location>Fundação Social Rural de Colatina, Colatina, Esoírito Santo, Brazil</location>
      <location>Hospital Vera Cruz AS, Belo Horizonte, Minas Gerais, Brazil</location>
      <location>Hospital Maternidade E Pronto Socorro Santa Lucia Ltda, Poços De Caldas, Minas Gerais, Brazil</location>
      <location>Universidade Estadual de Londrina, Londrina, Paraná, Brazil</location>
      <location>Eurolatino Natal Pesquisas Médicas Ltda, Natal, Rio Grande Do Norte, Brazil</location>
      <location>Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil</location>
      <location>Maestri E Kormann Consultoria Medico-Cientifica, Blumenau, Santa Catarina, Brazil</location>
      <location>Sociedade Literaria e Caritativa Santo Agostinho, Criciúma, Santa Catarina, Brazil</location>
      <location>Fundação Pio XII, Barretos, São Paulo, Brazil</location>
      <location>Santa Casa de Misericordia de Votuporanga, Votuporanga, São Paulo, Brazil</location>
      <location>Associacao Beneficente Siria, São Paulo, Brazil</location>
      <location>Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da USP - HCFMRP, São Paulo, Brazil</location>
      <location>Hospital Israelita Albert Einstein, São Paulo, Brazil</location>
      <location>Prevent Senior Private Operadora de Saude Ltda, São Paulo, Brazil</location>
      <location>Real e Benemérita Associação Portuguesa de Beneficência/SP, São Paulo, Brazil</location>
      <location>Santa Casa de Misericórdia, São Paulo, Brazil</location>
      <location>Secretaria de Saúde do Estado de São Paulo, São Paulo, Brazil</location>
      <location>Sociedade Beneficente de Senhoras Hospital Sírio-Libanês, São Paulo, Brazil</location>
      <location>Universidade Federal de São Paulo, São Paulo, Brazil</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04327401</url>
  </study>
  <study rank="708">
    <nct_id>NCT04284046</nct_id>
    <title>CT Scores Predict Mortality in 2019-nCoV Pneumonia</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>CT Scores Predict Mortality in 2019-nCoV Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Other">CT score</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>7-day mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>39</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>January 31, 2020</start_date>
    <primary_completion_date>February 18, 2020</primary_completion_date>
    <completion_date>February 18, 2020</completion_date>
    <study_first_posted>February 25, 2020</study_first_posted>
    <last_update_posted>February 25, 2020</last_update_posted>
    <locations>
      <location>Wuhan third hospital, Wuhan, Hubei, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04284046</url>
  </study>
  <study rank="709">
    <nct_id>NCT04280705</nct_id>
    <title>Adaptive COVID-19 Treatment Trial (ACTT)</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Corona Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Placebo</intervention>
      <intervention type="Drug">Remdesivir</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to recovery</outcome_measure>
      <outcome_measure>Change from baseline in alanine transaminase (ALT)</outcome_measure>
      <outcome_measure>Change from baseline in aspartate transaminase (AST)</outcome_measure>
      <outcome_measure>Change from baseline in creatinine</outcome_measure>
      <outcome_measure>Change from baseline in glucose</outcome_measure>
      <outcome_measure>Change from baseline in hemoglobin</outcome_measure>
      <outcome_measure>Change from baseline in platelets</outcome_measure>
      <outcome_measure>Change from baseline in prothrombin time (PT)</outcome_measure>
      <outcome_measure>Change from baseline in total bilirubin</outcome_measure>
      <outcome_measure>Change from baseline in white blood cell count (WBC) with differential</outcome_measure>
      <outcome_measure>Change in National Early Warning Score (NEWS) from baseline</outcome_measure>
      <outcome_measure>Clinical status using ordinal scale</outcome_measure>
      <outcome_measure>Cumulative incidence of Grade 3 and 4 clinical and/or laboratory adverse events (AEs)</outcome_measure>
      <outcome_measure>Cumulative incidence of serious adverse events (SAEs)</outcome_measure>
      <outcome_measure>Discontinuation or temporary suspension of investigational therapeutics</outcome_measure>
      <outcome_measure>Duration of hospitalization</outcome_measure>
      <outcome_measure>Duration of new non-invasive ventilation or high flow oxygen use</outcome_measure>
      <outcome_measure>Duration of new oxygen use</outcome_measure>
      <outcome_measure>Duration of new ventilator or extracorporeal membrane oxygenation (ECMO) use</outcome_measure>
      <outcome_measure>Incidence of new non-invasive ventilation or high flow oxygen use</outcome_measure>
      <outcome_measure>Incidence of new oxygen use</outcome_measure>
      <outcome_measure>Incidence of new ventilator or extracorporeal membrane oxygenation (ECMO) use</outcome_measure>
      <outcome_measure>Mean change in the ordinal scale</outcome_measure>
      <outcome_measure>Percentage of subjects reporting each severity rating on an 8-point ordinal scale</outcome_measure>
      <outcome_measure>Subject 14-day mortality</outcome_measure>
      <outcome_measure>Subject 29-day mortality</outcome_measure>
      <outcome_measure>Time to an improvement of one category using an ordinal scale</outcome_measure>
      <outcome_measure>Time to an improvement of two categories using an ordinal scale</outcome_measure>
      <outcome_measure>Time to discharge or to a National Early Warning Score (NEWS) of &lt;/= 2 and maintained for 24 hours, whichever occurs first</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>99 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>800</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>February 21, 2020</start_date>
    <primary_completion_date>April 1, 2023</primary_completion_date>
    <completion_date>April 1, 2023</completion_date>
    <study_first_posted>February 21, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>University of Alabama at Birmingham School of Medicine - Infectious Disease, Birmingham, Alabama, United States</location>
      <location>University of California San Diego Health - Jacobs Medical Center, La Jolla, California, United States</location>
      <location>University of California Los Angeles Medical Center - Westwood Clinic, Los Angeles, California, United States</location>
      <location>University of California Irvine Medical Center - Infectious Disease, Orange, California, United States</location>
      <location>VA Palo Alto Health Care System - Infectious Diseases, Palo Alto, California, United States</location>
      <location>Stanford University - Stanford Hospital and Clinics - Pediatrics - Infectious Diseases, Palo Alto, California, United States</location>
      <location>University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States</location>
      <location>Naval Medical Center San Diego - Infectious Disease Clinic, San Diego, California, United States</location>
      <location>University of California San Francisco - Zuckerberg San Francisco General Hospital - Division of Human Immunodeficiency Virus, Infectious Disease, and Global Medicine, San Francisco, California, United States</location>
      <location>Cedars Sinai Medical Center, West Hollywood, California, United States</location>
      <location>Rocky Mountain Regional Veteran Affairs Medical Center - Department of Infectious Diseases, Aurora, Colorado, United States</location>
      <location>Denver Health Division of Hospital Medicine - Main Campus, Denver, Colorado, United States</location>
      <location>University of Florida Health - Shands Hospital - Division of Infectious Diseases and Global Medicine, Gainesville, Florida, United States</location>
      <location>Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States</location>
      <location>Atlanta VA Medical Center - Infectious Diseases Clinic, Decatur, Georgia, United States</location>
      <location>Northwestern Hospital - Infectious Disease, Chicago, Illinois, United States</location>
      <location>University of Illinois at Chicago College of Medicine - Division of Infectious Diseases, Chicago, Illinois, United States</location>
      <location>Southeast Louisiana Veterans Health Care System (SLVHCS) - Section of Infectious Diseases, New Orleans, Louisiana, United States</location>
      <location>University of Maryland School of Medicine - Center for Vaccine Development - Baltimore, Annapolis, Maryland, United States</location>
      <location>Johns Hopkins Hospital - Medicine - Infectious Diseases, Baltimore, Maryland, United States</location>
      <location>Walter Reed National Military Medical Center, Bethesda, Maryland, United States</location>
      <location>National Institutes of Health - Clinical Center, National Institute of Allergy and Infectious Diseases Laboratory Of Immunoregulation, Clinical Research Section, Bethesda, Maryland, United States</location>
      <location>Massachusetts General Hospital - Infectious Diseases, Boston, Massachusetts, United States</location>
      <location>University of Massachusetts Medical School - Infectious Diseases and Immunology, Worcester, Massachusetts, United States</location>
      <location>University of Minnesota Medical Center, Fairview - Infectious Diseases and International Medicine, Minneapolis, Minnesota, United States</location>
      <location>Saint Louis University - Center for Vaccine Development, Saint Louis, Missouri, United States</location>
      <location>University of Nebraska Medical Center - Infectious Diseases, Omaha, Nebraska, United States</location>
      <location>Montefiore Medical Center - Infectious Diseases, Bronx, New York, United States</location>
      <location>New York University School of Medicine - Langone Medical Center - Microbiology - Parasitology, New York, New York, United States</location>
      <location>University of Rochester Medical Center - Vaccine Research Unit, Rochester, New York, United States</location>
      <location>Duke Human Vaccine Institute - Duke Vaccine and Trials Unit, Durham, North Carolina, United States</location>
      <location>Penn State Health Milton S. Hershey Medical Center - Division of Infectious Diseases, Hershey, Pennsylvania, United States</location>
      <location>Hospital of the University of Pennsylvania - Infectious Diseases, Philadelphia, Pennsylvania, United States</location>
      <location>University of Pennsylvania Perelman School of Medicine - Penn Institute for Immunology, Philadelphia, Pennsylvania, United States</location>
      <location>Vanderbilt University Medical Center - Infectious Diseases, Nashville, Tennessee, United States</location>
      <location>Brooke Army Medical Center, Fort Sam Houston, Texas, United States</location>
      <location>University of Texas Medical Branch - Division of Infectious Disease, Galveston, Texas, United States</location>
      <location>Baylor College of Medicine - Molecular Virology and Microbiology, Houston, Texas, United States</location>
      <location>University of Texas Health Science Center at San Antonio - Infectious Diseases, San Antonio, Texas, United States</location>
      <location>University of Virginia - Acute Care Surgery, Charlottesville, Virginia, United States</location>
      <location>Naval Medical Center Portsmouth - Infectious Disease Division, Portsmouth, Virginia, United States</location>
      <location>EvergreenHealth Infectious Disease Service, Kirkland, Washington, United States</location>
      <location>The University of Washington - Virology Research Clinic, Seattle, Washington, United States</location>
      <location>Providence Sacred Heart Medical Center, Spokane, Washington, United States</location>
      <location>Madigan Army Medical Center - Infectious Disease Clinic, Tacoma, Washington, United States</location>
      <location>University of Copenhagen - Centre of Excellence for Health, Immunity and Infections (CHIP) - Department of Infectious Diseases, Copenhagen, Denmark</location>
      <location>Universitatsklinikum Bonn, Medizinische Klinik I - Bereich Infektiologie/HIV der Medizinischen Klinik, Bonn, Nordrhein-Westfalen, Germany</location>
      <location>Universitatsklinikum Koeln Klinik I fur Innere Medizin Klinisches Studienzentrum fur Infektiologie I, Cologne, Germany</location>
      <location>Universitätsklinikum Frankfurt -Medizinische Klinik II - Infektiologie, Frankfurt, Germany</location>
      <location>AHEPA University Hospital - 1st Department of Internal Medicine, Thessaloniki, Central Macedonia, Greece</location>
      <location>Medical School of Athens University - Evangelismos Hospital - Department of Critical Care and Pulmonary Services, Athens, Greece</location>
      <location>National Center for Global Health and Medicine Hospital - Disease Control and Prevention Center, Tokyo, Japan</location>
      <location>Seoul National University Bundang Hospital - Division of Infectious Diseases, Bundang-gu Seongnam-si, Gyeonggi-do, Korea, Republic of</location>
      <location>Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of</location>
      <location>Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán - Departamento de Infectologia, Mexico City, Mexico</location>
      <location>Instituto Nacional de Enfermedades Respiratorias (INER) - Ismael Cosío Villegas, Mexico City, Mexico</location>
      <location>National University Health System - Division of Infectious Diseases, Singapore, Singapore</location>
      <location>Singapore General Hospital - Department of Infectious Diseases, Singapore, Singapore</location>
      <location>National Centre for Infectious Diseases (NCID), Singapore, Singapore</location>
      <location>Changi General Hospital - Clinical Trials and Research Unit (CTRU), Singapore, Singapore</location>
      <location>Ng Teng Fong General Hospital - Infectious Disease Service, Singapore, Singapore</location>
      <location>Khoo Teck Puat Hospital - Clinical Research Unit, Singapore, Singapore</location>
      <location>Hospital Clinic Barcelona, Servicio de Salud Internacional, Barcelona, Cataluña, Spain</location>
      <location>Hospital Germans Trias i Pujol - Servei Malalties Infeccioses, Barcelona, Cataluña, Spain</location>
      <location>Royal Sussex County Hospital - Department of Intensive Care Medicine, East Sussex, Brighton, United Kingdom</location>
      <location>Saint Thomas' Hospital - Directorate of Infection, London, London, City Of, United Kingdom</location>
      <location>Royal Victoria Infirmary - Department of Infectious Diseases, Level 6, Ward 19, Newcastle Upon Tyne, United Kingdom</location>
      <location>St. James's University Hospital - Infectious Diseases, Leeds, West Yorkshire, United Kingdom</location>
      <location>John Radcliffe Hospital, Headington, Oxford, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04280705</url>
  </study>
  <study rank="710">
    <nct_id>NCT04362319</nct_id>
    <title>Burnout and Medical Errors in the Anaesthesiology Fraternity During Covid-19 Pandemic</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Burnout, Professional</condition>
      <condition>Depression</condition>
      <condition>Medical Errors</condition>
      <condition>Covid-19</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Questionnaire forms</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Prevalence of burnout among anaesthesiology clinicians during Covid-19</outcome_measure>
      <outcome_measure>Prevalence of depression risk among anaesthesiology clinicians during Covid-19</outcome_measure>
      <outcome_measure>Prevalence of self-perceived medical errors among anaesthesiology clinicians during Covid-19</outcome_measure>
      <outcome_measure>Association of burnout, depression and medical errors among anaesthesiology clinicians during Covid-19</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Malaya</lead_sponsor>
      <collaborator>Ministry of Health, Malaysia</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>88</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <start_date>May 1, 2020</start_date>
    <primary_completion_date>May 31, 2020</primary_completion_date>
    <completion_date>June 30, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04362319</url>
  </study>
  <study rank="711">
    <nct_id>NCT04345861</nct_id>
    <title>Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial)</title>
    <acronym>COVIDOC</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infection</condition>
      <condition>Pneumonia, Viral</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine + placebo</intervention>
      <intervention type="Drug">hydroxychloroquine + azithromycin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to clinical improvement of at least 1 level on the ordinal scale between Day 1 (day of the first administration of study drug) to Day 11 (day after last day of treatment).</outcome_measure>
      <outcome_measure>Clinical status assessed by ordinal scale</outcome_measure>
      <outcome_measure>transfer to ICU</outcome_measure>
      <outcome_measure>Length of hospital day</outcome_measure>
      <outcome_measure>Hospital Mortality</outcome_measure>
      <outcome_measure>Need to Mechanical Ventilation</outcome_measure>
      <outcome_measure>Occurence of grade 3-4 adverse event</outcome_measure>
      <outcome_measure>QTc Lengthening</outcome_measure>
      <outcome_measure>Evolution of pulmonary CT scan images</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Montpellier</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 11, 2020</start_date>
    <primary_completion_date>September 6, 2020</primary_completion_date>
    <completion_date>April 6, 2021</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Montpellier University hospital, Montpellier, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04345861</url>
  </study>
  <study rank="712">
    <nct_id>NCT04345614</nct_id>
    <title>A Study of CM4620-Injectable Emulsion (IE) in Patients With Severe COVID-19 Pneumonia</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">CM4620-Injectable Emulsion</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Improvement on a 7-point Ordinal Scale</outcome_measure>
      <outcome_measure>Incidence of treatment-emergent adverse events (TEAE) (safety and tolerability)</outcome_measure>
      <outcome_measure>Change in estimated PaO2/FiO2</outcome_measure>
      <outcome_measure>Number of days alive and free of mechanical ventilation</outcome_measure>
      <outcome_measure>Time to discharge alive from hospital</outcome_measure>
      <outcome_measure>Number of patients alive on day 30 and day 60</outcome_measure>
      <outcome_measure>Change in interleukin (IL)-6 level</outcome_measure>
      <outcome_measure>Change in IL-17 level</outcome_measure>
      <outcome_measure>Change in tumor necrosis factor-alpha level</outcome_measure>
      <outcome_measure>Change in cytokine levels</outcome_measure>
      <outcome_measure>CM4620-IE serum concentration</outcome_measure>
      <outcome_measure>Procalcitonin levels</outcome_measure>
      <outcome_measure>Normalization of oxygen saturation</outcome_measure>
      <outcome_measure>Time to first normalization of oxygen saturation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>CalciMedica, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 8, 2020</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>September 2020</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Henry Ford Hospital, Detroit, Michigan, United States</location>
      <location>Methodist Hospital, Saint Louis Park, Minnesota, United States</location>
      <location>Regions Hospital, Saint Paul, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04345614</url>
  </study>
  <study rank="713">
    <nct_id>NCT04360811</nct_id>
    <title>Assessment of Obstetric, Fetal and Neonatal Risks and Vertical SARS-CoV-2 Transmission During COVID-19 Pandemic</title>
    <acronym>COroFet</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pregnancy</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">COVID 19 diagnostic test by PCR</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>number of positive COVID-19 women</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Toulouse</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>3600</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <start_date>April 17, 2020</start_date>
    <primary_completion_date>April 2021</primary_completion_date>
    <completion_date>April 2022</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>University Hospital of Toulouse, Toulouse, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04360811</url>
  </study>
  <study rank="714">
    <nct_id>NCT04344210</nct_id>
    <title>Impact of Tele-interventions During the COVID-19 Pandemic in Patients With Diabetes Mellitus</title>
    <acronym/>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
      <condition>Diabetes Mellitus, Type 2</condition>
      <condition>Diabetes Mellitus, Type 1</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Tele-interventions related to diabetes management and mental well-being</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Variation in HbA1c levels</outcome_measure>
      <outcome_measure>COVID-19 infection</outcome_measure>
      <outcome_measure>Variation in lipid profile</outcome_measure>
      <outcome_measure>Variation in blood pressure levels</outcome_measure>
      <outcome_measure>Comparison of emotional distress associated with the routine of living with diabetes after intervention between groups</outcome_measure>
      <outcome_measure>Comparison of eating disorders between groups</outcome_measure>
      <outcome_measure>Comparison of adherence to the proposed clinical treatment between groups</outcome_measure>
      <outcome_measure>Comparison of minor psychiatric disorders between groups</outcome_measure>
      <outcome_measure>Comparison of sleep pattern changes between groups</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Federal University of Rio Grande do Sul</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>149</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <start_date>April 17, 2020</start_date>
    <primary_completion_date>August 20, 2020</primary_completion_date>
    <completion_date>August 30, 2020</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04344210</url>
  </study>
  <study rank="715">
    <nct_id>NCT04359875</nct_id>
    <title>A Phone-call With a Student/General Practitioner Team to Impact Morbidity of Chronic Patients During COVID-19 Containment</title>
    <acronym>COVIQuest</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cardiovascular Diseases</condition>
      <condition>Mental Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Phone-call screening and management by a medical student/general practitioner tandem</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Hospitalization(s) at 1 month</outcome_measure>
      <outcome_measure>Phone-call from the general practitioner (in the experimental group only)</outcome_measure>
      <outcome_measure>Mortality at 1 month</outcome_measure>
      <outcome_measure>Use of primary care</outcome_measure>
      <outcome_measure>Use of secondary care</outcome_measure>
      <outcome_measure>Number of prescriptions related to the chronic disease dispensed by the pharmacy</outcome_measure>
      <outcome_measure>Number of hospitalization(s)</outcome_measure>
      <outcome_measure>Time to hospitalization(s)</outcome_measure>
      <outcome_measure>Hospitalization(s)' durations</outcome_measure>
      <outcome_measure>Reasons for hospitalization(s)</outcome_measure>
      <outcome_measure>Mortality at 6 months</outcome_measure>
      <outcome_measure>Cardiovascular events (MACE)</outcome_measure>
      <outcome_measure>Psychotropic drugs</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Tours</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>110 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>22000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Health Services Research</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>June 2020</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Dibao-Dina, Tours, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04359875</url>
  </study>
  <study rank="716">
    <nct_id>NCT04322487</nct_id>
    <title>Simple, Safe, Same: Lung Ultrasound for COVID-19</title>
    <acronym>LUSCOVID19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
      <condition>Epidemic Disease</condition>
      <condition>Pneumonia, Viral</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Lung ultrasound</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Lung ultrasound grading system for COVID-19 pneumonia</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Catholic University of the Sacred Heart</lead_sponsor>
      <collaborator>Valle del Serchio General Hospital, Lucca, Italy</collaborator>
      <collaborator>University of Trento, Trento, Italy</collaborator>
      <collaborator>Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy</collaborator>
      <collaborator>Bresciamed, Brescia, Italy</collaborator>
      <collaborator>118 USL Nordovest Toscana, Lucca, Italy</collaborator>
      <collaborator>General Hospital, Voghera, Italy</collaborator>
      <collaborator>Lodi General Hospital, Lodi, Italy</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 8, 2020</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>January 15, 2021</completion_date>
    <study_first_posted>March 26, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations>
      <location>Bresciamed, Brescia, Italy</location>
      <location>Pulmonary Medicine Unit, Lodi General Hospital, Lodi, Italy</location>
      <location>118 USL Nordovest Toscana, Lucca, Italy</location>
      <location>Diagnostic and Interventional Ultrasound Unit, Valle del Serchio General Hospital, Lucca, Italy</location>
      <location>Emergency Department, Fondazione IRCCS Policlinico San Matteo, and Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy</location>
      <location>Department of woman and child health and public health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy</location>
      <location>Pulmonary Medicine Unit, Dept. Medical and Surgical Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy</location>
      <location>Department of Information Engineering and Computer Science, Ultrasound Laboratory Trento, University of Trento, Trento, Italy</location>
      <location>Emergency Medicine Unit, General Hospital, Voghera, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04322487</url>
  </study>
  <study rank="717">
    <nct_id>NCT04349592</nct_id>
    <title>Qatar Prospective RCT Of Therapy Eliminating Covid Transmission</title>
    <acronym>Q-PROTECT</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine + Azithromycin</intervention>
      <intervention type="Drug">Hydroxychloroquine + Placebo</intervention>
      <intervention type="Other">Placebo + Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Proportion of virologically cured (no virus detected) cases at day 6</outcome_measure>
      <outcome_measure>The dichotomous virologic shedding endpoint as assessed at two weeks after study entry</outcome_measure>
      <outcome_measure>Quantitative viral load (assessed with each virology testing set)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hamad Medical Corporation</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>456</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 14, 2020</start_date>
    <primary_completion_date>May 14, 2020</primary_completion_date>
    <completion_date>May 30, 2020</completion_date>
    <study_first_posted>April 16, 2020</study_first_posted>
    <last_update_posted>April 16, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04349592</url>
  </study>
  <study rank="718">
    <nct_id>NCT04321174</nct_id>
    <title>COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir</title>
    <acronym>CORIPREV-LR</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infections</condition>
      <condition>Post-exposure Prophylaxis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Lopinavir/ritonavir</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Microbiologic evidence of infection</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
      <outcome_measure>Symptomatic COVID-19 disease</outcome_measure>
      <outcome_measure>Seropositivity</outcome_measure>
      <outcome_measure>Days of hospitalization attributable to COVID-19 disease</outcome_measure>
      <outcome_measure>Respiratory failure requiring ventilatory support attributable to COVID-19 disease</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>Short-term psychological impact of exposure to COVID-19 disease</outcome_measure>
      <outcome_measure>Long-term psychological impact of exposure to COVID-19 disease</outcome_measure>
      <outcome_measure>Health-related quality of life</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Darrell Tan</lead_sponsor>
      <collaborator>St. Michael's Hospital, Toronto</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Months</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1220</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 17, 2020</start_date>
    <primary_completion_date>March 31, 2021</primary_completion_date>
    <completion_date>March 31, 2022</completion_date>
    <study_first_posted>March 25, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>St. Paul's Hospital, Vancouver, British Columbia, Canada</location>
      <location>Sunnybrook Hospital, Toronto, Ontario, Canada</location>
      <location>St. Michael's Hospital, Toronto, Ontario, Canada</location>
      <location>Toronto General Hospital, Toronto, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04321174</url>
  </study>
  <study rank="719">
    <nct_id>NCT04318314</nct_id>
    <title>COVID-19: Healthcare Worker Bioresource: Immune Protection and Pathogenesis in SARS-CoV-2</title>
    <acronym>COVID19-HCW</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Health Care Worker Patient Transmission</condition>
      <condition>Coronavirus</condition>
      <condition>Coronavirus Infections</condition>
      <condition>Immunological Abnormality</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">COPAN swabbing and blood sample collection</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Seroconversion to SARS-CoV-2 positivity</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University College, London</lead_sponsor>
      <collaborator>St. Bartholomew's Hospital</collaborator>
      <collaborator>Royal Free Hospital NHS Foundation Trust</collaborator>
      <collaborator>UCLH</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 18, 2020</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>December 31, 2021</completion_date>
    <study_first_posted>March 23, 2020</study_first_posted>
    <last_update_posted>March 26, 2020</last_update_posted>
    <locations>
      <location>Barts Heart Center, London, United Kingdom</location>
      <location>Royal Free London NHS Foundation Trust, London, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04318314</url>
  </study>
  <study rank="720">
    <nct_id>NCT04323592</nct_id>
    <title>Efficacy of Methylprednisolone for Patients With COVID-19 Severe Acute Respiratory Syndrome</title>
    <acronym>MP-C19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Severe Acute Respiratory Syndrome (SARS) Pneumonia</condition>
      <condition>Coronavirus Infections</condition>
      <condition>ARDS, Human</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Methylprednisolone</intervention>
      <intervention type="Other">standard care</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Composite primary end-point</outcome_measure>
      <outcome_measure>death</outcome_measure>
      <outcome_measure>Admission to ICU</outcome_measure>
      <outcome_measure>Endotracheal intubation (invasive mechanical ventilation)</outcome_measure>
      <outcome_measure>reduction of C-reactive protein or CRP</outcome_measure>
      <outcome_measure>Reduction of mechanical ventilation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Trieste</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>104</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 23, 2020</start_date>
    <primary_completion_date>May 20, 2020</primary_completion_date>
    <completion_date>May 30, 2020</completion_date>
    <study_first_posted>March 26, 2020</study_first_posted>
    <last_update_posted>March 27, 2020</last_update_posted>
    <locations>
      <location>Marco Confalonieri, Trieste, TS, Italy</location>
    </locations>
    <study_documents>
      <study_document>
        <label>Study Protocol and Statistical Analysis Plan</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/92/NCT04323592/Prot_SAP_000.pdf</url>
      </study_document>
      <study_document>
        <label>Informed Consent Form</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/92/NCT04323592/ICF_001.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT04323592</url>
  </study>
  <study rank="721">
    <nct_id>NCT04324463</nct_id>
    <title>Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial</title>
    <acronym>ACT COVID19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
      <condition>Severe Acute Respiratory Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Azithromycin</intervention>
      <intervention type="Drug">Hydoxychloroquine or Chloroquine</intervention>
      <intervention type="Drug">Interferon-Beta</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Outpatients: Hospital Admission or Death</outcome_measure>
      <outcome_measure>Inpatients: Invasive mechanical ventilation or mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Population Health Research Institute</lead_sponsor>
      <collaborator>Bayer</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 21, 2020</start_date>
    <primary_completion_date>September 30, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>March 27, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Hamilton Health Sciences, Hamilton, Ontario, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04324463</url>
  </study>
  <study rank="722">
    <nct_id>NCT04363593</nct_id>
    <title>Serology COVID-19 From the Cornwall Hospital Union</title>
    <acronym>ROCOCO</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Corona Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Serological test</intervention>
      <intervention type="Biological">Serum test</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Serological test evaluation</outcome_measure>
      <outcome_measure>Population seroprevalence</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier de Cornouaille</lead_sponsor>
      <collaborator>Centre Hospitalier Régional et Universitaire de Brest</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>3200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <start_date>May 4, 2020</start_date>
    <primary_completion_date>November 4, 2020</primary_completion_date>
    <completion_date>November 4, 2020</completion_date>
    <study_first_posted>April 27, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>CH de Cornouaille, Quimper, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04363593</url>
  </study>
  <study rank="723">
    <nct_id>NCT04354155</nct_id>
    <title>COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Infection Viral</condition>
      <condition>Thromboses, Venous</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Enoxaparin Prefilled Syringe [Lovenox]</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Safety of in-hospital thromboprophylaxis</outcome_measure>
      <outcome_measure>Median twice-daily enoxaparin dose</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Neil Goldenberg</lead_sponsor>
      <collaborator>Johns Hopkins All Children's Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>38</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>May 15, 2020</start_date>
    <primary_completion_date>September 15, 2022</primary_completion_date>
    <completion_date>October 15, 2022</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04354155</url>
  </study>
  <study rank="724">
    <nct_id>NCT04355234</nct_id>
    <title>Prevalence and Impact of COVID-19 Infection in Pregnant Women, Fetuses and Newborns</title>
    <acronym>COVIPREG</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pregnancy</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">identify SARS-CoV-2 infection by serology</intervention>
      <intervention type="Biological">collection of biological samples</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Seroprevalence or Number of women who are positive for SARS-CoV-2 in parturient woman</outcome_measure>
      <outcome_measure>Consequences of SARS-CoV-2 infection in pregnant women and their newborns : Pregnancy outcome, maternal or neonatal complications</outcome_measure>
      <outcome_measure>Assessment of the vertical transmission of SARS-CoV-2 and the possible routes of this transmission in women who are positive for SARS-CoV-2 during pregnancy</outcome_measure>
      <outcome_measure>Assessment of susceptibility to infection during the 3 trimesters of pregnancy</outcome_measure>
      <outcome_measure>Evaluation of the confinement on the risk of exposure to the virus during pregnancy .</outcome_measure>
      <outcome_measure>collection of biological samples for new investigations in women who are positive for SARS-CoV-2 during pregnancy.</outcome_measure>
      <outcome_measure>Assessment of the rate of SARS-CoV-2 infection in pregnant women the risk factors for the disease.</outcome_measure>
      <outcome_measure>Assessment of the rate of SARS-CoV-2 infection in newborns and the risk factors for the disease.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>2200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <start_date>April 24, 2020</start_date>
    <primary_completion_date>August 31, 2021</primary_completion_date>
    <completion_date>August 31, 2021</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04355234</url>
  </study>
  <study rank="725">
    <nct_id>NCT04335747</nct_id>
    <title>COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Rheumatoid Arthritis</condition>
      <condition>Psoriatic Arthritis</condition>
      <condition>Axial Spondyloarthritis</condition>
      <condition>Systemic Lupus Erythematosus</condition>
      <condition>Giant Cell Arteritis</condition>
    </conditions>
    <interventions>
      <intervention type="Other">COVID-19 infection</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Disease activity</outcome_measure>
      <outcome_measure>Immune modulating treatments</outcome_measure>
      <outcome_measure>Biomarkers</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Salome Kristensen</lead_sponsor>
      <collaborator>Aalborg University Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>333</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 8, 2020</start_date>
    <primary_completion_date>August 1, 2021</primary_completion_date>
    <completion_date>September 1, 2021</completion_date>
    <study_first_posted>April 6, 2020</study_first_posted>
    <last_update_posted>April 7, 2020</last_update_posted>
    <locations>
      <location>Aalborg University Hospital, Aalborg, Denmark</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04335747</url>
  </study>
  <study rank="726">
    <nct_id>NCT04335773</nct_id>
    <title>COVID-19 in Hospitalised Norwegian Children - Risk Factors, Outcomes and Immunology</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pediatric Respiratory Diseases</condition>
      <condition>COVID</condition>
      <condition>Fatigue Post Viral</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Risk Factors for severe infection</outcome_measure>
      <outcome_measure>Immunulogical mechanisms</outcome_measure>
      <outcome_measure>Long term outcome</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Akershus</lead_sponsor>
      <collaborator>St. Olavs Hospital</collaborator>
      <collaborator>Helse Stavanger HF</collaborator>
      <collaborator>Haukeland University Hospital</collaborator>
      <collaborator>University Hospital of North Norway</collaborator>
      <collaborator>Alesund Hospital</collaborator>
      <collaborator>Norwegian Institute of Public Health</collaborator>
      <collaborator>The University of New South Wales</collaborator>
      <collaborator>University of Bristol</collaborator>
      <collaborator>Sykehuset Ostfold</collaborator>
      <collaborator>Nordlandssykehuset HF</collaborator>
      <collaborator>Vestre Viken Hospital Trust</collaborator>
      <collaborator>Helse Fonna</collaborator>
      <collaborator>Levanger Hospital</collaborator>
      <collaborator>Oslo University Hospital</collaborator>
      <collaborator>Sykehuset Innlandet HF</collaborator>
    </sponsors>
    <gender>All</gender>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>350</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 3, 2020</start_date>
    <primary_completion_date>December 31, 2030</primary_completion_date>
    <completion_date>December 31, 2030</completion_date>
    <study_first_posted>April 6, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations>
      <location>Akershus universistetssykehus, Lørenskog, Norway</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04335773</url>
  </study>
  <study rank="727">
    <nct_id>NCT04335188</nct_id>
    <title>COVID-19 Registry Rhineland-Palatinate (Germany)</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Prospective oberservational registry</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Chest x-ray</outcome_measure>
      <outcome_measure>Chest CT</outcome_measure>
      <outcome_measure>Supportive care - ICU</outcome_measure>
      <outcome_measure>Supportive care - oxygen therapy</outcome_measure>
      <outcome_measure>Supportive care - ventilation</outcome_measure>
      <outcome_measure>Medication</outcome_measure>
      <outcome_measure>Therapeutic strategies</outcome_measure>
      <outcome_measure>Lab parameters</outcome_measure>
      <outcome_measure>Intra-hospital complications</outcome_measure>
      <outcome_measure>Vital status at discharge</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>IHF GmbH - Institut für Herzinfarktforschung</lead_sponsor>
      <collaborator>Ministerium für Soziales, Arbeit, Gesundheit und Demografie des Landes Rheinland-Pfalz</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>4000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 6, 2020</start_date>
    <primary_completion_date>July 31, 2021</primary_completion_date>
    <completion_date>September 30, 2021</completion_date>
    <study_first_posted>April 6, 2020</study_first_posted>
    <last_update_posted>April 8, 2020</last_update_posted>
    <locations>
      <location>Klinikum der Stadt Ludwigshafen am Rhein GmbH, Klinik für Herzchirurgie, Ludwigshafen, RLP, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04335188</url>
  </study>
  <study rank="728">
    <nct_id>NCT04354558</nct_id>
    <title>French Single Centre Experience of Critically Ill Patients With Covid 19</title>
    <acronym>CovidAmiens20</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Epidemiology</condition>
      <condition>Sars-CoV2</condition>
      <condition>COVID 19</condition>
      <condition>Critical Care</condition>
      <condition>Prognostic</condition>
      <condition>Survival</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Variation of age between critically ill patients with SARS Cov2 admitted in ICU with non critically ill patients with SARS Cov2 admitted in ICU</outcome_measure>
      <outcome_measure>Variation of medical history between critically ill patients with SARS Cov2 admitted in ICU with non critically ill patients with SARS Cov2 admitted in ICU</outcome_measure>
      <outcome_measure>Variation of chronic drug used between critically ill patients with SARS Cov2 admitted in ICU with non critically ill patients with SARS Cov2 admitted in ICU</outcome_measure>
      <outcome_measure>Variation of chest CT scan at admission, between critically ill patients with SARS Cov2 admitted in ICU with non critically ill patients with SARS Cov2 admitted in ICU</outcome_measure>
      <outcome_measure>Variation of respiratory support at ICU admission, between critically ill patients with SARS Cov2 admitted in ICU with non critically ill patients with SARS Cov2 admitted in ICU</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier Universitaire, Amiens</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>April 2021</primary_completion_date>
    <completion_date>April 2021</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>CHU Amiens, Amiens, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04354558</url>
  </study>
  <study rank="729">
    <nct_id>NCT04365439</nct_id>
    <title>Convalescent Plasma for COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Blood Plasma Therapy</condition>
      <condition>COVID</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Blood plasma</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Titers of anti-SARS-CoV-2 antibodies in the plasma derived from convalescent donors</outcome_measure>
      <outcome_measure>Change in titers of anti-SARS-CoV-2 antibodies in patients' plasma</outcome_measure>
      <outcome_measure>Change in inflammatory cytokines concentration (e.g. IL-6, HMGB1)</outcome_measure>
      <outcome_measure>Viral load decay in the recipient after plasma transfusion with semiquantitative assessment of nasopharyngeal swabs</outcome_measure>
      <outcome_measure>Number of patients with improvement in the 7-points Ordinal Scale</outcome_measure>
      <outcome_measure>Proportion of patients with adverse events, severity of adverse events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Enos Bernasconi</lead_sponsor>
      <collaborator>Ente Ospedaliero Cantonale, Bellinzona</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 27, 2020</start_date>
    <primary_completion_date>May 30, 2020</primary_completion_date>
    <completion_date>June 30, 2020</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04365439</url>
  </study>
  <study rank="730">
    <nct_id>NCT04361019</nct_id>
    <title>Physical Activity in University Students Around COVID-19 Confinement</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Physical Activity</condition>
    </conditions>
    <interventions>
      <intervention type="Other">On-Line Survey</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>: International Physical Activity Questionnaire - Short Form</outcome_measure>
      <outcome_measure>Pittsburgh Sleep Quality Index: Subjective Sleep Quality and Sleep Duration domains</outcome_measure>
      <outcome_measure>Short Form 36 Health Survey: Bodily Pain domain</outcome_measure>
      <outcome_measure>EuroQol 5D: Self rated health</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Basque Country University</lead_sponsor>
      <collaborator>University of Cadiz</collaborator>
      <collaborator>University of Extremadura</collaborator>
      <collaborator>Universidad de Zaragoza</collaborator>
      <collaborator>Universidad de Granada</collaborator>
      <collaborator>University of Castilla-La Mancha</collaborator>
      <collaborator>University of Las Palmas de Gran Canaria</collaborator>
      <collaborator>Universidad de León</collaborator>
      <collaborator>University of Seville</collaborator>
      <collaborator>University of Valencia</collaborator>
      <collaborator>Universidad Miguel Hernandez de Elche</collaborator>
      <collaborator>Technical University of Madrid</collaborator>
      <collaborator>Universidad Pública de Navarra</collaborator>
      <collaborator>University of the Balearic Islands</collaborator>
      <collaborator>Universitat Jaume I</collaborator>
      <collaborator>University of Cantabria</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>25000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 16, 2020</start_date>
    <primary_completion_date>October 20, 2020</primary_completion_date>
    <completion_date>October 20, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Basque Country University (UPV-EHU),, Bilbao, Bizkaia, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04361019</url>
  </study>
  <study rank="731">
    <nct_id>NCT04334629</nct_id>
    <title>LIBA Trial in COVID-19</title>
    <acronym>LIBA</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
      <condition>Respiratory Distress Syndrome</condition>
      <condition>SARS-CoV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ibuprofen</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Disease progression</outcome_measure>
      <outcome_measure>Time to mechanical ventilation</outcome_measure>
      <outcome_measure>Overall survival</outcome_measure>
      <outcome_measure>Reduction in proportion of patients who require ventilation</outcome_measure>
      <outcome_measure>Reduction in length of Critical Care stay</outcome_measure>
      <outcome_measure>Reduction in length of Hospital stay</outcome_measure>
      <outcome_measure>Modulation of serum pro- and anti-inflammatory cytokines</outcome_measure>
      <outcome_measure>Reduction in duration of ventilation</outcome_measure>
      <outcome_measure>Increase in ventilator-free days</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>King's College London</lead_sponsor>
      <collaborator>Guy's &amp; St Thomas NHS Foundation Trust</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>230</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 27, 2020</start_date>
    <primary_completion_date>August 26, 2020</primary_completion_date>
    <completion_date>November 26, 2020</completion_date>
    <study_first_posted>April 6, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04334629</url>
  </study>
  <study rank="732">
    <nct_id>NCT04340219</nct_id>
    <title>Oncology-patient-reported Anxiety, Mood, and QoL During the COVID-19 Pandemic</title>
    <acronym>ONCOVID</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cancer</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Survey administration</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Distress at baseline measured by the COVID-19 Peritraumatic Distress Index (CPDI); in terms of proportions (0-28 vs ≥ 29).</outcome_measure>
      <outcome_measure>Depression at baseline measured by the 7-item depression subscale of the 21-item Depression, Anxiety, and Stress Scale (DASS-21) (DASS-21—Depression); in terms of proportions (0-4 vs ≥ 5).</outcome_measure>
      <outcome_measure>Anxiety at baseline measured by the 7-item anxiety subscale of the DASS-21 (DASS-21—Anxiety); in terms of proportions (0-3 vs ≥ 4).</outcome_measure>
      <outcome_measure>Stress at baseline measured by the 7-item stress subscale of the DASS-21 (DASS-21—Stress); in terms of proportions (0-7 vs ≥ 8).</outcome_measure>
      <outcome_measure>Distress measured at baseline by the CPDI; in terms of continuous values.</outcome_measure>
      <outcome_measure>Depression at baseline measured by the DASS-21—Depression; in terms of continuous values.</outcome_measure>
      <outcome_measure>Anxiety at baseline measured by the DASS-21—Anxiety; in terms of continuous values.</outcome_measure>
      <outcome_measure>Stress at baseline measured by the DASS-21—Stress; in terms of continuous values.</outcome_measure>
      <outcome_measure>Domain-specific quality of life at baseline measured by the 7-item physical health domain of the World Health Organization Quality of Life-BREF (WHOQOL-BREF) questionnaire (WHOQOL-BREF—Physical health); in terms of continuous values.</outcome_measure>
      <outcome_measure>Domain-specific quality of life at baseline measured by the 6-item psychological health domain of the WHOQOL-BREF questionnaire (WHOQOL-BREF—Psychological health); in terms of continuous values.</outcome_measure>
      <outcome_measure>Domain-specific quality of life at baseline measured by the 3-item social relationships domain of the WHOQOL-BREF questionnaire (WHOQOL-BREF—Social relationships); in terms of continuous values.</outcome_measure>
      <outcome_measure>Domain-specific quality of life at baseline measured by the 8-item environment domain of the WHOQOL-BREF questionnaire (WHOQOL-BREF—Environment); in terms of continuous values.</outcome_measure>
      <outcome_measure>Overall perception of quality of life and overall perception of health at baseline measured by the two items from the Overall QOL and General Health in the WHOQOL-BREF questionnaire—in terms of continuous values.</outcome_measure>
      <outcome_measure>Change from baseline in distress measured by CDPI; in terms of continuous values.</outcome_measure>
      <outcome_measure>Change from baseline in depression measured by the DASS-21—Depression; in terms of continuous values.</outcome_measure>
      <outcome_measure>Change from baseline in anxiety measured by the DASS-21—Anxiety; in terms of continues values.</outcome_measure>
      <outcome_measure>Change from baseline in stress measured by the DASS-21—Stress; in terms of continuous values.</outcome_measure>
      <outcome_measure>Change from baseline in domain-specific quality of life at baseline measured by the WHOQOL-BREF—Physical health; in terms of continuous values.</outcome_measure>
      <outcome_measure>Change from baseline in domain-specific quality of life at baseline measured by the WHOQOL-BREF—Psychological health; in terms of continuous values.</outcome_measure>
      <outcome_measure>Change from baseline in domain-specific quality of life measured by the WHOQOL-BREF—Social relationship; in terms of continuous values.</outcome_measure>
      <outcome_measure>Change from baseline in domain-specific quality of life measured by the WHOQOL-BREF—Environment; in terms of continuous values.</outcome_measure>
      <outcome_measure>Change from baseline in overall perception of quality of life and overall perception of health measured by the 2 items from the Overall QOL and General Health in the WHOQOL-BREF questionnaire; in terms of continuous values.</outcome_measure>
      <outcome_measure>The real-life impact of COVID-19 on systemic treatment administration will be assessed using descriptive statistics</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Ghent</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>180</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 30, 2020</start_date>
    <primary_completion_date>April 2020</primary_completion_date>
    <completion_date>September 2020</completion_date>
    <study_first_posted>April 9, 2020</study_first_posted>
    <last_update_posted>April 9, 2020</last_update_posted>
    <locations>
      <location>University Hospital Gent, Gent, Belgium</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04340219</url>
  </study>
  <study rank="733">
    <nct_id>NCT04357431</nct_id>
    <title>COVID-19 Among Egyptian Health Care Providers</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
    </conditions>
    <interventions>
      <intervention type="Other">self-administered questionnaire</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The percentage of knowledge regarding COVID-19 information</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assiut University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>600</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>May 2020</primary_completion_date>
    <completion_date>May 2020</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04357431</url>
  </study>
  <study rank="734">
    <nct_id>NCT04264858</nct_id>
    <title>Treatment of Acute Severe 2019-nCoV Pneumonia With Immunoglobulin From Cured Patients</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>2019-nCoV</condition>
      <condition>Immunoglobulin of Cured Patients</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Immunoglobulin of cured patients</intervention>
      <intervention type="Drug">γ-Globulin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to Clinical Improvement (TTCI)</outcome_measure>
      <outcome_measure>Clinical status assessed by the ordinal scale</outcome_measure>
      <outcome_measure>The differences in oxygen intake methods</outcome_measure>
      <outcome_measure>Duration (days) of supplemental oxygenation</outcome_measure>
      <outcome_measure>Duration (days) of mechanical ventilation</outcome_measure>
      <outcome_measure>The mean PaO2/FiO2</outcome_measure>
      <outcome_measure>The lesions of the pulmonary segment numbers involved in pulmonary CT [ every 7 days]</outcome_measure>
      <outcome_measure>Time to 2019-nCoV RT-PCR negativity in respiratory tract specimens [every 3 days]</outcome_measure>
      <outcome_measure>Dynamic changes of 2019-nCoV antibody titer in blood</outcome_measure>
      <outcome_measure>Length of hospital stay (days)</outcome_measure>
      <outcome_measure>All cause mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Wuhan Union Hospital, China</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 17, 2020</start_date>
    <primary_completion_date>April 30, 2020</primary_completion_date>
    <completion_date>May 31, 2020</completion_date>
    <study_first_posted>February 11, 2020</study_first_posted>
    <last_update_posted>March 17, 2020</last_update_posted>
    <locations>
      <location>Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04264858</url>
  </study>
  <study rank="735">
    <nct_id>NCT04356885</nct_id>
    <title>COVID-19 and Psychotic Symptoms in France</title>
    <acronym>SCHIZOVID-19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Mental Disorder</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Total score of the Cardiff Anomalous Perceptions Scale (CAPS)</outcome_measure>
      <outcome_measure>Paranoia Scale</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Montpellier</lead_sponsor>
      <collaborator>Epsylon Laboratory, EA 4556, University Paul Valéry Montpellier 3, France</collaborator>
      <collaborator>Laboratoy LIP/PC2S, University Grenobles-Alpes, Grenoble, France</collaborator>
      <collaborator>Centre référent de réhabilitation psychosociale de Grenoble, Grenoble, France</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>600</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>July 30, 2020</primary_completion_date>
    <completion_date>August 1, 2020</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>UH Montpellier, Montpellier, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04356885</url>
  </study>
  <study rank="736">
    <nct_id>NCT04363437</nct_id>
    <title>the COMBAT-COVID-19 Pilot Study</title>
    <acronym>COMBAT-COVID19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Colchicine</intervention>
      <intervention type="Drug">Usual Care and no Colchine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Percentage of Patients requiring supplemental oxygen</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Maimonides Medical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>120 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>70</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 23, 2020</start_date>
    <primary_completion_date>March 31, 2021</primary_completion_date>
    <completion_date>June 30, 2021</completion_date>
    <study_first_posted>April 27, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>Maimonides Medical Center, Brooklyn, New York, United States</location>
    </locations>
    <study_documents>
      <study_document>
        <label>Statistical Analysis Plan</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT04363437/SAP_000.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT04363437</url>
  </study>
  <study rank="737">
    <nct_id>NCT04321811</nct_id>
    <title>Behavior, Environment And Treatments for Covid-19</title>
    <acronym>BEAT19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Observation of patients with known, suspected, or at risk for COVID-19 infection</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Define Natural Symptom Course</outcome_measure>
      <outcome_measure>Time to Hospitalization</outcome_measure>
      <outcome_measure>Time to Symptomatic Recovery</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>xCures</lead_sponsor>
      <collaborator>Genetic Alliance</collaborator>
      <collaborator>LunaDNA</collaborator>
      <collaborator>Cancer Commons</collaborator>
      <collaborator>REDCap Cloud</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100000</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 21, 2020</start_date>
    <primary_completion_date>March 20, 2021</primary_completion_date>
    <completion_date>March 20, 2022</completion_date>
    <study_first_posted>March 25, 2020</study_first_posted>
    <last_update_posted>April 2, 2020</last_update_posted>
    <locations>
      <location>BEAT19.org, San Francisco, California, United States</location>
    </locations>
    <study_documents>
      <study_document>
        <label>Study Protocol and Informed Consent Form</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT04321811/Prot_ICF_000.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT04321811</url>
  </study>
  <study rank="738">
    <nct_id>NCT04339634</nct_id>
    <title>Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Frail Elderly Adults With Polypharmacy</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
      <condition>Drug Effect</condition>
      <condition>Drug Interaction</condition>
      <condition>Adverse Drug Event</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Simulation of Repurposed Drugs for COVID-19</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>To determine the Medication Risk Score of de-identified PACE's participants using their current drug regimen.</outcome_measure>
      <outcome_measure>To simulate the Medication Risk Score following the addition of different repurposed drugs against COVID-19 to their current drug regimen.</outcome_measure>
      <outcome_measure>To compare the impact on Medication Risk Score before and after the addition of repurposed drugs for COVID-19.</outcome_measure>
      <outcome_measure>To assess and compare the effects of various repurposed drugs for COVID-19 on each of the 5 factors computed by algorithms to derive the Medication Risk Score.</outcome_measure>
      <outcome_measure>To investigate the effects of various covariables on the Medication Risk Score in the presence of repurposed drugs for COVID-19.</outcome_measure>
      <outcome_measure>To explore the effects on Medication Risk Score of various repurposed drugs for COVID-19 within subgroups of patients classified by specific diseases or drugs used.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tabula Rasa HealthCare</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>55 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>12123</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>April 7, 2020</start_date>
    <primary_completion_date>July 7, 2020</primary_completion_date>
    <completion_date>April 6, 2021</completion_date>
    <study_first_posted>April 9, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>Tabula Rasa HealthCare Precision Pharmacotherapy Research and Development Institute, Orlando, Florida, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04339634</url>
  </study>
  <study rank="739">
    <nct_id>NCT04360954</nct_id>
    <title>Evaluation of Antibody Tests for COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
      <condition>Coronavirus</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Diagnostic test</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Test Sensitivity</outcome_measure>
      <outcome_measure>Test Specificity</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Washington University School of Medicine</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>April 27, 2020</start_date>
    <primary_completion_date>October 27, 2020</primary_completion_date>
    <completion_date>October 27, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Washington University School of Medicine, Saint Louis, Missouri, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04360954</url>
  </study>
  <study rank="740">
    <nct_id>NCT04344249</nct_id>
    <title>Cohort of Patients With Inflammatory Bowel Disease During COVID-19 Pandemic</title>
    <acronym>IBD-COVID-19</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>IBD</condition>
      <condition>COVID</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>IgG and IgM anti SARS-CoV-2</outcome_measure>
      <outcome_measure>Clinical factors and severity of COVID-19 infection</outcome_measure>
      <outcome_measure>demographic factors and severity of COVID-19 infection</outcome_measure>
      <outcome_measure>pharmacologic factors and severity of COVID-19 infection</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Nantes University Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>100 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>850</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>September 30, 2020</primary_completion_date>
    <completion_date>September 1, 2021</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>Chu Nantes, Nantes, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04344249</url>
  </study>
  <study rank="741">
    <nct_id>NCT04348227</nct_id>
    <title>How COVID-19 Virus Outbreak Affects Antimicrobial Resistance in a Low-middle-income Country's ICU?</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Ventilator Associated Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Enhanced hygiene measures</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>MDR pathogens in endotracheal aspirates</outcome_measure>
      <outcome_measure>Microorganisms in endotracheal aspirates</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hôpital Universitaire Fattouma Bourguiba</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Other</study_design>
    </study_designs>
    <start_date>January 1, 2019</start_date>
    <primary_completion_date>January 1, 2020</primary_completion_date>
    <completion_date>February 4, 2021</completion_date>
    <study_first_posted>April 16, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations>
      <location>Department of anesthesia and intensive care, Fattouma Bourguiba Hospital, Monastir, Tunisia</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04348227</url>
  </study>
  <study rank="742">
    <nct_id>NCT04353583</nct_id>
    <title>Renal Outcome in Patients With COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Acute Kidney Injury</condition>
      <condition>Corona Virus Infection</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Incidence of AKI</outcome_measure>
      <outcome_measure>Renal function changes during hospital stay</outcome_measure>
      <outcome_measure>Incidence of chronic kidney disease</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Giessen</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>July 2020</completion_date>
    <study_first_posted>April 20, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>University Hospital Giessen and Marburg, Giessen, Giessen, Hessen, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04353583</url>
  </study>
  <study rank="743">
    <nct_id>NCT04365309</nct_id>
    <title>Protective Effect of Aspirin on COVID-19 Patients</title>
    <acronym>PEAC</acronym>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Novel Coronavirus Pneumonia</condition>
      <condition>Aspirin</condition>
      <condition>Treatment</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Aspirin 100mg</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>clinical recovery time (TTCR)</outcome_measure>
      <outcome_measure>the time of SARS-CoV2 overcasting</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Xijing Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>85 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>128</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>February 10, 2020</start_date>
    <primary_completion_date>April 2020</primary_completion_date>
    <completion_date>June 2020</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Cai Yue, Xi'an, Shaanxi, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04365309</url>
  </study>
  <study rank="744">
    <nct_id>NCT04361123</nct_id>
    <title>Atrium COVID-19 Syndromic and Serologic Surveillance</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
      <condition>COVID</condition>
    </conditions>
    <interventions>
      <intervention type="Other">daily syndromic surveillance</intervention>
      <intervention type="Diagnostic Test">monthly serologic IgM/G test</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Seroprevalence of SARS-CoV-2 infection in the general population of North Carolina</outcome_measure>
      <outcome_measure>Seroprevalence of SARS-CoV-2 infection among health care workers of North Carolina</outcome_measure>
      <outcome_measure>Cumulative incidence of SARS-CoV-2 infection</outcome_measure>
      <outcome_measure>Monthly incidence of SARS-CoV-2 infection</outcome_measure>
      <outcome_measure>Stratified incidence of SARS-CoV-2 infection by age group</outcome_measure>
      <outcome_measure>Stratified incidence of SARS-CoV-2 infection by sex</outcome_measure>
      <outcome_measure>Stratified incidence of SARS-CoV-2 by season</outcome_measure>
      <outcome_measure>Stratified incidence of SARS-CoV-2 infection by geographic area (zip code)</outcome_measure>
      <outcome_measure>Stratified incidence of SARS-CoV-2 infection by preexisting comorbidities</outcome_measure>
      <outcome_measure>Stratified incidence of SARS-CoV-2 infection by COVID-2 contacts</outcome_measure>
      <outcome_measure>•Stratified incidence of SARS-CoV-2 infection by use of personal protective equipment (PPE) by health workers</outcome_measure>
      <outcome_measure>Relative risk of SARS-CoV-2 infection by age group</outcome_measure>
      <outcome_measure>Relative risk of SARS-CoV-2 infection by sex</outcome_measure>
      <outcome_measure>Relative risk of SARS-CoV-2 infection by season</outcome_measure>
      <outcome_measure>Relative risk of SARS-CoV-2 infection by geographic area (zip code)</outcome_measure>
      <outcome_measure>Relative risk of SARS-CoV-2 infection by preexisting comorbidities</outcome_measure>
      <outcome_measure>Relative risk of SARS-CoV-2 infection by COVID-2 contacts</outcome_measure>
      <outcome_measure>Relative risk of SARS-CoV-2 infection by use of PPE by health workers</outcome_measure>
      <outcome_measure>Incidence of sequelae</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Michael Runyon, MD</lead_sponsor>
      <collaborator>Atrium Health</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>450000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>December 2021</primary_completion_date>
    <completion_date>December 2021</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04361123</url>
  </study>
  <study rank="745">
    <nct_id>NCT04351295</nct_id>
    <title>Efficacy of Faviprevir in COVID-19 Treatment</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Favipiravir</intervention>
      <intervention type="Drug">Placebos</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of patients with viral cure</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tanta University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 17, 2020</start_date>
    <primary_completion_date>December 1, 2030</primary_completion_date>
    <completion_date>December 1, 2030</completion_date>
    <study_first_posted>April 17, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations>
      <location>Tanta University, Tanta, Egypt</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04351295</url>
  </study>
  <study rank="746">
    <nct_id>NCT04357769</nct_id>
    <title>COVID-19 Pandemic Burden in Severe Mental Disease Patients</title>
    <acronym>PsyCOVID</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Psychological Distress</condition>
      <condition>COVID</condition>
      <condition>Severe Mental Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Other">PSS (Perceived Stress Scale)</intervention>
      <intervention type="Other">GAD-7 (7-item Generalized Anxiety Disorder)</intervention>
      <intervention type="Other">PHQ-9 (9-item Patient Health Questionnaire)</intervention>
      <intervention type="Other">SPEQ (Specific Psychotic Experiences Questionnaire) - Paranoia and Grandiosity Subscales</intervention>
      <intervention type="Other">Zaritt Burden Interview</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Perceived Stress Scale (PSS) outcome</outcome_measure>
      <outcome_measure>Generalized Anxiety Disorder (GAD-7) scale outcome</outcome_measure>
      <outcome_measure>Patient Health Questionnaire (PHQ-9) scale outcome</outcome_measure>
      <outcome_measure>Specific Psychotic Experiences Questionnaire (SPEQ) - Paranoia subscale outcome</outcome_measure>
      <outcome_measure>Specific Psychotic Experiences Questionnaire (SPEQ) - Grandiosity subscale outcome</outcome_measure>
      <outcome_measure>Caregiver Burden</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Federico II University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <start_date>April 10, 2020</start_date>
    <primary_completion_date>April 20, 2020</primary_completion_date>
    <completion_date>April 25, 2020</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>University of Naples &quot;Federico II&quot;, Napoli, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04357769</url>
  </study>
  <study rank="747">
    <nct_id>NCT04356365</nct_id>
    <title>The Mental Health Status of the General Population During the COVID-19 Pandemic and Its Association With Adherence to Government-initiated Non-pharmacological Epidemiological Interventions (NPI's)</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Depression</condition>
      <condition>Generalized Anxiety</condition>
      <condition>Adherence to Non-pharmacological Epidemiological Interventions (NPIs)</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Cross-sectional study investigating the association of NPIs with mental health</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Patient Health Questionnaire 9</outcome_measure>
      <outcome_measure>Generalized Anxiety Disorder 7</outcome_measure>
      <outcome_measure>Measures of adherence</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Oslo</lead_sponsor>
      <collaborator>Modum Bad Psychiatric Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>10084</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <start_date>March 31, 2020</start_date>
    <primary_completion_date>April 7, 2020</primary_completion_date>
    <completion_date>April 7, 2020</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>University of Oslo, Oslo, Norway</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04356365</url>
  </study>
  <study rank="748">
    <nct_id>NCT04337502</nct_id>
    <title>Clinical and Radiomic Model of COVID-19</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
      <condition>Machine Learning</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Machine learning model</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Predictive performance</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Maastricht University</lead_sponsor>
      <collaborator>The Central Hospital of Wuhan</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>December 23, 2019</start_date>
    <primary_completion_date>January 20, 2020</primary_completion_date>
    <completion_date>March 3, 2020</completion_date>
    <study_first_posted>April 7, 2020</study_first_posted>
    <last_update_posted>April 7, 2020</last_update_posted>
    <locations>
      <location>The central hospital of Wuhan, Wuhan, Hubei, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04337502</url>
  </study>
  <study rank="749">
    <nct_id>NCT04326452</nct_id>
    <title>Treating COVID-19 With a Bidirectional Oxygenation Valve</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Device">bidirectional oxygenation mouthpiece</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Pulse oximetry level</outcome_measure>
      <outcome_measure>Respiratory rate</outcome_measure>
      <outcome_measure>Heart rate</outcome_measure>
      <outcome_measure>Blood pressure</outcome_measure>
      <outcome_measure>Systemic carbon dioxide</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>TMC HealthCare</lead_sponsor>
      <collaborator>PEEP Medical, LLC</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 27, 2020</start_date>
    <primary_completion_date>May 1, 2020</primary_completion_date>
    <completion_date>June 1, 2020</completion_date>
    <study_first_posted>March 30, 2020</study_first_posted>
    <last_update_posted>April 1, 2020</last_update_posted>
    <locations>
      <location>TMC HealthCare, Tucson, Arizona, United States</location>
      <location>Stanford University, Stanford, California, United States</location>
      <location>Emory Saint Joseph's Hospital, Atlanta, Georgia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04326452</url>
  </study>
  <study rank="750">
    <nct_id>NCT04335162</nct_id>
    <title>Cardiovascular Complications and COVID-19 (CovCardioVasc)</title>
    <acronym>CovCardioVasc</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
      <condition>Acute Coronary Syndrome</condition>
      <condition>Myocardial Infarction</condition>
      <condition>Myocarditis</condition>
      <condition>Venous Thromboembolism</condition>
      <condition>Deep Vein Thrombosis</condition>
      <condition>Pulmonary Embolism</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Determine the incidence of cardiomyopathies and venous thromboembolism</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>Duration of mechanical ventilation</outcome_measure>
      <outcome_measure>shock at day 28</outcome_measure>
      <outcome_measure>length of stay in the intensive care unit</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier Universitaire de Nice</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>February 28, 2020</start_date>
    <primary_completion_date>August 28, 2020</primary_completion_date>
    <completion_date>August 28, 2020</completion_date>
    <study_first_posted>April 6, 2020</study_first_posted>
    <last_update_posted>April 6, 2020</last_update_posted>
    <locations>
      <location>CHU de Nice, Nice, France</location>
      <location>Hôpitaux Universitaires Paris Centre - Hôpital Cochin, Paris, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04335162</url>
  </study>
  <study rank="751">
    <nct_id>NCT04312243</nct_id>
    <title>NO Prevention of COVID-19 for Healthcare Providers</title>
    <acronym>NOpreventCOVID</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infections</condition>
      <condition>Healthcare Associated Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Inhaled nitric oxide gas</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>COVID-19 diagnosis</outcome_measure>
      <outcome_measure>Positive SARS-CoV-2 rt-PCR test</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Massachusetts General Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>99 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>470</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 2, 2020</start_date>
    <primary_completion_date>March 20, 2021</primary_completion_date>
    <completion_date>March 20, 2022</completion_date>
    <study_first_posted>March 18, 2020</study_first_posted>
    <last_update_posted>April 3, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04312243</url>
  </study>
  <study rank="752">
    <nct_id>NCT04344197</nct_id>
    <title>Surgery During Covid-19: The Role of Asymptomatic Patients, a Survey</title>
    <acronym/>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Surgery</condition>
      <condition>COVID</condition>
      <condition>Asymptomatic Patient</condition>
      <condition>Covid-19</condition>
      <condition>Preventive Measures</condition>
    </conditions>
    <interventions>
      <intervention type="Other">global survey</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>overview of surgical management on preventive measures of hospital infection spread during covid 19</outcome_measure>
      <outcome_measure>testing policies and preventive measures for Covid-19, and their association with asymptomatic cases.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Rome Tor Vergata</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <start_date>April 2, 2020</start_date>
    <primary_completion_date>April 8, 2020</primary_completion_date>
    <completion_date>April 15, 2020</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>Tor Vergata Hospital, Rome, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04344197</url>
  </study>
  <study rank="753">
    <nct_id>NCT04335279</nct_id>
    <title>Evaluation of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together Program</title>
    <acronym>SPIN-CHAT</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Scleroderma</condition>
      <condition>Scleroderma, Systemic</condition>
      <condition>Systemic Sclerosis</condition>
    </conditions>
    <interventions>
      <intervention type="Other">SPIN-CHAT Program</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Anxiety: Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety 4a v1.0</outcome_measure>
      <outcome_measure>Depression symptoms: Patient Health Questionnaire (PHQ-8)</outcome_measure>
      <outcome_measure>Stress: Perceived Stress Scale (PSS)</outcome_measure>
      <outcome_measure>Loneliness: University of California, Los Angeles (UCLA) Loneliness Scale (ULS-6)</outcome_measure>
      <outcome_measure>Boredom: Multidimensional State Boredom Scale (MSBS-8)</outcome_measure>
      <outcome_measure>Physical activity: International Physical Activity Questionnaire - modified for the elderly (IPAQ-E)</outcome_measure>
      <outcome_measure>Frequency of social interactions</outcome_measure>
      <outcome_measure>Adverse Effects</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Lady Davis Institute</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>195</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <start_date>April 9, 2020</start_date>
    <primary_completion_date>June 3, 2020</primary_completion_date>
    <completion_date>June 3, 2020</completion_date>
    <study_first_posted>April 6, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Jewish General Hospital, Montreal, Quebec, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04335279</url>
  </study>
  <study rank="754">
    <nct_id>NCT04359849</nct_id>
    <title>Sequencing and Tracking of Phylogeny in COVID-19 Study</title>
    <acronym>STOP COVID 19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infection</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>To produce whole genome sequences for the SARS-CoV-2 virus from viral RNA samples</outcome_measure>
      <outcome_measure>To develop a phylogenetic map of the SARS-CoV-2 virus</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Portsmouth Hospitals NHS Trust</lead_sponsor>
      <collaborator>University of Portsmouth</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>7 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>May 2020</start_date>
    <primary_completion_date>May 2022</primary_completion_date>
    <completion_date>September 2022</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Portsmouth Hospitals NHS Trust, Queen Alexandra Hospital, Portsmouth, Hampshire, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04359849</url>
  </study>
  <study rank="755">
    <nct_id>NCT04322565</nct_id>
    <title>Colchicine Counteracting Inflammation in COVID-19 Pneumonia</title>
    <acronym>ColCOVID-19</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infections</condition>
      <condition>Pneumonia, Viral</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Colchicine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clinical improvement</outcome_measure>
      <outcome_measure>Hospital discharge</outcome_measure>
      <outcome_measure>Death</outcome_measure>
      <outcome_measure>Clinical status</outcome_measure>
      <outcome_measure>Mechanical ventilhation</outcome_measure>
      <outcome_measure>Hospitalization</outcome_measure>
      <outcome_measure>Time from treatment initiation to death</outcome_measure>
      <outcome_measure>Time to Negativization COVID 19</outcome_measure>
      <outcome_measure>Fever</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Azienda Ospedaliero-Universitaria di Parma</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>100 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>310</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>June 20, 2020</primary_completion_date>
    <completion_date>July 20, 2020</completion_date>
    <study_first_posted>March 26, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04322565</url>
  </study>
  <study rank="756">
    <nct_id>NCT04341012</nct_id>
    <title>Breath Analysis Based Disease Biomarkers of COVID-19 and Other Diseases</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Liver Diseases</condition>
      <condition>Liver Cancer</condition>
      <condition>COVID19</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Collection of breath sample</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Breath volatile organic compound profiles</outcome_measure>
      <outcome_measure>Utility of breath profiles for disease diagnosis or prognosis</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Mayo Clinic</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>September 10, 2019</start_date>
    <primary_completion_date>December 31, 2021</primary_completion_date>
    <completion_date>December 31, 2021</completion_date>
    <study_first_posted>April 10, 2020</study_first_posted>
    <last_update_posted>April 13, 2020</last_update_posted>
    <locations>
      <location>Mayo Clinic Florida, Jacksonville, Florida, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04341012</url>
  </study>
  <study rank="757">
    <nct_id>NCT04361526</nct_id>
    <title>Pilot Study on Cytokine Filtration in COVID-19 ARDS</title>
    <acronym>CytokCOVID19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infection</condition>
      <condition>Acute Respiratory Distress Syndrome</condition>
      <condition>COVID</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Cytokine Adsorption</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mechanical ventilation-free days</outcome_measure>
      <outcome_measure>30-day mortality</outcome_measure>
      <outcome_measure>length of ICU stay (days)</outcome_measure>
      <outcome_measure>length of hospital stay</outcome_measure>
      <outcome_measure>Duration of renal replacement and cathecolamines therapies</outcome_measure>
      <outcome_measure>Need for extracorporeal membrane oxygenation (ECMO) support</outcome_measure>
      <outcome_measure>multi-organ failure measured by the Sequential Organ Failure Assessment (SOFA) score</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Manuel Castellà</lead_sponsor>
      <collaborator>Hospital Clinic of Barcelona</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 17, 2020</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>July 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Hospital Clínic de Barcelona, Barcelona, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04361526</url>
  </study>
  <study rank="758">
    <nct_id>NCT04357041</nct_id>
    <title>COVID-19 Survey Study on Dietary Intake, Physical Activity and Overall Well-being</title>
    <acronym>CoVS</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>ALL, Adult</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Automated Self-Administered 24-Hour Dietary Recall (ASA24)</outcome_measure>
      <outcome_measure>International Physical Activity Questionnaire (IPAQ)</outcome_measure>
      <outcome_measure>Health-Related Quality of Life SF-12 Scale</outcome_measure>
      <outcome_measure>State trait inventory for cognitive and somatic anxiety (STISA).</outcome_measure>
      <outcome_measure>Beck Depression inventory (BDI)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Clinical Nutrition Research Center, Illinois Institute of Technology</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Other</study_design>
    </study_designs>
    <start_date>April 17, 2020</start_date>
    <primary_completion_date>December 2020</primary_completion_date>
    <completion_date>April 2021</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Clinical Nutrition Research Center, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04357041</url>
  </study>
  <study rank="759">
    <nct_id>NCT04355624</nct_id>
    <title>Kidney Involvement in COVID-19 Disease (COVKID)</title>
    <acronym>COVKID</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
      <condition>Kidney Injury</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Kidney involvement in COVID-19 disease</outcome_measure>
      <outcome_measure>Physiopathologic mechanism of kidney involvement in SARS-CoV-2 infection</outcome_measure>
      <outcome_measure>To identify risk factors for kidney involvement in in SARS-CoV-2 infection</outcome_measure>
      <outcome_measure>To evaluate the impact of kidney involvement in SARS-CoV-2 infection</outcome_measure>
      <outcome_measure>To assess the long-term health effect of kidney injury on survivors of SARS-CoV-2 infection in case of AKI KDIGO 2 or 3</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier Universitaire de Nice</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>April 30, 2020</primary_completion_date>
    <completion_date>July 30, 2020</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>Centre hospitalier d'Antibes Juan les pins, Antibes, France</location>
      <location>Centre hospitalier de Cannes, Cannes, France</location>
      <location>Centre hospitalier de Grasse, Grasse, France</location>
      <location>CHU de Nice, Nice, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04355624</url>
  </study>
  <study rank="760">
    <nct_id>NCT04363840</nct_id>
    <title>The LEAD COVID-19 Trial: Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations</title>
    <acronym>LEAD COVID-19</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
      <condition>Vitamin D Deficiency</condition>
      <condition>Coagulopathy</condition>
      <condition>Disseminated Intravascular Coagulation</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Aspirin 81 mg</intervention>
      <intervention type="Dietary Supplement">Vitamin D</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Hospitalization</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Louisiana State University Health Sciences Center in New Orleans</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>1080</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 2020</start_date>
    <primary_completion_date>December 2020</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>April 27, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04363840</url>
  </study>
  <study rank="761">
    <nct_id>NCT04351516</nct_id>
    <title>Test and Treat COVID 65plus+</title>
    <acronym>COVID65plus</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV 2</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>● Rate of hospitalization or death at day 7 after study inclusion</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital Tuebingen</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>65 Years</min_age>
    <age_groups>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>350</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 21, 2020</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>May 1, 2021</completion_date>
    <study_first_posted>April 17, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Uniklinikum Tuebingen, Tuebingen, Germany</location>
      <location>Uniklinikum Ulm, Ulm, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04351516</url>
  </study>
  <study rank="762">
    <nct_id>NCT04337047</nct_id>
    <title>Assessment of Distress in Crisis Situations During COVID-19</title>
    <acronym/>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Stress, Psychological</condition>
    </conditions>
    <interventions>
      <intervention type="Other">questionnaire assesment</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>quantify and qualify distress over a large population in times of pandemic crisis.</outcome_measure>
      <outcome_measure>qualify demographic data vs distress over a large population in times of pandemic crisis.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Wefight</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>2000</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 31, 2020</start_date>
    <primary_completion_date>April 30, 2020</primary_completion_date>
    <completion_date>May 31, 2020</completion_date>
    <study_first_posted>April 7, 2020</study_first_posted>
    <last_update_posted>April 7, 2020</last_update_posted>
    <locations>
      <location>Wefight, Montpellier, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04337047</url>
  </study>
  <study rank="763">
    <nct_id>NCT04306055</nct_id>
    <title>Blood Donor Recruitment During Epidemic of COVID-19</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Blood Donation</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Questionnaire with precaution information</intervention>
      <intervention type="Other">Experimental: Questionnaire without precaution information</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Differences of attitude about blood donation towards different questionnaires</outcome_measure>
      <outcome_measure>Rates of blood donation during 3 weeks</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Guangzhou Blood Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>19491</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Health Services Research</study_design>
    </study_designs>
    <start_date>March 13, 2020</start_date>
    <primary_completion_date>March 13, 2020</primary_completion_date>
    <completion_date>April 3, 2020</completion_date>
    <study_first_posted>March 12, 2020</study_first_posted>
    <last_update_posted>April 13, 2020</last_update_posted>
    <locations>
      <location>Guangzhou Blood Center, Guangzhou, Guangdong, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04306055</url>
  </study>
  <study rank="764">
    <nct_id>NCT04365361</nct_id>
    <title>The Psychological Impact of the COVID-19 on Students.</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Mental Health Wellness 1</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Stress level</outcome_measure>
      <outcome_measure>Anxiety and depressive symptoms</outcome_measure>
      <outcome_measure>Insomnia symptoms and the associated daytime impairment</outcome_measure>
      <outcome_measure>Psychological response to trauma</outcome_measure>
      <outcome_measure>Resilience</outcome_measure>
      <outcome_measure>Attitude and practice students regarding preventive measures</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>The University of Hong Kong</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>100 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Ecologic or Community</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 26, 2020</start_date>
    <primary_completion_date>December 30, 2020</primary_completion_date>
    <completion_date>March 31, 2021</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04365361</url>
  </study>
  <study rank="765">
    <nct_id>NCT04357613</nct_id>
    <title>IMATINIB IN COVID-19 DISEASE IN AGED PATIENTS.</title>
    <acronym>IMAGE-19</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Experimental drug</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>To evaluate the benefit of early imatinib therapy to prevent severe COVID-19 disease in hospitalized aged patients.</outcome_measure>
      <outcome_measure>To evaluate the feasibility of imatinib therapy.</outcome_measure>
      <outcome_measure>To evaluate safety of imatinib therapy</outcome_measure>
      <outcome_measure>To evaluate the clinical evolution</outcome_measure>
      <outcome_measure>To evaluate the progression rate to severe COVID-19 disease</outcome_measure>
      <outcome_measure>To evaluate mortality</outcome_measure>
      <outcome_measure>To evaluate viral load</outcome_measure>
      <outcome_measure>To evaluate plasmatic levels of imatinib</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Versailles Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>70 Years</min_age>
    <age_groups>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>99</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 1, 2020</start_date>
    <primary_completion_date>November 1, 2020</primary_completion_date>
    <completion_date>December 1, 2020</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>CHU Bordeaux, Bordeaux, France</location>
      <location>CH de Versailles, Le Chesnay, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04357613</url>
  </study>
  <study rank="766">
    <nct_id>NCT04320732</nct_id>
    <title>Risk Factors for Community- and Workplace Transmission of COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Observation of behavior and COVID-19 infection will be conducted.</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Rate of COVID-19 infection</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Oslo University Hospital</lead_sponsor>
      <collaborator>Age Labs AS</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>50000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 27, 2020</start_date>
    <primary_completion_date>March 27, 2022</primary_completion_date>
    <completion_date>March 20, 2030</completion_date>
    <study_first_posted>March 25, 2020</study_first_posted>
    <last_update_posted>March 31, 2020</last_update_posted>
    <locations>
      <location>Oslo University Hospital, Oslo, Norway</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04320732</url>
  </study>
  <study rank="767">
    <nct_id>NCT04320238</nct_id>
    <title>Experimental Trial of rhIFNα Nasal Drops to Prevent 2019-nCOV in Medical Staff</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>2019 Novel Coronavirus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">recombinant human interferon Alpha-1b</intervention>
      <intervention type="Drug">thymosin alpha 1</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>new-onset COVID-19</outcome_measure>
      <outcome_measure>Number of Participants with coronavirus related symptoms</outcome_measure>
      <outcome_measure>Number of Participants with adverse effect</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Shanghai Jiao Tong University School of Medicine</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>2944</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>January 21, 2020</start_date>
    <primary_completion_date>May 2020</primary_completion_date>
    <completion_date>June 2020</completion_date>
    <study_first_posted>March 24, 2020</study_first_posted>
    <last_update_posted>March 31, 2020</last_update_posted>
    <locations>
      <location>Taihe Hospital, Shiyan, Hubei, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04320238</url>
  </study>
  <study rank="768">
    <nct_id>NCT04340414</nct_id>
    <title>Safety and Effectiveness of Low-flow ECMO Driving by CVVH Machine in Severe NCP</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>ECMO</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Low flow ECMO driving by CVVH machine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>PaCO2</outcome_measure>
      <outcome_measure>Driving Pressure</outcome_measure>
      <outcome_measure>Tidal volume</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Peking Union Medical College Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>14 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 3, 2020</start_date>
    <primary_completion_date>August 15, 2020</primary_completion_date>
    <completion_date>October 15, 2020</completion_date>
    <study_first_posted>April 9, 2020</study_first_posted>
    <last_update_posted>April 9, 2020</last_update_posted>
    <locations>
      <location>Yun Long, Beijing, Beijing, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04340414</url>
  </study>
  <study rank="769">
    <nct_id>NCT04337008</nct_id>
    <title>Renin Angiotensin System - CoronaVirus</title>
    <acronym>SRA-COV</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID 19</condition>
    </conditions>
    <interventions>
      <intervention type="Other">blood draw</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>overactivity of the renin / aldosterone system</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique Hopitaux De Marseille</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <start_date>April 3, 2020</start_date>
    <primary_completion_date>June 3, 2020</primary_completion_date>
    <completion_date>July 31, 2020</completion_date>
    <study_first_posted>April 7, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>ASSISTANCE PUBLIQUE HÖPITAUX de MARSEILLE, Marseille, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04337008</url>
  </study>
  <study rank="770">
    <nct_id>NCT04331886</nct_id>
    <title>An Observational Study of Patients With Coronavirus Disease 2019</title>
    <acronym>COVID-19</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Coronavirus</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Natural history of COVID-19: Characteristics of COVID-19</outcome_measure>
      <outcome_measure>Natural history of COVID-19: Participant demographics</outcome_measure>
      <outcome_measure>Natural history of COVID-19: Treatment use</outcome_measure>
      <outcome_measure>Time point of clinical response</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Target PharmaSolutions, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>5000</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Other</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>March 2021</primary_completion_date>
    <completion_date>March 2021</completion_date>
    <study_first_posted>April 2, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations>
      <location>University of Washington, Seattle, Washington, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04331886</url>
  </study>
  <study rank="771">
    <nct_id>NCT04340921</nct_id>
    <title>The Role of Adaptive Immunity in COVID-19 Associated Myocardial Injury</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cardiovascular Disease Acute</condition>
      <condition>Cardiomyopathies</condition>
      <condition>COVID</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">COVID-19 exposure</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>T-cell immunophenotype</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>ITU admission</outcome_measure>
      <outcome_measure>Myocardial injury</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Barts &amp; The London NHS Trust</lead_sponsor>
      <collaborator>Queen Mary University of London</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>140</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 10, 2020</start_date>
    <primary_completion_date>April 10, 2020</primary_completion_date>
    <completion_date>June 10, 2020</completion_date>
    <study_first_posted>April 10, 2020</study_first_posted>
    <last_update_posted>April 10, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04340921</url>
  </study>
  <study rank="772">
    <nct_id>NCT04293887</nct_id>
    <title>Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Recombinant Human Interferon α1β</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Recombinant human interferon α1β</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The incidence of side effects</outcome_measure>
      <outcome_measure>Time from patient enrollment to clinical remission</outcome_measure>
      <outcome_measure>Proportion of patients with normal body</outcome_measure>
      <outcome_measure>Proportion of patients without dyspnea</outcome_measure>
      <outcome_measure>Proportion of patients without cough</outcome_measure>
      <outcome_measure>Proportion</outcome_measure>
      <outcome_measure>The negative conversion rate of new coronavirus nucleic acid</outcome_measure>
      <outcome_measure>Frequency of serious adverse drug events.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tongji Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Early Phase 1</phase>
    </phases>
    <enrollment>328</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 1, 2020</start_date>
    <primary_completion_date>May 30, 2020</primary_completion_date>
    <completion_date>June 30, 2020</completion_date>
    <study_first_posted>March 3, 2020</study_first_posted>
    <last_update_posted>March 3, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04293887</url>
  </study>
  <study rank="773">
    <nct_id>NCT04333654</nct_id>
    <title>Hydroxychloroquine in Outpatient Adults With COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine SAR321068</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change from baseline to Day 3 in nasopharyngeal SARS-CoV-2 viral load (if quantitative PCR is available)</outcome_measure>
      <outcome_measure>Number of participants by PCR result status (positive or negative) (if quantitative PCR is not available)</outcome_measure>
      <outcome_measure>Change from baseline to Day 5 in nasopharyngeal SARS-CoV-2 viral load</outcome_measure>
      <outcome_measure>Number of participants by PCR result status (positive or negative)</outcome_measure>
      <outcome_measure>Number of participants with COVID-19 symptoms by severity</outcome_measure>
      <outcome_measure>Time to resolution of COVID-19 Symptoms</outcome_measure>
      <outcome_measure>Time to resolution of fever</outcome_measure>
      <outcome_measure>Percentage of participants with resolution of fever</outcome_measure>
      <outcome_measure>Percentage of participants hospitalized</outcome_measure>
      <outcome_measure>Number of participants with Adverse Events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sanofi</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>210</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 12, 2020</start_date>
    <primary_completion_date>May 2020</primary_completion_date>
    <completion_date>May 2020</completion_date>
    <study_first_posted>April 3, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Investigational Site Number 8400001, Boston, Massachusetts, United States</location>
      <location>Investigational Site Number 2501001, Bordeaux Cedex, France</location>
      <location>Investigational Site Number 2501002, Paris, France</location>
      <location>Investigational Site Number 5281001, Groningen, Netherlands</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04333654</url>
  </study>
  <study rank="774">
    <nct_id>NCT04338945</nct_id>
    <title>Impact of Pandemic COVID-19 on Surgical Specialities Residents in Italy</title>
    <acronym/>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">COVID-surgRES questionaire</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Measure of the impact of COVID Emergency on surgical specialist training programs</outcome_measure>
      <outcome_measure>Measure of impact of COVID Emergency on wellness of residents</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ospedale Policlinico San Martino</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 15, 2020</start_date>
    <primary_completion_date>April 15, 2020</primary_completion_date>
    <completion_date>May 1, 2020</completion_date>
    <study_first_posted>April 8, 2020</study_first_posted>
    <last_update_posted>April 10, 2020</last_update_posted>
    <locations>
      <location>U.O.C. Chirurgia Generale Universitaria &quot;V. Bonomo&quot;, Bari, Italy</location>
      <location>Ospedale Perrino Asl Brindisi, Brindisi, Italy</location>
      <location>Dipartimento di scienze mediche e chirurgiche, Università di Catanzaro, Catanzaro, Italy</location>
      <location>Ospedale Policlinico San Martino, Genova, Italy</location>
      <location>Azienda Ospedaliera San Camillo-Forlanini, Roma, Italy</location>
      <location>IRCCS Fondazione Policlinico Universitario Agostino Gemelli, Roma, Italy</location>
      <location>Ospedale Cristo re, Roma, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04338945</url>
  </study>
  <study rank="775">
    <nct_id>NCT04346420</nct_id>
    <title>Impact of the Double-Trunk Mask on Oxygenation Titration in COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
      <condition>Hypoxemia</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Standard interface</intervention>
      <intervention type="Device">Double-Trunk Mask</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in O2 output</outcome_measure>
      <outcome_measure>Comfort with the interfaces</outcome_measure>
      <outcome_measure>Changes in PaO2</outcome_measure>
      <outcome_measure>Changes in PaCO2</outcome_measure>
      <outcome_measure>Changes in pH</outcome_measure>
      <outcome_measure>Changes in respiratory rate</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <start_date>April 9, 2020</start_date>
    <primary_completion_date>June 30, 2020</primary_completion_date>
    <completion_date>June 30, 2020</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>Cliniques universitaires Saint-Luc, Brussels, Brussels Capital, Belgium</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04346420</url>
  </study>
  <study rank="776">
    <nct_id>NCT04316884</nct_id>
    <title>Mechanisms for Organ Dysfunction in Covid-19</title>
    <acronym>UMODCOVID19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Organ Dysfunction Syndrome Sepsis</condition>
      <condition>Organ Dysfunction Syndrome, Multiple</condition>
      <condition>Septic Shock</condition>
      <condition>Acute Kidney Injury</condition>
      <condition>Acute Respiratory Distress Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Acute Kidney Injury</outcome_measure>
      <outcome_measure>ARDS</outcome_measure>
      <outcome_measure>30 day mortality</outcome_measure>
      <outcome_measure>1 year mortality</outcome_measure>
      <outcome_measure>Chronic Kidney Disease</outcome_measure>
      <outcome_measure>SOFA-score</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Uppsala University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 12, 2020</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>December 31, 2021</completion_date>
    <study_first_posted>March 20, 2020</study_first_posted>
    <last_update_posted>March 20, 2020</last_update_posted>
    <locations>
      <location>Uppsala University Hospital, Uppsala, Sweden</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04316884</url>
  </study>
  <study rank="777">
    <nct_id>NCT04337489</nct_id>
    <title>Remote Monitoring Use In Cases Of Suspected COVID-19 (Coronavirus)</title>
    <acronym>REMOTE-COVID</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
    </conditions>
    <interventions>
      <intervention type="Device">SensiumVitals wearable sensor</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Deterioration resulting in healthcare review</outcome_measure>
      <outcome_measure>Hospitalisation</outcome_measure>
      <outcome_measure>Participant anxiety</outcome_measure>
      <outcome_measure>Participant depression</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Imperial College London</lead_sponsor>
      <collaborator>CW+ Charity</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>95 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>April 1, 2021</primary_completion_date>
    <completion_date>April 1, 2021</completion_date>
    <study_first_posted>April 7, 2020</study_first_posted>
    <last_update_posted>April 7, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04337489</url>
  </study>
  <study rank="778">
    <nct_id>NCT04296643</nct_id>
    <title>Medical Masks vs N95 Respirators for COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
      <condition>N95</condition>
      <condition>Medical Mask</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Medical Mask</intervention>
      <intervention type="Device">N95 respirator</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>RT-PCR confirmed COVID-19 infection</outcome_measure>
      <outcome_measure>Acute respiratory illness</outcome_measure>
      <outcome_measure>Absenteeism</outcome_measure>
      <outcome_measure>Lower respiratory infection</outcome_measure>
      <outcome_measure>Pneumonia</outcome_measure>
      <outcome_measure>ICU admission</outcome_measure>
      <outcome_measure>Mechanical ventilation</outcome_measure>
      <outcome_measure>Death</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>McMaster University</lead_sponsor>
      <collaborator>Vancouver Coastal Health</collaborator>
      <collaborator>University of Alberta</collaborator>
      <collaborator>Dalhousie University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>576</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>December 1, 2020</primary_completion_date>
    <completion_date>January 1, 2021</completion_date>
    <study_first_posted>March 5, 2020</study_first_posted>
    <last_update_posted>March 5, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04296643</url>
  </study>
  <study rank="779">
    <nct_id>NCT04343898</nct_id>
    <title>Study of the Treatment and Outcomes in Critically Ill Patients With COVID-19</title>
    <acronym>STOP-COVID</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Other">No intervention</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>14-Day Mortality</outcome_measure>
      <outcome_measure>21-Day Mortality</outcome_measure>
      <outcome_measure>28-Day Mortality</outcome_measure>
      <outcome_measure>60-Day Mortality</outcome_measure>
      <outcome_measure>90-Day Mortality</outcome_measure>
      <outcome_measure>1-Year Mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Brigham and Women's Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>2000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Other</study_design>
    </study_designs>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>April 15, 2020</primary_completion_date>
    <completion_date>June 1, 2022</completion_date>
    <study_first_posted>April 13, 2020</study_first_posted>
    <last_update_posted>April 16, 2020</last_update_posted>
    <locations>
      <location>Brigham and Women's Hospital, Boston, Massachusetts, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04343898</url>
  </study>
  <study rank="780">
    <nct_id>NCT04351347</nct_id>
    <title>The Efficacy of Ivermectin and Nitazoxanide in COVID-19 Treatment</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Chloroquine</intervention>
      <intervention type="Drug">Nitazoxanide</intervention>
      <intervention type="Drug">Ivermectin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of patients with virological cure</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tanta University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 17, 2020</start_date>
    <primary_completion_date>December 1, 2030</primary_completion_date>
    <completion_date>December 1, 2030</completion_date>
    <study_first_posted>April 17, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations>
      <location>Tanta University, Tanta, Egypt</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04351347</url>
  </study>
  <study rank="781">
    <nct_id>NCT04346342</nct_id>
    <title>PRactice of VENTilation in COVID-19 Patients (PRoVENT-COVID)</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
      <condition>Mechanical Ventilation</condition>
      <condition>Acute Respiratory Failure</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Ventilation Mode</outcome_measure>
      <outcome_measure>Tidal volume set</outcome_measure>
      <outcome_measure>Expiratory tidal volume</outcome_measure>
      <outcome_measure>Positive end-expiratory pressure</outcome_measure>
      <outcome_measure>Maximum airway pressure or plateau pressure (Pplateau) or peak pressure (Ppeak) (cm H2O);</outcome_measure>
      <outcome_measure>Level of pressure support above PEEP</outcome_measure>
      <outcome_measure>Inspired fraction of oxygen</outcome_measure>
      <outcome_measure>Set and measured respiratory rate</outcome_measure>
      <outcome_measure>Inspiration to expiration ratio</outcome_measure>
      <outcome_measure>Number of ventilation-free days and alive at day 28</outcome_measure>
      <outcome_measure>Duration of ventilation in survivors;</outcome_measure>
      <outcome_measure>Use of prone positioning</outcome_measure>
      <outcome_measure>Use of recruitment maneuvers</outcome_measure>
      <outcome_measure>Incidence of acute kidney injury</outcome_measure>
      <outcome_measure>Duration of ICU stay</outcome_measure>
      <outcome_measure>Duration of hospital stay</outcome_measure>
      <outcome_measure>ICU mortality</outcome_measure>
      <outcome_measure>Hospital mortality</outcome_measure>
      <outcome_measure>28-day mortality</outcome_measure>
      <outcome_measure>90-day mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>March 6, 2020</start_date>
    <primary_completion_date>May 2020</primary_completion_date>
    <completion_date>August 2020</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>Flevoziekenhuis, Almere, Netherlands</location>
      <location>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Amsterdam, Netherlands</location>
      <location>Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands</location>
      <location>Gelre hospitals, Apeldoorn, Netherlands</location>
      <location>Rijnstate Hospital, Arnhem, Netherlands</location>
      <location>Amphia Hospital, Breda, Netherlands</location>
      <location>Reinier de Graaf Groep, Delft, Netherlands</location>
      <location>Haga Hospital, Den Haag, Netherlands</location>
      <location>Medical Center Haaglanden, Den Haag, Netherlands</location>
      <location>Gelderse Vallei Hospital, Ede, Netherlands</location>
      <location>Catharina Ziekenhuis, Eindhoven, Netherlands</location>
      <location>Maxima Medical Center, Eindhoven, Netherlands</location>
      <location>University Medical Center Groningen, Groningen, Netherlands</location>
      <location>Spaarne Gasthuis, Haarlem, Netherlands</location>
      <location>Dijklander Ziekenhuis, Hoorn, Netherlands</location>
      <location>Medical Centre Leeuwarden, Leeuwarden, Netherlands</location>
      <location>Maasstad Hospital, Rotterdam, Netherlands</location>
      <location>Zuyderland Medical Centre, Sittard, Netherlands</location>
      <location>UMC Utrecht, Utrecht, Netherlands</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04346342</url>
  </study>
  <study rank="782">
    <nct_id>NCT04319016</nct_id>
    <title>Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy</title>
    <acronym>COVID-preg</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Infection Viral</condition>
    </conditions>
    <interventions>
      <intervention type="Other">pregnant women with laboratory-confirmed 2019-n-CoV</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Maternal and perinatal outcomes</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Federico II University</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Other</study_design>
    </study_designs>
    <start_date>January 1, 2020</start_date>
    <primary_completion_date>April 30, 2020</primary_completion_date>
    <completion_date>May 1, 2020</completion_date>
    <study_first_posted>March 24, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Gabriele Saccone, Napoli, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04319016</url>
  </study>
  <study rank="783">
    <nct_id>NCT04344561</nct_id>
    <title>Incline Positioning in COVID-19 Patients for Improvement in Oxygen Saturation</title>
    <acronym>UPSAT</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
      <condition>Hypoxic Respiratory Failure</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Postural Positioning</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Incidence of Mechanical Ventilation</outcome_measure>
      <outcome_measure>Percentage of time in the assigned position</outcome_measure>
      <outcome_measure>Number of participants with supplemental oxygen requirements</outcome_measure>
      <outcome_measure>Change in mean oxyhemoglobin saturation</outcome_measure>
      <outcome_measure>Change in Nocturnal Oxyhemoglobin saturation</outcome_measure>
      <outcome_measure>Change in Heart Rate</outcome_measure>
      <outcome_measure>Change in Respiratory Rate</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Johns Hopkins University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>70</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>May 2021</primary_completion_date>
    <completion_date>May 2021</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04344561</url>
  </study>
  <study rank="784">
    <nct_id>NCT04346186</nct_id>
    <title>COVID-19: Investigation of Transmission and Immunisation Among Hospital Staff</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">IgM and IgG diagnostic kits to SARS-CoV-2</intervention>
      <intervention type="Diagnostic Test">Elisa-test for IgM and IgG to SARS-CoV-2</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Positive IgM/IgG tests</outcome_measure>
      <outcome_measure>Comparison of the point of care test and Elisa</outcome_measure>
      <outcome_measure>Re-infection rate</outcome_measure>
      <outcome_measure>IgM/IgG positive participants on follow-up test</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Herlev Hospital</lead_sponsor>
      <collaborator>Nordsjaellands Hospital</collaborator>
      <collaborator>Hvidovre University Hospital</collaborator>
      <collaborator>Rigshospitalet, Denmark</collaborator>
      <collaborator>Mental Health Services in the Capital Region, Denmark</collaborator>
      <collaborator>University Hospital Bispebjerg and Frederiksberg</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>30000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>October 1, 2020</primary_completion_date>
    <completion_date>August 1, 2021</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>Herlev Hospital, Herlev, Region Hovedstaden, Denmark</location>
      <location>Bispebjerg Hospital, København NV, Region Hovedstaden, Denmark</location>
      <location>Psykiatrisk Center Ballerup, Ballerup, Denmark</location>
      <location>Psykiatrisk Center København, Copenhagen, Denmark</location>
      <location>Rigshospitalet, Copenhagen, Denmark</location>
      <location>Psykiatrisk Center Amager, Copenhagen, Denmark</location>
      <location>Psykiatrisk Center Stolpegaard, Gentofte, Denmark</location>
      <location>Børne- og Ungdomspsykiatrisk Center, Glostrup, Denmark</location>
      <location>Psykiatrisk Center Glostrup, Glostrup, Denmark</location>
      <location>Nordsjaellands Hospital, Hillerød, Denmark</location>
      <location>Psykiatrisk Center Nordsjælland, Hillerød, Denmark</location>
      <location>Psykiatrisk Center Sankt Hans, Roskilde, Denmark</location>
      <location>Bornholms Hospital, Rønne, Denmark</location>
      <location>Psykiatrisk Center Bornholm, Rønne, Denmark</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04346186</url>
  </study>
  <study rank="785">
    <nct_id>NCT04302688</nct_id>
    <title>Accurate Classification System for Patients With COVID-19 Pneumonitis</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pneumonitis</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>survival status</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Renmin Hospital of Wuhan University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>669</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>December 10, 2019</start_date>
    <primary_completion_date>February 10, 2020</primary_completion_date>
    <completion_date>March 4, 2020</completion_date>
    <study_first_posted>March 10, 2020</study_first_posted>
    <last_update_posted>March 10, 2020</last_update_posted>
    <locations>
      <location>Renmin Hospital of Wuhan University, Wuhan, Hubei, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04302688</url>
  </study>
  <study rank="786">
    <nct_id>NCT04347408</nct_id>
    <title>Rapid Diagnostics, Antibody Testing and Host Response in Children With COVID-19</title>
    <acronym>RAPID-19</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Loop mediated isothermal amplification COVID-19</intervention>
      <intervention type="Diagnostic Test">Covid-19 Antibody testing (IgG and IgM)</intervention>
      <intervention type="Diagnostic Test">Cytokine profile</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>SARS-Cov2 positive molecular testing of throat/nasal swabs</outcome_measure>
      <outcome_measure>Immunoglobulins (G and M) to SARS-Cov2 in plasma</outcome_measure>
      <outcome_measure>Blood cytokine levels</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Queen's University, Belfast</lead_sponsor>
      <collaborator>Belfast Health and Social Care Trust</collaborator>
    </sponsors>
    <gender>All</gender>
    <max_age>15 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases/>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 13, 2020</start_date>
    <primary_completion_date>October 13, 2020</primary_completion_date>
    <completion_date>October 13, 2020</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 16, 2020</last_update_posted>
    <locations>
      <location>Royal Belfast Hospital for Sick Children, Belfast, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04347408</url>
  </study>
  <study rank="787">
    <nct_id>NCT04357314</nct_id>
    <title>Myocardial Infarction Rates Overview During COVID-19 Pandemic In France: MODIF Study</title>
    <acronym>MODIF</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Myocardial Infarction</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Rates of patients presenting with acute myocardial infarction</outcome_measure>
      <outcome_measure>Patient profile during admission for acute myocardial infarction</outcome_measure>
      <outcome_measure>Rate of death due to myocardial infarction at home</outcome_measure>
      <outcome_measure>Medical care times analysis</outcome_measure>
      <outcome_measure>Proportion of patients who underwent systemic thrombolysis</outcome_measure>
      <outcome_measure>Proportion of patients infected with COVID-19</outcome_measure>
      <outcome_measure>Clinical evolution of patients</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>French Cardiology Society</lead_sponsor>
      <collaborator>Institut National de la Santé Et de la Recherche Médicale, France</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>April 27, 2020</start_date>
    <primary_completion_date>June 30, 2020</primary_completion_date>
    <completion_date>July 31, 2020</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04357314</url>
  </study>
  <study rank="788">
    <nct_id>NCT04333849</nct_id>
    <title>Telephony Or Videophony for Isolated elDerly in Maine-Et-Loire 49 During COVID-19</title>
    <acronym>TOVID-49</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Preferred means of communication for elderly people in isolation, hospitalized in the acute care geriatric unit or residing at St Nicolas nursing home (Angers UH).</outcome_measure>
      <outcome_measure>proportion of elderly people with loss of functional independence to communicate with their relatives.</outcome_measure>
      <outcome_measure>level of satisfaction of patients who have benefited from a telephone call.</outcome_measure>
      <outcome_measure>level of satisfaction of patients who have benefited from a videophone call.</outcome_measure>
      <outcome_measure>satisfaction level of older people according to the means of communication used.</outcome_measure>
      <outcome_measure>impact of age on the preferred means of communication.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Angers</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>70 Years</min_age>
    <age_groups>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 27, 2020</start_date>
    <primary_completion_date>September 2020</primary_completion_date>
    <completion_date>September 2020</completion_date>
    <study_first_posted>April 3, 2020</study_first_posted>
    <last_update_posted>April 8, 2020</last_update_posted>
    <locations>
      <location>Angers University Hospital, Angers, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04333849</url>
  </study>
  <study rank="789">
    <nct_id>NCT04348461</nct_id>
    <title>BAttLe Against COVID-19 Using MesenchYmal Stromal Cells</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
      <condition>Respiratory Distress Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Efficacy of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Survival Rate)</outcome_measure>
      <outcome_measure>Safety of the administration of allogeneic mesenchymal stem cells derived from adipose tissue assessed by Adverse Event Rate</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz</lead_sponsor>
      <collaborator>Instituto de Investigación Sanitaria y Biomédica de Alicante</collaborator>
      <collaborator>Hospital General Universitario Gregorio Marañon</collaborator>
      <collaborator>Clinica Universidad de Navarra, Universidad de Navarra</collaborator>
      <collaborator>Hospital Universitario de Salamanca</collaborator>
      <collaborator>Hospital General Universitario de Alicante</collaborator>
      <collaborator>Hospital Clínico Universitario Virgen de la Arrixaca</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 6, 2020</start_date>
    <primary_completion_date>September 15, 2020</primary_completion_date>
    <completion_date>September 30, 2020</completion_date>
    <study_first_posted>April 16, 2020</study_first_posted>
    <last_update_posted>April 16, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04348461</url>
  </study>
  <study rank="790">
    <nct_id>NCT04279899</nct_id>
    <title>The Investigation of the Neonates With or With Risk of COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Neonatal Infection</condition>
      <condition>Perinatal Problems</condition>
      <condition>Infectious Disease</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>The death of newborns with COVID-19</outcome_measure>
      <outcome_measure>The SARS-CoV-2 infection of neonates born to mothers with COVID-19</outcome_measure>
      <outcome_measure>The Chinese standardized Denver Developmental Screening Test (DDST) in neonates with or with risk of COVID-19</outcome_measure>
      <outcome_measure>The small for gestational age newborns in the neonates born to mothers with COVID-19</outcome_measure>
      <outcome_measure>The preterm delivery of neonates born to mothers with COVID-19</outcome_measure>
      <outcome_measure>The disease severity of neonates with COVID-19</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Children's Hospital of Fudan University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <max_age>28 Days</max_age>
    <age_groups>
      <age_group>Child</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>February 1, 2020</start_date>
    <primary_completion_date>November 30, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>February 21, 2020</study_first_posted>
    <last_update_posted>February 21, 2020</last_update_posted>
    <locations>
      <location>Maternal and Child Health Hospital of Hubei Province, Wuhan, Hubei, China</location>
      <location>Children Hospital of Fudan University, Shanghai, Shanghai, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04279899</url>
  </study>
  <study rank="791">
    <nct_id>NCT03808922</nct_id>
    <title>Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Lower Respiratory Tract Infection</condition>
      <condition>Parainfluenza</condition>
      <condition>Immunocompromised</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">DAS181</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">DAS181 COVID-19</intervention>
      <intervention type="Drug">DAS181 OL</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Percent of subjects who Return to Room Air (RTRA) (main study)</outcome_measure>
      <outcome_measure>Percent of subjects with improved COVID-19 Clinical Status Scale (sub-study)</outcome_measure>
      <outcome_measure>All-cause mortality rate (main study)</outcome_measure>
      <outcome_measure>Time (in days) to RTRA (main study)</outcome_measure>
      <outcome_measure>Percent of subjects who achieve clinical stability (main study)</outcome_measure>
      <outcome_measure>Percent of subjects discharged (without mortality and hospice) (main study)</outcome_measure>
      <outcome_measure>Time (in days) to first hospital discharge (without hospice) (main study)</outcome_measure>
      <outcome_measure>Total number of inpatient days (main study)</outcome_measure>
      <outcome_measure>Baseline SAD-RV infection-related mortality rate (main study)</outcome_measure>
      <outcome_measure>Change in pulmonary function (FEV1% predicted) (main study)</outcome_measure>
      <outcome_measure>Time to improved COVID19 clinical status (Sub-study)</outcome_measure>
      <outcome_measure>Time to RTRA</outcome_measure>
      <outcome_measure>Time to Clinical stability</outcome_measure>
      <outcome_measure>Time to SARS-CoV-2 RNA in the respiratory specimens being undetectable</outcome_measure>
      <outcome_measure>Time to Clinical deterioration</outcome_measure>
      <outcome_measure>Time to Discharge from hospital (without readmission before Day 28).</outcome_measure>
      <outcome_measure>Time to Death (all causes)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ansun Biopharma, Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>250</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 23, 2019</start_date>
    <primary_completion_date>April 30, 2021</primary_completion_date>
    <completion_date>December 28, 2021</completion_date>
    <study_first_posted>January 18, 2019</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations>
      <location>City of Hope cancer Center, Duarte, California, United States</location>
      <location>UCLA, Los Angeles, California, United States</location>
      <location>Children's Hospital Colorado, Aurora, Colorado, United States</location>
      <location>Ann &amp; Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States</location>
      <location>University of Chicago, Chicago, Illinois, United States</location>
      <location>Loyola University Medical Center, Maywood, Illinois, United States</location>
      <location>University of Kansas Medical Center, Fairway, Kansas, United States</location>
      <location>Brigham and Women's Hospital, Boston, Massachusetts, United States</location>
      <location>Washington University, Saint Louis, Missouri, United States</location>
      <location>University of Nebraska Medical Center, Omaha, Nebraska, United States</location>
      <location>Duke University, Durham, North Carolina, United States</location>
      <location>Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States</location>
      <location>Oregon Health &amp; Science University, Portland, Oregon, United States</location>
      <location>University of Pennsylvania, Philadelphia, Pennsylvania, United States</location>
      <location>University of Pittsburgh Medical Center Health System, Pittsburgh, Pennsylvania, United States</location>
      <location>Vanderbilt University Medical Center, Nashville, Tennessee, United States</location>
      <location>Cook Children's, Fort Worth, Texas, United States</location>
      <location>MD Anderson, Houston, Texas, United States</location>
      <location>VCU Health System, Richmond, Virginia, United States</location>
      <location>Seattle Children's Hospital, Seattle, Washington, United States</location>
      <location>Fred Hutchinson Cancer Research Center, Seattle, Washington, United States</location>
      <location>Medical College of Wisconsin, Milwaukee, Wisconsin, United States</location>
      <location>Westmead Hospital, Sydney, New South Wales, Australia</location>
      <location>The Wesley Hospital, Brisbane, Queensland, Australia</location>
      <location>Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia</location>
      <location>Royal Melbourne Hospital, Melbourne, Victoria, Australia</location>
      <location>Seoul National University Bundang Hospital, Seongnam-si, Guenoggi-do, Korea, Republic of</location>
      <location>Samsung Medical Center, Gangnam-gu, Seoul, Korea, Republic of</location>
      <location>Seoul National University Hospital, Jongno-gu, Seoul, Korea, Republic of</location>
      <location>The Catholic University of Korea, Seoul St. Mary's Hospital, Seocho-gu, Seoul, Korea, Republic of</location>
      <location>Asan Medical Center, Songpa-gu, Seoul, Korea, Republic of</location>
      <location>National Taiwan University Hospital, Zhongzheng Dist., Taipei City, Taiwan</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03808922</url>
  </study>
  <study rank="792">
    <nct_id>NCT04290871</nct_id>
    <title>Nitric Oxide Gas Inhalation for Severe Acute Respiratory Syndrome in COVID-19.</title>
    <acronym>NOSARSCOVID</acronym>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
      <condition>SARS (Severe Acute Respiratory Syndrome)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nitric Oxide Gas</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>SARS-free patients at 14 days</outcome_measure>
      <outcome_measure>Survival at 28 days</outcome_measure>
      <outcome_measure>Survival at 90 days</outcome_measure>
      <outcome_measure>SARS-free days at 28 days</outcome_measure>
      <outcome_measure>SARS -free days at 90 days</outcome_measure>
      <outcome_measure>Renal Replacement Therapy</outcome_measure>
      <outcome_measure>Liver Failure</outcome_measure>
      <outcome_measure>Mechanical Support of Circulation</outcome_measure>
      <outcome_measure>PaO2/FiO2 ratio in ambient air</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Xijing Hospital</lead_sponsor>
      <collaborator>Massachusetts General Hospital</collaborator>
      <collaborator>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 23, 2020</start_date>
    <primary_completion_date>March 1, 2021</primary_completion_date>
    <completion_date>March 1, 2022</completion_date>
    <study_first_posted>March 2, 2020</study_first_posted>
    <last_update_posted>March 24, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04290871</url>
  </study>
  <study rank="793">
    <nct_id>NCT04092478</nct_id>
    <title>'' The Abdominal Crunch Position for COVID-19 Patients ''</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Anesthesia, Spinal</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Spinal Anesthesia Position</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Inter spinal distance</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Konya Training and Research Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>October 23, 2019</start_date>
    <primary_completion_date>January 8, 2020</primary_completion_date>
    <completion_date>January 31, 2020</completion_date>
    <study_first_posted>September 17, 2019</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>Yasin Tire, Konya, Meram, Turkey</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04092478</url>
  </study>
  <study rank="794">
    <nct_id>NCT04365348</nct_id>
    <title>The Psychological Impact of COVID-19 Outbreak on COVID-19 Survivors and Their Families</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Mental Health Wellness 1</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Stress level</outcome_measure>
      <outcome_measure>Negative emotion</outcome_measure>
      <outcome_measure>Psychological response to trauma</outcome_measure>
      <outcome_measure>Severity of insomnia symptoms and the associated daytime impairment</outcome_measure>
      <outcome_measure>Resilience</outcome_measure>
      <outcome_measure>Quality of family functioning</outcome_measure>
      <outcome_measure>Social support</outcome_measure>
      <outcome_measure>Psychological effects</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>The University of Hong Kong</lead_sponsor>
      <collaborator>Queen Mary Hospital, Hong Kong</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>100 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 27, 2020</start_date>
    <primary_completion_date>March 31, 2021</primary_completion_date>
    <completion_date>June 30, 2021</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Agnes, Hong Kong, Hong Kong</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04365348</url>
  </study>
  <study rank="795">
    <nct_id>NCT04337151</nct_id>
    <title>Blood Titanium Analysis of Patients With MAGEC Spine Rods in the COVID-19 Environment</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>MAGEC Rod</condition>
    </conditions>
    <interventions>
      <intervention type="Device">MAGEC Spine Rod</intervention>
      <intervention type="Diagnostic Test">Titanium blood test</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Titanium level</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Royal National Orthopaedic Hospital NHS Trust</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>January 2021</primary_completion_date>
    <completion_date>March 2021</completion_date>
    <study_first_posted>April 7, 2020</study_first_posted>
    <last_update_posted>April 7, 2020</last_update_posted>
    <locations>
      <location>Royal National Orthopaedic Hospital, Stanmore, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04337151</url>
  </study>
  <study rank="796">
    <nct_id>NCT04341493</nct_id>
    <title>Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nitazoxanide 500 MG</intervention>
      <intervention type="Drug">Hydroxychloroquine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mechanical ventilation requirement</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hugo Mendieta Zeron</lead_sponsor>
      <collaborator>Materno-Perinatal Hospital of the State of Mexico</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>5 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>86</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 6, 2020</start_date>
    <primary_completion_date>August 30, 2020</primary_completion_date>
    <completion_date>December 30, 2020</completion_date>
    <study_first_posted>April 10, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Materno-Perinatal Hospital &quot;Mónica Pretelini&quot;, Toluca, Mexico</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04341493</url>
  </study>
  <study rank="797">
    <nct_id>NCT04315480</nct_id>
    <title>Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tocilizumab</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>arrest in deterioration of pulmonary function</outcome_measure>
      <outcome_measure>improving in pulmonary function</outcome_measure>
      <outcome_measure>need of oro-tracheal intubation</outcome_measure>
      <outcome_measure>death</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Università Politecnica delle Marche</lead_sponsor>
      <collaborator>Azienda Ospedaliera Ospedali Riuniti Marche Nord</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>38</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 12, 2020</start_date>
    <primary_completion_date>April 9, 2020</primary_completion_date>
    <completion_date>May 2020</completion_date>
    <study_first_posted>March 19, 2020</study_first_posted>
    <last_update_posted>April 13, 2020</last_update_posted>
    <locations>
      <location>Università Politecnica delle Marche, Ancona, AN, Italy</location>
    </locations>
    <study_documents>
      <study_document>
        <label>Study Protocol</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/80/NCT04315480/Prot_000.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT04315480</url>
  </study>
  <study rank="798">
    <nct_id>NCT04340479</nct_id>
    <title>The Use of Ultrasound in Establishing COVID-19 Infection as Part of a Trauma Evaluation</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
      <condition>Trauma</condition>
      <condition>Ultrasound</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Ultrasound lung imaging as part of FAST+ evaluation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Correlation of FAST+ pulmonary findings with active COVID infection</outcome_measure>
      <outcome_measure>Description of additional ancillary findings of the FAST+ examination among infected and non-infected patients</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Colorado, Denver</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>May 1, 2020</start_date>
    <primary_completion_date>May 1, 2021</primary_completion_date>
    <completion_date>May 1, 2021</completion_date>
    <study_first_posted>April 9, 2020</study_first_posted>
    <last_update_posted>April 10, 2020</last_update_posted>
    <locations>
      <location>Children's Hospital Colorado, Aurora, Colorado, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04340479</url>
  </study>
  <study rank="799">
    <nct_id>NCT04328454</nct_id>
    <title>Clinical Characteristics and Prognostic Factors of Patients With COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
    </conditions>
    <interventions>
      <intervention type="Other">retrospective analysis</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to negative conversion of severe acute respiratory syndrome coronavirus 2</outcome_measure>
      <outcome_measure>Length of stay in hospital</outcome_measure>
      <outcome_measure>Survival</outcome_measure>
      <outcome_measure>Intubation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Shanghai 10th People's Hospital</lead_sponsor>
      <collaborator>Chibi People's Hospital, Hubei Province</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>January 30, 2020</start_date>
    <primary_completion_date>April 2, 2020</primary_completion_date>
    <completion_date>April 15, 2020</completion_date>
    <study_first_posted>March 31, 2020</study_first_posted>
    <last_update_posted>March 31, 2020</last_update_posted>
    <locations>
      <location>Shanghai 10th People's Hospital, Shanghai, Shanghai, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04328454</url>
  </study>
  <study rank="800">
    <nct_id>NCT04362059</nct_id>
    <title>A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19</title>
    <acronym>COVSurf</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Respiratory Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Device">COVSurf Drug Delivery System</intervention>
      <intervention type="Other">Standard of Care</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Oxygenation Improvement</outcome_measure>
      <outcome_measure>Pulmonary ventilation Improvement</outcome_measure>
      <outcome_measure>Safety Assessment of Frequency and Severity of Adverse Events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital Southampton NHS Foundation Trust</lead_sponsor>
      <collaborator>Bill and Melinda Gates Foundation</collaborator>
      <collaborator>University College, London</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 27, 2020</start_date>
    <primary_completion_date>July 27, 2020</primary_completion_date>
    <completion_date>November 2, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04362059</url>
  </study>
  <study rank="801">
    <nct_id>NCT04346446</nct_id>
    <title>Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Convalescent Plasma Transfusion</intervention>
      <intervention type="Other">Supportive Care</intervention>
      <intervention type="Drug">Random Donor Plasma</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Proportion of patients remaining free of mechanical ventilation in both groups</outcome_measure>
      <outcome_measure>Mortality in both groups</outcome_measure>
      <outcome_measure>Improvement in Pa02/Fi02 ratio in both groups</outcome_measure>
      <outcome_measure>Improvement in SOFA score in both groups</outcome_measure>
      <outcome_measure>Duration of hospital Stay in both group.</outcome_measure>
      <outcome_measure>Duration of Intensive Care Unit stay in both groups.</outcome_measure>
      <outcome_measure>Requirements of Vasopressor in both groups.</outcome_measure>
      <outcome_measure>Days free of dialysis in both groups.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Institute of Liver and Biliary Sciences, India</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 21, 2020</start_date>
    <primary_completion_date>June 30, 2020</primary_completion_date>
    <completion_date>June 30, 2020</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Maulana Azad medical College, New Delhi, Delhi, India</location>
      <location>Institute of Liver and Biliary Sciences, New Delhi, Delhi, India</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04346446</url>
  </study>
  <study rank="802">
    <nct_id>NCT04360850</nct_id>
    <title>Use of Telehealth Technology by Mental Health Care Professionals in Times of COVID-19 Pandemic</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Online Therapy</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">online survey</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>responses to the survey questions</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Washington</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>10000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Ecologic or Community</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 24, 2020</start_date>
    <primary_completion_date>October 2025</primary_completion_date>
    <completion_date>October 2025</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>University of Washington, Seattle, Washington, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04360850</url>
  </study>
  <study rank="803">
    <nct_id>NCT04365582</nct_id>
    <title>OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome</title>
    <acronym>OUTCOV</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Azithromycin</intervention>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Drug">Lopinavir 200Mg/Ritonavir 50Mg Tab</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Hospital admission</outcome_measure>
      <outcome_measure>Effect of treatment on Death at D20</outcome_measure>
      <outcome_measure>Effect of treatment on Death at D60</outcome_measure>
      <outcome_measure>Effect of treatment on Death due to COVID at D20</outcome_measure>
      <outcome_measure>Effect of treatment on Death due to COVID at D60</outcome_measure>
      <outcome_measure>Effect of treatment on need for ICU stay at D20</outcome_measure>
      <outcome_measure>Effect of treatment on need for ICU stay at D60</outcome_measure>
      <outcome_measure>Effect of treatment on duration of ICU stay at D20</outcome_measure>
      <outcome_measure>Effect of treatment on duration of ICU stay at D60</outcome_measure>
      <outcome_measure>Effect of treatment on need of mechanical ventilation at D20</outcome_measure>
      <outcome_measure>Effect of treatment on need of mechanical ventilation at D60</outcome_measure>
      <outcome_measure>Effect of treatment on duration of mechanical ventilation at D20</outcome_measure>
      <outcome_measure>Effect of treatment on duration of mechanical ventilation at D60</outcome_measure>
      <outcome_measure>Effect of treatment on time to hospitalization at D20</outcome_measure>
      <outcome_measure>Effect of treatment on time to hospitalization at D60</outcome_measure>
      <outcome_measure>Effect of treatment on Duration of Hospital stay et D20</outcome_measure>
      <outcome_measure>Effect of treatment on Duration of Hospital stay et D60</outcome_measure>
      <outcome_measure>Effect of treatment on Duration of symptoms at D20</outcome_measure>
      <outcome_measure>Effect of treatment on Duration of symptoms at D60</outcome_measure>
      <outcome_measure>Incidence of Treatment-Emergent Adverse Events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Groupe Hospitalier Paris Saint Joseph</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>50 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>640</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 28, 2020</start_date>
    <primary_completion_date>July 28, 2020</primary_completion_date>
    <completion_date>January 28, 2021</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Hôpital Privé d'Antony, Antony, France</location>
      <location>Hôpital Avicenne, Bobigny, France</location>
      <location>Centre Hospitalier Intercommunal de Créteil, Créteil, France</location>
      <location>Groupe Hospitalier Paris Saint-Joseph, Paris, France</location>
      <location>Institut Mutualiste Montsouris, Paris, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04365582</url>
  </study>
  <study rank="804">
    <nct_id>NCT04327804</nct_id>
    <title>A Longitudinal Study of COVID-19 Positive Patients Testing Nasal Swabs and Collecting Blood Samples for Research</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Odd/Even birth year intervention groups</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Detection of SARS-CoV-2 virus</outcome_measure>
      <outcome_measure>Trajectory of COVID-19 and antibody development</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Dr. Deneen Vojta</lead_sponsor>
      <collaborator>PATH</collaborator>
      <collaborator>Mayo Clinic</collaborator>
      <collaborator>Bill and Melinda Gates Foundation</collaborator>
      <collaborator>UnitedHealth Group</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 25, 2020</start_date>
    <primary_completion_date>April 3, 2020</primary_completion_date>
    <completion_date>April 10, 2020</completion_date>
    <study_first_posted>March 31, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>Everett Clinic, Seattle, Washington, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04327804</url>
  </study>
  <study rank="805">
    <nct_id>NCT04345640</nct_id>
    <title>The Spectrum and Profile of COVID-19 Infection and Its Impact on Liver.</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Liver Cirrhoses</condition>
    </conditions>
    <interventions>
      <intervention type="Other">no intervention</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Spontaneous recovery or death in both groups</outcome_measure>
      <outcome_measure>Severity of prior as well as present decompensation in both groups</outcome_measure>
      <outcome_measure>Duration of prior as well as present decompensation in both groups</outcome_measure>
      <outcome_measure>Improvement in severity assessment Indices Model for End Stage Liver Disease (MELD) scores in both groups</outcome_measure>
      <outcome_measure>Improvement in severity assessment Indices Child-Turcotte-Pugh (CTP) scores in both groups</outcome_measure>
      <outcome_measure>Improvement in severity assessment Indices Sequential Organ Failure Assessment (SOFA) scores in both groups</outcome_measure>
      <outcome_measure>Improvement in severity assessment Indices Acute Physiology And Chronic Health Evaluation (APACHE) scores II in both groups</outcome_measure>
      <outcome_measure>Improvement in severity assessment Indices Chronic Liver Failure-Sequential Organ Failure Assessment (CLIF SOFA) scores in both groups.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Institute of Liver and Biliary Sciences, India</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 14, 2020</start_date>
    <primary_completion_date>June 30, 2020</primary_completion_date>
    <completion_date>June 30, 2020</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>Institute of Liver and Biliary Sciences, New Delhi, Delhi, India</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04345640</url>
  </study>
  <study rank="806">
    <nct_id>NCT04362969</nct_id>
    <title>COVID-EC Study: Clinical Characteristics of Patients With COVID-19 in Guayaquil, Ecuador</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Clinical characteristics of patients with COVID-19</outcome_measure>
      <outcome_measure>Prognosis of patients, in terms of need for admission to intensive care, use of mechanical ventilation or death</outcome_measure>
      <outcome_measure>Clinical characteristics of the patients with the worst prognosis</outcome_measure>
      <outcome_measure>Relationship between the different treatments and the prognosis</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hospital San Carlos, Madrid</lead_sponsor>
      <collaborator>Universidad Catolica Santiago de Guayaquil</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>May 2020</primary_completion_date>
    <completion_date>May 2020</completion_date>
    <study_first_posted>April 27, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04362969</url>
  </study>
  <study rank="807">
    <nct_id>NCT04325906</nct_id>
    <title>Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Prone Positioning</condition>
      <condition>High Flow Nasal Cannula</condition>
      <condition>Acute Respiratory Distress Syndrome</condition>
      <condition>Corona Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Device">high flow nasal cannula (HFNC)</intervention>
      <intervention type="Procedure">Prone positioning (PP)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Treatment failure</outcome_measure>
      <outcome_measure>Intubation rate</outcome_measure>
      <outcome_measure>Efficacy of PP</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Rush University Medical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>346</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2, 2020</start_date>
    <primary_completion_date>May 31, 2020</primary_completion_date>
    <completion_date>June 30, 2020</completion_date>
    <study_first_posted>March 30, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Rush University Medical Center, Chicago, Illinois, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04325906</url>
  </study>
  <study rank="808">
    <nct_id>NCT04344964</nct_id>
    <title>Endoscopy-related Phone Consultation During the COVID-19 Outbreak</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Colon Polyp</condition>
      <condition>Colon Disease</condition>
      <condition>Reflux, Gastroesophageal</condition>
      <condition>Varices, Esophageal</condition>
    </conditions>
    <interventions>
      <intervention type="Other">None - NA</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Failed to attend patients</outcome_measure>
      <outcome_measure>Patient satisfaction with the phone consult</outcome_measure>
      <outcome_measure>Consultant satisfaction with the phone consult</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Austin Health</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>June 15, 2020</primary_completion_date>
    <completion_date>June 15, 2020</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04344964</url>
  </study>
  <study rank="809">
    <nct_id>NCT04346628</nct_id>
    <title>Oral Favipiravir Compared to Standard Supportive Care in Subjects With Mild COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Favipiravir</intervention>
      <intervention type="Other">Standard of care treatment</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time until cessation of oral shedding of SARS-CoV-2 virus</outcome_measure>
      <outcome_measure>Count of participants with clinical worsening of COVID-19 disease</outcome_measure>
      <outcome_measure>Sars-CoV-2 viral load</outcome_measure>
      <outcome_measure>Count of participants with development of SARS-CoV-2 antibodies</outcome_measure>
      <outcome_measure>Time until cessation of symptoms</outcome_measure>
      <outcome_measure>Cmax of favipiravir</outcome_measure>
      <outcome_measure>Cmin of favipiravir</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Stanford University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>April 2021</primary_completion_date>
    <completion_date>April 2021</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>Stanford University, Stanford, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04346628</url>
  </study>
  <study rank="810">
    <nct_id>NCT04327388</nct_id>
    <title>Sarilumab COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Corona Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sarilumab SAR153191</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Phase 2: Time to resolution of fever for at least 48 hours without antipyretics or until discharge, whichever is sooner</outcome_measure>
      <outcome_measure>Phase 3: The percentage of patients reporting each severity rating on the 7-point ordinal scale</outcome_measure>
      <outcome_measure>Phase 2: The time to improvement in oxygenation</outcome_measure>
      <outcome_measure>Phase 2: Mean change in 7-point ordinal scale from baseline to Day 15</outcome_measure>
      <outcome_measure>Phase 2: Clinical status using the 7-point ordinal scale at Day 15</outcome_measure>
      <outcome_measure>Phase 2: Time to improvement of two categories from admission using the 7-point ordinal scale</outcome_measure>
      <outcome_measure>Phase 2 and 3 : Time to resolution of fever</outcome_measure>
      <outcome_measure>Phase 2 and 3 : Time to improvement in oxygenation</outcome_measure>
      <outcome_measure>Phase 2 and 3: Time to resolution of fever and improvement in oxygenation</outcome_measure>
      <outcome_measure>Phase 2 and 3:Time to change in NEWS2 from baseline</outcome_measure>
      <outcome_measure>Phase 2 and 3: Time to NEWS2 of &lt;2 and maintained for 24 hours</outcome_measure>
      <outcome_measure>Phase 2 and 3: Mean change from baseline to days 3, 5, 8, 11, 15, and 29 in NEWS2</outcome_measure>
      <outcome_measure>Phase 2 and 3:Days with fever</outcome_measure>
      <outcome_measure>Phase 2 and 3: Alive off supplemental oxygen at day 29</outcome_measure>
      <outcome_measure>Phase 2 and 3: Days of resting respiratory rate &gt;24 breaths/min</outcome_measure>
      <outcome_measure>Phase 2 and 3:Days of hypoxemia</outcome_measure>
      <outcome_measure>Phase 2 and 3: Days of supplemental oxygen use</outcome_measure>
      <outcome_measure>Phase 2 and 3: Time to saturation ≥94% on room air</outcome_measure>
      <outcome_measure>Phase 2 and 3: Ventilator free days in the first 28 days (to day 29)</outcome_measure>
      <outcome_measure>Phase 2 and 3: The number of patients with Initiation of mechanical ventilation, non-invasive ventilation, or use of high flow nasal cannula</outcome_measure>
      <outcome_measure>Phase 2 and 3: Proportion of patients requiring rescue medication during the 28-day period</outcome_measure>
      <outcome_measure>Phase 2 and 3: The number of patients transferred to the ICU or the need to transfer to the ICU (if the ICU is not available)</outcome_measure>
      <outcome_measure>Phase 2 and 3: Days of hospitalization among survivors</outcome_measure>
      <outcome_measure>Phase 2 and 3: Incidence of death</outcome_measure>
      <outcome_measure>Phase 3: Mean change in the 7-point ordinal scale from baseline to days 3, 5, 8, 11, 15, and 29 (or until discharge)</outcome_measure>
      <outcome_measure>Phase 3: Clinical status using the 7-point ordinal scale at days 3, 5, 8, 11,15, and 29</outcome_measure>
      <outcome_measure>Phase 3: Time to improvement of two categories from admission using the 7-point ordinal scale</outcome_measure>
      <outcome_measure>Phase 2 and 3: Incidence of serious adverse events</outcome_measure>
      <outcome_measure>Phase 2 and 3: The incidence of major or opportunistic bacterial or fungal infections</outcome_measure>
      <outcome_measure>Phase 2 and 3: The incidence of major or opportunistic bacterial or fungal infections in patients with grade 4 neutropenia</outcome_measure>
      <outcome_measure>Phase 2 and 3: The incidence of hypersensitivity reactions, infusion reactions, gastrointestinal perforation</outcome_measure>
      <outcome_measure>The number of patients with clinically significant laboratory abnormalities</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sanofi</lead_sponsor>
      <collaborator>Regeneron Pharmaceuticals</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 29, 2020</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>June 2021</completion_date>
    <study_first_posted>March 31, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Investigational Site Number 1240001, Montreal, Canada</location>
      <location>Investigational Site Number 1240002, Toronto, Canada</location>
      <location>Investigational Site Number 1240003, Vancouver, Canada</location>
      <location>Investigational Site Number 2500001, Bordeaux Cedex, France</location>
      <location>Investigational Site Number 2500006, La Roche Sur Yon Cedex 9, France</location>
      <location>Investigational Site Number 2500002, Nantes, France</location>
      <location>Investigational Site Number 2500005, Paris Cedex 18, France</location>
      <location>Investigational Site Number 2500003, Strasbourg, France</location>
      <location>Investigational Site Number 2500004, Suresnes, France</location>
      <location>Investigational Site Number 2760003, Bonn, Germany</location>
      <location>Investigational Site Number 2760002, Essen, Germany</location>
      <location>Investigational Site Number 2760004, Köln, Germany</location>
      <location>Investigational Site Number 2760001, Münster, Germany</location>
      <location>Investigational Site Number 3760003, Ashdod, Israel</location>
      <location>Investigational Site Number 3760001, Ramat Gan, Israel</location>
      <location>Investigational Site Number 3800005, Milano, Italy</location>
      <location>Investigational Site Number 3800001, Milano, Italy</location>
      <location>Investigational Site Number 3800002, Milano, Italy</location>
      <location>Investigational Site Number 3800003, Modena, Italy</location>
      <location>Investigational Site Number 3800004, Parma, Italy</location>
      <location>Investigational Site Number 3920002, Fuchu-Shi, Japan</location>
      <location>Investigational Site Number 6430002, Moscow, Russian Federation</location>
      <location>Investigational Site Number 7240003, Barcelona, Spain</location>
      <location>Investigational Site Number 7240004, Barcelona, Spain</location>
      <location>Investigational Site Number 7240002, Madrid, Spain</location>
      <location>Investigational Site Number 7240005, Madrid, Spain</location>
      <location>Investigational Site Number 7240001, Madrid, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04327388</url>
  </study>
  <study rank="811">
    <nct_id>NCT04344327</nct_id>
    <title>Early Risk Stratification of Patient Hospitalized for SARS-CoV2 Infection: Critical COVID-19 France CCF</title>
    <acronym>CCF</acronym>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Infection Viral</condition>
      <condition>Infection, Hospital</condition>
      <condition>COVID</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Death rate</outcome_measure>
      <outcome_measure>Transfer to intensive care unit</outcome_measure>
      <outcome_measure>Ventilation analysis</outcome_measure>
      <outcome_measure>Construction of a predictive score for COVID-19 severe form</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>French Cardiology Society</lead_sponsor>
      <collaborator>Institut National de la Santé Et de la Recherche Médicale, France</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>2878</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>April 10, 2020</start_date>
    <primary_completion_date>April 21, 2020</primary_completion_date>
    <completion_date>April 21, 2020</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>CHU d'Amiens, Amiens, France</location>
      <location>CHU Annecy, Annecy, France</location>
      <location>CHU de Bordeaux, Bordeaux, France</location>
      <location>CHU de Caen, Caen, France</location>
      <location>Cotentin hospital, Cherbourg, France</location>
      <location>CHU Dijon, Dijon, France</location>
      <location>Elbeuf Louviers Val de Reuil, Elbeuf, France</location>
      <location>CHU de Fréjus / Saint-Raphael, Fréjus, France</location>
      <location>Lille Catholic Institute Hospital Group, Lille, Lille, France</location>
      <location>CHU de Lyon, Lyon, France</location>
      <location>APHM, Marseille, France</location>
      <location>Jacques Cartier Private Hospital, Massy, Massy, France</location>
      <location>CHR d'Orléans, Orléans, France</location>
      <location>Bichat (APHP), Paris, France</location>
      <location>Georges Pompidou European Hospital (AP-HP), Paris, France</location>
      <location>Institut Mutualiste Montsouris, Paris, Paris, France</location>
      <location>CHU de Reims, Reims, France</location>
      <location>CHU de Rouen, Rouen, France</location>
      <location>CHU Saint Etienne, Saint-Étienne, France</location>
      <location>CHU de Strasbourg, Strasbourg, France</location>
      <location>CHU de Toulouse, Toulouse, France</location>
      <location>Saint Gatien hospital, Tours, France</location>
      <location>CHU de Nancy, Vandœuvre-lès-Nancy, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04344327</url>
  </study>
  <study rank="812">
    <nct_id>NCT04344535</nct_id>
    <title>Convalescent Plasma vs. Standard Plasma for COVID-19</title>
    <acronym/>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Convalescent Plasma</intervention>
      <intervention type="Biological">Standard Donor Plasma</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>28 day ventilator free days</outcome_measure>
      <outcome_measure>90 day all-cause mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Stony Brook University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 8, 2020</start_date>
    <primary_completion_date>April 30, 2021</primary_completion_date>
    <completion_date>August 31, 2021</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations>
      <location>Stony Brook University Hospital, Stony Brook, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04344535</url>
  </study>
  <study rank="813">
    <nct_id>NCT04338906</nct_id>
    <title>Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19</title>
    <acronym>CLOCC</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Camostat Mesilate</intervention>
      <intervention type="Drug">Placebo</intervention>
      <intervention type="Drug">Hydroxychloroquine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Not hospitalized</outcome_measure>
      <outcome_measure>Time to improvement of 2 categories from admission on a 7-point ordinal scale</outcome_measure>
      <outcome_measure>Proportion of participants in each group with normalization of fever</outcome_measure>
      <outcome_measure>Proportion of participants in each group with oxygen saturation &gt; 94% on room air for &gt;24h</outcome_measure>
      <outcome_measure>Time to fever normalization (if febrile at baseline)</outcome_measure>
      <outcome_measure>Time to first negative SARS-CoV-2 PCR in NP swap (if pos. at baseline)</outcome_measure>
      <outcome_measure>Time to first negative SARS-CoV-2 PCR in lower respiratory tract specimens (sputum, bronchoalveolar lavage, tracheal aspirate) (if positive at baseline)</outcome_measure>
      <outcome_measure>Duration of oxygen therapy</outcome_measure>
      <outcome_measure>Proportion of participants in each group with need for mechanical ventilation</outcome_measure>
      <outcome_measure>Duration of hospitalization</outcome_measure>
      <outcome_measure>All cause mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Heinrich-Heine University, Duesseldorf</lead_sponsor>
      <collaborator>Universitätsklinikum Hamburg-Eppendorf</collaborator>
      <collaborator>University Hospital, Frankfurt</collaborator>
      <collaborator>St. Georg Hospital Leipzig, Germany</collaborator>
      <collaborator>Hospital Schwabing Munich, Germany</collaborator>
      <collaborator>Missioklinik, Wuerzburg, Germany</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>334</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>June 1, 2020</start_date>
    <primary_completion_date>June 1, 2021</primary_completion_date>
    <completion_date>December 31, 2021</completion_date>
    <study_first_posted>April 8, 2020</study_first_posted>
    <last_update_posted>April 8, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04338906</url>
  </study>
  <study rank="814">
    <nct_id>NCT04325893</nct_id>
    <title>Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease</title>
    <acronym>HYCOVID</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of death from any cause, or the need for intubation and mechanical ventilation during the 14 days following inclusion and start of treatment.</outcome_measure>
      <outcome_measure>Number of death from any cause, or the need for intubation and mechanical ventilation during the 28 days following inclusion and start of treatment.</outcome_measure>
      <outcome_measure>Clinical evolution on the WHO Ordinal Scale for Clinical Improvement for COVID-19 between day 0 and day 14</outcome_measure>
      <outcome_measure>Clinical evolution on the WHO Ordinal Scale for Clinical Improvement for COVID-19 between day 0 and day 28.</outcome_measure>
      <outcome_measure>Number of all-cause mortality at day 14</outcome_measure>
      <outcome_measure>Number of all-cause mortality at day 28</outcome_measure>
      <outcome_measure>Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal samples at day 5</outcome_measure>
      <outcome_measure>Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal samples at day 10</outcome_measure>
      <outcome_measure>The rate of venous thromboembolic events at day 28, documented and confirmed by an adjudication committee.</outcome_measure>
      <outcome_measure>Number of all-cause mortality at day 28 in patients aged 75 and older</outcome_measure>
      <outcome_measure>Clinical evolution on the WHO OSCI scale for COVID-19 between day 0 and day 28 for patients aged 75 or older</outcome_measure>
      <outcome_measure>Rate of severe adverse events at day 28</outcome_measure>
      <outcome_measure>Number of all-cause mortality at day 14 in patients aged 75 and older</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Angers</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>September 2020</primary_completion_date>
    <completion_date>September 2020</completion_date>
    <study_first_posted>March 30, 2020</study_first_posted>
    <last_update_posted>April 8, 2020</last_update_posted>
    <locations>
      <location>CH Agen, Agen, France</location>
      <location>CHU Amiens, Amiens, France</location>
      <location>CHU Angers, Angers, France</location>
      <location>APHP Avicenne, Bobigny, France</location>
      <location>CHU Brest, Brest, France</location>
      <location>CHU Caen, Caen, France</location>
      <location>CH Cherbroug, Cherbourg, France</location>
      <location>CH Cholet, Cholet, France</location>
      <location>CH Colmar, Colmar, France</location>
      <location>APHP Henri Mondor, Créteil, France</location>
      <location>CHU Dijon, Dijon, France</location>
      <location>CHD Vendée, La Roche-sur-Yon, France</location>
      <location>CH Laval, Laval, France</location>
      <location>CH Le Mans, Le Mans, France</location>
      <location>CHU Limoges, Limoges, France</location>
      <location>CH Lorient, Lorient, France</location>
      <location>CH Melun, Melun, France</location>
      <location>CHU Nantes, Nantes, France</location>
      <location>Hôpital Privé du Confluent, Nantes, France</location>
      <location>CH Niort, Niort, France</location>
      <location>CHR Orléans, Orléans, France</location>
      <location>APHP Saint-Antoine, Paris, France</location>
      <location>La Pitié-Salpétrière, Paris, France</location>
      <location>CHU Poitiers, Poitiers, France</location>
      <location>CH Pointoise, Pontoise, France</location>
      <location>CH Quimper, Quimper, France</location>
      <location>CH Saint-Brieuc, Saint-Brieuc, France</location>
      <location>CH Saint-Nazaire, Saint-Nazaire, France</location>
      <location>CHU Saint-Etienne, Saint-Étienne, France</location>
      <location>CHU Toulouse, Toulouse, France</location>
      <location>CH Tourcoing, Tourcoing, France</location>
      <location>CHU Tours, Tours, France</location>
      <location>CH Valenciennes, Valenciennes, France</location>
      <location>Clinique Tessier Valenciennes, Valenciennes, France</location>
      <location>CH Vannes, Vannes, France</location>
      <location>CH Versailles, Versailles, France</location>
      <location>CH Princesse Grace, Monaco, Monaco</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04325893</url>
  </study>
  <study rank="815">
    <nct_id>NCT04359901</nct_id>
    <title>Sarilumab for Patients With Moderate COVID-19 Disease: A Randomized Controlled Trial With a Play-The-Winner Design</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">SARILUMAB</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Intubation or death</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Westyn Branch-Elliman</lead_sponsor>
      <collaborator>VA Boston Healthcare System</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 10, 2020</start_date>
    <primary_completion_date>April 10, 2022</primary_completion_date>
    <completion_date>April 10, 2023</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>VA Boston Healthcare System, Boston, Massachusetts, United States</location>
    </locations>
    <study_documents>
      <study_document>
        <label>Study Protocol and Statistical Analysis Plan</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT04359901/Prot_SAP_000.pdf</url>
      </study_document>
      <study_document>
        <label>Informed Consent Form</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT04359901/ICF_001.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT04359901</url>
  </study>
  <study rank="816">
    <nct_id>NCT04326725</nct_id>
    <title>Proflaxis Using Hydroxychloroquine Plus Vitamins-Zinc During COVID-19 Pandemia</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pneumonitis</condition>
      <condition>Coronavirus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Plaquenil 200Mg Tablet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Protection against COVID-19</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Istinye University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>20 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 20, 2020</start_date>
    <primary_completion_date>July 1, 2020</primary_completion_date>
    <completion_date>September 1, 2020</completion_date>
    <study_first_posted>March 30, 2020</study_first_posted>
    <last_update_posted>April 10, 2020</last_update_posted>
    <locations>
      <location>Istinye University Medical School, Istanbul, Turkey</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04326725</url>
  </study>
  <study rank="817">
    <nct_id>NCT04341714</nct_id>
    <title>Efficiency and Satisfaction With Telephone Consultation in Neuro-urology: Experience of the COVID-19 Pandemic</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Efficacy, Self</condition>
      <condition>Satisfaction, Patient</condition>
      <condition>Telemedicine</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Satisfaction evaluation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Efficiency of the telephone consultation</outcome_measure>
      <outcome_measure>Satisfaction of the telephone consultation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Pierre and Marie Curie University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 16, 2020</start_date>
    <primary_completion_date>May 30, 2020</primary_completion_date>
    <completion_date>June 15, 2020</completion_date>
    <study_first_posted>April 10, 2020</study_first_posted>
    <last_update_posted>April 10, 2020</last_update_posted>
    <locations>
      <location>Department of Neuro- Urology, Hôpital Tenon, Paris, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04341714</url>
  </study>
  <study rank="818">
    <nct_id>NCT04321369</nct_id>
    <title>Impact of Swab Site and Sample Collector on Testing Sensitivity for COVID-19 Virus in Symptomatic Individuals</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Infections, Respiratory</condition>
      <condition>Fever</condition>
      <condition>Cough</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Testing Sensitivity for SARS-CoV-2 Virus in Symptomatic Individuals</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Accuracy of patient administered tests</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Dr. Deneen Vojta</lead_sponsor>
      <collaborator>Quest Diagnostics</collaborator>
      <collaborator>Bill and Melinda Gates Foundation</collaborator>
      <collaborator>UnitedHealth Group</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>533</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>March 9, 2020</start_date>
    <primary_completion_date>March 23, 2020</primary_completion_date>
    <completion_date>March 23, 2020</completion_date>
    <study_first_posted>March 25, 2020</study_first_posted>
    <last_update_posted>April 13, 2020</last_update_posted>
    <locations>
      <location>Everett Clinic, Seattle, Washington, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04321369</url>
  </study>
  <study rank="819">
    <nct_id>NCT04326387</nct_id>
    <title>Evaluation of Novel Diagnostic Tests for COVID-19</title>
    <acronym>COVIDx</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Acute Disease</condition>
      <condition>Coronavirus</condition>
      <condition>Respiratory Viral Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">SAMBA II (Diagnostic for the Real World)</intervention>
      <intervention type="Diagnostic Test">Public Health England Gold Standard</intervention>
      <intervention type="Diagnostic Test">Cambridge Validated Viral Detection Method</intervention>
      <intervention type="Diagnostic Test">Radiological Detection</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>SAMBA COVID-19 POC PCR Test</outcome_measure>
      <outcome_measure>Patient acceptability</outcome_measure>
      <outcome_measure>Immune Response Positivity</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>CCTU- Cancer Theme</lead_sponsor>
      <collaborator>Cambridge University Hospitals NHS Foundation Trust</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>16 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 6, 2020</start_date>
    <primary_completion_date>April 7, 2021</primary_completion_date>
    <completion_date>October 7, 2021</completion_date>
    <study_first_posted>March 30, 2020</study_first_posted>
    <last_update_posted>April 10, 2020</last_update_posted>
    <locations>
      <location>Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04326387</url>
  </study>
  <study rank="820">
    <nct_id>NCT04292340</nct_id>
    <title>Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 1</outcome_measure>
      <outcome_measure>The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3</outcome_measure>
      <outcome_measure>The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7</outcome_measure>
      <outcome_measure>Numbers of participants with different Clinical outcomes</outcome_measure>
      <outcome_measure>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Shanghai Public Health Clinical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>February 1, 2020</start_date>
    <primary_completion_date>July 31, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>March 3, 2020</study_first_posted>
    <last_update_posted>March 3, 2020</last_update_posted>
    <locations>
      <location>Shanghai Public Health Clinical Center, Shanghai, Shanghai, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04292340</url>
  </study>
  <study rank="821">
    <nct_id>NCT04346082</nct_id>
    <title>Feasibility of Online Based Mindfulness Interventions During COVID-19 Outbreak</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Stress</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">online mindfulness group</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>rate of recruitment</outcome_measure>
      <outcome_measure>rate of attendence</outcome_measure>
      <outcome_measure>Depression, Anxiety and Stress Scale (DASS-21)</outcome_measure>
      <outcome_measure>Sense of Coherence Scale</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Chinese University of Hong Kong</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 1, 2020</start_date>
    <primary_completion_date>April 30, 2021</primary_completion_date>
    <completion_date>April 30, 2021</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>School of public health and primary care, Hong Kong, Hong Kong</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04346082</url>
  </study>
  <study rank="822">
    <nct_id>NCT04326114</nct_id>
    <title>Effectiveness and Safety of Respiratory Training in the Prevention and Severity of COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Disease, Infectious</condition>
      <condition>Respiratory Disease</condition>
      <condition>Safety Issues</condition>
      <condition>Effectiveness</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Inspiratory training device</intervention>
      <intervention type="Device">Expiratory training device</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>COVID-19 disease diagnosis</outcome_measure>
      <outcome_measure>COVID-19 disease symptoms severity</outcome_measure>
      <outcome_measure>Adverse effects</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Universidad Complutense de Madrid</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>240</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 26, 2020</start_date>
    <primary_completion_date>September 26, 2020</primary_completion_date>
    <completion_date>October 12, 2020</completion_date>
    <study_first_posted>March 30, 2020</study_first_posted>
    <last_update_posted>March 30, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04326114</url>
  </study>
  <study rank="823">
    <nct_id>NCT04361253</nct_id>
    <title>Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy</title>
    <acronym>(ESCAPE)</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
      <condition>Infectious Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">High-Titer COVID-19 Convalescent Plasma (HT-CCP)</intervention>
      <intervention type="Biological">Standard Plasma (FFP)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Modified WHO Ordinal Scale (MOS) score</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Brigham and Women's Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>12 Months</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>220</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>June 2021</primary_completion_date>
    <completion_date>December 2021</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04361253</url>
  </study>
  <study rank="824">
    <nct_id>NCT04322123</nct_id>
    <title>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)</title>
    <acronym>Coalition-I</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine Oral Product</intervention>
      <intervention type="Drug">Hydroxychloroquine + azithromycin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Evaluation of the clinical status</outcome_measure>
      <outcome_measure>Ordinal scale in 7 days</outcome_measure>
      <outcome_measure>Need of intubation and mechanical ventilation</outcome_measure>
      <outcome_measure>Use of mechanical ventilation during hospital stay</outcome_measure>
      <outcome_measure>Use of non-invasive ventilation</outcome_measure>
      <outcome_measure>Hospital Length of Stay</outcome_measure>
      <outcome_measure>All-cause mortality</outcome_measure>
      <outcome_measure>Thromboembolic complications</outcome_measure>
      <outcome_measure>Acute renal disfunction</outcome_measure>
      <outcome_measure>Presence of virus at day 10 in subset of 180 patients</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hospital do Coracao</lead_sponsor>
      <collaborator>Hospital Israelita Albert Einstein</collaborator>
      <collaborator>Hospital Sirio-Libanes</collaborator>
      <collaborator>Brazilian Research In Intensive Care Network</collaborator>
      <collaborator>EMS</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>630</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>August 30, 2020</primary_completion_date>
    <completion_date>August 30, 2020</completion_date>
    <study_first_posted>March 26, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Hospital Geral Clériston Andrade, Feira De Santana, BA, Brazil</location>
      <location>Hospital Ana Nery - HAN/SESAB, Salvador, BA, Brazil</location>
      <location>HHospital SAMUR, Vitória Da Conquista, BA, Brazil</location>
      <location>Hospital Geral de Vitória da Conquista, Vitória Da Conquista, BA, Brazil</location>
      <location>Hospital de Brasília, Brasilia, DF, Brazil</location>
      <location>Instituto de Cardiologia do Distrito Federal, Brasília, DF, Brazil</location>
      <location>Hospital Maternidade São José - UNESC - Fundação Social Rural de Colatina, Colatina, ES, Brazil</location>
      <location>Hospital Vila da Serra, Nova Lima, MG, Brazil</location>
      <location>Santa Casa de Misericórdia de São João Del Rei, São João Del Rei, MG, Brazil</location>
      <location>Associação Evangélica Beneficente de Londrina - Hospital Evangélico de Londrina, Londrina, PR, Brazil</location>
      <location>Instituto Estadual do Cérebro Paulo Niemeyer, Rio De Janeiro, RJ, Brazil</location>
      <location>Hospital Geral de Caxias do Sul, Caxias do Sul, RS, Brazil</location>
      <location>Hospital Santa Rita - Irmandade Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil</location>
      <location>Hospital São Francisco - Irmandade Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil</location>
      <location>Hospital São José, Criciuma, SC, Brazil</location>
      <location>Hospital Baía Sul - Baía Sul Medical Center, Florianópolis, SC, Brazil</location>
      <location>Hospital Nereu Ramos, Florianópolis, Sc, Brazil</location>
      <location>Centro Hospitalar Unimed, Joinville, SC, Brazil</location>
      <location>Hospital de Amor - Unidade Barretos (Fundação PIO XII), Barretos, SP, Brazil</location>
      <location>Casa de Saúde Santa Marcelina, São Paulo, SP, Brazil</location>
      <location>Hospital Albert Einstein, São Paulo, SP, Brazil</location>
      <location>Hospital Beneficência Portuguesa - Real e Benemérita Associação Portuguesa de Beneficência, São Paulo, SP, Brazil</location>
      <location>Hospital BP Mirante - Real e Benemérita, São Paulo, SP, Brazil</location>
      <location>Hospital das Clínicas da FMUSP, São Paulo, SP, Brazil</location>
      <location>Hospital do Servidor Público Estadual - HSPE - IAMSPE, São Paulo, SP, Brazil</location>
      <location>Hospital São Paulo - UNIFESP, São Paulo, SP, Brazil</location>
      <location>Hospital Sírio-Libanês, São Paulo, SP, Brazil</location>
      <location>Hospital SEPACO, São Paulo, S, Brazil</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04322123</url>
  </study>
  <study rank="825">
    <nct_id>NCT04358627</nct_id>
    <title>Dexmedetomidine to Improve Outcomes of ARDS in Critical Care COVID-19 Patients</title>
    <acronym>COVID-DEX</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Acute Respiratory Distress Syndrome</condition>
      <condition>Inflammation</condition>
      <condition>Dexmedetomidine</condition>
      <condition>Cytokine Storm</condition>
      <condition>Delirium, Emergence</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Dexmedetomidine Injectable Product</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mechanical ventilation</outcome_measure>
      <outcome_measure>Duration of mechanical ventilation</outcome_measure>
      <outcome_measure>Delirium on recovery from sedation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hospital Clinic of Barcelona</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>99 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>May 30, 2020</primary_completion_date>
    <completion_date>June 30, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04358627</url>
  </study>
  <study rank="826">
    <nct_id>NCT04346589</nct_id>
    <title>Convalescent Antibodies Infusion in Critically Ill COVID 19 Patients</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pneumonia, Ventilator-Associated</condition>
      <condition>Coronavirus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Anti-coronavirus antibodies (immunoglobulins)obtained with DFPP from convalescent patients</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of mechanical ventilation days.</outcome_measure>
      <outcome_measure>Survival</outcome_measure>
      <outcome_measure>Shift to Continuous Positive Airway Pressure (CPAP) ventilation</outcome_measure>
      <outcome_measure>Referral to a sub-intensive care unit or discharge</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>A.O. Ospedale Papa Giovanni XXIII</lead_sponsor>
      <collaborator>Aferetica - Italy (BO)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>July 2020</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations>
      <location>IRFMN - Clinical Research Center for Rare Diseases, Ranica, BG, Italy</location>
      <location>ASST HPG23 - Unit of Nephrology, Bergamo, Italy</location>
      <location>ASST Papa Giovanni XXIII - Microbiology and Virology Unit, Bergamo, Italy</location>
      <location>Asst Pg23 - S.I.M.T, Bergamo, Italy</location>
      <location>ASST-PG23 - Intensive Care Unit, Bergamo, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04346589</url>
  </study>
  <study rank="827">
    <nct_id>NCT04346953</nct_id>
    <title>Video-Based Exercise for Individuals With Social Isolation Due to Coronavirus (COVID-19)</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Healthy Lifestyle</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Video based exercise</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>International Physical Activity Questionnaire - Short Form</outcome_measure>
      <outcome_measure>Nottingham Health Profile</outcome_measure>
      <outcome_measure>Beck Depression Inventory</outcome_measure>
      <outcome_measure>Beck Anxiety Inventory</outcome_measure>
      <outcome_measure>Pittsburgh Sleep Quality Index</outcome_measure>
      <outcome_measure>Timed Get Up and Go Test</outcome_measure>
      <outcome_measure>Flamingo Balance Test</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Istinye University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>40 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>128</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>June 1, 2020</primary_completion_date>
    <completion_date>July 31, 2020</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04346953</url>
  </study>
  <study rank="828">
    <nct_id>NCT04324047</nct_id>
    <title>Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients</title>
    <acronym>CORIMUNO-19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Corona Virus Infection</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Survival</outcome_measure>
      <outcome_measure>WHO progression scale COVID 19</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 27, 2020</start_date>
    <primary_completion_date>March 27, 2021</primary_completion_date>
    <completion_date>December 31, 2021</completion_date>
    <study_first_posted>March 27, 2020</study_first_posted>
    <last_update_posted>April 1, 2020</last_update_posted>
    <locations>
      <location>Kremlin Bictre APHP, Le Kremlin-Bicêtre, Ile De France, France</location>
      <location>Cochin Aphp, Paris, Ile De France, France</location>
      <location>Hegp Aphp, Paris, Ile De France, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04324047</url>
  </study>
  <study rank="829">
    <nct_id>NCT04363502</nct_id>
    <title>Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Clazakizumab</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in C-reactive protein (CRP) level</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Johns Hopkins University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>100 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>July 2020</completion_date>
    <study_first_posted>April 27, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04363502</url>
  </study>
  <study rank="830">
    <nct_id>NCT04315870</nct_id>
    <title>Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) in Pregnancy: The Italian Registry on Coronavirus in Pregnancy.</title>
    <acronym>I-COVID</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Infection Viral</condition>
    </conditions>
    <interventions>
      <intervention type="Other">pregnant women with laboratory-confirmed 2019-n-CoV</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Maternal and perinatal outcomes</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Federico II University</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Other</study_design>
    </study_designs>
    <start_date>January 1, 2020</start_date>
    <primary_completion_date>April 20, 2020</primary_completion_date>
    <completion_date>April 30, 2020</completion_date>
    <study_first_posted>March 20, 2020</study_first_posted>
    <last_update_posted>March 20, 2020</last_update_posted>
    <locations>
      <location>University of Naples Federico II, Napoli, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04315870</url>
  </study>
  <study rank="831">
    <nct_id>NCT04342702</nct_id>
    <title>A Study on the Prospective Cohort Library of COVID-19 in Southeran</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Follow-up</condition>
      <condition>COVID-19</condition>
      <condition>Infectious Diseases</condition>
      <condition>Respiratory</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>days to cure</outcome_measure>
      <outcome_measure>Days of turning negative on RT-PCR test</outcome_measure>
      <outcome_measure>36-Item Short Form Survey Instrument (SF-36)</outcome_measure>
      <outcome_measure>C-reactive protein</outcome_measure>
      <outcome_measure>number of cases returning to positive result in RT-PCR test</outcome_measure>
      <outcome_measure>Number of positive outcome of IgG for antibody of COVID-19</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Second Affiliated Hospital of Wenzhou Medical University</lead_sponsor>
      <collaborator>Wenzhou Medical University</collaborator>
      <collaborator>First Affiliated Hospital of Wenzhou Medical University</collaborator>
      <collaborator>Wenzhou Central Hospital And Sixth People's Hospital of Wenzhou Medical University</collaborator>
      <collaborator>Yueqing Hospital of Wenzhou Medical University</collaborator>
      <collaborator>Ruian Hospital of Wenzhou Medical University</collaborator>
      <collaborator>Cangnan Hospital of Wenzhou Medical University</collaborator>
      <collaborator>Pingyang Hospital of Wenzhou Medical University</collaborator>
      <collaborator>Yongjia People's Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>504</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 16, 2020</start_date>
    <primary_completion_date>March 2021</primary_completion_date>
    <completion_date>March 2021</completion_date>
    <study_first_posted>April 13, 2020</study_first_posted>
    <last_update_posted>April 13, 2020</last_update_posted>
    <locations>
      <location>Wenzhou Medical University, Wenzhou, Zhejiang, China</location>
      <location>The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04342702</url>
  </study>
  <study rank="832">
    <nct_id>NCT04365335</nct_id>
    <title>Stress Biomarkers Leading to Professional Burnout Among People Involved in a Mobile Intensive Care Unit During the COVID-19 Pandemic</title>
    <acronym>AUTONOMIC</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Occupational Stress</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Assessment of work-related stress</intervention>
      <intervention type="Biological">Saliva sample collection</intervention>
      <intervention type="Other">Cardiac and electrodermal recordings</intervention>
      <intervention type="Behavioral">Assessment of behavioral response to emotional stimulation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Professional burnout</outcome_measure>
      <outcome_measure>Mindfulness level</outcome_measure>
      <outcome_measure>Perceived stress level following the emotional stimulation</outcome_measure>
      <outcome_measure>Parasympathetic flexibility evolution during emotional recall</outcome_measure>
      <outcome_measure>Sympathetic tone at rest</outcome_measure>
      <outcome_measure>Corticotropic activation at rest</outcome_measure>
      <outcome_measure>Mood disorders (anxiety / depression)</outcome_measure>
      <outcome_measure>Post-traumatic stress disorder</outcome_measure>
      <outcome_measure>Sleep quality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Direction Centrale du Service de Santé des Armées</lead_sponsor>
      <collaborator>Institut de Recherche Biomedicale des Armees</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>June 2020</primary_completion_date>
    <completion_date>June 2020</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04365335</url>
  </study>
  <study rank="833">
    <nct_id>NCT04351906</nct_id>
    <title>Low-flow Extracorporeal Carbon Dioxide Removal in COVID-19-associated Acute Respiratory Distress Syndrome</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>ARDS</condition>
      <condition>Hypercapnic Respiratory Failure</condition>
      <condition>AKI</condition>
    </conditions>
    <interventions>
      <intervention type="Device">ECCO2R</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Delta change in arterial partial pressure of carbon dioxide during ECCO2R treatment</outcome_measure>
      <outcome_measure>Change in vasopressor use during ECCO2R</outcome_measure>
      <outcome_measure>Assessment of changes in tidal volume during ECCO2R</outcome_measure>
      <outcome_measure>Assessment of changes in pH during ECCO2R</outcome_measure>
      <outcome_measure>Assessment of changes in Positive End-Expiratory Pressure during ECCO2R</outcome_measure>
      <outcome_measure>Number of participants with adverse events directly related to ECCO2R</outcome_measure>
      <outcome_measure>Rate of technical adverse events related to ECCO2R</outcome_measure>
      <outcome_measure>Delta change in venous partial pressure of carbon dioxide before and after ECCO2R membrane</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Giessen</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>April 2020</primary_completion_date>
    <completion_date>May 2020</completion_date>
    <study_first_posted>April 17, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>University Hospital Giessen and Marburg, Giessen, Giessen, Hessen, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04351906</url>
  </study>
  <study rank="834">
    <nct_id>NCT04337918</nct_id>
    <title>Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection</title>
    <acronym>NOCOVID</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Corona Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">NORS (Nitric Oxide Releasing Solution)</intervention>
      <intervention type="Drug">NORS (Nitric Oxide Releasing Solution)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Prevention Study: Measure the effect of NORS on the prevention of COVID-19 infection among health care professionals at risk of exposure to COVID-19</outcome_measure>
      <outcome_measure>Treatment Sub Study: Measure the efficacy of NORS at reducing the progression of COVID- 19</outcome_measure>
      <outcome_measure>Prevention Study: Measure the effect of NORS on the prevention of progression of COVID- 19</outcome_measure>
      <outcome_measure>Prevention Study: Measure the tolerability of NORS treatments</outcome_measure>
      <outcome_measure>Treatment Sub Study: Measure the virucidal effect of NORS Treatments</outcome_measure>
      <outcome_measure>Treatment Sub Study: Determine effect of NORS on the speed of clinical recovery</outcome_measure>
      <outcome_measure>Treatment Sub Study: Determine the reduction in clinical symptoms</outcome_measure>
      <outcome_measure>Treatment &amp; Sub Study: Determine positive sero-conversion for SARS-CoV-2</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sanotize Research and Development corp.</lead_sponsor>
      <collaborator>The Emmes Company, LLC</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>19 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 27, 2020</start_date>
    <primary_completion_date>July 31, 2020</primary_completion_date>
    <completion_date>September 30, 2020</completion_date>
    <study_first_posted>April 8, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04337918</url>
  </study>
  <study rank="835">
    <nct_id>NCT04326036</nct_id>
    <title>Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection</title>
    <acronym>GARM-COVID19</acronym>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pulmonary Alveolar Proteinosis</condition>
      <condition>COPD</condition>
      <condition>Idiopathic Pulmonary Fibrosis</condition>
      <condition>Viral Pneumonia</condition>
      <condition>Coronavirus Infection</condition>
      <condition>Interstitial Lung Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF)</intervention>
      <intervention type="Device">Centricyte 1000</intervention>
      <intervention type="Procedure">IV Deployment Of cSVF In Sterile Normal Saline IV Solution</intervention>
      <intervention type="Drug">Liberase Enzyme (Roche)</intervention>
      <intervention type="Drug">Sterile Normal Saline for Intravenous Use</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Incidence of Treatment-Emergent Adverse Events</outcome_measure>
      <outcome_measure>Pulmonary Function Analysis</outcome_measure>
      <outcome_measure>Digital Oximetry</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Healeon Medical Inc</lead_sponsor>
      <collaborator>Robert W. Alexander, MD</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Early Phase 1</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 25, 2020</start_date>
    <primary_completion_date>November 1, 2021</primary_completion_date>
    <completion_date>December 31, 2021</completion_date>
    <study_first_posted>March 30, 2020</study_first_posted>
    <last_update_posted>March 31, 2020</last_update_posted>
    <locations>
      <location>Robert W. Alexander, MD, FICS, LLC, Stevensville, Montana, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04326036</url>
  </study>
  <study rank="836">
    <nct_id>NCT04344548</nct_id>
    <title>Phase I / II Clinical Study of Immunotherapy Based on Adoptive Cell Transfer as a Therapeutic Alternative for Patients With COVID-19 in Colombia</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Allogeneic NK transfer</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Adverse effects and Safety</outcome_measure>
      <outcome_measure>NK transfer Immunogenicity</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Universidad Nacional de Colombia</lead_sponsor>
      <collaborator>Fundación Salud de los Andes</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 13, 2020</start_date>
    <primary_completion_date>June 10, 2020</primary_completion_date>
    <completion_date>November 10, 2020</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>Fundacion Salud De Los Andes, Bogotá, Bogotá Distrito Capital, Colombia</location>
      <location>Universidad Nacional de Colombia, Bogota, Cundinamarca, Colombia</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04344548</url>
  </study>
  <study rank="837">
    <nct_id>NCT04322396</nct_id>
    <title>Proactive Prophylaxis With Azithromycin and Chloroquine in Hospitalized Patients With COVID-19</title>
    <acronym>ProPAC-COVID</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Virus Diseases</condition>
      <condition>Infection Viral</condition>
      <condition>Corona Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Azithromycin</intervention>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Drug">Placebo oral tablet</intervention>
      <intervention type="Drug">Placebo oral tablet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of days alive and discharged from hospital within 14 days</outcome_measure>
      <outcome_measure>Categorization of hospitalization status</outcome_measure>
      <outcome_measure>Admitted to intensive care unit, if admitted to ICU then length of stay</outcome_measure>
      <outcome_measure>Have used Non-invasive ventilation (NIV) during hospitalization</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>Length of hospitalization</outcome_measure>
      <outcome_measure>Days alive and discharged from hospital</outcome_measure>
      <outcome_measure>Number of readmissions (all causes)</outcome_measure>
      <outcome_measure>Number of days using non-invasive ventilation (NIV)</outcome_measure>
      <outcome_measure>Change in patient's oxygen partial pressure</outcome_measure>
      <outcome_measure>Change in patient's carbondioxid partial pressure</outcome_measure>
      <outcome_measure>Level of pH in blood</outcome_measure>
      <outcome_measure>Time for no oxygen supplement (or regular oxygen supplement &quot;LTOT&quot;)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Chronic Obstructive Pulmonary Disease Trial Network, Denmark</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>226</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 6, 2020</start_date>
    <primary_completion_date>October 31, 2020</primary_completion_date>
    <completion_date>March 31, 2021</completion_date>
    <study_first_posted>March 26, 2020</study_first_posted>
    <last_update_posted>April 13, 2020</last_update_posted>
    <locations>
      <location>Aalborg Sygehus, Aalborg, Denmark</location>
      <location>Bispebjerg Hospital, Copenhagen, Denmark</location>
      <location>Herlev-Gentofte Hospital, Copenhagen, Denmark</location>
      <location>Hvidovre Hospital, Copenhagen, Denmark</location>
      <location>Nordsjællands Hospital, Hillerød, Denmark</location>
      <location>Odense Universitetshospital, Odense, Denmark</location>
      <location>Roskilde Sygehus, Roskilde, Denmark</location>
      <location>Slagelse Sygehus, Slagelse, Denmark</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04322396</url>
  </study>
  <study rank="838">
    <nct_id>NCT04346693</nct_id>
    <title>An Open Randomized Study of Dalargin Effectiveness in Patients With Severe and Critical Manifestations of SARS-COVID-19</title>
    <acronym/>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Acute Respiratory Tract Infection</condition>
      <condition>Acute Respiratory Insufficiency</condition>
      <condition>Pneumonia</condition>
      <condition>Septic Shock</condition>
      <condition>Hypoxemia</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Standard therapy recommended by the Ministry of Health of the Russian Federation.</intervention>
      <intervention type="Procedure">Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection</intervention>
      <intervention type="Procedure">Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin inhalation</intervention>
      <intervention type="Procedure">Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection combined with Dalargin inhalation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The change of viral load in patients with SARS-COVID-19.</outcome_measure>
      <outcome_measure>The frequency of development of Acute Respiratory Distress Syndrome (ADRS)</outcome_measure>
      <outcome_measure>Duration of hospitalization</outcome_measure>
      <outcome_measure>The frequency of early mortality</outcome_measure>
      <outcome_measure>The frequency of late mortality</outcome_measure>
      <outcome_measure>Clinical status at the time of completion of participation in the study</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Burnasyan Federal Medical Biophysical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>320</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Factorial Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 8, 2020</start_date>
    <primary_completion_date>December 2020</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04346693</url>
  </study>
  <study rank="839">
    <nct_id>NCT04341610</nct_id>
    <title>ASC Therapy for Patients With Severe Respiratory COVID-19</title>
    <acronym>ASC COVID-19</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Respiratory Tract Diseases</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Stem Cell Product</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Changes in clinical critical treatment index</outcome_measure>
      <outcome_measure>Days of respirator treatment</outcome_measure>
      <outcome_measure>Improvement of clinical symptoms including duration of fever and respiratory need</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>Marker of Immunological function -CD4+ and CD8+ T cell count</outcome_measure>
      <outcome_measure>C-reactive protein and leucocyte</outcome_measure>
      <outcome_measure>Cytokine profile</outcome_measure>
      <outcome_measure>Glomerular Filtration Rate</outcome_measure>
      <outcome_measure>Duration of hospitalization</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Rigshospitalet, Denmark</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>January 30, 2021</primary_completion_date>
    <completion_date>April 30, 2021</completion_date>
    <study_first_posted>April 10, 2020</study_first_posted>
    <last_update_posted>April 10, 2020</last_update_posted>
    <locations>
      <location>2014 Department of Cardiology, The Heart Centre, University Hospital Rigshospitalet, Copenhagen, Denmark</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04341610</url>
  </study>
  <study rank="840">
    <nct_id>NCT04343664</nct_id>
    <title>Mental Health Assessment Among Community Member During the Covid-19 Pandemic in Indonesia</title>
    <acronym>New</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Mental Stress</condition>
      <condition>Mental Health Wellness 1</condition>
      <condition>Depression</condition>
      <condition>Anxiety</condition>
      <condition>Behavior Problem</condition>
      <condition>Emotional Problem</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Depression</outcome_measure>
      <outcome_measure>Anxiety symptoms</outcome_measure>
      <outcome_measure>Stress related problems</outcome_measure>
      <outcome_measure>Behavior and emotional problem among children and adolescents</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tjhin Wiguna</lead_sponsor>
      <collaborator>Fakultas Kedokteran Universitas Indonesia</collaborator>
      <collaborator>Dr Cipto Mangunkusumo General Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>4 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>10000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Ecologic or Community</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <start_date>April 12, 2020</start_date>
    <primary_completion_date>June 30, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>April 13, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>dr. Cipto Mangunkusumo General Hospital, Jakarta Pusat, DKI Jakarta, Indonesia</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04343664</url>
  </study>
  <study rank="841">
    <nct_id>NCT04352699</nct_id>
    <title>Outcomes of Urological Surgery During Periods of Social COVID-19 Containemnt: is it Reasonable to Limit Access to Surgical Care for All?</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Surgery</condition>
      <condition>Complication of Surgical Procedure</condition>
      <condition>COVID</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Rate of UCI admission for surgery-related complication</outcome_measure>
      <outcome_measure>Rate of surgery-specific death</outcome_measure>
      <outcome_measure>Rate of coronaviruse positive serologies</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier Universitaire de Nice</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>March 15, 2020</start_date>
    <primary_completion_date>April 17, 2020</primary_completion_date>
    <completion_date>May 1, 2020</completion_date>
    <study_first_posted>April 20, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations>
      <location>CHU de Nice, Nice, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04352699</url>
  </study>
  <study rank="842">
    <nct_id>NCT04341519</nct_id>
    <title>Psychological Burden in ICU Survivors of Severe COVID-19 Pneumonia, Their Relatives and Their Healthcare Providers</title>
    <acronym>BURDENCOV</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Corona Virus Infection</condition>
      <condition>Post-traumatic Stress Disorder</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">PTSD</intervention>
      <intervention type="Behavioral">Burnout</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>PTSD Family members sup 22</outcome_measure>
      <outcome_measure>PTSD Family members</outcome_measure>
      <outcome_measure>PTSD Patients</outcome_measure>
      <outcome_measure>PTSD healthcare providers</outcome_measure>
      <outcome_measure>HADS Family members</outcome_measure>
      <outcome_measure>HADS Patients</outcome_measure>
      <outcome_measure>SF36 Patients</outcome_measure>
      <outcome_measure>Questionnaire Family members</outcome_measure>
      <outcome_measure>Questionnaire Patients</outcome_measure>
      <outcome_measure>Questionnaire healthcare providers</outcome_measure>
      <outcome_measure>MBI healthcare providers</outcome_measure>
      <outcome_measure>Karasec instrument healthcare providers</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1464</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 9, 2020</start_date>
    <primary_completion_date>November 30, 2020</primary_completion_date>
    <completion_date>December 31, 2021</completion_date>
    <study_first_posted>April 10, 2020</study_first_posted>
    <last_update_posted>April 10, 2020</last_update_posted>
    <locations>
      <location>Saint-Louis Hospital, Paris, Ile De France, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04341519</url>
  </study>
  <study rank="843">
    <nct_id>NCT04274322</nct_id>
    <title>Identifying Critically-ill Patients With COVID-19 Who Will Benefit Most From Nutrition Support Therapy: Validation of the NUTRIC Nutritional Risk Assessment Tool</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Critically Ill</condition>
      <condition>Coronavirus Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Nutrition support</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>28-day all cause mortality</outcome_measure>
      <outcome_measure>All cause infection</outcome_measure>
      <outcome_measure>The rate of complications</outcome_measure>
      <outcome_measure>Length of ICU stay</outcome_measure>
      <outcome_measure>Duration of mechanical ventilation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Peking University Third Hospital</lead_sponsor>
      <collaborator>School of Pharmaceutical Sciences, Peking University, Beijing, China</collaborator>
      <collaborator>Department of Medicine, Queen's University, Kingston, Ontario, Canada</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>117</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>February 19, 2020</start_date>
    <primary_completion_date>April 4, 2020</primary_completion_date>
    <completion_date>July 2020</completion_date>
    <study_first_posted>February 18, 2020</study_first_posted>
    <last_update_posted>April 8, 2020</last_update_posted>
    <locations>
      <location>Peking University Third Hospital, Beijing, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04274322</url>
  </study>
  <study rank="844">
    <nct_id>NCT04324073</nct_id>
    <title>Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI</title>
    <acronym>CORIMUNO-SARI</acronym>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Corona Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Sarilumab</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Survival without needs of ventilator utilization at day 14.</outcome_measure>
      <outcome_measure>WHO progression scale &lt;=5 at day 4</outcome_measure>
      <outcome_measure>Cumulative incidence of successful tracheal extubation (defined as duration extubation &gt; 48h) at day 14</outcome_measure>
      <outcome_measure>WHO progression scale at day 4</outcome_measure>
      <outcome_measure>WHO progression scale</outcome_measure>
      <outcome_measure>Survival</outcome_measure>
      <outcome_measure>28-day ventilator free-days</outcome_measure>
      <outcome_measure>respiratory acidosis at day 4</outcome_measure>
      <outcome_measure>PaO2/FiO2 ratio</outcome_measure>
      <outcome_measure>time to oxygen supply independency</outcome_measure>
      <outcome_measure>duration of hospitalization</outcome_measure>
      <outcome_measure>time to negative viral excretion</outcome_measure>
      <outcome_measure>time to ICU discharge</outcome_measure>
      <outcome_measure>time to hospital discharge</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>239</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 27, 2020</start_date>
    <primary_completion_date>March 27, 2021</primary_completion_date>
    <completion_date>December 31, 2021</completion_date>
    <study_first_posted>March 27, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>Kremlin Bicetre hospital APHP, Le Kremlin-Bicêtre, Ile De France, France</location>
      <location>Cochin Aphp, Paris, Ile De France, France</location>
      <location>HEGP, Paris, Ile De France, France</location>
      <location>NECKER Hospital, Paris, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04324073</url>
  </study>
  <study rank="845">
    <nct_id>NCT04344041</nct_id>
    <title>COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial)</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">cholecalciferol 200,000 IU</intervention>
      <intervention type="Drug">cholecalciferol 50,000 IU</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of death of any cause, during the 14 days following the inclusion and intervention.</outcome_measure>
      <outcome_measure>Number of death of any cause, during the 28 days following the inclusion and intervention.</outcome_measure>
      <outcome_measure>Clinical evolution between day 0 and day 14 based on the change of the WHO Ordinal Scale for Clinical Improvement (OSCI) for COVID-19</outcome_measure>
      <outcome_measure>Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19</outcome_measure>
      <outcome_measure>Rate of patients with at least one severe adverse event at day 28, according to the regulations</outcome_measure>
      <outcome_measure>Number of death of any cause during the 14 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD &lt;25nmol/L) at baseline</outcome_measure>
      <outcome_measure>Number of death of any cause during the 28 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD &lt;25nmol/L) at baseline</outcome_measure>
      <outcome_measure>Clinical evolution between day 0 and day 14 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD &lt;25nmol/L) at baseline</outcome_measure>
      <outcome_measure>Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD&lt;25nmol/L) at baseline</outcome_measure>
      <outcome_measure>Number of death of any cause during the 14 days following the inclusion and intervention, depending on serum vitamin D concentration achieved at day 7 (25-OHD&lt;75nmol/L or 25-OHD≥75nmol/L)</outcome_measure>
      <outcome_measure>Number of death of any cause during the 28 days following the inclusion and intervention, depending on serum vitamin D concentration achieved at day 7 (25-OHD&lt;75nmol/L or 25-OHD≥75nmol/L)</outcome_measure>
      <outcome_measure>Clinical evolution between day 0 and day 14 based on the change of the OSCI for COVID-19, depending on serum vitamin D concentration achieved at day 7 (25-OHD&lt;75nmol/L or 25-OHD≥75nmol/L)</outcome_measure>
      <outcome_measure>Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19, depending on serum vitamin D concentration achieved at day 7 (25-OHD&lt;75nmol/L or 25-OHD≥75nmol/L)</outcome_measure>
      <outcome_measure>Number of death of any cause during the 14 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD&lt;25nmol/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (&lt;75nmol/L or ≥75nmol/L)</outcome_measure>
      <outcome_measure>Number of death of any cause during the 28 days following the inclusion and intervention, in patients with severe hypovitaminosis D (25-OHD&lt;25nmol/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (&lt;75nmol/L or ≥75nmol/L)</outcome_measure>
      <outcome_measure>Clinical evolution between day 0 and day 14 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD&lt;25nmol/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (&lt;75nmol/L or ≥75nmol/L)</outcome_measure>
      <outcome_measure>Clinical evolution between day 0 and day 28 based on the change of the OSCI for COVID-19, in patients with severe hypovitaminosis D (25-OHD&lt;25nmol/L) at day 0, depending on serum vitamin D concentration achieved at day 7 (&lt;75nmol/L or ≥75nmol/L)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Angers</lead_sponsor>
      <collaborator>Mylan Laboratories</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>70 Years</min_age>
    <age_groups>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>260</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>July 2020</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>CHU Angers, Angers, France</location>
      <location>CHU Bordeaux, Bordeaux, France</location>
      <location>CH Le Mans, Le Mans, France</location>
      <location>CHU Lille, Lille, France</location>
      <location>CHU Limoges, Limoges, France</location>
      <location>CHU Nantes, Nantes, France</location>
      <location>CHU Nice, Nice, France</location>
      <location>CHU Saint Etienne, Saint Etienne, France</location>
      <location>CH Saumur, Saumur, France</location>
      <location>CHU Tours, Tours, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04344041</url>
  </study>
  <study rank="846">
    <nct_id>NCT04321278</nct_id>
    <title>Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infections</condition>
      <condition>Pneumonia, Viral</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine + azithromycin</intervention>
      <intervention type="Drug">Hydroxychloroquine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Evaluation of the clinical status</outcome_measure>
      <outcome_measure>All-cause mortality</outcome_measure>
      <outcome_measure>Number of days free from mechanical ventilation</outcome_measure>
      <outcome_measure>Duration of mechanical ventilation</outcome_measure>
      <outcome_measure>Duration of hospitalization</outcome_measure>
      <outcome_measure>Other secondary infections</outcome_measure>
      <outcome_measure>Time from treatment start to death</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hospital Israelita Albert Einstein</lead_sponsor>
      <collaborator>EMS</collaborator>
      <collaborator>Hospital do Coracao</collaborator>
      <collaborator>Hospital Sirio-Libanes</collaborator>
      <collaborator>Brazilian Research In Intensive Care Network</collaborator>
      <collaborator>Cristália Produtos Químicos Farmacêuticos Ltda.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>440</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 28, 2020</start_date>
    <primary_completion_date>August 30, 2020</primary_completion_date>
    <completion_date>August 30, 2020</completion_date>
    <study_first_posted>March 25, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Instituto de Cardiologia do Distrito Federal, Brasília, Distrito Federal, Brazil</location>
      <location>Fundação Social Rural de Colatina, Colatina, Espirito Santo, Brazil</location>
      <location>Hospital Vera Cruz AS, Belo Horizonte, Minas Gerais, Brazil</location>
      <location>Hospital Maternidade E Pronto Socorro Santa Lucia Ltda, Poços De Caldas, Minas Gerais, Brazil</location>
      <location>Universidade Estadual de Londrina, Londrina, Paraná, Brazil</location>
      <location>Hospital Adventista de Belém, Belém, Pará, Brazil</location>
      <location>Hospital Giselda Trigueiro, Natal, Rio Grande Do Norte, Brazil</location>
      <location>Hospital Universitário Onofre Lopes, Natal, Rio Grande Do Norte, Brazil</location>
      <location>Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil</location>
      <location>Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil</location>
      <location>Maestri E Kormann Consultoria Medico-Cientifica, Blumenau, Santa Catarina, Brazil</location>
      <location>Sociedade Literaria e Caritativa Santo Agostinho, Criciúma, Santa Catarina, Brazil</location>
      <location>Fundação Pio XII, Barretos, São Paulo, Brazil</location>
      <location>Santa Casa de Misericordia de Votuporanga, Votuporanga, São Paulo, Brazil</location>
      <location>Hospital Israelita Albert Einstein, São Paulo, Brazil</location>
      <location>AMICO Saude LTDA, São Paulo, Brazil</location>
      <location>Associacao Beneficente Siria, São Paulo, Brazil</location>
      <location>Hospital Vila Santa Catarina, São Paulo, Brazil</location>
      <location>Prevent Senior Private Operadora de Saude Ltda, São Paulo, Brazil</location>
      <location>Real e Benemérita Associação Portuguesa de Beneficência/SP, São Paulo, Brazil</location>
      <location>Real e Benemérita Associação Portuguesa de Beneficência/SP, São Paulo, Brazil</location>
      <location>Santa Casa de Misericórdia, São Paulo, Brazil</location>
      <location>Secretaria de Saúde do Estado de São Paulo, São Paulo, Brazil</location>
      <location>Serv Social da Industria do papel, papelão e cortiça do estado de SP, São Paulo, Brazil</location>
      <location>Sociedade Beneficente de Senhoras Hospital Sírio-Libanês, São Paulo, Brazil</location>
      <location>Universidade Federal de São Paulo, São Paulo, Brazil</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04321278</url>
  </study>
  <study rank="847">
    <nct_id>NCT04345289</nct_id>
    <title>Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia</title>
    <acronym>CCAP</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
      <condition>Corona Virus Infection</condition>
      <condition>Viral Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Convalescent anti-SARS-CoV-2 plasma</intervention>
      <intervention type="Drug">Sarilumab</intervention>
      <intervention type="Drug">Baricitinib</intervention>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Other">Injective placebo</intervention>
      <intervention type="Other">Oral placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>All-cause mortality or need of invasive mechanical ventilation</outcome_measure>
      <outcome_measure>Frequency of adverse events</outcome_measure>
      <outcome_measure>Frequency of severe adverse events</outcome_measure>
      <outcome_measure>Time to improvement of at least 2 categories relative to baseline on a 7-category ordinal scale of clinical status</outcome_measure>
      <outcome_measure>Ventilator-free days</outcome_measure>
      <outcome_measure>Organ failure-free days</outcome_measure>
      <outcome_measure>Duration of ICU stay</outcome_measure>
      <outcome_measure>Mortality rate</outcome_measure>
      <outcome_measure>Length of hospital stay</outcome_measure>
      <outcome_measure>Duration of supplemental oxygen</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Thomas Benfield</lead_sponsor>
      <collaborator>Hvidovre University Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>1500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>June 15, 2021</primary_completion_date>
    <completion_date>June 15, 2021</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>Aalborg University Hospital, Aalborg, Denmark</location>
      <location>Aarhus University Hospital, Arhus, Denmark</location>
      <location>Bispebjerg Hospital, Copenhagen, Denmark</location>
      <location>Rigshospitalet, Copenhagen, Denmark</location>
      <location>Herlev Gentofte Hospital, Herlev, Denmark</location>
      <location>Herning Hospital, Herning, Denmark</location>
      <location>Nordsjællands Hospital, Hillerød, Denmark</location>
      <location>Hvidovre Hospital, Hvidovre, Denmark</location>
      <location>Kolding Hospital, Kolding, Denmark</location>
      <location>Odense University Hospital, Odense, Denmark</location>
      <location>Roskilde Hospital, Roskilde, Denmark</location>
      <location>Vejle Hospital, Vejle, Denmark</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04345289</url>
  </study>
  <study rank="848">
    <nct_id>NCT04359303</nct_id>
    <title>Indirect Endovenous Systemic Ozone for New Coronavirus Disease (COVID19) in Non-intubated Patients</title>
    <acronym>OzonoCOVID19</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Systemic indirect endovenous ozone therapy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>COVID19 clinical scale</outcome_measure>
      <outcome_measure>Number of died patients</outcome_measure>
      <outcome_measure>Oro/nasopharynx virus</outcome_measure>
      <outcome_measure>Thorax imaging (0=none; 1=unilateral; 2=bilateral; 3=ground-glass opacification; 4=consolidation)</outcome_measure>
      <outcome_measure>Days in hospital</outcome_measure>
      <outcome_measure>Venous gas blood analysis</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Javier Hidalgo Tallón</lead_sponsor>
      <collaborator>Sociedad Española de Ozonoterapia</collaborator>
      <collaborator>Universidad Católica San Antonio de Murcia</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>June 2020</primary_completion_date>
    <completion_date>June 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>SEOT, Valencia, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04359303</url>
  </study>
  <study rank="849">
    <nct_id>NCT04358783</nct_id>
    <title>Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia</title>
    <acronym>COP-COVID-19</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Plasma</intervention>
      <intervention type="Other">Best Available Therapy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Early all-cause mortality</outcome_measure>
      <outcome_measure>Time in days for SARS-CoV-2 RT-PCR negatives</outcome_measure>
      <outcome_measure>The serum anti-SARS-CoV-2 antibody titres</outcome_measure>
      <outcome_measure>Detection of serum antibodies</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hospital Universitario Dr. Jose E. Gonzalez</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 27, 2020</start_date>
    <primary_completion_date>February 1, 2021</primary_completion_date>
    <completion_date>May 30, 2021</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Hospital Universitario José E. Gonzalez, Monterrey, Nuevo Leon, Mexico</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04358783</url>
  </study>
  <study rank="850">
    <nct_id>NCT04353037</nct_id>
    <title>PATCH 2&amp;3:Prevention &amp; Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
      <condition>Corona Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Group A HCQ</intervention>
      <intervention type="Drug">Group B Control</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Sub Study 1: Patients</outcome_measure>
      <outcome_measure>Sub Study 2: Health Care Workers</outcome_measure>
      <outcome_measure>Sub Study 1: Patients: Rate of secondary infection of co-inhabitants</outcome_measure>
      <outcome_measure>Sub Study 1: Patients: Adverse Events</outcome_measure>
      <outcome_measure>Sub Study 1: Patients: Negative for COVID-19</outcome_measure>
      <outcome_measure>Sub Study 2:Health Care Workers:Number of shifts missed</outcome_measure>
      <outcome_measure>Sub Study 2:Health Care Workers:Rate of adverse events</outcome_measure>
      <outcome_measure>Sub Study 2:Health Care Workers:Rate of hospitalization</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>UnitedHealth Group</lead_sponsor>
      <collaborator>ProHealth Care Associates</collaborator>
      <collaborator>University of Pennsylvania Perelman School of Medicine</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>50 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>850</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Care Provider)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 7, 2020</start_date>
    <primary_completion_date>April 2021</primary_completion_date>
    <completion_date>June 15, 2021</completion_date>
    <study_first_posted>April 20, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>ProHealth New York, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04353037</url>
  </study>
  <study rank="851">
    <nct_id>NCT04344912</nct_id>
    <title>Impact of COVID19 Outbreak in Cardiac Acute Care</title>
    <acronym>CCU-COVID19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Acute Coronary Syndrome</condition>
      <condition>Heart Failure</condition>
      <condition>COVID</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Data collection</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Incidence of recurrent Major Cardiovascular Events (MACE) and urgent rehospitalization</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
      <collaborator>Action, France</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Other</study_design>
    </study_designs>
    <start_date>March 20, 2020</start_date>
    <primary_completion_date>June 2020</primary_completion_date>
    <completion_date>August 2020</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Unité de Soins Intensifs de Cardiologie, Pitié Salpêtrière Hospital, AP-HP, Paris, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04344912</url>
  </study>
  <study rank="852">
    <nct_id>NCT04320056</nct_id>
    <title>Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decrease During SARS-CoV-2 Pneumonia (COVID-19)</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
      <condition>Pneumonia</condition>
      <condition>Oxygen Toxicity</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Standard administration of oxygen flow</intervention>
      <intervention type="Device">Automated oxygen administration - FreeO2</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The number of interventions</outcome_measure>
      <outcome_measure>Duration of interventions</outcome_measure>
      <outcome_measure>Mean oxygen flow</outcome_measure>
      <outcome_measure>Time within theSpO2 target</outcome_measure>
      <outcome_measure>Time with hypoxemia</outcome_measure>
      <outcome_measure>Time with hyperoxemia</outcome_measure>
      <outcome_measure>Rate of ICU admission</outcome_measure>
      <outcome_measure>Rate of needed non invasive respiratory support</outcome_measure>
      <outcome_measure>Rate of intubation</outcome_measure>
      <outcome_measure>NEWS 2 score evolution</outcome_measure>
      <outcome_measure>EWSO2 score evolution</outcome_measure>
      <outcome_measure>Cost-effectiveness</outcome_measure>
      <outcome_measure>length of stay</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Laval University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>216</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>April 30, 2021</primary_completion_date>
    <completion_date>October 31, 2021</completion_date>
    <study_first_posted>March 24, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Quebec, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04320056</url>
  </study>
  <study rank="853">
    <nct_id>NCT04359329</nct_id>
    <title>Estrogen Patch for COVID-19 Symptoms</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Estradiol patch</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Rate of Hospitalization</outcome_measure>
      <outcome_measure>Rate of Transfer to Intensive Care Unit</outcome_measure>
      <outcome_measure>Rate of Intubation</outcome_measure>
      <outcome_measure>Rate of Death</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sharon Nachman</lead_sponsor>
      <collaborator>Stony Brook University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>110</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>November 15, 2020</primary_completion_date>
    <completion_date>November 15, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Stony Brook University Hospital, Stony Brook, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04359329</url>
  </study>
  <study rank="854">
    <nct_id>NCT04260594</nct_id>
    <title>Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>2019-nCoV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Arbidol</intervention>
      <intervention type="Other">basic treatment</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Virus negative conversion rate in the first week</outcome_measure>
      <outcome_measure>Virus negative conversion rate</outcome_measure>
      <outcome_measure>Antipyretic rate</outcome_measure>
      <outcome_measure>Symptom relief time</outcome_measure>
      <outcome_measure>Finger oxygen improvement rate</outcome_measure>
      <outcome_measure>Disease progression rate</outcome_measure>
      <outcome_measure>Mortality rate</outcome_measure>
      <outcome_measure>Incidence of severe adverse reactions</outcome_measure>
      <outcome_measure>Change curve of peripheral blood lymphocyte count</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Jieming QU</lead_sponsor>
      <collaborator>Ruijin Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>380</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>February 7, 2020</start_date>
    <primary_completion_date>July 1, 2020</primary_completion_date>
    <completion_date>December 30, 2020</completion_date>
    <study_first_posted>February 7, 2020</study_first_posted>
    <last_update_posted>February 7, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04260594</url>
  </study>
  <study rank="855">
    <nct_id>NCT04314232</nct_id>
    <title>Mechanisms to Morbidity and Mortality for Covid-19</title>
    <acronym>COVID MECH</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
      <condition>SARS</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Change in viral expression in association to organspecific biomarkers</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Akershus</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 23, 2020</start_date>
    <primary_completion_date>December 31, 2021</primary_completion_date>
    <completion_date>December 31, 2021</completion_date>
    <study_first_posted>March 19, 2020</study_first_posted>
    <last_update_posted>March 19, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04314232</url>
  </study>
  <study rank="856">
    <nct_id>NCT04336748</nct_id>
    <title>HCQ for Primary Prophylaxis Against COVID19 in Health-care Workers</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sars-CoV2</condition>
      <condition>Infection Viral</condition>
      <condition>Healthcare Worker</condition>
      <condition>Prophylaxis</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Symptomatic or asymptomatic SARS-CoV-2 infection confirmed by PCR</outcome_measure>
      <outcome_measure>Viral load during SARS-CoV-2 infection</outcome_measure>
      <outcome_measure>Seroconversion during the study period</outcome_measure>
      <outcome_measure>Incidence of any acute respiratory infection</outcome_measure>
      <outcome_measure>Days of sick leave</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Medical University of Vienna</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>440</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>August 2020</completion_date>
    <study_first_posted>April 7, 2020</study_first_posted>
    <last_update_posted>April 7, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04336748</url>
  </study>
  <study rank="857">
    <nct_id>NCT04330261</nct_id>
    <title>Clinical Characteristics and Outcomes of Pediatric COVID-19</title>
    <acronym>PERN-COVID-19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>SARS-CoV-2 Infection</condition>
      <condition>Pediatric ALL</condition>
      <condition>Pneumonia, Viral</condition>
      <condition>Pandemic Response</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Exposure (not intervention) - SARS-CoV-2 infection</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clinical characteristics of children with SARS-CoV-2</outcome_measure>
      <outcome_measure>Factors associated with severe COVID-19 outcomes</outcome_measure>
      <outcome_measure>Health care resource utilization for COVID-19 patient management</outcome_measure>
      <outcome_measure>Sensitivity and specificity of COVID-19 case screening policies</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Calgary</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>12500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 18, 2020</start_date>
    <primary_completion_date>March 17, 2021</primary_completion_date>
    <completion_date>March 17, 2022</completion_date>
    <study_first_posted>April 1, 2020</study_first_posted>
    <last_update_posted>April 1, 2020</last_update_posted>
    <locations>
      <location>University of Calgary/Alberta Children's Hospital, Calgary, Alberta, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04330261</url>
  </study>
  <study rank="858">
    <nct_id>NCT04347460</nct_id>
    <title>Establishing a COVID-19 Prospective Cohort for Identification of Secondary HLH</title>
    <acronym>COVIDHLH</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Presence of sHLH as determined by expert chart review by two independent reviewers</outcome_measure>
      <outcome_measure>Determine the incidence of patients fulfilling HLH criteria in Covid 19 viral infection</outcome_measure>
      <outcome_measure>Determine the incidence of patients fulfilling modified 2004 HLH diagnostic criteria (Ferritin &gt; 10000 μg/L) in Covid 19 viral infection</outcome_measure>
      <outcome_measure>Characterization and incidence of the hyper-inflammatory state in COVID-19</outcome_measure>
      <outcome_measure>all cause mortality assesed on day 15</outcome_measure>
      <outcome_measure>all cause mortality assesed on day 29</outcome_measure>
      <outcome_measure>immunophenotpye</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Technische Universität München</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 27, 2020</start_date>
    <primary_completion_date>July 1, 2020</primary_completion_date>
    <completion_date>August 31, 2020</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>Department of nephrology, Klinikum rechts der Isar, München, Bavaria, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04347460</url>
  </study>
  <study rank="859">
    <nct_id>NCT04326426</nct_id>
    <title>ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection</title>
    <acronym/>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tradipitant</intervention>
      <intervention type="Drug">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to improvement on a 7-point ordinal scale as compared to baseline</outcome_measure>
      <outcome_measure>Treatment and prevention of inflammatory lung injury as measured by change in baseline of interleukin-6 (IL-6)</outcome_measure>
      <outcome_measure>Rate of Decline of COVID-19 viral load assessed by RT-PCR from nasopharyngeal samples</outcome_measure>
      <outcome_measure>In-hospital mortality</outcome_measure>
      <outcome_measure>Mean change in NEWS2 score from baseline</outcome_measure>
      <outcome_measure>Understand the effect of genetics for treatment response through whole genome sequence of the participant and the COVID-19 virus</outcome_measure>
      <outcome_measure>Reduction from baseline of NRS for cough</outcome_measure>
      <outcome_measure>Reduction from baseline of NRS for nausea</outcome_measure>
      <outcome_measure>Time to normalization of fever for at least 48 hours</outcome_measure>
      <outcome_measure>Time to improvement in oxygenation for at least 48 hours</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Vanda Pharmaceuticals</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 13, 2020</start_date>
    <primary_completion_date>August 1, 2020</primary_completion_date>
    <completion_date>August 31, 2020</completion_date>
    <study_first_posted>March 30, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations>
      <location>Lenox Hill Hospital Northwell Health, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04326426</url>
  </study>
  <study rank="860">
    <nct_id>NCT04338672</nct_id>
    <title>The Impact of the Covid-19 Outbreak on Emergency Room Attendances of Surgical Patients</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Emergency Service, Hospital</condition>
      <condition>General Surgery</condition>
    </conditions>
    <interventions>
      <intervention type="Other">COVID-19 Pandemic</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Rates of emergency visits needing surgical consult</outcome_measure>
      <outcome_measure>The ratio of severe presentations to non-severe presentations</outcome_measure>
      <outcome_measure>The impact of age on ED attendance rates</outcome_measure>
      <outcome_measure>Differences in ED surgical visits (in terms of capacity and severity) of surgical patients depending on the presentation and the co morbidity</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sheba Medical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>10000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>April 5, 2020</start_date>
    <primary_completion_date>April 1, 2021</primary_completion_date>
    <completion_date>April 1, 2022</completion_date>
    <study_first_posted>April 8, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>Sheba Medical Center, Ramat Gan, Israel</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04338672</url>
  </study>
  <study rank="861">
    <nct_id>NCT04357847</nct_id>
    <title>Assessment of Endothelial and Haemostatic Changes During Severe SARS-CoV-2 Infection</title>
    <acronym>Covid-Thelium</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid-19</condition>
      <condition>Endothelial Dysfunction</condition>
      <condition>Thrombosis</condition>
      <condition>Critically Ill</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Association of InterCellular Adhesion Molecule-1 plasma level with 28 days mortality</outcome_measure>
      <outcome_measure>Association of Endothelin-1 plasma level with 28 days mortality</outcome_measure>
      <outcome_measure>Association of Vascular Endothelial Growth Factor A plasma level with 28 days mortality</outcome_measure>
      <outcome_measure>Association of soluble Vascular Endothelial Growth Factor Receptor type 1 with 28 days mortality</outcome_measure>
      <outcome_measure>Association of syndecan -1 plasma level with 28 days mortality</outcome_measure>
      <outcome_measure>Association of D-dimers plasma levels with thrombotic events</outcome_measure>
      <outcome_measure>Association of von Willebrandt Factor with thrombotic events</outcome_measure>
      <outcome_measure>Association of Viscoelastic testing with thrombotic events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Rouen</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 9, 2020</start_date>
    <primary_completion_date>July 31, 2020</primary_completion_date>
    <completion_date>August 31, 2020</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Rouen University Hospital, Rouen, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04357847</url>
  </study>
  <study rank="862">
    <nct_id>NCT04366219</nct_id>
    <title>Impact of SARS-COV2 Infection and Confinement on Diagnostic and Therapeutic Management of Lung Cancer: Ambispective Study Extended Over 2 Time Periods</title>
    <acronym>CBP-COVID</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
      <condition>SARS-CoV 2</condition>
      <condition>Lung Cancer</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Comparison of clinical characteristics</outcome_measure>
      <outcome_measure>Comparison of diagnostic procedures</outcome_measure>
      <outcome_measure>Comparison of treatments (according to stage of disease)</outcome_measure>
      <outcome_measure>Comparison of patients management deadlines</outcome_measure>
      <outcome_measure>Comparison of survival</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier le Mans</lead_sponsor>
      <collaborator>ONCOPL</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>2000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Other</study_design>
    </study_designs>
    <start_date>June 2020</start_date>
    <primary_completion_date>August 28, 2020</primary_completion_date>
    <completion_date>August 28, 2022</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04366219</url>
  </study>
  <study rank="863">
    <nct_id>NCT04327180</nct_id>
    <title>PREdiction of DIagnosed Covid-19 infecTion in IUC Patients</title>
    <acronym>PREDICT</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Infection Viral</condition>
      <condition>Coronavirus</condition>
      <condition>ARDS</condition>
      <condition>Pneumonia</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Correlation between nasal and deep PCR positivity for Covid-19 patients performed and all predictors for Covid-19 patients performed within 24 hours of admission to ICU</outcome_measure>
      <outcome_measure>Coinfections</outcome_measure>
      <outcome_measure>Respiratory dysfunction requiring mechanical ventilation</outcome_measure>
      <outcome_measure>Sequential Organ Failure Assessment (SOFA) Score</outcome_measure>
      <outcome_measure>SAPS II score</outcome_measure>
      <outcome_measure>Disseminated Intravascular Coagulation (DIC) score</outcome_measure>
      <outcome_measure>Number of days on vasopressive amines</outcome_measure>
      <outcome_measure>Occurrence of an event of venous or arterial thromboembolic disease</outcome_measure>
      <outcome_measure>Number of days with extra renal treatment (ERA)</outcome_measure>
      <outcome_measure>Number of patients alive after ICU stay less than 28 days will be tracked</outcome_measure>
      <outcome_measure>Short Form 36</outcome_measure>
      <outcome_measure>Hospital anxiety and depression scale (HADS)</outcome_measure>
      <outcome_measure>Impact of Event Scale - revised (IES-R)</outcome_measure>
      <outcome_measure>Post-traumatic stress disorder Checklist version DSM-5 (PSL-5)</outcome_measure>
      <outcome_measure>Modified Medical Research Council (MMRC) Dyspnea Scale</outcome_measure>
      <outcome_measure>Correlation between number of patient deaths and all predictors for Covid-19 including anamnestic, clinical, biological, radiological parameters</outcome_measure>
      <outcome_measure>Viral clearance</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Lille</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 30, 2020</start_date>
    <primary_completion_date>September 2021</primary_completion_date>
    <completion_date>September 2021</completion_date>
    <study_first_posted>March 30, 2020</study_first_posted>
    <last_update_posted>April 6, 2020</last_update_posted>
    <locations>
      <location>Hôpital Roger Salengro, ICU, CHU Lille, Lille, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04327180</url>
  </study>
  <study rank="864">
    <nct_id>NCT04345406</nct_id>
    <title>Angiotensin Converting Enzyme Inhibitors in Treatment of Covid 19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ACEIs</intervention>
      <intervention type="Drug">Conventional treatment</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>number of patients with virological cure</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tanta University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>December 1, 2029</primary_completion_date>
    <completion_date>December 1, 2029</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>Tanta University, Tanta, Egypt</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04345406</url>
  </study>
  <study rank="865">
    <nct_id>NCT04341922</nct_id>
    <title>A Online-delivered Cognitive-behavioral Intervention for Dysfunctional Worry Related to the Covid-19 Pandemic</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Dysfunctional Worry</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Internet-delivered cognitive behavior therapy (ICBT) for dysfunctional worry related to the Covid-19 pandemic</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The self-rated Generalized Anxiety Disorder Scale-7 (GAD-7)</outcome_measure>
      <outcome_measure>Montgomery Åsberg Depression Rating Scale - Self report (MADRS-S)</outcome_measure>
      <outcome_measure>Adapted Covid-19 version of the Work and Social Adjustment Scale (WSAS)</outcome_measure>
      <outcome_measure>Insomnia Severity Index (ISI)</outcome_measure>
      <outcome_measure>Adapted Swedish version of the CoRonavIruS Health Impact Survey (CRISIS)</outcome_measure>
      <outcome_measure>Intolerance of uncertainty Scale (IUS)</outcome_measure>
      <outcome_measure>Patient Satisfaction Questionnaire (PSQ)</outcome_measure>
      <outcome_measure>Adverse events (AE)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Karolinska Institutet</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>16 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>670</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 10, 2020</start_date>
    <primary_completion_date>June 10, 2021</primary_completion_date>
    <completion_date>June 10, 2021</completion_date>
    <study_first_posted>April 10, 2020</study_first_posted>
    <last_update_posted>April 10, 2020</last_update_posted>
    <locations>
      <location>Karolinska Institutet, Stockholm, Sweden</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04341922</url>
  </study>
  <study rank="866">
    <nct_id>NCT04334434</nct_id>
    <title>Telerehabilitation in Individuals Over 65 Years of Age Having Social Isolation Due to Coronavirus (Covid-19)</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Telerehabilitation</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Telerehabilitation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Physical Activity Scale for the Elderly</outcome_measure>
      <outcome_measure>Nottingham Health Profile</outcome_measure>
      <outcome_measure>Loneliness Scale for the Elderly</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Kubra Koce, MSc PT</lead_sponsor>
      <collaborator>Istanbul University-Cerrahpasa</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>65 Years</min_age>
    <age_groups>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>June 1, 2020</primary_completion_date>
    <completion_date>July 31, 2020</completion_date>
    <study_first_posted>April 6, 2020</study_first_posted>
    <last_update_posted>April 16, 2020</last_update_posted>
    <locations>
      <location>Istanbul university Cerrahpasa, Istanbul, Turkey</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04334434</url>
  </study>
  <study rank="867">
    <nct_id>NCT04320862</nct_id>
    <title>COVID-19 Pandemic Response Network</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>SARS-CoV-2</condition>
      <condition>Coronavirus</condition>
      <condition>Influenza -Like Illness</condition>
      <condition>Lower Resp Tract Infection</condition>
      <condition>Upper Resp Tract Infection</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Number of participants who experience inpatient admission</outcome_measure>
      <outcome_measure>Number of participants admitted to the intensive care unit</outcome_measure>
      <outcome_measure>Number of participants requiring mechanical ventilation</outcome_measure>
      <outcome_measure>Number of deceased participants</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Duke University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>200000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 3, 2020</start_date>
    <primary_completion_date>December 31, 2021</primary_completion_date>
    <completion_date>December 31, 2021</completion_date>
    <study_first_posted>March 25, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>Duke University Medical Center, Durham, North Carolina, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04320862</url>
  </study>
  <study rank="868">
    <nct_id>NCT04345549</nct_id>
    <title>Ayurveda Self-Management for Flu Like Symptoms During the Covid-19 Outbreak</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Flu Like Symptom</condition>
      <condition>Flu Like Illness</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Individualised Ayurveda</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to achieve afebrile</outcome_measure>
      <outcome_measure>Severity of influenza symptom score</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Aarogyam UK</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>18</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <start_date>February 26, 2020</start_date>
    <primary_completion_date>March 30, 2020</primary_completion_date>
    <completion_date>March 30, 2020</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>Aarogyam, Leicester, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04345549</url>
  </study>
  <study rank="869">
    <nct_id>NCT04344834</nct_id>
    <title>Impact of Covid-19 on Egyptian Health Care Workers and General Population Mental Health</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Mental Health Issue</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Online questionnaire</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Depression</outcome_measure>
      <outcome_measure>Anxiety</outcome_measure>
      <outcome_measure>Obsessive compulsive disorder</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assiut University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Ecologic or Community</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <start_date>May 2020</start_date>
    <primary_completion_date>October 2020</primary_completion_date>
    <completion_date>October 2020</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04344834</url>
  </study>
  <study rank="870">
    <nct_id>NCT04358952</nct_id>
    <title>Myocardial Involvement of Severe Acute Respiratory Syndrome-Cov-2 (Covid19) Infected Patients</title>
    <acronym>COCARDE</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cardiomyopathies</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Global Longitudinal Strain</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Left ventricular function</outcome_measure>
      <outcome_measure>inflammatory biological parameters</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Toulouse</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 4, 2020</start_date>
    <primary_completion_date>November 4, 2020</primary_completion_date>
    <completion_date>November 4, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>UHToulouse, Toulouse, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04358952</url>
  </study>
  <study rank="871">
    <nct_id>NCT04290858</nct_id>
    <title>Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID19 Infection</title>
    <acronym>NoCovid</acronym>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infections</condition>
      <condition>Pneumonia, Viral</condition>
      <condition>Dyspnea</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nitric Oxide</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Reduction in the incidence of intubation and mechanical ventilation</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>Negative conversion of COVID-19 RT-PCR from upper respiratory tract</outcome_measure>
      <outcome_measure>Time to clinical recovery</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Xijing Hospital</lead_sponsor>
      <collaborator>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 1, 2020</start_date>
    <primary_completion_date>March 1, 2021</primary_completion_date>
    <completion_date>February 1, 2022</completion_date>
    <study_first_posted>March 2, 2020</study_first_posted>
    <last_update_posted>March 24, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04290858</url>
  </study>
  <study rank="872">
    <nct_id>NCT04324736</nct_id>
    <title>&quot;COVID-19 and Diabetes Outcomes&quot;</title>
    <acronym>CORONADO</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
      <condition>Diabetes</condition>
    </conditions>
    <interventions>
      <intervention type="Other">no interventional study</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Assess the prevalence of severe forms among hospitalized patients with diabètes and COVID-19</outcome_measure>
      <outcome_measure>describe the clinical and biological characteristics of hospitalized subjects with diabetes and COVID-19</outcome_measure>
      <outcome_measure>describe the prognosis of hospitalized subjects with diabetes and COVID-19</outcome_measure>
      <outcome_measure>describe the care management of hospitalized subjects with diabetes and COVID-19</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Nantes University Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Other</study_design>
    </study_designs>
    <start_date>March 10, 2020</start_date>
    <primary_completion_date>April 10, 2020</primary_completion_date>
    <completion_date>May 8, 2020</completion_date>
    <study_first_posted>March 27, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>CHU Nantes, Nantes, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04324736</url>
  </study>
  <study rank="873">
    <nct_id>NCT04283461</nct_id>
    <title>Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection (COVID-19)</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Corona Virus Infection</condition>
      <condition>Immunisations</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">mRNA-1273</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Frequency of solicited local reactogenicity adverse events (AEs)</outcome_measure>
      <outcome_measure>Frequency of any medically-attended adverse events (MAAEs)</outcome_measure>
      <outcome_measure>Frequency of any new-onset chronic medical conditions (NOCMCs)</outcome_measure>
      <outcome_measure>Frequency of any serious adverse events (SAEs)</outcome_measure>
      <outcome_measure>Frequency of any unsolicited adverse events (AEs)</outcome_measure>
      <outcome_measure>Frequency of solicited systemic reactogenicity adverse events (AEs)</outcome_measure>
      <outcome_measure>Grade of any unsolicited adverse events (AEs)</outcome_measure>
      <outcome_measure>Grade of solicited local reactogenicity adverse events (AEs)</outcome_measure>
      <outcome_measure>Grade of solicited systemic reactogenicity adverse events (AEs)</outcome_measure>
      <outcome_measure>Geometric mean fold rise (GMFR) in IgG titer from baseline</outcome_measure>
      <outcome_measure>Geometric mean titer (GMT) of antibody</outcome_measure>
      <outcome_measure>Percentage of subjects who seroconverted</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>45</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>March 3, 2020</start_date>
    <primary_completion_date>June 1, 2021</primary_completion_date>
    <completion_date>June 1, 2021</completion_date>
    <study_first_posted>February 25, 2020</study_first_posted>
    <last_update_posted>April 13, 2020</last_update_posted>
    <locations>
      <location>Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States</location>
      <location>National Institutes of Health - Clinical Center - Vaccine Research Center Clinical Trials Program, Bethesda, Maryland, United States</location>
      <location>Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases, Seattle, Washington, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04283461</url>
  </study>
  <study rank="874">
    <nct_id>NCT04346160</nct_id>
    <title>A Study to Assess the Virus RNA, and miRNA Levels Related to Viral Infection, and Inflammatory Response in Tears of Patients Affected by COVID-19 Disease</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
      <condition>Conjunctivitis</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Schirmer Test I</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>virus molecular analysis</outcome_measure>
      <outcome_measure>host molecular analysis</outcome_measure>
      <outcome_measure>Epidemiologic data</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>G. d'Annunzio University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 14, 2020</start_date>
    <primary_completion_date>April 30, 2020</primary_completion_date>
    <completion_date>April 30, 2020</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations>
      <location>Ophtalmology Clinic, G.d'Annunzio University, Chieti, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04346160</url>
  </study>
  <study rank="875">
    <nct_id>NCT04354766</nct_id>
    <title>COVID-19 : Neutralizing Human Monoclonal Antibodies Against SARS-Cov-2</title>
    <acronym>ANTI-COV-2</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Blood sample</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Production of several human monoclonal antibodies capable of neutralizing the infection of a target cell by SARS-COV-2.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hospices Civils de Lyon</lead_sponsor>
      <collaborator>Eurobio Scientific</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 27, 2020</start_date>
    <primary_completion_date>July 2020</primary_completion_date>
    <completion_date>July 2020</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>Hôpital de la Croix-Rousse, Lyon, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04354766</url>
  </study>
  <study rank="876">
    <nct_id>NCT04354792</nct_id>
    <title>Asymptomatic COVID-19 Infection Among Healthcare Workers</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Immunologic Activity Alteration</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Serum SARs COV 2 IGg screening in health care workers</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of IGg seropositive health care workers</outcome_measure>
      <outcome_measure>Differentiation between low risk and high risk HCWs</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Kasr El Aini Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>25 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <start_date>April 25, 2020</start_date>
    <primary_completion_date>June 30, 2020</primary_completion_date>
    <completion_date>July 10, 2020</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04354792</url>
  </study>
  <study rank="877">
    <nct_id>NCT04359290</nct_id>
    <title>Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS</title>
    <acronym>RuXoCoil</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>ARDS, Human</condition>
      <condition>COVID</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Ruxolitinib administration</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Overall survival</outcome_measure>
      <outcome_measure>Assessment of the duration of ventilation support</outcome_measure>
      <outcome_measure>cytokine storm</outcome_measure>
      <outcome_measure>time on ICU</outcome_measure>
      <outcome_measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</outcome_measure>
      <outcome_measure>time frame for seroconversion under ruxolitinib treatment (SARS-Co-19- IgG)</outcome_measure>
      <outcome_measure>pulmonary function assessed by a CT scan</outcome_measure>
      <outcome_measure>overall survival</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Philipps University Marburg Medical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>15</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 2020</start_date>
    <primary_completion_date>September 2020</primary_completion_date>
    <completion_date>November 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04359290</url>
  </study>
  <study rank="878">
    <nct_id>NCT04280224</nct_id>
    <title>NK Cells Treatment for COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Novel Coronavirus Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">NK Cells</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Improvement of clinical symptoms including duration of fever</outcome_measure>
      <outcome_measure>Improvement of clinical symptoms including respiratory frequency</outcome_measure>
      <outcome_measure>Number of participants with treatment-related adverse events evaluated with CTCAE,version 4.0</outcome_measure>
      <outcome_measure>Time of virus nucleic acid test negative</outcome_measure>
      <outcome_measure>CD4+ and CD8+ T cell count</outcome_measure>
      <outcome_measure>Rate of mortality within 28-days</outcome_measure>
      <outcome_measure>Size of lesion area by thoracic imaging</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Xinxiang medical university</lead_sponsor>
      <collaborator>First Affiliated Hospital of Xinjiang Medical University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>February 15, 2020</start_date>
    <primary_completion_date>September 30, 2020</primary_completion_date>
    <completion_date>December 30, 2020</completion_date>
    <study_first_posted>February 21, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04280224</url>
  </study>
  <study rank="879">
    <nct_id>NCT04290780</nct_id>
    <title>COVID-19 - Multicenter Study on Nosocomial Transmission of SARS-CoV-2 Virus</title>
    <acronym>NOSO-COR</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Infection Viral</condition>
    </conditions>
    <interventions>
      <intervention type="Other">nosocomial infection/hospital acquired infection</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>nosocomial infection</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Hospices Civils de Lyon</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 9, 2020</start_date>
    <primary_completion_date>October 10, 2020</primary_completion_date>
    <completion_date>October 30, 2020</completion_date>
    <study_first_posted>March 2, 2020</study_first_posted>
    <last_update_posted>April 13, 2020</last_update_posted>
    <locations>
      <location>Service Hygiène, Epidémiologie et Prévention, Lyon, France</location>
      <location>Service Hygiène, Epidémiologie et Prévention, Lyon, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04290780</url>
  </study>
  <study rank="880">
    <nct_id>NCT04288713</nct_id>
    <title>Eculizumab (Soliris) in Covid-19 Infected Patients</title>
    <acronym>SOLID-C19</acronym>
    <status open="Y">Available</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Eculizumab</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Hudson Medical</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Expanded Access</study_types>
    <exp_acc_types>
      <exp_acc_type>Individual Patients</exp_acc_type>
      <exp_acc_type>Treatment IND/Protocol</exp_acc_type>
    </exp_acc_types>
    <study_designs/>
    <study_first_posted>February 28, 2020</study_first_posted>
    <last_update_posted>March 30, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04288713</url>
  </study>
  <study rank="881">
    <nct_id>NCT04343404</nct_id>
    <title>PLACE OF VENOVENOUS ECMO IN THE MANAGEMENT OF SEVERE REFRACTORY ARDS ASSOCIATED WITH SARS-COV-2</title>
    <acronym>ECMO-COVID-19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Respiratory Distress Syndrome</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Retrospective description of COVID-19 patients receiving respiratory ECMO-VV supplementation and what happens to them</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Strasbourg, France</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>April 15, 2020</primary_completion_date>
    <completion_date>April 15, 2020</completion_date>
    <study_first_posted>April 13, 2020</study_first_posted>
    <last_update_posted>April 13, 2020</last_update_posted>
    <locations>
      <location>Service de Chirurgie Thoracique Nouvel Hôpital Civil Hôpitaux Universitaires de Strasbourg, Strasbourg, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04343404</url>
  </study>
  <study rank="882">
    <nct_id>NCT04322513</nct_id>
    <title>Biomarkers for Identification of COVID-19 Infection</title>
    <acronym>B-DT-COV2</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Biomarkers expression</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Biomarkers expression</outcome_measure>
      <outcome_measure>Liver Biomarkers expression</outcome_measure>
      <outcome_measure>biomarkers expression (microRNAs, oxidative stress, IL-2, IL-6, TNF-alfa, leukocytes, subtypes lymphocytes) after treatment</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Catanzaro</lead_sponsor>
      <collaborator>Azienda Ospedaliera Pugliese Ciaccio</collaborator>
      <collaborator>Azienda Ospedaliera Policlinico &quot;Mater Domini&quot;</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>14 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>110</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 24, 2020</start_date>
    <primary_completion_date>June 30, 2020</primary_completion_date>
    <completion_date>August 30, 2020</completion_date>
    <study_first_posted>March 26, 2020</study_first_posted>
    <last_update_posted>April 13, 2020</last_update_posted>
    <locations>
      <location>Luca Gallelli, Catanzaro, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04322513</url>
  </study>
  <study rank="883">
    <nct_id>NCT04318366</nct_id>
    <title>COVID-19 Patients Characterization, Biobank, Treatment Response and Outcome Predictor</title>
    <acronym>COVID-BioB</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Observational Study</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Characterize Patients With SARS-Cov-2 Infection and to Create a Biobank to Identify Predictors of Disease Severity, Mortality and Treatment Response</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Università Vita-Salute San Raffaele</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 19, 2020</start_date>
    <primary_completion_date>March 19, 2022</primary_completion_date>
    <completion_date>March 19, 2022</completion_date>
    <study_first_posted>March 24, 2020</study_first_posted>
    <last_update_posted>March 31, 2020</last_update_posted>
    <locations>
      <location>Autoimmunity and Vascular Inflammation Unit, Division of Regenerative Medicine, Stem Cells and Gene Therapy - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy</location>
      <location>AIDS Immunopathogenesis Unit - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy</location>
      <location>Department of Infection Diseases - IRCCS San Raffaele Scientific Institute -, Milan, Lombardy, Italy</location>
      <location>Department of Internal Medicine - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy</location>
      <location>Diabetes Research Institute -IRCCS San Raffaele Scientific Istitute, Milan, Lombardy, Italy</location>
      <location>Division of Immunology, Transplantation and Infectious Diseases - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy</location>
      <location>Division of Research of Regenerative Medicine, Cell and Gene Therapy - IRCCS San Raffaele Scientific Istitute, Milan, Lombardy, Italy</location>
      <location>Laboratory of Microbiology and Virology - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy</location>
      <location>Nephrology Unit - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy</location>
      <location>Strategic Program in Nephrology and Dialysis - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy</location>
      <location>Viral pathogens and biosafety Unit - IRCCS San Raffaele Scietific Institute, Milan, Lombardy, Italy</location>
      <location>Unit of Immunology, Rheumatology, Allergy and Rare Diseases - IRCCS San Raffaele Scientific Institute, Milan, Lombardy, Italy</location>
      <location>Università Vita-Salute San Raffaele, Milano, Mi, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04318366</url>
  </study>
  <study rank="884">
    <nct_id>NCT04345887</nct_id>
    <title>Spironolactone in Covid-19 Induced ARDS</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Respiratory Distress Syndrome, Adult</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Spironolactone 100mg</intervention>
      <intervention type="Drug">Placebo oral tablet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>p/f ratio</outcome_measure>
      <outcome_measure>SOFA</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Istanbul University-Cerrahpasa</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 21, 2020</start_date>
    <primary_completion_date>July 21, 2020</primary_completion_date>
    <completion_date>October 21, 2020</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>Istanbul University-Cerrahpaşa, Istanbul, Turkey</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04345887</url>
  </study>
  <study rank="885">
    <nct_id>NCT04320953</nct_id>
    <title>Non-contact Endoscopy at Covid-19 Outbreak</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Gastrointestinal Disease</condition>
      <condition>Infectious Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Non-contact MCE system</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Technical success</outcome_measure>
      <outcome_measure>Clinical success</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Changhai Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>5</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <start_date>March 16, 2020</start_date>
    <primary_completion_date>March 26, 2020</primary_completion_date>
    <completion_date>April 9, 2020</completion_date>
    <study_first_posted>March 25, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations>
      <location>Changhai Hospital, Shanghai, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04320953</url>
  </study>
  <study rank="886">
    <nct_id>NCT04338802</nct_id>
    <title>Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Nintedanib</condition>
      <condition>Safety</condition>
      <condition>Effect of Drugs</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nintedanib 150 MG</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Changes in forced vital capacity (FVC)</outcome_measure>
      <outcome_measure>Changes in carbon monoxide dispersion (DLco%)</outcome_measure>
      <outcome_measure>Changes in the six-minute walk test (6MWT)</outcome_measure>
      <outcome_measure>Changes in High resolution CT score</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Huilan Zhang</lead_sponsor>
      <collaborator>Tongji Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>96</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2, 2020</start_date>
    <primary_completion_date>May 4, 2020</primary_completion_date>
    <completion_date>August 1, 2020</completion_date>
    <study_first_posted>April 8, 2020</study_first_posted>
    <last_update_posted>April 8, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04338802</url>
  </study>
  <study rank="887">
    <nct_id>NCT04308187</nct_id>
    <title>Influence of the COvid-19 Epidemic on STRESS</title>
    <acronym>COVISTRESS</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Stress, Psychological</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Stress</outcome_measure>
      <outcome_measure>Perception and knowledge of the epidemic</outcome_measure>
      <outcome_measure>Feeling of information on the part of companies / establishments / governments</outcome_measure>
      <outcome_measure>Means of protection</outcome_measure>
      <outcome_measure>Feelings of fear generated and its impact on feelings of stigmatization towards ethnic groups or categories of patients</outcome_measure>
      <outcome_measure>Sociodemographic factors and lifestyle habits</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Clermont-Ferrand</lead_sponsor>
      <collaborator>Faculty of Medicine, Clermont-Ferrand, France</collaborator>
      <collaborator>UMR CNRS 6024 LaPSCo, Clermont-Ferrand, France</collaborator>
      <collaborator>Wittyfit, Paris, France</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>50000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <start_date>March 11, 2020</start_date>
    <primary_completion_date>March 2022</primary_completion_date>
    <completion_date>March 2022</completion_date>
    <study_first_posted>March 13, 2020</study_first_posted>
    <last_update_posted>March 13, 2020</last_update_posted>
    <locations>
      <location>University Hospital, Clermont-Ferrand, Clermont-Ferrand, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04308187</url>
  </study>
  <study rank="888">
    <nct_id>NCT04299152</nct_id>
    <title>Stem Cell Educator Therapy Treat the Viral Inflammation in COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Severe Acute Respiratory Syndrome (SARS) Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Combination Product">Stem Cell Educator-Treated Mononuclear Cells Apheresis</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Determine the number of Covid-19 patients who were unable to complete SCE Therapy</outcome_measure>
      <outcome_measure>Examine the percentage of activated T cells after SCE therapy by flow cytometry</outcome_measure>
      <outcome_measure>Assess the percentage of Th17 cells after SCE therapy by flow cytometry</outcome_measure>
      <outcome_measure>Chest imaging changes by computed tomography (CT) scan of the chest</outcome_measure>
      <outcome_measure>Quantification of the SARS-CoV-2 viral load by real time RT-PCR</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tianhe Stem Cell Biotechnologies Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Care Provider)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 10, 2020</start_date>
    <primary_completion_date>October 9, 2020</primary_completion_date>
    <completion_date>November 10, 2020</completion_date>
    <study_first_posted>March 6, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04299152</url>
  </study>
  <study rank="889">
    <nct_id>NCT04365166</nct_id>
    <title>Study of Clinical and Immune Severity Profiles of Patients Infected With SARS-Cov2 (COVID-19)</title>
    <acronym>REACOVIM</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Respiratory Tract Infections</condition>
      <condition>Respiratory Tract Disease</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>Immune response - Plasma cytokine profile</outcome_measure>
      <outcome_measure>Immune response - Phenotype of circulating cells</outcome_measure>
      <outcome_measure>Severity criteria - Duration of stay in intensive care unit</outcome_measure>
      <outcome_measure>Severity criteria - Duration of hospitalization stay</outcome_measure>
      <outcome_measure>Severity criteria - Duration of period out of hospital</outcome_measure>
      <outcome_measure>Severity criteria - Duration without mechanical ventilation</outcome_measure>
      <outcome_measure>Severity criteria - Duration without ventilation</outcome_measure>
      <outcome_measure>Severity criteria - Duration without intubation</outcome_measure>
      <outcome_measure>Severity criteria - Number of transfusions</outcome_measure>
      <outcome_measure>Severity criteria - Duration of the period without cathecholamines</outcome_measure>
      <outcome_measure>Severity criteria - Duration of the period without dialysis</outcome_measure>
      <outcome_measure>Severity criteria - SOFA</outcome_measure>
      <outcome_measure>Severity criteria - LIS</outcome_measure>
      <outcome_measure>SARS-Cov2 viral load</outcome_measure>
      <outcome_measure>Emergence of concomitant infections</outcome_measure>
      <outcome_measure>Emergence of concomitant infections - Phenotype of circulating cells</outcome_measure>
      <outcome_measure>Stress physiological profile - Sympathetic tone</outcome_measure>
      <outcome_measure>Stress physiological profile - Temperature</outcome_measure>
      <outcome_measure>Stress physiological profile - Glucocorticoids</outcome_measure>
      <outcome_measure>Angiotensin converting enzyme type II (ACE2) polymorphism - ACE</outcome_measure>
      <outcome_measure>Angiotensin converting enzyme type II (ACE2) polymorphism - ACE2/ACE1</outcome_measure>
      <outcome_measure>Comorbidities - diabetes</outcome_measure>
      <outcome_measure>Comorbidities - Heart disease</outcome_measure>
      <outcome_measure>Comorbidities - organ failure</outcome_measure>
      <outcome_measure>Plasma concentrations of several metabolic pathways - GABA</outcome_measure>
      <outcome_measure>Plasma concentrations of several metabolic pathways - Glucocorticoid</outcome_measure>
      <outcome_measure>Plasma concentrations of several metabolic pathways - Tryptophan</outcome_measure>
      <outcome_measure>Plasma concentrations of several metabolic pathways - Serotonin</outcome_measure>
      <outcome_measure>Plasma concentrations of several metabolic pathways - Dopamin</outcome_measure>
      <outcome_measure>Plasma concentrations of several metabolic pathways - Cathecholamines</outcome_measure>
      <outcome_measure>Plasma concentrations of several metabolic pathways - Arachidonic acid derivatives</outcome_measure>
      <outcome_measure>Plasma concentrations of several metabolic pathways - Endocannabinoids</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Direction Centrale du Service de Santé des Armées</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>April 20, 2022</primary_completion_date>
    <completion_date>April 20, 2022</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Percy Military Teaching Hospital, Clamart, France</location>
      <location>Bégin Military Teaching Hospital, Saint-Mandé, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04365166</url>
  </study>
  <study rank="890">
    <nct_id>NCT04322344</nct_id>
    <title>Escin in Patients With Covid-19 Infection</title>
    <acronym>add-on-COV2</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Escin</intervention>
      <intervention type="Drug">standard therapy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mortality rate</outcome_measure>
      <outcome_measure>Clinical status evaluated in agreement with guidelines</outcome_measure>
      <outcome_measure>The differences in oxygen intake methods</outcome_measure>
      <outcome_measure>Time of hospitalization (days)</outcome_measure>
      <outcome_measure>Time of hospitalization in intensive care units</outcome_measure>
      <outcome_measure>Pulmonary function</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Catanzaro</lead_sponsor>
      <collaborator>Azienda Ospedaliera Pugliese Ciaccio</collaborator>
      <collaborator>Azienda Ospedaliera Policlinico &quot;Mater Domini&quot;</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Care Provider)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <start_date>March 23, 2020</start_date>
    <primary_completion_date>June 30, 2020</primary_completion_date>
    <completion_date>August 30, 2020</completion_date>
    <study_first_posted>March 26, 2020</study_first_posted>
    <last_update_posted>March 27, 2020</last_update_posted>
    <locations>
      <location>Luca Gallelli, Catanzaro, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04322344</url>
  </study>
  <study rank="891">
    <nct_id>NCT04306393</nct_id>
    <title>Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19</title>
    <acronym>NOSARSCOVID</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS (Severe Acute Respiratory Syndrome)</condition>
      <condition>Coronavirus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nitric Oxide Gas</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change of arterial oxygenation at 48 hours from enrollment</outcome_measure>
      <outcome_measure>Time to reach normoxemia during the first 28 days after enrollment</outcome_measure>
      <outcome_measure>Proportion of SARS-nCoV-2 free patients during the first 28 days after enrollment</outcome_measure>
      <outcome_measure>Survival at 28 days from enrollment</outcome_measure>
      <outcome_measure>Survival at 90 days from enrollment</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Massachusetts General Hospital</lead_sponsor>
      <collaborator>Xijing Hospital</collaborator>
      <collaborator>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</collaborator>
      <collaborator>Niguarda Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>99 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 21, 2020</start_date>
    <primary_completion_date>March 21, 2021</primary_completion_date>
    <completion_date>March 21, 2022</completion_date>
    <study_first_posted>March 12, 2020</study_first_posted>
    <last_update_posted>April 7, 2020</last_update_posted>
    <locations>
      <location>University of Alabama, Birmingham, Alabama, United States</location>
      <location>Louisiana State University Health Shreveport, Shreveport, Louisiana, United States</location>
      <location>Massachusetts General Hospital, Boston, Massachusetts, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04306393</url>
  </study>
  <study rank="892">
    <nct_id>NCT04337983</nct_id>
    <title>Hemodynamic Characteristics of Patients With SARS-CoV-2</title>
    <acronym>PiCCOVID</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
      <condition>SARS-CoV-2</condition>
      <condition>COVID-19</condition>
      <condition>Acute Respiratory Distress Syndrome</condition>
      <condition>Shock</condition>
      <condition>Acute Circulatory Failure</condition>
      <condition>Left Ventricular Dysfunction</condition>
      <condition>Fluid Overload</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Transpulmonary thermodilution</intervention>
      <intervention type="Device">Echocardiography</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Body temperature</outcome_measure>
      <outcome_measure>Blood pressure</outcome_measure>
      <outcome_measure>Pulse (heart rate)</outcome_measure>
      <outcome_measure>Respiratory rate</outcome_measure>
      <outcome_measure>Data provided by transpulmonary thermodilution-CI</outcome_measure>
      <outcome_measure>Data provided by transpulmonary thermodilution-GEDV</outcome_measure>
      <outcome_measure>Data provided by transpulmonary thermodilution-EVLW</outcome_measure>
      <outcome_measure>Data provided by transpulmonary thermodilution-PVPI</outcome_measure>
      <outcome_measure>Incidence of abnormal laboratory test results</outcome_measure>
      <outcome_measure>Incidence of new-onset or reversible systolic left ventricular dysfunction</outcome_measure>
      <outcome_measure>Changes of extravascular lung water measured by transpulmonary thermodilution</outcome_measure>
      <outcome_measure>Changes of pulmonary vascular permeability index measured by transpulmonary thermodilution</outcome_measure>
      <outcome_measure>Correlation between the hemodynamic characteristics and 90-day mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Bicetre Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>October 2020</primary_completion_date>
    <completion_date>April 2021</completion_date>
    <study_first_posted>April 8, 2020</study_first_posted>
    <last_update_posted>April 8, 2020</last_update_posted>
    <locations>
      <location>Bicetre Hospital, Paris, Val-de-Marne, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04337983</url>
  </study>
  <study rank="893">
    <nct_id>NCT04361552</nct_id>
    <title>Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cerebrovascular Accident</condition>
      <condition>Chronic Obstructive Pulmonary Disease</condition>
      <condition>Chronic Renal Failure</condition>
      <condition>Coronary Artery Disease</condition>
      <condition>Diabetes Mellitus</condition>
      <condition>Malignant Neoplasm</condition>
      <condition>SARS Coronavirus 2 Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Best Practice</intervention>
      <intervention type="Biological">Tocilizumab</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>7-day length of invasive mechanical ventilation (MV)</outcome_measure>
      <outcome_measure>30-day mortality rate</outcome_measure>
      <outcome_measure>Rate of intensive care (ICU) transfer</outcome_measure>
      <outcome_measure>Rate of invasive mechanical ventilation</outcome_measure>
      <outcome_measure>Rate of tracheostomy</outcome_measure>
      <outcome_measure>Length of ICU stay</outcome_measure>
      <outcome_measure>Length of hospital stay</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Emory University</lead_sponsor>
      <collaborator>National Cancer Institute (NCI)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>180</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 30, 2020</start_date>
    <primary_completion_date>May 30, 2022</primary_completion_date>
    <completion_date>May 30, 2022</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04361552</url>
  </study>
  <study rank="894">
    <nct_id>NCT04322773</nct_id>
    <title>Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure</title>
    <acronym>TOCIVID</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Corona Virus Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">RoActemra iv</intervention>
      <intervention type="Drug">RoActemra sc</intervention>
      <intervention type="Drug">Kevzara sc</intervention>
      <intervention type="Other">Standard medical care</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to independence from supplementary oxygen therapy</outcome_measure>
      <outcome_measure>Number of deaths</outcome_measure>
      <outcome_measure>Days out of hospital and alive</outcome_measure>
      <outcome_measure>Ventilator free days alive and out of hospital</outcome_measure>
      <outcome_measure>C-reactive protein (CRP) level</outcome_measure>
      <outcome_measure>Number of participants with serious adverse events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Marius Henriksen</lead_sponsor>
      <collaborator>Lars Erik Kristensen</collaborator>
      <collaborator>Frederiksberg University Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 5, 2020</start_date>
    <primary_completion_date>June 1, 2021</primary_completion_date>
    <completion_date>June 1, 2021</completion_date>
    <study_first_posted>March 26, 2020</study_first_posted>
    <last_update_posted>April 7, 2020</last_update_posted>
    <locations>
      <location>Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark</location>
      <location>Hillerød Hospital, Hillerød, Denmark</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04322773</url>
  </study>
  <study rank="895">
    <nct_id>NCT04324684</nct_id>
    <title>Prognostic Factors Keeping Track for Covid-19 Pneumonia</title>
    <acronym>NIKE_C19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pneumonia, Viral</condition>
      <condition>Hypertension</condition>
      <condition>Diabetes Mellitus</condition>
      <condition>Obesity</condition>
      <condition>Cardiovascular Diseases</condition>
      <condition>Obstructive Lung Disease</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>rate of recovery</outcome_measure>
      <outcome_measure>time to improvement</outcome_measure>
      <outcome_measure>efficacy of treatments</outcome_measure>
      <outcome_measure>organ failure</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Catholic University of the Sacred Heart</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>100 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>198</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 31, 2020</start_date>
    <primary_completion_date>May 5, 2020</primary_completion_date>
    <completion_date>May 30, 2020</completion_date>
    <study_first_posted>March 27, 2020</study_first_posted>
    <last_update_posted>April 13, 2020</last_update_posted>
    <locations>
      <location>Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04324684</url>
  </study>
  <study rank="896">
    <nct_id>NCT04363333</nct_id>
    <title>Obstructive Sleep Apnea &amp; Covid-19 Outcomes</title>
    <acronym>OSACOVID-19</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
      <condition>Obstructive Sleep Apnea</condition>
      <condition>Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Polysomnography</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The rate of clinical improvement</outcome_measure>
      <outcome_measure>Clinical status</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Koç University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>275</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>November 30, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>April 27, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Koc University, Istanbul, Turkey</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04363333</url>
  </study>
  <study rank="897">
    <nct_id>NCT04346329</nct_id>
    <title>Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to COVID-19</title>
    <acronym>Chloroquine UN</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Drug">Placebo oral tablet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Adverse effects</outcome_measure>
      <outcome_measure>Immune-score</outcome_measure>
      <outcome_measure>COVID-19 prevention</outcome_measure>
      <outcome_measure>Clinical response</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Universidad Nacional de Colombia</lead_sponsor>
      <collaborator>Fundación Salud de los Andes</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>86</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Care Provider)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>June 1, 2020</primary_completion_date>
    <completion_date>October 1, 2020</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>Facultad de Medicina - Universidad Nacional de Colombia, Bogota, Cundinamarca, Colombia</location>
      <location>Universidad Nacional de Colombia, Bogota, Cundinamarca, Colombia</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04346329</url>
  </study>
  <study rank="898">
    <nct_id>NCT04336410</nct_id>
    <title>Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">INO-4800</intervention>
      <intervention type="Device">CELLECTRA® 2000</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Percentage of Participants with Adverse Events (AEs)</outcome_measure>
      <outcome_measure>Percentage of Participants with Administration (Injection) Site Reactions</outcome_measure>
      <outcome_measure>Percentage of Participants with Adverse Events of Special Interest (AESIs)</outcome_measure>
      <outcome_measure>Change from Baseline in Antigen-Specific Binding Antibody Titers</outcome_measure>
      <outcome_measure>Change from Baseline in Antigen-Specific Interferon-Gamma (IFN-γ) Cellular Immune Response</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Inovio Pharmaceuticals</lead_sponsor>
      <collaborator>Coalition for Epidemic Preparedness Innovations (CEPI)</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>50 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>40</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 3, 2020</start_date>
    <primary_completion_date>April 2021</primary_completion_date>
    <completion_date>April 2021</completion_date>
    <study_first_posted>April 7, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Center for Pharmaceutical Research, Kansas City, Missouri, United States</location>
      <location>University of Pennsylvania, Philadelphia, Pennsylvania, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04336410</url>
  </study>
  <study rank="899">
    <nct_id>NCT04359225</nct_id>
    <title>A Comparison of 3D and 2D Telemedicine During Covid 19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Telehealth</condition>
    </conditions>
    <interventions>
      <intervention type="Other">3D Telemedicine</intervention>
      <intervention type="Other">2D Telemedicine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>University Hospitals of North Northway questionnaire</outcome_measure>
      <outcome_measure>Mental effort rating scale</outcome_measure>
      <outcome_measure>Telehealth Usability Questionnaire</outcome_measure>
      <outcome_measure>Subjective feedback interview</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>NHS Greater Glasgow and Clyde</lead_sponsor>
      <collaborator>University of Strathclyde</collaborator>
      <collaborator>Glasgow Royal Infirmary</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>1 Year</min_age>
    <max_age>95 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Triple (Participant, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <start_date>June 30, 2020</start_date>
    <primary_completion_date>December 31, 2021</primary_completion_date>
    <completion_date>December 31, 2021</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Canniesburn Regional Plastic Surgery and Burns Unit, Glasgow, Scotland, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04359225</url>
  </study>
  <study rank="900">
    <nct_id>NCT04345419</nct_id>
    <title>A Real-life Experience on Treatment of Patients With COVID 19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Chloroquine</intervention>
      <intervention type="Drug">Favipiravir</intervention>
      <intervention type="Drug">Nitazoxanide</intervention>
      <intervention type="Drug">Ivermectin</intervention>
      <intervention type="Drug">Niclosamide</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of patients with decreased viral load</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tanta University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>December 2029</primary_completion_date>
    <completion_date>December 2029</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>Tanta university hospital, Tanta, Egypt</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04345419</url>
  </study>
  <study rank="901">
    <nct_id>NCT04354272</nct_id>
    <title>Evaluation of Dental Emergency Treatments During COVID19 Crisis</title>
    <acronym>URGDENTCOVID</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Orofacial Pain</condition>
      <condition>Orofacial Edema</condition>
      <condition>Dental Trauma</condition>
      <condition>Oral Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Questionnaire</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Pain score evolution measured by a 0-10 numeric scale (NS) where 0 is no pain and 10 the worst pain imaginable</outcome_measure>
      <outcome_measure>Pain scores evolution 3 days and 7 days after first visit measured by a numeric scale where 0 is no pain and 10 the worst pain imaginable</outcome_measure>
      <outcome_measure>welcoming quality from hospital staff</outcome_measure>
      <outcome_measure>anxiety score</outcome_measure>
      <outcome_measure>perception of the technical quality of the emergency treatment</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>840</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 13, 2020</start_date>
    <primary_completion_date>June 20, 2020</primary_completion_date>
    <completion_date>June 20, 2020</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04354272</url>
  </study>
  <study rank="902">
    <nct_id>NCT04336761</nct_id>
    <title>Prevalence of Covid-19 in Children Admitted to Paediatric Emergency Departments During the Pandemic Period in France</title>
    <acronym>INCOVPED</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
      <condition>COVID</condition>
      <condition>Infection Viral</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">nasopharyngeal swab</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Prevalence of positivity of COVID-19 virus measured by rt-PCR</outcome_measure>
      <outcome_measure>Prevalence of positivity of COVID-19 virus measured by rt-PCR in the following subpopulations of emergency patients</outcome_measure>
      <outcome_measure>Respiratory signs of children tested within 28 day</outcome_measure>
      <outcome_measure>Percentage of children hospitalized tested within 28 day</outcome_measure>
      <outcome_measure>Contact frequency</outcome_measure>
      <outcome_measure>Prevalence of positivity of other respiratory viruses measured by rt-PCR</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Lille</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <max_age>18 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>914</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>December 2020</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>April 7, 2020</study_first_posted>
    <last_update_posted>April 7, 2020</last_update_posted>
    <locations>
      <location>CH Louis MOURIER, Colombes, France</location>
      <location>Hôpital Mère Enfant CHU, Nantes, France</location>
      <location>Hôpitaux Pédiatriques de Nice CHU-Lenval, Nice, France</location>
      <location>Hôpital des enfants - CHU, Toulouse, France</location>
      <location>CHU de Tours, Tours, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04336761</url>
  </study>
  <study rank="903">
    <nct_id>NCT04355637</nct_id>
    <title>Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Inhaled budesonide</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Proportion of patients in both arms fulfilling the criteria for treatment failure</outcome_measure>
      <outcome_measure>ICU admission</outcome_measure>
      <outcome_measure>ICU refusal</outcome_measure>
      <outcome_measure>Occurrence of complications</outcome_measure>
      <outcome_measure>lactate dehydrogenase (LDH)</outcome_measure>
      <outcome_measure>C Reactive Protein (CRP)</outcome_measure>
      <outcome_measure>ferritin</outcome_measure>
      <outcome_measure>D-dimer</outcome_measure>
      <outcome_measure>leukocyte counts</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sara Varea</lead_sponsor>
      <collaborator>Fundacion Clinic per a la Recerca Biomédica</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>79 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 18, 2020</start_date>
    <primary_completion_date>August 31, 2020</primary_completion_date>
    <completion_date>October 18, 2020</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain</location>
      <location>Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain</location>
      <location>Hospital de Sabadell-Parc Tauli, Sabadell, Barcelona, Spain</location>
      <location>Hospital del Mar, Barcelona, Spain</location>
      <location>Hospital Universitari Vall d'Hebron, Barcelona, Spain</location>
      <location>Hospital Clinic of Barcelona, Barcelona, Spain</location>
      <location>Hospital de la Santa Creu i Sant Pau, Barcelona, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04355637</url>
  </study>
  <study rank="904">
    <nct_id>NCT04351542</nct_id>
    <title>Ayurveda for Flu Like Illness During Covid-19 Outbreak</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Flu Like Illness</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Ayurveda</intervention>
      <intervention type="Other">Usual Care</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to achieve afebrile</outcome_measure>
      <outcome_measure>Severity of symptom score</outcome_measure>
      <outcome_measure>Patient reported improvement</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Aarogyam UK</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>32</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Care Provider)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <start_date>March 6, 2020</start_date>
    <primary_completion_date>April 6, 2020</primary_completion_date>
    <completion_date>April 12, 2020</completion_date>
    <study_first_posted>April 17, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations>
      <location>Aarogyam, Leicester, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04351542</url>
  </study>
  <study rank="905">
    <nct_id>NCT04322786</nct_id>
    <title>The Use of Angiotensin Converting Enzyme Inhibitors and Incident Respiratory Infections, Are They Harmful or Protective?</title>
    <acronym/>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid-19, Coronavirus, Angiotensin Converting Enzyme Inhibitors, Influenza, Electronic Health Records, Epidemiology, Comorbidity, Incidence, United Kingdom</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ACE inhibitor</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Incidence of influenza</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University College, London</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1302508</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>January 1, 1998</start_date>
    <primary_completion_date>May 31, 2016</primary_completion_date>
    <completion_date>March 31, 2020</completion_date>
    <study_first_posted>March 26, 2020</study_first_posted>
    <last_update_posted>March 26, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04322786</url>
  </study>
  <study rank="906">
    <nct_id>NCT04344119</nct_id>
    <title>Assessment of Chilbains Occuring During Covid-19 Infection</title>
    <acronym>ChilblainCOVID</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Skin Manifestations</condition>
      <condition>COVID</condition>
      <condition>Chilblains</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Clinical skin manifestations</outcome_measure>
      <outcome_measure>Histology and biological data</outcome_measure>
      <outcome_measure>Non invasive vascular examination</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier Universitaire de Nice</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 9, 2020</start_date>
    <primary_completion_date>June 30, 2020</primary_completion_date>
    <completion_date>June 30, 2020</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>CHU de Nice, Nice, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04344119</url>
  </study>
  <study rank="907">
    <nct_id>NCT04366167</nct_id>
    <title>Patient Recovery From Heart Surgery During the Covid-19 Pandemic</title>
    <acronym>CardiacCovid</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cardiac Surgery</condition>
      <condition>COVID</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Cardiac surgery</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in Impact of Events scores</outcome_measure>
      <outcome_measure>Survival</outcome_measure>
      <outcome_measure>Morbidity</outcome_measure>
      <outcome_measure>Change in Health-related quality of life scores</outcome_measure>
      <outcome_measure>Change in Depression scores</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Barts &amp; The London NHS Trust</lead_sponsor>
      <collaborator>Queen Mary University of London</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>120 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 18, 2020</start_date>
    <primary_completion_date>April 19, 2021</primary_completion_date>
    <completion_date>December 31, 2021</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>St Bartholomew's Hospital, London, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04366167</url>
  </study>
  <study rank="908">
    <nct_id>NCT04347798</nct_id>
    <title>IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT</title>
    <acronym>IMPACT</acronym>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Covid-19 Infection</condition>
      <condition>Rheumatoid Arthritis</condition>
      <condition>Psoriatic Arthritis</condition>
      <condition>Hydroxychloroquine</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Hydroxychloroquine/Chloroquine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Impact of anti-malarials on the development and severity of Covid-19 in the anti-malarial group compared to the non-anti-malarial group</outcome_measure>
      <outcome_measure>Incidence of Covid-19 infection in the anti-malarial group compared to the non-anti-malarial group</outcome_measure>
      <outcome_measure>Incidence of Covid-19 infection in the sub-groups of patients on biologic agents with different mechanisms of action</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Alberta</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>April 2021</primary_completion_date>
    <completion_date>April 2021</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations>
      <location>University of Alberta, Edmonton, Alberta, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04347798</url>
  </study>
  <study rank="909">
    <nct_id>NCT04342208</nct_id>
    <title>Evaluate the Working Environments of Individuals Working From Home During Covid-19 Outbreak</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Musculoskeletal Pain</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>The Rapid Office Strain Assessment (ROSA)</outcome_measure>
      <outcome_measure>The Standardised Nordic Questionnaries (NMQ)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Istanbul University-Cerrahpasa</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Other</study_design>
    </study_designs>
    <start_date>April 10, 2020</start_date>
    <primary_completion_date>June 1, 2020</primary_completion_date>
    <completion_date>July 1, 2020</completion_date>
    <study_first_posted>April 10, 2020</study_first_posted>
    <last_update_posted>April 10, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04342208</url>
  </study>
  <study rank="910">
    <nct_id>NCT04344106</nct_id>
    <title>Prone Positioning in Spontaneously Breathing Nonintubated Covid-19 Patient: a Pilot Study</title>
    <acronym>ProCov</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infection</condition>
      <condition>Oxygen Deficiency</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Prone positioning</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Proportion of &quot;responder&quot; patients to prone position</outcome_measure>
      <outcome_measure>proportion of &quot;persistent responders&quot; patients after prone position</outcome_measure>
      <outcome_measure>Evolution of PaO2</outcome_measure>
      <outcome_measure>Duration of prone positioning and PaO2 evolution</outcome_measure>
      <outcome_measure>Evolution of Spo2</outcome_measure>
      <outcome_measure>EVA Dyspnea</outcome_measure>
      <outcome_measure>Intolerance to prone positioning</outcome_measure>
      <outcome_measure>Tolerance to prone positioning</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>ELHARRAR Xavier</lead_sponsor>
      <collaborator>Centre Hospitalier Intercommunal Aix-Pertuis</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>25</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>April 15, 2020</primary_completion_date>
    <completion_date>May 1, 2020</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations>
      <location>CHI Aix-Pertuis, Aix-en-Provence, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04344106</url>
  </study>
  <study rank="911">
    <nct_id>NCT04363606</nct_id>
    <title>Chronic Fatigue Etiology and Recovery in Covid-19 Patients: the Role of Fatigability</title>
    <acronym>FatCovid-19</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Chronic Fatigue Syndrome</condition>
      <condition>Intensive Care Unit</condition>
      <condition>Muscle</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Questionnaires</intervention>
      <intervention type="Biological">blood test</intervention>
      <intervention type="Other">Maximal effort test</intervention>
      <intervention type="Device">actigraphy</intervention>
      <intervention type="Device">Neuromuscular evaluation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>voluntary maximum force reduction</outcome_measure>
      <outcome_measure>Neuromuscular function : cortical activity</outcome_measure>
      <outcome_measure>Neuromuscular function : Peripheral function</outcome_measure>
      <outcome_measure>Maximal oxygen uptake (VO2max)</outcome_measure>
      <outcome_measure>quality of sleep</outcome_measure>
      <outcome_measure>muscle volume</outcome_measure>
      <outcome_measure>metabolic fatigue</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier Universitaire de Saint Etienne</lead_sponsor>
      <collaborator>University of Saint-Etienne</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>40 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>52</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Diagnostic</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>April 2021</primary_completion_date>
    <completion_date>December 2021</completion_date>
    <study_first_posted>April 27, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>Chu Saint-Etienne, Saint Etienne, France</location>
      <location>Clinique Mutualiste Saint Etienne, Saint Etienne, France</location>
      <location>Hôpital privé de la Loire, Saint-Étienne, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04363606</url>
  </study>
  <study rank="912">
    <nct_id>NCT04352985</nct_id>
    <title>Evaluating the Use of Polymyxin B Cartridge Hemoperfusion for Patients With Septic Shock and COVID 19</title>
    <acronym/>
    <status open="Y">Available</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Septic Shock</condition>
      <condition>Endotoxemia</condition>
      <condition>COVID</condition>
      <condition>Corona Virus Infection</condition>
      <condition>Sepsis, Severe</condition>
    </conditions>
    <interventions>
      <intervention type="Device">Toraymyxin PMX-20R (PMX Cartridge)</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>Spectral Diagnostics (US) Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Expanded Access</study_types>
    <exp_acc_types>
      <exp_acc_type>Intermediate-size Population</exp_acc_type>
    </exp_acc_types>
    <study_designs/>
    <study_first_posted>April 20, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04352985</url>
  </study>
  <study rank="913">
    <nct_id>NCT04349371</nct_id>
    <title>Saved From COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Chloroquine</intervention>
      <intervention type="Drug">Placebo oral tablet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of symptomatic illness in at risk healthcare workers</outcome_measure>
      <outcome_measure>Number of healthcare workers with symptomatic COVID infections</outcome_measure>
      <outcome_measure>Number of severe illness in at risk healthcare workers</outcome_measure>
      <outcome_measure>Number of sero-conversions in at risk healthcare workers</outcome_measure>
      <outcome_measure>Percentage of patients with adverse events Grade 3 or higher</outcome_measure>
      <outcome_measure>Percentage of patients with GI intolerance</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Columbia University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>350</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>April 2021</primary_completion_date>
    <completion_date>April 2021</completion_date>
    <study_first_posted>April 16, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>Columbia University Irving Medical Center/NYP, New York, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04349371</url>
  </study>
  <study rank="914">
    <nct_id>NCT04327479</nct_id>
    <title>Characterization of Cardiovascular Diseases and Risk Factors in Patients With Suspected SARS-CoV2/Covid-19 Infection</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cardiovascular Diseases</condition>
      <condition>Cardiovascular Risk Factor</condition>
      <condition>SARS</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Assessment of cardiovascular diseases and cardiovascular risk factors</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>All-cause mortality</outcome_measure>
      <outcome_measure>30-day mortality</outcome_measure>
      <outcome_measure>Major adverse cardiovascular events</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Essen</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>728</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 26, 2020</start_date>
    <primary_completion_date>March 25, 2026</primary_completion_date>
    <completion_date>March 25, 2026</completion_date>
    <study_first_posted>March 31, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>University Hospital Essen, Essen, NRW, Germany</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04327479</url>
  </study>
  <study rank="915">
    <nct_id>NCT04305574</nct_id>
    <title>Social Media Use During COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
      <condition>Depression</condition>
      <condition>Anxiety</condition>
      <condition>Stress</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Use of social media during COVID-19</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Assessment of COVID-19 situation</outcome_measure>
      <outcome_measure>Depression, Anxiety and Stress Scale</outcome_measure>
      <outcome_measure>Familiarity and trust in COVID-related rumours</outcome_measure>
      <outcome_measure>Availability heuristic</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Jean Liu</lead_sponsor>
      <collaborator>Yale-NUS College</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>21 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>5000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <start_date>March 8, 2020</start_date>
    <primary_completion_date>May 31, 2020</primary_completion_date>
    <completion_date>May 31, 2020</completion_date>
    <study_first_posted>March 12, 2020</study_first_posted>
    <last_update_posted>March 17, 2020</last_update_posted>
    <locations>
      <location>Yale-NUS College, Singapore, Singapore</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04305574</url>
  </study>
  <study rank="916">
    <nct_id>NCT04347031</nct_id>
    <title>An Open Randomized Study of the Effectiveness of Mefloquine for the Treatment of Patients With COVID19</title>
    <acronym/>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pneumonia, Viral</condition>
      <condition>Respiratory Failure</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Mefloquine</intervention>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Combination Product">Mefloquine + azithromycin + / - tocilizumab</intervention>
      <intervention type="Combination Product">Hydroxychloroquine + azithromycin + / - tocilizumab</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>1st primary endpoint for group 1</outcome_measure>
      <outcome_measure>2nd primary endpoint for group 1</outcome_measure>
      <outcome_measure>1st primary endpoint for group 2</outcome_measure>
      <outcome_measure>2nd primary endpoint for group 2</outcome_measure>
      <outcome_measure>1st secondary endpoint for group 1</outcome_measure>
      <outcome_measure>2nd secondary endpoint for group 1</outcome_measure>
      <outcome_measure>3d secondary endpoint for group 1</outcome_measure>
      <outcome_measure>4th secondary endpoint for group 1</outcome_measure>
      <outcome_measure>5th secondary endpoint for group 1</outcome_measure>
      <outcome_measure>6th secondary endpoint for group 1</outcome_measure>
      <outcome_measure>1st secondary endpoint for group 2</outcome_measure>
      <outcome_measure>2nd secondary endpoint for group 2</outcome_measure>
      <outcome_measure>3d secondary endpoint for group 2</outcome_measure>
      <outcome_measure>4th secondary endpoint for group 2</outcome_measure>
      <outcome_measure>5th secondary endpoint for group 2</outcome_measure>
      <outcome_measure>6th secondary endpoint for group 2</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Burnasyan Federal Medical Biophysical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>60 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>320</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 8, 2020</start_date>
    <primary_completion_date>August 1, 2020</primary_completion_date>
    <completion_date>August 1, 2020</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04347031</url>
  </study>
  <study rank="917">
    <nct_id>NCT04365530</nct_id>
    <title>Become of Patients Infected or Suspected of Being Infected by Covid-19 and Supported by the GHPSJ and the Establishments of the Paris Plaisance Hospital City</title>
    <acronym>COVIDGHPSJCite</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Clinical consequences of a Covid-19 infection in the care population</outcome_measure>
      <outcome_measure>Risk factors at M6</outcome_measure>
      <outcome_measure>Risk factors at year 1</outcome_measure>
      <outcome_measure>Risk factors at year 2</outcome_measure>
      <outcome_measure>Impact of hospital reorganization on medical care at M6</outcome_measure>
      <outcome_measure>Impact of hospital reorganization on medical care at Year 1</outcome_measure>
      <outcome_measure>Impact of hospital reorganization on medical care at Year 2</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Groupe Hospitalier Paris Saint Joseph</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>2000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Other</study_design>
    </study_designs>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>April 1, 2022</primary_completion_date>
    <completion_date>December 31, 2022</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Hôpital Marie Lannelongue, Le Plessis-Robinson, France</location>
      <location>AURA Paris Plaisance, Paris, France</location>
      <location>Fondation Sainte-Marie, Paris, France</location>
      <location>Groupe Hospitalier Paris Saint-Joseph, Paris, France</location>
      <location>Hôpital Bellan, Paris, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04365530</url>
  </study>
  <study rank="918">
    <nct_id>NCT04362150</nct_id>
    <title>Long-term Impact of Infection With Novel Coronavirus (COVID-19)</title>
    <acronym>LIINC</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Participant age</outcome_measure>
      <outcome_measure>Participant sex</outcome_measure>
      <outcome_measure>Participant race/ethnicity</outcome_measure>
      <outcome_measure>Proportion of participants previously hospitalized.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of California, San Francisco</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>100 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>800</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 17, 2020</start_date>
    <primary_completion_date>December 31, 2022</primary_completion_date>
    <completion_date>December 21, 2024</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Zuckerberg San Francisco General Hospital (ZSFG), San Francisco, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04362150</url>
  </study>
  <study rank="919">
    <nct_id>NCT04362358</nct_id>
    <title>Online Cognitive Behavioral Therapy (CBT) for Stress Disorders in Health Workers Involved in the Care of Patients During the Covid-19 Epidemic</title>
    <acronym>REST</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Stress - Prevention of Sleep Disorders, PTSD and Depression</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Online cognitive behavioral therapy (CBT)</intervention>
      <intervention type="Behavioral">Online bibliotherapy programme</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Significant score reduction at the Perceived Stress Scale</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Strasbourg, France</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>May 1, 2020</start_date>
    <primary_completion_date>October 1, 2021</primary_completion_date>
    <completion_date>October 1, 2021</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04362358</url>
  </study>
  <study rank="920">
    <nct_id>NCT04363528</nct_id>
    <title>Incidence of Deep Vein Thrombosis at Doppler Echo in Covid-19 Patients With SARS-Cov-2 Pneumopathy Hospitalized in ICU</title>
    <acronym>COVIDOP-DVT</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Deep Vein Thrombosis</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Doppler Echo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Incidence of Deep Vein Thrombosis at Doppler Echo in Patients With SARS-Cov-2 Pneumopathy Hospitalized in ICU</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Versailles Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <start_date>April 27, 2020</start_date>
    <primary_completion_date>October 30, 2020</primary_completion_date>
    <completion_date>October 30, 2020</completion_date>
    <study_first_posted>April 27, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>Centre Hospitalier de Versailles, Le Chesnay, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04363528</url>
  </study>
  <study rank="921">
    <nct_id>NCT04348370</nct_id>
    <title>BCG Vaccine for Health Care Workers as Defense Against COVID 19</title>
    <acronym>BADAS</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
      <condition>Coronavirus Infection</condition>
      <condition>Coronavirus as the Cause of Diseases Classified Elsewhere</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">BCG Vaccine</intervention>
      <intervention type="Biological">Placebo Vaccine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Incidence of COVID 19 Infection</outcome_measure>
      <outcome_measure>Disease Severity</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Texas A&amp;M University</lead_sponsor>
      <collaborator>Baylor College of Medicine</collaborator>
      <collaborator>M.D. Anderson Cancer Center</collaborator>
      <collaborator>Cedars-Sinai Medical Center</collaborator>
      <collaborator>Harvard University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>1800</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>May 2021</primary_completion_date>
    <completion_date>November 2021</completion_date>
    <study_first_posted>April 16, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>Cedars-Sinai Medical Center, Los Angeles, California, United States</location>
      <location>Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States</location>
      <location>Texas A&amp;M Family Care Clinic, Bryan, Texas, United States</location>
      <location>Baylor College of Medicine, Houston, Texas, United States</location>
      <location>Baylor St. Luke's Medical Center, Houston, Texas, United States</location>
      <location>Harris Health System - Ben Taub Hospital, Houston, Texas, United States</location>
      <location>MD Anderson Cancer Center, Houston, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04348370</url>
  </study>
  <study rank="922">
    <nct_id>NCT04279795</nct_id>
    <title>Detection of 2019 Novel Coronavirus in Multiple Organ System and Its Relationship With Clinical Manifestations</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Positive rate of 2019 Novel Coronavirus RNA</outcome_measure>
      <outcome_measure>Survival rate</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Third Affiliated Hospital, Sun Yat-Sen University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>January 20, 2020</start_date>
    <primary_completion_date>January 31, 2021</primary_completion_date>
    <completion_date>February 28, 2021</completion_date>
    <study_first_posted>February 21, 2020</study_first_posted>
    <last_update_posted>February 21, 2020</last_update_posted>
    <locations>
      <location>The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04279795</url>
  </study>
  <study rank="923">
    <nct_id>NCT04279782</nct_id>
    <title>Clinical Features of Suspected and Confirmed Patients of 2019 Novel Coronavirus Infection</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Comprehensive treatment</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Survival rate</outcome_measure>
      <outcome_measure>Chest computed tomography</outcome_measure>
      <outcome_measure>Recovery Time</outcome_measure>
      <outcome_measure>Depression evaluation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Third Affiliated Hospital, Sun Yat-Sen University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>January 20, 2020</start_date>
    <primary_completion_date>January 31, 2021</primary_completion_date>
    <completion_date>February 28, 2021</completion_date>
    <study_first_posted>February 21, 2020</study_first_posted>
    <last_update_posted>February 24, 2020</last_update_posted>
    <locations>
      <location>The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04279782</url>
  </study>
  <study rank="924">
    <nct_id>NCT04350281</nct_id>
    <title>Double Therapy With IFN-beta 1b and Hydroxychloroquine</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Interferon Beta-1B</intervention>
      <intervention type="Drug">Hydroxychloroquine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to negative NPS viral load</outcome_measure>
      <outcome_measure>Time to NEWS 0</outcome_measure>
      <outcome_measure>Length of Hospitalisation</outcome_measure>
      <outcome_measure>Time to negative viral load in all clinical samples</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>Inflammatory markers changes</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>The University of Hong Kong</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 9, 2020</start_date>
    <primary_completion_date>March 31, 2022</primary_completion_date>
    <completion_date>July 31, 2022</completion_date>
    <study_first_posted>April 17, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations>
      <location>The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04350281</url>
  </study>
  <study rank="925">
    <nct_id>NCT04343729</nct_id>
    <title>Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19</title>
    <acronym>MetCOVID</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV Infection</condition>
      <condition>Severe Acute Respiratory Syndrome (SARS) Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Methylprednisolone Sodium Succinate</intervention>
      <intervention type="Drug">Placebo solution</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mortality rate at day 28</outcome_measure>
      <outcome_measure>Proportion of patients with SARS</outcome_measure>
      <outcome_measure>Mortality rate on days 7, 14 and 28</outcome_measure>
      <outcome_measure>Incidence of orotracheal intubation</outcome_measure>
      <outcome_measure>Change in oxygenation index</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Fundação de Medicina Tropical Dr. Heitor Vieira Dourado</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>420</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 18, 2020</start_date>
    <primary_completion_date>September 2020</primary_completion_date>
    <completion_date>September 2020</completion_date>
    <study_first_posted>April 13, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz, Manaus, Amazonas, Brazil</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04343729</url>
  </study>
  <study rank="926">
    <nct_id>NCT04341584</nct_id>
    <title>CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection</title>
    <acronym>CORIMUNO-ANA</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Corona Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Anakinra</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Survival without needs of ventilator utilization at day 14</outcome_measure>
      <outcome_measure>WHO progression scale ≤ 5</outcome_measure>
      <outcome_measure>Cumulative incidence of successful tracheal extubation (defined as duration extubation &gt; 48h) or withdrawal of NIV or high flow (for &gt; 48h), at day 14</outcome_measure>
      <outcome_measure>Decrease of at least one point in WHO progression scale score</outcome_measure>
      <outcome_measure>WHO progression scale</outcome_measure>
      <outcome_measure>Survival</outcome_measure>
      <outcome_measure>28-day ventilator free-days</outcome_measure>
      <outcome_measure>Respiratory acidosis</outcome_measure>
      <outcome_measure>PaO2/FiO2 ratio</outcome_measure>
      <outcome_measure>Time to oxygen supply independency</outcome_measure>
      <outcome_measure>Duration of hospitalization</outcome_measure>
      <outcome_measure>Time to negative viral excretion</outcome_measure>
      <outcome_measure>Time to ICU discharge</outcome_measure>
      <outcome_measure>Time to hospital discharge</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>240</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>May 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>April 10, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04341584</url>
  </study>
  <study rank="927">
    <nct_id>NCT04292327</nct_id>
    <title>Clinical Progressive Characteristics and Treatment Effects of 2019-novel Coronavirus</title>
    <acronym>2019-nCoV</acronym>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pneumonia Caused by Human Coronavirus</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>The time interval of Nucleic acid detection become negative</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Fujian Provincial Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>January 1, 2020</start_date>
    <primary_completion_date>April 30, 2020</primary_completion_date>
    <completion_date>July 31, 2020</completion_date>
    <study_first_posted>March 3, 2020</study_first_posted>
    <last_update_posted>March 3, 2020</last_update_posted>
    <locations>
      <location>Fujian Provincial Hospital, Fuzhou, Fujian, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04292327</url>
  </study>
  <study rank="928">
    <nct_id>NCT04340557</nct_id>
    <title>Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Losartan</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mechanical ventilation</outcome_measure>
      <outcome_measure>ICU transfer</outcome_measure>
      <outcome_measure>Oxygen therapy</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sharp HealthCare</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>March 27, 2020</start_date>
    <primary_completion_date>October 6, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>April 9, 2020</study_first_posted>
    <last_update_posted>April 9, 2020</last_update_posted>
    <locations>
      <location>Sharp Grossmont Hospital, La Mesa, California, United States</location>
      <location>Sharp Chula Vista Medical Center, San Diego, California, United States</location>
      <location>Sharp Coronado Hospital, San Diego, California, United States</location>
      <location>Sharp Memorial Hospital, San Diego, California, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04340557</url>
  </study>
  <study rank="929">
    <nct_id>NCT04269525</nct_id>
    <title>Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pneumonia, Viral</condition>
      <condition>Pneumonia, Ventilator-Associated</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">UC-MSCs</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Oxygenation index</outcome_measure>
      <outcome_measure>28 day mortality</outcome_measure>
      <outcome_measure>Hospital stay</outcome_measure>
      <outcome_measure>2019-nCoV nucleic acid test</outcome_measure>
      <outcome_measure>Improvement of lung imaging examinations</outcome_measure>
      <outcome_measure>White blood cell count</outcome_measure>
      <outcome_measure>Lymphocyte count</outcome_measure>
      <outcome_measure>Lymphocyte percentage</outcome_measure>
      <outcome_measure>Procalcitonin</outcome_measure>
      <outcome_measure>interleukin(IL)-2</outcome_measure>
      <outcome_measure>IL-4</outcome_measure>
      <outcome_measure>IL-6</outcome_measure>
      <outcome_measure>IL-8</outcome_measure>
      <outcome_measure>IL-10</outcome_measure>
      <outcome_measure>tumor necrosis factor(TNF)-α</outcome_measure>
      <outcome_measure>γ-interferon(IFN)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>ZhiYong Peng</lead_sponsor>
      <collaborator>Tuohua Biological Technology Co. Ltd</collaborator>
      <collaborator>Zhongnan Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>10</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>February 6, 2020</start_date>
    <primary_completion_date>April 30, 2020</primary_completion_date>
    <completion_date>September 30, 2020</completion_date>
    <study_first_posted>February 13, 2020</study_first_posted>
    <last_update_posted>February 17, 2020</last_update_posted>
    <locations>
      <location>Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04269525</url>
  </study>
  <study rank="930">
    <nct_id>NCT04325672</nct_id>
    <title>Convalescent Plasma to Limit Coronavirus Associated Complications</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">Convalescent Plasma</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>RNA in SARS-CoV-2</outcome_measure>
      <outcome_measure>ICU Admissions</outcome_measure>
      <outcome_measure>Hospital Mortality</outcome_measure>
      <outcome_measure>Hospital Length of Stay (LOS)</outcome_measure>
      <outcome_measure>Type of respiratory support</outcome_measure>
      <outcome_measure>Duration of respiratory support</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Mayo Clinic</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Basic Science</study_design>
    </study_designs>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>December 31, 2022</primary_completion_date>
    <completion_date>December 31, 2022</completion_date>
    <study_first_posted>March 27, 2020</study_first_posted>
    <last_update_posted>April 8, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04325672</url>
  </study>
  <study rank="931">
    <nct_id>NCT04261907</nct_id>
    <title>Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>2019-nCoV</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">ASC09/ritonavir group</intervention>
      <intervention type="Drug">lopinavir/ritonavir group</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The incidence of composite adverse outcome</outcome_measure>
      <outcome_measure>Time to recovery</outcome_measure>
      <outcome_measure>Rate of no fever</outcome_measure>
      <outcome_measure>Rate of no cough</outcome_measure>
      <outcome_measure>Rate of no dyspnea</outcome_measure>
      <outcome_measure>Rate of no requring supplemental oxygen</outcome_measure>
      <outcome_measure>Rate of undectable viral RNA</outcome_measure>
      <outcome_measure>Rate of mechanical ventilation</outcome_measure>
      <outcome_measure>Rate of ICU admission</outcome_measure>
      <outcome_measure>Time and rate of laboratory indicators related to disease improvement to return to normal</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>First Affiliated Hospital of Zhejiang University</lead_sponsor>
      <collaborator>Ascletis Pharmaceuticals Co., Ltd.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>160</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>February 7, 2020</start_date>
    <primary_completion_date>May 31, 2020</primary_completion_date>
    <completion_date>June 30, 2020</completion_date>
    <study_first_posted>February 10, 2020</study_first_posted>
    <last_update_posted>February 10, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04261907</url>
  </study>
  <study rank="932">
    <nct_id>NCT04326075</nct_id>
    <title>Early CPAP in COVID Patients With Respiratory Failure.</title>
    <acronym>EC-COVID-RCT</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>CPAP Ventilation</condition>
      <condition>COVID-19</condition>
      <condition>Emergency Departments</condition>
    </conditions>
    <interventions>
      <intervention type="Device">CPAP treatment</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Death or need of intubation</outcome_measure>
      <outcome_measure>30-day mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Mario Negri Institute for Pharmacological Research</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>900</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 6, 2020</start_date>
    <primary_completion_date>October 5, 2020</primary_completion_date>
    <completion_date>November 9, 2020</completion_date>
    <study_first_posted>March 30, 2020</study_first_posted>
    <last_update_posted>March 31, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04326075</url>
  </study>
  <study rank="933">
    <nct_id>NCT04337190</nct_id>
    <title>Impact of Angiotensin II Receptor Blockers Treatment in Patients With COVID 19 (COVID-ARA2)</title>
    <acronym>COVID-ARA2</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
      <condition>Acute Respiratory Distress Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">blood sampling</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>ACE2 level change over time</outcome_measure>
      <outcome_measure>ACE2 activity over time</outcome_measure>
      <outcome_measure>Mortality at day 28</outcome_measure>
      <outcome_measure>ARDS severity</outcome_measure>
      <outcome_measure>Duration of mechanical ventilation</outcome_measure>
      <outcome_measure>Need for prone positionning</outcome_measure>
      <outcome_measure>Need for extracorporeal membran oxygenation</outcome_measure>
      <outcome_measure>Use of paralytic agents</outcome_measure>
      <outcome_measure>Need for renal replacement therapy</outcome_measure>
      <outcome_measure>Need for vasoactive drugs (norepinephrine, dobutamine,epinephrine)</outcome_measure>
      <outcome_measure>Sequential Organ Failure Assessment (SOFA) score</outcome_measure>
      <outcome_measure>Number of session(s) of prone positionning</outcome_measure>
      <outcome_measure>Duration of extracorporeal membran oxygenation treatment</outcome_measure>
      <outcome_measure>Type of vasoactive drugs</outcome_measure>
      <outcome_measure>Duration of vasoactive treatment</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Angers</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 3, 2020</start_date>
    <primary_completion_date>October 6, 2020</primary_completion_date>
    <completion_date>December 6, 2020</completion_date>
    <study_first_posted>April 7, 2020</study_first_posted>
    <last_update_posted>April 10, 2020</last_update_posted>
    <locations>
      <location>University Hospital Angers, Angers, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04337190</url>
  </study>
  <study rank="934">
    <nct_id>NCT04061382</nct_id>
    <title>Sero-epidemiological Survey of England in 2019/2020</title>
    <acronym>STORY</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Serogroup C Meningococcal Meningitis</condition>
      <condition>Diphtheria</condition>
      <condition>COVID-19</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Venepuncture</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Feasibility of developing an England based sero-epidemiological programme in 0-24 year olds</outcome_measure>
      <outcome_measure>Feasibility of developing an England based sero epidemiological survey in 0-24 year olds</outcome_measure>
      <outcome_measure>Recruitment rate</outcome_measure>
      <outcome_measure>Cost</outcome_measure>
      <outcome_measure>To assess, in relevant age groups, immunity against infections and vaccine preventable diseases</outcome_measure>
      <outcome_measure>Sera collection</outcome_measure>
      <outcome_measure>Exploratory</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Oxford</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <max_age>24 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>3500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>October 15, 2019</start_date>
    <primary_completion_date>November 30, 2020</primary_completion_date>
    <completion_date>November 30, 2020</completion_date>
    <study_first_posted>August 19, 2019</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Centre for Clinical Vaccinology &amp; Tropical Medicine (CCVTM), Oxford, Oxfordshire, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04061382</url>
  </study>
  <study rank="935">
    <nct_id>NCT04264533</nct_id>
    <title>Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Vitamin C</condition>
      <condition>Pneumonia, Viral</condition>
      <condition>Pneumonia, Ventilator-Associated</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">VC</intervention>
      <intervention type="Drug">Sterile Water for Injection</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Ventilation-free days</outcome_measure>
      <outcome_measure>28-days mortality</outcome_measure>
      <outcome_measure>ICU length of stay</outcome_measure>
      <outcome_measure>Demand for first aid measuments</outcome_measure>
      <outcome_measure>Vasopressor days</outcome_measure>
      <outcome_measure>Respiratory indexes</outcome_measure>
      <outcome_measure>Ventilator parameters</outcome_measure>
      <outcome_measure>APACHE II scores</outcome_measure>
      <outcome_measure>SOFA scores</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>ZhiYong Peng</lead_sponsor>
      <collaborator>Zhongnan Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>140</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Triple (Participant, Care Provider, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>February 14, 2020</start_date>
    <primary_completion_date>September 30, 2020</primary_completion_date>
    <completion_date>September 30, 2020</completion_date>
    <study_first_posted>February 11, 2020</study_first_posted>
    <last_update_posted>March 10, 2020</last_update_posted>
    <locations>
      <location>Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04264533</url>
  </study>
  <study rank="936">
    <nct_id>NCT04338841</nct_id>
    <title>HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With a SARS-CoV-2 Infection</title>
    <acronym>HOME-CoV</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Other">HOME-CoV rule implementation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>the composite rate of adverse outcomes</outcome_measure>
      <outcome_measure>The rate of hospitalization</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Angers</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>4000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 9, 2020</start_date>
    <primary_completion_date>June 1, 2020</primary_completion_date>
    <completion_date>June 1, 2020</completion_date>
    <study_first_posted>April 8, 2020</study_first_posted>
    <last_update_posted>April 13, 2020</last_update_posted>
    <locations>
      <location>Clinique Universitaire Saint-Luc, Bruxelles, Belgium</location>
      <location>CHU de Liège, Liege, Belgium</location>
      <location>Ch Argenteuil, Argenteuil, France</location>
      <location>CHU Brest, Brest, France</location>
      <location>CH Cholet, Cholet, France</location>
      <location>CHU Clermont Ferrand, Clermont Ferrand, France</location>
      <location>Ch Colmar, Colmar, France</location>
      <location>CH Alpes Lemant, Contamine-sur-Arve, France</location>
      <location>CHU Dijon, Dijon, France</location>
      <location>CH Le Mans, Le Mans, France</location>
      <location>CH Libourne, Libourne, France</location>
      <location>CH Limoges, Limoges, France</location>
      <location>Ch Longjumeau, Longjumeau, France</location>
      <location>Hospices Civils de Lyon (University Hospital of Lyon), Lyon, France</location>
      <location>Chu Montpellier, Montpellier, France</location>
      <location>Centre Hospitalier Universitaire de Nantes, Nantes, France</location>
      <location>CH Niort, Niort, France</location>
      <location>Hopital Paris Saint Joseph, Paris, France</location>
      <location>Hopital Saint Antoine, Paris, France</location>
      <location>Hôpital Bichat, Paris, France</location>
      <location>Hôpital Lariboisière, Paris, France</location>
      <location>CHU de Poitiers, Poitiers, France</location>
      <location>CH Reims, Reims, France</location>
      <location>Ch Remiremont, Remiremont, France</location>
      <location>Chu Rennes, Rennes, France</location>
      <location>CHU de Rouen, Rouen, France</location>
      <location>CHU de St Etienne, Saint Etienne, France</location>
      <location>CH de Saint-Brieuc, Saint-Brieuc, France</location>
      <location>Ch Troyes, Troyes, France</location>
      <location>CH VICHY, Vichy, France</location>
      <location>CH Princesse Grace, Monaco, Monaco</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04338841</url>
  </study>
  <study rank="937">
    <nct_id>NCT04323527</nct_id>
    <title>Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2</title>
    <acronym>CloroCOVID19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV Infection</condition>
      <condition>Severe Acute Respiratory Syndrome (SARS) Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Chloroquine diphosphate</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Mortality rate reduction of 50% by day 28</outcome_measure>
      <outcome_measure>Absolute mortality on days 7 and 14</outcome_measure>
      <outcome_measure>Improvement in overall subject's clinical status assessed in standardized clinical questionnaires on days 14 and 28</outcome_measure>
      <outcome_measure>Improvement in daily clinical status assessed in standardized clinical questionnaires during hospitalization</outcome_measure>
      <outcome_measure>Duration of supplemental oxygen (if applicable)</outcome_measure>
      <outcome_measure>Duration of mechanical ventilation (if applicable)</outcome_measure>
      <outcome_measure>Absolute duration of hospital stay in days</outcome_measure>
      <outcome_measure>Prevalence of grade 3 and 4 adverse events</outcome_measure>
      <outcome_measure>Prevalence of serious adverse events</outcome_measure>
      <outcome_measure>Change in serum creatinine level</outcome_measure>
      <outcome_measure>Change in serum troponin I level</outcome_measure>
      <outcome_measure>Change in serum aspartate aminotransferase level</outcome_measure>
      <outcome_measure>Change in serum CK-MB level</outcome_measure>
      <outcome_measure>Change in detectable viral load in respiratory tract swabs</outcome_measure>
      <outcome_measure>Viral concentration in blood samples</outcome_measure>
      <outcome_measure>Absolute number of causes leading to participant death (if applicable)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Fundação de Medicina Tropical Dr. Heitor Vieira Dourado</lead_sponsor>
      <collaborator>Marcus Vinícius Guimarães de Lacerda</collaborator>
      <collaborator>Mayla Gabriela Silva Borba</collaborator>
      <collaborator>Wuelton Marcelo Monteiro</collaborator>
      <collaborator>Gisely Cardoso de Melo</collaborator>
      <collaborator>Fernando Fonseca de Almeida e Val</collaborator>
      <collaborator>Felipe Gomes Naveca</collaborator>
      <collaborator>Maria Paula Gomes Mourão</collaborator>
      <collaborator>Ludmila Abrahão Hajjar</collaborator>
      <collaborator>Jorge Souza Mendonça</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>440</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 23, 2020</start_date>
    <primary_completion_date>August 31, 2020</primary_completion_date>
    <completion_date>August 31, 2020</completion_date>
    <study_first_posted>March 26, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>Hospital e Pronto Socorro Delphina Rinaldi Abdel Aziz, Manaus, Amazonas, Brazil</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04323527</url>
  </study>
  <study rank="938">
    <nct_id>NCT04349163</nct_id>
    <title>Resilience Evaluation of Caregivers During the SARS-CoV2 Epidemic Period : Prospective Cohort.</title>
    <acronym>Resi-CoV</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Psychological</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Questionnaire</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>compare the level of resilience between physicians and caregivers of different specialties and in different workplaces according to the covid-19 epidemic.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Angers</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>280</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>May 15, 2020</primary_completion_date>
    <completion_date>May 25, 2020</completion_date>
    <study_first_posted>April 16, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04349163</url>
  </study>
  <study rank="939">
    <nct_id>NCT04275388</nct_id>
    <title>Xiyanping Injection for the Treatment of New Coronavirus Infected Pneumonia</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>2019 Novel Coronavirus Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Xiyanping injection</intervention>
      <intervention type="Drug">Lopinavir / ritonavir, alpha-interferon nebulization</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Clinical recovery time</outcome_measure>
      <outcome_measure>Complete fever time</outcome_measure>
      <outcome_measure>Cough relief time</outcome_measure>
      <outcome_measure>Virus negative time</outcome_measure>
      <outcome_measure>Incidence of severe or critical neocoronavirus pneumonia</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Jiangxi Qingfeng Pharmaceutical Co. Ltd.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>348</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>February 14, 2020</start_date>
    <primary_completion_date>May 14, 2020</primary_completion_date>
    <completion_date>December 14, 2021</completion_date>
    <study_first_posted>February 19, 2020</study_first_posted>
    <last_update_posted>February 19, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04275388</url>
  </study>
  <study rank="940">
    <nct_id>NCT04302766</nct_id>
    <title>Expanded Access Remdesivir (RDV; GS-5734™)</title>
    <acronym/>
    <status open="Y">Available</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Disease 2019</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Remdesivir</intervention>
    </interventions>
    <outcome_measures/>
    <sponsors>
      <lead_sponsor>U.S. Army Medical Research and Development Command</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <funded_bys>
      <funded_by>U.S. Fed</funded_by>
    </funded_bys>
    <study_types>Expanded Access</study_types>
    <exp_acc_types>
      <exp_acc_type>Intermediate-size Population</exp_acc_type>
      <exp_acc_type>Treatment IND/Protocol</exp_acc_type>
    </exp_acc_types>
    <study_designs/>
    <study_first_posted>March 10, 2020</study_first_posted>
    <last_update_posted>April 10, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04302766</url>
  </study>
  <study rank="941">
    <nct_id>NCT04342728</nct_id>
    <title>Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation</title>
    <acronym>COVIDAtoZ</acronym>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
      <condition>Corona Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Dietary Supplement">Ascorbic Acid</intervention>
      <intervention type="Dietary Supplement">Zinc Gluconate</intervention>
      <intervention type="Dietary Supplement">Ascorbic Acid and Zinc Gluconate</intervention>
      <intervention type="Other">Standard of Care</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Symptom Reduction</outcome_measure>
      <outcome_measure>Symptom Resolution: Fever</outcome_measure>
      <outcome_measure>Symptom Resolution: Cough</outcome_measure>
      <outcome_measure>Symptom Resolution: Shortness of Breath</outcome_measure>
      <outcome_measure>Symptom Resolution: Fatigue</outcome_measure>
      <outcome_measure>Day 5 Symptoms</outcome_measure>
      <outcome_measure>Hospitalizations</outcome_measure>
      <outcome_measure>Severity of Symptoms</outcome_measure>
      <outcome_measure>Adjunctive Medications</outcome_measure>
      <outcome_measure>Supplementation Side Effects</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>The Cleveland Clinic</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>520</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <start_date>April 8, 2020</start_date>
    <primary_completion_date>September 30, 2020</primary_completion_date>
    <completion_date>April 30, 2021</completion_date>
    <study_first_posted>April 13, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations>
      <location>Cleveland Clinic, Cleveland, Ohio, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04342728</url>
  </study>
  <study rank="942">
    <nct_id>NCT04245631</nct_id>
    <title>Development of a Simple, Fast and Portable Recombinase Aided Amplification Assay for 2019-nCoV</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>New Coronavirus</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Recombinase aided amplification (RAA) assay</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Detection sensitivity is greater than 95%</outcome_measure>
      <outcome_measure>Detection specificity is greater than 95%</outcome_measure>
      <outcome_measure>Consistent with existing universal reagent detection rates greater than 95%</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Beijing Ditan Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>1 Year</min_age>
    <max_age>90 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>January 1, 2020</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>January 29, 2020</study_first_posted>
    <last_update_posted>April 10, 2020</last_update_posted>
    <locations>
      <location>Department of Hepatology Division 2, Beijing Ditan Hospital, Beijing, Beijing, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04245631</url>
  </study>
  <study rank="943">
    <nct_id>NCT04350710</nct_id>
    <title>Description of Respiratory Mechanics in Patients With SARS-CoV-2 Associated ARDS</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Acute Respiratory Distress Syndrome</condition>
      <condition>COVID</condition>
    </conditions>
    <interventions>
      <intervention type="Other">PEEP trial</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Recruitment-to Inflation ratio (R/I ratio)</outcome_measure>
      <outcome_measure>PaO2/FiO2 (mmHg)</outcome_measure>
      <outcome_measure>Lung volume recruited (VRec)</outcome_measure>
      <outcome_measure>Plateau pressure (cm H2O)</outcome_measure>
      <outcome_measure>Oesophagal pressure (cm H2O)</outcome_measure>
      <outcome_measure>weight (Kg)</outcome_measure>
      <outcome_measure>urine output (mL)</outcome_measure>
      <outcome_measure>serum creatinine (Umo/L)</outcome_measure>
      <outcome_measure>Mean arterial pressure (mmHg)</outcome_measure>
      <outcome_measure>Peak Pressure (cm H2O)</outcome_measure>
      <outcome_measure>PEEP total (cm H2O)</outcome_measure>
      <outcome_measure>PEP Set (cm H2O)</outcome_measure>
      <outcome_measure>Height (cm)</outcome_measure>
      <outcome_measure>Airway pening pressure (cm H2O)</outcome_measure>
      <outcome_measure>Expired volume in PEEP setted at 15 cmH2O (mL)</outcome_measure>
      <outcome_measure>Expired volume in PEEP setted at 5 cmH2O (mL)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Angers</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 18, 2020</start_date>
    <primary_completion_date>April 20, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>April 17, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations>
      <location>CHU, Angers, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04350710</url>
  </study>
  <study rank="944">
    <nct_id>NCT04361838</nct_id>
    <title>The COVID-19 ICU PRAYER Study</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">prayer</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Impact of multi-denominational prayer on clinical outcomes of critically ill COVID-19 patients in the Intensive Care Unit on mortality.</outcome_measure>
      <outcome_measure>Difference in patient outcomes - Acute Physiology and Chronic Health Enquiry. APACHE II score.</outcome_measure>
      <outcome_measure>Difference in patient outcomes - Sequential Organ Failure Assessment - SOFA Score</outcome_measure>
      <outcome_measure>Difference in patient outcomes - Length of stay in ICU.</outcome_measure>
      <outcome_measure>Difference in patient outcomes - Length of ventilator support</outcome_measure>
      <outcome_measure>Difference in patient outcomes - length of vasopressor support</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Kansas City Heart Rhythm Institute</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>110 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Care Provider)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <start_date>May 1, 2020</start_date>
    <primary_completion_date>August 31, 2020</primary_completion_date>
    <completion_date>August 31, 2020</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04361838</url>
  </study>
  <study rank="945">
    <nct_id>NCT03331445</nct_id>
    <title>Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections</title>
    <acronym>NONTM</acronym>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Respiratory Tract Infections</condition>
      <condition>Corona Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Measure the safety of 160ppm inhaled nitric oxide delivery in NTM subjects</outcome_measure>
      <outcome_measure>Measure the effect of 160ppm inhaled nitric oxide delivery on lung spirometry in NTM subjects</outcome_measure>
      <outcome_measure>Measure the antimicrobial effect of 160ppm inhaled nitric oxide on lung NTM bacterial load in the sputum</outcome_measure>
      <outcome_measure>Measure the effect of 160ppm inhaled nitric oxide on Quality of Life (CRISS) Score</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of British Columbia</lead_sponsor>
      <collaborator>Mallinckrodt</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>14 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>October 24, 2017</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>March 31, 2021</completion_date>
    <study_first_posted>November 6, 2017</study_first_posted>
    <last_update_posted>March 31, 2020</last_update_posted>
    <locations>
      <location>Diamond Centre, Vancouver, British Columbia, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03331445</url>
  </study>
  <study rank="946">
    <nct_id>NCT04322682</nct_id>
    <title>Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)</title>
    <acronym>COVID-19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Corona Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Colchicine</intervention>
      <intervention type="Drug">Placebo oral tablet</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of participants who die or require hospitalization due to COVID-19 infection</outcome_measure>
      <outcome_measure>Number of participants who die</outcome_measure>
      <outcome_measure>Number of participants requiring hospitalization due to COVID-19 infection</outcome_measure>
      <outcome_measure>Number of participants requiring mechanical ventilation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Montreal Heart Institute</lead_sponsor>
      <collaborator>DACIMA Software</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>40 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>6000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 23, 2020</start_date>
    <primary_completion_date>September 2020</primary_completion_date>
    <completion_date>September 2020</completion_date>
    <study_first_posted>March 26, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>University of California, San Francisco - San Francisco General Hospital, San Francisco, California, United States</location>
      <location>New York University School of Medecine, New York, New York, United States</location>
      <location>Montreal Heart Institute, Montreal, Quebec, Canada</location>
      <location>Hospital Universitario La Paz, IdiPaz, La Paz, Madrid, Spain</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04322682</url>
  </study>
  <study rank="947">
    <nct_id>NCT04335630</nct_id>
    <title>Cardiovascular Manifestations of COVID-19</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cardiovascular Diseases</condition>
      <condition>COVID</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Electrocardiogram, telemetry, echocardiogram, laboratory values</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Prevalence of cardiomyopathy, myocardial infarction, heart failure, clinically significant arrhythmias, cardiogenic shock or cardiac arrest.</outcome_measure>
      <outcome_measure>Prevalence of pericarditis, pericardial effusion, valvular disease.</outcome_measure>
      <outcome_measure>Identification of characteristic electrocardiographic patterns related to COVID-19</outcome_measure>
      <outcome_measure>Role of active cardiovascular disease in clinical outcomes of patients with COVID-19 including length of ICU stay, length of hospitalization and mortality.</outcome_measure>
      <outcome_measure>Role of pre-existing cardiovascular comorbidities in clinical course of COVID-19</outcome_measure>
      <outcome_measure>Role of treatment with ACE inhibitors or ARBs in the clinical course of COVID-19</outcome_measure>
      <outcome_measure>Role of insurance type on clinical outcomes of patients with COVID-19</outcome_measure>
      <outcome_measure>Effect of age, gender and race on clinical course of COVID-19 and prevalence of cardiovascular complications</outcome_measure>
      <outcome_measure>Role of active smoking on clinical course of COVID-19 and prevalence of cardiovascular complications</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Memorial Hermann Health System</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>March 30, 2020</start_date>
    <primary_completion_date>March 2021</primary_completion_date>
    <completion_date>March 2022</completion_date>
    <study_first_posted>April 6, 2020</study_first_posted>
    <last_update_posted>April 7, 2020</last_update_posted>
    <locations>
      <location>Memorial Hermann Hospital-Texas Medical Center, Houston, Texas, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04335630</url>
  </study>
  <study rank="948">
    <nct_id>NCT04255940</nct_id>
    <title>2019-nCoV Outbreak and Cardiovascular Diseases</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cardiovascular Death; Major Adverse Cardiovascular Events</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Cardiovascular Death</outcome_measure>
      <outcome_measure>Major Adverse Cardiovascular Events</outcome_measure>
      <outcome_measure>Times From symptom onset to hospital arrival</outcome_measure>
      <outcome_measure>Anxiety</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Qilu Hospital of Shandong University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>12000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>January 20, 2020</start_date>
    <primary_completion_date>April 30, 2020</primary_completion_date>
    <completion_date>April 30, 2020</completion_date>
    <study_first_posted>February 5, 2020</study_first_posted>
    <last_update_posted>February 5, 2020</last_update_posted>
    <locations>
      <location>Affiliated Hospital of Binzhou Medical Universty, Binzhou, Shandong, China</location>
      <location>Heze Municipal Hospital, Heze, Shandong, China</location>
      <location>Shandong University Qilu Hospital, Jinan, Shandong, China</location>
      <location>Jinan Central Hospital, Shandong University, Jinan, Shandong, China</location>
      <location>First Hospital Affiliated with Shandong First Medical University, Jinan, Shandong, China</location>
      <location>Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China</location>
      <location>The Second Hospital of Shandong University, Jinan, Shandong, China</location>
      <location>Jining Hospital of Traditional Chinese Medicine, Jining, Shandong, China</location>
      <location>Qihe People's Hospital, Qihe, Shandong, China</location>
      <location>Affiliated Hospital of Qingdao University Medical College, Qingdao, Shandong, China</location>
      <location>Weihai Municipal Hospital, Weihai, Shandong, China</location>
      <location>Central Hospital of Zibo, Zibo, Shandong, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04255940</url>
  </study>
  <study rank="949">
    <nct_id>NCT04281693</nct_id>
    <title>A New Screening Strategy for 2019 Novel Coronavirus Infection</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Novel Coronavirus Infection Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Standard screening strategy</intervention>
      <intervention type="Diagnostic Test">New screening strategy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Screening accuracy</outcome_measure>
      <outcome_measure>Cost-effectiveness analysis</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Affiliated Hospital to Academy of Military Medical Sciences</lead_sponsor>
      <collaborator>The Fifth Medical Center of Chinese PLA General Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>230</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Screening</study_design>
    </study_designs>
    <start_date>February 2020</start_date>
    <primary_completion_date>March 2020</primary_completion_date>
    <completion_date>March 2020</completion_date>
    <study_first_posted>February 24, 2020</study_first_posted>
    <last_update_posted>February 24, 2020</last_update_posted>
    <locations>
      <location>the Fifth Medical Center of Chinese PLA General Hospital, Beijing, Beijing, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04281693</url>
  </study>
  <study rank="950">
    <nct_id>NCT04363788</nct_id>
    <title>Needle Stick Injuries in Emergency Medical Service Practice</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Cardiac Arrest</condition>
      <condition>Needle Stick</condition>
      <condition>Injuries</condition>
      <condition>Glowe</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">double gloves</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of visible puncture</outcome_measure>
      <outcome_measure>WLT</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Lazarski University</lead_sponsor>
      <collaborator>Medical University of Bialystok</collaborator>
      <collaborator>Poznan University of Medical Sciences</collaborator>
    </sponsors>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>February 28, 2020</start_date>
    <primary_completion_date>April 24, 2020</primary_completion_date>
    <completion_date>April 24, 2020</completion_date>
    <study_first_posted>April 27, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Lazarski Univeristy, Warsaw, Poland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04363788</url>
  </study>
  <study rank="951">
    <nct_id>NCT04344509</nct_id>
    <title>Microbial Etiology of Ventilator-associated Pneumonia in SARS-CoV-2 Infected Patients</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Ventilator Associated Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Bacterial species isolated</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Prevalence of the microorganisms responsible for VAP among patients infected or not by the SARS-CoV-2</outcome_measure>
      <outcome_measure>Prevalence of multi-drug resistant bacteria responsible for VAP among patients infected or not by the SARS-CoV-2</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Poitiers University Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>100 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>10000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>April 2020</start_date>
    <primary_completion_date>September 2020</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>April 14, 2020</study_first_posted>
    <last_update_posted>April 14, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04344509</url>
  </study>
  <study rank="952">
    <nct_id>NCT04356833</nct_id>
    <title>Nebulised Rt-PA for ARDS Due to COVID-19</title>
    <acronym>PACA</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">nebulised recombinant tissue-Plasminogen Activator (rt-PA)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>treatment efficacy - Percentage change in PaO2/FiO2 ratio</outcome_measure>
      <outcome_measure>Safety as measured by bleeds</outcome_measure>
      <outcome_measure>Safety as measured by other (non-bleed related) adverse events</outcome_measure>
      <outcome_measure>Safety as measured by fibrinogen levels</outcome_measure>
      <outcome_measure>Absolute change in PaO2/FiO2 ratio</outcome_measure>
      <outcome_measure>Changes in respiratory compliance</outcome_measure>
      <outcome_measure>Clinical status as determined by a 7 point ordinal scale</outcome_measure>
      <outcome_measure>Sequential Organ Failure Assessment (SOFA) score</outcome_measure>
      <outcome_measure>Follow up period - oxygen free days</outcome_measure>
      <outcome_measure>Follow up period - ventilator free days</outcome_measure>
      <outcome_measure>Follow up period - intensive care stay</outcome_measure>
      <outcome_measure>New oxygen via ventilation use - incidence</outcome_measure>
      <outcome_measure>New oxygen via ventilation use - duration</outcome_measure>
      <outcome_measure>Incidence of new mechanical ventilation use</outcome_measure>
      <outcome_measure>Duration of new mechanical ventilation use</outcome_measure>
      <outcome_measure>In hospital mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University College, London</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>16 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>24</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Sequential Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 14, 2020</start_date>
    <primary_completion_date>January 14, 2021</primary_completion_date>
    <completion_date>January 14, 2021</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04356833</url>
  </study>
  <study rank="953">
    <nct_id>NCT04259892</nct_id>
    <title>Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection</title>
    <acronym>Cov-CONTACT</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">2019-nCoV PCR</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of Participants with presence of 2019-nCoV in at least one of nasopharyngeal swab</outcome_measure>
      <outcome_measure>For each participant, time (days) between the last contact with the laboratory-confirmed 2019-nCoV case and the first positive PCR</outcome_measure>
      <outcome_measure>For each participant, time (days) between the first positive PCR and the first negative PCR</outcome_measure>
      <outcome_measure>Number of Participants with presence of at least one of the following symptoms: fever &gt; 38°C, asthenia/fatigue/malaise, headache, thrills/sweating, myalgia/aches, cough, dyspnea, Acute Respiratory Distress Syndrome, diarrhe</outcome_measure>
      <outcome_measure>Number of Participants with positive serology in the 90 days following last contact</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Institut National de la Santé Et de la Recherche Médicale, France</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>February 4, 2020</start_date>
    <primary_completion_date>October 4, 2020</primary_completion_date>
    <completion_date>February 4, 2021</completion_date>
    <study_first_posted>February 7, 2020</study_first_posted>
    <last_update_posted>February 17, 2020</last_update_posted>
    <locations>
      <location>CIC 1425, Paris, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04259892</url>
  </study>
  <study rank="954">
    <nct_id>NCT04365322</nct_id>
    <title>Study of Specific Viral Immune Responses Induced by SARS-CoV-2</title>
    <acronym>COV-CREM</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS-CoV Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Additional biological samples</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Specific immune responses</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Centre Hospitalier Universitaire de Besancon</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>June 1, 2020</primary_completion_date>
    <completion_date>April 20, 2025</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>CHU Jean Minjoz, Besançon, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04365322</url>
  </study>
  <study rank="955">
    <nct_id>NCT04251871</nct_id>
    <title>Treatment and Prevention of Traditional Chinese Medicines (TCMs) on 2019-nCoV Infection</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pneumonia Caused by Human Coronavirus (Disorder)</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules</intervention>
      <intervention type="Drug">Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to complete remission of 2019-nCoV infection-associated symptoms</outcome_measure>
      <outcome_measure>The incidence of dyspnea with low oxygen saturation level and high respiratory rate</outcome_measure>
      <outcome_measure>Number of subjects who develop complications of 2019-nCoV infection</outcome_measure>
      <outcome_measure>Time to virus shedding</outcome_measure>
      <outcome_measure>Time to improvement of abnormalities in Chest radiology</outcome_measure>
      <outcome_measure>The evaluation of Traditional Chinese Medicine (TCM) symptoms before and after treatment</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Beijing 302 Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>14 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>January 22, 2020</start_date>
    <primary_completion_date>January 22, 2021</primary_completion_date>
    <completion_date>January 22, 2021</completion_date>
    <study_first_posted>February 5, 2020</study_first_posted>
    <last_update_posted>February 5, 2020</last_update_posted>
    <locations>
      <location>The Fifth Medical Center, General Hospital of PLA, Beijing, Beijing, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04251871</url>
  </study>
  <study rank="956">
    <nct_id>NCT04260308</nct_id>
    <title>A Survey of Psychological Status of Medical Workers and Residents in the Context of 2019 Novel Coronavirus Pneumonia</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Virus; Pneumonia</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>GHQ-12(general health questionnaire-12)</outcome_measure>
      <outcome_measure>IES-R(Impact of Event Scale-Revised)</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Huazhong University of Science and Technology</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>30000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>February 3, 2020</start_date>
    <primary_completion_date>April 15, 2020</primary_completion_date>
    <completion_date>April 20, 2020</completion_date>
    <study_first_posted>February 7, 2020</study_first_posted>
    <last_update_posted>February 7, 2020</last_update_posted>
    <locations>
      <location>Tongji Hospital，Tongji Medical College Affiliated，Huazhong University of Science ＆ Technology, Wuhan, Hubei, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04260308</url>
  </study>
  <study rank="957">
    <nct_id>NCT04275245</nct_id>
    <title>Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>2019-nCoVs Infection Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Meplazumab for Injection</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>2019 nCoV nucleic acid detection</outcome_measure>
      <outcome_measure>Recovery of body temperature</outcome_measure>
      <outcome_measure>Recovery of resting respiratory rate</outcome_measure>
      <outcome_measure>Recovery of SPO2</outcome_measure>
      <outcome_measure>Chest CT / chest film changes</outcome_measure>
      <outcome_measure>PaO2 / FiO2</outcome_measure>
      <outcome_measure>Time to reach the isolation release standard</outcome_measure>
      <outcome_measure>Changes of inflammatory immune status</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Tang-Du Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>February 3, 2020</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>February 19, 2020</study_first_posted>
    <last_update_posted>February 19, 2020</last_update_posted>
    <locations>
      <location>Tangdu Hospital, Xi'an, Shaanxi, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04275245</url>
  </study>
  <study rank="958">
    <nct_id>NCT04307459</nct_id>
    <title>Acute Respiratory Failure and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Real Life</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infections</condition>
      <condition>Respiratory Failure</condition>
      <condition>Ventilator Lung</condition>
    </conditions>
    <interventions>
      <intervention type="Other">standard operating procedures</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Real life data of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection</outcome_measure>
      <outcome_measure>in-hospital mortality</outcome_measure>
      <outcome_measure>30 days mortality</outcome_measure>
      <outcome_measure>6 months mortality</outcome_measure>
      <outcome_measure>Intubation rate</outcome_measure>
      <outcome_measure>Time to Intubation</outcome_measure>
      <outcome_measure>Time to ventilation</outcome_measure>
      <outcome_measure>Non invasive to Invasive time</outcome_measure>
      <outcome_measure>Recovery rate</outcome_measure>
      <outcome_measure>Recurrence rate</outcome_measure>
      <outcome_measure>Risk factor for COVID19</outcome_measure>
      <outcome_measure>Blood tests and outcome</outcome_measure>
      <outcome_measure>Antiviral therapy</outcome_measure>
      <outcome_measure>Coinfections</outcome_measure>
      <outcome_measure>Radiological findings</outcome_measure>
      <outcome_measure>Ultrasound findings</outcome_measure>
      <outcome_measure>Myocardial injury</outcome_measure>
      <outcome_measure>Medical management</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Milan</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 19, 2020</start_date>
    <primary_completion_date>April 19, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>March 13, 2020</study_first_posted>
    <last_update_posted>March 17, 2020</last_update_posted>
    <locations>
      <location>Luigi Sacco University Hospital, Milan, Lombardia, Italy</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04307459</url>
  </study>
  <study rank="959">
    <nct_id>NCT04322279</nct_id>
    <title>Factors Associated With a Positive SARS-CoV-2 Serology in Contact Subjects at High/Moderate Risk of Coronavirus SARS-CoV-2 Infection (CoV-CONTACT-SERO)</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Serology</intervention>
      <intervention type="Genetic">Sequencing</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of Participants with positive serology in the 90 days following last contact</outcome_measure>
      <outcome_measure>fever &gt; 38°C, asthenia/fatigue/malaise, headache, thrills/sweating, myalgia/aches, cough, dyspnea, Acute Respiratory Distress Syndrome, diarrhea</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Institut National de la Santé Et de la Recherche Médicale, France</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 9, 2020</start_date>
    <primary_completion_date>May 1, 2020</primary_completion_date>
    <completion_date>May 1, 2020</completion_date>
    <study_first_posted>March 26, 2020</study_first_posted>
    <last_update_posted>March 26, 2020</last_update_posted>
    <locations>
      <location>CIC 1425, Paris, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04322279</url>
  </study>
  <study rank="960">
    <nct_id>NCT04363047</nct_id>
    <title>Immune Cells in Inflammatory Arthritis With Coronaviruses, Including COVID-19</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>SARS Virus</condition>
    </conditions>
    <interventions>
      <intervention type="Other">40ml blood sample</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Prevalence and abundance of CD4+ T lymphocytes</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Manchester</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>125</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>May 1, 2020</start_date>
    <primary_completion_date>May 1, 2021</primary_completion_date>
    <completion_date>May 1, 2021</completion_date>
    <study_first_posted>April 27, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Universit of Manchester, Manchester, Greater Manchester, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04363047</url>
  </study>
  <study rank="961">
    <nct_id>NCT04339686</nct_id>
    <title>Multicentric Retrospective Observational Study of Thoracic Scanner Performance in COVID Screening.</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>The Gold Standard for Current SARS CoV2 Detection is RT-PCR</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Thoracic CT Scan</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Diagnostic performance of chest CT in screening for pulmonary lesions in clinical suspicions of COVID.</outcome_measure>
      <outcome_measure>Compare the diagnostic performance of chest CT and RT-PCR in COVID 19 at the initial consultation (screening).</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Poitiers University Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>100 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>56000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>September 2020</primary_completion_date>
    <completion_date>November 2020</completion_date>
    <study_first_posted>April 9, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Chu de Poitiers, Poitiers, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04339686</url>
  </study>
  <study rank="962">
    <nct_id>NCT04365608</nct_id>
    <title>Prehospital Intubation With Personal Protective Equipment</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Intubation Complication</condition>
      <condition>Intubation; Difficult or Failed</condition>
      <condition>Cardiac Arrest</condition>
      <condition>Influenza</condition>
      <condition>Safety Issues</condition>
    </conditions>
    <interventions>
      <intervention type="Procedure">Direct laryngoscopy</intervention>
      <intervention type="Procedure">Vie Scope laryngoscopy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Intubation success rate during at the first laryngoscopy</outcome_measure>
      <outcome_measure>Intubation difficulty Scale score</outcome_measure>
      <outcome_measure>Complications related to tracheal intubation</outcome_measure>
      <outcome_measure>Time to completion of tracheal intubation (TI) procedure</outcome_measure>
      <outcome_measure>Duration of the interruption of chest compression during ETI procedure</outcome_measure>
      <outcome_measure>Laryngeal View during intubation</outcome_measure>
      <outcome_measure>POGO score</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Lazarski University</lead_sponsor>
      <collaborator>Poznan University of Medical Sciences</collaborator>
      <collaborator>Wroclaw Medical University</collaborator>
      <collaborator>Medical University of Bialystok</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 20, 2020</start_date>
    <primary_completion_date>May 20, 2020</primary_completion_date>
    <completion_date>May 20, 2020</completion_date>
    <study_first_posted>April 28, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Emergency Medical Service, Poznan, Poland</location>
      <location>Emergency Medical Service, Warsaw, Poland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04365608</url>
  </study>
  <study rank="963">
    <nct_id>NCT04355052</nct_id>
    <title>Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to &quot;no Treatment&quot; in SARS CoV 2 Virus</title>
    <acronym>COSTA</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID - 19</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">hydroxychloroquine in combination with camostat mesylate</intervention>
      <intervention type="Drug">Hydroxychloroquine in combination of Azithromycin</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>clinical state as reflected by NEWS scoring</outcome_measure>
      <outcome_measure>positive PCR</outcome_measure>
      <outcome_measure>prevention of ICU</outcome_measure>
      <outcome_measure>prevention of assisted ventilation</outcome_measure>
      <outcome_measure>prevention of ECMO</outcome_measure>
      <outcome_measure>death</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Sheba Medical Center</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>120 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>250</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 11, 2020</start_date>
    <primary_completion_date>October 11, 2020</primary_completion_date>
    <completion_date>December 11, 2020</completion_date>
    <study_first_posted>April 21, 2020</study_first_posted>
    <last_update_posted>April 21, 2020</last_update_posted>
    <locations>
      <location>Sheba Medical Center, Ramat Gan, Israel</location>
      <location>Sheba Medical Center, Tel HaShomer, Israel</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04355052</url>
  </study>
  <study rank="964">
    <nct_id>NCT04357886</nct_id>
    <title>Comparison of New Coronavirus (COVID-19) Awareness in Individuals of Different Age Groups: Analysis of Turkey</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Healthy</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>COVID-19 Awareness Survey</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Istanbul University-Cerrahpasa</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>15 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>May 2020</start_date>
    <primary_completion_date>May 2020</primary_completion_date>
    <completion_date>June 2020</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>Istanbul University-Cerrahpasa, Istanbul, Turkey</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04357886</url>
  </study>
  <study rank="965">
    <nct_id>NCT04341727</nct_id>
    <title>Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection</title>
    <acronym>WU352</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine Sulfate</intervention>
      <intervention type="Drug">Azithromycin</intervention>
      <intervention type="Drug">Chloroquine Sulfate</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Hours to recovery</outcome_measure>
      <outcome_measure>Time fever resolution</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Washington University School of Medicine</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 4, 2020</start_date>
    <primary_completion_date>April 1, 2021</primary_completion_date>
    <completion_date>August 1, 2021</completion_date>
    <study_first_posted>April 10, 2020</study_first_posted>
    <last_update_posted>April 10, 2020</last_update_posted>
    <locations>
      <location>Washington University School of Medicine Infectious Disease Clinical Research Unit, Saint Louis, Missouri, United States</location>
      <location>Washington University School of Medicine, Saint Louis, Missouri, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04341727</url>
  </study>
  <study rank="966">
    <nct_id>NCT03648372</nct_id>
    <title>A Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19)</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Neoplasms</condition>
      <condition>Lymphoma</condition>
      <condition>Hematologic Neoplasms</condition>
      <condition>Coronavirus Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">TAK-981</intervention>
      <intervention type="Drug">Standard of care</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Dose Escalation and Cancer Treatment Expansions: Number of Participants Reporting one or More Treatment Emergent Adverse Events (TEAEs)</outcome_measure>
      <outcome_measure>Dose Escalation and Cancer Treatment Expansions: Number of Participants With Dose Limiting Toxicities (DLTs)</outcome_measure>
      <outcome_measure>Dose Escalation and Cancer Treatment Expansions: Number of Participants With one or More Serious Adverse Events (SAEs)</outcome_measure>
      <outcome_measure>Dose Escalation and Cancer Treatment Expansions: Number of Participants With one or More TEAEs Leading to Dose Modifications and Treatment Discontinuations</outcome_measure>
      <outcome_measure>Dose Escalation and Cancer Treatment Expansions: Number of Participants With Greater Than or Equal to (&gt;=) Grade 3 TEAEs</outcome_measure>
      <outcome_measure>Dose Escalation and Cancer Treatment Expansions: Number of Participants With Clinically Significant Laboratory Values</outcome_measure>
      <outcome_measure>Dose Escalation and Cancer Treatment Expansions: Number of Participants With Clinically Significant Vital Sign Measurements</outcome_measure>
      <outcome_measure>Dose Escalation and Cancer Treatment Expansions: Number of Participants who Experience Cytokine Release Syndrome CRS)</outcome_measure>
      <outcome_measure>COVID-19 Expansion: Number of Participants With &gt;=2 log Reduction From Baseline in Viral Load or Below Level of Detection (Negative) in Nasopharyngeal or Oropharyngeal Samples</outcome_measure>
      <outcome_measure>Dose Escalation and Cancer Treatment Expansions, Cmax: Maximum Observed Plasma Concentration for TAK-981</outcome_measure>
      <outcome_measure>Dose Escalation and Cancer Treatment Expansions, Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-981</outcome_measure>
      <outcome_measure>Dose Escalation and Cancer Treatment Expansions, AUCt: Area Under the Plasma Concentration-time Curve from Time 0 to Time t Over the Dosing Interval for TAK-981</outcome_measure>
      <outcome_measure>Dose Escalation and Cancer Treatment Expansions, AUC∞: Area Under the Plasma Concentration-time Curve from Time 0 to Infinity for TAK-981</outcome_measure>
      <outcome_measure>Dose Escalation and Cancer Treatment Expansions, Terminal Disposition Phase Half-life (t1/2z) for TAK-981</outcome_measure>
      <outcome_measure>Dose Escalation and Cancer Treatment Expansions, Total Clearance After Intravenous Administration (CL) for TAK-981</outcome_measure>
      <outcome_measure>Dose Escalation and Cancer Treatment Expansions, Volume of Distribution at Steady State After Intravenous Administration (Vss) for TAK-981</outcome_measure>
      <outcome_measure>Dose Escalation and Cancer Treatment Expansions: Overall Response Rate (ORR)</outcome_measure>
      <outcome_measure>Dose Escalation and Cancer Treatment Expansions: Duration of Response (DOR)</outcome_measure>
      <outcome_measure>Dose Escalation and Cancer Treatment Expansions: Disease Control Rate (DCR)</outcome_measure>
      <outcome_measure>Dose Escalation and Cancer Treatment Expansions: Progression-free Survival (PFS)</outcome_measure>
      <outcome_measure>Dose Escalation and Cancer Treatment Expansions: Time to Response (TTR)</outcome_measure>
      <outcome_measure>Dose Escalation and Cancer Treatment Expansions: Percentage of Participants at Each Dose Level Demonstrating Adduct Formation in Post-dose Skin or Tumor Biopsies</outcome_measure>
      <outcome_measure>Dose Escalation and Cancer Treatment Expansions: Percent Change in Small Ubiquitin-like Modifier (SUMO) 2/3 Signal With Pre and Post-dose Skin or Tumor Biopsies at Each Dose Level</outcome_measure>
      <outcome_measure>COVID-19 Expansion: Number of Participants Reporting one or More TEAEs</outcome_measure>
      <outcome_measure>COVID-19 Expansion: Number of Participants Based on Severity of TEAEs</outcome_measure>
      <outcome_measure>COVID-19 Expansion: Number of Participants Based on Duration of TEAEs</outcome_measure>
      <outcome_measure>COVID-19 Expansion: Number of Participants who Experience CRS</outcome_measure>
      <outcome_measure>COVID-19 Expansion: Change from Baseline in National Early Warning Score (NEWS)</outcome_measure>
      <outcome_measure>COVID-19 Expansion: Percentage of Participants Reporting Each Hospitalization Severity Rating</outcome_measure>
      <outcome_measure>COVID-19 Expansion: Change From Baseline in SARS-CoV-2 Viral Load in Nasopharyngeal or Oropharyngeal Samples</outcome_measure>
      <outcome_measure>COVID-19 Expansion: Percentage of Participants Requiring Oxygen Supplementation; Assisted or Positive Pressure Non-invasive Ventilation; and Invasive Ventilation, on Days 3, 5, 8, 11, 15, and 30</outcome_measure>
      <outcome_measure>COVID-19 Expansion: Percentage of Participants That met Intensive Care Unit (ICU) Criteria</outcome_measure>
      <outcome_measure>COVID-19 Expansion: Duration of Hospitalization</outcome_measure>
      <outcome_measure>COVID-19 Expansion: Time to Viral Ribonucleic Acid (RNA) Negativity in Nasopharyngeal or Oropharyngeal Samples</outcome_measure>
      <outcome_measure>COVID-19 Expansion: Time to Discharge or to a NEWS of Less Than or Equal to (&lt;=) 3 and Maintained for 24 Hours</outcome_measure>
      <outcome_measure>COVID-19 Expansion: Number of Deaths in Hospital due to any Cause in First 30 Days and in 90 Days</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Millennium Pharmaceuticals, Inc.</lead_sponsor>
      <collaborator>Takeda</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>October 1, 2018</start_date>
    <primary_completion_date>February 16, 2021</primary_completion_date>
    <completion_date>October 6, 2021</completion_date>
    <study_first_posted>August 27, 2018</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>University of California San Diego Moores Cancer Center, La Jolla, California, United States</location>
      <location>Massachusetts General Hospital, Boston, Massachusetts, United States</location>
      <location>Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States</location>
      <location>HealthPartners Cancer Care Center - Regions Hospital, Saint Paul, Minnesota, United States</location>
      <location>University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States</location>
      <location>Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States</location>
      <location>The University of Texas MD Anderson Cancer Center, Houston, Texas, United States</location>
      <location>Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03648372</url>
  </study>
  <study rank="967">
    <nct_id>NCT04335851</nct_id>
    <title>Video-Based Exercises and Well-Being During Social Isolation</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Social Isolation</condition>
      <condition>Physical Inactivity</condition>
      <condition>Well-Being</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Video based aerobic exercise</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>World Health Organization Quality of Life Questionnaire Bref</outcome_measure>
      <outcome_measure>Rapid Assessment of Physical Activity</outcome_measure>
      <outcome_measure>Global Rating of Change Scale</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Biruni University</lead_sponsor>
      <collaborator>Istanbul University-Cerrahpasa</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>35 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Non-Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 6, 2020</start_date>
    <primary_completion_date>May 13, 2020</primary_completion_date>
    <completion_date>June 30, 2020</completion_date>
    <study_first_posted>April 6, 2020</study_first_posted>
    <last_update_posted>April 6, 2020</last_update_posted>
    <locations>
      <location>Biruni University, Istanbul, Turkey</location>
      <location>Istanbul University Cerrahpasa, Istanbul, Turkey</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04335851</url>
  </study>
  <study rank="968">
    <nct_id>NCT04346927</nct_id>
    <title>Telerehabilitation for Patients Diagnosed With Coronavirus</title>
    <acronym>COVID-19</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Telerehabilitation</condition>
      <condition>Coronavirus</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Telerehabilitation</intervention>
      <intervention type="Other">exercise brochure</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Visual Analogue Scale</outcome_measure>
      <outcome_measure>Modified Borg Scale</outcome_measure>
      <outcome_measure>Leicester Cough Questionnaire</outcome_measure>
      <outcome_measure>Timed Up and Go</outcome_measure>
      <outcome_measure>30 Second Chair Stand Test</outcome_measure>
      <outcome_measure>The Beck Depression Inventory</outcome_measure>
      <outcome_measure>The Beck Anxiety Inventory</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Yasemin Çırak</lead_sponsor>
      <collaborator>Istinye University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>70 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 10, 2020</start_date>
    <primary_completion_date>June 10, 2020</primary_completion_date>
    <completion_date>July 31, 2020</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04346927</url>
  </study>
  <study rank="969">
    <nct_id>NCT04319211</nct_id>
    <title>Effects of Social Isolation From Coronavirus; on Physical Activity, Quality of Life and Stress</title>
    <acronym>COVID-19</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Healthy People</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Determination of physical activity, quality of life, stress levels of isolated people at home with the danger of coronavirus.</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>International Physical Activity Questionnaire (IPAQ)</outcome_measure>
      <outcome_measure>Health-Related Quality of Life SF-12 Scale</outcome_measure>
      <outcome_measure>Beck Depression Scale</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Istanbul University-Cerrahpasa</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>55 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>200</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <start_date>March 25, 2020</start_date>
    <primary_completion_date>May 15, 2020</primary_completion_date>
    <completion_date>July 20, 2020</completion_date>
    <study_first_posted>March 24, 2020</study_first_posted>
    <last_update_posted>March 24, 2020</last_update_posted>
    <locations>
      <location>Istanbul University Cerrahpasa, Istanbul, Turkey</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04319211</url>
  </study>
  <study rank="970">
    <nct_id>NCT04331808</nct_id>
    <title>CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)</title>
    <acronym>CORIMUNO-TOC</acronym>
    <status open="N">Active, not recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Corona Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Tocilizumab</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Survival without needs of ventilator utilization at day 14. Group 1</outcome_measure>
      <outcome_measure>WHO progression scale &lt;=5 at day 4. Group 1.</outcome_measure>
      <outcome_measure>Cumulative incidence of successful tracheal extubation (defined as duration extubation &gt; 48h) at day 14. Group 2.</outcome_measure>
      <outcome_measure>WHO progression scale at day 4. Group 2.</outcome_measure>
      <outcome_measure>WHO progression scale</outcome_measure>
      <outcome_measure>Survival</outcome_measure>
      <outcome_measure>28-day ventilator free-days</outcome_measure>
      <outcome_measure>respiratory acidosis at day 4</outcome_measure>
      <outcome_measure>PaO2/FiO2 ratio</outcome_measure>
      <outcome_measure>time to oxygen supply independency</outcome_measure>
      <outcome_measure>duration of hospitalization</outcome_measure>
      <outcome_measure>time to negative viral excretion</outcome_measure>
      <outcome_measure>time to ICU discharge</outcome_measure>
      <outcome_measure>time to hospital discharge</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Assistance Publique - Hôpitaux de Paris</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>228</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 30, 2020</start_date>
    <primary_completion_date>March 31, 2021</primary_completion_date>
    <completion_date>December 31, 2021</completion_date>
    <study_first_posted>April 2, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>APHP- Hopital Tenon, Paris, France</location>
      <location>APHP - Beaujon, Paris, France</location>
      <location>APHP - Bichat, Paris, France</location>
      <location>APHP - Hopital Necker, Paris, France</location>
      <location>APHP - Pitié Salpêtrière, Paris, France</location>
      <location>APHP - Saint Louis, Paris, France</location>
      <location>CHU Strasbourg, Strasbourg, France</location>
      <location>Institut Gustave Roussy, Villejuif, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04331808</url>
  </study>
  <study rank="971">
    <nct_id>NCT04328467</nct_id>
    <title>Pre-exposure Prophylaxis for SARS-Coronavirus-2</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Corona Virus Infection</condition>
      <condition>ARDS</condition>
      <condition>Acute Respiratory Distress Syndrome</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>COVID-19-free survival</outcome_measure>
      <outcome_measure>Incidence of confirmed SARS-CoV-2 detection</outcome_measure>
      <outcome_measure>Incidence of possible COVID-19 symptoms</outcome_measure>
      <outcome_measure>Incidence of all-cause study medicine discontinuation</outcome_measure>
      <outcome_measure>Ordinal Scale of COVID-19 Disease maximum severity if COVID-19 diagnosed at study end</outcome_measure>
      <outcome_measure>Incidence of Hospitalization for COVID-19 or death</outcome_measure>
      <outcome_measure>Incidence of study medication-related side effects</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Minnesota</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>3500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 6, 2020</start_date>
    <primary_completion_date>August 2020</primary_completion_date>
    <completion_date>August 2020</completion_date>
    <study_first_posted>March 31, 2020</study_first_posted>
    <last_update_posted>April 10, 2020</last_update_posted>
    <locations>
      <location>Nationwide Enrollment via Internet, please email: covid19@umn.edu, Minneapolis, Minnesota, United States</location>
      <location>University of Minnesota, Minneapolis, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04328467</url>
  </study>
  <study rank="972">
    <nct_id>NCT04353154</nct_id>
    <title>The RAPID COVID TRIAGE Algorithm</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Spartan Cube Point-of Care Covid-19 test</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Sensitivity</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ottawa Heart Institute Research Corporation</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>20</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>August 31, 2020</primary_completion_date>
    <completion_date>February 28, 2021</completion_date>
    <study_first_posted>April 20, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04353154</url>
  </study>
  <study rank="973">
    <nct_id>NCT04353245</nct_id>
    <title>Study of Biomarkers in the Long-term Impact of Coronavirus Infection in the Cardiorespiratory System</title>
    <acronym>PostCOVID19</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID19</condition>
      <condition>Corona Virus Infection</condition>
      <condition>Myocardial Injury</condition>
      <condition>Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Other">BIOMARKERS IN THE LONG TERM IMPACT OF CORONAVIRUS INFECTION IN THE CARDIORRESPIRATORY SYSTEM</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Fibrosis</outcome_measure>
      <outcome_measure>Ergospirometers</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Sao Paulo General Hospital</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>130</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Control</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>June 1, 2020</start_date>
    <primary_completion_date>September 30, 2021</primary_completion_date>
    <completion_date>September 30, 2021</completion_date>
    <study_first_posted>April 20, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations>
      <location>Instituto do Coração - Hospital das Clínicas - Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04353245</url>
  </study>
  <study rank="974">
    <nct_id>NCT04280913</nct_id>
    <title>Clinical Outcomes of Patients With COVID19</title>
    <acronym/>
    <status open="N">Withdrawn</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Disease 2019</condition>
    </conditions>
    <interventions>
      <intervention type="Other">retrospective analysis</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to negative conversion of severe acute respiratory syndrome coronavirus 2</outcome_measure>
      <outcome_measure>Length of stay in hospital</outcome_measure>
      <outcome_measure>Survival</outcome_measure>
      <outcome_measure>Intubation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Guangzhou Institute of Respiratory Disease</lead_sponsor>
      <collaborator>Huizhou Municipal Central Hospital</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>0</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Retrospective</study_design>
    </study_designs>
    <start_date>February 22, 2020</start_date>
    <primary_completion_date>March 31, 2020</primary_completion_date>
    <completion_date>March 31, 2020</completion_date>
    <study_first_posted>February 21, 2020</study_first_posted>
    <last_update_posted>March 19, 2020</last_update_posted>
    <locations>
      <location>HuiZhou Municipal Central Hospital, Huizhou, Guangdong, China</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04280913</url>
  </study>
  <study rank="975">
    <nct_id>NCT04333251</nct_id>
    <title>Study Testing Convalescent Plasma vs Best Supportive Care</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pneumonia, Interstitial</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">high-titer anti-Sars-CoV-2 plasma</intervention>
      <intervention type="Other">oxygen therapy</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>reduction in oxygen and ventilation support</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Baylor Research Institute</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>115</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 1, 2020</start_date>
    <primary_completion_date>December 31, 2022</primary_completion_date>
    <completion_date>December 31, 2022</completion_date>
    <study_first_posted>April 3, 2020</study_first_posted>
    <last_update_posted>April 6, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04333251</url>
  </study>
  <study rank="976">
    <nct_id>NCT04359407</nct_id>
    <title>Prone Positioning and Regional Ventilation in Mechanically Ventilated COVID Patients</title>
    <acronym>COVID_EIT</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Severe Acute Respiratory Syndrome Coronavirus 2</condition>
      <condition>Electric Impedance</condition>
      <condition>Prone Positioning</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Prone positioning</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Tidal electrical Impedance</outcome_measure>
      <outcome_measure>Intrapulmonary shunt</outcome_measure>
      <outcome_measure>Volumetric capnography</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Walid HABRE</lead_sponsor>
      <collaborator>University Hospital, Geneva</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>16</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 27, 2020</start_date>
    <primary_completion_date>December 31, 2020</primary_completion_date>
    <completion_date>January 31, 2021</completion_date>
    <study_first_posted>April 24, 2020</study_first_posted>
    <last_update_posted>April 24, 2020</last_update_posted>
    <locations>
      <location>University Hospitals of Geneva, Geneva, Switzerland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04359407</url>
  </study>
  <study rank="977">
    <nct_id>NCT04353141</nct_id>
    <title>International Lung UltraSound Analysis (ILUSA) Study</title>
    <acronym>ILUSA</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID</condition>
      <condition>Pregnancy Complications, Infectious</condition>
      <condition>Pregnancy Related</condition>
      <condition>Pregnancy, High Risk</condition>
      <condition>Pregnancy Disease</condition>
      <condition>Pneumonia</condition>
      <condition>Pneumonia, Viral</condition>
      <condition>Diagnoses Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">standardized Lung Ultrasound (LUS) examination</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Diagnostic performance of LUS to predict poor outcome</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>KU Leuven</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1850</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>May 31, 2020</primary_completion_date>
    <completion_date>December 31, 2020</completion_date>
    <study_first_posted>April 20, 2020</study_first_posted>
    <last_update_posted>April 20, 2020</last_update_posted>
    <locations>
      <location>University Hospitals Leuven, Leuven, Belgium</location>
      <location>University of Brescia, Brescia, Italy</location>
      <location>University of Foggia, Foggia, Italy</location>
      <location>University of Milan, Milan, Italy</location>
      <location>University of Parma, Parma, Italy</location>
      <location>Fondazione Policlinico Universitario A. Gemelli, Roma, Italy</location>
      <location>Queen Charlotte's &amp; Chelsea Hospital, London, United Kingdom</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04353141</url>
  </study>
  <study rank="978">
    <nct_id>NCT03852537</nct_id>
    <title>Steroid Dosing by bioMARker Guided Titration in Critically Ill Patients With Pneumonia</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Pneumonia</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Methylprednisolone</intervention>
      <intervention type="Other">Usual Care</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Feasibility of the timely initiation of corticosteroids and implementation of biomarker-titrated corticosteroid dosing: percentage of eligible patients adhered to the timely initiation</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>Progression of disease</outcome_measure>
      <outcome_measure>Evolution of respiratory failure</outcome_measure>
      <outcome_measure>Evolution of kidney failure</outcome_measure>
      <outcome_measure>Evolution of shock</outcome_measure>
      <outcome_measure>Length of stay</outcome_measure>
      <outcome_measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]: Hyperglycemia</outcome_measure>
      <outcome_measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]: Delirium</outcome_measure>
      <outcome_measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]: Secondary Infection</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Mayo Clinic</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>90</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Double (Participant, Investigator)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>December 2, 2019</start_date>
    <primary_completion_date>July 2021</primary_completion_date>
    <completion_date>July 2022</completion_date>
    <study_first_posted>February 25, 2019</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Mayo Clinic in Rochester, Rochester, Minnesota, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03852537</url>
  </study>
  <study rank="979">
    <nct_id>NCT04333875</nct_id>
    <title>Morbidity and Mortality Due to Deferral of Aortic Valve Replacement in Patients With Severe Aortic Stenosis</title>
    <acronym>AS DEFER</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Aortic Valve Stenosis</condition>
    </conditions>
    <interventions>
      <intervention type="Device">TAVR or SAVR</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Composite of all-cause mortality, disabling and non-disabling stroke, and hospitalization for heart failure</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital Inselspital, Berne</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>100</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 20, 2020</start_date>
    <primary_completion_date>December 2020</primary_completion_date>
    <completion_date>December 2020</completion_date>
    <study_first_posted>April 3, 2020</study_first_posted>
    <last_update_posted>April 7, 2020</last_update_posted>
    <locations>
      <location>Department of Cardiology, Bern University Hospital, Bern, Switzerland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04333875</url>
  </study>
  <study rank="980">
    <nct_id>NCT04316377</nct_id>
    <title>Norwegian Coronavirus Disease 2019 Study</title>
    <acronym>NO COVID-19</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Corona Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine Sulfate</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Rate of decline in SARS-CoV-2 viral load</outcome_measure>
      <outcome_measure>Change in National Early Warning Score score</outcome_measure>
      <outcome_measure>Admission to intensive care unit</outcome_measure>
      <outcome_measure>In-hospital mortality</outcome_measure>
      <outcome_measure>Duration of hospital admission</outcome_measure>
      <outcome_measure>Mortality at 30 and 90 days</outcome_measure>
      <outcome_measure>Clinical status</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University Hospital, Akershus</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 4</phase>
    </phases>
    <enrollment>202</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 25, 2020</start_date>
    <primary_completion_date>April 1, 2021</primary_completion_date>
    <completion_date>March 3, 2025</completion_date>
    <study_first_posted>March 20, 2020</study_first_posted>
    <last_update_posted>April 3, 2020</last_update_posted>
    <locations>
      <location>Akershus University Hospital, Lørenskog, Norway</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04316377</url>
  </study>
  <study rank="981">
    <nct_id>NCT04276688</nct_id>
    <title>Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Novel Coronavirus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Lopinavir/ritonavir</intervention>
      <intervention type="Drug">Ribavirin</intervention>
      <intervention type="Drug">Interferon Beta-1B</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Time to negative NPS</outcome_measure>
      <outcome_measure>Time to negative saliva</outcome_measure>
      <outcome_measure>Time to clinical improvement</outcome_measure>
      <outcome_measure>Hospitalisation</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>Immune reaction</outcome_measure>
      <outcome_measure>Adverse events</outcome_measure>
      <outcome_measure>Time to negative all clinical specimens</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>The University of Hong Kong</lead_sponsor>
      <collaborator>Hospital Authority, Hong Kong</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>127</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>February 10, 2020</start_date>
    <primary_completion_date>March 30, 2020</primary_completion_date>
    <completion_date>March 31, 2020</completion_date>
    <study_first_posted>February 19, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04276688</url>
  </study>
  <study rank="982">
    <nct_id>NCT04356144</nct_id>
    <title>Thrombomodulin-modified Thrombin Generation Assay (TGA-TM) in Patients With Critical Infections</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Disseminated Intravascular Coagulation</condition>
      <condition>Critical Illness</condition>
      <condition>Sars-CoV2</condition>
      <condition>Viral Infection</condition>
      <condition>Coagulation Disorder, Blood</condition>
      <condition>Covid19</condition>
    </conditions>
    <interventions>
      <intervention type="Diagnostic Test">Thrombin Generation Assay (TGA)</intervention>
      <intervention type="Diagnostic Test">Thrombomodulin Modified Thrombin Generation Assay (TGA-TM)</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>ETP (AUC) without rhThrombomodulin (rhTM)</outcome_measure>
      <outcome_measure>ETP (AUC) with rhThrombomodulin (rhTM)</outcome_measure>
      <outcome_measure>ETP-ratio</outcome_measure>
      <outcome_measure>ETP-Normalisation</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Medical University of Vienna</lead_sponsor>
      <collaborator>Medical Scientific Fund of the Mayor of Vienna</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>60</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>April 17, 2020</start_date>
    <primary_completion_date>October 1, 2020</primary_completion_date>
    <completion_date>December 1, 2020</completion_date>
    <study_first_posted>April 22, 2020</study_first_posted>
    <last_update_posted>April 22, 2020</last_update_posted>
    <locations>
      <location>Medical University Vienna, Vienna, Austria</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04356144</url>
  </study>
  <study rank="983">
    <nct_id>NCT04346940</nct_id>
    <title>The Effectiveness of Telerehabilitation-Based Exercises in Elderly People</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Telerehabilitation</condition>
      <condition>Elderly People</condition>
      <condition>Social Isolation</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Telerehabilitation</intervention>
      <intervention type="Other">Exercise brochure</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Standardized Mini Mental Test</outcome_measure>
      <outcome_measure>Mini Nutritional Assesment</outcome_measure>
      <outcome_measure>Short Physical Performance Test</outcome_measure>
      <outcome_measure>Single Leg Stance Test</outcome_measure>
      <outcome_measure>Charlson Comorbidity Index</outcome_measure>
      <outcome_measure>Clinic Fragility Scale</outcome_measure>
      <outcome_measure>Pittsburgh Sleep Quality Index</outcome_measure>
      <outcome_measure>Social Isolation Survey</outcome_measure>
      <outcome_measure>Quality of life scale in the elderly</outcome_measure>
      <outcome_measure>The Physical Activity Scale for the Elderly</outcome_measure>
      <outcome_measure>Timed Up and Go Test</outcome_measure>
      <outcome_measure>30 Second Chair Stand Test</outcome_measure>
      <outcome_measure>The Beck Depression Inventory</outcome_measure>
      <outcome_measure>The Beck Anxiety Inventory</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Istinye University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>60 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>April 10, 2020</start_date>
    <primary_completion_date>June 10, 2020</primary_completion_date>
    <completion_date>July 31, 2020</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04346940</url>
  </study>
  <study rank="984">
    <nct_id>NCT04319172</nct_id>
    <title>Multicentric Study of Coronavirus Disease 2019 (COVID-2019) in Solid Organ Transplant Recipients</title>
    <acronym>COVIDSOT</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Transplant Recipient</condition>
      <condition>Infections, Coronavirus</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Incidence of coronavirus infection in Solid Organ Transplant Recipients</outcome_measure>
      <outcome_measure>Clinical manifestations of coronavirus infection in Solid Organ Transplant Recipients</outcome_measure>
      <outcome_measure>Presence of other risk factors</outcome_measure>
      <outcome_measure>Establish the frequency and type of complications related to the net state of the patient immunosuppression</outcome_measure>
      <outcome_measure>Frequency of co-infections</outcome_measure>
      <outcome_measure>Mortality</outcome_measure>
      <outcome_measure>Laboratory characteristics</outcome_measure>
      <outcome_measure>Determination of coronavirus viral load</outcome_measure>
      <outcome_measure>Microbiological testing</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</lead_sponsor>
      <collaborator>Spanish Network for Research in Infectious Diseases</collaborator>
      <collaborator>GESITRA-IC</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>16 Years</min_age>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 2020</start_date>
    <primary_completion_date>March 2022</primary_completion_date>
    <completion_date>April 2022</completion_date>
    <study_first_posted>March 24, 2020</study_first_posted>
    <last_update_posted>March 24, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04319172</url>
  </study>
  <study rank="985">
    <nct_id>NCT04363177</nct_id>
    <title>Global Mental Health of Urban Mothers</title>
    <acronym>MUM</acronym>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Perinatal Depression</condition>
      <condition>COVID19</condition>
      <condition>Anxiety</condition>
      <condition>PTSD</condition>
      <condition>Pregnancy Related</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Web-based psychosocial peer-to-peer support</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Edinburgh Postnatal Depression Scale (EPDS)</outcome_measure>
      <outcome_measure>Mental health status and COVID-19</outcome_measure>
      <outcome_measure>Socio-economic status</outcome_measure>
      <outcome_measure>Elective CS</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Karolinska Institutet</lead_sponsor>
      <collaborator>Swiss National Science Foundation</collaborator>
    </sponsors>
    <gender>Female</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>300</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>June 2020</start_date>
    <primary_completion_date>June 2021</primary_completion_date>
    <completion_date>June 2023</completion_date>
    <study_first_posted>April 27, 2020</study_first_posted>
    <last_update_posted>April 27, 2020</last_update_posted>
    <locations>
      <location>Shanghai Women's and Children's Health Center, Shanghai, Shanghai, China</location>
      <location>Chinese University Hong Kong, Hong Kong, Hong Kong</location>
      <location>Mamma till Mamma, Stockholm, Sweden</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04363177</url>
  </study>
  <study rank="986">
    <nct_id>NCT03680274</nct_id>
    <title>Lessening Organ Dysfunction With VITamin C</title>
    <acronym>LOVIT</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Sepsis</condition>
      <condition>Vitamin C</condition>
      <condition>Intensive Care Unit</condition>
      <condition>COVID-19</condition>
      <condition>Pandemic</condition>
      <condition>Coronavirus</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Vitamin C</intervention>
      <intervention type="Other">Control</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Number of deceased participants or with persistent organ dysfunction</outcome_measure>
      <outcome_measure>Number of participants with persistent organ dysfunction-free days in intensive care unit</outcome_measure>
      <outcome_measure>Number of participants deceased at 6 months</outcome_measure>
      <outcome_measure>Score of health related quality of life in 6-month survivors</outcome_measure>
      <outcome_measure>Global tissue dysoxia</outcome_measure>
      <outcome_measure>Organ function (including renal function)</outcome_measure>
      <outcome_measure>Rate of inflammation</outcome_measure>
      <outcome_measure>Rate of infection</outcome_measure>
      <outcome_measure>Rate of endothelial injury</outcome_measure>
      <outcome_measure>Occurrence of stage 3 acute kidney injury</outcome_measure>
      <outcome_measure>Acute hemolysis</outcome_measure>
      <outcome_measure>Hypoglycemia</outcome_measure>
      <outcome_measure>Vitamin C volume of distribution</outcome_measure>
      <outcome_measure>Vitamin C clearance</outcome_measure>
      <outcome_measure>Vitamin C plasma concentration</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Université de Sherbrooke</lead_sponsor>
      <collaborator>Lotte &amp; John Hecht Memorial Foundation</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>800</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>November 8, 2018</start_date>
    <primary_completion_date>December 31, 2021</primary_completion_date>
    <completion_date>December 31, 2022</completion_date>
    <study_first_posted>September 21, 2018</study_first_posted>
    <last_update_posted>April 10, 2020</last_update_posted>
    <locations>
      <location>Research Center of the CHUS, Sherbrooke, Quebec, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT03680274</url>
  </study>
  <study rank="987">
    <nct_id>NCT04326309</nct_id>
    <title>Audio Data Collection for Identification and Classification of Coughing</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>COVID-19</condition>
      <condition>Coronavirus Infections</condition>
      <condition>Hay Fever</condition>
      <condition>Asthma</condition>
      <condition>Chronic Obstructive Pulmonary Disease</condition>
      <condition>Influenza</condition>
      <condition>Common Cold</condition>
      <condition>Respiratory Tract Infections</condition>
      <condition>Healthy</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Dataset size</outcome_measure>
      <outcome_measure>Cough sound identification</outcome_measure>
      <outcome_measure>Improvement of the existing model</outcome_measure>
      <outcome_measure>Evaluate the usability of the application</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>HealthMode Inc.</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>1000</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 25, 2020</start_date>
    <primary_completion_date>September 25, 2022</primary_completion_date>
    <completion_date>September 25, 2022</completion_date>
    <study_first_posted>March 30, 2020</study_first_posted>
    <last_update_posted>March 30, 2020</last_update_posted>
    <locations>
      <location>Virtual Facility, Bronx, New York, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04326309</url>
  </study>
  <study rank="988">
    <nct_id>NCT04346966</nct_id>
    <title>The Effectiveness of Video-Based Exercises in Young Adults</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Social Isolation</condition>
      <condition>Exercise</condition>
      <condition>Healthy</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Study Group</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>International Physical Activity Questionnaire (Short Form)</outcome_measure>
      <outcome_measure>Short Form-36 (SF-36)</outcome_measure>
      <outcome_measure>The Pittsburgh Sleep Quality Index</outcome_measure>
      <outcome_measure>Distress Tolerance Scale</outcome_measure>
      <outcome_measure>Beck Anxiety Inventory</outcome_measure>
      <outcome_measure>Nottingham Health Profile</outcome_measure>
      <outcome_measure>Sit And Reach Test</outcome_measure>
      <outcome_measure>Shoulder Flexibility Test</outcome_measure>
      <outcome_measure>Curl-Up Test</outcome_measure>
      <outcome_measure>Repetitive Squat Test</outcome_measure>
      <outcome_measure>Side Plank Test</outcome_measure>
      <outcome_measure>Timed Up and Go Test</outcome_measure>
      <outcome_measure>Single Leg Stance Test</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Istinye University</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>40 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>128</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Prevention</study_design>
    </study_designs>
    <start_date>April 20, 2020</start_date>
    <primary_completion_date>June 20, 2020</primary_completion_date>
    <completion_date>October 20, 2020</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04346966</url>
  </study>
  <study rank="989">
    <nct_id>NCT04308668</nct_id>
    <title>Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2</title>
    <acronym>COVID-19 PEP</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Corona Virus Infection</condition>
      <condition>Acute Respiratory Distress Syndrome</condition>
      <condition>SARS-CoV Infection</condition>
      <condition>Coronavirus</condition>
      <condition>Coronavirus Infections</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">Hydroxychloroquine</intervention>
      <intervention type="Other">Placebo</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Incidence of COVID19 Disease among those who are asymptomatic at trial entry</outcome_measure>
      <outcome_measure>Ordinal Scale of COVID19 Disease Severity at 14 days among those who are symptomatic at trial entry</outcome_measure>
      <outcome_measure>Incidence of Hospitalization</outcome_measure>
      <outcome_measure>Incidence of Death</outcome_measure>
      <outcome_measure>Incidence of Confirmed SARS-CoV-2 Detection</outcome_measure>
      <outcome_measure>Incidence of Symptoms Compatible with COVID19 (possible disease)</outcome_measure>
      <outcome_measure>Incidence of All-Cause Study Medicine Discontinuation or Withdrawal</outcome_measure>
      <outcome_measure>Overall symptom severity at 5 and 14 day</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Minnesota</lead_sponsor>
      <collaborator>McGill University Health Centre/Research Institute of the McGill University Health Centre</collaborator>
      <collaborator>University of Manitoba</collaborator>
      <collaborator>University of Alberta</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>3000</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>March 17, 2020</start_date>
    <primary_completion_date>April 21, 2020</primary_completion_date>
    <completion_date>May 12, 2020</completion_date>
    <study_first_posted>March 16, 2020</study_first_posted>
    <last_update_posted>April 8, 2020</last_update_posted>
    <locations>
      <location>Nationwide Enrollment via Internet, please email: covid19@umn.edu, Minneapolis, Minnesota, United States</location>
      <location>University of Minnesota, Minneapolis, Minnesota, United States</location>
      <location>Internet, New York, New York, United States</location>
      <location>University of Alberta, Edmonton, Alberta, Canada</location>
      <location>University of Manitoba, Winnipeg, Manitoba, Canada</location>
      <location>Research Institute of the McGill University Heath Centre, Montréal, Quebec, Canada</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04308668</url>
  </study>
  <study rank="990">
    <nct_id>NCT04351880</nct_id>
    <title>Meals MATTER: A Trial of Medically Tailored Meals 2 Weeks vs. 4 Weeks Post Hospital Discharge</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Heart Failure</condition>
      <condition>Copd</condition>
      <condition>Liver Failure</condition>
      <condition>Covid19</condition>
      <condition>Diabetes Mellitus</condition>
      <condition>Cancer</condition>
      <condition>End Stage Renal Disease</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Medically Tailored Meals</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Anxiety and Depression measured through the Hospital Anxiety and Depression Scale</outcome_measure>
      <outcome_measure>Functional Status measured through the Katz Activities of Daily Living Scale</outcome_measure>
      <outcome_measure>Re-hospitalization and Emergency Department Visits</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Kaiser Permanente</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>640</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Investigator)</study_design>
      <study_design>Primary Purpose: Other</study_design>
    </study_designs>
    <start_date>April 15, 2020</start_date>
    <primary_completion_date>February 2021</primary_completion_date>
    <completion_date>July 2021</completion_date>
    <study_first_posted>April 17, 2020</study_first_posted>
    <last_update_posted>April 17, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04351880</url>
  </study>
  <study rank="991">
    <nct_id>NCT04262921</nct_id>
    <title>Clinical Characterisation Protocol for Severe Emerging Infections</title>
    <acronym>CCP-nCoV</acronym>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus Infections</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Clinical features</outcome_measure>
      <outcome_measure>Response to treatment</outcome_measure>
      <outcome_measure>Pathogen replication, excretion and evolution, within the host</outcome_measure>
      <outcome_measure>Immune host responses to infection and therapy</outcome_measure>
      <outcome_measure>Host genetic variants</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Institut National de la Santé Et de la Recherche Médicale, France</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>500</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Other</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>February 7, 2020</start_date>
    <primary_completion_date>August 7, 2020</primary_completion_date>
    <completion_date>August 7, 2023</completion_date>
    <study_first_posted>February 10, 2020</study_first_posted>
    <last_update_posted>February 11, 2020</last_update_posted>
    <locations>
      <location>CHU Pellegrin, service des Maladies Infectieuses et Tropicales, Bordeaux, France</location>
      <location>APHP La Pitié Salpêtrière, service des Maladies Infectieuses et Tropicales, Paris, France</location>
      <location>APHP Bichat, Service de réanimation médicale et infectieuse, Paris, France</location>
      <location>APHP Bichat, Service des Maladies Infectieuses et Tropicales, Paris, France</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04262921</url>
  </study>
  <study rank="992">
    <nct_id>NCT04329897</nct_id>
    <title>Acceptance and Commitment Therapy Delivered by Automated Software Messaging</title>
    <acronym/>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hip Osteoarthritis</condition>
      <condition>Knee Osteoarthritis</condition>
      <condition>Mental Stress</condition>
      <condition>Coronavirus</condition>
    </conditions>
    <interventions>
      <intervention type="Behavioral">Software Messaging</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Change in reported pain intensity score (PROMIS Pain Intensity 3A) Patient-reported outcomes measurement information system Pain Intensity (PROMIS) 3A short form scores collected from all participating subjects.</outcome_measure>
      <outcome_measure>Change in reported pain intensity score (PROMIS Pain Intensity 1A) Patient-reported outcomes measurement information system Pain Intensity (PROMIS) 1A short form scores collected from all participating subjects.</outcome_measure>
      <outcome_measure>Change in reported pain interference score Patient-reported outcomes measurement information system (PROMIS) Pain Interference 8A short form scores collected from all participating subjects.</outcome_measure>
      <outcome_measure>Change in reported emotional distress (anxiety) score. Patient-reported outcomes measurement information system (PROMIS) Emotional Distress-Anxiety 8A short form scores collected from all participating subjects.</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>University of Iowa</lead_sponsor>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>82</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Supportive Care</study_design>
    </study_designs>
    <start_date>April 5, 2020</start_date>
    <primary_completion_date>May 30, 2020</primary_completion_date>
    <completion_date>June 30, 2020</completion_date>
    <study_first_posted>April 1, 2020</study_first_posted>
    <last_update_posted>April 8, 2020</last_update_posted>
    <locations>
      <location>University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04329897</url>
  </study>
  <study rank="993">
    <nct_id>NCT04363775</nct_id>
    <title>Comparison of VieScope vs. Macintosh Laryngoscope for Intubation in Level Cpersonal Protective Equipment Conditions</title>
    <acronym/>
    <status open="N">Completed</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Tracheal Intubation</condition>
      <condition>Infection</condition>
      <condition>Projection</condition>
    </conditions>
    <interventions>
      <intervention type="Device">The standard Macintosh laryngoscope</intervention>
      <intervention type="Device">The Vie Scope laryngoscope</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>time to intubation</outcome_measure>
      <outcome_measure>success of intubation</outcome_measure>
      <outcome_measure>Number of optimalization maneuvers</outcome_measure>
      <outcome_measure>Procedure Ease of use</outcome_measure>
      <outcome_measure>the degree of visibility of the glottis</outcome_measure>
      <outcome_measure>Cormack - Lehane grade</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Lazarski University</lead_sponsor>
      <collaborator>Poznan University of Medical Sciences</collaborator>
      <collaborator>Wroclaw Medical University</collaborator>
      <collaborator>Medical University of Bialystok</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>35</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Crossover Assignment</study_design>
      <study_design>Masking: Single (Outcomes Assessor)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>January 20, 2020</start_date>
    <primary_completion_date>February 23, 2020</primary_completion_date>
    <completion_date>February 25, 2020</completion_date>
    <study_first_posted>April 27, 2020</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>Lazarski Univeristy, Warsaw, Poland</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04363775</url>
  </study>
  <study rank="994">
    <nct_id>NCT04346979</nct_id>
    <title>Telerehabilitation-based Yoga and Mindfulness Home Program in Postmenopausal Women Having Social Isolation</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Telerehabilitation</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Telerehabilitation-Based</intervention>
      <intervention type="Other">Video-Based</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>The Brief Resilience Scale</outcome_measure>
      <outcome_measure>Nottingham Health Profile</outcome_measure>
      <outcome_measure>Mindful Attention Awareness Scale</outcome_measure>
      <outcome_measure>The Body Awareness Questionnaire</outcome_measure>
      <outcome_measure>Richard-Campbell Sleep Questionnaire</outcome_measure>
      <outcome_measure>Lateral bridge test</outcome_measure>
      <outcome_measure>Functional reach test</outcome_measure>
      <outcome_measure>Beck Depression Scale</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Istinye University</lead_sponsor>
    </sponsors>
    <gender>Female</gender>
    <min_age>45 Years</min_age>
    <max_age>65 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Not Applicable</phase>
    </phases>
    <enrollment>50</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Single (Participant)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>May 1, 2020</start_date>
    <primary_completion_date>July 1, 2020</primary_completion_date>
    <completion_date>August 1, 2020</completion_date>
    <study_first_posted>April 15, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04346979</url>
  </study>
  <study rank="995">
    <nct_id>NCT04339842</nct_id>
    <title>Eating Habits of Adults During the Quarantine</title>
    <acronym/>
    <status open="Y">Recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Health Behavior</condition>
      <condition>Eating Behavior</condition>
    </conditions>
    <interventions>
      <intervention type="Other">Assessment of Dietary Changes in Adults in the Quarantine</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Changes in the Eating Habits of Adults during the Quarantine</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Eliz Arter</lead_sponsor>
      <collaborator>Cyprus Science University</collaborator>
      <collaborator>Eastern Mediterranean University</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>80 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>400</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Case-Only</study_design>
      <study_design>Time Perspective: Cross-Sectional</study_design>
    </study_designs>
    <start_date>April 10, 2020</start_date>
    <primary_completion_date>May 31, 2020</primary_completion_date>
    <completion_date>May 31, 2020</completion_date>
    <study_first_posted>April 9, 2020</study_first_posted>
    <last_update_posted>April 15, 2020</last_update_posted>
    <locations>
      <location>Online, Nicosia, Cyprus</location>
    </locations>
    <study_documents>
      <study_document>
        <label>Study Protocol and Statistical Analysis Plan</label>
        <url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT04339842/Prot_SAP_000.pdf</url>
      </study_document>
    </study_documents>
    <url>https://ClinicalTrials.gov/show/NCT04339842</url>
  </study>
  <study rank="996">
    <nct_id>NCT04276987</nct_id>
    <title>A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia</title>
    <acronym/>
    <status open="Y">Not yet recruiting</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Coronavirus</condition>
    </conditions>
    <interventions>
      <intervention type="Biological">MSCs-derived exosomes</intervention>
    </interventions>
    <outcome_measures>
      <outcome_measure>Adverse reaction (AE) and severe adverse reaction (SAE)</outcome_measure>
      <outcome_measure>Time to clinical improvement (TTIC)</outcome_measure>
      <outcome_measure>Number of patients weaning from mechanical ventilation</outcome_measure>
      <outcome_measure>Duration (days) of ICU monitoring</outcome_measure>
      <outcome_measure>Duration (days) of vasoactive agents usage</outcome_measure>
      <outcome_measure>Duration (days) of mechanical ventilation supply</outcome_measure>
      <outcome_measure>Number of patients with improved organ failure</outcome_measure>
      <outcome_measure>Rate of mortality</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>Ruijin Hospital</lead_sponsor>
      <collaborator>Shanghai Public Health Clinical Center</collaborator>
      <collaborator>Wuhan Jinyintan Hospital, Wuhan, China</collaborator>
      <collaborator>Cellular Biomedicine Group Ltd.</collaborator>
    </sponsors>
    <gender>All</gender>
    <min_age>18 Years</min_age>
    <max_age>75 Years</max_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases>
      <phase>Phase 1</phase>
    </phases>
    <enrollment>30</enrollment>
    <funded_bys>
      <funded_by>Other</funded_by>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: None (Open Label)</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <start_date>February 15, 2020</start_date>
    <primary_completion_date>May 31, 2020</primary_completion_date>
    <completion_date>July 31, 2020</completion_date>
    <study_first_posted>February 19, 2020</study_first_posted>
    <last_update_posted>February 25, 2020</last_update_posted>
    <locations/>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT04276987</url>
  </study>
  <study rank="997">
    <nct_id>NCT01306084</nct_id>
    <title>Viral Infections in Healthy and Immunocompromised Hosts</title>
    <acronym/>
    <status open="N">Enrolling by invitation</status>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Herpes Viruses</condition>
    </conditions>
    <interventions/>
    <outcome_measures>
      <outcome_measure>Sample collection, analysis of immune function, or review of tissue bx or clinical rpts from outside labs in designated pop. w/ viral, suspected, or recovered from a viral infection or a close contact of people w/or suspected to have a viral inf...</outcome_measure>
    </outcome_measures>
    <sponsors>
      <lead_sponsor>National Institute of Allergy and Infectious Diseases (NIAID)</lead_sponsor>
      <collaborator>National Institutes of Health Clinical Center (CC)</collaborator>
    </sponsors>
    <gender>All</gender>
    <age_groups>
      <age_group>Child</age_group>
      <age_group>Adult</age_group>
      <age_group>Older Adult</age_group>
    </age_groups>
    <phases/>
    <enrollment>164</enrollment>
    <funded_bys>
      <funded_by>NIH</funded_by>
    </funded_bys>
    <study_types>Observational</study_types>
    <exp_acc_types/>
    <study_designs>
      <study_design>Observational Model: Cohort</study_design>
      <study_design>Time Perspective: Prospective</study_design>
    </study_designs>
    <start_date>March 5, 2011</start_date>
    <study_first_posted>March 1, 2011</study_first_posted>
    <last_update_posted>April 28, 2020</last_update_posted>
    <locations>
      <location>National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States</location>
    </locations>
    <documents/>
    <url>https://ClinicalTrials.gov/show/NCT01306084</url>
  </study>
</search_results>
